0001447362-22-000045.txt : 20220228 0001447362-22-000045.hdr.sgml : 20220228 20220228164443 ACCESSION NUMBER: 0001447362-22-000045 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 104 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220228 DATE AS OF CHANGE: 20220228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CASTLE BIOSCIENCES INC CENTRAL INDEX KEY: 0001447362 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 770701774 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38984 FILM NUMBER: 22690618 BUSINESS ADDRESS: STREET 1: 505 S FRIENDSWOOD DRIVE STREET 2: SUITE 401 CITY: FRIENDSWOOD STATE: TX ZIP: 77546 BUSINESS PHONE: 866-788-9007 MAIL ADDRESS: STREET 1: 505 S FRIENDSWOOD DRIVE STREET 2: SUITE 401 CITY: FRIENDSWOOD STATE: TX ZIP: 77546 10-K 1 cstl-20211231.htm 10-K cstl-20211231
00014473622021FYfalsehttp://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602MemberP5Yhttp://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2021-01-31#OtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrentP4Y00014473622021-01-012021-12-3100014473622021-06-30iso4217:USD00014473622022-02-21xbrli:shares00014473622021-12-3100014473622020-12-31iso4217:USDxbrli:shares00014473622020-01-012020-12-310001447362us-gaap:PreferredStockMember2019-12-310001447362us-gaap:CommonStockMember2019-12-310001447362us-gaap:AdditionalPaidInCapitalMember2019-12-310001447362us-gaap:RetainedEarningsMember2019-12-3100014473622019-12-310001447362us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001447362us-gaap:CommonStockMember2020-01-012020-12-310001447362us-gaap:RetainedEarningsMember2020-01-012020-12-310001447362us-gaap:PreferredStockMember2020-12-310001447362us-gaap:CommonStockMember2020-12-310001447362us-gaap:AdditionalPaidInCapitalMember2020-12-310001447362us-gaap:RetainedEarningsMember2020-12-310001447362srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2020-12-310001447362srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-12-310001447362us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001447362us-gaap:CommonStockMember2021-01-012021-12-310001447362us-gaap:RetainedEarningsMember2021-01-012021-12-310001447362us-gaap:PreferredStockMember2021-12-310001447362us-gaap:CommonStockMember2021-12-310001447362us-gaap:AdditionalPaidInCapitalMember2021-12-310001447362us-gaap:RetainedEarningsMember2021-12-31cstl:segment0001447362srt:MinimumMember2021-01-012021-12-310001447362srt:MaximumMember2021-01-012021-12-3100014473622020-04-102020-04-100001447362us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001447362us-gaap:AccountingStandardsUpdate201602Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-01-0100014473622020-04-16cstl:claim0001447362cstl:DermatologicMember2021-01-012021-12-310001447362cstl:DermatologicMember2020-01-012020-12-310001447362us-gaap:ServiceOtherMember2021-01-012021-12-310001447362us-gaap:ServiceOtherMember2020-01-012020-12-310001447362us-gaap:RevenueFromContractWithCustomerMembercstl:MedicareMembercstl:ThirdPartyPayorConcentrationRiskMember2021-01-012021-12-31xbrli:pure0001447362us-gaap:RevenueFromContractWithCustomerMembercstl:MedicareMembercstl:ThirdPartyPayorConcentrationRiskMember2020-01-012020-12-310001447362cstl:MedicareMembercstl:AccountsReceivableCurrentMembercstl:ThirdPartyPayorConcentrationRiskMember2021-01-012021-12-310001447362cstl:MedicareMembercstl:AccountsReceivableCurrentMembercstl:ThirdPartyPayorConcentrationRiskMember2020-01-012020-12-310001447362cstl:AccountsReceivableNoncurrentMembercstl:MedicareMembercstl:ThirdPartyPayorConcentrationRiskMember2021-01-012021-12-310001447362cstl:AccountsReceivableNoncurrentMembercstl:MedicareMembercstl:ThirdPartyPayorConcentrationRiskMember2020-01-012020-12-310001447362cstl:MedicareAdvantagePlansMemberus-gaap:RevenueFromContractWithCustomerMembercstl:ThirdPartyPayorConcentrationRiskMember2021-01-012021-12-310001447362cstl:MedicareAdvantagePlansMemberus-gaap:RevenueFromContractWithCustomerMembercstl:ThirdPartyPayorConcentrationRiskMember2020-01-012020-12-310001447362cstl:MedicareAdvantagePlansMembercstl:AccountsReceivableCurrentMembercstl:ThirdPartyPayorConcentrationRiskMember2021-01-012021-12-310001447362cstl:MedicareAdvantagePlansMembercstl:AccountsReceivableCurrentMembercstl:ThirdPartyPayorConcentrationRiskMember2020-01-012020-12-310001447362cstl:MedicareAdvantagePlansMembercstl:AccountsReceivableNoncurrentMembercstl:ThirdPartyPayorConcentrationRiskMember2021-01-012021-12-310001447362cstl:MedicareAdvantagePlansMembercstl:AccountsReceivableNoncurrentMembercstl:ThirdPartyPayorConcentrationRiskMember2020-01-012020-12-310001447362us-gaap:RevenueFromContractWithCustomerMembercstl:BlueCrossBlueShieldPlansMembercstl:ThirdPartyPayorConcentrationRiskMember2021-01-012021-12-310001447362us-gaap:RevenueFromContractWithCustomerMembercstl:BlueCrossBlueShieldPlansMembercstl:ThirdPartyPayorConcentrationRiskMember2020-01-012020-12-310001447362cstl:AccountsReceivableCurrentMembercstl:BlueCrossBlueShieldPlansMembercstl:ThirdPartyPayorConcentrationRiskMember2021-01-012021-12-310001447362cstl:AccountsReceivableCurrentMembercstl:BlueCrossBlueShieldPlansMembercstl:ThirdPartyPayorConcentrationRiskMember2020-01-012020-12-310001447362cstl:AccountsReceivableNoncurrentMembercstl:BlueCrossBlueShieldPlansMembercstl:ThirdPartyPayorConcentrationRiskMember2021-01-012021-12-310001447362cstl:AccountsReceivableNoncurrentMembercstl:BlueCrossBlueShieldPlansMembercstl:ThirdPartyPayorConcentrationRiskMember2020-01-012020-12-310001447362cstl:StockOptionsAndRestrictedStockUnitsMember2021-01-012021-12-310001447362cstl:StockOptionsAndRestrictedStockUnitsMember2020-01-012020-12-310001447362us-gaap:WarrantMember2021-01-012021-12-310001447362us-gaap:WarrantMember2020-01-012020-12-310001447362us-gaap:EmployeeStockMember2021-01-012021-12-310001447362us-gaap:EmployeeStockMember2020-01-012020-12-310001447362cstl:MyriadMyPathLLCMember2021-05-282021-05-280001447362cstl:MyriadMyPathLLCMemberus-gaap:DevelopedTechnologyRightsMember2021-05-282021-05-280001447362cstl:CernosticsIncMember2021-12-032021-12-030001447362cstl:CernosticsIncMember2021-12-310001447362cstl:CernosticsIncMember2021-12-03cstl:day00014473622021-12-030001447362us-gaap:DevelopedTechnologyRightsMembercstl:CernosticsIncMember2021-12-032021-12-030001447362cstl:DevelopedWorkforceMembercstl:CernosticsIncMember2021-12-032021-12-030001447362us-gaap:LeaseholdImprovementsMember2021-12-310001447362us-gaap:LeaseholdImprovementsMember2020-12-310001447362us-gaap:EquipmentMember2021-12-310001447362us-gaap:EquipmentMember2020-12-310001447362us-gaap:ComputerEquipmentMember2021-12-310001447362us-gaap:ComputerEquipmentMember2020-12-310001447362us-gaap:FurnitureAndFixturesMember2021-12-310001447362us-gaap:FurnitureAndFixturesMember2020-12-310001447362us-gaap:ConstructionInProgressMember2021-12-310001447362us-gaap:ConstructionInProgressMember2020-12-310001447362us-gaap:CostOfSalesMember2021-01-012021-12-310001447362us-gaap:CostOfSalesMember2020-01-012020-12-310001447362us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001447362us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001447362us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-310001447362us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310001447362us-gaap:DevelopedTechnologyRightsMember2021-12-310001447362us-gaap:DevelopedTechnologyRightsMember2021-01-012021-12-310001447362cstl:AssembledWorkforceMember2021-12-310001447362cstl:AssembledWorkforceMember2021-01-012021-12-310001447362cstl:OfficeSpaceMember2021-01-012021-12-31cstl:renewal_option0001447362cstl:OfficeAndLaboratoryFacilityMember2021-01-012021-12-31cstl:facility0001447362cstl:TwoThousandEighteenLoanAndSecurityAgreementMemberus-gaap:NotesPayableToBanksMember2018-11-300001447362srt:MinimumMembercstl:TwoThousandEighteenLoanAndSecurityAgreementMemberus-gaap:NotesPayableToBanksMember2018-11-300001447362cstl:TwoThousandEighteenLoanAndSecurityAgreementMemberus-gaap:NotesPayableToBanksMemberus-gaap:LondonInterbankOfferedRateLIBORMember2018-11-302018-11-30cstl:installment0001447362cstl:TwoThousandEighteenLoanAndSecurityAgreementMemberus-gaap:NotesPayableToBanksMember2018-11-302018-11-300001447362cstl:TwoThousandEighteenLoanAndSecurityAgreementMemberus-gaap:NotesPayableToBanksMember2020-12-212020-12-210001447362cstl:TwoThousandEighteenLoanAndSecurityAgreementMemberus-gaap:NotesPayableToBanksMember2020-01-012020-12-310001447362us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001447362us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001447362us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001447362us-gaap:FairValueMeasurementsRecurringMember2021-12-310001447362us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001447362us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001447362us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001447362us-gaap:FairValueMeasurementsRecurringMember2020-12-310001447362us-gaap:MeasurementInputPriceVolatilityMemberus-gaap:IncomeApproachValuationTechniqueMember2021-01-012021-12-310001447362us-gaap:IncomeApproachValuationTechniqueMemberus-gaap:MeasurementInputDiscountRateMember2021-01-012021-12-310001447362cstl:FollowOnPublicOfferingMember2020-06-292020-06-290001447362cstl:FollowOnPublicOfferingMember2020-06-290001447362us-gaap:OverAllotmentOptionMember2020-06-292020-06-290001447362us-gaap:OverAllotmentOptionMember2020-06-292020-07-020001447362cstl:FollowOnPublicOfferingMember2020-07-022020-07-020001447362cstl:FollowOnPublicOfferingMember2020-12-182020-12-180001447362us-gaap:OverAllotmentOptionMember2020-12-182020-12-180001447362cstl:FollowOnPublicOfferingMember2020-12-180001447362us-gaap:CommonStockMember2020-12-110001447362us-gaap:CommonStockMember2020-12-290001447362cstl:IncentiveStockOptionsMember2021-01-012021-12-310001447362us-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:EmployeeStockOptionMember2021-01-012021-12-310001447362cstl:TwoThousandNineteenEquityIncentivePlanMember2021-12-310001447362cstl:TwoThousandNineteenEquityIncentivePlanMemberus-gaap:SubsequentEventMember2022-01-012022-01-010001447362us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001447362us-gaap:RestrictedStockUnitsRSUMember2019-12-310001447362us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001447362us-gaap:RestrictedStockUnitsRSUMember2020-12-310001447362us-gaap:RestrictedStockUnitsRSUMember2021-12-310001447362us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember2021-10-01cstl:employee0001447362us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember2021-10-012021-10-010001447362us-gaap:EmployeeStockMembercstl:EmployeeStockPurchasePlanMember2021-01-012021-12-31cstl:purchase_period0001447362us-gaap:EmployeeStockMembercstl:EmployeeStockPurchasePlanMember2021-12-310001447362us-gaap:EmployeeStockMembercstl:EmployeeStockPurchasePlanMember2022-01-012022-01-010001447362us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001447362cstl:EmployeeStockPurchasePlanMember2021-01-012021-12-310001447362cstl:EmployeeStockPurchasePlanMember2020-01-012020-12-310001447362us-gaap:EmployeeStockMember2021-01-012021-12-310001447362us-gaap:EmployeeStockMember2020-01-012020-12-310001447362us-gaap:DomesticCountryMember2021-12-310001447362us-gaap:StateAndLocalJurisdictionMember2021-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2021
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to _________

Commission File Number: 001-38984
CASTLE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware77-0701774
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
505 S. Friendswood Drive, Suite 401, Friendswood, Texas
77546
(Address of principal executive offices)
(Zip Code)
(866) 788-9007
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par value per shareCSTLThe Nasdaq Global Market

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ¨
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of ‘‘large accelerated filer,’’ ‘‘accelerated filer,’’ ‘‘smaller reporting company,’’ and ‘‘emerging growth company’’ in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☒
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒
The aggregate market value of voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2021 (the last business day of the registrant’s most recently completed second fiscal quarter) was $1.5 billion based on the closing price of the registrant’s common stock on June 30, 2021, as reported by the Nasdaq Global Market.
As of February 21, 2022, there were 25,410,602 shares of common stock, $0.001 par value per share, issued and outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement to be filed with the Securities and Exchange Commission, or SEC, subsequent to the date hereof pursuant to Regulation 14A in connection with the registrant’s 2022 Annual Meeting of Stockholders, are incorporated by reference into Part III of this Annual Report on Form 10-K. The registrant intends to file such proxy statement with the SEC not later than 120 days after the conclusion of its fiscal year ended December 31, 2021.

Table of Contents
Page
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
Item 9C.
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
Item 15.
Item 16.
F-1

1
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. The forward-looking statements are contained principally in the sections entitled “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business.” These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about:
•estimates of our total addressable market, future revenue, expenses, capital requirements and our needs for additional financing;
•expectations with respect to reimbursement for our products, including third-party payor reimbursement and coverage decisions;
•anticipated cost, timing and success of our product candidates, and our plans to research, develop and commercialize new tests;
•the impact of the COVID-19 pandemic on our business;
•our ability to obtain funding for our operations, including funding necessary to complete the expansion of our operations and development of our pipeline products;
•the implementation of our business model and strategic plans for our products, technologies and business;
•expectations with respect to acquisitions of businesses, assets, products or technologies;
•our ability to manage and grow our business by expanding our sales to existing customers or introducing our products to new customers;
•our ability to develop and maintain sales and marketing capabilities;
•regulatory developments in the United States and foreign countries;
•the performance of our third-party suppliers;
•the success of competing diagnostic products that are or become available;
•our ability to attract and retain key personnel; and
•our expectations regarding our ability to obtain and maintain intellectual property protection for our products and our ability to operate our business without infringing on the intellectual property rights of others.
In some cases, you can identify these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expects,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. These forward-looking statements reflect our management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Annual Report on Form 10-K and are subject to risks and uncertainties. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. We discuss many of the risks associated with the forward-looking statements in this Annual Report on Form 10-K in greater detail in the section entitled “Risk Factors.” Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

2
RISK FACTORS SUMMARY
We face many risks and uncertainties, as more fully described in this Annual Report on Form 10-K under the heading “Risk Factors.” Some of these risks and uncertainties are summarized below. The summary below does not contain all of the information that may be important to you, and you should read this summary together with the more detailed discussion of these risks and uncertainties contained in “Risk Factors.”
Risk Related to our Financial Condition
•We rely upon a small number of third-party payors for a significant portion of our revenue.
•Our method of recognizing revenue may not reflect our underlying business.
•We have incurred significant losses since inception, and we may never achieve profitability.
•We are an early, commercial-stage company and have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.
•Our financial results could fluctuate in the future, causing the market price of our stock to decline substantially.
•If our internal control over financial reporting is ineffective, we may not be able to accurately report our financial results or file our periodic reports in a timely manner.
•We may need to raise additional capital to commercialize new products, to expand operations or to fund existing operations.
Risks Related to our Business
•We have been, and may continue to be, adversely impacted by the COVID-19 pandemic, which has, at times, caused decreased test report volume.
•Our revenue heavily relies upon the sale of a single product and our current or future products may not achieve or maintain significant commercial market acceptance.
•Billing for our products is complex and we require substantial time and resources to collect payment.
•We rely on third parties for sample collection, preparation and delivery.
•A depletion or loss of our sample database could significantly harm our business.
•If our primary clinical laboratory facility becomes damaged or inoperable or we are required to vacate our existing facility, our ability to conduct our laboratory work for our commercial products and pursue our research and development efforts may be jeopardized.
•New product development is lengthy and complex and our revenues could be limited if we are unable to increase and support adoption of our products by both physicians and other healthcare providers.
•We rely on limited or sole suppliers for some of the reagents, equipment, chips and other materials used by our products, and we may not be able to find replacements or transition to alternative suppliers if these suppliers are unable or unwilling to continue providing these materials.
•The sizes of the addressable markets for our current and future products have not been established with precision and may be smaller than we estimate.
•The diagnostic testing industry is subject to rapid change, which could make our current or future products obsolete.
Risks Related to Reimbursement and Government Regulation
•We currently have limited reimbursement coverage for our lead product, DecisionDx-Melanoma, and if third-party payors, including government and commercial payors, do not provide sufficient coverage of, or adequate reimbursement for, our products, our commercial success, including revenue, will be negatively affected.
•We conduct business in a heavily regulated industry and failure to comply with regulatory requirements, including those established by the Centers for Medicare & Medicaid Services (“CMS”), and the U.S. Food and Drug Administration (“FDA”) or changes in enforcement discretion for laboratory developed tests could harm our business.
•Data from our clinical studies may change materially, which could harm our business.
•Changes in healthcare policy, statutes or regulations, or our ability to comply with applicable healthcare requirements, could have a material adverse effect on our business and operations.

Risks Related to Intellectual Property

•If we are unable to obtain and maintain sufficient intellectual property protection for our technology, our ability to successfully commercialize our products may be impaired.
•Our commercial success depends significantly on our ability to operate without infringing upon the intellectual property rights of third parties.
3
•We rely on information technology systems that we license from third parties and other royalty-bearing license agreements.
Risks Related to Employee Matters and Managing Growth and Other Risks Related to Our Business
•We are highly dependent on the services of our key personnel, including our President and Chief Executive Officer.
•Our employees and any current or potential commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
•We have, and may continue to, engage in strategic transactions, such as the acquisition of businesses, assets, products or technologies, which could be disruptive to our existing operations, divert the attention of our management team and adversely impact our liquidity, cash flows, financial condition and results of operations.
•Our business may be negatively impacted by cyber-security threats, natural disasters and public health crises.
•Product or professional liability lawsuits against us could cause us to incur substantial liabilities and could limit our commercialization of our products.
Risks Related to Ownership of Our Common Stock.
•The price of our common stock may be volatile or may decline regardless of our operating performance, and you may lose all or part of your investment.
•We have broad discretion in the use of working capital and may not use it effectively or in ways that increase our share price.
•Related party transactions that create conflicts of interest, or the appearances of conflicts of interest, may harm our business and cause our stock price to decline.
•The concentration of our stock ownership will likely limit your ability to influence corporate matters, including the ability to influence the outcome of director elections and other matters requiring stockholder approval.
•Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.
•Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
4
PART I

Item 1. Business.
As used in this Annual Report on Form 10-K, unless the context indicates or otherwise requires, “Castle Biosciences,” “the Company,” “we,” “us,” and “our” refer to Castle Biosciences, Inc., a Delaware Corporation.
Overview
Castle Biosciences is improving health through innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the personalized information our diagnostic and prognostic tests provide.
Vision and Foundational Strategy
Since our inception in 2008, it has been our vision to transform disease management by keeping people first: patients, clinicians, employees and investors. This foundational strategy remains the guidepost for the direction of our company and the basis of long-term value creation.
cstl-20211231_g1.jpg
Our foundational strategy focuses on executing four principles:
Address Areas With Unmet Clinical Need. Our commercial and pipeline tests address many treatment plan challenges facing physicians by providing physicians and their patients with a laboratory report that contains clinically actionable and personalized information from our proprietary tests to inform the treatment plan for each patient.
Leverage Advanced Technologies For Innovative Tests. We focus on multi-analyte assays with algorithmic analysis (“MAAAs”) that enable us to characterize an individual patient’s tissue biology to improve risk-stratification, improve diagnostic certainty and predict therapy response. Our expectation is that incorporating our personalized test results into the shared decision-making between a patient and their clinician should result in improved treatment plan decisions and lead to optimized health outcomes with a reduction in healthcare costs. Due to the biological complexity of the diseases we target, we believe that MAAAs are the optimal approach to precision testing.
Provide Robust Data To Support The Clinical Value Of Our Tests. We conduct extensive clinical utility and validity studies to support the adoption of, and reimbursement for, our products. This growing set of data is key in educating physicians and patients about the consistent value of our commercial products. Regarding our lead product, DecisionDx-Melanoma, in 2015, we published our initial two peer-reviewed manuscripts. As of February 28, 2022, we have more than 35 peer-reviewed publications supporting the clinical utility and validity of DecisionDx-Melanoma, including multiple prospective studies and two systematic reviews with meta-analyses involving over 6,000 unique patients. We anticipate analyzing more than 20,000 additional patients’ data in cutaneous melanoma studies in 2022. Across our testing portfolio, we currently have 16 ongoing clinical research studies and as of December 31, 2021 we had 341 committed/contributing clinical research sites and 7,800
5
patients enrolled in studies. In order to maintain our competitive advantage and increase sales of our products, we will continue to generate additional clinical data to support the use of our products.
Accelerate Test Adoption Through Commercial Excellence. Our commercial team focuses on educating clinicians on the value of incorporating the results of MAAA tests to make more informed treatment plan decisions. In the field of dermatology, this approach has resulted in established relationships with clinicians that allow us to optimize our interactions, increase adoption of our current products and identify areas of unmet clinical need to efficiently launch additional, complementary products. Our significant investment in developing evidence of the value of our tests has resulted in rigorous scientific support and peer-reviewed publications in leading journals, which allows our commercial team to have substantive, in-depth dialogues with physicians. Through these established relationships, we have been able to integrate our products into physicians’ workflows and identify further educational programs, which we believe fosters adoption of our products. We believe our history of commercial success in dermatology will translate into other markets, including ocular oncology and gastroenterology.
Our Test Portfolio
We map out the continuum of diagnostic test services as starting with (i) screening of healthy individuals, to (ii) supporting diagnostic clarity in patients with signs or symptoms of disease, to (iii) risk-stratification or prognosis, to (iv) response to treatment for specific treatment selection and to (v) late-stage testing for use in resistant metastatic disease. We currently focus our investments on innovative test services that assist in providing diagnostic clarity in patients with signs or symptoms of disease, risk-stratification and response to treatment. We have five commercially available proprietary tests that assist physicians and patients along this continuum and focus on answering clinical questions arising during the treatment of dermatologic cancers, uveal melanoma and Barrett’s esophagus (“BE”): DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, myPath Melanoma, DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. Together, we believe these commercial products support an estimated total addressable market (“TAM”) of $3.0 billion in the United States. Currently, our revenue is primarily generated by our DecisionDx®-Melanoma risk stratification test for cutaneous melanoma and our DecisionDx®-UM risk stratification test for uveal melanoma.
In 2021, we announced the launch of our innovative pipeline initiative to develop a genomic test aimed at predicting response to systemic therapy in patients with moderate to severe psoriasis, atopic dermatitis and related inflammatory skin conditions. If successful, this inflammatory skin pipeline test has the potential to add approximately $1.9 billion to our current estimated U.S. TAM. In 2021, we formed a steering committee comprised of leading experts in the field, received Institutional Revenue Board (“IRB”) approval and enrolled our first patient in the development and validation study for this genomic test. We believe we are on track to launch this test by the end of 2025. We have initiated work on additional pipeline tests which branch out upstream, downstream and parallel to our commercial tests, within or adjacent to our established dermatology commercial call points.
cstl-20211231_g2.jpg
6
Operational Pillars Supporting Castle’s Growth
Our near and long-term growth plans are focused on three operational pillars: our strong core dermatology business, pipeline initiatives and strategic opportunities.

cstl-20211231_g3.jpg
Strong Core Dermatology Business
The foundation of our business is our dermatologic cancer franchise, and our lead product is DecisionDx-Melanoma. DecisionDx-Melanoma is a proprietary multi-gene expression profile (“GEP”) risk stratification test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma, a deadly skin cancer. In the management of melanoma, as with nearly all diseases, treatment plans are directed by patient risk-stratification. This test has two distinct, complementary clinically actionable uses. The first revolves around predicting the likelihood of having a sentinel lymph node (“SLN”) negative biopsy result so that physicians and patients can discuss the risk and benefit of undergoing the SLN biopsy (“SLNB”) surgical procedure. The second use is to inform the appropriate treatment plan during the initial five years post-diagnosis, regardless of the decision to undergo or avoid invasive SLNB surgery. In a typical year, we estimate approximately 130,000 patients are diagnosed with invasive cutaneous melanoma in the United States. We launched DecisionDx-Melanoma in May 2013. Based on the substantial clinical evidence that we have developed, we have received Medicare coverage for DecisionDx-Melanoma, which represents approximately 50% of the addressable patient population for this test.
In 2021, we initiated a collaboration with the National Cancer Institute (“NCI”) to link Surveillance, Epidemiology, and End Results (“SEER”) Program registries’ data on cutaneous melanoma cases with DecisionDx-Melanoma testing data. The analysis of the first subset of data from patients 65 years and older confirmed the performance of our test to risk stratify the likelihood of progression. The analysis also showed that patients tested with DecisionDx-Melanoma had improved overall survival rates compared to untested patients. In addition to confirming results from previous studies, this data from a large, real-world and unselected patient population, confirmed that patients who received a DecisionDx-Melanoma test result lived longer than patients whose clinicians relied solely on traditional clinicopathologic factors. The first phase of the collaboration links SEER cutaneous melanoma registries that were diagnosed between 2013 and 2018 with DecisionDx-Melanoma results and additional clinicopathologic information from patients tested between 2013 and 2018. We expect that the peer-reviewed publication will be available in 2022. The next planned phase of the collaboration with the NCI is to link the SEER registries’ cutaneous melanoma cases diagnosed post-2018. We expect further data read outs later in 2022 and beyond.
On August 31, 2020, we commercially launched our cutaneous squamous cell carcinoma (“SCC”) proprietary GEP test, DecisionDx®‑SCC, for use in patients with one or more risk factors (also referred to as “high-risk” SCC). On November 2, 2020, we commercially launched our proprietary GEP test for difficult-to-diagnose melanocytic lesions, DecisionDx® DiffDx™-Melanoma for use in patients with a melanocytic lesion and uncertainty related to the malignancy of the lesion. We
7
believe that these two additional skin cancer tests address areas of high clinical need in dermatological cancer and, together, represent an estimated addressable population of approximately 500,000 patients in the United States.
We further expanded our commercially available dermatologic portfolio in May 2021 when we acquired Myriad myPath, LLC (“Myriad myPath Laboratory”) from Myriad Genetics, Inc. for a cash purchase price of $32.5 million. myPath Melanoma is a clinically validated GEP test that addresses the same unmet clinical need as our DecisionDx DiffDx-Melanoma test. Today, we offer both our myPath Melanoma test and our DecisionDx DiffDx-Melanoma test under an offering that we refer to as our comprehensive diagnostic offering (“CDO”) of molecular testing solutions. By offering both of these tests in a single offering, we believe we have demonstrated the ability to improve the test result performance for patients with difficult-to-diagnose melanocytic lesions.
Pipeline Initiatives
We identify areas of significant unmet clinical needs in the treatment of skin cancer and other diseases and leverage our expertise in genomics and other advanced technologies, data analytics and artificial intelligence to develop clinically actionable products. We focus first on confirming the unmet clinical needs of clinicians treating skin cancer and other diseases, which we gather from in-depth conversations with our customers and thought leaders as well as feedback our sales and medical affairs representatives receive from clinicians. Once we have generated a pipeline test that we believe will address an unmet clinical need, we work to validate the product candidate through extensive testing of patient tissue samples, many of which will be housed in Castle’s own biorepository and annotated with clinical outcomes data. We use our extensive data bank of patient tissue samples and clinical outcomes data to conduct development and validation studies, as well as clinical studies to collect new samples in additional diseases.
We have significant expertise in developing proprietary algorithms, conducting clinical studies and using the necessary instrumentation required for efficiently developing our pipeline products.
In 2021, we announced the launch of our innovative pipeline initiative to develop a genomic test aimed at predicting response to systemic therapy in patients with moderate to severe psoriasis, atopic dermatitis and related inflammatory skin conditions. In the U.S. alone, there are approximately 18 million patients diagnosed with psoriasis and atopic dermatitis. Approximately 450,000 of these patients annually are eligible for systemic therapies. If successful, this inflammatory skin disease pipeline test has the potential to add approximately $1.9 billion to our current estimated U.S. TAM. In 2021, we initiated a 4,800 patient, prospective, multi-center clinical study to develop and validate this pipeline test, and have 50 committed centers, out of the initial target of 50. Based upon our current development and validation timelines, we expect to launch this pipeline test by the end of 2025.
Although we are still in the early stages of development, we believe that, utilizing our existing sales channels, we could launch three to five new tests by the end of 2025, potentially adding approximately $1.7 billion to our current U.S. TAM.
Strategic Opportunities
A key pillar of our growth plan is to identify targeted, complementary strategic opportunities. Our M&A philosophy includes entering markets where we expect our history of commercial success in the field of dermatology will translate well. Further, we seek opportunities where we expect to leverage advanced technologies to bring innovative tests to clinicians and patients, where there is an opportunity to transform disease management in areas with unmet clinical need and provide actionable information to answer clinical questions, and where we have the potential to create a suite of tests for use by a single clinician.
We further expanded our commercially available dermatologic portfolio in May 2021, when we completed the acquisition of the Myriad myPath Laboratory, as mentioned above.
In December 2021, we extended our commercial portfolio of proprietary tests into the gastroenterology market through our acquisition of Cernostics, Inc. (“Cernostics”) and the TissueCypher® platform. The TissueCypher platform focuses on unlocking, in the case of the initial test for use in patients with BE, the importance of the location of the expression of proteins or lack thereof within the morphology of the disease (also known as spatialomics). This “spatialomic” information is then interpreted using artificial intelligence approaches to predict the likelihood of progression to high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite or low-grade dysplasia BE. We believe the addition of expertise in the spatialomics area positions us for continued growth and success in the diagnostics space, complementing our first-to-market dermatologic franchise and our proprietary test for uveal melanoma.
Our History of Transforming Disease Management
In addition to our dermatologic franchise and our initial entry into the gastroenterology market with our TissueCypher test for BE, we also market tests for patients diagnosed with uveal melanoma (“UM”), a rare cancer of the eye. DecisionDx®-UM is a proprietary GEP test that provides risk-stratification information for patients with UM.
8
We believe DecisionDx-UM is the standard of care in the management of newly diagnosed UM in the majority of ocular oncology practices in the U.S., and it is estimated that nearly 8 in 10 patients diagnosed with UM in the U.S. receive the DecisionDx-UM test as part of their diagnostic workup. We launched DecisionDx-UM in January 2010. Based on the substantial clinical evidence that we have developed, we received Medicare coverage for DecisionDx-UM, which represents approximately 50% of the addressable patient population as well as widespread commercial payor coverage.
Test Adoption
The number of test reports we generate is a key indicator that we use to assess our business. A test report is generated when we receive a sample in our laboratory, and then the relevant test information is entered into our Laboratory Information Management System, the expression of the biomarkers is measured, then a proprietary algorithmic analysis of the combined biomarkers is performed to generate a report providing the results of that analysis, which is sent to the clinician who ordered the test. The numbers of GEP test reports delivered by us and our net revenues during the past five years are presented in the table below:
Years Ended December 31,
20212020201920182017
DecisionDx-Melanoma
20,32816,23215,52912,0329,300
DecisionDx‑SCC(1)
3,510485———
CDO(2)
2,66273———
Dermatologic Total
26,50016,79015,52912,0329,300
DecisionDx-UM
1,6181,3951,5261,4131,314
Grand Total28,11818,18517,05513,44510,614
Net Revenues (in thousands)$94,085 $62,649 $51,865 $22,786 $13,754 
(1)We commercially launched DecisionDx-SCC on August 31, 2020.
(2)Includes DecisionDx DiffDx-Melanoma, which we commercially launched on November 2, 2020, and myPath Melanoma, which we began offering following our acquisition of Myriad myPath Laboratory on May 28, 2021. We offer both our myPath Melanoma and DecisionDx DiffDx-Melanoma under our CDO.
Dermatologic Franchise Overview
Skin cancer is the uncontrolled growth of abnormal skin cells. There are six types of pre-cancers and skin cancers that result in a total annual incidence of 5.5 million patients. The three most common forms of skin cancers are basal cell carcinomas, SCC and cutaneous melanoma. SCC, the second most common form of skin cancer, is an uncontrolled growth of abnormal cells arising from the squamous cells in the epidermis, the skin’s outermost layer. Melanoma, an aggressive form of skin cancer, originates in the pigment-producing melanocytes in the basal layer of the epidermis. We do not, at this time, have an active focus on basal cell carcinomas.
9
Pre-cancers include suspicious pigmented lesions, which are unusual-looking lesions that may be melanoma, and actinic keratosis. The estimated TAM for our dermatologic commercial products, which is based on estimated patient population assuming average reimbursement rate among all payors, is set forth below:
cstl-20211231_g4.jpg
1.Annual U.S. incidence for Stage I, II or III melanoma estimated at 130,000; Annual U.S. incidence for squamous cell carcinoma estimated at 1,000,000 with addressable market limited to carcinomas with one or more high risk features; Annual U.S. incidence for suspicious pigmented lesion biopsies estimated at 2,000,000 with addressable market limited to the 15% with an indeterminant biopsy.

Cutaneous Melanoma
Melanoma tumors originate in the pigment-producing melanocytes in the basal layer of the epidermis. Published statistics suggest that there were nearly 300,000 new cases of melanoma diagnosed worldwide, with the U.S. Surveillance, Epidemiology, and End Results (“SEER”) database estimating that approximately 96,000 invasive cutaneous melanomas are diagnosed in the United States annually, however, multiple publications report that melanoma diagnoses are underreported by between 30% and 72% annually in the United States. Using the mean of the underreporting of these four studies, we estimate the annual incidence of cutaneous melanoma to be 130,000, representing an estimated U.S. TAM of $540 million. According to these publications, the underreporting of melanoma diagnoses reflects the fact that the majority of diagnoses are made by community-based dermatologists and dermatopathologists rather than institutional-based specialists who more typically have tumor registry support. Based on currently available data, we estimate the targetable clinician base is between 11,000 and 15,000.
Additionally, the incidence of melanoma has steadily increased annually over the last several decades, with an estimated growth in the United States of more than 50% during the past ten years.
After a diagnosis of invasive cutaneous melanoma, healthcare providers have traditionally relied solely on clinical and pathology factors from the initial biopsy to estimate the patient’s risk of metastasis to then determine a risk-based treatment plan. This estimation or “staging” process is then used to determine nearly all treatment decisions. Invasive melanoma tumors are staged as Stage I through Stage IV. Stage I tumors have invaded the dermis but are thin, with less than or equal to 2.0 mm invasion into the dermis if not ulcerated, or less than or equal to 1.0 mm invasion into the dermis if ulcerated. Stage I tumors have the lowest population-based risk of metastasis and death from melanoma. Stage II tumors, though localized, are thicker than 2.0 mm if not ulcerated or greater than 1.0 mm if ulcerated. Stage III tumors have evidence of regional metastasis, such as palpable metastasis at the regional lymph node basin, in-transit or satellite disease, or melanoma cell(s) in the SLN tissue but without evidence of distant metastatic spread. Stage IV tumors are those in which distant metastasis, such as to the lung or brain, has been detected.
All patients who are diagnosed with an invasive cutaneous melanoma will undergo a wide local excision procedure with the surgical margins determined by the depth of the tumor. Invasive SLNB surgery is generally recommended to be considered for patients with melanomas greater than or equal to 0.8 mm thick or for thinner melanomas accompanied by an adverse pathologic feature such as ulceration, high mitotic rate or transected base. Tumors with these anatomic based features are believed to result in an SLN-positive biopsy result 5% or more of the time. If the SLNB surgery is performed, then the wide local excision is performed at that time. As noted above, an SLN-positive biopsy result, meaning that at least one melanoma cell was seen in the SLN tissue, leads to re-staging the patient as Stage III. Guideline committees do not recommend SLNB surgery if the likelihood of a positive SLN result is less than 5%. They recommend discussing and considering SLNB surgery if the likelihood of a
10
positive SLN result falls between 5% and 10%, and recommend discussing and offering SLNB surgery if the likelihood exceeds 10%. Guideline committees have generally converged on the 5% threshold due to a reported regional false negative rate of the SLNB surgery of 5% (meaning that 5% of the time, or more, the guideline committees expect a patient with an SLN-negative biopsy result will subsequently develop SLN metastasis). However, the published literature documents a median regional false negative rate of 18% and an 11% surgical complication rate. The “regional false negative rate” measures the rate that metastasis to the regional lymph node in patients with a negative SLNB surgical result.
The traditional clinical and pathology staging system for invasive cutaneous melanoma is based upon the anatomic findings of the melanoma; that is what the pathologist can see under the microscope from an initial tumor biopsy and what the physician can feel or see during a clinical exam or upon imaging. While this staging system provides population-based risk of metastasis estimates based on clinical and pathology factors, it does not evaluate nor incorporate the biology of the patient’s primary tissue biology.
Importantly, while it was formerly believed that SLNB surgery improved melanoma specific survival, the NCI conducted a landmark, prospective, randomized multi-center study (“the MSLT-I study”) which showed that the death rate from melanoma was the same in patients who were randomized to the SLNB surgery and those who merely underwent observation, indicating that SLNB surgery is prognostic, and not therapeutic, as it relates to the risk of death from melanoma. On average, 12% of patients undergoing the SLNB surgery will have an SLN-positive biopsy result and 88% will not. Invasive SLNB surgery carries significant healthcare burden. For example, the overall complication rate of SLNB surgery was shown to be 11.3% in a systematic review of 21 articles representing 9,047 patients. A separate review reported that the regional false negative rate of the SLNB surgery ranged from 5% to 21%, with a median rate of 18%.
Both the complication and false negative rates are above the recommended 5% and 10% positivity rates proposed by guideline committees as thresholds at which physicians should either consider (5%) or offer (10%) the procedure to their patients. Further, the SLNB surgery requires the use of general anesthesia, and nearly half of these surgeries are performed in an in-patient setting, leading to an average reimbursed cost of $20,000 to $24,000. Finally, the 88% SLN-negative rate in these surgeries carries significant patient and healthcare system implications because 88% of patients undergoing an SLNB surgery will have no change in their treatment plan or their staging, but are still exposed to the complications from the surgery, including general anesthesia risks, high medical costs and a median false negative rate of 18%. Thus, while it is true that patients who are SLN positive, or re-staged to Stage III, have a higher population-based rate of metastasis and death from melanoma, invasive SLNB surgery does not improve melanoma-specific survival, carries risk of complications, a high false negative rate and significant costs.
In addition to the significant clinical issues involved in only using traditional clinical and pathology factors to evaluate the appropriateness of SLNB surgery, there is a discord between an individual’s “stage” and their actual risk of metastasis or death from melanoma. Based on data from SEER and the American Joint Committee on Cancer (“AJCC”), out of the cutaneous melanoma tumors diagnosed as Stage I, II or III, 80% are classified as Stage I (the lowest risk) and 12% are classified as Stage II (the next lowest risk). However, these data also show that melanomas initially diagnosed as Stage I or II under the traditional staging framework account for 60% of all deaths in patients receiving Stage I, II or III diagnoses. Furthermore, while patients with Stage III melanoma are at a higher population risk of metastasis and death from melanoma than Stage I or II, the five-year melanoma-specific survival rate for Stage II patients is 77%. We believe that the limitations of the current staging system not only result in unnecessary SLNB surgeries for certain low-risk patients, but also lead to overtreatment with adjuvant immune-oncology and targeted therapies for certain patients with Stage III melanoma.
11
In summary, risk-stratification, or the risk of metastasis, determines the treatment plans in newly diagnosed patients, including the recommendation for the SLNB surgery, decisions around the initiation of advanced imaging for active surveillance, frequency and specialty for clinical follow-up, initiation of adjuvant therapy and discussion of clinical trial enrollment opportunities. The top portion of the graphic below summarizes the two decision points that DecisionDx-Melanoma impacts. The lower portion summarizes the limitations of relying on clinical and pathology factors alone to determine risk of metastasis that informs SLNB surgery and subsequent treatment plan decisions.
cstl-20211231_g5.jpg
cstl-20211231_g6.jpgcstl-20211231_g7.jpg
Source: AJCC v7 J Clin Oncol 2009; SEER data release 2017; Morton et al. N Engl J Med 2014; Whiteman et al. J Invest Dermatol 2015; Shaikh et al. J Natl Cancer Inst 2016; Poklepovic and Carvajal. Oncology 2018; Sondak and Zager. Ann Surg Oncol 2010. Moody et al. Euro Jrnl Surg Onc 2017.
Cutaneous Squamous Cell Carcinoma
Cutaneous SCC the second most common form of skin cancer, is an uncontrolled growth of abnormal cells arising from the squamous cells in the epidermis, the skin’s outermost layer. Approximately one million patients are diagnosed with SCC annually in the United States. While worldwide data on SCC diagnoses are inconsistently reported, the incidence outside the United States is estimated to be greater than two million diagnoses annually.
Historically, SCC has been classified as one of the “non-melanoma skin cancers” with a clinical focus on curative primary surgery. However, high risk SCC is now recognized as a significant cause of morbidity and mortality, and due to the rate of increased incidence, more patients are now estimated to die annually from SCC in the United States (approximately 15,000 patients) than from cutaneous melanoma. Similar to melanoma, treatment plan decisions are based solely upon clinical and pathology factors from the initial biopsy to estimate a patient’s risk of recurrence or metastasis. However, unlike melanoma, which uses population-based risk analysis of these factors, the estimates are based upon small patient cohorts, and our research shows that most clinicians rely upon individual clinical and pathologic features rather than a staging “group” for guiding treatment plan decisions. Our DecisionDx-SCC test, which we launched on August 31, 2020, is intended for guiding the
12
treatment of the estimated 20% of SCC patients, or 200,000 annually, who present with one or more high risk features, representing an estimated U.S. TAM of $820 million.
Identifying high risk SCC presents challenges for physicians. Unlike in cutaneous melanoma, where longitudinal databases were developed in an attempt to align population-based risk of metastasis with particular clinical and pathology factors, the same level of organization has not been given to SCC. To date, there has been a lack of reliance on the two primary staging systems in the United States, the AJCC version 8 and the Brigham and Women’s Hospital (“BWH”) system, which are marked by widely divergent classifications for its two risk categories (high and low). Further, the National Comprehensive Cancer Network (“NCCN”) staging method organizes clinical and pathology features into three risk categories (low, high and very high) based on their association with recurrence risk. A 2014 study compared the then-current AJCC version 7 and NCCN systems to assess concordance between the two. The AJCC system classified 82% as low risk while the NCCN system classified 13% as low risk. Because of the level of discordance among the risk assessment staging systems for SCC, and the lack of available databases, these staging systems end up minimally impacting treatment plans, with patients frequently being over- and under-treated, because of hesitancy by physicians to rely on them.
The two principal staging systems for SCC, AJCC (which is limited to head and neck SCC) and BWH, both classify patients according to the tumor (T), node (N) and metastasis (M) staging method and rely upon a combination of clinical or pathology factors to stage or classify risk of metastasis. The NCCN’s staging method identifies the majority of patients who do go on to metastasize, but its system suffers from the lowest positive predictive value (“PPV”) compared to the AJCC and BWH staging methods. Our initial clinical validation study of 321 patients was focused on patients with one or more high-risk features. Within this study cohort, using the risk criteria established within the NCCN guidelines demonstrated a sensitivity of 96% while PPV was 7% and negative predictive value (“NPV”) was 90.5%. The low PPV means that 93 out of 100 SCC instances labeled as high risk by the NCCN criteria did not actually metastasize. The AJCC and BWH guidelines demonstrated a sensitivity of 38.5% and 25%, respectively, PPV of 33% and 35%, respectively and NPV of 88% and 86%, respectively. A physician that relies solely upon NCCN criteria, given the low PPV, may end up developing an adjuvant treatment plan that includes radiation, or chemotherapy or complete lymph surgical dissection, or a combination of these, for a “high-risk” patient that is ultimately appropriate for only one out of fourteen high-risk patients who will metastasize, but not for the remaining thirteen patients who would not have metastasized. The AJCC and BWH staging systems do demonstrate stronger PPV but would still recommend that two out of three patients undergo an adjuvant treatment plan who will not benefit. These accuracy metrics have created significant discordance in the approach to managing patients with high-risk features, from one end of the spectrum advocating surgical intervention for all high-risk patients to another extreme calling for a “watch and wait” approach for all high-risk patients. The end result is an unacceptable clinical discordance in the approach to treatment plans and significant over- and under-treatment for a diagnosis that leads to the most skin cancer deaths in the United States.
DecisionDx-SCC was developed to improve upon the PPV of the current staging systems for SCC. The test has been shown to be an accurate and independent predictor of recurrence risk in a cohort of 420 cutaneous SCC tumors and demonstrated a PPV of greater than 50% in that cohort. We believe that integrating DecisionDx-SCC can drive risk-appropriate treatment management decisions for physicians and patients.
Difficult-to-Diagnose Melanocytic Lesions
Difficult-to-diagnose melanocytic lesions are pigmented lesions are unusual-looking lesions that may be melanoma. There are approximately two million skin biopsies performed annually specifically to rule in or rule out a diagnosis of melanoma in the United States. Approximately 15% of these biopsies are classified as indeterminate, in which case a pathologist cannot make a definitive diagnosis as to whether the biopsy is benign or malignant. A pigmented lesion biopsy that is difficult to diagnose may lead to an indeterminate diagnosis, in which case the treating physician generally leans towards making a conservative decision and assumes that the lesion is melanoma. A definitive diagnosis of invasive cutaneous melanoma results in a treatment plan that involves wider margins for the definitive wide local excision surgery, consideration of the SLNB surgery and post-diagnosis management plans, including frequent, high intensity surveillance using advanced imaging, frequent clinical visits and encouragement to enroll in clinical studies. If the indeterminate lesion was benign, the recommendation in the majority of cases would be no additional intervention. Thus, the tendency of physicians to treat an indeterminate diagnosis as melanoma leads to significant over-treatment decisions, complications and increased healthcare costs.
myPath Melanoma and DecisionDx DiffDx-Melanoma are independent GEP tests that together comprise Castle’s CDO of molecular testing solutions for difficult-to-diagnose melanocytic lesions.
Our CDO has robust diagnostic resolution for melanocytic lesions with unknown malignant potential, with validation studies demonstrating accurate diagnosis of benign and malignant lesions for 97% of cases tested.
We estimate the U.S. TAM at $600 million for our CDO, comprised of myPath Melanoma and DecisionDx DiffDx-Melanoma.
13
Uveal Melanoma Overview
The incidence of uveal melanoma has remained relatively constant over time with approximately 2,000 patients diagnosed annually in the United States, representing an estimated U.S. TAM of $8.0 million. Uveal melanomas arise from the three tissues comprising the uveal tract and vary by location with approximately 90% occurring in the choroid, 5% in the ciliary body and 5% in the iris. Uveal melanoma may also be referred to as ocular melanoma.
Approximately 97% of patients with uveal melanoma have no evidence of metastatic disease at the time of diagnosis and the success rate for definitive treatment of the primary tumor is over 90%. However, within three years, approximately 30% of all patients will experience metastases. Prior to commercial availability of DecisionDx-UM, other clinical staging and molecular diagnostic tests for uveal melanoma had been commercialized, but due to the lack of prospective studies, coupled with their low accuracy, tests were primarily used for research purposes rather than for clinical management of patients in the United States. As a result, nearly all U.S. centers grouped patients into a single, high-risk treatment plan that included frequent, high intensity surveillance using advanced imaging, frequent clinical visits and encouragement to enroll in clinical studies.
DecisionDx-UM is our proprietary GEP test that helps healthcare providers predict the risk of metastasis in patients with uveal melanoma. The test has been shown to have higher prognostic accuracy than chromosomal testing, mutation analysis or clinical features of the tumor, and is recommended by the NCCN for prognosis of uveal melanoma tumors.
Barrett’s Esophagus Overview
There are approximately 4 million patients in the U.S. currently diagnosed with BE and approximately 400,000 endoscopies are performed annually on BE patients—either for initial diagnosis or repeat endoscopy for assessing possible progression of BE (active surveillance). We estimate the U.S. TAM at $1 billion for our TissueCypher Barrett’s Esophagus Assay test, which we acquired through our acquisition of Cernostics on December 3, 2021.
cstl-20211231_g8.jpg

1.384,000 upper GI endoscopies/year with confirmed dx of BE (ND, IND, LGD) x $2,513 = U.S. only TAM of ~$1 billion 
The TissueCypher Barrett’s Esophagus Assay is a protein-based MAAA test that was designed and developed to address these limitations in the current standard of care for risk stratification of patients with BE. TissueCypher guides clinical management of BE by:
1.Identifying patients who are at high risk of developing EAC but are currently missed due to reliance on traditional histopathology and clinical variables. This should enable early therapeutic intervention to prevent EAC, or increase surveillance for early detection of EAC at a treatable stage; and
2.Identifying patients who are at low risk of developing EAC, enabling extension of surveillance intervals and reduction in unnecessary procedures.
14
Our Testing Solutions
We use MAAA to characterize an individual patient’s tissue biology to inform specific prognosis of tumor development, death due to disease, metastasis or recurrence and aid the decision-making process of the treating physician and their patient to help optimize health outcomes and reduce healthcare costs. Due to the biological complexity of diseases, developing accurate products takes scientific diligence, stringent clinical protocols, machine learning expertise, proprietary algorithms and significant investments of time and capital. In addition, the underlying tissue samples and associated clinical outcomes data required to develop and validate these products are difficult to obtain. Once successfully developed and validated, commercial success requires generating ongoing evidence, such as clinical use documentation, to support appropriate physician adoption, reimbursement success and guideline inclusion.
We currently market five proprietary MAAA tests for use in the dermatologic, ocular and gastroenterology fields: DecisionDx-Melanoma, DecisionDx-SCC, our CDO, DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. The accuracy of each product in our portfolio is supported by multiple studies published in peer-reviewed journals since completion of the initial clinical validation studies. Also, multiple clinical impact studies have demonstrated a significant impact on physician decisions to alter their treatment plan when the results of our tests are considered in concert with the traditional clinical and pathology factors. DecisionDx-Melanoma, DecisionDx-UM, TissueCypher and myPath Melanoma are currently reimbursed by Medicare. In addition, we have received widespread positive private payor coverage and positive guideline inclusion for DecisionDx-UM, our first melanoma test, launched in January 2010. Since our inception, we have processed more than 100,000 clinical patient samples across our product portfolio.
cstl-20211231_g9.jpg
Our products are designed to provide the following benefits:
•Clinically Actionable Information for Physicians. Our commercial tests provide physicians and their patients with reports that contain clinically actionable information to inform the treatment plan for each individual patient. Our reports are updated as new clinical data is generated that may enable additional clinical decisions to be made. Studies show that clinicians use our test results to make treatment plan changes. For example, four studies were initially conducted to evaluate the clinical actionability of our DecisionDx-Melanoma test, physicians utilizing the results of our test reports changed a patient’s treatment in approximately 50% of cases, indicating physician confidence in the evidence underlying our reports.
•Informed Patient Care. The clinical evidence shows that our products are accurate predictors of a patient’s specific risk of progression to cancer, or metastasis or recurrence of their cancer based upon the gene expression profile of an ocular or dermatologic tumor or, in the case of our BE test, the spatial assessment of biomarkers, independent of available clinical and pathology factors. Physicians use this information to identify patients who are likely to benefit from an escalation of care as well as those who may avoid unnecessary treatments, such as medical, surgical and radiation interventions.
15
•Reduced Healthcare Costs for Payors. We believe our products have the potential to reduce overall healthcare costs by enabling physicians and their patients to avoid unnecessary medical and surgical interventions. As an example, without DecisionDx-Melanoma, 88% of patients who receive the SLNB surgery, which has an average in-patient reimbursed cost of $20,000 to $24,000, are found to be SLN-negative and remain classified as low risk. If all patients eligible for the SLNB surgery were tested with DecisionDx-Melanoma and their test results were acted upon, we estimate the potential savings to the U.S. healthcare system could be up to $250 million, after considering the cost of DecisionDx-Melanoma.

DecisionDx-Melanoma
cstl-20211231_g10.jpg
Overview
DecisionDx-Melanoma is our proprietary risk stratification GEP test developed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. As of February 28, 2022, we have received orders from more than 9,300 clinicians for an aggregate of more than 90,000 tests. Under the traditional staging methods, melanomas are classified into low or and high-risk categories based on population-wide clinical and pathology features, and risk of recurrence guides a physician’s treatment plan recommendations about whether or not to offer invasive SLNB surgery, frequency and use of clinical imaging and follow-up, and/or adjuvant therapy consideration. Limitations of the current AJCC staging recommendations, and the NCCN recommendations for patient management, are demonstrated by the statistic that nearly 60% of the patients who die each year from melanoma are initially diagnosed with Stage I or II melanoma (the two lowest categories of risk). This reflects a need for better risk-stratification or prognostic markers to identify high-risk patients.
To address this need for a more accurate predictor of metastatic risk, we discovered, developed, validated and continue to support the performance of the DecisionDx-Melanoma test. This product is designed to help physicians identify high-risk tumors from among patients receiving a Stage I, II or III diagnosis based on the expression of 31 genes in the primary tissue. DecisionDx-Melanoma does not change the standard diagnostic workflow followed when performing a biopsy of a suspicious lesion, and utilizes the formalin-fixed, paraffin embedded biopsy or wide local excision tissue used to diagnose melanoma and determine AJCC stage. An additional biopsy is not needed. Test results are reported as GEP main classes (Class 1 (low risk) or Class 2(high risk)) or as subclasses (Class 1A represents the lowest risk group, Class 1B/2A represents an increased risk group and Class 2B represents the highest risk group), based on a continuous score ranging from 0-1.
In March 2021, we announced that DecisionDx-Melanoma utilizes an Integrated Test Result (“ITR”), designed to provide more precise risk prediction for patients with Stage I, II or III melanoma. The ITR is calculated by an independently validated algorithm (“i31-GEP”) that uses the DecisionDx-Melanoma continuous score in combination with clinical and pathology factors to provide a precise and personalized prediction of SLN positivity. In October 2021, we announced the completion of independent validation of a new, separate algorithm that integrates the DecisionDx-Melanoma continuous score to provide a prediction of an individual patient’s risk of metastasis and recurrence (“ROR”). This new i31-GEP algorithm for ROR includes the additional endpoints of recurrence-free survival (“RFS”) and distant metastasis-free survival, which are not currently provided by the American Joint Committee on Cancer Eighth Edition staging system. These endpoints are anticipated to be helpful when determining appropriate treatment pathways for each patient’s disease. Results generated by the i31-GEP algorithm guide discussions and recommendations, within current risk-based guidelines, for the SLNB surgical procedure or for surveillance methodologies. i31-GEP to predict SLN metastasis is an artificial intelligence-based neural network algorithm (independently validated in a cohort of 1,674 prospective, consecutively tested patients with T1-T4 cutaneous melanoma) that integrates the DecisionDx-Melanoma test result with the patient’s traditional clinical and pathology features, such as Breslow thickness, ulceration, mitotic rate and age. i31-GEP for ROR combines the 31-GEP continuous score with tumor thickness, ulceration status, mitotic rate, SLN status, age and tumor location to predict likelihood of recurrence, distant metastasis and melanoma specific death within 5 years of the melanoma diagnosis. The algorithm was developed using 1,581 tumors from patients diagnosed with melanoma and was validated in 523 patients. We expect to launch an app based on i31-GEP and the ITR later in 2022.
16
Clinical Validation
We have published more than 35 peer-reviewed articles demonstrating the analytical validity, clinical validity and clinical utility of DecisionDx-Melanoma, and we believe the clinical validation studies represent the largest clinical validation program of the metastatic risk of cutaneous melanoma ever conducted. Based on our published data, we have shown that DecisionDx-Melanoma is an accurate independent predictor of the risk of metastasis or recurrence.
Our first study, published in January 2015, analyzed 104 patients with Stage I, II and III melanoma from an independent cohort with long-term outcomes data. This study reported a five-year disease-free survival rate of 98% for patients with Stage I and II melanoma who received a DecisionDx-Melanoma Class 1 test result. In addition, the study also reported that only 2% of patients with a Class 1 test result were SLN-positive.
Our January 2019 study published in the Journal of the American Academy of Dermatology reviewed data on 690 patients with Stage I, II and III melanoma from three previously published long-term archival publications, and enabled analysis of clinically important subgroups considered low-risk based on staging criteria. Overall, the study reported a five-year melanoma specific survival rate of 99% for patients with Stage I, II or III melanoma who received a DecisionDx-Melanoma Class 1A test result.
Our long-term outcomes study data shows that DecisionDx-Melanoma can provide a more specific individual risk of metastasis and death from melanoma that is distinct from the AJCC staging approach that limits prediction to clinical and pathology factors. The only endpoint reported by the AJCC staging approach is death from melanoma. Within patients diagnosed with Stage I melanoma, a DecisionDx-Melanoma Class 2B result predominantly identifies a patient with a risk of death that is similar to a patient with Stage IIIA melanoma (see graph below). By comparison, DecisionDx-Melanoma Class 1A results indicate a 99.7% likelihood of survival from melanoma at five years. Within patients diagnosed with Stage II melanoma, DecisionDx-Melanoma can distinguish between patients who have a very low risk of death from melanoma (>97.1% likelihood of survival at 5-years) from those who have a higher risk of death from melanoma that is similar to a patient with Stage IIB melanoma. Within patients diagnosed with Stage III melanoma, DecisionDx-Melanoma can identify patients who have a likelihood of death from melanoma similar to a patient with Stage IIA melanoma, with the remainder having a risk similar to a patient with Stage IIIC melanoma.
The ability of DecisionDx-Melanoma to accurately reclassify the risk of recurrence or risk of death is clinically significant because NCCN guidelines recommend that the duration and frequency of follow-up and intensity of cross-sectional imaging be based on a patient’s individual conditional probability of recurrence. The NCCN guideline cut-point for these decisions is between Stage I-IIA versus Stage IIB-III. For example, the chart below demonstrates that a patient diagnosed with Stage I melanoma but who has received a DecisionDx-Melanoma Class 2B test result has a melanoma specific survival rate of 92.8%, which is similar to the risk for a patient diagnosed with Stage IIIA melanoma. Today, patients diagnosed with Stage III melanoma are recommended to have an increased follow-up schedule, undergo routine cross-sectional imaging, consider initiation of adjuvant therapy, such as an anti-PD1 inhibitor, and consider enrollment in a clinical trial.
cstl-20211231_g11.jpg
The first prospective, multi-center study of 322 patients diagnosed with Stage I, II and III melanoma was published in August 2017. This initial analysis reported a RFS rate of 97% and overall survival rate of 99% for patients with Stage I, II and III
17
melanoma who received a DecisionDx-Melanoma Class 1 test result. Since that time, six prospective studies have been published and each consistently demonstrate the accurate and independent prognostic value provided by DecisionDx-Melanoma for identifying low- and high-risk melanoma tumors.
When evaluating DecisionDx-Melanoma, one of the most important criteria is whether the test adds new information that is independent of the traditional clinical and pathology factors. The formal statistical method used to evaluate independence is the Cox multivariate analysis. Outputs of the Cox multivariate analysis include statistical significance, measured by p-value, as well as the power of the result, measured by Hazard Ratio (“HR”). A p-value of less than 0.05 indicates statistical significance and thus independence. If statistical significance is reached, then the HR indicates the power of the result, with a higher HR indicating greater outcome prediction. For example, an HR of nine means that patients with a high-risk test result are nine times more likely to experience metastasis or death than a low-risk test result. The table below shows the Cox multivariate analysis of the disease-free survival, melanoma-specific survival and recurrence free survival from the four performance studies noted above.
cstl-20211231_g12.jpg
The American Academy of Dermatology and other organizations use the Strength of Recommendation Taxonomy (“SORT”) system to evaluate prognostic tests such as DecisionDx-Melanoma. The SORT system ranks evidence of clinical validity as levels 1, 2 or 3, and assigns a strength of recommendation as levels A, B or C. A SORT level 1A is the highest level and 3C is the lowest. For SORT ranking, “a systematic review or meta-analysis of good quality studies” or “a prospective study with good follow-up” represents a level 1 for good quality evidence of clinical validity. For SORT strength of recommendation, “consistent, good quality evidence” represents a level A recommendation. A systematic review and meta-analysis was published in the Journal of the American Academy of Dermatology in 2020 in an article titled “Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.” This meta-analysis reviewed multiple peer-reviewed published clinical validation studies of DecisionDx-Melanoma, including prospective studies. The meta-analysis and the prospective studies satisfied the level 1 ranking of good quality studies and the consistency of DecisionDx-Melanoma data across these studies satisfied the level A strength of recommendation. Thus, the authors concluded that DecisionDx-Melanoma achieved a 1A level of evidence of clinical validity and strength of recommendation under the SORT system. Furthermore, as shown below, the multi-variate analysis for RFS found DecisionDx-Melanoma to be the strongest predictor of ROR compared to the evaluable clinical and pathology factors.
cstl-20211231_g13.jpg
18
In addition, we conducted a prospective, multi-center study of 1,421 patients, which was published in Future Oncology in January 2019, that focused on the performance of DecisionDx-Melanoma to predict metastasis to the SLN. This study found that patients with a DecisionDx-Melanoma Class 1A test result with melanomas less than or equal to 2.0 mm thick, which represents 86% of all melanomas, have a 95% probability for an SLN-negative biopsy result. Analyzing this data by age shows that patients 65 years of age or older have a 98% NPV, those between 64 and 55 years of age have a 95% NPV and patients under 55 years of age have a 92% NPV. For physicians and patients evaluating whether to use DecisionDx-Melanoma to guide decision-making on the SLNB surgery, the impact on melanoma specific survival is an important consideration if the SLN status is not known. To address this, we analyzed the long-term outcome data from our Gastman 2019 publication and showed that patients of all ages with a melanoma less than or equal to 2.0 mm thick and a DecisionDx-Melanoma Class 1A test result had a five-year melanoma specific survival rate of 99.6%, while similar patients 55 years or older had a melanoma specific survival rate of 99.3%. This study showed that use of DecisionDx-Melanoma for patients with melanomas of less than or equal to 2.0 mm thick could potentially result in 74% fewer SLNB surgeries.
Clinical Utility
We completed and published four consecutive studies between September 2016 and March 2018 documenting how DecisionDx-Melanoma impacts treatment plan decisions. Based on the results of our DecisionDx-Melanoma test reports, physicians changed their treatment plan recommendations approximately 50% of the time. This change in the management of patient treatment plan recommendations compares favorably to leading molecular diagnostic tests as well as to the SLNB surgery, which only changes clinical decision-making approximately 12% of the time.
StudyDesign# of Patients% Change in Management
Berger et al. CMRO 2016Prospectively tested cohort, multi-center. Retrospective pre-test / post-test management.15653%
Dillon et al. SKIN J Cutan Med 2018Prospective, multi-center: pre-test / post-test management.24749%
Farberg et al. J Drugs Derm 2017169 physician impact study: patient vignettes with pre-test / post-test management.n/a47-50%
Schuitevoerder et al. J Drugs Derm 2018Prospectively tested cohort, single center. Retrospective pre-test / post-test management; and modeling of prospective cohort.9152%
Building on our clinical utility evidence, in October 2020, the publication in Future Oncology of a retrospective study, titled “Integrating the melanoma 31-gene expression profile test to surgical oncology practice within national guideline and staging recommendations,” showed that DecisionDx-Melanoma impacted management decisions for patients diagnosed with Stage I – III melanoma under the AJCC framework. Study authors developed a recommended melanoma patient care algorithm that incorporates DecisionDx-Melanoma to help inform frequency and duration of follow-up visits, blood work and surveillance imaging in line with predicted metastatic risk. The patients’ DecisionDx-Melanoma test result was found to have an impact on the number and duration of follow-up and surveillance visits, and patients assessed as having a high risk of metastasis (designated by a DecisionDx-Melanoma Class 2 test result) received more intensive management than patients assessed as having a low risk (designated by a DecisionDx-Melanoma Class 1 test result). Clinicians using the test were shown to adjust patient management in a risk-appropriate direction, within recommendations of national guidelines.
These studies illustrate how physicians use DecisionDx-Melanoma to inform the treatment pathway for patients who have been diagnosed with invasive cutaneous melanoma. Our DecisionDx-Melanoma test informs two initial treatment decisions: (1) to determine whether to offer and recommend the SLNB surgery to patients with melanomas less than or equal to 2.0 mm thick, and (2) following this decision, to guide the appropriate post-SLNB surgery treatment plan for their patients, including decision-making regarding advanced imaging, frequency of clinical visits, referral to medical oncology, adjuvant therapy, clinical trial enrollment, and watchful waiting.
Health Economics
We believe our products have the potential to reduce overall healthcare costs by enabling physicians and their patients to avoid unnecessary medical and surgical interventions. As an example, without DecisionDx-Melanoma, 88% of patients who receive the SLNB surgery, which has an average in-patient reimbursed cost of $20,000 to $24,000, are found to be SLN-negative and remain classified as low risk under the AJCC framework. If all patients eligible for the SLNB surgery were tested using DecisionDx-Melanoma and their test results were acted upon, we estimate the potential savings to the U.S. healthcare system could be up to $250 million, after considering the cost of DecisionDx-Melanoma.
In addition, DecisionDx-Melanoma can be used to make more informed decisions on advanced imaging, frequency of clinical visits, referral to medical oncology, adjuvant therapy initiation and clinical trial enrollment. In some cases, a DecisionDx-Melanoma test result may guide an appropriate reduction in these decisions based upon a low risk of metastasis, while in others
19
it will guide an appropriate increase in medical or surgical intervention with the end result being improved use of healthcare resources.
The American Medical Association’s (“the AMA’s”) Current Procedural Terminology Editorial Panel accepted Castle’s application for a Category I MAAA, Current Procedural Terminology (“CPT”) code for its DecisionDx-Melanoma test. The CPT Editorial Panel is an independent group of expert volunteers representing various sectors of the healthcare industry. Its role is to ensure that code changes undergo evidence-based review and meet specific criteria. The code became effective on January 1, 2021. With this acceptance, two of our proprietary MAAA tests, DecisionDx-Melanoma and DecisionDx-UM, have met the criteria required for a Category I MAAA CPT code.
DecisionDx-SCC
cstl-20211231_g14.jpg
The current treatment pathway (staging systems that rely on combination of clinical or pathology factors to stage or classify risk of metastasis) for patients identified as having high-risk cutaneous SCC suffers from a low PPV for risk of metastasis or recurrence. As a result, many patients categorized as high risk received adjuvant therapy and other unnecessary medical and surgical interventions even though they would not have gone on to metastasize. Conversely, the low predictive accuracy of current methods to identify high-risk patients can lead to undertreatment if patients with a truly high biologic risk are missed. Because these patients cannot currently be identified, they will miss the opportunity to receive the most aggressive of today’s therapeutic options.
To address this clinical need in SCC, we developed DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of SCC metastasis for patients with one or more risk factors. The test result, in which patients are stratified into a Class 1, 2A or 2B risk category, predicts individual metastatic risk to inform risk-appropriate management. The test is designed to provide a better PPV while maintaining similar NPV. We commercially launched DecisionDx-SCC on August 31, 2020. Nine peer-reviewed publications have demonstrated that DecisionDx-SCC is an independent predictor of metastatic risk and/or that integrating DecisionDx-SCC with current prognostic methods can add positive predictive value to clinician decisions regarding staging and management.
In 2020, development and validation data on DecisionDx-SCC was published in the Journal of the American Academy of Dermatology in an article titled “Validation of a 40-Gene Expression Profile Test to Predict Metastatic Risk in Localized High-Risk Cutaneous Squamous Cell Carcinoma.” The study findings indicate that DecisionDx-SCC demonstrated strong independent prognostic value in multivariate analysis compared to the traditional BWH and AJCC staging systems. More recently, further validation results of a cohort of 420 patients with high-risk SCC from 33 U.S. centers were published in Future Oncology. The study titled, “Enhanced Metastatic Risk Assessment in Cutaneous Squamous Cell Carcinoma With the 40-Gene Expression Profile Test,” upheld previous results demonstrating that DecisionDx-SCC demonstrated significant prognostic value, and that cases with a Class 1 result had metastasis rates near the general SCC population while Class 2B patients had rates greater than 50%. Additionally, a study focused on tumors of the head and neck region also showed strong stratification of risk by DecisionDx-SCC in that cohort, and independent value added to risk prognosis by the test in multivariable models that include other risk factors. We have ongoing multi-center studies involving more than 75 U.S. centers.
Comprehensive Diagnostic Offering
cstl-20211231_g15.jpg
cstl-20211231_g16.jpg
Of the two million suspicious pigmented lesions biopsied annually in the U.S., we estimate that approximately 300,000 of those cannot confidently be classified as either benign or malignant through traditional histopathology methods. A biopsy of a pigmented lesion may lead to an indeterminate diagnosis, in which case the treating physician generally leans towards making a conservative decision and assumes that the lesion is melanoma.
20
To address this clinical need, we developed DecisionDx DiffDx-Melanoma, a proprietary 35-GEP test designed to be used as an ancillary tool to histopathology when the distinction between a benign lesion and melanoma is uncertain. We commercially launched this product on November 2, 2020. DiffDx-Melanoma classifies these lesions as benign (gene expression profile suggestive of benign neoplasm); intermediate-risk (gene express profile cannot exclude malignancy); or malignant (gene expression profile suggestive of melanoma). Interpreted in the context of other clinical, laboratory and histopathologic information, DiffDx-Melanoma is designed to add diagnostic clarity and confidence for dermatopathologists while helping dermatologists deliver more informed patient management plans. Validation of this test included a variety of benign and malignant lesions. DecisionDx DiffDx-Melanoma, in tandem with myPath Melanoma, enables us to provide our CDO of molecular testing solutions for difficult-to-diagnose melanocytic lesions.
In 2020, two studies were published in SKIN: The Journal of Cutaneous Medicine. The development and validation study, “Development and Validation of a Diagnostic 35-Gene Expression Profile Test for Ambiguous or Difficult-To-Diagnose Suspicious Pigmented Skin Lesions,” showed that our DecisionDx DiffDx-Melanoma test had a technical success rate of 97%, meaning that a test result was successfully generated, and achieved accuracy metrics that could alleviate uncertainty in difficult-to-diagnose lesions leading to decreased unnecessary procedures while appropriately identifying at-risk patients. The clinical utility study, “A 35-Gene Expression Profile Test for Use in Suspicious Pigmented Lesions Impacts Clinical Management Decisions of Dermatopathologists and Dermatologists,” concluded that the diagnosis of challenging melanocytic neoplasms and subsequent clinical management decisions were influenced by DecisionDx DiffDx-Melanoma results in alignment with the test result. The utility of the test may provide the opportunity for clinicians to deliver more informed patient management plans.
Similar to DecisionDx DiffDx-Melanoma, myPath Melanoma is a proprietary GEP test that we acquired from Myriad Genetics, Inc. in May 2021, following rigorous validation in cutaneous melanocytic lesions to accurately differentiate between benign and malignant melanocytic lesions of unknown potential. myPath Melanoma has over 35,000 clinically resulted cases and 9 publications supporting the accurate diagnosis of benign or malignant lesions by the test. The test evaluates the expression of 23 genes using standard quantitative qRT-PCR and provides an accurate and objective classification suggestive of benign, intermediate, or malignant lesions.
We currently offer both myPath Melanoma and DecisionDx DiffDx-Melanoma in an integrated workflow to enhance both accuracy and technical reliability of diagnostic testing. This comprehensive diagnostic workflow leverages the strengths of both diagnostic GEP tests to provide improved diagnostic clarity. This offering is supported by 12 peer-reviewed publications.
DecisionDx-UM
cstl-20211231_g17.jpg
Overview
At the time of diagnosis nearly all patients with uveal melanoma have no evidence of metastasis yet, approximately 30% of uveal melanoma patients will metastasize within five years and nearly 50% of uveal melanoma patients will metastasize at some point. Traditional clinical staging and molecular diagnostic tests for uveal melanoma have been commercialized, but until recent years the lack of prospective studies of these tests, coupled with low accuracy, resulted in these tests primarily being used for research purposes rather than for clinical management of patients in the U.S. As a result, before commercial availability of DecisionDx-UM, nearly all U.S. centers grouped patients into a single, high-risk treatment plan that included frequent, high intensity surveillance using advanced imaging, frequent clinical visits and encouragement to enroll in clinical studies.
DecisionDx-UM is our proprietary GEP test that helps healthcare providers predict the risk of metastasis in patients with uveal melanoma. We licensed the intellectual property for DecisionDx-UM from The Washington University in St. Louis, Missouri (“WUSTL”). and completed analytical validation and began marketing DecisionDx-UM in late 2009 for use in patients diagnosed with uveal melanoma without evidence of metastatic disease. DecisionDx-UM identifies patients at low risk for progression of their uveal melanoma so that their physicians can appropriately de-escalate the level of care provided. DecisionDx-UM is delivered to approximately 1,600 patients annually, representing approximately 80% of the patients diagnosed in the United States.
Twenty-one peer-reviewed publications involving more than 3,000 patients support the clinical validity and utility of DecisionDx-UM.
The Kaplan-Meier plot from the initial prospective, multi-center Collaborative Ocular Oncology Group (“COOG”) study found that a DecisionDx-UM Class 2 result was more strongly associated with metastasis than any other clinical, pathological or molecular factor, and the negative predictive value for patients with a DecisionDx-UM Class 1 result was 99%. This study also
21
compared DecisionDx-UM to the traditional staging based on clinical and pathology factors, and chromosome 3 status (an alternative molecular test to predict the risk of metastasis in uveal melanoma), using Cox multivariate analysis, and found that the only statistically significant factor in predicting a likelihood of metastasis was DecisionDx-UM.
cstl-20211231_g18.jpg
The data from the COOG study, as well as the consistency shown from the additional clinical validity studies, has supported widespread adoption of DecisionDx-UM with more than 90% of the ocular oncology institutions in the United States ordering this test. DecisionDx-UM has been used to guide treatment plan decisions regarding the intensity of a patient’s surveillance and management plan as well as clinical trial enrollment. The current NCCN Guidelines for Uveal Melanoma (last updated June 2021) incorporate DecisionDx-UM as the first risk of distant metastasis predictor and recommend that class result be used to guide frequency and intensity of systemic imaging.
TissueCypher
cstl-20211231_g19.jpg
Esophageal cancer is one of the fastest-growing cancers (by incidence) in the world. The incidence of this once rare cancer has increased by more than 500% since the 1970s. Esophageal cancer remains highly lethal, with a five-year survival rate of 19%.
Chronic reflux in the esophagus causes changes to the molecular and cellular features of the esophagus, which often results in a condition called BE. BE is a serious complication of GERD and a risk factor for the development of esophageal cancer.
There are approximately 4 million patients in the U.S. diagnosed with BE, and annually, approximately 400,000 endoscopies are performed on BE patients. The TissueCypher Barrett’s Esophagus Assay, which is supported by eight peer reviewed publications, addresses an unmet need in BE, as it is designed to objectively and accurately predict progression from non-dysplastic, indefinite for dysplasia and low-grade dysplasia BE to high-grade dysplasia or esophageal adenocarcinoma (“EAC”). This is critical, as EAC is highly lethal, and endoscopic eradication therapy in patients with BE has been proven to reduce progression to EAC. As of February 28, 2022, two abstracts for GI conferences (podium presentations at European Society of Gastrointestinal Endoscopy Days 2022 and Digestive Disease Week 2022) and one peer-reviewed publication have been accepted.
BE is the only known precursor to EAC, which is highly lethal and has a five-year survival rate of 19%, according to Cancer Facts and Figures, ACS 2020. Treatment options, particularly for advanced EAC, are limited, and early detection is critical for optimal patient management. As a result, an estimated 4 million patients with BE in the U.S. are in active surveillance programs, which involve periodic endoscopic surveillance of the esophagus with the goal of detecting malignant progression at a treatable stage. During the endoscopy, biopsies are obtained from the affected tissue, and BE is graded based upon pathology features (histologic assessment) of these biopsies into High-Grade Dysplasia (“HGD”), Low-Grade Dysplasia (“LGD”), Indefinite Dysplasia (“IND”) and Non-Dysplastic (“ND”). Generally, patients with HGD undergo esophageal eradication therapy, which may include ablation or surgical removal of the BE lesions. Patients with LGD generally undergo either endoscopic surveillance every three to six months or endoscopic eradication therapy, while patients with IND or ND generally undergo endoscopic surveillance every three months to five years. While treatment decisions, including surveillance timing, are
22
directed by pathology grading, this approach is limited by significant inter-observer variation (pathology discordance) in the grading of tissue biopsies. This discordance is found between community pathologists, as well as pathologists who specialize in BE in large academic centers. Furthermore, molecular and cellular changes associated with progression to cancer often precede the morphologic changes that pathologists can evaluate using histology.
Additionally, while patients with ND, IND and LGD do have a lower rate of progression to EAC than HGD, due to the higher incidence of ND, IND and LGD, these patients represent approximately 63% of patients who may progress to EAC. Since endoscopic eradication therapy is performed with the expectation that it will reduce or stop progression to EAC, the fact that the majority of patients who progress are not graded as having HGD represents a significant unmet clinical need. In addition, the recommendations for the frequency of endoscopic surveillance are based upon low to moderate quality evidence. Together, these limitations in the current standard of care for risk assessment of patients with BE leads to overuse of endoscopies and imprecise use of endoscopic eradication therapy procedures, adding unnecessary costs that fail to reduce the incidence and mortality associated with EAC.
The TissueCypher Barrett’s Esophagus Assay is a protein-based MAAA test that was designed and developed to address these limitations in the current standard of care for risk stratification of patients with BE. TissueCypher guides clinical management of BE by:
1.Identifying patients who are at high risk of developing EAC but are currently missed due to reliance on traditional histopathology and clinical variables. This should enable early therapeutic intervention to prevent EAC, or increase surveillance for early detection of EAC at a treatable stage; and
2.Identifying patients who are at low risk of developing EAC, enabling extension of surveillance intervals and reduction in unnecessary procedures.
The TissueCypher Barrett’s Esophagus Assay is a laboratory developed test (“LDT”) provided as a testing service to healthcare providers across the United States, and provides automated, objective risk stratification for patients with ND, IND and LGD BE. It is the only commercially available test providing prognostic risk assessment from esophageal pinch biopsies.
Our Commercial Channel
Sales and Marketing
Our sales and marketing efforts are primarily focused on the United States skin cancer and gastroenterology markets. We employ a direct sales and marketing strategy to educate clinicians on the clinical and economic benefits of our products. Our sales approach is highly technical, and our team is trained to articulate the scientific and clinical evidence behind our products and how they influence the clinical care pathway and ultimately improve patient outcomes. Our sales force is focused on educating and informing the entire patient care team, which consists of treating clinicians, nurses, laboratory and pathology personnel, and finance administrators, on the appropriate use and value of our tests.
The principal focus of our current commercial efforts is to educate clinicians and pathologists on the value of our molecular diagnostic testing products through our direct sales force in the U.S. In dermatology, we began 2020 with 32 outside sales territories. In the third quarter of 2020, we expanded our dermatologic commercial team to create a dedicated sales force of ten territories to support the launch of our DecisionDx Diff-Dx Melanoma test to dermatopathologists. During the first half of 2021, we folded this dedicated team into our existing sales team and completed a further expansion, bringing our dermatologic sales force to the mid-60s. In connection with our acquisition of Cernostics in December 2021, we hired an initial commercial team of approximately 14 outside sales territories, along with commensurate internal sales associates and medical science liaisons, to support our launch of the TissueCypher Barrett’s Esophagus Assay. This dedicated team focuses on gastroenterology specialists that diagnose and manage patients with BE. However, we will continue to evaluate our mix of outside sales territories, inside sales support, marketing and medical affairs in the context of our dermatologic tests and gastroenterology tests and adjust our investments based upon these evaluations.
In 2021, we entered into an agreement with Modernizing Medicine (“ModMed”) that established an interface with ModMed’s electronic health records system, EMA®. The interface is designed to enable dermatologic clinicians to order our DecisionDx skin cancer tests from directly within a patient’s medical record in EMA. Our full suite of dermatologic tests is now available to order within EMA.
DecisionDx-UM addresses a small cancer market, and patients are managed by a small group of ocular oncology surgeons, generally ophthalmology or retina trained specialists. We serve these patients and their physicians by providing highly technical interactions that focus on optimizing the appropriate use of our proprietary and ancillary products.
23
Medical Affairs
We also deploy an experienced medical affairs group to assist education of treating physicians and key opinion leaders, to identify and engage sites for our sponsored clinical studies and to evaluate collaborative study opportunities. Our medical affairs strategy complements our sales, marketing and clinical research operations efforts.
Reimbursement
The primary source of revenue for our products is reimbursement from third-party payors, which includes government payors, such as Medicare and the U.S. General Services Administration (“GSA”), and commercial payors, such as insurance companies. Achieving broad coverage and reimbursement of our current products by third-party payors and continued Medicare coverage are key components of our financial success. De novo coverage by government and third-party payors for our pipeline tests will be important over time.
Government Payors
Medicare coverage is limited to items and services that are within the scope of a Medicare benefit category and that are reasonable and necessary for the diagnosis or treatment of an illness or injury. Local coverage determinations (“LCDs”) are made through an evidence-based process by Medicare Administrative Contractors (“MACs”) with opportunities for public participation.
Palmetto GBA MolDX (“Palmetto”) the MAC responsible for administering MolDX, the program that assesses molecular diagnostic technologies, issued a final LCD for DecisionDx-Melanoma, which became effective on December 3, 2018. Noridian Healthcare Solutions, LLC (“Noridian”), the MAC responsible for administering claims for laboratory services performed in Arizona, adopted the same coverage policy as Palmetto on that date, and subsequently issued a final LCD on February 10, 2019. This LCD provided for coverage for patients who are eligible for the SLNB surgery with cutaneous melanoma tumors of 2.0 mm in thickness or less, and patients with clinically negative SLN basins who are being considered for the SLNB surgery to determine eligibility for adjuvant therapy. Melanomas less than or equal to 2.0 mm thick represent 86% of all melanomas. The median age at diagnosis is 63 years old, therefore the Medicare eligible population represents close to 50% of the addressable market.
Palmetto issued a final expanded LCD for DecisionDx-Melanoma, effective November 22, 2020. With this expanded LCD and the accompanying billing and coding articles, in 2021 approximately 96% of the DecisionDx-Melanoma tests performed for Medicare patients have met the coverage criteria. Noridian has adopted the same coverage policy as Palmetto and also issued an expanded final LCD for DecisionDx-Melanoma, effective December 6, 2020.
Separately, Palmetto issued a final LCD for DecisionDx-UM, which became effective in July 2017, and Noridian issued a similar LCD that became effective in September 2017. The Noridian LCD provides for coverage to determine metastatic risk in connection with the management of a patient’s newly diagnosed uveal melanoma and to guide surveillance and referral to medical oncology for those patients. Similar to cutaneous melanoma, the median age at diagnosis for uveal melanoma is estimated at 58-62 years old, therefore the Medicare eligible population represents close to 45% of the addressable market.
On May 17, 2019, CMS determined that DecisionDx-UM meets the criteria for “existing advanced diagnostic laboratory test” status, also referred to as “existing ADLT” status. For 2020, our rate was set by Noridian, our local MAC, but effective in 2021 our rate is set annually based upon the median private payor rate for the first half of the second preceding calendar year. Our rate for 2021 was $7,776 and will remain at $7,776 for 2022, in each case based on the calculation of the median private payor rate.
Also, on May 17, 2019, CMS determined that DecisionDx-Melanoma meets the criteria for “new ADLT” status. Accordingly, from July 1, 2019 through March 31, 2020, the Medicare reimbursement rate was equal to the initial list price of $7,193. From April 1, 2020 through December 31, 2021, the rate was also $7,193, which was calculated based upon the median private payor rate for DecisionDx-Melanoma from July 1, 2019 to November 30, 2019. CMS has informed us that the rate for 2022 will continue to be $7,193, based on the median private payor rate.
myPath Melanoma is currently covered under a MolDX LCD policy through Noridian that oversees laboratories in both Utah and Arizona. Noridian issued an LCD that became effective in June 2019. On September 6, 2019, myPath Melanoma was approved as a new ADLT. The rate for 2022 will be $1,950.
TissueCypher is performed in our Pittsburgh, Pennsylvania laboratory and falls under the Medicare jurisdiction that is managed by Novitas Solutions (“Novitas”). Novitas previously reviewed TissueCypher and we are receiving payments for claims according to the Clinical Lab Fee Schedule (“CLFS”). For 2022, CMS published in its CLFS a payment amount of $2,513 for the test.
24
Beginning in 2023, the rates for the DecisionDx-Melanoma, DecisionDx-UM, and myPath Melanoma tests will be set annually based upon the median private payor rate for the first half of the second preceding calendar year. For example, the rate for 2023 will be set using median private payor rate data from January 1, 2021 to June 30, 2021.
In the second quarter of 2020, we submitted our technical assessment dossier for DecisionDx-SCC to Palmetto and Noridian. The dossier was accepted as complete in the third quarter of 2020. In early 2021, we submitted our technical assessment dossier for DecisionDx DiffDx-Melanoma. The dossier was accepted as complete in the first quarter of 2021. We expect that draft LCDs for DecisionDx-SCC and DecisionDx DiffDx-Melanoma could potentially be posted by the end of the second quarter of 2022 resulting in potentially final LCDs effective in 2023. However, there is no assurance that the timing of any draft or final LCD will match our expectations or our historical experience with LCDs for our other tests.
In the second quarter of 2021, Palmetto and the other MACs that participate in the MolDX program posted a revised draft LCD for DecisionDx-Melanoma. The draft LCD includes commentary about two publications regarding the clinical utility of GEP tests and was posted to give providers an opportunity to comment. Each of the draft LCDs include an assessment stating that the MAC does not believe that the new data is sufficient to change the coverage criteria. We have submitted comments on the draft LCD. The comment period on the last of these draft LCDs closed on August 8, 2021. We are unable to predict when the final draft LCD will be posted.
The U.S. Federal Supply Schedule, also known as the GSA Schedule and the Multiple Award Schedule, is a long-term government-wide contract with commercial companies. In August 2021, we were awarded a five-year GSA contract from the Veterans Health Administration for our DecisionDx-Melanoma GEP test.
Commercial Third-Party Payors
We are actively engaged in efforts to achieve broad coverage and reimbursement for our products, followed by contracting with commercial payors. Achieving positive coverage reduces the need for appeals and reduces failures to collect from the patient’s commercial payor. Even with positive coverage decisions, we still experience delays in time to payment. Achieving in-network contracts with third-party payors can shorten the time required to receive payments. Implementing our strategy includes our managed care and medical affairs teams educating third-party payors regarding our strong clinical utility and outcomes data, which we believe validates the value of our products and will persuade more third-party payors to provide value-based reimbursement.
We have broad positive policy coverage for our DecisionDx-UM test, have executed contracts with certain commercial payors and anticipate further increases in contracting. We also have positive policy recommendations from many third-party technical assessment review groups. In 2021, we received payment on approximately 93% of all claims for this test.
We began engaging commercial third-party payors for positive coverage for DecisionDx-Melanoma and have seen some positive coverage policies. With the continued evidence development, we anticipate additional positive coverage policies occurring.
Dependence on Third-Party Payors
We receive a substantial portion of our revenue from a small number of third-party payors, primarily Medicare, BlueCross BlueShield affiliates and Medicare Advantage plans. Our revenue from patients covered by Medicare, Medicare Advantage plans, and BlueCross BlueShield plans, as a percentage of total revenue, was 57%, 28% and 7%, respectively, for the year ended December 31, 2021. BlueCross BlueShield plans and Medicare Advantage plans represent an aggregation of multiple payors making independent reimbursement decisions; however, these plans often base reimbursement decisions on common guidelines which can influence multiple plans simultaneously.
Competition
We are focused on improving health through innovative tests that guide patient care. We believe, today, that there is limited existing competition for our products that provide evidence-based genomic and proteomic solutions to physicians and their patients.
We believe the principal competitive factors in our target markets include:
•Proprietary, disciplined approach to genomic and proteomic analysis including the use of proprietary deep learning, machine learning, artificial intelligence and other techniques to identify and optimize biomarker selection and algorithmic approaches to answer the clinically important questions with accurate tests. This involves the ability to design and efficiently conduct the right clinical studies at the right time;
25
•Research and development investments to document the quality, quantity, consistency and strength of the clinical validity data, the impact our products have on clinical use, and demonstration of net health outcome improvement that reduce health system costs;
•Maintaining a strong reputation with the treating physician by providing consistent, transparent, and clinically relevant information that will improve the appropriate management of their patients;
•Ease of use in accessing our products, reimbursement support for our patients and laboratory reports that clearly communicate the clinically relevant data points;
•Demonstrated ability to work with, and secure coverage and reimbursement from, governmental and commercial payors;
•Ability to efficiently commercialize pipeline products to the same customer base as our current products.
We believe we compete favorably on the factors described above.
Today, our principal competition for DecisionDx-Melanoma is existing traditional clinical and pathology staging criteria. While some clinical and pathology criteria have changed over time, this approach has been the standard of care in the United States for many years, and physicians may be unwilling to accept the validity of the published data and adopt our test until it has become incorporated into national guidelines. In addition, we may, in the near future, face competition from a limited number of companies who are working in this disease space, such as SkylineDx and Neracare.
We are unaware of late-stage work being performed to develop and validate a product that would compete with DecisionDx-SCC. We believe that the current primary competitor for DecisionDx-SCC is existing traditional clinical and pathology staging criteria.
DecisionDx-UM competes with a subsidiary of LabCorp and several academic laboratories all of which have had tests available for several years. To date, our data has demonstrated that DecisionDx-UM is clinically and statistically superior to these products.
Today, principal competition for the TissueCypher Barrett’s Esophagus Assay is existing traditional clinical and pathology assessment. In the future this assessment may include the use of immunohistochemical evaluation of individual protein biomarkers as an aid to pathology. While some clinical and pathology criteria have changed over time, this approach has been the standard of care in the United States for many years, and physicians may be unwilling to accept the validity of the published data and adopt our test until this has become incorporated into clinical guideline recommendations from gastrointestinal clinical societies, or other national guidelines. In addition, we may in the near future, face competition from a limited number of companies who are working in this disease space, such as Interpace Diagnostics. Other companies actively engaged in GERD screening to diagnose BE may also look to develop prognostic assays for patients diagnosed with BE, and these could compete with TissueCypher in the future.
Laboratory Operations
Our LDTs, consisting of DecisionDx-Melanoma, DecisionDx-SCC, our CDO and DecisionDx-UM, are currently performed in our College of American Pathologists (“CAP”) accredited, Clinical Laboratory Improvement Amendments of 1988 (“CLIA”)-certified laboratory in Phoenix, Arizona, which went operational in April 2016. As of 2021, we have an approximately 29,700 square feet of facility space supporting our growth and providing certain operational redundancy. We currently perform all laboratory procedures involved in our tests from receiving a requisition form to issuance of the final test result in these facilities. We performed more than 28,000 proprietary GEP tests in 2021. We provide our proprietary DecisionDx-Melanoma, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma and DecisionDx-UM products for patients in all fifty states including those that require specific, additional, out-of-state lab licenses or qualifications such as New York, California, Pennsylvania, Maryland, and Rhode Island. Upon receipt, orders and samples are processed through an automated laboratory information management system which, in addition to tracking sample chain of custody, initiates and tracks accessioning, sample eligibility, technical data generation, algorithmic analysis and results reporting. Most of samples are received as paraffin embedded sections from a formalin fixed tissue specimen.
We have a laboratory and associated facilities totaling approximately 8,100 square feet of space in Pittsburgh, Pennsylvania, for the purpose of producing TissueCypher, an LDT with utility in the BE disease space. While this lab is CLIA-certified and positioned to operate in all states except New York, we are working to achieve anticipated CAP accreditation and New York Permitted Lab status in 2022. Our expanded laboratory footprint should also enable us to use this facility to process our dermatology tests, as or if needed.
26
Our laboratory facilities house all functions related to quality control and assurance, licensing, accreditation and regulatory compliance. Our quality management program ensures the quality of our laboratory services and products through continuous monitoring of a broad range of key performance indicators including technical, customer service and cybersecurity metrics. Through this program, we promote a philosophy of continuous improvement based upon adherence to validated standards. Our Phoenix facilities houses our clinical research operations and local information technology support, with a similar focus of operation in our Pittsburgh facility.
Raw Materials and Suppliers
We procure certain reagents, equipment, chips/cards and other materials used to perform our tests from sole suppliers such as ThermoFisher Scientific, Inc. and Qiagen, Inc. Some of these items are unique to these suppliers and vendors. While we have developed alternate sourcing strategies for these materials and vendors, and while we have experienced no business interruption due to an inability to source these materials, we cannot be certain whether these strategies will be effective or whether alternative sources will be available when we need them. If these suppliers can no longer provide us with the materials we need to perform our test services, they do not meet our quality specifications, or we cannot obtain acceptable substitute materials, our business would be negatively affected.
License Agreement with The Washington University
In November 2009, we entered into a license agreement (“the License Agreement”) with WUSTL to license certain patent rights and technical information from WUSTL for the development of melanoma products (the “Products”), and services (the “Services”). The rights licensed under this agreement are used in DecisionDx-UM only.
Under the License Agreement, we obtain an exclusive, worldwide, royalty-bearing license to certain patent rights owned by WUSTL (“the Patent Rights”) and a non-exclusive, worldwide license to certain technical information and research property owned by WUSTL, with the right to grant sublicenses under certain conditions, in order to develop the Products and Services. WUSTL retains the right to use the Patent Rights for research purposes.
The Patent Rights that we license pursuant to the License Agreement have been generated through the use of U.S. government funding and are therefore subject to certain federal regulations. See “Risk Factors—Risks Related to Intellectual Property—Our in-licensed intellectual property has been discovered through government funded programs and thus may be subject to federal regulations such as “march-in” rights, certain reporting requirements and a preference for U.S.-based companies, and compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.”
Under the License Agreement, we are required to use best efforts to carry out the activities under an agreed-upon development plan (“the Development Plan”) and meet any and all milestones set forth in the Development Plan. We are required to make milestone payments to WUSTL upon successful completion of development and commercialization milestones as set forth in the Development Plan. For each Product or Service that receives FDA approval, premarket approval or premarket notification, we are obligated to make a milestone payment to WUSTL in the mid-four digits. For the issuance of the first U.S. patent and the first foreign patent, we are obligated to make aggregate milestone payments to WUSTL in the low-five digits.
Under the License Agreement, we were obligated to pay WUSTL an initial license issue fee in the low-five digits. We are also obligated to make royalty payments to WUSTL equal to (i) a percentage in the mid-single digits of our and any of our affiliates’ or sub-licensees’ net sales of Products and (ii) a percentage in the low-single digits of our and any of our affiliates’ or sub-licensees’ revenue from Services. We are also obligated to make royalty payments to WUSTL in the low-to-mid single digit percentage of net sales, with minimum royalty payments to WUSTL every six-month period following the first commercial sale.
The term of the License Agreement will continue for ten years following the last-to-expire valid claim relating to the Patent Rights, unless terminated earlier. WUSTL may terminate the License Agreement upon written notice in the event of (i) our material breach if such breach remains uncured for 90 days, (ii) the exercise of certain rights by us with respect to the Patent Rights and/or the licensed technical information outside the scope of the License Agreement, or (iii) for certain insolvency-related events. We may terminate the License Agreement without cause upon written notice to WUSTL and payment of any amount due to WUSTL under the License Agreement.
Intellectual Property
Our core technology for our products is related to methods and devices for analysis of genetic expression. Using this technology, we are able to provide a more accurate prediction of a patient’s metastatic risk as compared to other methods. We have secured and continue to pursue intellectual property rights globally, including through patent protection covering analysis of metastasis in cutaneous melanoma, as well as treatment of cutaneous SCC. We also rely on trademarks, trade secrets, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position. For more information, please see “Risk Factors—Risks Related to Intellectual Property.”
27
Patents and Patent Applications
We have developed a global patent portfolio that as of December 31, 2021, is comprised as follows:
Number of Applications and Patents
Commercial FocusUnited StatesInternationalTotal
Owned Patent Families
Methods for predicting risk of metastasis in cutaneous melanoma2 15 17 
Methods of diagnosing and treating patients with pigmented skin lesions1 1 2 
Methods of diagnosing and treating patients with cutaneous squamous cell carcinoma2 10 12 
Determining Prognosis and Treatment based on Clinical-Pathologic Factors and Continuous Multigene-Expression Profile Scores1 — 1 
Genes and gene signatures for diagnosis and treatment of melanoma5 29 34 
Method for automated tissue analysis 2 3 5 
Systems and compositions for diagnosing BE and methods of using same3 13 16 
Methods of predicting progression of BE2 16 18 
Licensed Portfolio from WUSTL
Method for predicting risk of metastasis2 — 2 
Compositions and methods for detecting cancer metastasis2 2 4 
Total22 89 111 

Included in the table above are 12 issued U.S. patents and 60 issued international patents. This global patent portfolio has filing dates ranging from 2009 to 2021, and therefore are projected to expire between 2029 and 2041, subject to any patent term extension or patent term adjustment that might be available in a particular jurisdiction. The owned and licensed families contain issued patents and pending applications that relate to devices, systems, and methods for macromolecular analysis, and reflect our active and ongoing research programs.
Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are granted a term of 20 years from the earliest effective non-provisional filing date. In addition, in certain instances, a patent term can be extended to recapture a period due to delay by the United States Patent and Trademark Office (“USPTO”) in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following FDA approval. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective non-provisional filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.
Trademarks and Trade Secrets
As of the date of this Annual Report on Form 10-K, our U.S. trademark portfolio contained 13 trademark registrations.
We rely upon trade secrets, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our competitive position. We seek to protect our intellectual property and proprietary technology, in part, by entering into confidentiality agreements and intellectual property assignment agreements with our employees, consultants, corporate partners and, as applicable, our advisors. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with an employee or a third party. These agreements may be breached, and we may not have adequate remedies for any breach. We additionally seek to preserve the integrity and confidentiality of our data and trade secrets, such as our proprietary algorithms, by maintaining the physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners,
28
collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.
Government Regulation and Product Approval
Regulations
Clinical Laboratory Improvement Amendments of 1988 (“CLIA”)
As a clinical reference laboratory, we are required to hold certain federal, state and local licenses, certifications and permits to conduct our business. Under CLIA, we are required to hold a certificate applicable to the type of laboratory tests we perform and to comply with standards applicable to our operations, including test processes, personnel, facilities administration, equipment maintenance, recordkeeping, quality systems and proficiency testing. We must maintain CLIA compliance and certification to be eligible to bill for diagnostic services provided to Medicare beneficiaries.
To renew our CLIA certificate, we are subject to survey and inspection every two years to assess compliance with program standards. Because our Phoenix, Arizona laboratory is a CAP accredited laboratory, CMS may defer the survey and inspection to those conducted by CAP. We may also be subject to additional unannounced inspections. The regulatory and compliance standards applicable to the testing we perform change periodically, and any such changes are published by CAP. Our SOPs documents & records are updated accordingly and as needed. Any such changes may have a material effect on our business.
Penalties for non-compliance with CLIA requirements include suspension, limitation or revocation of the laboratory’s CLIA certificate, as well as directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit or criminal penalties.
State Laboratory Licensing
In addition to federal certification requirements of laboratories under CLIA, CLIA provides that states may adopt laboratory regulations and licensure requirements that are more stringent than those under federal law. Such laws, among other things, establish standards for the day-to-day operation of a clinical reference laboratory, which includes ensuring personnel have the adequate knowledge of training to maintain quality control. We currently provide laboratory services in all 50 states. Additionally, we maintain licenses in New York, California, Maryland, Pennsylvania and Rhode Island which require specific licensure for out-of-state laboratories that accept specimens from those states.
Because we receive specimens from the state of New York, our clinical reference laboratory is required to be licensed by New York, have a lab director with a specific certificate of qualification and is subject to biennial New York state inspections to ensure the lab is compliant with New York licensing standards. New York regulations also mandate proficiency testing for laboratories licensed under New York state law, regardless of whether such laboratories are located in New York. If a laboratory is out of compliance with New York statutory or regulatory standards, the New York State Department of Health (“NYSDOH”) may suspend, limit, revoke or annul the laboratory’s New York license, censure the holder of the license, or assess civil money penalties. We have received formal approval from NYSDOH to offer the following of our proprietary assays to New York patients: DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, DecisionDx-SCC, DecisionDx DiffDx-Melanoma and myPath Melanoma. Additionally, we are working through the NYSDOH submission and approval process for our newly acquired laboratory and product, TissueCypher, which has utility in the BE disease space.
Federal Oversight of Laboratory Developed Tests
The laws and regulations governing the marketing of diagnostic products are evolving, extremely complex, and in many instances, there are no significant regulatory or judicial interpretations of these laws and regulations. Clinical laboratory tests are regulated under CLIA, as administered by CMS, as well as by applicable state laws. In addition, the Federal Food, Drug and Cosmetic Act (“FDCA”) defines a medical device to include any instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory, intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals. Our in vitro testing products are considered by the FDA to be subject to regulation as medical devices. Among other things, pursuant to the FDCA and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, pre-market clearance or approval, marketing and promotion, and sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. In addition, the FDA regulates the export of medical devices manufactured in the United States to international markets.
Although the FDA has statutory authority to assure that medical devices are safe and effective for their intended uses, the FDA has generally exercised its enforcement discretion and not enforced applicable regulations with respect to in vitro diagnostics that are designed, manufactured, and used within a single laboratory for use only in that laboratory. These tests are referred to
29
as LDTs. As a result, we believe our diagnostic services are currently subject to the FDA’s enforcement discretion and are not currently subject to the FDA’s oversight. However, reagents, instruments, software or components provided by third parties and used to perform LDTs may be subject to regulation.
In recent years, the FDA has stated its intention to modify its enforcement discretion policy with respect to LDTs. For example, on July 31, 2014, the FDA notified Congress of its intent to modify, in a risk-based manner, its policy of enforcement discretion with respect to LDTs. On October 3, 2014, the FDA issued two draft guidance documents entitled “Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs),” or the Framework Guidance, and “FDA Notification and Medical Device Reporting for Laboratory Developed Tests (LDTs),” or the Reporting Guidance. The Framework Guidance states that FDA intends to modify its policy of enforcement discretion with respect to LDTs in a risk-based manner consistent with the classification of medical devices generally in Classes I through III. The Reporting Guidance would further enable FDA to collect information regarding the LDTs currently being offered for clinical use through a notification process, as well as to enforce its regulations for reporting safety issues and collecting information on any known or suspected adverse events related to the use of an LDT.
Although the FDA halted finalization of the guidance in November 2016 to allow for further public discussion on an appropriate oversight approach to LDTs and to give congressional authorizing committees the opportunity to develop a legislative solution, the FDA could ultimately modify its current approach to LDTs in a way that would subject our products marketed as LDTs to the enforcement of regulatory requirements.
Medical Device Regulatory Framework
Although we currently market our proprietary testing products as LDTs, which are currently subject to enforcement discretion, we could be subject to more onerous FDA compliance obligations in the future. Specifically, if the FDA begins to actively regulate LDTs, then, unless an exemption applies, each new or significantly modified medical device we seek to commercially distribute in the United States will require either a premarket notification to the FDA requesting permission for commercial distribution under Section 510(k) of the FDCA, also referred to as a 510(k) clearance, or approval from the FDA of a premarket approval (“PMA”), application. Both the 510(k) clearance and PMA processes can be resource intensive, expensive, and lengthy, and require payment of significant user fees.
Device Classification
Under the FDCA, medical devices are classified into one of three classes-Class I, Class II or Class III depending on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurances with respect to safety and effectiveness.
Class I devices are those with the lowest risk to the patient and are those for which safety and effectiveness can be reasonably assured by adherence to a set of FDA regulations, referred to as the General Controls for Medical Devices, which require compliance with the applicable portions of the FDA’s Quality System Regulation, facility registration and product listing, reporting of adverse events and malfunctions, and appropriate, truthful and non-misleading labeling and promotional materials. Some Class I devices also require premarket clearance by the FDA through the 510(k) premarket notification process described below. Most Class I products are exempt from the premarket notification requirements.
Class II devices are those that are subject to the General Controls, and Special Controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These Special Controls can include performance standards, patient registries, FDA guidance documents and post-market surveillance. Most Class II devices are subject to premarket review and clearance by the FDA. Premarket review and clearance by the FDA for Class II devices is accomplished through the 510(k) premarket notification process.
Class III devices include devices deemed by the FDA to pose the greatest risk such as life-supporting or life-sustaining devices, or implantable devices, in addition to those deemed novel and not substantially equivalent following the 510(k) process. The safety and effectiveness of Class III devices cannot be reasonably assured solely by the General Controls and Special Controls described above. Therefore, these devices are subject to the PMA application process, which is generally more costly and time-consuming than the 510(k) process. Through the PMA application process, the applicant must submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use to the FDA’s satisfaction. Accordingly, a PMA typically includes, but is not limited to, extensive technical information regarding device design and development, pre-clinical and clinical trial data, manufacturing information, labeling and financial disclosure information for the clinical investigators in device studies. The PMA application must provide valid scientific evidence that demonstrates to the FDA’s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use.
30
The Investigational Device Process
In the United States, absent certain limited exceptions, human clinical trials intended to support medical device clearance or approval require an investigational device exemption (“IDE”), application. Some types of studies deemed to present “non-significant risk” are deemed to have an approved IDE once certain requirements are addressed and IRB approval is obtained. If the device presents a “significant risk” to human health, as defined by the FDA, the sponsor must submit an IDE application to the FDA and obtain IDE approval prior to commencing the human clinical trials. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. Generally, clinical trials for a significant risk device may begin once the IDE application is approved by the FDA and the study protocol and informed consent are approved by appropriate IRBs at the clinical trial sites. Submission of an IDE will not necessarily result in the ability to commence clinical trials, and although the FDA’s approval of an IDE allows clinical testing to go forward for a specified number of subjects, it does not bind the FDA to accept the results of the trial as sufficient to prove the product’s safety and efficacy, even if the trial meets its intended success criteria.
All clinical trials must be conducted in accordance with the FDA’s IDE regulations that govern investigational device labeling, prohibit promotion and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. Clinical trials must further comply with the FDA’s good clinical practice regulations for IRB approval and for informed consent and other human subject protections. Required records and reports are subject to inspection by the FDA. The results of clinical testing may be unfavorable, or, even if the intended safety and efficacy success criteria are achieved, may not be considered sufficient for the FDA to grant marketing approval or clearance of a product. The commencement or completion of any clinical trial may be delayed or halted, or be inadequate to support approval of a PMA application, for numerous reasons.
The 510(k) Clearance Process
Under the 510(k) clearance process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device is “substantially equivalent” to a legally marketed predicate device. A predicate device is a legally marketed device that is not subject to a PMA, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class III to Class II or I, or a device that was previously found substantially equivalent through the 510(k) process. To be “substantially equivalent,” the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data is sometimes required to support substantial equivalence.
After a 510(k) premarket notification is submitted, the FDA determines whether to accept it for substantive review. If it lacks necessary information for substantive review, the FDA will refuse to accept the 510(k) notification. If it is accepted for filing, the FDA begins a substantive review. By statute, the FDA is required to complete its review of a 510(k) notification within 90 days of receiving the 510(k) notification. As a practical matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device is substantially equivalent, it will grant clearance to commercially market the device.
If the FDA determines that the device is not “substantially equivalent” to a predicate device, or if the device is automatically classified into Class III, the device sponsor must then fulfill the much more rigorous premarketing requirements of the PMA approval process, or seek reclassification of the device through the de novo process. The de novo classification process is an alternate pathway to classify medical devices that are automatically classified into Class III, but which are low to moderate risk. A manufacturer can submit a petition for direct de novo review if the manufacturer is unable to identify an appropriate predicate device and the new device or new use of the device presents a moderate or low risk. De novo classification may also be available after receipt of a “not substantially equivalent” letter following submission of a 510(k) to FDA.
After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a new or major change in its intended use, will require a new 510(k) clearance or, depending on the modification, could require a PMA application. The FDA requires each manufacturer to determine whether the proposed change requires a new submission in the first instance, but the FDA can review any such decision and disagree with a manufacturer’s determination. Many minor modifications are accomplished by a letter-to-file in which the manufacturer documents the change in an internal letter-to-file. The letter-to-file is in lieu of submitting a new 510(k) to obtain clearance for such change. The FDA can always review these letters to file in an inspection. If the FDA disagrees with a manufacturer’s determination regarding whether a new premarket submission is required for the modification of an existing 510(k)-cleared device, the FDA can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or approval of a PMA application is obtained. In addition, in these circumstances, the FDA can impose significant regulatory fines or penalties for failure to submit the requisite application(s).
31
The PMA Approval Process
Following receipt of a PMA application, the FDA conducts an administrative review to determine whether the application is sufficiently complete to permit a substantive review. If it is not, the agency will refuse to file the PMA. If it is, the FDA will accept the application for filing and begin the review. The FDA has 180 days to review a filed PMA application, however, in practice the application review process often exceeds this deadline. During this review period, the FDA may request additional information or clarification of information already provided, and the FDA may issue a major deficiency letter to the applicant, requesting the applicant’s response to deficiencies communicated by the FDA.
Before approving or denying a PMA, an FDA advisory committee may review the PMA at a public meeting and provide the FDA with the committee’s recommendation on whether the FDA should approve the submission, approve it with specific conditions, or not approve it. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.
Prior to approval of a PMA, the FDA may conduct inspections of the clinical trial data and clinical trial sites, as well as inspections of the manufacturing facility and processes. Overall, the FDA review of a PMA application generally takes between one and three years but may take significantly longer. The FDA can delay, limit or deny approval of a PMA application for many reasons, including:
•the device may not be shown safe or effective to the FDA’s satisfaction;
•the data from pre-clinical studies and/or clinical trials may be found unreliable or insufficient to support approval;
•the manufacturing process or facilities may not meet applicable requirements; and
•changes in FDA approval policies or adoption of new regulations may require additional data.
If the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the latter of which usually contains a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of the device, subject to the conditions of approval and the limitations established in the approval letter. If the FDA’s evaluation of a PMA application or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. The FDA also may determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when the data are available. The PMA process can be expensive, uncertain and lengthy and a number of devices for which the FDA approval has been sought by other companies have never been approved by the FDA for marketing.
New PMA applications or PMA supplements are required for modification to the manufacturing process, equipment or facility, quality control procedures, sterilization, packaging, expiration date, labeling, device specifications, ingredients, materials or design of a device that has been approved through the PMA process. PMA supplements often require submission of the same type of information as an initial PMA application, except that the supplement is limited to information needed to support any changes from the device covered by the approved PMA application and may or may not require as extensive technical or clinical data or the convening of an advisory panel, depending on the nature of the proposed change.
In approving a PMA application, as a condition of approval, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional or longer-term safety and effectiveness data for the device. The FDA may also approve a PMA application with other post-approval conditions intended to ensure the safety and effectiveness of the device, such as, among other things, restrictions on labeling, promotion, sale, distribution and use. New PMA applications or PMA supplements may also be required for modifications to any approved diagnostic tests, including modifications to our manufacturing processes, device labeling and device design, based on the findings of post-approval studies.
Federal and State Physician Self-Referral Prohibitions
We are subject to the federal physician self-referral prohibitions, commonly known as the Stark Law, and to comparable state laws. Together these restrictions generally prohibit us from billing a patient or any governmental or private payor for certain designated health services, including clinical laboratory services, when the physician ordering the service, or any member of such physician’s immediate family, has a financial interest, such as an ownership or investment interest in or compensation arrangement with us, unless the arrangement meets an exception to the prohibition.
32
Sanctions for a Stark Law violation include the following:
•denial of payment for the services provided in violation of the prohibition;
•refunds of amounts collected by an entity in violation of the Stark Law;
•a civil penalty for each bill or claim for a service arising out of the prohibited referral;
•the imposition of up to three times the amounts for each item or service wrongfully claimed;
•possible exclusion from federal healthcare programs, including Medicare and Medicaid; and
•a civil penalty for each arrangement or scheme that the parties know (or should know) has the principal purpose of circumventing the Stark Law’s prohibition.
These prohibitions apply regardless of any intent by the parties to induce or reward referrals or the reasons for the financial relationship and the referral. In addition, knowing violations of the Stark Law may also serve as the basis for liability under the federal False Claims Act (“the FCA”), which can result in additional civil and criminal penalties.
Federal and State Anti-Kickback Laws
The federal Anti-Kickback Statute (“the AKS”) makes it a felony for a person or entity, including a clinical laboratory, to knowingly and willfully offer, pay, solicit or receive any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in order to induce business that is reimbursable under any federal healthcare program. A violation of the AKS may result in imprisonment for up to ten years and fines for each violation and administrative civil money penalties, including an additional amount of up to three times the amount of the remuneration paid. Convictions under the AKS result in mandatory exclusion from federal healthcare programs for a minimum of five years. In addition, The U.S. Department of Health and Human Services (“HHS”) has the authority to impose civil assessments and fines and to exclude healthcare providers and others engaged in prohibited activities from Medicare, Medicaid and other federal healthcare programs. In addition, the government may assert that a claim that includes items or services resulting from a violation of the AKS constitutes a false or fraudulent claim under the FCA, which is discussed in greater detail below. Additionally, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.
Although the AKS applies only to items and services reimbursable under any federal healthcare program, a number of states have passed statutes substantially similar to the AKS that apply to all payors. Penalties of such state laws include imprisonment and significant monetary fines.
Federal and state law enforcement authorities scrutinize arrangements between healthcare providers and potential referral sources to ensure that the arrangements are not designed as a mechanism to induce patient care referrals or induce the purchase or prescribing of particular products or services. Generally, courts have taken a broad interpretation of the scope of the AKS, holding that the statute may be violated if merely one purpose of a payment arrangement is to induce referrals or purchases.
In addition to statutory exceptions to the AKS, regulations provide for a number of safe harbors. If an arrangement meets the provisions of a safe harbor, it is deemed not to violate the AKS. An arrangement must fully comply with each element of an applicable safe harbor in order to qualify for protection.
Failure to meet the requirements of the safe harbor, however, does not render an arrangement illegal. Rather, the government may evaluate such arrangements on a case-by-case basis, taking into account all facts and circumstances.
The Eliminating Kickbacks in Recovery Act
The Eliminating Kickbacks in Recovery Act of 2018 (“EKRA”) prohibits knowingly and willfully soliciting or receiving any remuneration (including any kickback, bribe or rebate) directly or indirectly, overtly or covertly, in cash or in kind, in return for referring a patient or patronage to a laboratory; or paying or offering any remuneration (including any kickback, bribe or rebate) directly or indirectly, overtly or covertly, in cash or in kind, to induce a referral of an individual to a laboratory or in exchange for an individual using the services of that laboratory. EKRA was enacted to help reduce opioid-related fraud and abuse. However, EKRA defines the term “laboratory” broadly and without reference to any connection to substance use disorder treatment. EKRA applies to all payors including commercial payors and government payors. The law includes a limited number of exceptions, some of which closely align with corresponding AKS exceptions and safe harbors, and others that materially differ. Currently, there is no regulation interpreting or implementing EKRA, nor any guidance released by a federal agency regarding the scope of EKRA.
33
Other Federal and State Healthcare Laws
In addition to the requirements discussed above, several other healthcare fraud and abuse laws could have an effect on our business. For example, provisions of the Social Security Act permit Medicare and Medicaid to exclude an entity that charges the federal healthcare programs substantially in excess of its usual charges for its services. The terms “usual charge” and “substantially in excess” are subject to varying interpretations.
The FCA prohibits, among other things, a person from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment or approval and from, making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim in order to secure payment or retaining an overpayment by the federal government. In addition to actions initiated by the government itself, the statute authorizes actions to be brought on behalf of the federal government by a private party having knowledge of the alleged fraud, through the FCA’s “qui tam” or whistleblower provision. Because the complaint is initially filed under seal, the action may be pending for some time before the defendant is even aware of the action. If the government intervenes and is ultimately successful in obtaining redress in the matter or if the plaintiff succeeds in obtaining redress without the government’s involvement, then the plaintiff will receive a percentage of the recovery. Finally, the Social Security Act includes its own provisions that prohibit the filing of false claims or submitting false statements in order to obtain payment. Several states have enacted comparable false claims laws which may be broader in scope and apply regardless of payor.
The civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented, or caused to be presented, a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. A person who offers or provides to a Medicare or Medicaid beneficiary any remuneration, including waivers of co-payments and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary’s selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services may be liable under the civil monetary penalties statute. Moreover, in certain cases, providers who routinely waive copayments and deductibles for Medicare and Medicaid beneficiaries, for example, in connection with patient assistance programs, can also be held liable under the AKS and FCA. One of the statutory exceptions to the prohibition is non-routine, unadvertised waivers of copayments or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable collection efforts. The Office of Inspector General of HHS (“the OIG”) emphasizes, however, that this exception should only be used occasionally to address special financial needs of a particular patient. Although this prohibition applies only to federal healthcare program beneficiaries, applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud, may also be implicated for similar practices offered to patients covered by commercial payor.
The federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of, or payment for, healthcare benefits, items or services. Like the AKS, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.
The Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “ACA”) also imposed annual reporting requirements on manufacturers of certain devices, drugs and biologics for certain payments and transfers of value by them and in some cases their distributors to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. Any failure to comply with these reporting requirements could result in significant fines and penalties. Because we manufacture our own LDTs solely for use by or within our own laboratory, we believe that we are exempt from these reporting requirements. We cannot assure you, however, that the government will agree with our determination, and a determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations or financial condition.
State equivalents of each of the above federal laws, such as anti-kickback and false claims laws, may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by non-governmental third-party payors, including private insurers.
If our operations are found to be in violation of any of the fraud and abuse laws described above or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, contractual damages,
34
reputational harm, integrity oversight and reporting obligations, diminished profits and future earnings, and the curtailment or restructuring of our operations.
International Regulations
Many countries in which we may offer any of our testing products in the future have anti-kickback regulations prohibiting providers from offering, paying, soliciting or receiving remuneration, directly or indirectly, in order to induce business that is reimbursable under any national healthcare program. In situations involving physicians employed by state-funded institutions or national healthcare agencies, violation of the local anti-kickback law may also constitute a violation of the U.S. Foreign Corrupt Practices Act (“FCPA”).
The FCPA prohibits any U.S. individual, business entity or employee of a U.S. business entity to offer or provide, directly or through a third party, including any potential distributors we may rely on in certain markets, anything of value to a foreign government official with corrupt intent to influence an award or continuation of business or to gain an unfair advantage, whether or not such conduct violates local laws. In addition, it is illegal for a company that reports to the SEC to have false or inaccurate books or records or to fail to maintain a system of internal accounting controls. We will also be required to maintain accurate information and control over sales and distributors’ activities that may fall within the purview of the FCPA, its books and records provisions and its anti-bribery provisions.
The standard of intent and knowledge in the Anti-Bribery cases is minimal-intent and knowledge are usually inferred from that fact that bribery took place. The accounting provisions do not require intent. Violations of the FCPA’s anti-bribery provisions for corporations and other business entities are subject to a fine of up to $2 million and officers, directors, stockholders, employees, and agents are subject to a fine of up to $100,000 and imprisonment for up to five years. Other countries, including the United Kingdom and other OECD Anti-Bribery Convention members, have similar anti-corruption regulations, such as the United Kingdom Anti-Bribery Act.
When marketing our testing products outside of the United States, we may be subject to foreign regulatory requirements governing human clinical testing, prohibitions on the import of tissue necessary for us to perform our testing products or restrictions on the export of tissue imposed by countries outside of the United States or the import of tissue into the United States, and marketing approval. These requirements vary by jurisdiction, differ from those in the United States and may in some cases require us to perform additional pre-clinical or clinical testing. In many countries outside of the United States, coverage, pricing and reimbursement approvals are also required.
Privacy and Security Laws
Health Insurance Portability and Accountability Act
Under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH”) HHS has issued regulations to protect the privacy and provide for the security of protected health information (“PHI”) used or disclosed by certain entities including healthcare providers, such as us. HIPAA also regulates standardization of data content, codes and formats used in certain healthcare transactions and standardization of identifiers for health plans and providers. Penalties for violations of HIPAA and HITECH laws and regulations include significant civil and criminal penalties.
Three standards have been promulgated under HIPAA’s and HITECH’s regulations: the Standards for Privacy of Individually Identifiable Health Information, which restrict the use and disclosure of certain individually identifiable health information, the Standards for Electronic Transactions, which establish standards for common healthcare transactions, such as claims information, plan eligibility, payment information and the use of electronic signatures, and the Security Standards for the Protection of Electronic Protected Health Information, which require covered entities and business associates to implement and maintain certain security measures to safeguard certain electronic health information, including the adoption of administrative, physical and technical safeguards to protect such information.
The HIPAA privacy regulations cover the use and disclosure of PHI by covered entities and business associates, which are defined to include subcontractors that create, receive, maintain, or transmit PHI on behalf of a covered entity, as well as their covered subcontractors. They also set forth certain rights that an individual has with respect to his or her PHI maintained by a covered entity, including the right to access or amend certain records containing PHI, or to request restrictions on the use or disclosure of PHI. The HIPAA security regulations establish requirements for safeguarding the confidentiality, integrity, and availability of PHI that is electronically transmitted or electronically stored. HITECH, among other things, established certain health information security breach notification requirements. A covered entity must notify any individual whose PHI is breached according to the specifications set forth in the breach notification rule. The HIPAA privacy and security regulations establish a uniform federal “floor” and do not preempt state laws that are more stringent or provide individuals with greater rights with respect to the privacy or security of, and access to, their records containing PHI or insofar as such state laws apply to personal information that is broader in scope than PHI.
35
Individuals (or their personal representatives, as applicable) have the right to access test reports directly from laboratories and to direct that copies of those reports be transmitted to persons or entities designated by the individual.
HIPAA authorizes state attorneys general to file suit on behalf of their residents for violations. Courts are able to award damages, costs and attorneys’ fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to file suit against us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care cases in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA covered entities, such as us, and their business associates for compliance with the HIPAA privacy and security standards. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the civil monetary penalty paid by the violator.
As a covered entity with downstream vendors and subcontractors and, in certain instances, as a business associate of other covered entities with whom we have entered into a business associate agreement, we have certain obligations under HIPAA regarding the use and disclosure of any PHI that may be provided to us. HIPAA and HITECH impose civil and criminal penalties against covered entities and business associates for noncompliance with privacy and security requirements. Further, various states, such as California and Massachusetts, have implemented similar privacy laws and regulations that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information (“PII”).
Numerous other federal, state and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of patient health information. We intend to continue to comprehensively protect all personal information and to comply with all applicable laws regarding the protection of such information.
Reimbursement for Clinical Laboratory Services
We generate revenue on our products from several sources, including third-party payors, laboratory services intermediaries, and self-paying individuals. Depending on the billing arrangement and applicable law, we must bill various third-party payors, such as insurance companies, Medicare, Medicaid, and patients, all of which have different billing requirements. Compliance with applicable laws and regulations as well as internal compliance policies and procedures adds further complexity to the billing process. CMS establishes new procedures and continuously evaluates and implements changes to the reimbursement process for billing the Medicare program.
To receive reimbursement from third-party payors, we bill our tests using a variety of CPT codes, as defined by the AMA. For those genetic tests we conduct that do not have a dedicated CPT code, tests may be billed under a miscellaneous code for an unlisted molecular pathology procedure. Because these miscellaneous codes do not describe a specific service, the third-party payor claim may need to be examined to determine the service that was provided, whether the service was appropriate and medically necessary and whether payment should be rendered. This process can require a letter of medical necessity from the ordering physician and it can result in a delay in processing the claim, a lower reimbursement amount, or denial of the claim.
With the evolution of genetic testing, we have seen individual third-party payors’ medical coverage policies around the CPT codes we bill and their associated payment rates change over time, resulting in changes to our reimbursement revenues. We believe all of our products provide significant clinical value and reduction in downstream healthcare spend, as evidenced in research studies and clinical publications, which we believe will continue to support and drive third-party payor reimbursement.
Under Medicare, payment for products like ours is generally made under the CLFS with payment amounts assigned to specific procedure billing codes. In April 2014, Congress passed the Protecting Access to Medicare Act (“PAMA”), which included substantial changes to the way in which clinical laboratory services will be paid under Medicare. Under PAMA, certain laboratories were required to report to CMS private payor payment rates and volumes for their tests. CMS uses this data to calculate a weighted median payment rate for each test, which will be used to establish revised Medicare CLFS reimbursement rates for the test. Laboratories that fail to report the required payment information may be subject to substantial civil penalties. We bill Medicare for our products, and therefore we are subject to reporting requirements under PAMA. See “Reimbursement—Government Payors” above for additional information.
PAMA also authorizes the adoption of new, temporary billing codes and/or unique test identifiers for FDA-cleared or approved tests as well as ADLTs. The AMA’s CPT Editorial Panel has approved a proposal to create a new section of billing codes to facilitate implementation of this section of PAMA. These proprietary laboratory analyses codes may be requested by a clinical laboratory or manufacturer to specifically identify their test. If approved, the codes are issued by the AMA on a quarterly basis. Our DecisionDx-UM test was granted a Category I MAAA CPT code and was effective January 1, 2020. Our DecisionDx-Melanoma test was granted a Category I MAAA CPT code and was effective January 1, 2021.
36
Healthcare Reform
In March 2010, the ACA became law. The ACA contains a number of provisions that are expected to impact our business and operations, some of which in ways we cannot currently predict, including those governing enrollment in state and federal healthcare programs, reimbursement changes and fraud and abuse, which impact existing state and federal healthcare programs and will result in the development of new programs. Among other things, the ACA required each medical device manufacturer to pay a sales tax equal to 2.3% of the price for which such manufacturer sells its medical devices, and began to apply to sales of taxable medical devices after December 31, 2012, but was suspended in 2016. Further, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the medical device tax and “Cadillac” tax on high-cost employer-sponsored health coverage and, effective January 1, 2021, also eliminates the health insurer tax. The ACA also contains a number of other provisions, including provisions governing enrollment in federal and state healthcare programs, reimbursement matters and fraud and abuse, which we expect will impact our industry and our operations in ways that we cannot currently predict.
Since 2016, there have been efforts to repeal all or part of the ACA, and the previous administration and the U.S. Congress have taken action to roll back certain provisions of the ACA. For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. Thus, the ACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is also unclear how such challenges and the healthcare reform measures of the Biden administration will impact the ACA.
In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, on August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective on April 1, 2013 which, due to subsequent legislative amendments to the statute including the Infrastructure Investment and Jobs Act, will remain in effect through 2031, unless additional Congressional action is taken. The Coronavirus Aid, Relief and Economic Security Act enacted on March 27, 2020 (“the CARES Act”) and other COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2022. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Further, Congress is considering additional health reform measures as part of other reform initiatives.
We anticipate there will continue to be proposals by legislators at both the federal and state levels, regulators and commercial third-party payors to reduce costs while expanding individual healthcare benefits. Certain of these changes could impose additional limitations on the prices we will be able to charge for our products and the coverage of or the amounts of reimbursement available for our products from third-party payors, including government and commercial payors. In addition, it is possible that additional governmental action will be taken in response to the COVID-19 crisis in the future.
37
Human Capital Resources
Overview
Our vision is to transform disease management by keeping people first: patients, clinicians, employees and investors. We understand the importance of maintaining a strong corporate culture with our employees at the center, based on the cornerstones we laid in 2008 at our inception: trust, excellence, collaboration, integrity, innovation and excitement. We strive to find members of our team who embody the values of our company. As of December 31, 2021, we had 345 employees, of whom 342 were full-time employees. During the year ended December 31, 2021, we added 144 employees to our team, a 71.6% increase from 2020. We face competition for experienced, qualified personnel in our industry, particularly for highly skilled scientists, laboratory technicians and salespeople versed in diagnostic and prognostic testing services.
The tables below provide information on the distribution of our employees by functional area and by location as of December 31, 2021:
Number of Employees
Laboratory Testing Operations76
Research & Development65
Sales & Marketing106
Administrative & General98
Total as of December 31, 2021345

Number of Employees
Friendswood, Texas76
Phoenix, Arizona111
Pittsburgh, Pennsylvania15
Home-based throughout the U.S.143
Total as of December 31, 2021345

Our employees are not represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.
Diversity, Equity and Inclusion
We recognize the importance of diversity, equity and inclusion in recruiting, developing and retaining the best available talent. We are committed to further understanding and building upon our existing diversity, equity and inclusion strengths and are in the process of identifying opportunities and developing related initiatives.
As of December 31, 2021, our employees were 64.6% female and 35.4% male. Our overall employee population as of December 31, 2021 was 64.3% White, 7.2% Hispanic or Latino, 4.6% Asian, 3.5% Black or African-American and 20.4% two or more races (not Hispanic or Latino) and other. In executive positions, which we define as Executive Director or Regional Business Director level and above, our employee population as of December 31, 2021 was 75.0% White, 3.6% Hispanic or Latino and 21.4% other (not Hispanic or Latino). Females represented 35.7% of employees in executive positions.
In December 2021, we adopted an affirmative action plan which includes annual compensation analyses and ongoing reviews of our selection and hiring practices alongside a continued focus on building and maintaining a diverse workforce. We are continuing to further assess and understand additional measures that can advance diversity, equity and inclusion at Castle.
Compensation, Benefits and Professional Development
We are committed to offering competitive benefits and compensation packages to our employees. In addition to competitive base pay, we offer the following benefits, among others, to our full-time employees:
•a defined contribution 401(k) plan with employer matching contributions;
•an annual bonus opportunity;
•equity compensation, including stock options and/or restricted stock units and an employee stock purchase plan;
38
•medical, dental and vision plans;
•paid maternity, paternity and adoption leave policies;
•paid holidays and paid time off; and
•an employee assistance program.
We survey all new hires 90 days after the start of their employment to solicit feedback on employee engagement. We provide performance reviews at least once per year, with pay raises commensurate with market and performance indicators. Our turnover remains low for the year ended December 31, 2021.
We prioritize and encourage internal growth and professional development of our employees. To encourage employee development, we offer a professional development reimbursement program to eligible employees who attend job-related professional development activities.
Corporate and Other Information
We were incorporated in Delaware in September 2007. Our principal executive offices are located at 505 S. Friendswood Drive, Suite 401, Friendswood, Texas 77456 and our telephone number is (866) 788-9007. Our corporate website address is www.CastleBiosciences.com. Information contained on, or accessible through, our website is not considered part of this Annual Report on Form 10-K or our other filings with the SEC. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to such reports filed or furnished pursuant to Section 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended (“the Exchange Act”) are available free of charge on our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.
This Annual Report on Form 10-K contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K, including logos, artwork and other visual displays, may appear without the ® or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, endorsement of or sponsorship of us by, any other companies.
39
Item 1A. Risk Factors.
Risk Factors
You should consider carefully the risks described below, as well as the other information in this Annual Report on Form 10‑K, before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the factors described as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” when evaluating our business. If any of the following risks actually occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.
Risks Related to Our Financial Condition
Our reliance upon a small number of third-party payors for a significant portion of our revenue may materially adversely affect our financial condition and results of operations.
We receive a substantial portion of our revenue from a small number of third-party payors, primarily Medicare. Our revenue for our test reports provided for patients covered by Medicare and Medicare Advantage plans as a percentage of total revenue, was 57% and 28%, respectively, for the year ended December 31, 2021 and 58% and 29%, respectively, for the year ended December 31, 2020. If our largest current payors were to significantly reduce, or cease to pay, the amount they reimburse for our products, or if they do not reach favorable coverage and reimbursement decisions for our products, or attempt to recover amounts they had already paid, it could have a material adverse effect on our business, financial condition and results of operations and cause significant fluctuations in our results of operations.
Due to how we recognize revenue, our quarterly revenues may not reflect our underlying business.
We have concluded that our contracts include variable consideration because the amounts paid by Medicare or commercial health insurance carriers may be paid at less than our standard rates or not paid at all, with such differences considered implicit price concessions. Variable consideration attributable to these price concessions is measured at the expected value using the ‘‘most likely amount’’ method under Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”). The amounts are determined by historical average collection rates by test type and payor category taking into consideration the range of possible outcomes, the predictive value of our past experiences, the time period of when uncertainties expect to be resolved and the amount of consideration that is susceptible to factors outside of our influence, such as the judgment and actions of third parties. Determining variable consideration through a consideration of these factors involves a significant level of estimation uncertainty, and our estimations may turn out to be incorrect. Such variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. Variable consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in the absence of a predictable pattern and history of collectability with a payor. Variable consideration for Medicare claims that are not covered by an LCD, including those claims subject to approval by an Administrative Law Judge (“ALJ”) at an appeal hearing, is deemed to be fully constrained due to factors outside our influence (i.e., judgment or actions of third parties) and the uncertainty of the amount to be received is not expected to be resolved for a long period of time. Variable consideration is evaluated each reporting period and adjustments are recorded as increases or decreases in revenues. As a result of the timing and amount of adjustments for variable consideration, our operating results and comparisons of such results on a period-to-period basis may be difficult to understand and may not be meaningful. In addition, these fluctuations in revenue may make it difficult for us, for research analysts and for investors to accurately forecast our revenue and operating results. If our revenue or operating results fall below expectations, the price of our common stock would likely decline.
We have incurred significant losses since inception, and we may never achieve profitability.
Since our inception, we have had a history of net losses. For the year ended December 31, 2021, we had a net loss of $31.3 million and as of December 31, 2021 had an accumulated deficit of $93.8 million. We cannot predict if we will achieve profitability in the near future or at all. We expect to incur losses in the future as we plan to invest significant additional funds toward the expansion of our commercial organization, the conduct of clinical utility and validity studies to support adoption of our products and the development or acquisition of additional products. We also expect significant increases in our stock-based compensation expense in future periods, reflecting higher stock option valuations as a public company and additional awards outstanding due to increased headcount. Additionally, our performance could be affected by the ongoing impacts of COVID-19. Due to the requirements associated with being a public company, including those associated with no longer qualifying as an
40
emerging growth company and a smaller reporting company and becoming a large accelerated filer, we expect to continue incur significant additional legal, accounting and other expenses. We also expect that any acquisitions of businesses, assets, products or technologies will increase our expenses. These increased expenses will make it harder for us to achieve future profitability. We may also incur significant losses in the future for a number of reasons, many of which are beyond our control, including the other risks described in this Annual Report on Form 10‑K, adoption of our products, coverage of and reimbursement rates for our products from third-party payors, and future research and development activities. Our failure to achieve profitability in the future could cause the market price of our common stock to decline and make it more difficult or costly for us to raise additional capital.
We are an early, commercial-stage company and have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.
We are an early commercial-stage company and have a limited operating history. Our limited operating history may make it difficult to evaluate our current business and this makes predictions about our future success or viability subject to significant uncertainty. In particular, we intend to use a portion of our working capital to increase our headcount, including through the expansion of our sales and marketing and research and development teams, which will increase our operating costs in a manner not historically reflected in our consolidated financial statements. In combination with our other anticipated increased operating expenses in connection with the ongoing demands of a public company, these anticipated changes in our operating expenses may make it difficult to evaluate our current business, assess our future performance relative to prior performance and accurately predict our future performance.
We will continue to encounter risks and difficulties frequently experienced by early commercial-stage companies, including those associated with increasing the size of our organization and the prioritization of our commercial, research and business development activities. If we do not address these risks successfully, our business could suffer.
Changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations and affect our reported operating results.
Accounting principles generally accepted in the United States of America are subject to interpretation by the Financial Accounting Standards Board, the SEC, and various bodies formed to promulgate and interpret appropriate accounting principles. A change in accounting standards or practices can have a significant effect on our reported results and may even affect our reporting of transactions completed before the change is effective. New accounting pronouncements and varying interpretations of accounting pronouncements have occurred and may occur in the future. Changes to existing rules or the questioning of current practices may adversely affect our reported financial results or the way we conduct our business. As of December 31, 2021, we are no longer an emerging growth company and now apply public company adoption dates for new or revised accounting standards.
Our quarterly and annual operating results and cash flows may fluctuate in the future, which could cause the market price of our stock to decline substantially.
Numerous factors, many of which are outside our control may cause or contribute to significant fluctuations in our quarterly and annual operating results. For example, following the onset of the COVID-19 pandemic in 2020 we experienced decreases in revenue and test report volumes. These fluctuations may make financial planning and forecasting uncertain. In addition, these fluctuations may result in unanticipated decreases in our available cash, which could negatively affect our business and prospects. In addition, one or more of such factors may cause our revenue or operating expenses in one period to be disproportionately higher or lower relative to the others. As a result, comparing our operating results on a period-to-period basis may be difficult to understand and may not be meaningful. You should not rely on our past results as indicative of our future performance.
In addition, a significant portion of our operating expense is relatively fixed in nature, and planned expenditures are based in part on expectations regarding future revenue. Accordingly, unexpected revenue shortfalls could decrease our gross margins and cause significant changes in our operating results from quarter to quarter. If this occurs, the trading price of our stock could fall substantially.
This variability and unpredictability caused by factors such as those described above could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.
41
If our internal control over financial reporting is not effective, we may not be able to accurately report our financial results or file our periodic reports in a timely manner, which may cause adverse effects on our business and may cause investors to lose confidence in our reported financial information and may lead to a decline in our stock price.
Effective internal control over financial reporting is necessary for us to provide reliable financial reports in a timely manner. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim consolidated financial statements will not be prevented or detected on a timely basis. If we fail to adequately staff our accounting and finance function, or fail to maintain adequate internal control over financial reporting, any new or recurring material weaknesses could prevent our management from concluding our internal control over financial reporting is effective and could result in our auditor issuing an adverse opinion on our internal control over financial reporting. If we identify any future significant deficiencies or material weaknesses, the accuracy and timeliness of our financial reporting may be adversely affected, our ability to prevent material misstatements in our consolidated financial statements could be impaired, a material misstatement in our consolidated financial statements could occur and we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports, which could cause our business to suffer and our stock price to decline.
Since becoming a publicly traded company in 2019, we have increased the headcount of our accounting and finance functions to further support the demands placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley”). We expect to continue expending significant time and resources related to our internal control over financial reporting, including by further expanding our finance and accounting staff over time, but there can be no assurance our efforts will be effective.
We may need to raise additional capital to fund our existing operations, commercialize new products or expand our operations.
We believe our existing cash and cash equivalents and anticipated cash generated from sales of our products will be sufficient to fund our operations for the foreseeable future. If our available cash and cash equivalents and anticipated cash generated from sales of our products are insufficient to satisfy our liquidity requirements including because of lower demand for our products, lower than currently expected rates of reimbursement from third-party payors or other risks described in this Annual Report on Form 10-K, we may finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not currently have any committed external source of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.
We may consider raising additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons, including to:
•increase our sales and marketing efforts for DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, myPath Melanoma, DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay and address competitive developments among these or future commercial products;
•fund ongoing evidence development for our existing products as well as additional pipeline programs;
•expand our laboratory testing facility and related testing capacity;
•expand our technologies into other types of skin cancer, ocular cancer or GI management and detection products;
•acquire, license or invest in technologies;
•acquire or invest in complementary businesses or assets; and
•finance capital expenditures and general and administrative expenses.
Our present and future funding requirements will depend on many factors, including:
•our ability to achieve revenue growth;
•our rate of progress in establishing payor coverage and reimbursement arrangements with third-party payors;
•our rate of progress in, and cost of the sales, marketing, coverage and reimbursement activities associated with, establishing adoption of our lead product, DecisionDx-Melanoma, among our other products;
•the cost of expanding our laboratory operations and offerings, including our sales, marketing, coverage and reimbursement efforts;
•our rate of progress in, and cost of research and development activities associated with, diagnostic products in research and early development;
42
•the potential cost of, and delays in, the development of new products as a result of changes in regulatory oversight applicable to our products;
•acquisitions of businesses, assets, products or technologies;
•the effects of the COVID-19 pandemic; and
•the effect of competing technological and market developments.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends.
If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or products, or grant licenses on terms that may not be favorable to us.
Any disruptions to, or volatility in, the credit and financial markets or any deterioration in overall economic conditions may make any necessary debt or equity financing more difficult to obtain, more costly and/or more dilutive. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our commercialization, research and development efforts or grant rights to third parties to market and/or develop products that we would otherwise prefer to market and develop ourselves.
Risks Related to Our Business
The COVID-19 pandemic has adversely impacted and could continue to adversely impact our business, including the demand for our test reports, as well as the business or operations of physicians and other healthcare providers who order our test reports and the third-party payors responsible for reimbursement for our tests, customers and other third parties with whom we conduct business.
Public health crises such as pandemics or similar outbreaks have adversely impacted and could continue to adversely impact our business. As a result of the ongoing COVID-19 pandemic, or public health crises, and federal, state and local government responses to these events, we have and/or may in the future experience disruptions that could adversely impact our business, including, but not limited to:
•decreased test report volume due to a decline in orders of DecisionDx-Melanoma and DecisionDx-UM tests as patient visits for routine examinations and biopsies have been, and may continue to be, delayed and/or canceled;
•disruption of our sales and commercialization activities due to limitations on our ability to communicate with physicians as a result of travel restrictions and hindered means of communicating with physicians;
•delays or disruptions by third parties in the collection, preparation or delivery of the tumor samples that we test;
•delays or difficulties in delivering test reports, interruptions in research and development and other limitations of key business activities due to members of our workforce becoming ill, compliance with applicable vaccination mandates and/or stay-at-home or other similar orders imposed by or that may be imposed by state and local governments, including at our Phoenix, Arizona, Pittsburgh, Pennsylvania and Friendswood, Texas locations;
•delayed reimbursement from third party payors, disruption in our supply channel and other adverse impacts on our business resulting from the negative effects of the COVID-19 pandemic on our suppliers, service providers and other third parties on whom we rely; and
•delayed or postponed interactions with regulators and other important agencies and contractors, due to limitations in employee resources, travel restrictions or forced furlough of government employees.
Following the onset of the COVID-19 pandemic, we experienced declines in orders and test report volume. For example, in the second quarter of 2020, test reports delivered for our lead product, DecisionDx-Melanoma, decreased 18.5% compared to the second quarter of 2019. For the year ended December 31, 2020, our growth in DecisionDx-Melanoma test report volume was 4.5%, compared to year-over-year growth of 29.1% for the year ended December 31, 2019. Our analysis of third-party data indicates that cutaneous melanoma diagnoses for the year ended December 31, 2020 were down approximately 20% compared to the year ended December 31, 2019. In the first quarter of 2021, test reports delivered for DecisionDx-Melanoma decreased by 11.2% compared to the first quarter of 2020. We believe the adverse impacts on our test report volume growth were linked to delays in the diagnoses as well as the cumulative impact on promotional responsiveness as a result of reduced sales calls per day and in-person sales calls during the COVID-19 pandemic.
43
Our future results will be dependent upon the extent and duration of the COVID-19 crisis, including the emergence and spread of variants of the virus, such as the Omicron variant, and government restrictions, which are beyond our control. Although state and local government restrictions put in place to slow the spread of the virus have been eased in certain locations, restrictions may be reinstated from time to time in various regions depending on the circumstances, potentially impacting the flow of future patient visits as well as access to current and future clinician customers. Even with the easing of state and local restrictions and the availability of vaccinations, patient visits and diagnosis of cutaneous melanoma, and other diseases covered by our diagnostic and prognostic tests, may be impacted by continued apprehension regarding possible exposure to the virus as well as shifting from in-person clinical visits to telehealth approaches which may result in missed or delayed diagnoses of skin cancer and other diseases. For example, our analysis of third-party data indicates that cutaneous melanoma diagnoses during the year ended December 31, 2021 remain approximately 11% below historical 2019 levels. As conditions are continuously evolving, we are unable to predict how our future test report volume will be impacted or the extent to which our results of operations, financial condition or cash flows will be impacted by the COVID-19 pandemic, or other future public health crises. Accordingly, the test report data presented above and elsewhere in this Annual Report on Form 10-K is not necessarily indicative of our results of operations that can be expected in future periods.
Under legislation enacted (or that may be enacted) by the United States federal government to respond to COVID-19, we have received and may receive in the future, cash payments or other forms of assistance allocated to healthcare and other companies. The eligibility requirements for any such payments or other assistance may be subject to restrictive terms and conditions, which may be ambiguous or subject to further modification, interpretation and guidance issued by government agencies on an ongoing basis. In the event we fail to comply with any of the terms or conditions associated with a payment we receive or if the terms and conditions or related interpretations change, we may be required to return it. The receipt of government payments or other assistance during the COVID-19 crisis has generated negative publicity for some companies and may continue to generate negative publicity for companies in the future. If we receive any negative publicity as a result of receiving or accepting a government payment or other assistance, such as the $1.9 million in provider relief funds we received from HHS on April 16, 2020, it could harm our reputation, trigger a review or audit by applicable government agencies and/or adversely impact our stock price.
The COVID-19 crisis continues to rapidly evolve. The extent to which COVID-19 will further impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the crisis, resurgences of the virus, the emergence and spread of variants of the virus, vaccination rates, vaccination mandates, vaccination effectiveness, therapeutic treatments, the use of telemedicine, travel restrictions, stay-at-home or other similar orders and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the virus. Any of these factors, individually or in combination, could materially and adversely affect our business, results of operations, financial condition or cash flows. In addition, the current and potential adverse impacts of the COVID-19 crisis on our business, financial condition, results of operations and growth prospects, may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this “Risk Factors” section.
Our revenue currently depends primarily on sales of DecisionDx-Melanoma, and we will need to generate sufficient revenue from this and other products to grow our business.
Most of our revenue in 2021 and 2020 was derived from the sale of our lead product, DecisionDx-Melanoma. While we also derive revenue from DecisionDx-UM, DecisionDx-SCC, our CDO (which consists of myPath Melanoma and DecisionDx DiffDx-Melanoma) and TissueCypher Barrett’s Esophagus Assay, we expect that the majority of our revenue for the foreseeable future will be derived from sales of DecisionDx-Melanoma. Further, we believe that our long-term commercial success will depend on our ability to develop and market additional products. Our ability to derive revenue from DecisionDx-Melanoma, DecisionDx-UM, DecisionDx-SCC, our CDO and TissueCypher Barrett’s Esophagus Assay and any future products that we commercialize or acquire is uncertain and depends on favorable coverage and reimbursement policies from government payors, such as Medicare, and from private payors, such as insurance companies. Without positive coverage policies, our products may not be reimbursed and we may not be able to recognize revenue. If we are unable to increase sales and expand coverage and reimbursement for DecisionDx-Melanoma, develop and commercialize other products, and successfully obtain coverage and adequate reimbursement for such products, our revenue and our ability to achieve profitability would be impaired, and the market price of our stock could decline substantially.
Billing for our products is complex and requires substantial time and resources to collect payment.
Billing for clinical laboratory testing services is complex, time-consuming and expensive. Depending on the billing arrangement and applicable law, we bill various payors, including Medicare, Medicaid, private insurance companies, private healthcare institutions, and patients, all of which have different billing requirements. We generally bill third-party payors for products and pursue reimbursement on a case-by-case basis where pricing contracts are not in place. To the extent laws or contracts require us to bill patient co-payments or co-insurance, we must also comply with these requirements. We may also
44
face increased risk in our collection efforts, including potential write-offs of accounts receivable and long collection cycles, which could adversely affect our business, results of operations and financial condition.
Several factors make the billing process complex, including:
•differences between the billing rates and reimbursement rates for our products;
•compliance with complex federal and state regulations related to billing government healthcare programs, including Medicare, Medicaid, Veterans Administration and TRICARE;
•risk of government audits related to billing;
•disputes among payors as to which party is responsible for payment;
•differences in coverage and information and billing requirements among payors, including the need for prior authorization and/or advanced notification;
•the effect of patient co-payments or co-insurance and our ability to collect such payments from patients;
•changes to billing codes used for our products;
•changes to requirements related to our current or future clinical studies, including our registry studies, which can affect eligibility for payment;
•ongoing monitoring provisions of LCDs for our products, which can affect the circumstances under which a claim would be considered medically necessary;
•incorrect or missing billing information; and
•the resources required to manage the billing and claims appeals process.
We use standard industry billing codes, known as CPT codes, to bill for our products. If these codes were to change, there is a risk of an error being made in the claim adjudication process. Such errors can occur with claims submission, third-party transmission or in the processing of the claim by the payor. Claim adjudication errors may result in a delay in payment processing or a reduction in the amount of the payment we receive.
As we introduce new products, we may need to add new codes to our billing process as well as our financial reporting systems. Failure or delays in effecting these changes in external billing and internal systems and processes could negatively affect our collection rates, revenue and cost of collecting.
Additionally, our billing activities require us to implement compliance procedures and oversight, train and monitor our employees, and undertake internal audits to evaluate compliance with applicable laws and regulations as well as internal compliance policies and procedures. When payors deny our claims, we may challenge the reason, low payment amount or payment denials. Payors also conduct external audits to evaluate payments, which add further complexity to the billing process. If the payor makes an overpayment determination, there is a risk that we may be required to return all or some portion of prior payments we have received.
Additionally, the ACA requires providers and suppliers to report and return any overpayments received from government payors under the Medicare and Medicaid programs within 60 days of identification. Failure to identify and return such overpayments exposes the provider or supplier to liability under federal false claims laws. These billing complexities, and the related uncertainty in obtaining payment for our products, could negatively affect our revenue and cash flow, our ability to achieve profitability, and the consistency and comparability of our results of operations.
In addition to the complexities noted above, we rely upon a third-party software application in the administration of our billing and collection process. We transitioned from a third-party billing service provider and added additional headcount to move our billing process in-house using a third-party software application starting January 1, 2021. Any significant disruption or deficiency in the design of our billing process could adversely impact our ability to generate and send invoices, calculate revenues, track payments and collect our accounts receivable. Although to date we have not experienced any disruptions or identified any deficiencies with our new billing system, there can be no assurances that any disruptions or deficiencies will not occur in the future. Additionally, any failure in the design or operation of our internal controls related to our billing and collection processes could adversely impact our ability to conclude on the effectiveness of our internal control over financial reporting and could cause our auditor to issue an adverse opinion on our internal control over financial reporting.
45
We rely on third parties for tissue sample collection, preparation and delivery. Any defects in sample collection or preparation by such third parties and any delays in delivery of such samples could cause errors in our test reports and delay our ability to deliver test reports in a timely manner, which could significantly harm our business.
The tissue samples that we test are biopsied, preserved, prepared and delivered to us by third parties, including dermatopathologists and laboratory facilities. As such, we rely on these third parties to prepare, label and deliver the tissue samples that we test in compliance with applicable laws and guidelines, and in a timely manner. Therefore, the accuracy and correctness of the test reports that we deliver are dependent on proper chain of custody and appropriate methods of sample collection or preparation utilized by these third parties, and our ability to timely deliver reports is dependent upon the ability of these third parties to provide these samples to us in a timely manner. The ability of these third parties to provide these samples to us in a timely manner could be delayed by events beyond our control, including but not limited to natural disasters and public health epidemics, such as the COVID-19 crisis. Any errors in any part of the sample collection or preparation process could cause us to deliver incorrect test reports, potentially resulting in harm to patients whose physicians implement a change in treatment decisions based upon our test report. If we are unable to timely deliver test reports, physicians may be less likely to recommend and order our products. The occurrence of any of the foregoing could significantly harm our reputation and our results of operations, causing significant harm to our business.
We rely on our database of samples for the development and improvement of our products. Depletion or loss of our samples could significantly harm our business.
The development and validation of accurate products is a complex process that requires access to tissue specimens and long-term outcomes data. Our research and development efforts to improve our existing commercial products and develop new pipeline products may require the depletion of our existing database of samples. If our samples are lost or destroyed, or substantially depleted before we are able to generate meaningful data, we may be unable to improve our existing products, continue the development of pipeline products or validate product candidates. While we have historically been able to create and maintain a large sample bank to expand the clinical use of our products and develop new products, we may be unable to do so in the future. If we were unable to maintain or replenish our sample bank, we may be unable to improve our products or develop new products.
If our primary clinical laboratory facility becomes damaged or inoperable or we are required to vacate our existing facility, our ability to conduct our laboratory analysis and pursue our research and development efforts may be jeopardized.
We currently perform most of our testing and store our database of tumor samples at our primary clinical laboratory facility in Phoenix, Arizona. Our facility and equipment could be harmed or rendered inoperable by natural or man-made disasters, including war, fire, earthquake, power loss, communications failure, terrorism, burglary, public health crises (including restrictions that may be imposed on businesses by state and local governments under stay-at-home or similar orders and mandates) or other events, which may make it difficult or impossible for us to perform our testing services for some period of time or to receive and store samples. The inability to perform tests or to reduce the backlog of sample analysis that could develop if our facility becomes inoperable, for even a short period of time, may result in the loss of revenue, loss of customers or harm to our reputation, and we may be unable to regain that revenue, those customers or repair our reputation in the future. Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters and man-made disasters or other sudden, unforeseen and severe adverse events.
In addition, the loss of our tissue samples due to such events could limit or prevent our ability to conduct research and development analysis on existing tests as well as tests in active pipeline development.
While we have a business continuity plan in place, and have completed the build out of an additional laboratory facility in close proximity to our primary facility to support our growth and provide certain operational redundancy, our facilities and the equipment we use to perform our testing and research and development could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facilities, to locate and qualify a new facility, replace certain pieces of equipment or license or transfer our proprietary technology to a third-party, particularly in light of licensure and accreditation requirements. Even in the unlikely event that we are able to find a third party with such qualifications to enable us to resume our operations, we may be unable to negotiate commercially reasonable terms.
We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our business, may not provide coverage in amounts sufficient to cover our potential losses and may not continue to be available to us on acceptable terms, if at all.
Our current or future products may not achieve or maintain significant commercial market acceptance.
We believe our commercial success is dependent upon our ability to continue to successfully market and sell our products, to continue to expand our current relationships and develop new relationships with healthcare providers, to expand and maintain
46
coverage for our products, and to develop and commercialize new products. Our ability to achieve and maintain commercial market acceptance of our existing and future products will depend on a number of factors, including:
•our ability to increase awareness of our products through successful clinical utility and validity studies;
•the rate of adoption of our products by physicians and other healthcare providers;
•our ability to achieve guideline inclusion for our products;
•the timeliness with which we can provide our clinical reports to the ordering physician;
•the timing and scope of any regulatory approval for our products, if such approvals become required, and maintaining ongoing compliance with regulatory requirements;
•our ability to obtain and maintain positive coverage decisions for our products from government and commercial payors;
•our ability to obtain and maintain adequate reimbursement from third-party payors, including Medicare, Medicare Advantage plans and BlueCross BlueShield plans, which accounted for an aggregate of approximately 92% and 93% of our total revenue for the years ended December 31, 2021 and 2020, respectively;
•the impact of our investments in research and development and commercial growth;
•negative publicity regarding our or our competitors’ products resulting from scientific publications, or defects or errors in the products; and
•our ability to further validate our products through clinical research and accompanying publications.
We cannot assure you that we will be successful in addressing each of these factors or other factors that might affect the market acceptance of our products. If we are unsuccessful in achieving and maintaining market acceptance of our products, our business and results of operations will suffer.
New product development involves a lengthy and complex process, and we may be unable to develop and commercialize, or receive reimbursement for, on a timely basis, or at all, new products.
We continually seek to develop new product offerings, which requires us to devote considerable resources to research and development. Before we can commercialize a new pipeline product, we will need to expend significant resources in order to conduct substantial research and development, including clinical utility and validity studies, and further develop and scale our laboratory processes and infrastructure to accommodate additional products. For example, in 2021, we launched our innovative pipeline to develop a genomic test aimed at predicting response to systemic therapy in patients with moderate to severe psoriasis, atopic dermatitis and related inflammatory skin conditions. We have initiated a 4,800 patient, prospective, multi-center clinical study to develop and validate this inflammatory skin disease pipeline test with the expectation of launching this pipeline test by the end of 2025.
Our product development process takes time and involves a high degree of risk, and such development efforts may fail for many reasons, including failure of the product to perform as expected, failure to successfully complete analytic and clinical validation, or failure to demonstrate the clinical utility of the product.
As we develop new products, we will have to make significant investments in research and development, marketing, selling, coverage and reimbursement activities. Typically, few research and development projects result in a commercialized product, and there can be no assurance that we will be able to successfully develop new products that can be commercialized. At any point, we may abandon development of a product or we may be required to expend considerable resources conducting research, which would adversely affect the timing for generating potential revenue from a new product and our ability to invest in other products in our pipeline. If a clinical validation study fails to demonstrate the prospectively defined endpoints of the study or if we fail to sufficiently demonstrate analytical validity or clinical utility, we might choose to abandon the development of the product, which could harm our business. In addition, competitors may develop and commercialize competing products or technologies faster than us or at a lower cost.
We may experience limits on our revenue if we are unable to increase and support adoption of our products by physicians and other healthcare providers.
Physicians and other healthcare providers may be unwilling to adopt our products due to their reliance on existing traditional clinical and pathology staging criteria and our ability to generate revenue from our products would be significantly impaired if we were unable to educate physicians, healthcare providers, patients and third-party payors about the benefits and advantages of our products. The COVID-19 crisis has impacted our in-person healthcare interactions, such as field-based sales and medical affairs, and we have had to convert visits, programs and projects to be performed online and by telephone. Although our in-person healthcare interactions have recently increased, they may become subject to restrictions or cancellations from time to
47
time, due to the uncertainties surrounding the duration, extent and ongoing impacts of the COVID-19 crisis, possibly impacting the effectiveness of our efforts. We will need to continue to educate physicians and pathologists about the benefits and cost-effectiveness of our products through published papers, presentations at scientific conferences, one-on-one marketing efforts by our sales force and one-on-one education by our medical affairs team. However, physicians and other healthcare providers may be reluctant to adopt our products in circumstances where our products are not incorporated into the current standard of care or practice guidelines. For example, while clinical utility of DecisionDx-Melanoma has been demonstrated in peer-reviewed publications, the SLNB surgery is the most widely used staging tool for determining a cutaneous melanoma patient’s metastatic risk. Whether healthcare providers adopt DecisionDx-Melanoma as a complementary or triage diagnostic method relative to the SLNB surgery will depend on our ability to increase awareness of DecisionDx-Melanoma and its clinical validation.
In addition, all of our testing services are performed by our certified laboratory located in Phoenix, Arizona, under CLIA, rather than by local laboratory or pathology practices. Accordingly, it may be difficult for us to collect samples from pathologists, and pathologists may be reluctant to support our testing services.
We rely on limited or sole suppliers for some of the reagents, equipment, chips and other materials used by our products, and we may not be able to find replacements or transition to alternative suppliers.
We rely on limited or sole suppliers for certain reagents and other materials and components that we use for our products. Some of these items are unique to these suppliers and vendors. While we have developed alternate sourcing strategies for these materials and vendors, we cannot be certain whether these strategies will be effective or the alternative sources will be available when we need them. If these suppliers can no longer provide us with the materials we need, if the materials do not meet our quality specifications or are otherwise unusable, if we cannot obtain acceptable substitute materials, or if we elect to change suppliers, an interruption in laboratory operations could occur, we may not be able to deliver patient reports on a timely basis, or at all, and we may incur higher one-time switching costs. Any such interruption may significantly affect our future revenue, cause us to incur higher costs, and harm our customer relationships and reputation. In addition, in order to mitigate these risks, we maintain inventories of these supplies at higher levels than would be the case if multiple sources of supply were available. If our testing volume decreases or we switch suppliers, we may hold excess supplies with expiration dates that occur before use which would adversely affect our losses and cash flow position. As we introduce any new products, we may experience supply issues as we ramp test volume. If we should encounter delays or difficulties in securing, reconfiguring or revalidating the equipment, reagents or other materials we require for our products, our business, financial condition, results of operations and reputation could be adversely affected.
If our products do not meet the expectations of physicians and patients, our operating results, reputation and business could suffer.
Our success depends on physician and patient confidence that we can provide reliable, high-quality information that will improve treatment outcomes, lower healthcare costs and enable better patient care. We believe that patients, physicians and other healthcare providers are likely to be particularly sensitive to defects and errors in our products, including if our products fail to accurately predict risk of metastasis with high accuracy from samples, and there can be no guarantee that our products will meet their expectations. As a result, the failure of our products to perform as expected could significantly impair our operating results and our reputation, including if we become subject to legal claims arising from any defects or errors in our products or reports.
If we are unable to compete successfully, our business will suffer and we may be unable to increase or sustain our revenue or achieve profitability.
We face competition from companies and academic institutions that have either developed or may seek to develop products intended to compete with our products.
In addition, competitors may develop their own versions of our solutions in countries where we do not have patents or where our intellectual property rights are not recognized and compete with us in those countries, including encouraging the use of their solutions by physicians in other countries.
Some potential competitors may have longer operating histories, larger customer bases, greater brand recognition and market penetration, substantially greater financial, technological and research and development resources and selling and marketing capabilities, and more experience dealing with third-party payors. As a result, they may be able to respond more quickly to changes in customer requirements, devote greater resources to the development, promotion and sale of their products than we do or sell their products at prices designed to win significant levels of market share. We may not be able to compete effectively against these organizations. Increased competition and cost-saving initiatives on the part of governmental entities and other third-party payors are likely to result in pricing pressures, which could harm our sales, profitability or ability to gain market share. In addition, competitors may be acquired by, receive investments from or enter into other commercial relationships with larger, well-established and well-financed companies. Certain potential competitors may be able to secure key inputs from vendors on more favorable terms, devote greater resources to marketing and promotional campaigns, adopt more aggressive
48
pricing policies and devote substantially more resources to test development than we can. In addition, companies or governments that control access to testing through umbrella contracts or regional preferences could promote our competitors or prevent us from performing certain services. If we are unable to compete successfully against current and future competitors, our business will suffer and we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability and could cause our stock price to decline. As we add new tests and services, we will face many of these same competitive risks for these new tests.
The sizes of the markets for our current and future products have not been established with precision and may be smaller than we estimate.
Our estimates of the total addressable markets for DecisionDx-Melanoma, DecisionDx-UM, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma and TissueCypher for BE are based on a number of internal and third-party estimates, including, without limitation, the annual rate of patients with the applicable form of skin cancer, the list price of our products relative to the reimbursement we expect to receive from third-party payors and the assumed prices at which we can sell our products in markets that have not been established. For example, we estimate that the total addressable market for DecisionDx-Melanoma is approximately $540 million, which is based, in part, on our review of multiple publications which show that diagnosis of melanoma is underreported by 30% to 72%. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for our current or future products may prove to be incorrect. If the actual number of patients who would benefit from our products, the price at which we can sell future products, or the annual total addressable market for our products is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business.
The diagnostic testing industry is subject to rapid change, which could make our current or future products obsolete.
Our industry is characterized by rapid changes, including technological and scientific breakthroughs, frequent new product introductions and enhancements and evolving industry standards, all of which could make our current products and the other products we are developing obsolete. Our future success will depend on our ability to keep pace with the evolving needs of physicians and patients on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of scientific and technological advances. In recent years, there have been numerous advances in technologies relating to the diagnosis and treatment of cancer. There have also been advances in methods used to analyze very large amounts of molecular information. We must continuously enhance our existing products and develop new products to keep pace with evolving standards of care. If we do not update our products to reflect new scientific knowledge about cancer biology, information about new cancer therapies or relevant clinical studies, our products could become obsolete and sales of our current products and any new products we develop could decline or fail to grow as expected.
Risks Related to Reimbursement and Government Regulation
We currently have limited reimbursement coverage for our lead product, DecisionDx-Melanoma, and if third-party payors, including government and commercial payors, do not provide sufficient coverage of, or adequate reimbursement for, our products, our commercial success, including revenue, will be negatively affected.
Our revenue depends on achieving broad coverage and adequate reimbursement for our products from third-party payors, including both government and commercial third-party payors. If third-party payors do not provide coverage of, or do not provide adequate reimbursement for, a substantial portion of the list price of our products, we may need to seek additional payment from the patient beyond any co-payments and deductibles, which may adversely affect demand for our products. Coverage determinations by a third-party payor may depend on a number of factors, including, but not limited to, a third-party payor’s determination of whether our products are appropriate, medically necessary or cost-effective. If we are unable to provide third-party payors with sufficient evidence of the clinical utility and validity of our products, they may not provide coverage, or may provide limited coverage, which will adversely affect our revenues and our ability to succeed. To the extent that more competitors enter our markets, the availability of coverage and the reimbursement rate for our products may decrease as we encounter pricing pressure from these competitors.
Since each third-party payor makes its own decision as to whether to establish a policy to cover our products, enter into a contract with us and set the amount it will reimburse for a product, these negotiations are a time-consuming and costly process, and they do not guarantee that the third-party payor will provide coverage or adequate reimbursement for our products. In addition, the determinations by a third-party payor whether to cover our products and the amount it will reimburse for them are often made on an indication-by-indication basis.
In cases where there is no coverage policy or we do not have a contracted rate for reimbursement as a participating provider, the patient is typically responsible for a greater share of the cost of the product, which may result in further delay of our revenue, increase our collection costs or decrease the likelihood of collection.
49
Our claims for reimbursement from third-party payors may be denied upon submission, and we may need to take additional steps to receive payment, such as appealing the denials. Such appeals and other processes are time-consuming and expensive, and may not result in payment. Third-party payors may perform audits of historically paid claims and attempt to recoup funds years after the funds were initially distributed if the third-party payors believe the funds were paid in error or determine that our products were medically unnecessary. If a third-party payor audits our claims and issues a negative audit finding, and we are not able to overturn the audit findings through appeal, the recoupment may result in a material adverse effect on our revenue. Additionally, in some cases commercial third-party payors for whom we are not a participating provider may elect at any time to review claims previously paid and determine the amount they paid was too much. In these situations, the third-party payor will typically notify us of their decision and then offset whatever amount they determine they overpaid against amounts they owe us on current claims. We cannot predict when, or how often, a third-party payor might engage in these reviews and we may not be able to dispute these retroactive adjustments.
Under ASC 606, we recognize revenue at the amount we expect to be entitled, subject to a constraint for variable consideration, in the period in which our tests are delivered to the treating physician. We have determined that our contracts contain variable consideration under ASC 606 because the amounts paid by third-party payors may be paid at less than our standard rates or not paid at all, with such differences considered implicit price concessions. Variable consideration is recognized only to the extent it is probable that a significant reversal of revenue will not occur in future periods when the uncertainties are resolved.
Variable consideration is evaluated each reporting period and adjustments are recorded as increases or decreases in revenues. Variable consideration for Medicare claims that are not covered by an LCD, including those claims subject to approval by an ALJ at an appeal hearing, is deemed to be fully constrained due to factors outside our influence (i.e., judgment or actions of third parties) and the uncertainty of the amount to be received is not expected to be resolved for a long period of time. For these fully constrained claims, we generally recognize revenue in the period the uncertainties are resolved, if favorable. In June 2017 we submitted to the Office of Medicare Hearings and Appeals (“OMHA”) a request to participate in an appeal program developed with the intent of providing appellants a means to have large volumes of claim disputes adjudicated at an accelerated rate. We submitted 2,698 DecisionDx-Melanoma claims dating from 2013 through spring 2017 for adjudication on a consolidated basis. In March 2020, OMHA issued a decision denying payment on all of these claims. In accordance with ASC 606 and consistent with prior periods, we have not recognized (fully constrained the variable consideration) any revenues attributable to these claims in our consolidated financial statements pending the outcome of this matter. We have appealed this decision, but there can be no assurances regarding the timing or the outcome of this or any other appeal decision. Due to potential future changes in Medicare coverage policies and appeal cycles, insurance coverage policies, contractual rates and other trends in the reimbursement of our tests, our revenues may fluctuate significantly from period to period.
Although we are an in-network participating provider with some commercial third-party payors, including several Blue Cross Blue Shield plans, and certain large, national commercial third-party payors, including Aetna, other commercial third-party payors have issued non-coverage policies that currently categorize our tests as experimental or investigational. If we are not successful in obtaining coverage from third-party payors, in reversing existing non-coverage policies, or if other third-party payors issue similar non-coverage policies, this could have a material adverse effect on our business and operations.
Palmetto, the MAC responsible for administering MolDX, the program that assesses molecular diagnostic technologies, issued a final LCD for DecisionDx-Melanoma, which became effective on December 3, 2018 and issued a final expanded LCD effective November 22, 2020. This LCD provides for coverage of DecisionDx-Melanoma for certain SLNB-eligible patients with cutaneous melanoma tumors with clinically negative sentinel node basins who are being considered for SLNB to determine eligibility for adjuvant therapy. The final expanded LCD also covers use of DecisionDx-Melanoma by physicians for assessment of appropriate treatment plans, regardless of the decision to undergo or avoid the SLNB surgery. Similarly, Palmetto issued a final LCD for DecisionDx-UM effective July 10, 2017. This LCD provides for coverage of DecisionDx-UM to determine metastatic risk in connection with the management of a patient’s newly diagnosed uveal melanoma and to guide surveillance and referral to medical oncology for those patients. We worked with Palmetto to obtain these positive coverage decisions through the submission of a detailed dossier of analytical and clinical data to substantiate that the tests meet Medicare’s medical necessity requirements. Per their joint operating agreement, Noridian, the MAC responsible for administering claims for laboratory services performed in Arizona, has adopted the same coverage policy as Palmetto for DecisionDx-UM and DecisionDx-Melanoma. This coverage process is lengthy, time-consuming, has changed over time, may change in the future and requires significant dedication of resources, and as we develop new products, we may be unsuccessful in receiving LCD determinations for those products or in maintaining our current LCDs. On a periodic basis, CMS requests bids for its MAC services, and MAC jurisdictions have changed in the past. A change in our MAC, or future changes in the MolDX program, the elimination of the program, or a change in the administrator of that program, may affect our ability to obtain Medicare coverage and reimbursement for products for which we have coverage, for products for which we do not yet have coverage, or for any products we may launch in the future, or delay payments for our tests.
Under Medicare, payment for products like ours is generally made under the CLFS, with payment amounts assigned to specific procedure billing codes. In April 2014, Congress passed PAMA, which included substantial changes to the way in which
50
clinical laboratory services are paid under Medicare. Under PAMA, certain laboratories are required to report to CMS commercial third-party payor payment rates and volumes for each test they perform. CMS uses this data to calculate a weighted median payment rate for each test, which will be used to establish revised Medicare CLFS reimbursement rates for the test. Laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. We bill Medicare for our products, and therefore we are subject to reporting requirements under PAMA.
In the second quarter of 2020, we submitted our technical assessment dossier for DecisionDx-SCC to Palmetto and Noridian. The dossier was accepted as complete in the third quarter of 2020. In early 2021, we submitted our technical assessment dossier for DecisionDx DiffDx-Melanoma. The dossier was accepted as complete in the first quarter of 2021. We expect that draft LCDs for DecisionDx-SCC and DecisionDx DiffDx-Melanoma could potentially be posted by the end of the second quarter of 2022 resulting in potentially final LCDs effective in 2023. However, there is no assurance that the timing of any draft or final LCD will match our expectations or our historical experience with LCDs for our other tests.
In the second quarter of 2021, Palmetto and the other MACs that participate in the MolDX program posted a draft revised LCD for DecisionDx-Melanoma. The draft LCD includes commentary about two publications regarding the clinical utility of GEP tests and was posted to give providers an opportunity to comment. Each of the draft LCDs include an assessment stating that the MAC does not believe that the new data is sufficient to change the coverage criteria. We have submitted comments on the draft LCD. The comment period on the last of these draft LCDs closed on August 8, 2021. We are unable to predict when the final draft LCD will be posted.
If we are unable to obtain and maintain adequate reimbursement rates from commercial third-party payors, this may adversely affect our Medicare rate. It is unclear what impact new pricing structures, such as those adopted under PAMA, may have on our business, financial condition, results of operations or cash flows.
The U.S. federal government continues to show significant interest in pursuing healthcare reform and reducing healthcare costs. Similarly, commercial third-party payors may seek to reduce costs by limiting coverage or reducing reimbursement for our products. Any government-adopted reform measures or changes to commercial third-party payor coverage and reimbursement policies could cause significant pressure on the pricing of, and reimbursement for, healthcare products and services, including our products, which could decrease demand for our products, and adversely affect our sales and revenue.
In addition, some third-party payors have implemented, or are in the process of implementing, laboratory benefit management programs, often using third-party benefit managers to manage these programs. The stated goals of these programs are to help improve the quality of outpatient laboratory services, support evidence-based guidelines for patient care and lower costs. The impact on laboratories, such as ours, of active laboratory benefit management by third parties is unclear, and we expect that it could have a negative impact on our revenue in the short term. It is possible that third-party payors will resist reimbursement for the products that we offer, in favor of less expensive products, may require pre-approval for our products or may impose additional pricing pressure on and substantial administrative burden for reimbursement for our products.
We expect to continue to focus substantial resources on increasing coverage and reimbursement for our current products and any future products we may develop. We believe it may take several years to achieve broad coverage and adequate contracted reimbursement with a majority of third-party payors for our products.
However, we cannot predict whether, under what circumstances, or at what payment levels third-party payors will cover and reimburse our products. If we fail to establish and maintain broad adoption of, and coverage and reimbursement for, our products, our ability to generate revenue could be harmed and our future prospects and our business could suffer.
Our products are currently marketed as laboratory developed tests, and any changes in regulations or the FDA’s enforcement discretion for laboratory developed tests, or violations of regulations by us, could adversely affect our business, prospects, results of operations or financial condition.
The diagnostics industry is highly regulated, and we cannot assure you that the regulatory environment in which we operate will not change significantly and adversely in the future. In many instances, there are no significant regulatory or judicial interpretations of these laws and regulations. Although the FDA has statutory authority to assure that medical devices are safe and effective for their intended uses, the FDA has generally exercised its enforcement discretion and not enforced applicable regulations with respect to in vitro diagnostics that are designed, manufactured and used within a single laboratory. These tests are referred to as LDTs. We currently market our products as LDTs.
The FDA has adopted a policy of enforcement discretion with respect to LDTs whereby the FDA does not actively require premarket review of LDTs or otherwise impose its requirements applicable to other medical devices on LDTs. However, the FDA has stated its intention to modify its enforcement discretion policy with respect to LDTs. The FDA could ultimately modify its current approach to LDTs in a way that would subject our products marketed as LDTs to the enforcement of additional regulatory requirements. Moreover, legislative measures have recently been proposed in Congress that, if ultimately enacted, could provide the FDA with additional authority to require premarket review of and regulate LDTs. If and when such
51
changes to the regulatory framework occur, we could for the first time be subject to enforcement of regulatory requirements as a device manufacturer such as registration and listing requirements, medical device reporting requirements and the requirements of the FDA’s Quality System Regulation. We may be required to conduct clinical trials prior to continuing to sell our existing products or launching any other products we may develop. This may increase the cost of conducting, or otherwise harm, our business.
Moreover, even if the FDA does not modify its policy of enforcement discretion, the FDA may disagree that we are marketing our LDTs within the scope of its policy of enforcement discretion and may impose significant regulatory requirements. While we believe that we are currently in material compliance with applicable laws and regulations as historically enforced by the FDA, we cannot assure you that the FDA will agree with our determination. A determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations or financial condition.
If the FDA begins to actively regulate our diagnostic products, we may be required to obtain premarket clearance under Section 510(k) of FDCA or a PMA. The process for submitting a 510(k) premarket notification and receiving FDA clearance usually takes from three to 12 months, but it can take significantly longer and clearance is never guaranteed. The process for submitting and obtaining FDA approval of a PMA is much more costly, lengthy and uncertain. It generally takes from one to three years or even longer, and approval is not guaranteed. PMA approval typically requires extensive clinical data and can be significantly longer, more expensive and more uncertain than the 510(k) clearance process. Despite the time, effort and expense expended, there can be no assurance that a particular device ultimately will be cleared or approved by the FDA through either the 510(k) clearance process or the PMA process on a timely basis, or at all. Moreover, there can be no assurance that any cleared or approved labeling claims will be consistent with our current claims or adequate to support continued adoption of and reimbursement for our products. If premarket review is required for some or all of our products, the FDA may require that we stop selling our products pending clearance or approval, which would negatively impact our business. Even if our products are allowed to remain on the market prior to clearance or approval, demand or reimbursement for our products may decline if there is uncertainty about our products, if we are required to label our products as investigational by the FDA, or if the FDA limits the labeling claims we are permitted to make for our products. As a result, we could experience significantly increased development costs and a delay in generating additional revenue from our products, or from other pipeline products.
If the FDA imposes significant changes to the regulation of LDTs it could reduce our revenues or increase our costs and adversely affect our business, prospects, results of operations or financial condition.
We conduct business in a heavily regulated industry, and failure to comply with federal, state and foreign laboratory licensing requirements and the applicable requirements of the FDA or any other regulatory authority, could cause us to lose the ability to perform our tests, experience disruptions to our business, or become subject to administrative or judicial sanctions.
The diagnostics industry is highly regulated, and the laws and regulations governing the marketing of diagnostic tests are extremely complex. Areas of the regulatory environment that may affect our ability to conduct business include, without limitation:
•federal and state laws applicable to test ordering, documentation of tests ordered, billing practices and claims payment and/or regulatory agencies enforcing those laws and regulations;
•federal and state fraud and abuse laws;
•federal and state laboratory anti-mark-up laws;
•coverage and reimbursement levels by Medicare, Medicaid, other governmental payors and private insurers;
•restrictions on coverage of and reimbursement for tests;
•federal and state laws governing laboratory testing, including CLIA, and state licensing laws and accreditation requirements;
•federal and state laws and enforcement policies governing the development, use and distribution of diagnostic medical devices, including LDTs;
•federal, state and local laws governing the handling and disposal of medical and hazardous waste;
•federal and state Occupational Safety and Health Administration rules and regulations; and
•HIPAA and similar state data privacy laws.
In particular, the FDCA defines a medical device to include any instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component, part, or accessory, intended for use in the
52
diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals. Our products are considered by the FDA to be subject to regulation as medical devices, and marketed under FDA’s policy of enforcement discretion for LDTs. Among other things, pursuant to the FDCA and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, marketing and promotion, and sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. In addition, the FDA regulates the import and export of medical devices manufactured between the United States and international markets.
We are also subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations establish specific standards with respect to personnel qualifications, facility administration, proficiency testing, quality control, quality assurance and inspections. Any testing subject to CLIA regulation must be performed in a CLIA certified or accredited lab. CLIA certification or accreditation is also required in order for us to be eligible to bill state and federal healthcare programs, as well as commercial third-party payors, for our products.
We have a current CLIA accreditation under the College of American Pathologists (“CAP”) program to conduct our tests at our clinical reference laboratory in Phoenix, Arizona. CAP maintains a clinical laboratory accreditation program. While not required for the operation of a CLIA-certified laboratory, many private insurers require CAP accreditation as a condition to contracting with clinical laboratories to cover their tests. In addition, some countries outside the United States require CAP accreditation as a condition to permitting clinical laboratories to test samples taken from their citizens. CAP accredited laboratories are surveyed for compliance with CAP standards every two years in order to maintain accreditation. Failure to maintain CAP accreditation could have a material adverse effect on the sales of our products and the results of our operations.
Therefore, to maintain our CLIA accreditation, we have elected to be subject to survey and inspection every two years by CAP. Moreover, CLIA inspectors may make random inspections of our laboratory from time to time.
Our most recent CAP inspection occurred in the fourth quarter of 2020 and our CLIA accreditation certificate expires on December 20, 2022.
In addition, certain states require our laboratory to be licensed in such states in order to test specimens from those states. Accordingly, our laboratory is also licensed by California, Maryland, New York, Pennsylvania and Rhode Island. Other states may have similar requirements or may adopt similar requirements in the future.
Although we have obtained licenses from states where we believe we are required to be licensed, we may become aware of other states that require out-of-state laboratories to obtain licensure in order to accept specimens from the state, and it is possible that other states currently have such requirements or will have such requirements in the future.
In order to test specimens from New York, LDTs must be approved by NYSDOH on a test-by-test basis before they are offered. Our laboratory director must also be separately qualified to be a laboratory director in New York. DecisionDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-SCC and DecisionDx DiffDx-Melanoma have each been formally approved. Our laboratory director has been qualified by NYSDOH. We are subject to periodic inspection by the NYSDOH and are required to demonstrate ongoing compliance with NYSDOH regulations and standards. To the extent NYSDOH identified any non-compliance and we are unable to remedy such non-compliance, the State of New York could withdraw approval for our products. We will need to seek NYSDOH approval of any future LDTs we develop and want to offer for clinical testing to New York residents, and there can be no assurance that we will be able to obtain such approval.
We may also be subject to regulation in foreign jurisdictions as we seek to expand international utilization of our products or such jurisdictions adopt new licensure requirements, which may require review of our products in order to offer them or may have other limitations such as restrictions on the transport of human tissue samples necessary for us to perform our tests that may limit our ability to make our products available outside of the United States. Complying with licensure requirements in new jurisdictions may be expensive, time-consuming and subject us to significant and unanticipated delays.
Failure to comply with applicable clinical laboratory licensure requirements may result in a range of enforcement actions, including suspension, limitation or revocation of our CLIA accreditation and/or state licenses, imposition of a directed plan of action, onsite monitoring, civil monetary penalties, criminal sanctions and revocation of the laboratory’s approval to receive Medicare and Medicaid payment for its services, as well as significant adverse publicity. Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing clinical laboratory licensure or our failure to renew our CLIA accreditation, or a state or foreign license, could have a material adverse effect on our business, financial condition and results of operations. Even if we were able to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so.
53
Doing business with the public sector, including the U.S. government, subjects us to risk of audits, investigations, sanctions and penalties.
We have and may enter into contracts in the future with the U.S. government or other governmental entities, and this subjects us to statutes and regulations applicable to companies doing business with the government. Government contracts normally contain additional requirements that may increase our costs of doing business, reduce our profits and expose us to liability for failure to comply with these terms and conditions. Such requirements may include mandatory socioeconomic compliance requirements, including labor requirements, non-discrimination and affirmative action programs and environmental compliance requirements. Being a government contractor also subjects us to reviews, audits and investigations regarding our compliance. If we fail to comply with our obligations associated with being a government contractor, our contracts may be subject to termination, and we may be subject to financial and/or other liability under our contracts, which could adversely affect our results of operations.
The FDA may modify its enforcement discretion policy with respect to LDTs in a risk-based manner, and we may become subject to extensive regulatory requirements and may be required to conduct additional clinical trials prior to continuing to sell our existing tests or launching any other tests we may develop, which may increase the cost of conducting, or otherwise harm, our business.
If the FDA changes or ends its policy of enforcement discretion with respect to LDTs, and our products become subject to the FDA’s requirements for premarket review of medical devices, we may be required to cease commercial sales of our products and conduct clinical trials prior to making submissions to the FDA to obtain premarket clearance or approval. If we are required to conduct such clinical trials, delays in the commencement or completion of clinical trials could significantly increase our product development costs and delay commercialization of any currently marketed testing that we may be required to cease selling or the commercialization of any future tests that we may develop. Many of the factors that may cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to delay or denial of regulatory clearance or approval. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the eligibility criteria for the clinical trial.
The FDA requires medical device manufacturers to comply with, among other things, current good manufacturing practices for medical devices, known as the Quality System Regulation, which requires manufacturers to follow elaborate design, testing, control, documentation and other quality assurance procedures during the manufacturing process; the medical device reporting regulation, which requires that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; labeling regulations, including the FDA’s general prohibition against promoting products for unapproved or ‘‘off-label’’ uses; and the reports of corrections and removals regulation, which requires manufacturers to report to the FDA if a device correction or removal was initiated to reduce a risk to health posed by the device or to remedy a violation of the FDCA caused by the device which may present a risk to health.
Even if we were able to obtain FDA clearance or approval for one or more of our products, if required, a diagnostic test may be subject to limitations on the indications for which it may be marketed or to other regulatory conditions. In addition, such clearance or approval may contain requirements for costly post-market testing and surveillance to monitor the safety or efficacy of the test.
In addition, the FDA’s and other regulatory authorities’ policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approvals. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing authorization that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.
Interim, topline and preliminary data from our clinical studies that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.
From time to time, we may publicly disclose preliminary or topline data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are
54
available. From time to time, we may also disclose interim data from our clinical studies. Interim data from clinical studies that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our reputation and marketing efforts.
Further, others, including healthcare providers or payors, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding our business. If the topline or interim data that we report differ from actual results, or if others, including healthcare providers or payors, disagree with the conclusions reached, our ability to commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.
Changes in healthcare policy could increase our costs, decrease our revenues and impact sales of and reimbursement for our products.
In March 2010, the ACA became law. This law substantially changed the way healthcare is financed by both government and commercial third-party payors, and significantly impacted our industry. The ACA contains a number of provisions that are expected to impact our business and operations, some of which in ways we cannot currently predict, including those governing enrollment in state and federal healthcare programs, reimbursement changes and fraud and abuse, which impact existing state and federal healthcare programs and will result in the development of new programs. Among other things, the ACA required medical device manufacturers to pay a sales tax equal to 2.3% of the price for which such manufacturer sells its medical devices, and began to apply to sales of taxable medical devices after December 31, 2012, but was suspended in 2016. Further, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the medical device tax and “Cadillac” tax on high-cost employer-sponsored health coverage and, effective January 1, 2021, also eliminated the health insurer tax.
Since 2016, there have been efforts to repeal all or part of the ACA, and the previous administration and the U.S. Congress have taken action to roll back certain provisions of the ACA.
For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February 15, 2021 and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.
On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective on April 1, 2013 and, due to subsequent legislative amendments to the statute, including the Infrastructure Investment and Jobs Act, will remain in effect through 2031, unless additional Congressional action is taken. The CARES Act and other COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2022. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Further, Congress is considering additional health reform measures as part of other reform initiatives.
We anticipate there will continue to be proposals by legislators at both the federal and state levels, regulators and commercial third-party payors to reduce costs while expanding individual healthcare benefits. For example, it is possible that additional governmental action is taken in response to the COVID-19 crisis. Certain of these changes could impose additional limitations on the prices we will be able to charge for our products, the coverage of or the amounts of reimbursement available for our products from third-party payors, including government and commercial payors.
We are subject to numerous federal and state healthcare statutes and regulations, and complying with laws pertaining to our business is an expensive and time-consuming process. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties and a material adverse effect to our business and operations.
Physicians, other healthcare providers and third-party payors play a primary role in the recommendation of our products. Our arrangements with healthcare providers, third-party payors and customers may expose us to broadly applicable fraud and abuse
55
and other healthcare laws and regulations that affect the business and financial arrangements and relationships through which we market and sell our products. The laws that affect our ability to operate include, but are not limited to:
•the AKS, which prohibits, among other things, any person or entity from knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term ‘‘remuneration’’ has been broadly interpreted to include anything of value, such as specimen collection materials or test kits. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, however these are drawn narrowly. Additionally, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and monetary penalties of up to $100,000 for each violation, plus up to three times the remuneration involved, imprisonment of up to ten years and exclusion from government healthcare programs. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA;
•the Stark Law, which prohibits a physician from making a referral for certain designated health services covered by the Medicare or Medicaid program, including laboratory and pathology services, if the physician or an immediate family member of the physician has a financial relationship with the entity providing the designated health services and prohibits that entity from billing, presenting or causing to be presented a claim for the designated health services furnished pursuant to the prohibited referral, unless an exception applies. Sanctions for violating the Stark Law include denial of payment, civil monetary penalties and exclusion from the federal healthcare programs. Failure to refund amounts received as a result of a prohibited referral on a timely basis may constitute a false or fraudulent claim and may result in civil penalties and additional penalties under the FCA;
•federal civil and criminal false claims laws, such as the FCA, which can be enforced by private citizens through civil qui tam action, and civil monetary penalty laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented through distribution of template medical necessity language or other coverage and reimbursement information, false, fictitious or fraudulent claims for payment or approval by the federal government, including federal healthcare programs, such as Medicare and Medicaid, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim, or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government. In addition, a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA. Private individuals can bring False Claims Act ‘‘qui tam’’ actions, on behalf of the government and such individuals, commonly known as ‘‘whistleblowers,’’ may share in amounts paid by the entity to the government in fines or settlement. When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs;
•EKRA, prohibits payments for referrals to recovery homes, clinical treatment facilities, and laboratories. EKRA’s reach extends beyond federal healthcare programs to include private insurance (i.e., it is an “all payor” statute). For purposes of EKRA, the term “laboratory” is defined broadly and without reference to any connection to substance use disorder treatment. The law includes a limited number of exceptions, some of which closely align with corresponding federal Anti-Kickback Statute exceptions and safe harbors, and others that materially differ;
•HIPAA, which, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, in connection with the delivery of or payment for healthcare benefits, items or services. Like the AKS, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
•HIPAA, as amended by HITECH, and their implementing regulations, which imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates, individuals or entities that perform services for them that involve individually identifiable health information as well as their covered subcontractors. Failure to comply with the HIPAA’s obligations can result in civil monetary penalties, and, in certain circumstances, criminal penalties. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable
56
to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce HIPAA and seek attorneys’ fees and costs associated with pursuing federal civil actions;
•state laws that prohibit other specified practices, such as billing physicians for tests that they order or providing tests at no or discounted cost to induce physician or patient adoption; insurance fraud laws; waiving coinsurance, copayments, deductibles, and other amounts owed by patients; billing a state Medicaid program at a price that is higher than what is charged to one or more other third-party payors employing, exercising control over or splitting professional fees with licensed professionals in violation of state laws prohibiting fee splitting or the corporate practice of medicine and other professions;
•federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;
•the federal transparency requirements under the Physician Payments Sunshine Act, created under the ACA, which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children’s Health Insurance Program to annually report to CMS information related to payments and other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals and information regarding physician ownership and investment interests, including such ownership and investment interests held by a physician’s immediate family members. Failure to submit required information may result in civil monetary penalties for all payments, transfers of value or ownership or investment interests that are not timely, accurately, and completely reported in an annual submission, and may result in liability under other federal laws or regulations. We believe that we are exempt from these reporting requirements. We cannot assure you, however, that our regulators, principally the federal government, will agree with our determination, and a determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business;
•the prohibition on reassignment of Medicare claims, which, subject to certain exceptions, precludes the reassignment of Medicare claims to any other part;
•state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by any non-governmental third-party payors, including private insurers; and
•federal, state and foreign laws that govern the privacy and security of health information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts.
As a clinical laboratory, our business practices may face additional scrutiny from government regulatory agencies such as the Department of Justice, the OIG and CMS. Certain arrangements between clinical laboratories and referring physicians have been identified in fraud alerts issued by the OIG as implicating the AKS. The OIG has stated that it is particularly concerned about these types of arrangements because the choice of laboratory, as well as the decision to order laboratory tests, typically are made or strongly influenced by the physician, with little or no input from patients. Moreover, the provision of payments or other items of value by a clinical laboratory to a referral source could be prohibited under the Stark Law unless the arrangement meets all criteria of an applicable exception. The government has been active in enforcement of these laws as they apply to clinical laboratories.
We have entered into consulting and scientific advisory board arrangements, speaking arrangements and clinical research agreements with physicians and other healthcare providers, including some who could influence the use of our products. Because of the complex and far-reaching nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for which we could be subject to other significant penalties. We could be adversely affected if regulatory agencies interpret our financial relationships with providers who may influence the ordering of and use of our products to be in violation of applicable laws.
The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies, healthcare providers and other third parties, including charitable foundations, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities may conclude that our business practices, including our consulting arrangements with physicians, as well as our financial assistance programs, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. Responding to investigations can be time and resource-consuming and can divert management’s
57
attention from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business.
Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations is costly. If our operations are found to be in violation of any of these laws or any other current or future governmental laws and regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. If any of the physicians or other healthcare providers or entities with whom we do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.
We are subject to certain U.S. anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations and may become subject to their similar foreign equivalents. We can face serious consequences for violations.
U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations prohibit, among other things, companies and their employees, agents, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving, directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of these trade laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect that we may engage in non-U.S. activities over time. We expect to rely on third-party suppliers and/or third parties to obtain necessary permits, licenses, and patent registrations. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.
We are subject to stringent and changing state, federal, local, foreign, and other privacy and security obligations, and our failure to comply or perceived failure to comply with those obligations could result in regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.
In the ordinary course of our business, we collect, store, use, transmit, disclose, or otherwise process (“Process”) confidential, proprietary, and sensitive data, including PHI, personal information, credit card and other financial information, intellectual property and proprietary business information owned or controlled by ourselves or our customers, payors and other parties. Our data processing activities subject us to numerous data privacy and security obligations, such as laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts and other obligations that govern the Processing of personal information by us and on our behalf.
In the United States, numerous federal, state, and local governments have enacted data privacy and security laws, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act). For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. Additionally, California has enacted several laws governing the Processing of personal information, such as the California Consumer Privacy Act of 2018 (“CCPA”), which provides California residents certain rights relate to their personal information, and the California Confidentiality of Medical Information Act, which restricts the use and disclosure of health information and other personal information. Although the CCPA exempts some personal information processed in the context of clinical trials, the CCPA, to the extent applicable to our business and operations, may increase compliance costs and potential liability with respect to other personal information we maintain about California residents. In addition, other states have enacted or proposed privacy laws, further complicating compliance efforts. Outside the United States, there are also an increasing number of laws, regulations, industry standards and other obligations concerning privacy and security, including for example the European Union’s (“EU”) General Data Protection Regulation (EU) 2016/679 (“GDPR”).
In addition, privacy advocates and industry groups have proposed, and may in the future propose, standards with which we are legally or contractually bound to comply. Moreover, certain jurisdictions have enacted data localization laws and cross-border personal information transfer laws, which could make it more difficult to transfer personal information across jurisdictions
58
(such as transferring or receiving personal information that originates in the EU). Existing mechanisms that may facilitate cross-border personal information transfers may change or be invalidated.
Our obligations related to data privacy and security are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective future legal framework. These laws may be subject to varying interpretations by courts and government stakeholders, creating complex compliance issues for us and our clients. Preparing for and complying with these obligations requires us to devote significant resources (including, without limitation, financial and time-related resources).
These obligations may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process personal information on our behalf. In addition, these obligations may require us to change our business model or to take on more onerous obligations in our contracts. Although we endeavor to comply with all applicable obligations, we may, at times, fail or be perceived to have failed to do so. Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations, which could negatively impact our business operations and compliance posture. Failure or perceived failure to comply with these obligations could result in significant consequences, including but not limited to government enforcement actions (which could include civil, criminal, and administrative penalties), private litigation, additional reporting requirements and/or oversight, bans on processing personal information, and orders to destroy or not use personal information. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: increase our cost of providing our services, decrease demand for our services, reduce our revenue, interrupt our business operations, limit our ability to develop our services, expenditure of time and resources to defend any claim or inquiry, and adverse publicity.
Ethical, legal and social concerns related to the use of genetic information could reduce demand for our products.
Genetic testing has raised ethical, legal, and social issues regarding privacy and the appropriate uses of the resulting information. Governmental authorities have, through the Genetic Information Nondisclosure Act of 2008, and could further, for social or other purposes, limit or regulate the use of genetic information or genetic testing or prohibit testing for genetic predisposition to certain conditions, particularly for those that have no known cure. Ethical and social concerns may also influence governmental authorities to deny or delay the issuance of patents for technology relevant to our business. While we do not currently perform genetic tests for genetic predisposition to certain conditions, these concerns may lead patients to refuse to use, or clinicians to be reluctant to order, our genomic tests or genetic tests for somatic mutations even if permissible. These and other ethical, legal and social concerns may limit market acceptance of our products or reduce the potential markets for our products, either of which could have an adverse effect on our business, financial condition, or results of operations.
Risks Related to Intellectual Property
If we are unable to obtain and maintain sufficient intellectual property protection for our technology, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize diagnostic tests similar or identical to ours, and our ability to successfully commercialize our products may be impaired.
We rely on patent protection as well as trademark, copyright, trade secret and other intellectual property rights protection as well as nondisclosure, confidentiality and other contractual restrictions to protect our brands and proprietary tests and technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us. In addition, we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property.
As is the case with other life science companies, our success depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely or jointly with others or in-license from others, particularly patents, in the United States and other countries with respect to our products and technologies. We apply for patents covering our products and technologies and uses thereof, as we deem appropriate. However, obtaining and enforcing life sciences patents is costly, time-consuming and complex, and we may fail to apply for patents on important tests, services and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions. We may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.
We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed from or to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.
Our patent portfolio includes 12 issued U.S. patents and ten pending U.S. patent applications, with foreign counterparts. It is possible that none of our pending patent applications will result in issued patents in a timely fashion or at all, and even if patents
59
are granted, they may not provide a basis for intellectual property protection of commercially viable tests or services, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties. It is possible that others will design around our future patented technologies. We may not be successful in defending any such challenges made against our patents or patent applications. Any successful third-party challenge to our patents could result in the unenforceability or invalidity of such patents and increased competition to our business. Even if our patents are held valid and enforceable, they may still be found insufficient to provide protection against competing products and services sufficient to achieve our business objectives. We may have to challenge the patents or patent applications of third parties, such as to counter infringement or unauthorized use. In addition, in an infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, or may refuse to enjoin the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. Even if we prevail against an infringer in a U.S. district court or foreign trial-level court, there is always the risk that the infringer will file an appeal and the initial court judgment will be overturned at the appeals court and/or that an adverse decision will be issued by the appeals court relating to the validity or enforceability of our patents. The outcome of patent litigation or other proceeding can be uncertain, and any attempt by us to enforce our patent rights against others or to challenge the patent rights of others may not be successful, or, if successful, may take substantial time and result in substantial cost, and may divert our efforts and attention from other aspects of our business.
The patent positions of life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in such companies’ patents has emerged to date in the United States or elsewhere. Courts frequently render opinions in the life sciences field that may affect the patentability of certain inventions or discoveries, including opinions that may affect the patentability of methods for analyzing or comparing DNA sequences.
In particular, the patent positions of companies engaged in the development and commercialization of genomic diagnostic tests are particularly uncertain. Various courts, including the U.S. Supreme Court, have rendered decisions that affect the scope of patentability of certain inventions or discoveries relating to certain diagnostic tests and related methods. These decisions state, among other things, that a patent claim that recites an abstract idea, natural phenomenon or law of nature (for example, the relationship between particular genetic variants and cancer) are not themselves patentable. Precisely what constitutes a law of nature is uncertain, and it is possible that certain aspects of genetic diagnostics tests would be considered natural laws. Accordingly, the evolving case law in the United States may adversely affect our ability to obtain patents and may facilitate third-party challenges to any owned or licensed patents. The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to life science technologies, which could make it difficult for us to stop the infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.
To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition, and our competitive position could be adversely affected, as could our business. Both the patent application process and the process of managing patent disputes can be time-consuming and expensive. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative:
•others may be able to develop and/or practice technology that is similar to our technology or aspects of our technology, but that are not covered by the claims of the patents that we own or control, assuming such patents have issued or do issue;
•we or our licensors or any future strategic partners might not have been the first to conceive or reduce to practice the inventions covered by the issued patents or pending patent applications that we own or have exclusively licensed;
•we or our licensors or any future strategic partners might not have been the first to file patent applications covering certain of our inventions;
•others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;
•it is possible that our pending patent applications will not lead to issued patents;
•issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;
•our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive tests for sale in our major commercial markets;
60
•third parties performing manufacturing or testing for us using our products or technologies could use the intellectual property of others without obtaining a proper license;
•parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property;
•we may not develop or in-license additional proprietary technologies that are patentable;
•we may not be able to obtain and maintain necessary licenses on commercially reasonable terms, or at all; and
•the patents of others may have an adverse effect on our business.
Should any of these events occur, they could significantly harm our business and results of operations.
Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
As is the case with other life sciences companies, our success is heavily dependent on intellectual property, particularly patents relating to our research programs and products. Obtaining and enforcing patents in the life sciences industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States or the USPTO rules and regulations could increase these uncertainties and costs. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (“AIA”), signed into law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The AIA includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent in USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. For applications filed after March 15, 2013 that do not claim the benefit of applications filed before that date, the AIA transitioned the United States from a first to invent system to a first-inventor-to-file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications, our ability to obtain future patents, and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.
The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations.
Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.
Our in-licensed intellectual property has been discovered through government funded programs and thus may be subject to federal regulations such as ‘‘march-in’’ rights, certain reporting requirements and a preference for U.S.-based companies, and compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.
Intellectual property rights that have been in-licensed pursuant to the License Agreement with WUSTL have been generated through the use of U.S. government funding, and are therefore subject to certain federal regulations. As a result, the United States federal government may retain certain rights to intellectual property embodied in our current or future product candidates under the Bayh-Dole Act. These federal government rights include a ‘‘nonexclusive, nontransferable, irrevocable, paid-up license’’ to use inventions for any governmental purpose. The Bayh-Dole Act also provides federal agencies with ‘‘march-in rights.’’ March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a ‘‘nonexclusive, partially exclusive, or exclusive license’’ to a ‘‘responsible applicant or applicants’’ if it determines that (1) adequate steps have not been taken to commercialize the invention, (2) government action is necessary to meet public health or safety needs or (3) government action is necessary to meet requirements for public use under federal regulations. If the patent owner refuses to do so, the government may grant the license itself.
The U.S. government also has the right to take title to these inventions if the licensor fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States, and the
61
License Agreement requires that we comply with this requirement. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our owned or future in-licensed intellectual property is also generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.
Issued patents covering our products and related technologies could be found invalid or unenforceable if challenged.
The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Some of our patents or patent applications (including licensed patents) have been, are being or may be challenged at a future point in time in an opposition, nullification, derivation, reexamination, inter partes review, post-grant review or interference action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether. Any successful third-party challenge to our patents in this or any other proceeding could result in the unenforceability or invalidity of such patents, which may lead to increased competition to our business, which could harm our business. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future diagnostic tests.
We may not be aware of all third-party intellectual property rights potentially relating to our products. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases (e.g., U.S. applications for which a request not to publish has been filed), not until such patent applications issue as patents. We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we have and may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO that could result in substantial cost to us. The outcome of such proceedings is uncertain. We can give no assurance that all of the potentially relevant art relating to our patents and patent applications has been found; overlooked prior art could be used by a third party to challenge the validity, enforceability and scope of our patents or prevent a patent from issuing from a pending patent application. As a result, we may not be able to obtain or maintain protection for certain inventions. No assurance can be given that other patent applications will not have priority over our patent applications. In addition, changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Therefore, the validity, enforceability and scope of our patents in the United States and other countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against our competitors. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and management distraction.
Our commercial success depends significantly on our ability to operate without infringing upon the intellectual property rights of third parties.
The life sciences industry is subject to rapid technological change and substantial litigation regarding patent and other intellectual property rights. Our potential competitors in both the United States and abroad, may have substantially greater resources and are likely to make substantial investments in patent portfolios and competing technologies, and may apply for or obtain patents that could prevent, limit or otherwise interfere with our ability to make, use and sell our products. Numerous third-party patents exist in fields relating to our products and technologies, and it is difficult for industry participants, including us, to identify all third-party patent rights relevant to our products and technologies. Moreover, because some patent applications are maintained as confidential for a certain period of time, we cannot be certain that third parties have not filed patent applications that cover our products and technologies.
Patents could be issued to third parties that we may ultimately be found to infringe. Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from using our technology. Our failure to obtain or maintain a license to any technology that we require may materially harm our business, financial condition and results of operations. Furthermore, we would be exposed to a threat of litigation.
62
From time to time, we may be party to, or threatened with, litigation or other proceedings with third parties, including non-practicing entities, who allege that our products, components of our products, and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. The types of situations in which we may become a party to such litigation or proceedings include:
•we may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or technologies do not infringe those third parties’ patents;
•we may participate at substantial cost in International Trade Commission proceedings to abate importation of products that would compete unfairly with our products or technologies;
•if a competitor files patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference, derivation or opposition proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position;
•if third parties initiate litigation claiming that our products or technologies infringe their patent or other intellectual property rights, we will need to defend against such proceedings;
•if third parties initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their products, services, or technologies do not infringe our patents or patents licensed to us, we will need to defend against such proceedings;
•we may be subject to ownership disputes relating to intellectual property, including disputes arising from conflicting obligations of consultants or others who are involved in developing our products and technologies; and
•if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our products or technologies infringe or misappropriate its patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we would need to defend against such proceedings.
These lawsuits and proceedings, regardless of merit, are time-consuming and expensive to initiate, maintain, defend or settle, and could divert the time and attention of managerial and technical personnel, which could materially adversely affect our business. Any such claim could also force us to do one or more of the following:
•incur substantial monetary liability for infringement or other violations of intellectual property rights, which we may have to pay if a court decides that the diagnostic test or technology at issue infringes or violates the third party’s rights, and if the court finds that the infringement was willful, we could be ordered to pay treble damages and the third party’s attorneys’ fees;
•stop manufacturing, offering for sale, selling, using, importing, exporting or licensing the diagnostic test or technology incorporating the allegedly infringing technology or stop incorporating the allegedly infringing technology into such test or technology;
•obtain from the owner of the infringed intellectual property right a license, which may require us to pay substantial upfront fees or royalties to sell or use the relevant technology and which may not be available on commercially reasonable terms, or at all;
•redesign our products and technologies so they do not infringe or violate the third party’s intellectual property rights, which may not be possible or may require substantial monetary expenditures and time;
•enter into cross-licenses with applicable third party, which could weaken our overall intellectual property position;
•lose the opportunity to license our technology to others or to collect royalty payments based upon successful protection and assertion of our intellectual property against others;
•find alternative suppliers for non-infringing technologies, which could be costly and create significant delay; or
•relinquish rights associated with one or more of our patent claims, if our claims are held invalid or otherwise unenforceable.
Third parties may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact our business, cause delays, or prohibit us from marketing or otherwise commercializing our products and technologies. Any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operation, financial condition or cash flows.
63
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a material adverse effect on the price of our common stock. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. The occurrence of any of these events may have a material adverse effect on our business, results of operation, financial condition or cash flows.
We depend on information technology systems that we license from third parties. Any failure of such systems or loss of licenses to the software that comprises an essential element of such systems could significantly harm our business.
We depend on information technology systems for significant elements of our operations, such as our laboratory information management systems, including test validation, specimen tracking and quality control, our bioinformatics analytical software systems, our test report generating systems and billing systems. For example, although we transitioned our billing and collection process in-house starting January 1, 2021, we continue to rely upon a third-party software application in the administration of these functions. Essential elements of these systems depend on software that we license from third parties. If we are unable to maintain the licenses to this software or our software providers discontinue or alter the programs on which we rely, it could render our test reports unreliable or hinder our ability to generate accurate test reports, among other things. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.
We rely on licenses from third parties, and if we lose these licenses or are not able to obtain licenses to third-party technology on reasonable grounds or at all, then we may not be able to continue to commercialize existing diagnostic tests, be subjected to future litigation and may not be able to commercialize new diagnostic tests in the future.
We are party to certain royalty-bearing license agreements that grant us rights to use certain intellectual property, including patents and patent applications, in certain specified fields of use. Although we intend to develop products and technologies through our own internal research, we may need to obtain additional licenses from others to advance our research, development and commercialization activities. Our license agreements impose, and we expect that future license agreements will impose, various development, diligence, commercialization and other obligations on us.
In the future, we may identify third-party technology we may need, including to develop or commercialize new diagnostic tests or services. In return for the use of a third party’s technology, we may agree to pay the licensor royalties based on sales of our solutions. Royalties are a component of the cost of our products or services and affect our margins. We may also need to negotiate licenses to patents or patent applications before or after introducing a commercialized test. The in-licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to in-license or acquire third-party intellectual property rights for technologies that we may consider attractive or necessary.
These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. In addition, we expect that competition for the in-licensing or acquisition of third-party intellectual property rights for technologies that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. We may not be able to obtain necessary or strategic licenses to patents or patent applications, and our business may suffer if we are unable to enter into these licenses on acceptable terms or at all, if any necessary licenses are subsequently terminated, if the licensors fail to abide by the terms of the licenses or fail to prevent infringement by third parties, or if the licensed patents or other rights are found to be invalid or unenforceable.
In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize tests and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties might have the freedom to seek regulatory approval of, and to market, tests identical to ours and we may be required to cease our development and commercialization activities. For example, we license certain intellectual property from WUSTL that is incorporated into DecisionDx-UM. In 2021, we provided over 1,600 test reports for DecisionDx-UM. If this license agreement were terminated, we would be unable to continue to issue test reports and thus sales of DecisionDx-UM. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.
Moreover, disputes may arise with respect to any one of our licensing agreements, including:
•the scope of rights granted under the license agreement and other interpretation-related issues;
64
•the extent to which our products, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;
•the sublicensing of patent and other rights under our collaborative development relationships;
•our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
•the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and
•the priority of invention of patented technology.
If we do not prevail in such disputes, we may lose any of such license agreements.
In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations.
The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected diagnostic tests, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.
Our failure to maintain such licenses could have a material adverse effect on our business, financial condition and results of operations. Any of these licenses could be terminated, such as if either party fails to abide by the terms of the license, or if the licensor fails to prevent infringement by third parties or if the licensed patents or other rights are found to be invalid or unenforceable. Absent the license agreements, we may infringe patents subject to those agreements, and if the license agreements are terminated, we may be subject to litigation by the licensor. Litigation could result in substantial costs and be a distraction to management. If we do not prevail, we may be required to pay damages, including treble damages, attorneys’ fees, costs and expenses, royalties or, be enjoined from selling our products or services, including DecisionDx-Melanoma and DecisionDx-UM, which could adversely affect our ability to offer our products or services, our ability to continue operations and our financial condition.
We may not be able to protect our intellectual property rights throughout the world.
Filing, prosecuting and defending patents on our products in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be inconsistent. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own tests or products and may also export infringing tests or products to territories where we have patent protection, but enforcement is not as strong as in the United States. These products may compete with our products. Our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to life science technologies, which could make it difficult for us to stop the infringement of our patents in such countries. We do not have patent rights in certain foreign countries in which a market may exist. Moreover, in foreign jurisdictions where we do have patent rights, proceedings to enforce our patent rights could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. We may not be able to stop a competitor from marketing and selling in foreign countries tests, products and services that are the same as or similar to our products and technologies, in which case our competitive position in the international market would be harmed.
65
If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business could be harmed.
In addition to pursuing patents on our technology, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We take steps to protect our trade secrets, in part, by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, academic institutions, corporate partners and, when needed, our advisers. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and, once disclosed, we are likely to lose trade secret protection and may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. If we are required to assert our rights against such party, it could result in significant cost and distraction.
Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets.
We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor, absent patent protection, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.
We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
We do and may employ individuals who previously worked with universities or other companies, including potential competitors. We could in the future be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of current or former employers or competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may become subject to claims that we caused an individual to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a current or former employer or competitor. Although, we are currently not subject to any such claims.
While we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management and other employees. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the current or former employers. Therefore, we could be required to obtain a license from such third-party employer to commercialize our products or technology. Such a license may not be available on commercially reasonable terms or at all.
Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition.
If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
We have not yet registered certain of our trademarks in all of our potential markets, although we have registrations for, among others, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-Melanoma, DecisionDx-SCC, myPath Melanoma and TissueCypher Barrett’s Esophagus Assay in the United States. Our current or future registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign
66
jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. In addition, third parties have used trademarks similar and identical to our trademarks in foreign jurisdictions, and have filed or may in the future file for registration of such trademarks. If they succeed in registering or developing common law rights in such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these trademarks to market our products in those countries. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Although these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.
We may be subject to claims challenging the inventorship of our patents and other intellectual property.
We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our products. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors’ ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, right to use, or right to exclude others from using, intellectual property that is important to our products. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.
In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.
Obtaining and maintaining our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications must be paid to the USPTO and various governmental patent agencies outside of the United States at several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction, such as failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we, or our licensors, fail to maintain the patents and patent applications covering our products and technologies, potential competitors may be able to enter the market without infringing our patents and this circumstance would have a material adverse effect on our business.
Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time.
Patents have a limited lifespan, and the protection patents afford is limited. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the term of a patent, and the protection it affords, is limited. Even if patents covering our products are obtained, once the patent term has expired, we may be open to competition from competitive tests or products. Given the amount of time required for the development, testing and regulatory review of potential new tests or products, patents protecting such tests or products might expire before or shortly after such tests or products are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing tests or other products similar or identical to ours.
67
Risks Related to Employee Matters and Managing Growth and Other Risks Related to Our Business
We are highly dependent on the services of our key personnel.
We are highly dependent on the services of our key personnel, including Derek J. Maetzold, our President and Chief Executive Officer. Although we have entered into agreements with our key personnel regarding their employment, they are not for a specific term and each of may terminate their employment with us at any time, though we are not aware of any present intention of any of these individuals to leave us.
Our research and development programs and laboratory operations depend on our ability to attract and retain highly skilled scientists and technicians. We may not be able to attract or retain qualified scientists and technicians in the future due to the competition for qualified personnel among life science businesses, particularly near our laboratory facilities and office spaces located in Phoenix, Arizona and Pittsburgh, Pennsylvania and our corporate headquarters in Friendswood, Texas. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. We may have difficulties locating, recruiting or retaining qualified salespeople. Recruiting and retention difficulties can limit our ability to support our research and development and sales programs. All of our employees are at-will, which means that either we or the employee may terminate their employment at any time.
Our employees, clinical investigators, consultants, speakers, vendors and any current or potential commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
We are exposed to the risk of fraud or other misconduct by our employees, clinical study investigators, consultants, speakers, vendors and any potential commercial partners. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: federal laws and regulations or those of comparable foreign regulatory authorities, including those laws that require the reporting of true, complete and accurate information; manufacturing standards; federal and state health and data privacy, security, fraud and abuse, government price reporting, transparency reporting requirements, and other healthcare laws and regulations in the United States and abroad; sexual harassment and other workplace misconduct; or laws that require the true, complete and accurate reporting of financial information or data. Such misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, as well as a disclosure program and other applicable policies and procedures, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional integrity reporting and oversight obligations, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.
We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy.
We have experienced significant revenue growth in a short period of time. We may not achieve similar growth rates in future periods. You should not rely on our operating results for any prior periods as an indication of our future operating performance. To effectively manage our anticipated future growth, we must continue to maintain and enhance our financial, accounting, laboratory operations, customer support and sales administration systems, processes and controls. Failure to effectively manage our anticipated growth could lead us to over-invest or under-invest in development, operational and administrative infrastructure, result in weaknesses in our infrastructure, systems, or internal controls, give rise to operational mistakes, losses, loss of customers, productivity or business opportunities, and result in loss of employees and reduced productivity of remaining employees.
We also anticipate further growth in our business operations. This future growth could create strain on our organizational, administrative and operational infrastructure, including laboratory operations, quality control, customer service and sales organization management. We expect to continue increasing our headcount and hire more specialized personnel in the future as we grow our business and expand our product offerings. We will need to continue to hire, train and manage additional qualified scientists, laboratory personnel, client and account services personnel, and sales and marketing staff and improve and maintain our technology to properly manage our growth. If our new hires perform poorly, if we are unsuccessful in hiring, training, managing and integrating these new employees or if we are not successful in retaining our existing employees, our business may be harmed.
68
In addition, our anticipated growth could require significant capital expenditures and might divert financial resources from other projects such as the development of new diagnostic tests and services. As we commercialize additional diagnostic and prognostic tests, we may need to incorporate new equipment, implement new technology systems, or hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher costs, declining quality, deteriorating customer service, and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products, and could damage our reputation and the prospects for our business.
We may not be able to maintain the quality or expected turnaround times of our products, or satisfy customer demand as it grows. Our ability to manage our growth properly will require us to continue to improve our operational, financial and management controls, as well as our reporting systems and procedures. The time and resources required to implement these new systems and procedures is uncertain, and failure to complete this in a timely and efficient manner could adversely affect our operations. If our management is unable to effectively manage our anticipated growth, our expenses may increase more than expected, our revenue could decline or grow more slowly than expected and we may be unable to implement our business strategy. The quality of our products and services may suffer, which could negatively affect our reputation and harm our ability to retain and attract customers.
We may engage in strategic transactions, such as the acquisition of businesses, assets, products or technologies, which could be disruptive to our existing operations, divert the attention of our management team and adversely impact our liquidity, cash flows, financial condition and results of operations.
From time to time, we may consider strategic opportunities and engage in transactions such as acquisitions of businesses, assets, products or technologies, as well as technology licenses or investments in complementary businesses. For example, in May 2021, we completed the acquisition of Myriad myPath Laboratory and in December 2021, we completed the acquisition of Cernostics. Any such transactions may entail numerous operational and financial risks, including:
•delays, difficulties and higher than expected costs associated with integration activities, such as those involving operational processes, regulatory and licensure compliance, personnel and information technology systems;
•disruption of our existing business operations and diversion of management’s time, focus and attention;
•decreases in our liquidity and operating cash flows, increases in our overall operating costs, substantial amounts of amortization expense, increased capital expenditure requirements and non-recurring charges, including possible impairments of acquired assets;
•incurrence of substantial debt or dilutive issuances of equity securities, the assumption of additional liabilities and exposure to unknown liabilities;
•inability to retain key personnel of any acquired businesses; and
•failure to realize any of the anticipated revenues, synergies, efficiencies or other benefits of a transaction within our estimated time frame or at all.
With regard to our acquisitions of the Myriad myPath Laboratory in May 2021 and Cernostics in December 2021, respectively, actual results may differ materially from our plans and expectations. For example, there can be no assurances regarding our ability to successfully scale and integrate the myPath Melanoma or TissueCypher Barrett’s Esophagus Assay into our commercial offerings and the ability of the combined strengths of Castle and Myriad myPath, LLC or Cernostics to position us for continued growth and success as a leader in the diagnostics space.
We are unable to predict the timing, size or nature of any future transactions, whether they will be completed or financed on favorable terms, if at all, or what the impact of those transactions might be on our financial results, including if such transactions are not effectively and profitably integrated into our business. Our failure to successfully complete the integration of any business that we acquire could have an adverse effect on our prospects, business activities, cash flows, financial condition, results of operations and stock price. Additionally, our ability to successfully integrate, manage and derive financial and other benefits from any acquired business, asset, product or technology is unproven.
Our ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to limitations.
As of December 31, 2021, we had federal net operating loss (“NOL”) carryforwards of approximately $99.4 million, of which $43.5 million will begin to expire in 2030 if not utilized to offset taxable income, and $55.9 million may be carried forward indefinitely. Also, as of December 31, 2021, we had state net operating loss carryforwards of $67.5 million, which begin to expire in 2028 if not utilized to offset state taxable income.
69
Under the legislation known as the Tax Cuts and Jobs Act of 2017 (“TCJA”), as modified by the CARES Act, federal NOLs generated in taxable years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such NOL carryforwards in taxable years beginning after December 31, 2020 is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the TCJA or the CARES Act.
In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an ‘‘ownership change’’ (which is generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporation’s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We have experienced ownership changes in the past and we may also experience additional ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our NOL carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations. In addition, at the state level, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.
If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences
In the ordinary course of business, we process proprietary, confidential, and sensitive information (including but not limited to intellectual property, proprietary business information and personal information). We manage and maintain our applications and information utilizing a combination of on-site systems, managed data centers, and cloud-based data centers, and we are increasingly dependent upon information technology systems, infrastructure and information to operate our business.
It is critical that we do so in a secure manner to maintain the confidentiality, availability and integrity of such information. We also have outsourced elements of our operations to third parties, including third-party service providers and technologies to help operate critical business systems to Process proprietary, confidential and sensitive information, and as a result we manage a number of third-party contractors who have access to our proprietary, confidential and sensitive information. Our ability to monitor these third parties’ cybersecurity information security practices is limited, and these third parties may not have adequate information security measures in place.
Cyberattacks, malicious internet-based activity, and online and offline fraud are prevalent, continue to increase, and are becoming increasingly difficult to detect. Threat actors, personnel (such as through theft or misuse), sophisticated nation-states, and nation-state-supported actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including cyber-attacks that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services. Despite the implementation of security measures designed to protect against a security incident, we and our contractors and consultants are vulnerable to a variety of evolving threats including but not limited to service interruptions, system malfunction, natural disasters, terrorism, war, public health crises, telecommunication and electrical failures, malware (including as a result of advanced persistent threat intrusions), malicious code, ransomware, supply chain attacks, denial-of-service attacks (such as credential stuffing), social engineering and other attempts to affect service reliability and threaten the confidentiality, integrity and availability of information. Ransomware attacks have become increasingly prevalent and severe and can lead to significant interruptions in our operations, loss of data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Supply-chain attacks have also increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners’ supply chains have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology systems (including our services) or the third-party information technology systems that support us and our services. Any of the previously identified or similar threats could cause a disruption or security incident, which could result in unauthorized, unlawful, or accidental loss of, damage to, modification of, destruction of, alteration of, encryption of, disclosure of, access to, or acquisition of our information and could interrupt our ability to provide our services.
While we have not experienced any such system failure, accident or material security incident to date, we cannot assure you that our data protection efforts and our investment in information technology have or will prevent security incidents, and we may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents, including
70
affected individuals, the Secretary of the HHS, states Attorneys General and others. Such disclosures are costly, and the disclosures or failure to comply could lead to adverse consequences.
If we or a third party upon whom we rely experience a security incident or are perceived to have experienced a security incident, we may experience government enforcement actions, additional reporting requirements and/or oversight, restrictions on processing data (including personal information), litigation, indemnification obligations, negative publicity, reputational harm, monetary fund diversions, interruptions in our operations, and other harms. Such consequences may disrupt our operations (including our ability to conduct our analyses, provide test results, bill payors or patients, process claims and appeals, provide customer assistance, conduct research and development activities, collect, process, and prepare company financial information, provide information about our products and other patient and physician education and outreach efforts through our website, and manage the administrative aspects of our business), damage our reputation, negatively impact our ability to grow our business, and others. For example, we maintain a tumor specimen database comprised of over 60,000 samples. Some of these samples were used to develop and validate DecisionDx-Melanoma, and, of those, some are currently being used to improve on the test and some will be used in the future. If we were to lose this database, our ability to further validate, improve and therefore maintain and grow sales of DecisionDx-Melanoma could be significantly impaired.
Our contracts may not contain limitations of liability, and there can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages if we fail to comply with applicable privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or adequately mitigate liabilities or damages with respect to claims, costs, expenses, litigation, fines, penalties, business loss, information loss, regulatory actions or material adverse impacts arising out of our privacy and security practices, Processing or security incidents we may experience, or that such coverage will continue to be available on commercially reasonable terms or at all.
Product or professional liability lawsuits against us could cause us to incur substantial liabilities and could limit our commercialization of our products.
We face an inherent risk of product and professional liability exposure related to our products. The marketing, sale and use of our products could lead to the filing of product liability claims were someone to allege that our products identified or reported inaccurate or incomplete information, or otherwise failed to perform as designed. We may also be subject to liability for errors in, a misunderstanding of or inappropriate reliance upon, the information we provide in the ordinary course of our business activities.
If we cannot successfully defend ourselves against claims that our products caused injury or otherwise failed to function properly, we could incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in:
•decreased demand for our current tests any tests that we may develop, and the inability to commercialize such tests;
•injury to our reputation and significant negative media attention;
•reluctance of experts willing to conduct our clinical studies;
•initiation of investigations by regulators;
•significant costs to defend the related litigation and diversion of management’s time and our resources;
•substantial monetary awards to study subjects or patients;
•product recalls, withdrawals or labeling, or marketing or promotional restrictions; and
•loss of revenue.
We currently carry product liability insurance. However, the amount of this insurance may not be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.
International expansion of our business exposes us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.
While we currently accept orders from customers outside of the United States, our historical business strategy has been directed toward customers within the United States. Our long-term business strategy contemplates potential international expansion. Doing business internationally involves a number of risks, including:
•multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, economic sanctions and embargoes, employment laws, regulatory requirements and other governmental approvals, permits and licenses;
71
•limits in our ability to penetrate international markets if we are not able to perform tests locally;
•logistics and regulations associated with shipping tissue samples, including infrastructure conditions and transportation delays;
•difficulties in staffing and managing foreign operations;
•failure to obtain regulatory approvals for the commercialization of our products in various countries;
•complexities and difficulties in obtaining intellectual property protection and enforcing our intellectual property;
•complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems;
•financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;
•natural disasters, political and economic instability, including wars, terrorism, and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; and
•regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors’ activities that may fall within the purview of the FCPA, its books and records provisions, or its anti-bribery provisions.
Any of these factors could significantly harm our future international expansion and operations and, consequently, our revenue and results of operations.
Requirements associated with being a public company will continue to increase our costs, as well as divert significant company resources and management attention.
We are subject to the reporting requirements of the Exchange Act or the other rules and regulations of the SEC and any securities exchange relating to public companies. Sarbanes-Oxley, as well as rules subsequently adopted by the SEC and The Nasdaq Stock Market LLC (“Nasdaq”) to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory ‘‘say on pay’’ voting requirements that now apply to us since we are no longer an emerging growth company effective December 31, 2021. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Compliance with the various reporting and other requirements applicable to public companies requires considerable time and attention of management. We cannot assure you that we will satisfy our obligations as a public company on a timely basis.
We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. We were previously afforded exemptions from certain public company reporting requirements and were permitted to apply scaled disclosure requirements as a result of our status as an emerging growth company and a smaller reporting company, respectively. However, effective December 31, 2021, we ceased to be an emerging growth company and are no longer be permitted to apply the related exemptions. For example, in connection with this change, beginning with this Annual Report on Form 10-K for the year ended December 31, 2021 we were required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting and were required to apply public company adoption dates to new and revised accounting standards. Further, we are now subject to the reporting deadlines of a large accelerated filer. Beginning with our first Quarterly Report on Form 10-Q for the fiscal year ending December 31, 2022, we will no longer be permitted to take advantage of scaled disclosure requirements for smaller reporting companies. If we are unable to comply with these requirements on a timely basis or if the attention of our management and personnel is diverted from other business concerns, it could have a material adverse effect on our business, financial condition and results of operations. The increased costs will increase our net loss or decrease our net income, and may require us to reduce costs in other areas of our business or increase the prices of our products. In addition, as we expand, it may be more difficult or more costly for us to obtain certain types of insurance, including directors’ and officers’ liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified personnel to serve on our board of directors, our board committees or as executive officers.
72
If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
We, and the third parties with whom we share our facilities, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous materials by us or the third parties with whom we share our facilities, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.
Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.
In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research and development. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.
Our business could be adversely impacted by inflation.
Recently, the rate of inflation in the U.S. has risen to levels not experienced in decades. We have begun to see some inflationary pressures, primarily in personnel and related costs. The extent of any future impacts from inflation on our business and our results of operations will be dependent upon how long the elevated inflation levels persist and if the rate of inflation were to further increase, neither of which we are able to predict. If elevated levels of inflation were to persist or if the rate of inflation were to accelerate, the purchasing power of our cash and cash equivalents may be eroded, our expenses could increase faster than anticipated and we may utilize our capital resources sooner than expected. Further, given the complexities of the reimbursement landscape in which we operate, our payors may be unwilling or unable to increase reimbursement rates to compensate for inflationary impacts.
Our business could be adversely affected by natural disasters, public health epidemics and other events beyond our control.
Although we maintain crisis management plans, our business operations are subject to interruption by natural disasters and other events and catastrophes beyond our control, including, but not limited to, earthquakes, floods, fires, tornadoes, hurricanes, power or other utility outages, telecommunications failures and public health crises. Further, outbreaks of epidemic diseases, such as the COVID-19 pandemic discussed above, or the fear of such events, could provoke responses, including government-imposed travel restrictions that could impede the mobility and effectiveness of our sales force, disrupt our operations or those of our suppliers and service providers. The ultimate impact of any of these or similar events is highly uncertain and could have a material adverse impact on our operations.
Risks Related to Ownership of Our Common Stock
The stock price of our common stock may be volatile or may decline regardless of our operating performance, and you may lose all or part of your investment.
The market price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including:
•our operating performance and the performance of other similar companies;
•our success in marketing and selling our products;
•reimbursement determinations by third-party payors and reimbursement rates for our products;
•changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by securities analysts that elect to follow our common stock;
•regulatory or legal developments in the United States and other countries;
•the level of expenses related to product development and clinical studies for our products;
•our ability to achieve product development goals in the timeframes we announce;
•announcements of clinical study results, regulatory developments, acquisitions, strategic alliances or significant agreements by us or by our competitors;
73
•the success or failure of our efforts to acquire, license or develop additional tests;
•recruitment or departure of key personnel;
•general economic conditions and market conditions specific to our industry;
•interest rates and the rate of inflation;
•the extent and duration of the impacts from the COVID-19 pandemic;
•trading activity by a limited number of stockholders who together beneficially own a significant percentage of our outstanding common stock;
•the size of our market float; and
•any other factors discussed in this Annual Report on Form 10-K.
In addition, the stock market in general, and diagnostic and life sciences companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our securities, regardless of our actual operating performance. In the past, stockholders have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and adversely affect our business.
If there are substantial sales of shares of our common stock, the price of our common stock could decline.
The price of our common stock could decline if there are substantial sales of our common stock, particularly sales by our directors, executive officers and significant stockholders, or if there is a large number of shares of our common stock available for sale and the market perceives that sales will occur. Shares held by directors, executive officers and other affiliates are subject to volume limitations under Rule 144 under the Securities Act of 1933.
Certain of our stockholders have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or our stockholders. We filed such a registration statement in January 2022 to register the resale of shares of our common stock issuable in connection with our acquisition of Cernostics in December 2021. We have registered shares of common stock that we have issued and may issue under our employee equity incentive plans. As a result, these shares will be able to be sold freely in the public market upon issuance.
The market price of the shares of our common stock could decline as a result of the sale of a substantial number of our shares of common stock in the public market or the perception in the market that the holders of a large number of shares intend to sell their shares.
We have broad discretion in the use of working capital and may not use it effectively or in ways that increase our share price.
We cannot specify with any certainty the particular uses of working capital, but we currently expect such uses will include: funding selling and marketing activities, including expansion of our sales force to support the ongoing commercialization of current and future products; research and development related to the continued support of our current products as well as the development of our product pipeline; and other general corporate purposes, including the additional costs associated with being a public company. The failure by our management to apply our working capital effectively could adversely affect our business and financial condition. Pending its use, we may invest working capital in a manner that does not produce income or that loses value. These investments may not yield a favorable return to our investors.
If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.
The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline.
Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules
74
and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.
These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related party transaction disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. In addition, we do not have a risk management program or processes or procedures for identifying and addressing risks to our business in other areas.
We have and may continue to enter into related party transactions that create conflicts of interest, or the appearances of conflicts of interest, which may harm our business and cause our stock price to decline.
We have entered into related party transactions that create conflicts of interest between our interests and the interests of our directors and executive officers. For example, we employ three children and a brother-in-law of Derek J. Maetzold, our President and Chief Executive Officer, three children and a son-in-law of Kristen M. Oelschlager, our Chief Operating Officer, and the son of Tobin W. Juvenal, our Chief Commercial Officer, in each case in non-officer positions. These arrangements are required to be disclosed in our annual proxy statement and/or in the notes to our consolidated financial statements based on certain criteria. We may engage in other transactions in the future involving our executive officers, directors and their family members and/or entities which they control or are affiliated, which could cause individuals in our management to seek to advance their economic interests or the economic interests of certain related parties above ours. Although we have a written policy on related party transactions that involves independent review and oversight by the audit committee of our board of directors, there can be no assurances that conflicts of interest will not exist, or that we will be able to adequately address or mitigate any actual or perceived conflicts of interest, and stockholders, analysts, proxy advisory firms, the news media and other parties may view these transactions as representing conflicts of interest or as otherwise inappropriate, which may result in negative public perception and reputational harm, and could impair our ability to enter into new customer relationships or attract and retain employees. Potential, perceived and actual conflicts of interest could cause investors to question the independence of our management, the adequacy and effectiveness of our disclosure controls and procedures or the integrity of our corporate governance procedures and compensation practices, which could have a material adverse effect on the trading price of our common stock and our business, financial condition and results of operations.
We do not intend to pay dividends for the foreseeable future.
We have never declared nor paid cash dividends on our capital stock. We currently intend to retain any future earnings to finance the operation and expansion of our business, and we do not expect to declare or pay any dividends in the foreseeable future. Consequently, stockholders must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investment.
The concentration of our stock ownership will likely limit your ability to influence corporate matters, including the ability to influence the outcome of director elections and other matters requiring stockholder approval.
Based upon shares outstanding as of December 31, 2021, our executive officers, directors and the known holders of more than 5% of our outstanding common stock, in the aggregate, beneficially owned approximately 27% of our common stock. As a result, these stockholders, acting together, will have significant influence over all matters that require approval by our stockholders, including the election of directors and approval of significant corporate transactions. Corporate actions might be taken even if other stockholders oppose them. This concentration of ownership might also have the effect of delaying or preventing a change of control of our company that other stockholders may view as beneficial.
Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.
Provisions of our amended and restated certificate of incorporation and amended and restated bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our amended and restated certificate of incorporation and amended and restated bylaws:
•permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate (including the right to approve an acquisition or other change in our control);
•provide that the authorized number of directors may be changed only by resolution of the board of directors;
75
•provide that the board of directors or any individual director may only be removed with cause and the affirmative vote of the holders of at least 66-2/3% of the voting power of all of our then outstanding common stock;
•provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;
•divide our board of directors into three classes;
•require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;
•provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder’s notice;
•do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose);
•provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors;
•provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf; (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; (iii) any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws; (iv) any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws; (v) any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi) any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court’s having personal jurisdiction over the indispensable parties named as defendants; provided these provisions of our amended and restated certificate of incorporation and amended and restated bylaws will not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and
•provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, subject to and contingent upon a final adjudication in the State of Delaware of the enforceability of such exclusive forum provision.
The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least 66-2/3% of our then-outstanding common stock.
In addition, as a Delaware corporation, we are subject to Section 203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision.
These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction.
76
Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf; (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; (iii) any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees arising out of or pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or amended and restated bylaws; (iv) any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws; (v) any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi) any action asserting a claim against us or any of our directors, officers or other employees that is governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court’s having personal jurisdiction over the indispensable parties named as defendants; provided these provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation and amended and restated bylaws provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, subject to and contingent upon a final adjudication in the State of Delaware of the enforceability of such exclusive forum provision. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.
These choice of forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees and may discourage these types of lawsuits. Furthermore, the enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions.
Item 1B. Unresolved Staff Comments.
None.
Item 2. Properties.
We have a lease agreement for approximately 23,700 square feet of office space in Friendswood, Texas that is used as our corporate headquarters. This lease commenced in late 2020 and has a 60-month term, with an option to renew for one additional five-year period. We also lease approximately 29,700 square feet of laboratory and office space in Phoenix, Arizona under two agreements, both of which expire on April 30, 2033. For both leases, there are options to renew for two additional five-year terms. In connection with our recent acquisition of Cernostics in December 2021, we have approximately 8,100 square feet of office and laboratory space in Pittsburgh, Pennsylvania under a lease which expires on November 30, 2022, with the option to renew for one additional year. In support of our growth strategy, we anticipate acquiring additional office and laboratory space in the near future.
Item 3. Legal Proceedings.
From time to time, we may be involved in legal proceedings arising in the ordinary course of business. We believe there is no threatened litigation or litigation pending that could have, individually or in the aggregate, a material adverse effect on our financial position, results of operations or cash flows.
77
Item 4. Mine Safety Disclosures.
Not applicable.
78
PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Market Information
Our Common Stock, $0.001 par value per share, began trading on the Nasdaq Global Market under the symbol “CSTL” on July 25, 2019. Prior to that date, there was no public trading market for our common stock.
Holders of Record
As of February 21, 2022, there were approximately 30 stockholders of record of our common stock, which does not include stockholders who hold shares in street name.
Dividend Policy
We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on, among other factors, our financial condition, operating results, capital requirements, contractual restrictions, general business conditions and other factors that our board of directors may deem relevant.
Securities Authorized for Issuance Under Our Equity Compensation Plans
Information regarding securities authorized for issuance under our equity compensation plans is incorporated herein by reference to Item 12, “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” of Part III of this Annual Report on Form 10-K.
Performance Graph
Not required for smaller reporting companies.
Recent Sales of Unregistered Equity Securities
None.
Use of Proceeds from IPO of Common Stock
On July 29, 2019, we completed the initial public offering of our common stock (our “IPO”), pursuant to which we issued and sold 4,600,000 shares of our common stock, including 600,000 shares associated with the full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $16.00 per share.
The offer and sale of all of the shares of our common stock in the IPO were registered under the Securities Act pursuant to our Registration Statements on Form S-1, as amended (File Nos. 333-232369 and 333-232796), which were declared or became effective on July 24, 2019.
There has been no material change in our planned use of the net proceeds from the IPO as described in the final prospectus filed with the SEC on July 26, 2019 relating to our Registration Statements on Form S-1 (File Nos. 333-232369 and 333-232796).
Since the effective date of our registration statement through December 31, 2021, we have not used any of the net proceeds from the IPO. Pending such uses, we have invested, and plan to continue to invest, the balance of the net proceeds from the IPO in cash and cash equivalent securities or highly liquid investment securities.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
None.
Item 6. Reserved.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis of financial condition and results of operations together with our consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results, performance or achievements could differ materially from any future results, performance or achievements discussed in these forward-looking statements. Factors
79
that could cause or contribute to such differences include, but are not limited to, those discussed in the section titled “Risk Factors.”
Overview
Castle Biosciences is improving health through innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the personalized information our diagnostic and prognostic tests provide.
We currently market five proprietary MAAAs, designed to answer clinical questions in dermatologic cancers, UM and BE. Our revenue is primarily generated by our DecisionDx®-Melanoma risk stratification test for cutaneous melanoma and our DecisionDx®-UM risk stratification test for UM.
The foundation of our business is our dermatologic cancer franchise, and our lead product is DecisionDx-Melanoma, a proprietary risk stratification GEP test that predicts the risk of metastasis, or recurrence for patients diagnosed with invasive cutaneous melanoma, a deadly skin cancer. In the management of melanoma, as with nearly all diseases, treatment plans are directed by patient risk-stratification. This test has two distinct, complementary clinically actionable uses. The first revolves around predicting the likelihood of having a SLN negative biopsy result so that physicians and patients can discuss the risk and benefit of undergoing the SLNB surgical procedure. The second use is to inform the appropriate treatment plan during the initial five years post-diagnosis, regardless of the decision to undergo or avoid invasive SLNB surgery. In a typical year, we estimate approximately 130,000 patients are diagnosed with invasive cutaneous melanoma in the United States. We launched DecisionDx-Melanoma in May 2013. Based on the substantial clinical evidence that we have developed, we have received Medicare coverage for DecisionDx-Melanoma, which represents approximately 50% of the addressable patient population for this test.
On August 31, 2020, we commercially launched our SCC proprietary GEP test, DecisionDx®‑SCC, for use in patients with one or more risk factors (also referred to as “high-risk” SCC). On November 2, 2020, we commercially launched our proprietary GEP test for difficult-to-diagnose melanocytic lesions, DecisionDx® DiffDx™-Melanoma for use in patients with a melanocytic lesion and uncertainty related to the malignancy of the lesion. We believe that these two additional skin cancer tests address areas of high clinical need in dermatological cancer and, together, represent an estimated addressable population of approximately 500,000 patients in the United States.
We further expanded our commercially available dermatologic portfolio in May 2021 when we acquired the myPath Laboratory from Myriad Genetics, Inc. for a cash purchase price of $32.5 million. myPath Melanoma is a clinically validated GEP test that addresses the same unmet clinical need as our DecisionDx DiffDx-Melanoma test. Today, we offer both our myPath Melanoma test and our DecisionDx DiffDx-Melanoma test under an offering that we refer to as our CDO of molecular testing solutions. By offering both of these tests in a single offering, we believe we have demonstrated the ability to improve the test result performance for patients with difficult-to-diagnose melanocytic lesions.
In 2021, we announced the launch of our innovative pipeline initiative to develop a genomic test aimed at predicting response to systemic therapy in patients with moderate to severe psoriasis, atopic dermatitis and related inflammatory skin conditions. In the U.S. alone, there are approximately 18 million patients diagnosed with psoriasis and atopic dermatitis. Approximately 450,000 of these patients annually are eligible for systemic therapies. If successful, this inflammatory skin disease pipeline test has the potential to add approximately $1.9 billion to our current estimated U.S. TAM. In 2021, we initiated a 4,800 patient, prospective, multi-center clinical study to develop and validate this pipeline test and have 50 committed centers, out of the initial target of 50. Based upon our current development and validation timelines, we expect to commercialize this pipeline test by the end of 2025.
In addition to our dermatologic franchise, we also market a test for patients diagnosed with UM, a rare cancer of the eye. DecisionDx®-UM is a proprietary, risk stratification GEP test that predicts the risk of metastasis for patients with UM. We believe DecisionDx-UM is the standard of care in the management of newly diagnosed UM in the majority of ocular oncology practices in the United States. We launched DecisionDx-UM in January 2010. Based on the substantial clinical evidence that we have developed, we received Medicare coverage for DecisionDx-UM, which represents approximately 50% of the addressable patient population.
In December 2021, we extended our commercial portfolio of proprietary tests into the gastroenterology market through our acquisition of Cernostics and the TissueCypher® platform. The TissueCypher platform focuses on unlocking, in the case of the initial test for use in patients with BE, the importance of the location of the expression of proteins or lack thereof within the morphology of the disease (also known as spatialomics). This “spatialomic” information is then interpreted using artificial intelligence approaches to predict the likelihood of progression to high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite or low-grade dysplasia BE. We believe the addition of expertise in the spatialomics area
80
positions us for continued growth and success in the diagnostics space, complementing our first-to-market dermatologic franchise and our proprietary test for UM.
The number of test reports we generate is a key indicator that we use to assess our business. A test report is generated when we receive a sample in our laboratory, and then the relevant test information is entered into our Laboratory Information Management System, the expression of the biomarkers is measured, then a proprietary algorithmic analysis of the combined biomarkers is performed to generate a report providing the results of that analysis, which is sent to the clinician who ordered the test. The numbers of GEP test reports delivered by us during the years ended December 31, 2021 and 2020 are presented in the table below:
Proprietary Dermatologic GEP Tests
 DecisionDx-
Melanoma
DecisionDx-SCC(1)
CDO(2)
Dermatologic TotalDecisionDx-UMGrand Total
Q1 20214,060 527 218 4,805 337 5,142 
Q2 20215,128 784 627 6,539 468 7,007 
Q3 20215,505 934 913 7,352 375 7,727 
Q4 20215,635 1,265 904 7,804 438 8,242 
For the year ended December 31, 202120,328 3,510 2,662 26,500 1,618 28,118 
Q1 20204,574 — — 4,574 361 4,935 
Q2 20203,008 — — 3,008 306 3,314 
Q3 20204,404 57 — 4,461 318 4,779 
Q4 20204,246 428 73 4,747 410 5,157 
For the year ended December 31, 202016,232 485 73 16,790 1,395 18,185 
(1)We commercially launched DecisionDx-SCC on August 31, 2020.
(2)Includes DecisionDx DiffDx-Melanoma, which we commercially launched on November 2, 2020, and myPath Melanoma, which we began offering following our acquisition of Myriad myPath Laboratory on May 28, 2021. We offer both our myPath Melanoma and DecisionDx DiffDx-Melanoma under our CDO.
For the year ended December 31, 2021, our dermatologic test report volume increased by 57.8%, reflecting growth in DecisionDx-Melanoma as well as the full year availability of DecisionDx-SCC and DecisionDx DiffDx-Melanoma (now offered as part of CDO). For a discussion of how we recognize revenue derived from our GEP tests, refer to “Net Revenues” under “Components of Results of Operations” below.
The principal focus of our current commercial efforts is to educate clinicians and pathologists on the value of our molecular diagnostic testing products through our direct sales force in the U.S. In dermatology, we began 2020 with 32 outside sales territories. In the third quarter of 2020, we expanded our dermatologic commercial team to create a dedicated sales force of ten territories to support the launch of our DecisionDx Diff-Dx Melanoma test to dermatopathologists. During the first half of 2021, we folded this dedicated team into our existing sales team and completed a further expansion, bringing our dermatologic sales force to the mid-60s. In connection with our acquisition of Cernostics in December 2021, we hired an initial commercial team of approximately 14 outside sales territories, along with commensurate internal sales associates and medical science liaisons, to support our launch of the TissueCypher Barrett’s Esophagus Assay. This dedicated team focuses on gastroenterology specialists that diagnose and manage patients with BE. However, we will continue to evaluate our mix of outside sales territories, inside sales support, marketing and medical affairs in the context of our dermatologic tests and gastroenterology tests and adjust our investments based upon these evaluations.
We continue to see new clinicians order our dermatologic tests for the first time. For the year ended December 31, 2021, we saw approximately 1,938 new ordering clinicians for our dermatologic tests compared to 1,396 during the same period of 2020. Total ordering clinicians for our dermatologic tests were approximately 5,900 for the year ended December 31, 2021.
For additional information on the metrics we disclose, refer to “Information about certain metrics” below.
In developing our DecisionDx-SCC and DecisionDx DiffDx-Melanoma tests, we believed that in addition to addressing significant unmet clinical needs, we would see strategic opportunities for leverage, as many of the clinicians currently ordering DecisionDx-Melanoma would likely be the same clinicians who would find value in these other skin cancer tests. For example,
81
we found that for the year ended December 31, 2021, approximately 78% of all clinicians ordering DecisionDx-SCC had also ordered our DecisionDx-Melanoma test during that same period.
We bill third-party payors and patients for the tests we perform. The majority of our revenue collections is paid by third-party insurers, including Medicare. We have received LCDs, which provide coverage for our DecisionDx-Melanoma, myPath Melanoma and DecisionDx-UM tests that meet certain criteria for Medicare and Medicare Advantage beneficiaries, representing approximately 60 million covered lives. In 2022, DecisionDx-UM has received coverage from United Healthcare that will represent approximately 43 million covered lives. A ‘‘covered life’’ means a subscriber, or a dependent of a subscriber, who is insured under an insurance carrier’s policy.
Palmetto, the MAC responsible for administering MolDX, the program that assesses molecular diagnostic technologies, issued a final expanded LCD for DecisionDx-Melanoma, effective November 22, 2020. With this expanded LCD and the accompanying billing and coding articles, we estimate that a significant majority of the DecisionDx-Melanoma tests performed for Medicare patients will meet the coverage criteria. Noridian, the MAC responsible for administering claims for laboratory services performed in Arizona, has adopted the same coverage policy as Palmetto and also issued an expanded final LCD for DecisionDx-Melanoma, effective December 6, 2020.
Separately, Palmetto issued a final LCD for DecisionDx-UM, which became effective in July 2017, and Noridian issued a similar LCD that became effective in September 2017. The Noridian LCD provides for coverage to determine metastatic risk in connection with the management of a patient’s newly diagnosed uveal melanoma and to guide surveillance and referral to medical oncology for those patients. Similar to cutaneous melanoma, the median age at diagnosis for uveal melanoma is estimated at 58-62 years old, therefore the Medicare eligible population represents close to 45% of the addressable market.
On May 17, 2019, CMS determined that DecisionDx-UM meets the criteria for “existing advanced diagnostic laboratory test” status, also referred to as “existing ADLT” status. For 2020, our rate was set by Noridian, our local MAC, but effective in 2021 our rate is set annually based upon the median private payor rate for the first half of the second preceding calendar year. Our rate for 2021 was $7,776 and will remain at $7,776 for 2022, in each case based on the calculation of the median private payor rate.
Also, on May 17, 2019, CMS determined that DecisionDx-Melanoma meets the criteria for “new ADLT” status. Accordingly, from July 1, 2019 through March 31, 2020, the Medicare reimbursement rate was equal to the initial list price of $7,193. From April 1, 2020 through December 31, 2021, the rate was also $7,193, which was calculated based upon the median private payor rate for DecisionDx-Melanoma from July 1, 2019 to November 30, 2019. CMS has informed us that the rate for 2022 will continue to be $7,193, based on the median private payor rate.
myPath Melanoma is currently covered under a MolDX LCD policy through Noridian that oversees laboratories in both Utah and Arizona. Noridian issued an LCD that became effective in June 2019. On September 6, 2019, myPath Melanoma was approved as a new ADLT. The rate for 2022 will be $1,950.
TissueCypher is performed in our Pittsburgh, Pennsylvania laboratory and falls under the Medicare jurisdiction that is managed by Novitas. Novitas previously reviewed TissueCypher and we are receiving payments for claims according to the CLFS. For 2022, CMS published in its CLFS a payment amount of $2,513 for the test.
Beginning in 2023, the rates for DecisionDx-Melanoma, DecisionDx-UM, and myPath Melanoma tests will be set annually based upon the median private payor rate for the first half of the second preceding calendar year. For example, the rate for 2023 will be set using median private payor rate data from January 1, 2021 to June 30, 2021.
In the second quarter of 2020, we submitted our technical assessment dossier for DecisionDx-SCC to Palmetto and Noridian. The dossier was accepted as complete in the third quarter of 2020. In early 2021, we submitted our technical assessment dossier for DecisionDx DiffDx-Melanoma. The dossier was accepted as complete in the first quarter of 2021. We expect that draft LCDs for DecisionDx-SCC and DecisionDx DiffDx-Melanoma could potentially be posted by the end of the second quarter of 2022 resulting in potentially final LCDs effective in 2023. However, there is no assurance that the timing of any draft or final LCD will match our expectations or our historical experience with LCDs for our other tests.
In the second quarter of 2021, Palmetto and the other MACs that participate in the MolDX program posted a revised draft LCD for DecisionDx-Melanoma. The draft LCD includes commentary about two publications regarding the clinical utility of GEP tests and was posted to give providers an opportunity to comment. Each of the draft LCDs include an assessment stating that the MAC does not believe that the new data is sufficient to change the coverage criteria. We have submitted comments on the draft LCD. The comment period on the last of these draft LCDs closed on August 8, 2021. We are unable to predict when the final draft LCD will be posted.
Since becoming a public company, we have financed our operations with the revenue generated from the sale of our products, proceeds from our July 2019 IPO, follow-on public offerings of common stock in June 2020 and December 2020 and bank debt, which has since been repaid in full. We believe that our existing cash and cash equivalents and anticipated cash generated
82
from sales of our products will be sufficient to fund our operations for the next 12 months and into the foreseeable future. However, we have based these estimates on assumptions, including those related to the impact of COVID-19 on our financial condition, that may prove to be wrong, and could result in us depleting our capital resources sooner than expected.
Our net (loss) income may fluctuate significantly from period to period, depending on the timing of our planned development activities, the growth of our sales and marketing activities and the timing of revenue recognition under ASC 606. We expect our expenses will increase substantially over time as we:
•execute clinical studies to generate evidence supporting our current and future product candidates;
•execute our commercialization strategy for our current and future commercial products;
•continue our ongoing and planned development of new products in our pipeline;
•seek to discover and develop additional product candidates;
•hire additional scientific and research and development staff; and
•add additional operational, financial and management information systems and personnel.
Furthermore, we expect to continue to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses.
Impact of COVID-19 Pandemic
We are continuing to closely monitor the impact of the COVID-19 pandemic on our business and taking proactive efforts designed to protect the health and safety of our workforce, continue our business operations and advance our corporate objectives. We are providing the following update with respect to the impact of COVID-19 on our business:
•We have maintained, and expect to continue to maintain, uninterrupted business operations with adequate access to reagents and consumables needed for testing patient samples and normal turnaround times for our delivery of test reports. We have continued to maintain our previously implemented adjustments to our operations designed to keep employees safe and comply with federal, state and local guidelines, including those regarding social distancing.
•Following the onset of the COVID-19 pandemic, we experienced declines in orders and test report volume. For example, in the second quarter of 2020, test reports delivered for our lead product, DecisionDx-Melanoma, decreased 18.5% compared to the second quarter of 2019. For the year ended December 31, 2020, our growth in DecisionDx-Melanoma test report volume was 4.5%, compared to year-over-year growth of 29.1% for the year ended December 31, 2019. Our analysis of third-party data indicates that cutaneous melanoma diagnoses for the year ended December 31, 2020 were down approximately 20% compared to the year ended December 31, 2019. In the first quarter of 2021, test reports delivered for DecisionDx-Melanoma decreased by 11.2% compared to the first quarter of 2020. We believe these decreases in our test report volume were linked to delays and/or cancellations in patient visits, resulting in fewer diagnostic biopsies and thus a reduction in the number of diagnoses of cutaneous melanoma in response, as well as the cumulative impact on promotional responsiveness as a result of reduced sales calls per day and in-person sales call during the COVID-19 pandemic.
•We saw positive trends in orders and test report volumes in the second, third, and fourth quarters of 2021. In the second, third and fourth quarters of 2021, test reports delivered for DecisionDx-Melanoma increased by 70.5%, 25.0% and 32.7%, respectively, compared to the same quarters in 2020.
•Our commercial team uses a combination of in-person, virtual, and non-personal promotional and educational efforts. Since the beginning of 2021, we have seen improvements in the number of promotional calls per day, as well as a continued shift from virtual to in-person sales calls. During the three-months ended December 31, 2021, in-person sales calls accounting for over 90% of all calls during such period. However, we have not yet achieved pre-COVID-19 levels of calls per day per sales representative.
•Our future results will be dependent upon the extent and duration of the COVID-19 crisis, including the emergence and spread of variants of the virus, such as the Omicron variant, and government restrictions, which are beyond our control. Although state and local government restrictions put in place to slow the spread of the virus have been eased in certain locations, restrictions may be reinstated from time to time in various regions depending on the circumstances, potentially impacting the flow of future patient visits as well as access to our sales targets. Even with the easing of state and local restrictions and the availability of vaccinations, patient visits and diagnoses of cutaneous melanoma may be impacted by continued apprehension regarding possible exposure to the virus. For example, our
83
analysis of third-party data indicates that cutaneous melanoma diagnoses during the year ended December 31, 2021 remain approximately 11% below the pre-COVID, 2019 levels.
•We continue to believe our cash, cash equivalents and anticipated cash to be generated from sales of our products, will be sufficient to fund our operations for the next 12 months and into the foreseeable future.
As conditions are continuously evolving, we are unable to predict how our future test report volume will be impacted, or the extent to which our results of operations, financial condition or cash flows will be impacted, by the COVID-19 pandemic, or other future public health crises. Accordingly, the test report data presented above is not necessarily indicative of our results of operations that can be expected for future periods. For more information on the potential impact of the COVID-19 pandemic on our business, see the risk factors included under “Risks Related to Our Business” and the other risk factors included in Part I, Item 1A., “Risk Factors,” of this Annual Report on Form 10-K.
Factors affecting our performance
We believe there are several important factors that have impacted, and that we expect will continue to impact, our operating performance and results of operations, including:
•Report volume. We believe that the number of reports we deliver to physicians is an important indicator of the growth of adoption among the healthcare provider community. Our revenue and costs are affected by the volume of testing and mix of customers. Our performance depends on our ability to retain and broaden adoption with existing prescribing physicians, as well as attract new physicians. In the near term, our report volume may be negatively impacted by ongoing developments of the COVID-19 pandemic as discussed above.
•Reimbursement. We believe that expanding reimbursement is an important indicator of the value of our products. Payors require extensive evidence of clinical utility, clinical validity, patient outcomes and health economic benefits in order to provide reimbursement for diagnostic products. Our revenue depends on our ability to demonstrate the value of our products to these payors.
•Gross margin. We believe that our gross margin is an important indicator of the operating performance of our business. Higher gross margins reflect the average selling price of our tests, as well as the operating efficiency of our laboratory operations.
•New product development. A significant aspect of our business is our investment in research and development activities, including activities related to the development of new products. In addition to the development of new product candidates, we believe these studies are critical to gaining physician adoption of new products and driving favorable coverage decisions by payors for such products.
Information about certain metrics
The following provides additional information about certain metrics we have disclosed in this Management’s Discussion and Analysis of Financial Condition and Results of Operation.
Test reports delivered for DecisionDx-Melanoma, DecisionDx-SCC, myPath Melanoma/DecisionDx DiffDx-Melanoma, DecisionDx-UM and TissueCypher Barret’s Esophagus Assay represents the number of completed test reports delivered by us during the reporting period indicated. The period in which a test report is delivered does not necessarily correspond with the period the related revenue, if any, is recognized, due to the timing and amount of adjustments for variable consideration under ASC 606. We use this metric to evaluate the growth in adoption of our tests and to measure against our internal performance objectives. We believe this metric is useful to investors in evaluating the volume of our business activity from period-to-period that may not be discernible from our reported revenues under ASC 606. We also sometimes present, on a limited basis, data on the number of orders received. We believe order data can provide additional insight on current demand trends, particularly during the COVID-19 pandemic and with respect to new product launches, when considered in conjunction with test report volume. However, orders received in a particular period do not necessarily correspond with actual delivered test reports or reported revenues for the same period or subsequent periods.
New ordering clinicians for our dermatologic tests represents the number of clinicians who ordered a dermatologic test from us for the first time during the reporting period specified. Our dermatologic tests consist of DecisionDx-Melanoma, DecisionDx-SCC and our CDO. We believe this metric is useful in evaluating the effectiveness of our sales and marketing efforts in establishing new relationships with clinicians and increasing the adoption of our suite of dermatologic tests. We also believe this metric provides useful information to investors in assessing our ability to expand the use of our dermatologic tests. Since this metric is based upon the reporting period in which an order is placed, it does not necessarily correspond to the reporting period in which a test report was delivered or revenue was recognized.
84
Components of the Results of Operations
Net Revenues
We generate revenues from the sale of our products. Currently, our revenues are primarily derived from the sale of DecisionDx-Melanoma and DecisionDx-UM. We bill third-party payors and patients for the tests we perform.
Under ASC 606, we recognize revenue at the amount we expect to be entitled, subject to a constraint for variable consideration, in the period in which our tests are delivered to the treating physicians. We have determined that our contracts contain variable consideration under ASC 606 because the amounts paid by third-party payors may be paid at less than our standard rates or not paid at all, with such differences considered implicit price concessions. Variable consideration is recognized only to the extent it is probable that a significant reversal of revenue will not occur in future periods when the uncertainties are resolved. Variable consideration is evaluated each reporting period and adjustments are recorded as increases or decreases in revenues. Variable consideration for Medicare claims that are not covered by an LCD, including those claims subject to approval by an ALJ at an appeal hearing, is deemed to be fully constrained due to factors outside our influence (i.e., judgment or actions of third parties) and the uncertainty of the amount to be received is not expected to be resolved for a long period of time. For these fully constrained claims, we generally recognize revenue in the period the uncertainty is favorably resolved, if at all. Due to potential future changes in Medicare coverage policies and appeal cycles, insurance coverage policies, contractual rates and other trends in the reimbursement of our tests, our revenues may fluctuate significantly from period-to-period. Additionally, our ability to recognize revenue for our recently launched tests, DecisionDx-SCC and DecisionDx DiffDx-Melanoma, is dependent on the development of reimbursement experience and coverage decisions for these tests. Due to limited reimbursement experience, we are currently recognizing revenues for these two tests on the basis of actual cash collections.
Our ability to increase our revenues will depend on our ability to further penetrate our target markets, and, in particular, generate sales through our direct sales force, develop and commercialize additional tests, obtain reimbursement from additional third-party payors and increase our reimbursement rate for tests performed.
Cost of Sales (exclusive of amortization of acquired intangible assets)
The components of our cost of sales are material and service costs associated with testing samples, personnel costs (including salaries, bonuses, benefits and stock-based compensation expense), electronic medical record set up costs, order and delivery systems, shipping charges to transport samples, third-party test fees, and allocated overhead including rent, information technology costs, equipment and facilities depreciation and utilities. Costs associated with testing samples are recorded when the test is processed, regardless of whether and when revenues are recognized with respect to that test. As a result, our cost of sales as a percentage of revenues may vary significantly from period-to-period because we do not recognize all revenues in the period in which the associated costs are incurred. We expect cost of sales in absolute dollars to increase as the number of tests we perform increases. Additionally, we expect cost of sales to increase with the expansion of laboratory capacity and staffing in advance of the anticipated growth of our recently launched tests.
Gross margin and gross margin percentage are key indicators we use to assess our business. See the table in “Results of Operations—Comparison of the years ended December 31, 2021 and 2020” for details.
Research and Development
Research and development expenses include costs incurred to develop our genomic tests, collect clinical samples and conduct clinical studies to develop and support our products. These costs consist of personnel costs (including salaries, bonuses, benefits and stock-based compensation expense), prototype materials, laboratory supplies, consulting costs, regulatory costs, electronic medical records set up costs, costs associated with setting up and conducting clinical studies and allocated overhead, including rent, information technology, equipment depreciation and utilities. We expense all research and development costs in the periods in which they are incurred. We expect our research and development expenses to increase in absolute dollars as we continue to invest in research and development activities related to developing enhanced and new products.
We expect to use a portion of our cash and cash equivalents to further support and accelerate our research and development activities, including three important studies that are underway to support our DecisionDx-Melanoma test. The first is the PERSONALize study, in which we are evaluating DecisionDx-Melanoma for interactions with adjuvant therapies. The second is the CONNECTION study, which is collecting long-term outcomes for up to 10,000 patients who have been tested with DecisionDx-Melanoma. The third is the DECIDE study, which is designed to determine the association of GEP test results with SLNB surgical decisions in patients eligible for SLNB as well as to track outcomes for patients who did and did not undergo SLNB. Also, as noted above, we recently initiated a 4,800 patient, prospective, multi-center clinical study to develop, validate and bring to market a pipeline test aimed at predicting response to systemic therapy in patients with moderate to severe psoriasis, atopic dermatitis and related inflammatory skin conditions. We have also initiated two additional disease studies for pipeline tests for new indications.
85
Selling, General and Administrative
Selling, general and administrative (“SG&A”) expenses include executive, selling and marketing, legal, finance and accounting, human resources, billing and client services. These expenses consist of personnel costs (including salaries, bonuses, benefits and stock-based compensation expense), direct marketing expenses, audit and legal expenses, consulting costs, training and medical education activities, payor outreach programs and allocated overhead, including rent, information technology, equipment depreciation, and utilities. We expect continued increases in SG&A expenses related to compliance with the rules and regulations of the SEC and Nasdaq (in particular as we no longer qualify as an emerging growth company and a smaller reporting company, and have become a large accelerated filer), investor relations activities and additional insurance expenses. Other administrative and professional services expenses within SG&A are expected to increase with the scale of our business, but selling and marketing-related expenses are expected to increase significantly, consistent with our growth strategy.
Amortization of Acquired Intangible Assets
Amortization of acquired intangible assets are primarily associated with developed technology.
Other Operating Income
Other operating income consists of an automatic payment received from HHS for provider relief funds pursuant to the CARES Act.
Interest Income
Interest income consists primarily of earnings on cash and cash equivalents, primarily money market funds.
Interest Expense
Interest expense is primarily attributable to borrowings under our term debt, which was fully repaid in December 2020, and also includes the related amortization of debt discount and issuance costs.
Loss on Extinguishment of Debt
The loss on extinguishment of debt is associated with the early repayment of our term loan facility in December 2020.
Income Tax (Benefit) Expense
In connection with our acquisition of Cernostics in December 2021, and taking into consideration the additional deferred tax liabilities resulting from such acquisition, we determined that a portion of our valuation allowance should be reduced, which was reflected in our income tax benefit for the year ended December 31, 2021. Our consolidated financial statements do not reflect any federal or state income tax benefits attributable to the net losses we have incurred, due to the uncertainty of realizing a benefit from those items. As of December 31, 2021, we had federal NOL carryforwards of $99.4 million, of which $43.5 million will begin to expire in 2030 if not utilized to offset federal taxable income, and $55.9 million may be carried forward indefinitely. Also, as of December 31, 2021, we had state NOL carryforwards of $67.5 million, which begin to expire in 2028 if not utilized to offset state taxable income.
86
Results of Operations
Certain prior year amounts in the tables below have been reclassified to conform to the current year presentation. Specifically, we no longer present gross margin on the face of our financial statements and therefore the cost of sales line is now presented within the operating expenses section. This reclassification had no impact on operating loss, loss before income taxes or net loss.
Comparison of the Years Ended December 31, 2021 and 2020
The following table summarizes our results of operations for the periods indicated (in thousands, except percentages):
 Years Ended December 31,Change
 20212020
Net revenues$94,085 $62,649 $31,436 50.2 %
Operating expenses and other operating income:
Cost of sales (exclusive of amortization of acquired intangible assets)15,822 9,685 6,137 63.4 %
Research and development29,646 13,256 16,390 123.6 %
Selling, general and administrative86,738 48,132 38,606 80.2 %
Amortization of acquired intangible assets1,958 — 1,958 
NA(1)
Other operating income— (1,882)1,882 100.0 %
Total operating expenses, net134,164 69,191 64,973 93.9 %
Operating loss(40,079)(6,542)(33,537)(512.6)%
Interest income68 373 (305)(81.8)%
Interest expense(1)(2,634)2,633 100.0 %
Loss on extinguishment of debt— (1,397)1,397 100.0 %
Loss before income taxes(40,012)(10,200)(29,812)(292.3)%
Income tax (benefit) expense(8,720)84 (8,804)
NM(2)
Net loss $(31,292)$(10,284)$(21,008)(204.3)%
(1) NA = Not applicable
(2) NM = Not meaningful
The following table indicates the amount of stock-based compensation expense reflected in the line items above (in thousands):
 Years Ended December 31,
 20212020Change
Cost of sales (exclusive of amortization of acquired intangible assets)$2,058 $1,049 $1,009 
Research and development4,522 1,492 3,030 
Selling, general and administrative15,160 5,768 9,392 
Total stock-based compensation expense$21,740 $8,309 $13,431 

The following table provides a disaggregation of net revenues by type (in thousands):
Years Ended December 31,
20212020Change
Dermatologic(1)
$85,753 $57,646 $28,107 
Other(2)
8,332 5,003 3,329 
Total net revenues$94,085 $62,649 $31,436 
(1)Dermatologic includes DecisionDx-Melanoma, DecisionDx-SCC and CDO.
(2)Other consists primarily of DecisionDx-UM.
87
The following table presents the calculation of gross margin (in thousands, except percentages):
 Years Ended December 31,
 20212020Change
Net revenues$94,085 $62,649 $31,436 
Less: Cost of sales (exclusive of amortization of acquired intangible assets)15,822 9,685 6,137 
Less: Amortization of acquired intangible assets1,958 — 1,958 
Gross margin$76,305 $52,964 $23,341 
Gross margin percentage81.1 %84.5 %(3.4)%
Net Revenues
Net revenues increased by $31.4 million, or 50.2%, to $94.1 million for the year ended December 31, 2021, primarily due to higher revenues from our dermatologic tests, which increased by $28.1 million. The higher dermatologic test revenue was primarily attributable to higher volume from DecisionDx-Melanoma, which increased 25.2%, higher per-unit revenues for DecisionDx-Melanoma, which reflect the expanded LCD for the test that became effective in the fourth quarter of 2020, and increased revenues from DecisionDx-SCC and our CDO. We believe the higher test report volume for DecisionDx-Melanoma during the year ended December 31, 2021 reflects the relaxing of COVID-19 restrictions, and the related positive impacts on the flow of patient visits, as well as the effects of our sales force expansions discussed above. Revenues from other tests (non-dermatologic) contributed $3.3 million to the overall increase in net revenues for the year ended December 31, 2021. This increase was principally due to the significantly higher Medicare rate for DecisionDx-UM that became effective January 1, 2021 and, to a lesser extent, the effect of a 16.0% increase in DecisionDx-UM test report volume. We believe the higher test report volume for DecisionDx-UM during the year ended December 31, 2021 is due in part to patients making up for missed eye exams from 2020 due to COVID-19 impacts. Net revenues include positive revenue adjustments related to tests delivered in previous periods, associated with changes in estimated variable consideration, of $3.3 million for the year ended December 31, 2021 compared to $0.2 million for the year ended December 31, 2020. The year-over-year increase is primarily attributable to favorable adjustments related to the settlement and collection during the year ended December 31, 2021 of certain groups of receivables from prior years.
Cost of Sales (exclusive of amortization of acquired intangible assets)
Cost of sales (exclusive of amortization of acquired intangible assets) for the year ended December 31, 2021 increased by $6.1 million, or 63.4%, compared to the year ended December 31, 2020, primarily due to higher personnel costs due to additional headcount in our laboratory testing operations, and increased costs of supplies and services, attributable to the higher activity levels. The additional personnel costs included a year-over-year increase in stock-based compensation expense of $1.0 million. Due to the nature of our business, a significant portion of our cost of sales expenses represent fixed costs associated with our testing operations. Accordingly, our cost of sales expense will not necessarily increase or decrease commensurately with the change in net revenues from period to period. We expect our cost of sales (exclusive of amortization of acquired intangible assets) to continue to increase in future periods as we hire additional laboratory personnel and related resources to support our expected growth in volume for our dermatologic, GI and pipeline tests
Gross Margin
Our gross margin percentage was 81.1% for the year ended December 31, 2021, compared to 84.5% for the same period in 2020. The decrease was largely due to amortization expense associated with our acquired intangible assets. In the near term, we expect that our gross margin percentage will decline as we invest in additional laboratory personnel and related resources to support the anticipated growth in our report volumes for tests in advance of obtaining reimbursement coverage. Additionally, our gross margin percentage will be negatively impacted by amortization of intangible assets associated with recent acquisitions.
Research and Development
Research and development expenses increased by $16.4 million, or 123.6%, for the year ended December 31, 2021, compared to the year ended December 31, 2020, primarily due to increases in personnel costs and costs incurred in our clinical studies. Approximately 55% of the increase is attributable to higher personnel costs, due to expansions in headcount in support of our growth, including higher stock-based compensation expense of $3.0 million compared to 2020. Approximately 27% of the increase was attributable to higher costs for clinical studies, including costs related to the PERSONALize, CONNECTION and DECIDE studies as well as our recently initiated a 4,800 patient, prospective, multi-center clinical study to develop, validate and bring to market a pipeline test for inflammatory skin diseases. Also, during the year ended December 31, 2021, we expanded evidence supporting our portfolio of tests with 15 peer-reviewed publications and initiated our collaboration with
88
NCI/SEER. We expect to continue to increase our research and development expenses as we fund ongoing evidence development for our existing products as well as additional pipeline programs.
Selling, General and Administrative
SG&A expense increased by $38.6 million, or 80.2%, for the year ended December 31, 2021 compared to the year ended December 31, 2020. Approximately 67% of the increase is attributable to higher personnel costs, particularly due to increased headcount, which includes salaries, stock-based compensation and bonuses. We expanded our sales organization headcount in the third quarter of 2020 in preparation for the commercial launch of our DecisionDx DiffDx-Melanoma test and further expanded our sales team during the first and second quarters of 2021, bringing our dermatology-facing commercial team to the mid-60s. The higher personnel costs also reflect expanded headcount in our administrative support functions. Stock-based compensation expense included in SG&A expense was $15.2 million for the year ended December 31, 2021 compared to $5.8 million for the year ended December 31, 2020. The remainder of the increase in SG&A expense was primarily associated with training events, travel, professional fees and other general increases. The higher expenses for training events and travel reflect both a higher headcount as well a return to more in-person activities in 2021 as result of easing of COVID-19 restrictions.
Amortization of Acquired Intangible Assets
Amortization of acquired intangible assets was $2.0 million for the year ended December 31, 2021 and was entirely associated with amortization of developed technology attributable to the acquisitions of Myriad myPath, LLC and Cernostics in May 2021 and December 2021, respectively. There was no such amortization during the year ended December 31, 2020. Amortization of acquired intangible assets is projected to be approximately $6.7 million for the year ending December 31, 2022, but may increase in the future to the extent we complete additional acquisitions.
Other Operating Income
Other operating income of $1.9 million for the year ended December 31, 2020 consisted entirely of the automatic payment received from HHS pursuant to the CARES Act for provider relief funds. We initially recognized income attributable to the payment in the second quarter of 2020 based on our expectation of meeting the requirements to retain the funds. However, due a change in requirements of the program in the third quarter of 2020, we reversed this income. However, in the fourth quarter of 2020, a legislative change was enacted affecting the program, under which we concluded it is reasonably assured we will qualify to retain the funds. Accordingly, we recognized the income again in the fourth quarter of 2020. There were no similar transactions during the year ended December 31, 2021. See Note 2 to the consolidated financial statements for additional information.
Interest Income
Interest income decreased by $0.3 million for the year ended December 31, 2021, compared to the year ended December 31, 2020, as a result of lower interest rates, despite our higher average balances of cash and cash equivalents.
Interest Expense
Interest expense was essentially zero for the year ended December 31, 2021 compared to $2.6 million for the year ended December 31, 2020. The decrease is a result of the early termination and repayment of all amounts due on our term loan facility in December 2020.
Loss on Extinguishment of Debt
We recorded an extinguishment loss of $1.4 million during the year ended December 31, 2020 related to the early repayment and termination of our term loan facility. The extinguishment loss was attributable to the write-off of the unamortized discount and issuance costs as well as early termination and prepayment fees. There were no similar transactions during the year ended December 31, 2021.
Income Tax (Benefit) Expense
Income tax (benefit) expense was $(8.7) million for the year ended December 31, 2021 compared to $0.1 million for the year ended December 31, 2020. Substantially all of the income tax (benefit) in the year ended December 31, 2021 was attributable to a reduction in our valuation allowance on net deferred tax assets resulting from our acquisition of Cernostics in December 2021. Specifically, we took into consideration the additional deferred tax liabilities resulting from the acquisition and determined that a portion of our existing valuation allowance should be reduced to offset this liability. Other than this item, the recorded income tax (benefit) expense includes minimal amounts because in both the years ended December 31, 2021 and 2020, the income tax benefit of the net loss was largely offset by corresponding changes in the valuation allowance on net deferred tax assets, as we have determined that it is more likely than not that these benefits will not be realized.
89
Stock-Based Compensation Expense
Stock-based compensation expense, which is allocated among cost of sales, research and development expense and SG&A expense, totaled $21.7 million for the year ended December 31, 2021 compared to $8.3 million for the year ended December 31, 2020, which we attribute in part to the addition of 144 employees in 2021, a 71.6% increase from 2020. We expect material increases in stock-based compensation expense in future periods, reflecting additional awards outstanding due to expected growth in our headcount. As of December 31, 2021, the total unrecognized stock-based compensation cost related to outstanding awards was $99.3 million, which is expected to be recognized on a straight-line basis over a weighted-average period of 3.3 years.
Liquidity and Capital Resources
Sources of Liquidity
Our principal sources of liquidity are our cash and cash equivalents and cash generated from the sale of our products. As of December 31, 2021 and 2020, we had cash and cash equivalents of $329.6 million and $409.9 million, respectively. In addition to the revenue generated from the sale of our commercial products, we have financed our operations through our IPO in July 2019, two follow-on public offerings of common stock in June 2020 and December 2020, and a $25.0 million secured term loan credit facility, which we repaid in full in December 2020.
On December 14, 2020, we filed an automatically effective shelf registration statement on Form S-3 (File No. 333-251331) with the SEC as a “well-known seasoned issuer.” The registration statement allows us to issue an indeterminate number or amount of common stock, preferred stock, debt securities and warrants from time-to-time in one or more offerings. However, there can be no assurance that we will complete any such offerings of securities. Any future offerings under this registration statement will be dependent upon, among other factors, market conditions, available pricing, our financial condition, investor perception of our prospects, our capital needs and our ability to maintain status as a well-known seasoned issuer.
Public Offerings of Common Stock
On June 29, 2020 and July 2, 2020, we issued and sold 2,000,000 and 300,000 shares of our common stock, respectively, of our common stock in a follow-on public offering at a price of $37.00 per share. We received $79.5 million in aggregate net proceeds, after deducting underwriting discounts and commissions and offering costs. The shares issued and sold on July 2, 2020 reflect the underwriters’ exercise in full of their 30-day option to purchase additional shares at the public offering price, less underwriting discounts and commissions.
On December 18, 2020, we issued and sold 4,600,000 shares of our common stock (including the exercise in full by the underwriters of their option to purchase an additional 600,000 shares) in a follow-on public offering at a price of $58.00 per share. We received $250.5 million in aggregate net proceeds, after deducting underwriting discounts and commissions and offering costs (excluding $0.4 million in offering costs that were incurred but not paid as of December 31, 2020). The shares issued and sold includes the underwriters’ exercise in full of their 30-day option to purchase additional shares at the public offering price, less underwriting discounts and commissions. On December 21, 2020, we used a portion of these proceeds to repay, in full, our outstanding term loan credit facility. See “Long-Term Debt” below for additional information.
As mentioned above, we expect to use a portion of these proceeds, as well as the approximately $65.9 million of net proceeds from our IPO in July 2019, to further support and accelerate our research and development activities, including the clinical studies noted above.
Medicare Advance Payment
On April 16, 2020, we received an advance payment of $8.3 million (“the Advance Payment”) from CMS under its Accelerated and Advance Payment Program, which was expanded to provide increased cash flow to service providers during the COVID-19 pandemic. CMS began recoupment of the Advance Payment in April 2021 by applying 25% of the Medicare payments otherwise owed to us against the balance of the Advance Payment. Recoupment of the full amount of the Advance Payment was complete by December 31, 2021.
Material Cash Requirements
Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, clinical research and development services, laboratory operations, equipment and related supplies, legal and other regulatory expenses, general administrative costs and, from time to time, expansion of our laboratory and office facilities in support of our growth. We anticipate that a substantial portion of our cash requirements in the foreseeable future will relate to the further commercialization of our currently marketed products, the development of our future product candidates in our pipeline and the potential commercialization of these pipeline products, should their development be successful.
90
In the past 12 months we completed two strategic opportunities, which we funded using our available cash on hand, and in the longer-term may evaluate and consummate other strategic acquisitions of businesses, assets, products or technologies, which we expect to be able to fund from our available cash and cash equivalents. In May 2021 and December 2021, we completed the acquisitions of the Myriad myPath Laboratory for $32.5 million and Cernostics, Inc. for $30.7 million, respectively. In both cases, the source of funding was from our existing cash and cash equivalents. Under the definitive agreement with Cernostics, we have also agreed to pay up to an additional $50 million in cash or our common stock, at our sole discretion, based on the achievement of certain commercial milestones relating to the year ending December 31, 2022. Our liability with respect to the commercial milestone payments will depend on our ability to successfully integrate Cernostics into our suite of commercial product offerings, while future cash requirements arising from any additional strategic acquisitions will depend on, among other things, our identification of a target company with a product offering that we view as complementary to our product offerings. See Note 5 to the consolidated financial statements for additional information on recent acquisitions.
Since our inception, we have generally incurred significant losses and negative cash flows. For the year ended December 31, 2021 we had a net loss of $31.3 million and an accumulated deficit of $93.8 million as of December 31, 2021. Our ability to generate revenue sufficient to achieve profitability will depend heavily on the successful commercialization of our currently marketed products and the products we plan to launch in the future as well as our spending on research and development activities. We expect to incur additional expenses and losses in the future as we invest in the commercialization of our existing products, the development of our future product candidates and the commercialization of our product candidates. Further, we expect that any acquisitions of businesses, products, assets or technologies will also increase our expenses. We believe that our existing cash and cash equivalents and anticipated cash generated from the sale of our commercial products will be sufficient to fund our operations for the next twelve months. We believe we will meet longer-term expected cash requirements and obligations through a combination of existing cash and cash equivalents, anticipated cash generated from sales of our products and issuances of equity securities or debt offerings, including through our shelf registration statement on Form S-3 that became automatically effective in December 2020. However, we have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. There are numerous risks and uncertainties associated with developing genomic tests, including, among others, the uncertainty of:
•successful commencement and completion of clinical study protocols;
•successful identification and acquisition of tissue samples;
•the development and validation of genomic classifiers; and
•acceptance of new genomic tests by physicians, patients and third-party payors.
Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate our exact working capital requirements. Our future funding requirements will depend on, and could increase significantly as a result of, many factors, including those listed above as well as those listed in the section titled “Risk Factors.”
We do not currently have any committed external source of funds. In the event additional funding is required, we expect that we would use a combination of equity and debt financings, which may not be available to us when needed, on terms that we deem to be favorable or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. Any disruptions to, or volatility in, the credit and financial markets or any deterioration in overall economic conditions may make any necessary debt or equity financing more difficult to obtain, more costly and/or more dilutive. If we are unable to raise additional funds through debt, or equity financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our product discovery and development activities or future commercialization efforts.
Leases
We have entered into various operating and finance leases, which are primarily associated with our laboratory facilities and office space. Total undiscounted future minimum payment obligations under our operating leases and finance leases as of December 31, 2021 totaled approximately $10.6 million, of which $1.4 million is payable in 2022 and $9.2 million is payable through the end of 2033. The leases expire on various dates through 2033 and provide certain options to renew for additional periods. We expect our lease obligations will increase in the near term as we expand our facilities, operations and headcount in support of the anticipated growth in our portfolio of commercial products and pipeline tests. Refer to Note 9 to the consolidated financial statements for additional information on our leasing arrangements.
91
Cash Flows
The following table summarizes our sources and uses of cash and cash equivalents for each of the periods presented (in thousands):
 Years Ended December 31,
 20212020
Net cash (used in) provided by operating activities$(18,983)$9,865 
Net cash used in investing activities(66,657)(4,748)
Net cash provided by financing activities5,421 305,890 
Net change in cash and cash equivalents(80,219)311,007 
Cash and cash equivalents, beginning of year409,852 98,845 
Cash and cash equivalents, end of year$329,633 $409,852 
Operating Activities
Net cash used in operating activities of $19.0 million for the year ended December 31, 2021 was primarily attributable to the net loss of $31.3 million, deferred income taxes of $8.7 million, recoupment of the Advance Payment of $8.3 million and increases in accounts receivable of $4.6 million, partially offset by stock compensation expense of $21.7 million, increases in accrued compensation of $6.2 million, depreciation and amortization of $3.4 million and increases in other accrued liabilities of $2.3 million.
Net cash provided by operating activities was $9.9 million for the year ended December 31, 2020 and was primarily attributable to net non-cash charges of $10.5 million (consisting of $8.3 million in stock-based compensation expense, $1.4 million of loss on extinguishment of debt, and $0.8 million in amortization of debt discount and issuance costs), the receipt of the Advance Payment of $8.3 million, increases in accrued compensation of $3.3 million and decreases in accounts receivable of $1.7 million, partially offset by the net loss of $10.3 million and increases in prepaid expenses and other current assets of $2.8 million, other assets of $1.4 million and inventory of $1.0 million.
Investing Activities
Net cash used in investing activities for the year ended December 31, 2021 was primarily attributable to our asset acquisitions of Myriad myPath LLC and Cernostics (which collectively totaled $63.2 million) and purchases of property and equipment of $3.5 million.
Net cash used in investing activities for the year ended December 31, 2020 consisted entirely of purchases of property and equipment.
Financing Activities
Net cash provided by financing activities for the year ended December 31, 2021 consisted primarily of $4.2 million of proceeds from exercise of common stock options and $2.3 million of proceeds from contributions to the employee stock purchase plan, partially offset by payment of employees’ taxes on vested restricted stock units of $0.8 million and payment of common stock offering costs of $0.3 million. We did not complete any public offerings of common stock during the year ended December 31, 2021.
Net cash provided by financing activities for the year ended December 31, 2020 consisted primarily of $330.0 million of proceeds from two public offerings of our common stock (net of underwriting discounts, commissions and issuance costs), $1.6 million of proceeds from contributions to the employee stock purchase plan and $1.6 million of proceeds from exercise of common stock options, partially offset by repayments of term debt, including extinguishment costs, of $27.4 million.
Inflation
We do not believe that inflation has had a material impact on our results of operations during the periods presented. However, recently, the rate of inflation in the U.S. has risen to levels not experienced in decades. We have begun to see some inflationary pressures, primarily in personnel and related costs. The extent of any future impacts from inflation on our business and our results of operations will be dependent upon how long the elevated inflation levels persist and if the rate of inflation were to further increase, neither of which we are able to predict.
92
Critical Accounting Estimates
Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.
While our significant accounting policies are described in more detail in Note 2 to our audited consolidated financial statements, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.
Revenue Recognition
We recognize revenue is recognized in accordance with ASC 606. In accordance with ASC 606, we follow a five-step process to recognize revenues: (1) identify the contract with the customer, (2) identify the performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenues when the performance obligations are satisfied. We have determined that we have a contract with the patient when the treating clinician orders the test. Our contracts generally contain a single performance obligation, which is the delivery of the test report, and we satisfy our performance obligation at a point-in-time upon the delivery of the test report to the treating physician, at which point we can bill for the report. The amount of revenue recognized reflects the amount of consideration to which we expect to be entitled, or the transaction price, and considers the effects of variable consideration.
All of our revenues from contracts with customers are associated with the provision of diagnostic and prognostic testing services. Most of our revenues are attributable to DecisionDx-Melanoma for cutaneous melanoma. We also provide a test for UM, DecisionDx-UM. We launched a test for patients with cutaneous SCC, DecisionDx-SCC in August 2020 and launched a test for use in patients with suspicious pigmented lesions, DecisionDx DiffDx-Melanoma in November 2020. We began offering a test for difficult-to-diagnose melanocytic lesions, myPath Melanoma, following an asset acquisition completed in May 2021 and began offering the TissueCypher® Barrett’s Esophagus Assay for patients with BE following an asset acquisition completed in December 2021. Information on the disaggregation of revenues is included below.
Once we satisfy our performance obligations and bill for the service, the timing of the collection of payments may vary based on the payment practices of the third-party payor and the existence of contractually established reimbursement rates. Most of the payments for our services are made by third-party payors, including Medicare and commercial health insurance carriers. Certain contracts contain a contractual commitment of a reimbursement rate that differs from our list prices. However, absent a contractually committed reimbursement rate with a commercial carrier or governmental program, our diagnostic tests may or may not be covered by these entities’ existing reimbursement policies. In addition, patients do not enter into direct agreements with us that commit them to pay any portion of the cost of the tests in the event that their insurance provider declines to reimburse us. We may pursue, on a case-by-case basis, reimbursement from such patients in the form of co-payments and co-insurance, in accordance with the contractual obligations that we have with the insurance carrier or health plan. These situations may result in a delay in the collection of payments.
The Medicare claims that are covered by policy under an LCD are generally paid at the established rate by our Medicare contractor within 30 days from receipt. Medicare claims that were either submitted to Medicare prior to the LCD’s effective date or are not covered by the terms of the LCD, but meet the definition of being medically reasonable and necessary pursuant to the controlling Section 1862(a)(1)(A) of the Social Security Act are generally appealed and may ultimately be paid at the first (termed “redetermination”), second (termed “reconsideration”) or third level of appeal (de novo hearing with an ALJ). A successful appeal at any of these levels results in payment.
In the absence of LCD coverage or contractually established reimbursement rates, we have concluded that our contracts include variable consideration because the amounts paid by Medicare or commercial health insurance carriers may be paid at less than our standard rates or not paid at all, with such differences considered implicit price concessions. Variable consideration attributable to these price concessions is measured at the expected value using the “most likely amount” method under ASC 606. The amounts are determined by historical average collection rates by test type and payor category taking into consideration the range of possible outcomes, the predictive value of our past experiences, the time period of when uncertainties expect to be resolved and the amount of consideration that is susceptible to factors outside of our influence, such as the judgment and actions of third parties. Such variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. Variable consideration may be constrained and excluded from the transaction price in situations where
93
there is no contractually agreed upon reimbursement coverage or in the absence of a predictable pattern and history of collectability with a payor. Variable consideration for Medicare claims that are not covered by an LCD, including those claims subject to approval by an ALJ at an appeal hearing, is deemed to be fully constrained due to factors outside our influence (i.e., judgment or actions of third parties) and the uncertainty of the amount to be received is not expected to be resolved for a long period of time. Variable consideration is evaluated each reporting period and adjustments are recorded as increases or decreases in revenues. Included in revenues for the years ended December 31, 2021 and 2020 were $3,324,000 and $176,000, respectively, of revenue increases associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. These amounts include (i) adjustments for actual collections versus estimated amounts and (ii) cash collections and the related recognition of revenue in current period for tests delivered in prior periods due to the release of the constraint on variable consideration.
DecisionDx-Melanoma Claims Consolidation
In June 2017, we submitted to OMHA a formal request to participate in a program that OMHA developed with the intent of providing appellants a means to have large volumes of claim disputes adjudicated at an accelerated rate. The program consolidates outstanding claims at the ALJ level and uses a statistical-sampling approach where five ALJs will determine reimbursement results for a sample of claims which are then extrapolated to the universe of claims. Our consolidation includes 2,698 DecisionDx-Melanoma claims dating from 2013 through spring 2017. Hearings were held in April 2019 with a supplemental hearing in May 2019. On March 12, 2020, OMHA issued a decision denying payment on all claims in the consolidation. We have filed an appeal to the decision, although no ruling on such appeal has been issued to date. In accordance with ASC 606 and consistent with prior periods, we have not recognized (fully constrained the variable consideration) any revenues attributable to these claims in our consolidated financial statements pending the outcome of this matter.
Stock-Based Compensation
Stock-based compensation expense for equity instruments issued to employees and non-employees, including stock options, restricted stock units (“RSUs”) and purchase rights issued under our 2019 Employee Stock Purchase Plan (“ESPP”) is measured based on the grant date fair value of the awards. For stock options and purchase rights granted under the ESPP, we estimate the grant date fair value using the Black-Scholes option-pricing valuation model. For RSUs, we use the closing price of our common stock on the date of grant to determine the fair value. We recognize compensation costs on a straight-line basis for all stock-based compensation awards over the requisite service period of the awards, which is generally the awards’ vesting period, typically four years for options and RSUs and the two-year offering period for the ESPP. Forfeitures are accounted for as they occur.
Set forth below is a description of the significant assumptions used in the option pricing model:
•Expected term. The expected term is the period of time that granted options are expected to be outstanding. For stock options, we have set the expected term using the simplified method based on the weighted average of both the period to vesting and the period to maturity for each option, as we have concluded that our stock option exercise history does not provide a reasonable basis upon which to estimate the expected term. For the ESPP, the expected term is the period of time from the offering date to the purchase date.
•Expected volatility. Previously, because of the limited period of time our stock had been traded in an active market, we calculated expected volatility by using the historical stock prices of a group of similar companies looking back over the estimated life of the option or the purchase rights under our ESPP and averaging the volatilities of these companies. In the third quarter of 2021, we adjusted this calculation to include our own stock price on a relative basis to the peer group in the calculation of expected volatility, as our common stock has now been traded in an active market for more than two years.
•Risk-free interest rate. We base the risk-free interest rate used in the Black-Scholes valuation model on the market yield in effect at the time of option grant and at the offering date for ESPP provided from the Federal Reserve Board’s Statistical Releases and historical publications from the Treasury constant maturities rates for the equivalent remaining terms.
•Dividend yield. We have not paid, and do not have plans to pay, cash dividends. Therefore, we use an expected dividend yield of zero in the Black-Scholes option valuation model.
The fair value of our common stock is also an assumption used to determine the fair value of stock options. Prior to our IPO, the estimated fair value of our common stock had been determined by our board of directors as of the date of each award, with input from management, considering our most recently available third-party valuations of common stock and our board of directors’ assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant, which intended all options granted to be exercisable at price per share not less than the per share fair value of our common stock underlying those options on the grant date.
94
Subsequent to our IPO, the fair value of our common stock is the closing selling price per share of our common stock as reported on the Nasdaq Global Market on the date of grant or other relevant determination date.
The following table sets forth the assumptions used to determine the fair value of stock options:
Years Ended December 31,
20212020
Average expected term (years)6.16
Expected stock price volatility
66.50% - 68.83%
59.57%- 67.02%
Risk-free interest rate
0.51% - 1.48%
0.28% - 1.76%
Dividend yield—%—%
The following table sets forth assumptions used to determine the fair value of the purchase rights issued under the ESPP:
Years Ended December 31,
20212020
Average expected term (years)1.21.2
Expected stock price volatility
61.13% - 86.50%
56.80% - 100.49%
Risk-free interest rate
0.06% - 0.20%
0.12% - 0.95%
Dividend yield—%—%
Intangible Assets
Our intangible assets, which are comprised primarily of acquired developed technology, are considered to be finite-lived and are amortized on a straight-line basis over their estimated useful lives. Estimating the useful lives of our intangible assets requires considerable judgment. In determining the estimated useful lives, management considers factors such as historical experience, industry and regulatory factors, competition, patent expirations and commercial plans. If new information becomes available in future periods, we may be required to revise our estimated useful lives. If the revised useful lives are shorter than originally estimated, our future amortization expense will increase.
Contingent Consideration
Under the terms of business combinations or asset acquisitions, we may be required to pay additional consideration if specified future events occur or if certain conditions are met. With respect to the additional consideration that may be payable in connection with our acquisition of Cernostics, which was treated as an asset acquisition for accounting purposes, we account for the contingent consideration as liability in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), under the guidance for obligations that must or may be settled by issuance of a variable number of shares. In accordance with ASC 480, we record the contingent consideration initially and subsequently at fair value with changes in fair value recorded in the statements of operations and comprehensive loss each period. This liability is classified as a “Level 3” fair value measurement (as defined in Note 11 to our consolidated financial statements) due to the use of significant unobservable inputs and a Monte Carlo simulation to determine its fair value. The Monte Carlo simulation uses projections of the commercial milestones for the applicable period as well as the corresponding targets and approximate timing of payment based on the terms of the arrangement. The analysis also uses assumptions for expected volatility of the financial metrics and a risk-adjusted discount rate. The assumptions and estimates we use in the Monte Carlo simulation require considerable judgment and may change in future periods as a result of new information.
Recent Accounting Pronouncements
Refer to Note 2, ‘‘Summary of Significant Accounting Policies,’’ in the accompanying notes to our consolidated financial statements included in this Annual Report on Form 10-K for a discussion of recent accounting pronouncements.
JOBS Act Accounting Election
Previously, we were an emerging growth company within the meaning of the JOBS Act. Section 107(b) of the JOBS Act provides that an emerging growth company can leverage the extended transition period, provided in Section 102(b) of the JOBS Act, for complying with new or revised accounting standards. However, because the market value of our common stock held by non-affiliates exceeded $700.0 million as of June 30, 2021, we are no longer an emerging growth company effective December 31, 2021. As a result, we now apply public company adoption dates for new or revised accounting standards. Further, we were required to comply with the auditor attestation requirements of Section 404(b) of Sarbanes-Oxley regarding our internal control over financial reporting as of December 31, 2021.
95
Item 7A. Quantitative and Qualitative Disclosures About Market Risk.
As a smaller reporting company, we are not required to provide the information required by this Item.
Item 8. Financial Statements and Supplementary Data.
The financial statements and supplementary data required by this item are included after the Signature page of this Annual Report on Form 10-K beginning on page F-1.
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.
None.
Item 9A. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2021. Based upon the evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2021, our disclosure controls and procedures were effective at the reasonable assurance level.
Management’s Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term as defined in Exchange Act Rule 13a-15(f). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.
As of December 31, 2021, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013 Framework). Based on this assessment, our management concluded that, as of December 31, 2021, our internal control over financial reporting was effective based on those criteria.
Under guidelines established by the SEC, companies are allowed to exclude acquisitions from their assessment of internal control over financial reporting during the first year of an acquisition while integrating the acquired company. Accordingly, our assessment of internal controls excluded our acquisition of Cernostics, completed on December 3, 2021. See Note 5 to the consolidated financial statements included in this Annual Report on Form 10-K for additional information on our acquisition of Cernostics. Operations from this acquisition represented approximately 13% of our total assets and 0% of our total revenue as of and for the year ended December 31, 2021.
Our independent registered public accounting firm, KPMG LLP, has audited the effectiveness of our internal control over financial reporting as of December 31, 2021, as stated in its report contained in Item 15 of this Annual Report on Form 10-K.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) or 15d-15(f) of the Exchange Act) that occurred during the fourth quarter of 2021 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
Item 9B. Other Information.
None.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
Not applicable.
96
PART III
Certain information required by Part III is omitted from this Annual Report on Form 10-K since we intend to file our definitive proxy statement for our 2022 Annual Meeting of Stockholders (“the Proxy Statement”) pursuant to Regulation 14A of the Exchange Act, not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and certain information to be included in the Proxy Statement is incorporated herein by reference.
Item 10. Directors, Executive Officers and Corporate Governance.
The information required by this item is to be included in the Proxy Statement as follows:
•The information relating to our executive officers is to be included in the section entitled “Executive Officers,”
•The information relating to our directors and nominees for director is to be included in the section entitled “Proposal 1: Election of Directors,”
•The information relating to our audit committee and audit committee financial expert is to be included in the section entitled “Information Regarding the Board of Directors and Corporate Governance,” and
•If required, the information regarding compliance with Section 16(a) of the Exchange Act is to be included in the section entitled “Delinquent Section 16(a) Reports.”
Such information will be included in the Proxy Statement and is incorporated herein by reference.
We have adopted a written Code of Business Conduct and Ethics (“Ethics Code”) that applies to all officers, directors and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. The Ethics Code is available on our website at www.CastleBiosciences.com. If we make any substantive amendments to the Ethics Code or grant any waiver from a provision of the Ethics Code to any executive officer or director, we will promptly disclose the nature of the amendment or waiver on our website or in a Current Report on Form 8-K.
Item 11. Executive Compensation.
The information required by this item is to be included in our Proxy Statement under the section entitled “Executive Compensation” and is incorporated herein by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
The information required by this item with respect to equity compensation plans is to be included in our Proxy Statement under the section entitled “Equity Compensation Plan Information” and the information required by this item with respect to security ownership of certain beneficial owners and management is to be included in our Proxy Statement under the section entitled “Security Ownership of Certain Beneficial Owners and Management” and in each case is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence.
The information required by this item is to be included in our Proxy Statement under the sections entitled “Transactions with Related Persons and Indemnifications—Related Person Transactions Policy and Procedures” and is incorporated herein by reference.
Item 14. Principal Accountant Fees and Services.
Our independent registered public accounting firm is KPMG LLP, San Diego, CA, Audit Firm ID: 185.
The information required by this item is to be included in our Proxy Statement under the section entitled “Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm” and is incorporated herein by reference.
97
PART IV
Item 15. Exhibit and Financial Statement Schedules.
(a)(1) Financial Statements.
The consolidated financial statements and supplementary data required by this item are included after the Signature page of this Annual Report on Form 10-K beginning on page F-1.
(a)(2) Financial Statement Schedules.
All schedules have been omitted because they are not required or because the required information is given in the Consolidated Financial Statements or Notes thereto.
(a)(3) Exhibits.
The exhibits listed in the Exhibit Index below are filed or incorporated by reference as part of this Annual Report on Form 10-K.

Exhibit Index
Exhibit NumberDescription of document
2.1†^
3.1
3.2
4.1
4.2
4.3
10.1+
10.2+
10.3+
10.4+
10.5+
10.6+
10.7+
10.8+
98
Exhibit NumberDescription of document
10.9+
10.10+
10.11+*
10.12+
10.13+
10.14+
10.15+
10.16+#
10.17+
10.18+
10.19+
10.20+
10.21+
10.22
10.23
10.24
10.25
10.26
10.27
99
Exhibit NumberDescription of document
10.28
10.29
10.30
10.31
10.32#
21.1*
23.1*
31.1*
31.2*
32.1**
101.INS*Inline XBRL Instance Document—the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document.
101.SCH*Inline XBRL Taxonomy Extension Schema.
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase.
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase.
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase.
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase.
104*Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101).
_____________________________________
*    Filed herewith
**    Furnished herewith.
+    Indicates management contract or compensatory plan.
#    Certain portions of this exhibit (indicated by “[***]”) have been omitted as we have determined (i) the omitted information is not material and (ii) the omitted information would likely cause harm to us if publicly disclosed.
†    Schedules and exhibits to the Agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.
^    Pursuant to Item 601(b)(10) of Regulation S-K, certain portions of this exhibit have been omitted (indicated by “[***]”) because the Company has determined that the information is not material and is the type that the Company treats as private or confidential.
Item 16. Form 10-K Summary.
None.

100
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 CASTLE BIOSCIENCES, INC.
   
Date:February 28, 2022By:/s/ Derek J. Maetzold
 
Derek J. Maetzold
President and Chief Executive Officer
(Principal Executive Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacity and on the dates indicated.
SIGNATURETITLEDATE
/s/ Derek J. MaetzoldPresident, Chief Executive Officer and Director February 28, 2022
(Derek J. Maetzold)
(Principal Executive Officer)
/s/ Frank Stokes
Chief Financial Officer
February 28, 2022
(Frank Stokes)
(Principal Financial and Accounting Officer)
/s/ Daniel M. Bradbury
Chairman of the Board of Directors
February 28, 2022
(Daniel M. Bradbury)
/s/ Mara G. AspinallMember of the Board of DirectorsFebruary 28, 2022
(Mara G. Aspinall)
/s/ Kimberlee S. CapleMember of the Board of DirectorsFebruary 28, 2022
(Kimberlee S. Caple)
/s/ G. Bradley ColeMember of the Board of DirectorsFebruary 28, 2022
(G. Bradley Cole)
/s/ Ellen GoldbergMember of the Board of DirectorsFebruary 28, 2022
(Ellen Goldberg)
/s/ Miles D. HarrisonMember of the Board of DirectorsFebruary 28, 2022
(Miles D. Harrison)
/s/ Tiffany P. OlsonMember of the Board of DirectorsFebruary 28, 2022
(Tiffany P. Olson)

101
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

F-1

Report of Independent Registered Public Accounting Firm
To the Stockholders and Board of Directors
Castle Biosciences, Inc.:
Opinion on Internal Control Over Financial Reporting
We have audited Castle Biosciences, Inc. and subsidiaries’ (the Company) internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and December 31, 2020, the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2021, and the related notes (collectively, the consolidated financial statements), and our report dated February 28, 2022 expressed an unqualified opinion on those consolidated financial statements.
The Company acquired Cernostics, Inc. during 2021, and management excluded from its assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2021, Cernostics, Inc.’s internal control over financial reporting associated with 13% of total assets and 0% of total revenues included in the consolidated financial statements of the Company as of and for the year ended December 31, 2021. Our audit of internal control over financial reporting of the Company also excluded an evaluation of the internal control over financial reporting of Cernostics, Inc.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ KPMG LLP

San Diego, California
February 28, 2022
F-2
Report of Independent Registered Public Accounting Firm
To the Stockholders and Board of Directors
Castle Biosciences, Inc.:
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Castle Biosciences, Inc. and subsidiaries (the Company) as of December 31, 2021 and December 31, 2020, the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2021, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and December 31, 2020, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 28, 2022 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.
Change in Accounting Principle
As discussed in Note 2 to the consolidated financial statements, the Company has changed its method of accounting for leases as of January 1, 2021 due to the adoption of ASC 842, Leases.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Measurement of Test Revenue
As discussed in Notes 2 and 3 of the consolidated financial statements, test revenue is recognized when the performance obligation is satisfied, upon delivery of the test report. The amount of revenue recognized reflects the amount of consideration to which the Company expects to be entitled and considers the effects of variable consideration. The measurement of test revenue is determined by contractually established rates as well as historical average collection rates by test type and payor category taking into consideration the range of possible outcomes, the predictive value of the Company’s past experiences, the time period of when uncertainties expect to be resolved and the amount of consideration that is susceptible to factors outside of the Company’s influence, such as the judgment and actions of third parties. The Company reported net revenues of $94,085 thousand for the year ended December 31, 2021, a portion of which related to test revenue.
F-3
We identified the evaluation of the measurement of test revenue as a critical audit matter. Evaluating the measurement of test revenue, specifically the estimation of the amount of test revenue expected to be collectible related to commercial payors and certain others, required especially complex and subjective auditor judgment.
The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the estimation of the expected collectible test revenue related to commercial payors and certain others. This included controls related to management’s review of the assumptions and inputs used in the determination of test revenue expected to be collectible from commercial payors and certain others. For a selection of tests, we evaluated certain historical data inputs that are used in management’s model to estimate test revenue expected to be collectible by comparing the data from the model to physician test requisition forms, proof of delivery, and cash collection activity. These data inputs included collection activity, amounts of historical claims, insurance payor categories, test dates, test types, claim aging categories, and revenue recognition dates. In addition, we inquired of the individuals who are responsible for monitoring and tracking the status of anticipated collections to understand the progress of these activities and any impact to management’s estimates.

/s/ KPMG LLP

We have served as the Company’s auditor since 2018.
San Diego, California
February 28, 2022

F-4
CASTLE BIOSCIENCES, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
December 31,
20212020
ASSETS
Current Assets  
Cash and cash equivalents$329,633 $409,852 
Accounts receivable, net17,282 12,759 
Inventory2,021 2,217 
Prepaid expenses and other current assets4,807 4,766 
Total current assets353,743 429,594 
Long-term accounts receivable, net1,308 1,096 
Property and equipment, net9,501 7,102 
Operating lease assets7,383 — 
Intangible assets, net88,922 — 
Other assets – long-term1,715 1,536 
Total assets$462,572 $439,328 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Accounts payable$2,546 $2,098 
Accrued compensation15,483 9,108 
Medicare advance payment— 6,615 
Operating lease liabilities1,179 — 
Other accrued and current liabilities5,678 3,055 
Total current liabilities24,886 20,876 
Contingent consideration18,287 — 
Noncurrent operating lease liabilities6,900 — 
Noncurrent portion of Medicare advance payment— 1,735 
Deferred tax liability635 — 
Other liabilities124 1,026 
Total liabilities50,832 23,637 
Commitments and Contingencies (Note 12)
Stockholders’ Equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized as of December 31, 2021 and 2020; no shares issued and outstanding as of December 31, 2021 and 2020.
— — 
Common stock, $0.001 par value; 200,000,000 authorized as of December 31, 2021 and 2020, respectively; 25,378,520 and 24,812,487 shares issued and outstanding as of December 31, 2021 and 2020, respectively.
25 25 
Additional paid-in capital505,482 478,162 
Accumulated deficit(93,767)(62,496)
Total stockholders’ equity411,740 415,691 
Total liabilities and stockholders’ equity$462,572 $439,328 

The accompanying notes are an integral part of these consolidated financial statements.
F-5
CASTLE BIOSCIENCES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except per share data)
Years Ended December 31,
20212020
NET REVENUES$94,085 $62,649 
OPERATING EXPENSES AND OTHER OPERATING INCOME
Cost of sales (exclusive of amortization of acquired intangible assets)15,822 9,685 
Research and development29,646 13,256 
Selling, general and administrative86,738 48,132 
Amortization of acquired intangible assets1,958 — 
Other operating income— (1,882)
Total operating expenses, net134,164 69,191 
Operating loss(40,079)(6,542)
Interest income68 373 
Interest expense(1)(2,634)
Loss on extinguishment of debt— (1,397)
Loss before income taxes(40,012)(10,200)
Income tax (benefit) expense(8,720)84 
Net loss and comprehensive loss$(31,292)$(10,284)
Loss per share attributable to common stockholders:
Basic$(1.24)$(0.54)
Diluted$(1.24)$(0.54)
Weighted-average shares outstanding:
Basic25,137 18,929 
Diluted25,137 18,929 



The accompanying notes are an integral part of these consolidated financial statements.


F-6

CASTLE BIOSCIENCES, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands, except share data)
Preferred StockCommon StockAdditional
Paid-in
Capital		Accumulated
Deficit		Total
Stockholders’
Equity
SharesAmountSharesAmount
BALANCE, JANUARY 1, 2020— $— 17,130,907 $17 $137,308 $(52,212)$85,113 
Stock-based compensation expense— — — — 8,309 — 8,309 
Exercise of common stock options— — 459,074 1 1,592 — 1,593 
Exercise of common stock warrants— — 241,052 — — — — 
Public offerings of common stock, net of underwriting discounts, commissions and offering costs— — 6,900,000 7 329,657 — 329,664 
Issuance of common stock under the employee stock purchase plan— — 81,454 — 1,296 — 1,296 
Net loss— — — — — (10,284)(10,284)
BALANCE, DECEMBER 31, 2020— $— 24,812,487 $25 $478,162 $(62,496)$415,691 
Adoption of ASU No. 2016-02— — — — — 21 21 
Stock-based compensation expense— — — — 21,740 — 21,740 
Exercise of common stock options— — 416,037 — 4,234 — 4,234 
Issuance of common stock from vested restricted stock units and payment of employees’ taxes— — 39,548 — (781)— (781)
Public offerings of common stock, adjustment to offering costs— — — — 39 — 39 
Issuance of common stock under the employee stock purchase plan— — 110,448 — 2,088 — 2,088 
Net loss— — — — — (31,292)(31,292)
BALANCE, DECEMBER 31, 2021— $— 25,378,520 $25 $505,482 $(93,767)$411,740 

The accompanying notes are an integral part of these consolidated financial statements.

F-7

CASTLE BIOSCIENCES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
 Years Ended December 31,
 20212020
OPERATING ACTIVITIES  
Net loss$(31,292)$(10,284)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization3,407 472 
Stock-based compensation expense21,740 8,309 
Amortization of debt discounts and issuance costs— 839 
Deferred income taxes(8,736)— 
Loss on extinguishment of debt— 1,397 
Other— (16)
Change in operating assets and liabilities:
Accounts receivable(4,631)1,663 
Prepaid expenses and other current assets617 (2,815)
Inventory327 (980)
Operating lease assets931 — 
Other assets(180)(1,401)
Accounts payable(182)169 
Operating lease liabilities(852)— 
Accrued compensation6,208 3,329 
Medicare advance payment(8,350)8,350 
Other accrued liabilities2,286 561 
Other liabilities(276)272 
Net cash (used in) provided by operating activities(18,983)9,865 
INVESTING ACTIVITIES
Purchases of property and equipment(3,483)(4,751)
Asset acquisitions, net of cash and cash equivalents acquired(63,184)— 
Proceeds from sale of property and equipment10 3 
Net cash used in investing activities(66,657)(4,748)
FINANCING ACTIVITIES
Proceeds from public offerings of common stock, net of underwriting discounts, commissions and offering costs— 330,041 
Payment of common stock offering costs(336)— 
Repayment of term debt— (27,359)
Proceeds from exercise of common stock options4,234 1,593 
Payment of employees’ taxes on vested restricted stock units(781)— 
Proceeds from contributions to the employee stock purchase plan2,312 1,615 
Repayment of principal portion of finance lease liabilities(8)— 
Net cash provided by financing activities5,421 305,890 
F-8

CASTLE BIOSCIENCES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)
(in thousands)
 Years Ended December 31,
 20212020
NET CHANGE IN CASH AND CASH EQUIVALENTS(80,219)311,007 
Beginning of year409,852 98,845 
End of year$329,633 $409,852 
SUPPLEMENTAL DISCLOSURE OF CASH PAID FOR:
Interest$1 $1,978 
Income taxes$16 $102 
DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Accrued purchases of property and equipment$33 $58 
Property and equipment acquired with tenant improvement allowance$54 $714 
Asset acquisition, receivable for purchase price adjustment$519 $— 
Asset acquisition, liability for contingent consideration$18,287 $— 
Common stock offering costs incurred but not paid$— $377 
Cashless exercise of common stock warrants$— $250 

The accompanying notes are an integral part of these consolidated financial statements.
F-9
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


1. Organization and Description of Business
Castle Biosciences, Inc. (the ‘‘Company’’, “we”, “us”, or “our”) was incorporated in the state of Delaware on September 12, 2007. We are a commercial-stage diagnostics company focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. We are based in Friendswood, Texas (a suburb of Houston, Texas) and laboratory operations are conducted at our facilities located in Phoenix, Arizona and in Pittsburgh, Pennsylvania.
Impact of COVID-19 Pandemic
Since the COVID-19 pandemic began in March 2020, we have maintained uninterrupted business operations with normal turnaround times for delivery of test reports, but have experienced declines in test report volume in certain periods, which we believe is linked to delays and/or cancellations in patient visits in response to COVID-19, resulting in reduced diagnostic biopsies and thus reduced diagnoses of cutaneous melanoma. The extent to which COVID-19 may further impact our business, consolidated results of operations, consolidated financial condition and consolidated cash flows will depend on future developments, which are highly uncertain and cannot be predicted with confidence.
2. Summary of Significant Accounting Policies
Basis of Presentation
Our consolidated financial statements include the accounts of Castle Biosciences, Inc. and our wholly owned subsidiaries and have been prepared in conformity with accounting principles generally accepted in the United States of America (‘‘U.S. GAAP’’). All intercompany accounts and transactions have been eliminated in consolidation.
Reclassification
Certain prior year amounts in our consolidated statements of operations and comprehensive loss have been reclassified to conform to the current year presentation. Specifically, we no longer present gross margin on our statements of operations and comprehensive loss and therefore the cost of sales line is now presented within the operating expenses section. This reclassification had no impact on operating loss, loss before income taxes, net loss, comprehensive loss or loss per share.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include revenue recognition, the valuation of stock-based compensation, assessing future tax exposure and the realization of deferred tax assets, the useful lives and recoverability of long-lived assets, the valuation of acquired intangible assets, the valuation of contingent consideration and other contingent liabilities. We base these estimates on historical and anticipated results, trends, and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. We have considered the potential impact of the COVID-19 pandemic on our estimates and assumptions. The extent to which the COVID-19 pandemic may impact our estimates in future periods is uncertain and subject to change.
Operating Segments
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment. All revenues are attributable to U.S.-based operations and all assets are held in the United States.
F-10
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Cash and Cash Equivalents including Concentrations of Credit Risk
Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less. Our cash equivalents consist of money market funds, which are not insured by the Federal Deposit Insurance Corporation (“FDIC”), that are primarily invested in short-term U.S. government obligations. Cash deposits at financial institutions may exceed the amount of insurance provided by the FDIC. Management believes that we are not exposed to significant credit risk on our cash deposits due to the financial position of the institutions in which deposits are held. We have not experienced any losses on our cash or cash equivalents.
Revenue Recognition
Revenue is recognized in accordance with Financial Accounting Standards Board (‘‘FASB’’) Accounting Standards Codification (‘‘ASC’’) Topic 606, Revenue from Contracts with Customers (‘‘ASC 606’’). In accordance with ASC 606, we follow a five-step process to recognize revenues: (1) identify the contract with the customer, (2) identify the performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenues when the performance obligations are satisfied. We have determined that we have a contract with the patient when the treating clinician orders the test. Our contracts generally contain a single performance obligation, which is the delivery of the test report, and we satisfy our performance obligation at a point in time upon the delivery of the test report to the treating physician, at which point we can bill for the report. The amount of revenue recognized reflects the amount of consideration to which we expect to be entitled, or the transaction price, and considers the effects of variable consideration. See Note 3 for further details.
Accounts Receivable and Allowance for Credit Losses
We classify accounts receivable balances that are expected to be paid more than one year from the consolidated balance sheet date as non-current assets. The estimated timing of payment utilized as a basis for classification as non-current is determined by analyses of historical payor-specific payment experience, adjusted for known factors that are expected to change the timing of future payments.
We accrue an allowance for credit losses against our accounts receivable based on management’s current estimate of amounts that will not be collected. Management’s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of customers’ financial condition and generally do not require collateral. Historically, our credit losses have not been significant. The allowance for credit losses was zero as of December 31, 2021 and 2020. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.
Inventory
We carry inventories of test supplies in our laboratory facilities. The inventories are carried at the lower of weighted average cost and net realizable value and expensed through cost of sales as the supplies are used.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between five and ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Our leasehold improvements primarily relate to our office and laboratory facilities in Friendswood, Texas and Phoenix, Arizona, and are generally being amortized through the end of the lease terms in 2025 and 2033, respectively. Maintenance and repairs are charged to expense as incurred, and material improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss in the period realized.
Intangible Assets
Our intangible assets, which are comprised primarily of acquired developed technology, are considered to be finite-lived and are amortized on a straight-line basis over their estimated useful lives.
Long-Lived Assets
We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than the carrying amount. Impairment, if
F-11
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

any, would be calculated based on the excess of the carrying amount of the long-lived asset over the long-lived asset’s fair value. There were no impairment charges recognized for the years ended December 31, 2021 and 2020.
Acquisitions
We assess acquisitions under ASC 805, Business Combinations, to determine whether a transaction represents the acquisition of assets or a business combination. Under this guidance, we apply a two-step model. The first step involves a screening test where we evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single asset or a group of similar assets. If the screening test is met, we account for the set as an asset acquisition. If the screening test is not met, we apply the second step of the model to determine if the set meets the definition of a business based on the guidance in ASC 805. If so, the transaction is treated as a business combination. Otherwise, it is treated as an asset acquisition. Asset acquisitions are accounted for by allocating the cost of the acquisition, including transaction costs, to the individual assets acquired and liabilities assumed on a relative fair value basis without recognition of goodwill. Business combinations are accounted for using the acquisition method. Under the acquisition method, goodwill is measured as a residual amount equal to the fair value of the consideration transferred less the net recognized fair value of the identifiable assets acquired and the liabilities assumed, as of the acquisition date, and transaction costs are expensed as incurred.
Contingent Consideration
Under the terms of business combinations or asset acquisitions, we may be required to pay additional consideration if specified future events occur or if certain conditions are met. With respect to the additional consideration that may be payable in connection with the Cernostics, Inc. (“Cernostics”) asset acquisition, we account for the contingent consideration as liability in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), under the guidance for obligations that must or may be settled by issuance of a variable number of shares. In accordance with ASC 480, we record the contingent consideration initially and subsequently at fair value with changes in fair value recorded in the statements of operations and comprehensive loss each period. For additional information on the contingent consideration, see Notes 5 and 11.
Other Operating Income
On April 10, 2020, we received an automatic payment of $1.9 million from the U.S. Department of Health and Human Services (“HHS”) pursuant to the Coronavirus Aid, Relief and Economic Security Act enacted on March 27, 2020, also known as the CARES Act, out of relief funds allocated by HHS to healthcare providers to reimburse healthcare related expenses or lost revenues attributable to COVID-19. This automatic payment was calculated by HHS in proportion to the providers’ share of Medicare fee-for-service reimbursements in 2019 and was applicable to all facilities and providers that received Medicare fee-for-service reimbursements in 2019. In the second quarter of 2020, based on guidance issued by HHS at the time that stated any reasonable method could be used to calculate lost revenues attributable to COVID-19, we concluded it would qualify to retain the relief funds and recognized the funds received as other operating income during the three months ended June 30, 2020. On September 19, 2020, HHS issued a notice of reporting requirements that changed the methodology for determining lost revenues to be based on a patient care operating income metric, as defined by HHS. Due to this change in methodology and uncertainty in its application, we determined that it was no longer reasonably assured of keeping the funds. Therefore, in the three months ended September 30, 2020, we reversed the previously recognized income. However, in the fourth quarter of 2020, a legislative change was enacted affecting the program, under which we concluded it is reasonably assured we will qualify to retain the funds. Accordingly, we recognized the income again in the fourth quarter of 2020.
Leases
Effective January 1, 2021, we account for leases in accordance with ASC 842, Leases. We categorize leases at their commencement as either operating or finance leases based on the criteria in ASC 842. Under ASC 842, we record right-of-use (“ROU”) assets and lease liabilities for each lease arrangement identified, except that we have elected the short-term lease exemption for all leases with a term of 12 months or less. Lease liabilities are recorded at the present value of future lease payments discounted using our incremental borrowing rate for the lease established at the commencement date and ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. For our operating leases, we recognize a single lease cost over the lease term on a straight-line basis. We have elected the practical expedient of not separating nonlease components from lease components in all leases. Periods prior to January 1, 2021 have not been restated for the adoption of ASC 842 and continue to reflect the accounting treatment of leases in accordance with the prior lease accounting guidance, ASC 840, Leases. Under ASC 840, landlord/tenant incentives, rent holidays and escalations in the base price of rent payments under operating leases were recognized on a straight-line basis over the lease term. Deferred rent balances were classified as current or non-current in the consolidated balance sheets based upon the period when reversal of the liability was expected to occur. See Note 9 for details on our leases.
F-12
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Cost of Sales (exclusive of amortization of acquired intangible assets)
Cost of sales is expensed as incurred and includes material and service costs associated with testing samples, personnel costs (including salaries, bonuses, benefits and stock-based compensation expense), electronic medical records, order and delivery systems, shipping charges to transport samples, third-party test fees, and allocated overhead including rent, information technology costs, equipment and facilities depreciation and utilities.
Research and Development
Research and development costs are charged to operations as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on behalf of us will be expensed as services are rendered or when the milestone is achieved.
Research and development costs include, but are not limited to, payroll and personnel-related expenses, stock-based compensation expense, materials, laboratory supplies, and consulting costs.
Selling, General and Administrative Expenses
Selling, general and administrative (“SG&A”) expenses are attributable to sales, marketing, executive, finance and accounting, legal and human resources functions. These expenses consist of personnel costs (including salaries, employee benefit costs, bonuses and stock-based compensation expenses), customer services expenses, direct marketing expenses, educational and promotional expenses, market research, audit and legal expenses, and consulting. We expense all SG&A costs as incurred.
Accrued Compensation
We accrue for liabilities under discretionary employee and executive bonus plans. These estimated compensation liabilities are based on progress against corporate objectives approved by our board of directors, compensation levels of eligible individuals, and target bonus percentage levels. The board of directors reviews and evaluates the performance against these objectives and ultimately determines what discretionary payments are made. We also accrue for liabilities under employee sales incentive bonus plans with accruals based on performance achieved to date compared to established targets. As of December 31, 2021 and 2020, we accrued approximately $12,071,000 and $7,175,000, respectively, for liabilities associated with these bonus plans. These amounts are classified as current or noncurrent accrued liabilities in the balance sheets based on the expected timing of payment.
Retirement Plan
We have an Internal Revenue Code (“IRC”) Section 401(k) profit sharing plan (the “Plan”) for eligible employees. The Plan is funded by employee contributions and provides for discretionary contributions in the form of matching and/or profit-sharing contributions. For the years ended December 31, 2021 and 2020, we provided a discretionary matching contribution of $2,036,000 and $789,000, respectively. The higher amount for the year ended December 31, 2021 reflects both an increase in the number of employees and a higher matching contribution rate compared to the year ended December 31, 2020.
Income Taxes
We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the statutory enactment date. Valuation allowances are established to reduce deferred tax assets when it is more likely than not that some portion or all of the deferred tax assets will not be realized.
Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50% likely to be realized upon settlement. A liability for unrecognized tax benefits is recorded for any tax benefits claimed in our tax returns that do not meet these recognition and measurement standards.
Our policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of tax expense. No material amounts of tax-related interest or penalties were recorded during the years ended December 31, 2021 and 2020.
F-13
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Stock-Based Compensation
Stock-based compensation expense for equity instruments issued to employees is measured based on the grant-date fair value of the awards. The fair value of employee stock options and offerings under the 2019 Employee Stock Purchase Plan (the “ESPP”) are estimated on the date of grant using the Black-Scholes option-pricing valuation model. For restricted stock units (“RSUs”), the fair value is equal to the closing price of our common stock on the date of grant. We recognize compensation costs on a straight-line basis for all employee stock-based compensation awards over the requisite service period of the awards. For options and RSUs, the requisite service period is generally the awards’ vesting period (typically four years). For the ESPP, the requisite service period is generally the period of time from the offering date to the purchase date. Forfeitures are accounted for as they occur.
Comprehensive Loss
Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive loss was the same as our reported net loss for all periods presented.
CARES Act Payroll Tax Deferral
The CARES Act permits employers to defer the payment of the employer share of social security taxes due for the period beginning March 27, 2020 and ending December 31, 2020. Of the amounts deferred, 50% were required to be paid by December 31, 2021 and the remaining 50% are required to be paid by December 31, 2022. We began deferring payment of the employer share of social security taxes in May 2020. Of the $551,000 originally deferred, 50% was repaid during the year ended December 31, 2021. As of December 31, 2021, the remaining $276,000 of such taxes was classified as a current liability on the consolidated balance sheet.
Recently Adopted Accounting Pronouncements
We were previously an emerging growth company (“EGC”) within the meaning of the Jumpstart Our Business Startups Act, as amended, (the “JOBS Act”) and elected to delay the adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements were made applicable to private companies, as permitted under the JOBS Act. Because the market value of our common stock held by non-affiliates exceeded $700.0 million as of June 30, 2021, we ceased to be an EGC effective December 31, 2021. Accordingly, we are no longer permitted to delay the adoption of new or revised accounting pronouncements and as such we adopted the pronouncements discussed below in the fourth quarter of 2021 effective as of the dates noted.
In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which supersedes ASC 840, Leases. ASU 2016-02 establishes ASC 842, Leases, and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized based on an effective interest method for finance leases or on a straight-line basis over the term of the lease for operating leases. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of classification. Leases with a term of 12 months or less may be accounted for similar to existing guidance for operating leases. We adopted ASU 2016-02 and ASC 842 using the modified retrospective approach with an effective date of January 1, 2021. Periods prior to January 1, 2021 have not been restated for the adoption of ASC 842 and continue to reflect the accounting treatment of leases in accordance with ASC 840. In connection with the adoption, we elected the package of practical expedients to not reassess prior conclusions about lease identification, lease classification and capitalized indirect costs. We did not elect the use of hindsight practical expedient. Upon adoption, effective January 1, 2021 we recognized operating lease right-of-use assets of $5,405,000, operating lease liabilities of $6,076,000, reductions to noncurrent liabilities of $751,000, reductions to current assets of $59,000 and a credit to accumulated deficit of $21,000. See Note 9 for disclosures about our leases.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement of expected credit losses for financial instruments carried at amortized cost, such as accounts receivable, held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. We adopted the standard effective January 1, 2021 using the modified retrospective approach. The adoption of this standard had no impact on our consolidated financial statements.
F-14
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which eliminates certain exceptions to the general principles in Topic 740 and simplifies other areas of the existing guidance. The adoption of ASU 2019-12 effective January 1, 2021 had no impact on our consolidated financial statements.
3. Revenue
All of our revenues from contracts with customers are associated with the provision of diagnostic and prognostic testing services. Most of our revenues are attributable to DecisionDx®-Melanoma for cutaneous melanoma. We also provide a test for uveal melanoma, DecisionDx®-UM. We launched a test for patients with cutaneous squamous cell carcinoma, DecisionDx®-SCC in August 2020 and launched a test for use in patients with suspicious pigmented lesions, DecisionDx® DiffDx™-Melanoma in November 2020. We began offering a test for difficult-to-diagnose melanocytic lesions, myPath Melanoma, following an asset acquisition completed in May 2021 and began offering the TissueCypher® Barrett’s Esophagus Assay for patients with BE following an asset acquisition completed in December 2021. Information on the disaggregation of revenues is included below.
Once we satisfy our performance obligations and bill for the service, the timing of the collection of payments may vary based on the payment practices of the third-party payor and the existence of contractually established reimbursement rates. Most of the payments for our services are made by third-party payors, including Medicare and commercial health insurance carriers. Certain contracts contain a contractual commitment of a reimbursement rate that differs from our list prices. However, absent a positive coverage policy, with or without a contractually committed reimbursement rate, with a commercial carrier or governmental program, our diagnostic tests may or may not be paid by these entities. In addition, patients do not enter into direct agreements with us that commit them to pay any portion of the cost of the tests in the event that their insurance provider declines to reimburse us. We may pursue, on a case-by-case basis, reimbursement from such patients in the form of co-payments and co-insurance, in accordance with the contractual obligations that we have with the insurance carrier or health plan. These situations may result in a delay in the collection of payments.
The Medicare claims that are covered by policy under a Local Coverage Determination (‘‘LCD’’) are generally paid at the established rate by our Medicare contractor within 30 days from receipt. Medicare claims that were either submitted to Medicare prior to the LCD coverage commencement date or are not covered by the terms of the LCD but meet the definition of being medically reasonable and necessary pursuant to the controlling Section 1862(a)(1)(A) of the Social Security Act are generally appealed and may ultimately be paid at the first (termed ‘‘redetermination’’), second (termed ‘‘reconsideration’’) or third level of appeal (de novo hearing with an Administrative Law Judge (“ALJ”)). A successful appeal at any of these levels results in payment.
In the absence of LCD coverage or contractually established reimbursements rates, we have concluded that our contracts include variable consideration because the amounts paid by Medicare or commercial health insurance carriers may be paid at less than our standard rates or not paid at all, with such differences considered implicit price concessions. Variable consideration attributable to these price concessions is measured at the expected value using the ‘‘most likely amount’’ method under ASC 606. The amounts are determined by historical average collection rates by test type and payor category taking into consideration the range of possible outcomes, the predictive value of our past experiences, the time period of when uncertainties expect to be resolved and the amount of consideration that is susceptible to factors outside of our influence, such as the judgment and actions of third parties. Such variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. Variable consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in the absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Variable consideration for Medicare claims that are not covered by an LCD, including those claims subject to approval by an ALJ at an appeal hearing, is deemed to be fully constrained due to factors outside our influence (i.e., judgment or actions of third parties) and the uncertainty of the amount to be received is not expected to be resolved for a long period of time. Variable consideration is evaluated each reporting period and adjustments are recorded as increases or decreases in revenues. Included in revenues for the years ended December 31, 2021 and 2020 were $3,324,000 and $176,000, respectively, of revenue increases associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. These amounts include (i) adjustments for actual collections versus estimated amounts and (ii) cash collections and the related recognition of revenue in current period for tests delivered in prior periods due to the release of the constraint on variable consideration.
F-15
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Because our contracts with customers have an expected duration of one year or less, we have elected the practical expedient in ASC 606 to not disclose information about our remaining performance obligations. Any incremental costs to obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of our contracts. Contract balances consisted of accounts receivable (both current and noncurrent) as of December 31, 2021 and 2020 and the Medicare advance payment (discussed further below) as of December 31, 2020.
Medicare Advance Payment
On April 16, 2020, we received an advance payment of $8.3 million (the “Advance Payment”) from the Centers for Medicare & Medicaid Services (“CMS”) under its Accelerated and Advance Payment Program, which was expanded to provide increased cash flow to service providers during the COVID-19 pandemic. CMS began recoupment of the Advance Payment in April 2021 by applying 25% of the Medicare payments otherwise owed to us against the balance of the Advance Payment. Recoupment of the full amount of the Advance Payment was complete by December 31, 2021.
DecisionDx-Melanoma Claims Consolidation
In June 2017, we submitted to the Office of Medicare Hearings and Appeals (‘‘OMHA’’) a formal request to participate in a program that OMHA developed with the intent of providing appellants a means to have large volumes of claim disputes adjudicated at an accelerated rate. The program consolidates outstanding claims at the ALJ level and uses a statistical-sampling approach where five ALJs will determine reimbursement results for a sample of claims which are then extrapolated to the universe of claims. The consolidation includes 2,698 DecisionDx-Melanoma claims dating from 2013 through spring 2017. Hearings were held in April 2019 with a supplemental hearing in May 2019. On March 12, 2020, OMHA issued a decision denying payment on all claims in the consolidation. We have filed an appeal to the decision, although no ruling on such appeal has been issued to date. In accordance with ASC 606 and consistent with prior periods, we have not recognized (fully constrained the variable consideration) any revenues attributable to these claims in our consolidated financial statements pending the outcome of this matter.
Disaggregation of revenues
The table below provides the disaggregation of revenue by type (in thousands):
Years Ended December 31,
20212020
Dermatologic$85,753 $57,646 
Other8,332 5,003 
Total net revenues$94,085 $62,649 
Payor Concentration
We rely upon reimbursements from third-party government payors (primarily Medicare) and private-payor insurance companies to collect accounts receivable related to sales of our diagnostic tests.
Our significant third-party payors and their related revenues as a percentage of total revenues and accounts receivable balances are as follows:
 Percentage of Revenues
Percentage of
 Accounts Receivable
 (current)
Percentage of
 Accounts Receivable
 (non-current)
 Year Ended December 31,As of December 31,As of December 31,
 202120202021202020212020
Medicare57 %58 %24 %15 %— %— %
Medicare Advantage plans28 %29 %40 %40 %— %25 %
BlueCross BlueShield plans7 %6 %22 %26 %58 %44 %
F-16
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

4. Loss Per Share
Basic loss per share is computed by dividing net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options or purchases under the 2019 Employee Stock Purchase Plan (“ESPP”). The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. However, potentially dilutive shares are excluded from the computation of diluted loss per share when their effect is antidilutive.
Due to us reporting a net loss for all periods presented, all potentially dilutive securities are antidilutive and are excluded from the computation of diluted loss per share for such periods.
The table below provides the weighted-average number of potential common shares associated with outstanding securities not included in our calculation of diluted loss per share for the years ended December 31, 2021 and 2020 because to do so would be antidilutive (in thousands):
Years Ended December 31,
20212020
Stock options and restricted stock units3,459 2,789 
Common stock warrants— 35 
Employee stock purchase plan62 100 
Total3,521 2,924 
In addition, in connection with the acquisition of Cernostics, we may issue shares of our common stock to satisfy the contingent consideration obligation, pending the outcome of certain commercial milestones, as discussed in Note 5.
5. Asset Acquisitions
Myriad myPath, LLC
On May 28, 2021, we completed the acquisition of all of the equity of Myriad myPath, LLC, a laboratory in Salt Lake City where the myPath Melanoma test for difficult-to-diagnose melanocytic lesions was developed and offered, for a cash purchase price of $32,500,000. Following the completion of the acquisition, we became the sole provider of the myPath Melanoma test. Based on the guidance in ASC 805, we concluded that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset and therefore the transaction represents an asset acquisition. We incurred $684,000 of direct transaction costs that were included in the cost of the acquisition. The allocation of the acquisition to individual assets resulted in an intangible asset representing developed technology of $33,054,000 and inventory of $130,000. The intangible asset has an estimated useful life of 12 years and is being amortized on a straight-line basis.
Cernostics, Inc.
On December 3, 2021, we completed the acquisition of Cernostics, Inc., which offers the TissueCypher® Barrett’s Esophagus Assay for patients with BE. We acquired Cernostics for an upfront cash purchase price of $30,732,000, including $653,000 of direct transaction costs. A portion of the upfront cash consideration is being held in escrow for a specified period following closing to secure post-closing adjustments and indemnification claims, if any. Our consolidated balance sheet at December 31, 2021 reflects a receivable of $519,000 for the post-closing purchase price adjustment, representing the difference between actual and estimated cash and working capital at closing, among other things. We have also agreed to pay up to an additional $50.0 million in cash or shares of our common stock, at our sole discretion, based on the achievement of certain commercial milestones relating to the year ending December 31, 2022 (“Earnout Payments”). The portion of any Earnout Payments that may be settled in shares of our common stock is subject to certain limitations and the aggregate number of shares that may be issued for the Earnout Payments may not exceed 5,034,653 shares. Any Earnout Payments in shares of our common stock will be based on the volume weighted-average price of our common stock for the 15 trading days ending December 30, 2022. The Earnout Payments represent contingent consideration. ASC 480, Distinguishing Liabilities from Equity, provides guidance on accounting for certain obligations that must or may be settled by issuance of a variable number of shares. In accordance with that guidance, we recognized a liability of $18,287,000, which represents the fair value of the obligation as of the acquisition date. See Note 11 for additional information on the measurement of the contingent consideration. Based on the guidance in ASC 805, we concluded that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset and therefore the transaction represents an asset acquisition.
F-17
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


The cost of the acquisition, which is comprised of the cash consideration, transaction costs and contingent consideration, was allocated to the assets acquired and the liabilities assumed as follows (in thousands):
December 3, 2021
Cash and cash equivalents$1,251 
Accounts receivable104 
Prepaid expenses and other current assets198 
Property and equipment455 
Intangible assets57,827 
Accounts payable(655)
Accrued compensation(167)
Other accrued and current liabilities(386)
Finance lease liabilities(237)
Deferred tax liabilities(9,371)
Total cost allocated$49,019 
The intangible assets were comprised of developed technology of $57,264,000 with an estimated useful life of 15 years and a developed workforce of $563,000, with an estimated useful life of five years, and each is being amortized on a straight-line basis.
6. Property and Equipment, Net
Property and equipment, net consisted of the following (in thousands):
As of December 31,
 20212020
Leasehold improvements$5,044 $1,388 
Lab equipment(1)
3,727 2,037 
Computer equipment2,457 1,305 
Furniture and fixtures1,288 436 
Construction-in-progress27 3,590 
Total12,543 8,756 
Less accumulated depreciation(1)
(3,042)(1,654)
Property and equipment, net$9,501 $7,102 
(1)    Includes lab equipment under a finance lease of $237 thousand and accumulated depreciation of $8 thousand.
Depreciation expense was recorded in the consolidated statements of operations and comprehensive loss as follows (in thousands):
Years Ended December 31,
 20212020
Cost of sales (exclusive of amortization of acquired intangible assets)$478 $341 
Research and development248 31 
Selling, general and administrative722 100 
Total$1,448 $472 
F-18
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

7. Intangible Assets, Net
Our intangible assets, net consist of the following (in thousands):
December 31, 2021
 Gross carrying valueAccumulated amortizationNetWeighted-Average Remaining Life (in years)
Developed technology$90,317 $(1,949)$88,368 13.2
Assembled workforce563 (9)554 4.9
Total intangible assets, net$90,880 $(1,958)$88,922 

There were no intangible assets as of December 31, 2020.

The estimated future aggregate amortization expense as of December 31, 2021 is as follows (in thousands):
Years Ending December 31,
2022$6,681 
20236,681 
20246,700 
20256,681 
20266,672 
Thereafter55,507 
Total$88,922 
Amortization expense of intangible assets was $2.0 million for the year ended December 31, 2021. No amortization expense was recorded for the year ended December 31, 2020.
8. Other Accrued and Current Liabilities
Other accrued liabilities consisted of the following (in thousands):
As of December 31,
 20212020
Accrued service fees$1,905 $1,543 
Clinical studies1,655 348 
Employee stock purchase plan contributions760 536 
Payroll tax liabilities695 276 
Accrued payor refunds386 — 
Other277 352 
Total$5,678 $3,055 
9. Leases
Operating Leases
We lease office space in Friendswood, Texas (the “Friendswood Lease”) for use as our corporate headquarters. The Friendswood Lease commenced in late 2020 under a 60-month term and a renewal option for one additional five-year term.
We lease two facilities in Phoenix, Arizona for laboratory and office space. For both leases, the current term extends until April 2033 with options to renew for two additional five-year terms.
F-19
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

We have not included the optional renewal periods in the measurement of the lease obligations because it is not reasonably certain that we will exercise these renewal options.
Our other operating leases primarily consist of office equipment.
Finance Lease
In connection with the December 2021 acquisition of Cernostics, we assumed a finance lease for laboratory equipment.
Discount Rates
We discount our lease obligations using our incremental borrowing rate at the commencement date. The incremental borrowing rate is the rate of interest we would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. We primarily consider industry data, our credit rating and the lease term to determine our incremental borrowing rate.
Lease Balances and Costs
Lease balances reflected in the consolidated balance sheet were as follows (in thousands):
Lease BalanceClassificationDecember 31, 2021
Lease Assets
OperatingOperating lease assets$7,383 
FinanceProperty and equipment, net$229 
Lease Liabilities
Current
OperatingOperating lease liabilities$1,179 
FinanceOther accrued and current liabilities$105 
Noncurrent
OperatingNoncurrent operating lease liabilities$6,900 
FinanceOther liabilities$124 
Costs associated with our leases were included in the consolidated statement of operations and comprehensive loss as follows (in thousands):
Lease CostYear Ended December 31, 2021
Operating lease cost(1)
$1,450 
Finance lease cost
Amortization of lease assets8 
Interest on finance lease liabilities1 
Short-term lease cost29 
Total lease cost$1,488 
(1)    Includes variable lease cost of $187 thousand for the year ended December 31, 2021.
F-20
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Other Information
Supplemental cash flow information on leases is as follows (in thousands):
 Year Ended December 31, 2021
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$1,145 
Operating cash flows from interest paid on finance leases$1 
Financing cash flows from finance leases    $8 
During the year ended December 31, 2021, we recorded $2.9 million in lease liabilities arising from obtaining ROU assets.
Information regarding the weighted-average lease term and weighted-average discount rate is presented below:
 December 31, 2021
Weighted-average remaining lease term (years)
Operating leases9.1
Finance leases2.3
Weighted-average discount rate
Operating leases4.9 %
Finance leases5.0 %
The following is a maturity analysis of our operating lease and finance lease liabilities as of December 31, 2021 (in thousands):
Operating leasesFinance leases
Years Ending December 31,
2022$1,258 $108 
20231,287 108 
20241,302 26 
20251,218 — 
2026689 — 
Thereafter4,609 — 
Total lease payments10,363 242 
Less: Interest component(2,284)(13)
Present value of lease payments$8,079 $229 
As of December 31, 2021, we have no material leases that have not yet commenced.
F-21
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Disclosures Under ASC 840
Future non-cancellable commitments under all operating leases were as follows as of December 31, 2020 (in thousands):
Years Ending December 31,
2021$1,164 
20221,148 
20231,142 
20241,154 
20251,119 
Thereafter1,037 
$6,764 
Rent expense was $548,000 for the year ended December 31, 2020.
10. Long-Term Debt
We had a Loan and Security Agreement with Oxford Finance LLC (“Oxford”) as collateral agent, and Oxford and Silicon Valley Bank as equal syndicated lenders (the “2018 LSA”). The 2018 LSA consisted of a $25.0 million secured term loan credit facility (the “Term Loan”). The Term Loan bore interest at a floating rate equal to the greater of (1) 8.55% and (2) the 30-day U.S. LIBOR rate as reported in The Wall Street Journal on the last business day of the month that preceded the month in which the interest was to accrue, plus 6.48%. We were permitted to make interest-only payments on the Term Loan through May 31, 2020. As required, we began to repay the principal in 30 equal monthly installments of $833,333 each beginning on June 1, 2020. All unpaid principal and accrued and unpaid interest were to be due at maturity on November 1, 2022. However, on December 21, 2020, we terminated the 2018 LSA and repaid in full all amounts due, which totaled $21.6 million as of such date, including the outstanding principal balance, the final payment amount, early termination and prepayment fees and accrued interest. The termination of the 2018 LSA resulted in the recognition of an extinguishment loss of $1.4 million, which was reflected in our statement of operations and comprehensive loss for the year ended December 31, 2020.
11. Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used in measuring fair value. There are three levels to the fair value hierarchy based on the reliability of inputs, as follows:
Level 1 – Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2 – Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.
Level 3 – Unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions.
Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or amounts recorded may not be indicative of the amount that us or holders of the instruments could realize in a current market exchange.
F-22
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

The table below provides information (in thousands), by level within the fair value hierarchy, of our financial assets and liabilities that are accounted for at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):
 
As of December 31, 2021
 Quoted Prices in Active Markets for Identical Items (Level 1)Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)		Total
Assets:    
Money market funds(1)
$327,721 $— $— $327,721 
Liabilities:
Contingent consideration$— $— $18,287 $18,287 
As of December 31, 2020
Quoted Prices in Active Markets for Identical Items (Level 1)Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)		Total
Assets:
Money market funds(1)
$409,480 $— $— $409,480 
(1) Classified as “Cash and cash equivalents” in the consolidated balance sheets.
Contingent Consideration
In connection with our acquisition of Cernostics, we have recorded a contingent consideration liability for the Earnout Payments. This liability is classified as a Level 3 fair value measurement due to the use of significant unobservable inputs and a Monte Carlo simulation to determine its fair value. The Monte Carlo simulation uses projections of the commercial milestones for the applicable period as well as the corresponding targets and approximate timing of payment based on the terms of the arrangement. The analysis also uses assumptions for expected volatility of the financial metrics and a risk-adjusted discount rate, which were 20.0% and 16.1%, respectively, at initial measurement on December 3, 2021. The contingent consideration liability is remeasured at fair value at each reporting period taking into account any updated assumptions or changes in circumstances. Any change in the fair value is recorded as a gain or loss in our consolidated statement of operations and comprehensive loss. There was no change in fair value from the initial recognition on December 3, 2021 through December 31, 2021.
The following table discloses the summary of changes in the contingent consideration liability measured at fair value using Level 3 inputs during the year ended December 31, 2021 (in thousands):
 Year Ended
December 31, 2021
Balance at beginning of period$— 
Acquisition of Cernostics18,287 
Change in fair value— 
Balance at end of period$18,287 
12. Commitments and Contingencies
From time to time, we may be involved in legal proceedings arising in the ordinary course of business. We believe there is no threatened litigation or litigation pending that could have, individually or in the aggregate, a material adverse effect on our financial position, results of operations or cash flows.
F-23
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

13. Stockholders’ Equity
Capital Stock
The Company’s Amended and Restated Certificate of Incorporation, dated July 29, 2019, authorizes the Company to issue up to 200,000,000 shares of common stock with a par value of $0.001 per share. The Company is also authorized to issue up to 10,000,000 shares of preferred stock with a par value of $0.001 per share. No dividends were declared or paid during the years ended December 31, 2021 or 2020.
On June 29, 2020, we issued and sold 2,000,000 shares of our common stock in a follow-on public offering at a price of $37.00 per share. We received $69,079,000 in net proceeds, after deducting underwriting discounts, commissions and offering costs. In connection with the offering, we granted the underwriters a 30-day option to purchase up to 300,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. On July 2, 2020, we issued and sold an additional 300,000 shares of common stock pursuant to the underwriters’ exercise in full of their option to purchase additional shares, which resulted in an additional net proceeds to us of $10,425,000. On December 18, 2020, we issued and sold 4,600,000 shares of our common stock in a follow-on public offering, including 600,000 shares associated with the full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $58.00 per share. We received $250,201,000 in aggregate net proceeds, after deducting underwriting discounts and commissions and offering costs.
Common Stock Warrants
The Company issued an aggregate of 209,238 shares and 31,814 shares of common stock December 11, 2020 and December 29, 2020, respectively, pursuant to net exercises by the holders of common stock warrants outstanding. In accordance with the net exercise provisions of the warrants, shares of common stock were withheld to satisfy the cost of these exercises.
There were no common stock warrants outstanding as of December 31, 2021 or 2020.
The common stock warrants were classified as stockholders’ equity and no adjustments were recorded for changes in fair value.
14. Stock Incentive Plans and Stock-Based Compensation
Stock Incentive Plans
Our stock incentive plans provide for the granting of options to purchase common stock and other equity-based awards to our employees, directors and consultants. On September 6, 2008, we adopted the 2008 Stock Plan (the “2008 Plan”), on August 15, 2018, we adopted the 2018 Stock Plan (the “2018 Plan”) and on July 24, 2019, we adopted the 2019 Equity Incentive Plan (the “2019 Plan”). Following the adoption of the 2018 Plan, no additional stock awards were granted under the 2008 Plan and following the adoption of the 2019 Plan, no additional stock awards were granted under the 2018 Plan.
Options under the plans may be granted as incentive stock options (“ISOs”) or non-statutory stock options (“NSOs”). ISOs may only be granted our employees (including directors who are also considered employees). NSOs may be granted our employees, directors and consultants. Options may be granted for terms up to ten years from the date of grant, as determined by the Board of Directors; provided, however, that with respect to an ISO granted to a person who owns stock representing more than 10% of the voting power of all classes of stock of ours, the terms shall be for no more than five years from the date of grant. The exercise price of options granted must be no less than 100% of the fair market value of the shares on the date of grant, provided, however, that with respect to an ISO granted to an employee who at the time of grant of such options owns stock representing more than 10% of the voting power of all classes of stock of ours, the exercise price shall not be less than 110% of the fair market value of the shares on the date of grant. Options generally vest over four years (generally 25% after one year and monthly thereafter), subject to the option holder’s continued service with us. We issue new shares to satisfy option exercises.
As of December 31, 2021, 46,741 shares remained available for grant under the 2019 Plan. On January 1, 2022, an additional 1,268,926 shares became available under the 2019 Plan pursuant to an automatic annual increase.
F-24
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Stock Options
Stock option activity under our stock plans for the years ended December 31, 2021 and 2020 is set forth below:
  Weighted-Average 
 Stock Options
Outstanding		Exercise
Price		Remaining
Contractual
Term (Years)		Aggregate
Intrinsic
Value
(in thousands)
Balance as of January 1, 20202,637,966 $13.30 
Granted1,286,065 $49.63 
Exercised(460,207)$3.53 
Forfeited/Cancelled(94,322)$27.51 
Balance as of December 31, 20203,369,502 $28.11 
Granted841,336 $48.97 
Exercised(414,890)$10.13 
Forfeited/Cancelled(209,260)$33.97 
Balance as of December 31, 20213,586,688 $34.75 8.3$45,970 
Exercisable at December 31, 2021(1)
1,332,487 $23.31 7.5$28,845 
(1)Vested and exercisable options. Additionally, outstanding unvested options to purchase an aggregate of 10,255 shares of common stock with a weighted-average exercise price of $2.39 per share may be exercised prior to vesting as of December 31, 2021 under early-exercise provisions. In the event of such exercise, the shares obtained upon exercise would be restricted and subject to forfeiture prior to vesting. No such early exercises have occurred as of December 31, 2021.
Restricted Stock Units
RSUs represent the right to receive shares of our common stock at a specified future date, subject to vesting. Our RSUs generally vest annually from the grant date in four equal installments subject to the holder’s continued service with us. We issue new shares to satisfy RSUs upon vesting.
The following table summarizes our RSU activity for the years ended December 31, 2021 and December 31, 2020:
Restricted Stock Units OutstandingWeighted-Average Grant Date Fair Value
Balance as of January 1, 2020— $— 
Granted161,477 $59.16 
Vested— $— 
Forfeited/Cancelled— $— 
Balance as of December 31, 2020161,477 $59.16 
Granted958,361 $43.05 
Vested (1)
(56,002)$61.07 
Forfeited/Cancelled(13,662)$62.80 
Balance as of December 31, 20211,050,174 $44.31 
(1)The aggregate number of shares withheld upon vesting for employee tax obligations was 16,440 for the year ended December 31, 2021.
RSU Awards to Related Parties
On October 1, 2021, the Audit Committee of our Board of Directors approved, at the recommendation of our Compensation Committee, a one-time award of RSUs to three employees who are the children of our Chief Executive Officer (“CEO”) which we have determined to be outside the ordinary course of business. Under the Internal Revenue Code (“IRC”), those owning more than a specified percentage of a company’s stock are not eligible to receive certain preferential tax benefits that are afforded to qualifying stock compensation arrangements. In determining eligibility under the Code, when calculating the number of shares of common stock owned, an individual must attribute all shares owned by specified family members. Because
F-25
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

of the stock ownership of our CEO and this attribution requirement, the three children have not been eligible to participate in the ESPP and, at times, have not qualified to receive stock option grants on terms as favorable as those received by other similar employees. Our Compensation Committee recommended, and our Audit Committee approved, a one-time grant of restricted stock units designed to compensate the three children for these differences. The aggregate number of shares underlying the restricted stock units granted to the three children was 17,275 which are included in the table above. The awards had an aggregate grant date fair value of $1,129,000, vested immediately upon grant and was recognized as stock-based compensation expense, included in selling, general and administrative expenses, during the year ended December 31, 2021.
Employee Stock Purchase Plan
The ESPP became effective July 24, 2019. Offerings under the ESPP are generally 24 months in length with four six-month purchase periods unless terminated earlier, as described below. Eligible employees who enroll in an offering are able to purchase shares of our common stock at a discount through payroll deductions, subject to certain limitations. The purchase price of the shares of common stock is the lesser of (i) 85% of the fair market value of such shares on the offering date and (ii) 85% of the fair market value of such shares on the purchase date. A new offering begins approximately every six months. Offerings are concurrent, but in the event the fair market value of a share of common stock on the first day of any purchase period during an offering (the “New Offering”) is less than or equal to the fair market value of a share of common stock on the offering date for an ongoing offering (the “Ongoing Offering”), then the Ongoing Offering terminates immediately following the purchase of shares on the purchase date immediately preceding the New Offering and the participants in the terminated Ongoing Offering are automatically enrolled in the New Offering. In such case, we account for this event as a modification of the Ongoing Offering. Notwithstanding the above, our Board of Directors (or an authorized committee thereof) may modify the terms of or suspend any future offerings prior to their commencement.
As of December 31, 2021, 639,466 shares remained available for issuance under the ESPP. The ESPP provides for certain automatic increases in the number of shares of common stock reserved for issuance, which resulted in an additional 253,785 shares becoming available under the ESPP effective January 1, 2022. We issue new shares to satisfy ESPP purchases.
Determining Fair Value - Summary of Assumptions
We use the Black-Scholes option pricing model to estimate the fair value of stock options and purchase rights granted under the ESPP at the date of grant, start of the offering or other relevant measurement date. Set forth below is a description of the significant assumptions used in the option pricing model:
•Expected term. The expected term is the period of time that granted options are expected to be outstanding. For stock options, we have set the expected term using the simplified method based on the weighted average of both the period to vesting and the period to maturity for each option, as we have concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate the expected term. For the ESPP, the expected term is the period of time from the offering date to the purchase date.
•Expected volatility. Previously, because of the limited period of time our stock had been traded in an active market, we calculated expected volatility by using the historical stock prices of a group of similar companies looking back over the estimated life of the option or the ESPP purchase right and averaging the volatilities of these companies. In the third quarter of 2021, we adjusted this calculation to include our own stock price on a relative basis to the peer group in the calculation of expected volatility, as our common stock has now been traded in an active market for more than two years.
•Risk-free interest rate. We base the risk-free interest rate used in the Black-Scholes valuation model on the market yield in effect at the time of option grant and at the offering date for the ESPP, provided from the Federal Reserve Board’s Statistical Releases and historical publications from the Treasury constant maturities rates for the equivalent remaining terms.
•Dividend yield. We have not paid, and does not have plans to pay, cash dividends. Therefore, we use an expected dividend yield of zero in the Black-Scholes option valuation model.
The fair value of our common stock is also an assumption used to determine the fair value of stock options. Prior to our initial public offering of common stock on July 29, 2019 (the “IPO”), our common stock was not publicly traded, therefore we estimated the fair value of our common stock. Following the IPO, the fair value of our common stock is the closing selling price per share of its common stock as reported on the Nasdaq Global Market on the date of grant or other relevant determination date.
F-26
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

We use the Black-Scholes option pricing model to estimate the fair value of each option grant on the date of grant or any other measurement date. The following table sets forth the assumptions used to determine the fair value of stock options:
 Years Ended December 31,
20212020
Average expected term (years)
6.1
6
Expected stock price volatility
66.50% - 68.83%
59.57% - 67.02%
Risk-free interest rate
0.51% - 1.48%
0.28% - 1.76%
Dividend yield
—%
—%

The following table sets forth assumptions used to determine the fair value of the purchase rights issued under the ESPP:
 Years Ended December 31,
20212020
Average expected term (years)
1.2
1.2
Expected stock price volatility
61.13% - 86.50%
56.80% - 100.49%
Risk-free interest rate
0.06% - 0.20%
0.12% - 0.95%
Dividend yield
—%
—%
We use the closing price of our common stock on the date of grant to determine the fair value of RSUs.
Stock-Based Compensation Expense
Stock-based compensation expense is included in the consolidated statements of operations and comprehensive loss as follows (in thousands):
 Years Ended December 31,
 20212020
Cost of sales (exclusive of amortization of acquired intangible assets)$2,058 $1,049 
Research and development4,522 1,492 
Selling, general and administrative15,160 5,768 
Total stock-based compensation expense$21,740 $8,309 
For the years ended December 31, 2021 and 2020, the weighted-average grant date fair value of stock options was $29.89 and $28.95 per option, respectively, and the weighted-average grant date fair value of the purchase rights granted under the ESPP was $27.60 and $17.43 per share, respectively. As of December 31, 2021, the total unrecognized stock-based compensation cost related to outstanding awards was $99,251,000, which is expected to be recognized on a straight-line basis over a weighted-average period of 3.3 years. The total unrecognized compensation cost will be adjusted for forfeitures in future periods as they occur. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2021 and 2020 was $27,191,000 and $18,377,000, respectively. The aggregate intrinsic value of shares issued under the ESPP was $6,341,000 and $1,797,000 during the years ended December 31, 2021 and 2020, respectively. The aggregate fair value of restricted stock units that vested during the year ended December 31, 2021 was $2,698,000. No tax benefits related to stock-based compensation were recorded in the consolidated statements of operations and comprehensive loss during the years ended December 31, 2021 and 2020 due to the valuation allowance on net deferred tax assets.
F-27
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

15. Income Taxes
The components of income tax expense (benefit) are as follows (in thousands):
Years Ended December 31,
20212020
Current tax expense
U.S. Federal$— $— 
State and local16 84 
Total current16 84 
Deferred tax (benefit) expense
U.S. Federal(8,726)— 
State and local(10)— 
Total deferred(8,736)— 
Total income tax (benefit) expense$(8,720)$84 
The differences between income taxes expected at the U.S. federal statutory rate (21%) and the reported income tax expense (benefit) are summarized as follows (in thousands):
Years Ended December 31,
20212020
Pre-tax loss$(40,012)$(10,200)
U.S. federal taxes at statutory rate(8,402)(2,142)
State income taxes(1,764)(311)
Non-deductible meals— 235 
Research and development (“R&D”) tax credit(1,658)(703)
Change in valuation allowance2,570 2,784 
Stock-based compensation(880)(781)
Non-deductible officers’ compensation1,571 963 
Other(157)39 
Total income tax (benefit) expense$(8,720)$84 
F-28
CASTLE BIOSCIENCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Significant components of deferred tax assets and liabilities are as follows (in thousands):
As of December 31,
20212020
Deferred tax assets:
Net operating loss (“NOL”) carryforwards$24,316 $13,720 
Accrued liabilities4,168 2,730 
Lease liabilities2,114 — 
Intangible assets— 46 
Stock-based compensation2,202 761 
R&D tax credit3,670 1,777 
Other240 — 
Total deferred tax assets36,710 19,034 
Less valuation allowance(17,774)(15,204)
Deferred tax assets, net$18,936 $3,830 
Deferred tax liabilities:
Prepaid expenses$(330)$(289)
Property and equipment(2,285)(776)
Intangible assets(12,913)— 
ROU assets(2,166)— 
Section 481(a) adjustment (cash to accrual)(1,877)(2,765)
Total deferred tax liabilities(19,571)(3,830)
Net deferred tax asset (liability)$(635)$— 
At December 31, 2021, we had NOL carryforwards for federal income tax purposes of approximately $99,365,000 of which $43,513,000 will begin to expire in 2030 if not utilized to offset taxable income, and $55,852,000 may be carried forward indefinitely. Future changes in ownership, as defined by Section 382 of the IRC, could limit the amount of NOL carryforwards used in any one year. Also, as of December 31, 2021, we had state net operating loss carryforwards of approximately $67,453,000, which begin to expire in 2028 if not utilized to offset state taxable income. Our R&D tax credit carryforwards of $3,670,000 at December 31, 2021 will begin to expire in 2034 if not utilized to offset federal income tax.
In general, under Section 382 and 383 of the IRC, a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change NOLs and certain tax credits, to offset future taxable income and tax. In general, an ownership change occurs if the aggregate stock ownership of certain stockholders changes by more than 50 percentage points over such stockholders’ lowest percentage of ownership during the testing period (generally three years). We performed a Section 382 analysis from inception through the year ended December 31, 2021 and concluded we had experienced an ownership change in 2011, 2014 and 2020. These changes in ownership did not result in the expiration of any NOLs or R&D credits. However, future changes in ownership may further limit the ability of us to utilize our NOL carryforwards and R&D tax credit carryforwards.
During the year ended December 31, 2021, in connection with the acquisition of Cernostics, we recorded additional net deferred tax liabilities of $9,371,000, primarily due to book-tax differences related to the acquired intangible assets. As a result of these additional deferred tax liabilities, we determined that $8,726,000 of our existing valuation allowance should be reduced, which was reflected in our income tax benefit for the year ended December 31, 2021. At December 31, 2021 and 2020, we placed a valuation allowance of $17,774,000 and $15,204,000, respectively, against our net deferred tax asset balances, as we have determined that it is more likely than not that they will not be realized.
We assessed whether we had any significant uncertain tax positions related to open tax years and concluded there were none. Accordingly, no reserve for uncertain tax positions has been recorded as of December 31, 2021 and 2020. We are generally no longer subject to tax examinations for U.S. federal income tax purposes for fiscal years prior to 2018 and fiscal years prior to 2017 for multiple state jurisdictions. However, since we have been in an NOL position since 2008, our 2008 to 2017 federal tax returns and our 2008 to 2016 state tax returns are potentially subject to examination adjustments to the extent of those NOL carryforwards.
F-29
 EX-10.11 2 exhibit1011non-employeedir.htm EX-10.11 Document

Exhibit 10.11
Castle Biosciences, Inc.
Non-Employee Director Compensation Policy
Adopted: June 8, 2019
Amended: January 24, 2022 (the “Effective Date”)

Each member of the Board of Directors (the “Board”) of Castle Biosciences, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (the “Director Compensation Policy”) for his or her Board service. This policy is updated and effective as of the Effective Date and may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board.

A Non-Employee Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash is to be paid or equity awards are to be granted, as the case may be.

Annual Cash Compensation

Commencing at the beginning of the first calendar quarter following the Effective Date, each Non-Employee Director will receive the cash compensation set forth below for service on the Board. The annual cash compensation amounts will be payable in equal quarterly installments, in arrears following the end of each quarter in which the service occurred, pro-rated for any partial months of service. All annual cash fees are vested upon payment.

1.Annual Board Service Retainer
a.All Eligible Directors: $42,000
2.Annual Board Chair Service Retainer (in addition to Board Service Retainer):
a.Chair of the Board: $42,000
3.Annual Committee Member Service Retainer (committee chairs will not receive this retainer in addition to the Committee Chair Service Retainer):
a.Member of the Audit Committee: $10,000
b.Member of the Compensation Committee: $7,500
c.Member of the Nominating and Corporate Governance Committee: $5,000
4.Annual Committee Chair Service Retainer:
a.Chair of the Audit Committee: $20,000
b.Chair of the Compensation Committee: $15,000
c.Chair of the Nominating and Corporate Governance Committee: $10,000

Equity Compensation

The equity compensation set forth below will be granted under the Company’s 2019 Equity Incentive Plan (the “Plan”). All stock options granted under this policy will be Nonstatutory Stock Options (as defined in the Plan), with a term of 10 years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan) and an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying common stock of the Company on the date of grant.

(a) Automatic Equity Grants.

(i) Initial Grants for New Directors. Without any further action of the Board, each person who, after the Effective Date, is elected or appointed for the first time to be a Non-Employee Director will automatically, upon the date of his or her initial election or appointment to be a Non-Employee Director (or, if such date is not a market trading day, the first market trading day thereafter), be granted two equity awards (the “Initial Grants”) having an aggregate value of $350,000, which shall be comprised of a Nonstatutory Stock Option to purchase shares of common stock (the “Initial Option Grant”) and a restricted stock unit (“RSU”) award covering shares of common stock (the “Initial RSU Grant”). The total number of shares subject to the Initial Grants will be calculated as follows:



•First, the number of stock option equivalent shares equal to the aggregate value of the Initial Grants (the “Total Initial Shares”) will be determined in accordance with the Company’s Black-Scholes valuation methodology for stock options, assuming solely for such valuation purposes a fair value of the Company’s common stock and an assumed exercise price equal to the average of the closing prices of the Company’s common stock for each trading day within the 30 calendar days prior to the grant date (such price, the “Average Price”) as well as other relevant assumptions consistent with the Company’s option valuation policies used for financial reporting purposes (the “30-Day Black-Scholes Method”), rounded down to the nearest whole share.

•Next, the Total Initial Shares shall be allocated as follows: (x) 67% of the Total Initial Shares, rounded down to the nearest whole number, shall be subject to the Initial Option Grant; and (y) 33% of the Total Initial Shares, divided by two and rounded to the nearest five shares, shall be subject to the Initial RSU Grant.

In the event that more than one Non-Employee Director is elected or appointed within a single calendar year, for each Non-Employee Director elected or appointed after the first election or appointment of a Non-Employee Director in such calendar year (each, a “Subsequent Director”), if the Average Price calculated for purposes of determining the Total Initial Shares underlying the Initial Grants for a Subsequent Director has not increased or decreased more than 10% compared to the Average Price calculated for purposes of determining the Total Initial Shares underlying the Initial Grants for the first Non-Employee Director elected or appointed in that same calendar year (the “First Director”), then the Total Initial Shares underlying the Initial Grants for such Subsequent Non-Employee Director shall be equal to the Total Initial Shares calculated for the First Director.

1/3rd of the shares subject to the Initial Option Grant will vest one year from the date of grant, with the remainder vesting in equal monthly installments over the remaining two-year period. The shares subject to the Initial RSU Grant will vest in a series of three successive equal annual installments over the three-year period measured from the date of grant.

(ii) Annual Grants. Without any further action of the Board, at the close of business on the date of each Annual Meeting of Stockholders following the Effective Date, each person who is then a Non-Employee Director will automatically be granted two equity awards (the “Annual Grants”) having an aggregate value of $200,000, which shall be comprised of a Nonstatutory Stock Option to purchase shares of common stock (the “Annual Option Grant”) and a RSU award covering shares of common stock (the “Annual RSU Grant”). The total number of shares subject to the Annual Grants will be calculated as follows.

•First, the number of stock option equivalent shares equal to the aggregate value of the Annual Grants (the “Total Annual Shares”) will be determined in accordance with the 30-Day Black-Scholes Method, rounded down to the nearest whole share.

•Next, the Total Annual Shares shall be allocated as follows: (x) 50% of the Total Annual Shares, rounded down to the nearest whole number, shall be subject to the Annual Option Grant; and (y) 50% of the Total Annual Shares, divided by two and rounded to the nearest five shares, shall be subject to the Annual RSU Grant.

The shares subject to each Annual Grant will vest in full on the one-year anniversary of the date of grant.

(b) Vesting; Change in Control. All vesting is subject to the Non-Employee Director’s Continuous Service (as defined in the Plan) on each applicable vesting date. Notwithstanding the foregoing vesting schedules, for each Non-Employee Director who remains in Continuous Service with the Company until immediately prior to the closing of a Change in Control (as defined in the Plan), the shares subject to his or her then-outstanding equity awards that were granted pursuant to this policy will become fully vested immediately prior to the closing of such Change in Control.

(c) Remaining Terms. The remaining terms and conditions of each award, including transferability, will be as set forth in the Company’s Director Option Grant Package in the form adopted from time to time by the Board.



Eligible Director Compensation Limit

Notwithstanding anything herein to the contrary, the cash compensation and equity compensation that each Eligible Director is entitled to receive under this Policy shall be subject to the limits set forth in Section 3(d) of the Plan.

Expenses

The Company will reimburse Non-Employee Director for ordinary, necessary and reasonable out-of-pocket travel expenses to cover in-person attendance at and participation in Board and committee meetings; provided, that the Non-Employee Director timely submit to the Company appropriate documentation substantiating such expenses in accordance with the Company’s travel and expense policy, as in effect from time to time.



 EX-21.1 3 exhibit211subsidiaries.htm EX-21.1 Document

Exhibit 21.1
CASTLE BIOSCIENCES, INC.
SUBSIDIARIES OF THE REGISTRANT


Name of SubsidiaryState of Incorporation
Myriad myPath, LLC
Delaware
Cernostics, Inc.Delaware

 EX-23.1 4 exhibit23consent10-k2021.htm EX-23.1 Document
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the registration statements (Nos. 333-251331 and 333-262178) on Form S-3 and (Nos. 333-232884, 333-237062 and 333-254179) on Form S-8 of our reports dated February 28, 2022, with respect to the consolidated financial statements of Castle Biosciences, Inc. and the effectiveness of internal control over financial reporting.
/s/ KPMG LLP
San Diego, California
February 28, 2022


EX-31.1 5 exhibit311yearend2021.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a),
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002
I, Derek J. Maetzold, certify that:
1I have reviewed this annual report on Form 10-K of Castle Biosciences, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 28, 2022/s/ Derek J. Maetzold
Derek J. Maetzold
President and Chief Executive Officer
(Principal Executive Officer)

 EX-31.2 6 exhibit312yearend2021.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a),
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002
I, Frank Stokes, certify that:
1I have reviewed this annual report on Form 10-K of Castle Biosciences, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:February 28, 2022/s/ Frank Stokes
Frank Stokes
Chief Financial Officer
(Principal Financial and Accounting Officer)



 EX-32.1 7 exhibit321yearend2021.htm EX-32.1 Document

Exhibit 32.1
 
CERTIFICATION OF
PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
UNDER SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002, 18 U.S.C. § 1350
In connection with the Annual Report on Form 10‑K for the fiscal year ended December 31, 2021 of Castle Biosciences, Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Derek J. Maetzold, President and Chief Executive Officer of the Company, and Frank Stokes, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:
(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date:February 28, 2022
/s/ Derek J. Maetzold/s/ Frank Stokes
Derek J. Maetzold
President and Chief Executive Officer
(Principal Executive Officer)		Frank Stokes
Chief Financial Officer
(Principal Financial and Accounting Officer)

This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Castle Biosciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.


 EX-101.SCH 8 cstl-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0002002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 1001003 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 1004006 - Statement - CONSOLIDATED STATEMENTS STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 1005007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 2102102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2203201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2105103 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Revenue - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Revenue - Payor Concentration (Details) link:presentationLink link:calculationLink link:definitionLink 2110104 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Loss Per Share - Schedule of Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2113105 - Disclosure - Asset Acquisitions link:presentationLink link:calculationLink link:definitionLink 2314303 - Disclosure - Asset Acquisition (Tables) link:presentationLink link:calculationLink link:definitionLink 2415406 - Disclosure - Asset Acquisitions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2416407 - Disclosure - Asset Acquisitions - Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2117106 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 2318304 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2419408 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2420409 - Disclosure - Property and Equipment, Net - Summary of Depreciation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2121107 - Disclosure - Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 2322305 - Disclosure - Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2423410 - Disclosure - Intangible Assets, Net - Summary of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2424411 - Disclosure - Intangible Asset, Net - Future Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 2425412 - Disclosure - Intangible Assets, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2126108 - Disclosure - Other Accrued and Current Liabilities link:presentationLink link:calculationLink link:definitionLink 2327306 - Disclosure - Other Accrued and Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2428413 - Disclosure - Other Accrued and Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2129109 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2330307 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2431414 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2432415 - Disclosure - Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2433416 - Disclosure - Leases - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2434417 - Disclosure - Leases - Other information (Details) link:presentationLink link:calculationLink link:definitionLink 2435418 - Disclosure - Leases - Operating Lease and Finance Lease Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 2435418 - Disclosure - Leases - Operating Lease and Finance Lease Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 2436419 - Disclosure - Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2137110 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 2438420 - Disclosure - Long-Term Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2139111 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2340308 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2441421 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2442422 - Disclosure - Fair Value Measurements - Changes in the Level 3 Fair Value Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2443423 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2144112 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2145113 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 2446424 - Disclosure - Stockholders’ Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2147114 - Disclosure - Stock Incentive Plans and Stock Based Compensation link:presentationLink link:calculationLink link:definitionLink 2348309 - Disclosure - Stock Incentive Plans and Stock Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2449425 - Disclosure - Stock Incentive Plans and Stock Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2450426 - Disclosure - Stock Incentive Plans and Stock Based Compensation - Activity Under Stock Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2451427 - Disclosure - Stock Incentive Plans and Stock Based Compensation - Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2452428 - Disclosure - Stock Incentive Plans and Stock Based Compensation - Assumptions Used in Fair Value of Stock Options and ESPP (Details) link:presentationLink link:calculationLink link:definitionLink 2453429 - Disclosure - Stock Incentive Plans and Stock Based Compensation - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2154115 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2355310 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2456430 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 2457431 - Disclosure - Income Taxes - Income Tax Expense Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2458432 - Disclosure - Income Taxes - Deferred Tax Assets And Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2459433 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 cstl-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 cstl-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 cstl-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT SUPPLEMENTAL DISCLOSURE OF CASH PAID FOR: Supplemental Cash Flow Information [Abstract] Asset Acquisition [Axis] Asset Acquisition [Axis] State and local Current State and Local Tax Expense (Benefit) Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Leasehold improvements Leasehold Improvements [Member] Net loss Net income (loss) Net loss Net Income (Loss) Attributable to Parent Operating lease assets Operating Lease, Right-of-Use Asset Net operating loss (“NOL”) carryforwards Deferred Tax Assets, Operating Loss Carryforwards Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Accrued compensation Employee-related Liabilities, Current Income Statement Location [Axis] Income Statement Location [Axis] Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Statistical Measurement [Domain] Statistical Measurement [Domain] Operating Segments Segment Reporting, Policy [Policy Text Block] Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accrued compensation Assets Acquisitions, Accrued Compensation Assets Acquisitions, Accrued Compensation Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Forfeited / Cancelled (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Cash purchase price Payments for Asset Acquisitions Payments for Asset Acquisitions Revenue from Contract with Customer [Abstract] Operating leases Operating Lease, Weighted Average Remaining Lease Term Other assets – long-term Other Assets, Noncurrent Non-deductible meals Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Number of shares available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Valuation, Income Approach Valuation, Income Approach [Member] NET CHANGE IN CASH AND CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity File Number Entity File Number Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Intangible assets Deferred Tax Liabilities, Intangible Assets Options exercised, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Forfeited/Cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Subsequent Event Type [Domain] Subsequent Event Type [Domain] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Amortization of acquired intangible assets Amortization of Intangible Assets Preferred stock, $0.001 par value; 10,000,000 shares authorized as of December 31, 2021 and 2020; no shares issued and outstanding as of December 31, 2021 and 2020. Preferred Stock, Value, Outstanding Estimated useful life (in years) Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Variable lease cost Variable Lease, Cost Operating leases Operating Lease, Weighted Average Discount Rate, Percent Antidilutive securities excluded from computation of earnings per share, amount (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Research and development Research and Development Expense [Member] Asset acquisition, transaction costs Asset Acquisition, Consideration Transferred, Transaction Cost Sale of Stock [Axis] Sale of Stock [Axis] ROU assets Deferred Tax Liabilities, Right-Of-Use Asset Deferred Tax Liabilities, Right-Of-Use Asset Deferred tax assets, net Deferred Tax Assets, Net of Valuation Allowance Business Combination and Asset Acquisition [Abstract] Business Combination and Asset Acquisition [Abstract] Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Total Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Assembled workforce Developed Workforce [Member] Developed Workforce Award Type [Domain] Award Type [Domain] Local Phone Number Local Phone Number ASSETS Assets [Abstract] Stock Option Activity, Additional Disclosures Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Options exercisable, number of options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Concentration risk percentage Concentration Risk, Percentage Intangible assets acquired Finite-lived Intangible Assets Acquired Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Finance lease liabilities Assets Acquisitions, Finance Lease Liability Assets Acquisitions, Finance Lease Liability Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Employees To Receive Awards Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Employees To Receive Awards Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Employees To Receive Awards Beginning balance (in shares) Ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Accumulated Deficit Retained Earnings [Member] Debt Instrument [Axis] Debt Instrument [Axis] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Asset acquisition, contingent consideration liability, measurement input Asset Acquisition, Contingent Consideration, Liability, Measurement Input Asset Acquisition, Contingent Consideration, Liability, Measurement Input Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Other Other Sundry Liabilities, Current Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Related Party [Axis] Related Party [Axis] Exercise of common stock warrants Stock Issued During Period, Value, Warrants Exercised Stock Issued During Period, Value, Warrants Exercised Accounts receivable Increase (Decrease) in Accounts Receivable Accrued purchases of property and equipment Capital Expenditures Incurred but Not yet Paid Operating lease assets in exchange for operating lease liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Shares withheld for tax withholding obligations Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Vesting percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Repayment of principal portion of finance lease liabilities Repayment of principal portion of finance lease liabilities Finance Lease, Principal Payments Number of operating segments Number of Operating Segments Accrued Compensation, Stock-Based Compensation Compensation Related Costs, Policy [Policy Text Block] Basic (in dollars per share) Earnings Per Share, Basic 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Revenue Revenue from Contract with Customer [Text Block] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Beginning balance (in shares) Ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Balance at beginning of period Balance at end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Restricted Stock Units Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Option to purchase, number of shares (in shares) Sale Of Stock, Option To Purchase Shares, Number Of Shares Sale Of Stock, Option To Purchase Shares, Number Of Shares Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Net deferred tax asset (liability) Deferred Tax Liabilities, Net Operating lease liabilities Operating Lease, Payments Other Other Noncash Income (Expense) Lease arrangement, term of contract Lease Arrangement, Term Of Contract Lease Arrangement, Term Of Contract Contingent consideration Asset Acquisition, Contingent Consideration, Liability, Noncurrent Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Research and Development Research and Development Expense, Policy [Policy Text Block] Accrued payor refunds Accrued Payor Refunds, Current Accrued Payor Refunds, Current Intangible assets Assets Acquisitions, Intangible Assets Assets Acquisitions, Intangible Assets Entity Voluntary Filers Entity Voluntary Filers Plan Name [Axis] Plan Name [Axis] Finance lease assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization Quoted Prices in Active Markets for Identical Items (Level 1) Fair Value, Inputs, Level 1 [Member] Asset acquisitions, net of cash and cash equivalents acquired Payments To Acquire Asset Acquisitions, Net Of Cash Acquired Payments To Acquire Asset Acquisitions, Net Of Cash Acquired INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Immediate Family Member of Management or Principal Owner Immediate Family Member of Management or Principal Owner [Member] Cernostics, Inc. Cernostics, Inc. [Member] Cernostics, Inc. Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] State income taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Entity Small Business Entity Small Business Operating leases Lessee, Operating Lease, Liability, Payment, Due [Abstract] Accounts payable Assets Acquisitions, Accounts Payable Assets Acquisitions, Accounts Payable Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total liabilities and stockholders’ equity Liabilities and Equity Other accrued and current liabilities Other accrued and current liabilities Other Accrued Liabilities, Current Third-Party Payor Concentration Risk Third-Party Payor Concentration Risk [Member] Third-Party Payor Concentration Risk [Member] Retirement Plan Pension and Other Postretirement Plans, Nonpension Benefits, Policy [Policy Text Block] First Year of Vesting Share-based Payment Arrangement, Tranche One [Member] Medicare advance payment Contract with Customer, Liability, Current Stock-based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 2026 Lessee, Operating Lease, Liability, to be Paid, Year Five 2024 Operating Leases, Future Minimum Payments, Due in Four Years Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Additional paid-in capital Additional Paid in Capital LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Accounts payable Increase (Decrease) in Accounts Payable Acquisition of Cernostics Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Organization and Description of Business Business Description and Basis of Presentation [Text Block] Loss Per Share Earnings Per Share [Text Block] OPERATING EXPENSES AND OTHER OPERATING INCOME Operating Expenses [Abstract] Entity Interactive Data Current Entity Interactive Data Current 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Four Exercise of common stock options Stock Issued During Period, Value, Stock Options Exercised Minimum Minimum [Member] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two 2022 Operating Leases, Future Minimum Payments, Due in Two Years Selling, general and administrative Selling, General and Administrative Expense Forfeited/Cancelled (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Other Service, Other [Member] Reclassification Reclassification, Comparability Adjustment [Policy Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Income Tax Authority [Domain] Income Tax Authority [Domain] Total deferred tax assets Deferred Tax Assets, Gross Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Address, State or Province Entity Address, State or Province Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Leases Lessee, Finance Leases [Text Block] Prepaid expenses and other current assets Assets Acquisitions, Prepaid Expenses And Other Current Assets Assets Acquisitions, Prepaid Expenses And Other Current Assets Lease arrangement, renewal term Lease Arrangement, Renewal Term Lease Arrangement, Renewal Term Number of facilities leased Lessee, Operating Lease, Number Of Facilities Leased Lessee, Operating Lease, Number Of Facilities Leased Employee stock purchase plan contributions Accrued Employee Benefits, Current Current Liabilities Liabilities, Current [Abstract] Public offerings of common stock, net of underwriting discounts, commissions and offering costs Stock Issued During Period, Value, New Issues Operating lease liabilities Increase (Decrease) in Operating Lease Liability Long-Term Debt Debt Disclosure [Text Block] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Schedule of Components of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Options exercisable, weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Stock Incentive Plans and Stock Based Compensation Share-based Payment Arrangement [Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Leases Lessee, Leases [Policy Text Block] ISOs Incentive Stock Options [Member] Incentive Stock Options [Member] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Less: accumulated depreciation Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Accounting Policies [Abstract] Accounting Policies [Abstract] Options outstanding, weighted average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Percentage of Accounts Receivable (non-current) Accounts Receivable, Noncurrent [Member] Accounts Receivable, Noncurrent [Member] Payment of common stock offering costs Payments of Stock Issuance Costs Public offering of common stock, net of underwriting discounts, commissions and offering costs (in shares) Stock Issued During Period, Shares, New Issues Accrued service fees Accrued Professional Fees, Current Amount received from CMS under its accelerated and advance payment program Centers For Medicare And Medicaid Services, Accelerated And Advanced Payment Program, Payment Received Centers For Medicare And Medicaid Services, Accelerated And Advanced Payment Program, Payment Received U.S. Federal Current Federal Tax Expense (Benefit) Operating lease liabilities Operating Lease, Liability Document Transition Report Document Transition Report Finance leases Finance Lease, Weighted Average Discount Rate, Percent Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Unrecognized compensation expense, period for recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted average grant date fair value at beginning balance (in dollars per share) Weighted average grant date fair value at ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Commitments and Contingencies (Note 12) Commitments and Contingencies Leases Lessee, Operating Leases [Text Block] Entity Emerging Growth Company Entity Emerging Growth Company Amortization of lease assets Finance Lease, Right-of-Use Asset, Amortization 2023 Operating Leases, Future Minimum Payments, Due in Three Years ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Auditor Name Auditor Name Cover [Abstract] Cover [Abstract] Debt Instrument, monthly installments principal amount Debt Instrument, Periodic Payment, Principal Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Accrued liabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Warrants outstanding (in shares) Class of Warrant or Right, Outstanding Less: Interest component Lessee, Operating Lease, Liability, Undiscounted Excess Amount Income Tax Authority [Axis] Income Tax Authority [Axis] Proceeds from sale of stock Sale of Stock, Consideration Received on Transaction Payments to acquire productive assets Payments to Acquire Productive Assets Thereafter Finance Lease, Liability, to be Paid, after Year Five Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Common stock, dividends declared (in dollars per share) Common Stock, Dividends, Per Share, Declared Selling, general and administrative Selling, General and Administrative Expenses [Member] Medicare Medicare [Member] Medicare [Member] NET REVENUES Total net revenues Revenue from Contract with Customer, Excluding Assessed Tax Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Less: Interest component Finance Lease, Liability, Undiscounted Excess Amount Stock options and restricted stock units Stock options Share-based Payment Arrangement, Option [Member] Equity [Abstract] Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Measurement Input Type [Domain] Measurement Input Type [Domain] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] 2026 Finance Lease, Liability, to be Paid, Year Five Common Stock Common Stock [Member] Interest income Investment Income, Interest Variable Rate [Axis] Variable Rate [Axis] Finance leases Finance Lease, Weighted Average Remaining Lease Term Other accrued and current liabilities Assets Acquisitions, Other Accrued And Current Liabilities Assets Acquisitions, Other Accrued And Current Liabilities Operating loss Operating Income (Loss) Discretionary matching contributions Defined Contribution Plan, Employer Discretionary Contribution Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Operating lease liabilities Operating Lease, Liability, Current Percentage of Accounts Receivable (current) Accounts Receivable, Current [Member] Accounts Receivable, Current [Member] 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Two Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Variable Rate [Domain] Variable Rate [Domain] Medicare Advantage plans Medicare Advantage Plans [Member] Medicare Advantage Plans [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation and amortization Depreciation Repayments of debt Repayments of Debt Common stock, dividends paid (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Total cost allocated Asset Acquisition, Assets Acquired and Liabilities Assumed, Net Asset Acquisition, Assets Acquired and Liabilities Assumed, Net Additional consideration payable based on achievement of certain commercial milestones Asset Acquisitions, Contingent Consideration Arrangements, Range of Outcomes, Value, High Asset Acquisitions, Contingent Consideration Arrangements, Range of Outcomes, Value, High Schedule of Lease Balances Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee Other liabilities Increase (Decrease) in Other Operating Liabilities Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Operating lease assets Increase (Decrease) In Operating Lease, Right-Of-Use Assets Increase (Decrease) In Operating Lease, Right-Of-Use Assets Cash and cash equivalents Assets Acquisitions, Cash Assets Acquisitions, Cash Section 481(a) adjustment (cash to accrual) Deferred Tax Liabilities, Change In Accounting Method Deferred Tax Liabilities, Change In Accounting Method Total liabilities Liabilities Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] 2022 Finite-Lived Intangible Asset, Expected Amortization, Year One Award Type [Axis] Award Type [Axis] Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Options outstanding, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Schedule of Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Measurement Input Type [Axis] Measurement Input Type [Axis] Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Operating loss carryforwards Operating Loss Carryforwards Common stock, shares issued (in shares) Common Stock, Shares, Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued City Area Code City Area Code Options exercisable, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Offering period Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Inventory Asset Acquisition, Inventory Asset Acquisition, Inventory Entity Address, City or Town Entity Address, City or Town Loss on extinguishment of debt Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Asset Acquisition Asset Acquisition [Table Text Block] Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Other accrued liabilities Increase (Decrease) in Other Accrued Liabilities Intangible Assets, Net Intangible Assets Disclosure [Text Block] Property, plant and equipment, useful life Property, Plant and Equipment, Useful Life Stockholders’ Equity Stockholders' Equity Attributable to Parent [Abstract] Variable consideration adjustments included in revenue Contract with Customer, Performance Obligation Satisfied in Previous Period Concentrations of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Risk-free interest rate, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum NOL carryforwards, not subject to expiration Operating Loss Carryforwards, Not Subject To Expiration Operating Loss Carryforwards, Not Subject To Expiration Noncurrent operating lease liabilities Operating Lease, Liability, Noncurrent Percentage of share price at grant date Share-Based Compensation Arrangement By Share-Based Payment Award, Price Of Common Stock, Percentage Share-Based Compensation Arrangement By Share-Based Payment Award, Price Of Common Stock, Percentage Total lease payments Finance Lease, Liability, Payment, Due Accounting Standards Update [Axis] Accounting Standards Update [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Total current Current Income Tax Expense (Benefit) Debt instrument, face amount Debt Instrument, Face Amount Interest expense Interest Expense 2022 Finance Lease, Liability, to be Paid, Year One Accrued compensation Increase (Decrease) in Employee Related Liabilities Expected stock price volatility, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Tax benefits related to stock-based compensation Share-based Payment Arrangement, Expense, Tax Benefit Weighted-average remaining lease term (years) Weighted Average Remaining Lease Term [Abstract] Weighted Average Remaining Lease Term Accumulated deficit Retained Earnings (Accumulated Deficit) Term of awards Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Selling, General and Administrative Expenses Selling, General and Administrative Expenses, Policy [Policy Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Issuance of common stock under the employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Entity Filer Category Entity Filer Category Present value of lease payments Finance Lease, Liability Total operating expenses, net Operating Expenses, Net Of Other Operating Income Operating Expenses, Net Of Other Operating Income Total deferred tax liabilities Deferred Tax Liabilities, Gross Number of offering periods Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Purchase Periods Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Purchase Periods Income Statement [Abstract] Income Statement [Abstract] Entity Registrant Name Entity Registrant Name Accounts receivable Assets Acquisitions, Accounts Receivable Assets Acquisitions, Accounts Receivable Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] 2024 Finance Lease, Liability, to be Paid, Year Three 2025 Finance Lease, Liability, to be Paid, Year Four Proceeds from exercise of common stock options Proceeds from Stock Options Exercised 2023 Finance Lease, Liability, to be Paid, Year Two Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Income tax (benefit) expense Total income tax (benefit) expense Income Tax Expense (Benefit) Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag Equity Components [Axis] Equity Components [Axis] Options outstanding, nonvested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Entity Tax Identification Number Entity Tax Identification Number Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Current assets Assets, Current Sale of Stock [Domain] Sale of Stock [Domain] Total lease payments Lessee, Operating Lease, Liability, to be Paid Concentration Risk Type [Domain] Concentration Risk Type [Domain] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Forfeited/Cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Asset Acquisition [Table] Asset Acquisition [Table] Inventory Inventory, Net Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Asset Acquisitions Asset Acquisition [Text Block] Dermatologic Dermatologic [Member] Dermatologic U.S. Federal Deferred Federal Income Tax Expense (Benefit) Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Decrease in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 2025 Operating Leases, Future Minimum Payments, Due in Five Years Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Entity Public Float Entity Public Float Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Options granted, weighted average grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] Common stock offering costs incurred but not paid Offering Costs Incurred But Not Yet Paid Offering Costs Incurred But Not Yet Paid Short-term lease cost Short-term Lease, Cost Prepaid expenses Deferred Tax Liabilities, Prepaid Expenses Options outstanding nonvested, weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Office and Laboratory Facility Office And Laboratory Facility [Member] Office And Laboratory Facility [Member] Notes Payable to Banks Notes Payable to Banks [Member] Statement [Line Items] Statement [Line Items] Purchase period Share-Based Compensation Arrangement By Share-Based Payment Award, Purchase Period Share-Based Compensation Arrangement By Share-Based Payment Award, Purchase Period Property and equipment, net Property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Employee stock purchase plan Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Medicare advance payment Increase (Decrease) in Contract with Customer, Liability Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Domestic Tax Authority Domestic Tax Authority [Member] Issuance of common stock from vested restricted stock units and payment of employees’ taxes Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Counterparty Name [Domain] Counterparty Name [Domain] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Debt Disclosure [Abstract] Debt Disclosure [Abstract] Total Operating Leases, Future Minimum Payments Due Deferred tax liabilities Assets Acquisitions, Deferred Tax Liabilities Assets Acquisitions, Deferred Tax Liabilities Finance lease liabilities Finance Lease, Liability, Current Purchase price of common stock, percentage of fair market value Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Allowance for Credit Losses Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Accounting Standards Update [Domain] Accounting Standards Update [Domain] Research and development (“R&D”) tax credit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Less valuation allowance Deferred tax assets, valuation allowance Deferred Tax Assets, Valuation Allowance Noncurrent portion of Medicare advance payment Contract with Customer, Liability, Noncurrent Auditor Location Auditor Location 2021 Operating Leases, Future Minimum Payments Due, Next Twelve Months Finite-lived intangible asset, useful life Finite-Lived Intangible Asset, Useful Life Interest on finance lease liabilities Finance Lease, Interest Expense Use of Estimates Use of Estimates, Policy [Policy Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Document Annual Report Document Annual Report Schedule of Share-based Payment Arrangement, Expensed and Capitalized, Amount Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Finance leases Finance Lease, Liability, Payment, Due [Abstract] Vesting [Axis] Vesting [Axis] Deferred tax (benefit) expense Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract] Title of 12(b) Security Title of 12(b) Security Proceeds from public offerings of common stock, net of underwriting discounts, commissions and offering costs Proceeds from Issuance of Common Stock Total assets Assets Plan Name [Domain] Plan Name [Domain] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Accrued bonuses Accrued Bonuses Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Repayment of term debt Repayments of Secured Debt Document Type Document Type Other Accrued and Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Product and Service [Domain] Product and Service [Domain] Research and development Research and Development Expense Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Clinical studies Accrued Clinical Studies, Current Accrued Clinical Studies, Current Noncurrent liabilities Liabilities, Noncurrent Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash (used in) provided by operating activities Net Cash Provided by (Used in) Operating Activities Tax credit carryforward Tax Credit Carryforward, Amount Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Furniture and fixtures Furniture and Fixtures [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Lease Cost Lease, Cost [Table Text Block] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in dollars per share) Earnings Per Share, Diluted State and Local Jurisdiction State and Local Jurisdiction [Member] Amortization of debt discounts and issuance costs Amortization of Debt Issuance Costs and Discounts Common stock offering price (in dollars per share) Sale of Stock, Price Per Share Vesting [Domain] Vesting [Domain] 2019 Equity Incentive Plan Two Thousand Nineteen Equity Incentive Plan [Member] Two Thousand Nineteen Equity Incentive Plan [Member] Income taxes Income Taxes Paid, Net Accounting Standards Update [Extensible Enumeration] Accounting Standards Update [Extensible Enumeration] Lease liabilities Deferred Tax Assets, Lease Liabilities Deferred Tax Assets, Lease Liabilities Payroll tax liabilities Accrued Payroll Taxes, Current Number of equal monthly installments Debt Instrument, Number Of Monthly Installments Debt Instrument, Number Of Monthly Installments Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Acquisitions, Contingent Consideration Business Combination And Asset Acquisitions, Policy [Policy Text Block] Business Combination And Asset Acquisitions, Policy Aggregate intrinsic value of shares issued under the ESPP Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Aggregate Intrinsic Value, Issued During The Period Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Aggregate Intrinsic Value, Issued During The Period Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax liability Deferred Income Tax Liabilities, Net Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Cashless exercise of common stock warrants Exercise Of Common Stock Warrants, Noncash Exercise Of Common Stock Warrants, Noncash Schedule of Share-based Payment Arrangement on Restricted Stock Units Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Lease arrangement, number of renewal options Lessee, Operating Lease, Number Of Options To Renew Lessee, Operating Lease, Number Of Options To Renew Myriad myPath, LLC Myriad myPath, LLC [Member] Myriad myPath, LLC Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Follow On Public Offering Follow On Public Offering [Member] Follow On Public Offering Fair Value Measurements Fair Value Disclosures [Text Block] Schedule of Finance Lease, Liability, Fiscal Year Maturity Finance Lease, Liability, Fiscal Year Maturity [Table Text Block] Loss before income taxes Pre-tax loss Income (Loss) Attributable to Parent, before Tax Accounts payable Accounts Payable, Current Concentration Risk Type [Axis] Concentration Risk Type [Axis] Long-lived assets, impairment charges Impairment, Long-Lived Asset, Held-for-Use Depreciation and amortization Depreciation, Depletion and Amortization Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Three Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Inventory Increase (Decrease) in Inventories Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Other operating income Other Operating Income (Expense), Net Grant date fair value of awards granted Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period, Grant Date Fair Value Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period, Grant Date Fair Value Cost of sales (exclusive of amortization of acquired intangible assets) Cost of Goods and Services Sold Document Period End Date Document Period End Date Net settlement of vested stock awards (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Entity Central Index Key Entity Central Index Key Weighted-average discount rate Leases, Weighted Average Discount Rate [Abstract] Leases, Weighted Average Discount Rate Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Stock Options Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Deferred tax assets: Deferred Tax Assets, Gross [Abstract] State and local Deferred State and Local Income Tax Expense (Benefit) Total lease cost Lease, Cost Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] R&D tax credit Deferred Tax Assets, Tax Credit Carryforwards, Research Income Statement Location [Domain] Income Statement Location [Domain] Current tax expense Current Federal, State and Local, Tax Expense (Benefit) [Abstract] DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Increase in number of shares authorized for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Other liabilities Other Liabilities, Noncurrent Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Trading Symbol Trading Symbol Loss per share attributable to common stockholders: Earnings Per Share [Abstract] Exercise of common stock warrants (in shares) Stock Issued During Period, Warrants Exercised Stock Issued During Period, Warrants Exercised Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss Percentage of Revenues Revenue from Contract with Customer Benchmark [Member] Schedule of Future Minimum Payments for Operating Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Other assets Increase (Decrease) in Other Operating Assets Deferred payroll taxes, CARES Act Deferred Payroll Taxes, CARES Act Deferred Payroll Taxes, CARES Act Lab equipment Equipment [Member] Number of trading days to determine volume weighted-average price of common stock Asset Acquisition, Earnout Payments, Number Of Trading Days To Determine Volume Weighted-Average Price Asset Acquisition, Earnout Payments, Number Of Trading Days To Determine Volume Weighted-Average Price Number of claims in adjudication process Revenue From Contract With Customer, Revenue Not Yet Recognized, Number Of Claims In Adjudication Process Number Of Disputed Claims Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Common stock warrants Warrant [Member] Maximum number of shares payable in earnout payment (in shares) Asset Acquisition, Contingent Consideration Arrangements, Range Of Outcomes, Value, High, Shares Asset Acquisition, Contingent Consideration Arrangements, Range Of Outcomes, Value, High, Shares Asset acquisition, liability for contingent consideration Asset Acquisition, Contingent Consideration, Liability Asset Acquisition [Domain] Asset Acquisition [Domain] NOL carryforwards, subject to expiration Operating Loss Carryforwards, Subject to Expiration Operating Loss Carryforwards, Subject to Expiration Total stock-based compensation expense Share-based Payment Arrangement, Expense Options exercisable, weighted average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Finance lease, right-of-use asset, accumulated amortization Finance Lease, Right-of-Use Asset, Accumulated Amortization Entity Current Reporting Status Entity Current Reporting Status Expected stock price volatility, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Weighted-Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Asset Acquisition [Line Items] Asset Acquisition [Line Items] Asset acquisition, receivable for purchase price adjustment Asset Acquisition, Post-Closing Purchase Price Adjustment, Receivable Asset Acquisition, Post-Closing Purchase Price Adjustment, Receivable Counterparty Name [Axis] Counterparty Name [Axis] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Construction-in-progress Construction in Progress [Member] Beginning of year End of year Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Percentage of voting power ownership Share-Based Compensation Arrangement, By Share-Based Payment Award, Percentage Of Voting Power Ownership Share-Based Compensation Arrangement, By Share-Based Payment Award, Percentage Of Voting Power Ownership Common stock issued and sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Stock options and restricted stock units Stock Options and Restricted Stock Units [Member] Stock Options and Restricted Stock Units Risk-free interest rate, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Schedules of Concentration of Risk, by Risk Factor Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Current Assets Assets, Current [Abstract] Gross carrying value Finite-Lived Intangible Assets, Gross Leases [Abstract] Leases [Abstract] Assembled workforce Assembled Workforce [Member] Assembled Workforce Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Income Taxes Income Tax, Policy [Policy Text Block] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Weighted-Average Remaining Life (in years) Finite-Lived Intangible Assets, Remaining Amortization Period Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Number of days contract with customer is generally paid Contract With Customer Customer, Payment Terms Contract With Customer Customer, Payment Terms Money market funds Cash and Cash Equivalents, Fair Value Disclosure Entity Address, Postal Zip Code Entity Address, Postal Zip Code Revenue Recognition, Cost of Sales (exclusive of amortization of acquired intangible assets) Revenue from Contract with Customer [Policy Text Block] Exercise of common stock options (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Aggregate fair value of restricted stock units vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Fair Value, Recurring Fair Value, Recurring [Member] Income Taxes Income Tax Disclosure [Text Block] Over-Allotment Option Over-Allotment Option [Member] Service period Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Weighted-average shares outstanding: Weighted Average Number of Shares Outstanding, Basic [Abstract] Related Party [Domain] Related Party [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Schedule of Share-based Payment Arrangement on Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Property and equipment Assets Acquisitions, Property, Plant and Equipment Assets Acquisitions, Property, Plant and Equipment Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Five Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] 2018 Loan and Security Agreement Two Thousand Eighteen Loan And Security Agreement [Member] Two Thousand Eighteen Loan And Security Agreement [Member] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Auditor Firm ID Auditor Firm ID Class of Stock [Line Items] Class of Stock [Line Items] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Entity Address, Address Line One Entity Address, Address Line One Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Entity Address, Address Line Two Entity Address, Address Line Two Change in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Issuance of common stock under the employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Consolidation Consolidation, Policy [Policy Text Block] Entity Shell Company Entity Shell Company Average expected term (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Employee stock purchase plan Employee Stock [Member] Payment of employees’ taxes on vested restricted stock units Payment, Tax Withholding, Share-based Payment Arrangement Stock-based compensation expense APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition BlueCross BlueShield plans BlueCross BlueShield Plans [Member] BlueCross BlueShield Plans [Member] Operating cash flows from interest paid on finance leases Finance Lease, Interest Payment on Liability Current Fiscal Year End Date Current Fiscal Year End Date Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Other operating income (loss), CARES Act Other Operating Income (Loss), CARES Act Other Operating Income (Loss), CARES Act Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Proceeds from contributions to the employee stock purchase plan Proceeds from Stock Plans Statement [Table] Statement [Table] Recently Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Other Deferred Tax Assets, Other Office Space Office Space [Member] Office Space [Member] Unrecognized compensation expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Statistical Measurement [Axis] Statistical Measurement [Axis] Accounts Receivable Accounts Receivable [Policy Text Block] U.S. federal taxes at statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Subsequent Event Subsequent Event [Member] Finance lease liability, noncurrent Finance Lease, Liability, Noncurrent Preferred Stock Preferred Stock [Member] Intangible assets, net Net Finite-Lived Intangible Assets, Net Measurement Input, Price Volatility Measurement Input, Price Volatility [Member] Cost of sales (exclusive of amortization of acquired intangible assets) Cost of Sales [Member] Property and equipment acquired with tenant improvement allowance Property And Equipment Acquired With Tenant Improvement Allowance Property And Equipment Acquired With Tenant Improvement Allowance Cash paid for amounts included in the measurement of lease liabilities Cash Flow, Lessee [Abstract] Cash Flow, Lessee Inventory Inventory, Policy [Policy Text Block] Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Long-term accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Noncurrent Subsequent Event Type [Axis] Subsequent Event Type [Axis] Common stock, $0.001 par value; 200,000,000 authorized as of December 31, 2021 and 2020, respectively; 25,378,520 and 24,812,487 shares issued and outstanding as of December 31, 2021 and 2020, respectively. Common Stock, Value, Outstanding Developed technology Developed Technology Rights [Member] Operating lease cost Operating Lease, Cost Computer equipment Computer Equipment [Member] Non-deductible officers’ compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officers' Compensation, Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officers' Compensation, Amount Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Common stock option period Sale Of Stock, Selling Period Sale Of Stock, Selling Period Operating leases, rent expense Operating Leases, Rent Expense Audit Information [Abstract] Audit Information [Abstract] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Share-based Payment Award, ESPP, Valuation Assumptions Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Deferred income taxes Total deferred Deferred Income Tax Expense (Benefit) EX-101.PRE 12 cstl-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 cstl-20211231_g1.jpg GRAPHIC begin 644 cstl-20211231_g1.jpg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�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end GRAPHIC 14 cstl-20211231_g10.jpg GRAPHIC begin 644 cstl-20211231_g10.jpg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

$GNGORO;Y:)Z--71XK^TK_P4$TW]G'XF/X:N/#=YJTT=M'OS+L/MY9]:^=RWBO&2X@G@L1*]%SG".BT<=M;7\OF?7YSP' MET>$Z>8X.#6(C3IU)ZMWC):Z-V7?1+8^XZCO;V+3K.:XGD6*&!#)(['"HH&2 M3]!4E>(_\% OB]_PJ?\ 9NU989/+U+Q!C2[7#88;_P#6,._$8;D=RM?H>98Z M&#PM3%5-H)O[NGSV/R/)\MJ9ACJ6!I;U)*/I=ZOY+5GF)_X*WZ&^L_98O!^I M21F;RDE^W(-PW8#8V_CC-?7:-O0,/XAFOQZ\4^!)/!&D^$+Z82+)K]D=1PW9 M/M$D:D?41Y_&OU[T"Z^VZ%93#D30(X/U4&OB>!<^S#,)UX8^5W'D:T2LI)OH MEY;GZ7XH\+Y3E-/"U,J@XJ;J*3YF[N#BNK?6^Q;KQ/\ :L_;7TG]EK5])T^Y MTFYUJ]U2%[@QPSB'R(P0JL20<[CN _W37ME?G=X\BA_;"_X*'?V7N^T:+:WG MV,E265[>U!,G(_A=E89']\&O8XNS;$8/#4Z>":5:K-1CL]WJ[/3R^9\]X?Y# M@\QQE6MF2;P]"G*<[-J]EHKJS[O1ZV/KW]E;]J?3?VI/#6I7]GI\VE3:7<"" M6VEF$K8*Y5\@#@\C\*]4K\\?^">?C2X^"?[5VJ>#KYF2WUAIM,D5C@+<0LQC M;Z_*ZX_V_:OT.J^$,XJ9CEZJ8A_O(MQETU7DO)HS\0>':.3YNZ.$5J,XQG#5 MOW6N[\T_E8H^'O\ CPD_Z^;C_P!'/11X>_X\)/\ KYN/_1ST5]0?#GE'_!1+ M_DPWXQ?]B=JG_I+)7\M%?U+_ /!1+_DPWXQ?]B=JG_I+)7\M%?KWAK_NU;_$ MOR/R;Q&_WBC_ (7^9_67^SO_ ,F_^!?^Q>L/_2:.NQKCOV=_^3?_ +_ -B] M8?\ I-'78U^3XC^++U?YGZI0_AQ]$%%%%8FI7U;5;?0]*NKZZD6&ULXGGFD8 MX5$4%F)^@!-?R@_M)_$K_A%]1$WC;QI;>3JWD-_R"=-<$.KGM),N4"]0A8G& M5S^*'P3^#^M_'_XL^'_!?ARV-UK7B2^CL;5/X0SG!9CV51EB>P!-?L'A_ELL M-AJF/K^ZI;7_ )5JWZ/]+GY)QYF4<3B:>!H:N.]OYGHEZK];'[O?\&XOPDD^ M''_!.J'5IA*LWC;Q!>ZP%=-NR-1':H!Z@_9RP/\ MU^%/ VDEFT_P *Z9!I MT3D8:78@#.?=FRQ]S7X#?\' 'AJY\/\ _!3OQI-/&RQZK9Z?>0'^^GV6-,_] M](P_"O+X1Q4<7Q!6Q+^TI-?>K?@>GQ9A983(:.&7V7%/[G?\3J_^",'_ 5! M^&/_ 3G\*^.%\8>'_%&J:UXHN[YTY[IIA(A<."KK@<$8QVKZ<_P"(5SQ1_P!%BT'_ ,$,O_QZO6SK#\-SQLY8 MZHU4TNO>[*VRMM8\G)L1Q%#!PC@J:=/6S]WN[[N^Y[U_Q$]? W_H4OB9_P" M5G_\DUY3^W!_P7]^"_[4G[)GCOP!I_A?Q_#J'B;2WM+26\L[40139#(S%9R0 M RCD FN;_P"(5SQ1_P!%BT'_ ,$,O_QZC_B%<\4?]%BT'_P0R_\ QZO/HT>$ MJ52-6%5WBTU\6ZU_E/0K5N*ZM.5*=)6DFG\.S^9^7OPN\92?#OXE^'O$$*[Y M=$U*WOT7.-QBE5\9]]N*_J;_ &B?BG-\./V4?'/C6UBCDN-#\*7^M0QN3M9X MK2295/?&5 K\ID_X-7?%"N#_ ,+BT'@Y_P"0#+_\>K]/OVQO!UWJ/[!OQ2T" MSCDO+Z;P'JMC D2$M/(=/E10J]9 MU<)97C\!0Q/UB'+=)QU3U2EV;\C^66[NI+ZZDFF9I)9G+NQZLQ.237]1O_!. M;X*V?[/W[#WPQ\,VMNUNUOH-M=W2N@5S%OV@[3XQ:?8R7?A7Q-9P6.H7$*9_L^\A78HE]!(FW:W3*L.. M,_$W[%G[=WQ#_8*^)$GB/P%J4$7VQ%BU#3KV,S6.IQJ2565 RGC)PRLK#)P1 MDY_J&\7^#])^('AB^T77--L=8T?4H6M[NRO(%F@N8V&"KHP(8'T(K\^?VE/^ M#:_X-_%9[J^\"ZOKWPYU28LZ118U#35).<>3(5D [ +* /0UPY#QA@_J2R_, MX^ZE:]KIKI=;Z>29W9YPCB_KCQ^62]YN]KV:?6SVU\['"_"G_@Z1\$ZG!;IX MU^&OB31YF;$TND7D5]&H]0LGE,?I7VS^R[_P4R^"?[8306_@GQSIMQK$X_Y! M%Z&LM0!XR!%( 7QGJFY?0FOR,^.O_!M?\^%=2\,>/H;=&<6]I,UE M>2 =E2;"%CZ"3\S7P+K.BZW\,/&,UE?VNI^']>T6XVRPS(]M=64R'N#AD92/ M8BO0_P!4\CS*#EEM2S79WMZQ>OXHX?\ 6K.\NFHYC3NGW5K^C6GX,_KFKQ?_ M (*-_P#)@OQF_P"Q,U7_ -)9*^>?^"#?_!0C6OVU/V>=5T/QE>_VCXT\ 316 MUQ>O_K=1M)5;R9I/60%'1F_BV@GDDGZ&_P""C?\ R8+\9O\ L3-5_P#262OS MEX"K@LSCA:WQ1G'\U9_-:GZ L=2QF6RQ-'X91?Y.Z^3/YE?@5_R6[P;_ -AR MR_\ 1Z5_65JFI0Z-IEQ>7#>7;VL332M_=5023^0K^37X%?\ );O!O_8E?UA>*]#7Q1X6U+36;RUU&UEM2W]T.A7/ZU]SXDV]KA[[6E^<3XOPYO[+$ M6[Q_)G\FOQ>^)-]\8OBKXD\6:G(TFH>)-2N-2G+')W2R,Y'T&<#V%?T6?\$3 M?@;#\#?^";OPZC\B.*^\4V?_ D=XZCF4W9\R(GW$!A'X5_-[XAT*Z\+:_?: M9>QM#>:=<26L\9ZI(C%6'X$$5_31_P $F?B=:_%C_@G'\']0M-J_V?XC"O1\0^:.7TH4_@YE^"=CS?#^TLPJSJ?%RO\U<^B**** M_'3]>/G/_@K7\&+'XY?\$[?BMIMY&7DTG0;C7;-E&62XLD-RF/\ >\LJ?9S7 M\SOA;Q+?>"_$VFZQIL[6NI:3=17EK,OWH98W#HP]PP!_"OZA?^"CGCZU^&?[ M!7Q@U:\GCMUC\(ZE;0M(>&GFMWAA7ZM)(B@>]?RW1QM-(JJK,S' ')-?L'A MQ*4L'6A+X>;\UK^A^1^(BBL92E'XN7\GI^I_6W\*O&Z_$SX7>&_$D:B./Q!I M5KJ2J/X1-$L@'_CU?SS_ /!>O_E*)\0O^N=A_P"D4-?T#_L\^#KCX=? 'P-X M?NEVW6A>'[#3Y@>SPVT<;?JIK^?C_@O7_P I1/B%_P!<[#_TBAKPO#]16;55 M#;EE;TYHGN\>.3RJFY[\T;_^ L^__P#@U\^'EKI/[*?CKQ.J_P"G:UXD^PR- MCI';V\;*/SG8U^G%?G7_ ,&RW_)@6N?]CC>?^DUI7Z*5\YQ5)RS:NW_-^22/ MH.%XJ.54$OY?S85_-S_P73T^'3?^"J?Q6CAC6-7FTZ4@#&6?3+1F/XL2?QK^ MD:OYO_\ @O%_RE9^*G^]I?\ Z:K.OH/#G_D95/\ _\ TJ)X7B'_ ,BZ'^-? M^DR/TU_X-GC_ ,:\-4_['.__ /2:SK]"Z_/3_@V>_P"4>&J?]CG?_P#I-9U^ MA=?.\3_\C6O_ (F?0<-?\BNA_A05_-#_ ,%F/^4FOQ<_["R_^B(Z_I>K^:'_ M (+,?\I-?BY_V%E_]$1U])X./%-Q&5M4,>GZ>)0D^K7)' MR01@Y.2>20#M4%CP*_F(^.?QEUS]H;XO>(O&WB29;C6O$U])?73*"$5F/"*" M3A5&% SP *_1O#W*9SQ+Q\E[L4TO-O?[E>_J?GG'^:0AAE@8OWI--^26WWO; MT/N/_@VG^&MUXL_;WU#7H]JVGA7PWI;)4*2)81!EM001D!M\D@]5E4^E??M>'QE MCXXK-)N&T;17RW_&Y[G!^!EA)Q\LB,,,#]0:_*W]KG]G*X_9J^*\VDB1KC2;U3=:;.WWGA)(VM_M*>#Z\' MO7Z@?$_XD:7\(_ FI>(=8F6"QTV(R/S\TAZ*B^K,< #U-?E+\-ND>M_)]// MYG]0>!]',EBJU>#MAK6E?9RZ6\TMWV=GNK>S>'? 6C_\%1/V,M<^#/BN6W7Q M=X<@^V>'-5G3=);,ORQ/NZX4D1OCJCCJ17I'_!&__@F/#_P3_P#@G+?>(;>" M;XE^*@)-8G5UD6PB!_=VD;#C:OWF()W.3SA5QX_^U9\?M/\ ^".G[&2BT>"? MXT_$B)X[$;5?^SE &96!_@A#C&?OR'N <'_!!/\ X*I7'[2OA-OA/\0-4:Z\ M=:!"TVDZA=2YEURS&"48LW:[NX^3\TE^E5I7=MR,XSTR*\G%QG*A.-+XK.WK;0[,OE2CBJ/-':RF.$;4=.4O"?]IHB2R]L[2WL.U?7OAWQ%9^+-$M]1T^8 M7%G=IOBD"E=P^A (_$5Y5\$_V%OA]\$GANK;2QK&K0X(OM2 FD5O[R+C:A]P M,CUKV(# KP^&\/F]&A;-:D9OI9:KUEHG]WS9]-QEC.'\1B>;(J,J<>MW[K_P MQU:_\"_[=1\!?\%;-1%Y\8_#-BO,D&E%R/\ ?E8#_P!!I?\ @IW\.)/AO\4_ M"?B[3,P_:K2.W:11]VXML;&_%"@Q_P!,ZH_\%(H?[;_;)T.S')DL;&#'^]-) M_P#%5]+?\%#_ (4?\+._9HU6:&/??^'675+?"@L53B5?7_5ECQU*BOS_ !F7 MO'2S>45[T90GDS9(QW MX='SZ;AZUY+\0'_X:Z_X*+PZ7M%QHNEWBV>W P;:URTN?4,X?\& KVLXSR>, MX?H1HO\ >8GEA\[VG\KIKYGS?#O#%/+N+<3+$+]S@U*K\DKP^=FFO0U?VE_A M#_PJW_@G;X#M9(_+NQJ45W9<12R'/T&T8[8KW__ ()Q7GVO]DKP^O\ MSQEN8_I^^<_UK"_X*FP>9^R\I_YY:Q;-]/ED']:G_P""7M[]J_9:MX_^??4K ME/IDJ?ZT\NPL,'Q1]6I[*@DODTOT)SC'5,PX'>,K?$\3*3_[>4G_ .W'SO\ M\%8/^3BM-_[ CS<[:MO:UFO.Y[6;4,BJ<,Y5_;=2I!Z M?E;YGJ _;B^$[''_ FVE<_[,O\ \372_'&[CO\ ]G_QA/"PDAF\/7LB,.C* M;9R#^5>*+_P2@^'",&_M/Q=P<_\ 'W#_ /&:]H^-&G1Z1^SMXLM(RS1VOAR\ MA0M]XA;9P,_E7VN$K9M/#UO[3A"/NOEY&WT=[W;\C\VQV'R"GB\-_8E6I-\Z MYN=)6U5K62\[GQQ_P2-_Y*QXH_[!2?\ HT5]]U\"?\$C?^2L>*/^P4G_ *-% M??=>;X=?\B2GZR_-GL>,'_)35?\ ##_TE!117._%OQW#\,?AEKWB"=@L>DV4 MMP,X^9@IVCGN6P,=\U]K6JQIP=2>B2;?HC\VP]&=:K&C35Y2:27FW9'P?^U/ M?BE?1G_ 47^#L'C']F"::T M@5;CPB\=Y;;5RRPJ/+D3/IL(;_@ KX__ &-_COX=^#OQKU#Q=XM&HW4TEO*( M/LT0D8S2L"[MDC^'=^+5]0^(O^"F_P +?%7A^^TN^L?$&;K=#GO;S98#\'$GX% M:^I7^X?I7YG_ /!/+XJ6_P ,/VH;2S\YFTKQ)OTLNRX)+',+$=B7"CVWFOTP M?[A^E?8< 9E]:RB$).\J;<'Z+;\&E\C\\\5LE^H<05*D%:%9*:]7I+Y\R;^9 M^>/[ 3#_ (;EU9&PRRQZDA!&0PWYQ^E8G[1'@'5?V'OVJK77M!C:WTN:;?]HSX/WFEJ MJKK%EFZTN;'*3*/N'_94\5TZ>+UP]>C"%1/:SYDF_2^O]UL[#X3_$W3?C%\/=+\1Z3)YEGJ<( MD"G[T+]'C;_:5L@_3TKX8_;Q_P"3]=$_[AG_ *,J?_@FQ^T'=?"WXFW'P_UQ MFM]/UF=HX$F&UK.^7Y=G/3?C:0?X@OOF/]O5-O[>6@_[2Z8?_(I%=N>9Y'-> M'Z6(VFJD%)=I*]_D]T>?POPS/(N+:^%WIRHSE!]XNUOFMGZ7ZGU-^WIXTD\# M_LI>++BWF6&YO(8["//5O.E2-P/?RV<_AFO!_P#@D/X"B?\ X2_Q/+'F9##I MEN^?N@YDE&/?]US[5ZQ_P4UT.35_V3]4FC90NFWUK<88>%7:--N/K[^O\ M78^?RF]+P\Q=2CO*JE)]E^[T]/\ Y)GUQ1117Z.?CI\N_P#!5OP+#KGP*TW7 M/*4W>AZBJK)_$(I@59?H66,_\!J;_@E/XNDUO]GJ^TN21I/[%U21(@3_ *N. M15DP/^!%S_P*M3_@I_K$6F_LMW,$A_>7VHV\48]2"7/Z*:Y?_@DCHTEK\'/$ ME\W^KO-6$:_\ B7/_H0K\WFN3C./L_M4_>^Y_P"43]DIR=3PYE[;[%;W/O5[ M?^!2_$\CU^0^(/\ @JE#GYO)\10@?2)%/_LM4_C#<-^R;_P4*.MPHT>G7&HI MJ3*J_?M[G_7JHZ<%I /0@59^&K?\)+_P5.=E^;;K]\W_ 'ZAF/\ [)7I/_!6 MKX4K?^&?#OC*WC'G:?*VFW; 0:^#?^"C_ (TN/C)^T;X;^'NELT@TYHX'"_,#=7#+V']U-GXEA7T;^QU\ M;[7QC^R7I>NZA<*K>';.2UU)CGY#;K]XYZYC"-]6KYK_ &!]!F_:#_:[\0>/ MM3B9H]->74%5_F"33,5B7.,'8F['NH/:OL.)LKYJB?KS-?C8=^T3\24^$?P2\2>(&D\N2PLG\@YP3,WR1@> MY=EKY1_X),_#"34_$7B;QM=@M]G4:;;,3]Z1\22M^ V#/^V:Z#_@K9\3?[.\ M&^'?"<,G[S4IVU"X08_U<8VIGORS''KM/I6!^R=^W3\._P!G_P"!^E>';JWU MV34(S)/>/#:J4:5V).#OY &T9]JXID M>19A3X*JRR^E*=7%S2?*M53C?\VFO21QO[?GA>X^ G[75CXOTE1"-4:'6(L+ MA1<1L!(/?<5#'_KH:_0'P9XKM?'7A'3-:L69K/5;6.ZASU"NH8 ^XS@^]? O M[=?[6'@/]IGP-I,>BV^KPZYI%V7CDN;=41H74B1,ACSD(1_NGUKWW_@F'\5% M\=?L]?V--)NOO"MRUJ5[F%_GC;]77_@%+AG,L-3X@Q.%PLU*G6]^-MN;=K\7 M\DBN-,GQM7A/!8W&TI0K8=^SE=:\CTB_32*]6SZ!\/?\>$G_ %\W'_HYZ*/# MW_'A)_U\W'_HYZ*_4#\//*/^"B7_ "8;\8O^Q.U3_P!)9*_EHK^I?_@HE_R8 M;\8O^Q.U3_TEDK^6BOU[PU_W:M_B7Y'Y-XC?[Q1_PO\ ,_JJ_9]^+GA.V^ O M@B.3Q/X>CDCT"P5E;480RD6\>01NZUTVJ?'KP+H=JT][XT\)V<"]9)]7MXU' MXE\5_)?143\-ZH7DOW(+:%II' M^BJ"37U%^S-_P1;_ &@OVF-6M5M_!-YX3T>8J9-5\1J;"&%#_$$8>:_T1">G M0#\FR[]_C9\UOYFDONZ^FOH<=;B[.,Q_%EI?9]FMO^#Y'\Z/\ P1__ ."B[?\ !/C]HUKS5UGN/ OB MR-+#7X8@6> *Q,5TB]VC);([J[CKC']%'PN^*OASXU^!-.\3>$]9T_7]!U:( M36M[9RB2*5>AY'0@@@J<$$$$ C%?@5_P4I_X(A_$#]CSQ1?:YX-T_4O&WPWE M+30W=I"9KS24Z^7(O"LKMO MD73[QXHY2./G3.UO^! U^H9MP_@\_BL?@*B4FM>S]5NFOZ1^993G^+R*3P.. MIMQOIW7H]FG^?4_K KY#_P""IG_!6'PK_P $]_ 4NGV4EGKWQ,U.$-I>B[]R MVZL2/M%SM.4C&#@?>XD+,>9)I6X M4?[3L![UY>6^'ZHU/;9E4CR1ULKV?JW:R[_F>GF''SK4_8Y=3ESRTN[77HE> M[[?D?T(?\$U_^"L?@/\ X*%^%XK*WDC\._$*RMO-U+P]/)\S;M? M%#4K;R\P_/;:!&X^>*%L?-(P.UY!QC*KQDM]X5\)GD,%#&2CE[;I]/7K;R[7 M/N,EGC9X.,L>DJGZ=+^?>Q_+C_P43_9.U3]C#]KCQ=X+OK66'3X[M[W1IB#L MO+"5BT+J>^!\C8Z.CCM7WY_P06_X*YZ#\,?"5O\ !7XGZO;Z/I]O,3X8UF\D MVP1"1B6M)G/"+N)*,Q &XJ< +7WA_P %0?\ @F)X;_X*-?"R"UFN(]"\;:#N M?1-:";@F0=UO,!RT+'!./F4@$?Q*W\_7[4W[%'Q,_8T\7R:/\0/"]_I'[UH[ M>^"&2QOL?Q0S#Y6!'..& Z@'BOU'+\=@N(LN6"Q3M55K][K[4>]^OS7F?F.8 M8'&F[V[6?V9=O+Y,_JEBF6>)7C971AE64Y!'L:QOB+\2-!^$?@O M4/$7B?5]/T+0]*B,]W>WLPBA@0=R3Z] !R20!DFOY;OAI^VQ\7_@WI,=AX5^ M)GC?0;&%=L=O9ZQ/'%&/15#8 ]A6+\5_VDOB!\=BG_"9^-/$_BA8VWHNIZC+ M<(C>H5F(!]\5XM/PUJ^T]^NN7R3O]U[?B>U/Q&I>S]RB^;S:M_G^!_0]^Q%_ MP5W^%?[=7Q4\2^#_ U/=Z?K&CSNVFQWX$9UVT4#-Q".H(.[,9&X* WIP .>@KYGBK*L%@<4J># MJDO\ TI&7 M_P %%_\ @L;\._\ @GYJ5EH4\,GB[QE<2PO<:+8W C:PM68;Y99""%;9DHA& M6.,[5.ZO>/V8_P!JWP'^V!\-+?Q7X!UZUUK39L+,BMMN+&3&3%/']Z-QGH>H MP02""?Q0_P""PW_!'KQU^SU\5M>^(7A&UUKQIX!UZYEU"XN=SWE]HTCL6=+C MJ[1C/RRG/'#$$9/PS\-?C!XK^#6M-J7A/Q)K?AN^9=K3Z;>R6SN.N"4(R/8U MRX7@O+\=E\*F"K>_U?2_9QZ6Z?C/M4L9$,;P3ZU.R.IX*D;N0?0UB?LZ?LM M>/OVM/'L/AWP#X;U+Q!J,KJ)7ACQ!:!CC?-*?DC7W8C\:]?AWA/^R*TL;B:R MT379*_5MGD\0<5?VM16#PU)ZM/N_1)'Z3_\ !JYI%T?'7QBU#RY!8BPTVW,F MT[&D,EPP&>F0 3CW%?I9_P %&_\ DP7XS?\ 8F:K_P"DLE<__P $ROV!M+_X M)Z_LVVOA.&XCU+Q!J,O]H:]J* A;JZ8 ;4!Y$:* JYY."3RQKH/^"C?_ "8+ M\9O^Q,U7_P!)9*_/\VS"GC<\^L4?A=K*_P ['WN5Y?4P62?5ZOQ*,F_* M]W;Y7/YE?@5_R6[P;_V'++_T>E?UI5_);\"O^2W>#?\ L.67_H]*_K2KZ?Q+ M_B8?TE_[:?->''\.OZQ_4_GA_P""\G[%>H_LP_MH:MXGM[/_ (I#XDS/K&GW M"#Y([EL&Y@;@ ,)"7 [K(ISG" MXW+6OB33H&DM6C/3S@,F!QT(;C/1F'-=V1YI@\YR]97CW::22Z7MLT^ZZKKZ M,X\ZRO&9/CWF>!5X-MOK:^Z:[/H^GJC^E+1M:L_$>DV]_I]U;7UC>1K-!<6\ MHDBF1AE65E)#*0001P0:DO\ 4+?2K*:ZNIH;:WMT,DLLKA$C4#)9B> .#_'_B[PU:JQ80:?JLT$2D]2$5L?I4WQ2_;#^*WQMTY[ M/Q=\1?&7B*SDQOM[_5IIHGQTRA;!_$5Y_P#Q#6M[2RKKE]'?[KV_$[O^(C4N M2[HOF]5;[[7_ /T _X+T?\ !6O0?VA=,C^#WPSU*WU?PQ:W*W.O:U;ON@U& M:-CY=O PX:)6^9G&0[;=O"DM\W_\$6OV+;[]L']M7P_)-9O)X3\#W$6NZW<% M?W8$;;H("?[TLB@8_NJYP0#7)_L-_P#!+OXK?MW^)K-?#>B3Z7X6DDQ=^)-1 MB:+3[= ?FV'&9G[!$SD]2HR1_09^PY^Q%X._8,^"%GX-\)0-(Y/GZGJHTUYJ^\I>?9>G1'G93EN,SO,%F M.-5J:L^R=MHKR[OUZGLE?SD?\%Z_^4HGQ"_ZYV'_ *10U_1O7\Y'_!>O_E*) M\0O^N=A_Z10U\[X<_P#(RG_@?_I43Z#Q"_Y%T/\ &ORD?I'_ ,&RW_)@6N?] MCC>?^DUI7Z*5^=?_ ;+?\F!:Y_V.-Y_Z36E?HI7S_%'_(VK_P")GO<,_P#( MJH?X4%?S?_\ !>+_ )2L_%3_ 'M+_P#359U_2!7\W_\ P7B_Y2L_%3_>TO\ M]-5G7T7AS_R,I_X'_P"E1/ \0O\ D70_QK_TF1^FO_!L]_RCPU3_ +'._P#_ M $FLZ_0NOST_X-GO^4>&J?\ 8YW_ /Z36=?H77SO$_\ R-:_^)GT'#7_ "*Z M'^%!7\T/_!9C_E)K\7/^PLO_ *(CK^EZOYH?^"S'_*37XN?]A9?_ $1'7TGA MQ_O]3_!^J/F_$3_<:?\ C_1GZ3?\&TOCW0_"W[%'BJ#4]:TG39W\73NL=U=Q MPLR_9;89 8@XX//M7Z*/\9O!\:%F\5^&U51DDZG!@#_OJOY)Z*^FS3@.&,Q< M\4ZSCS.]N6]OQ/G\CCS&QP=J)\W3.,C@H/F)*_4_["/_!M98^%=1TWQ)\DZ/86>EZ7I\0AMK2UB6*&!!P%55 ]!7#GW M&6&H4/J.4=K_*W=M_P![LO+?T+5G9Q:? M:16]O''#! @CCC1=JHH& .P XQ4C,$4LQPHY)/:BOD/_@I1^UM_PB6D2_#_ M ,/W"_VEJ$7_ !-IXVYM86Z0C'\3CKZ*??C\4SK.*.6X26+K[+9=6^B7K^"U M/W#AKA[$YUCX8#"K66[Z1BMY/T_%V74\1_;]_:R;X\^.O[%T>?/A70Y"L+(> M+Z;HTI_V1R%]LGOQW_\ P3(_97_MW4U^(FN6_P#H=DY31X9$XFE&0T_/9.B_ M[63QMY\&_93_ &>+W]I#XKVNCQ!XM+M\7&I7('$$(Z@?[3'Y1[G/0&OU7\.> M';+PCH-GI>FV\=G8V$2P00QC"QHHP *_+N#\KKYSF$L\S#6*?NKHY+:WE'IY M^C/W#Q$SS#<.93#AC*=)2C[S6ZB][_WIZW\K[71\S_\ !6C_ ()ZV/\ P4 _ M9HNM-M+>WC\<^&P]_P"&[MFV'SMOS6[-_P \Y0 #G@,$;C%?SH^&O$7BC]F_ MXPVNHV;7WAWQ=X-U/>H=3'/8W4+X*LIY!#*5*GW!K^M.OQX_X.*?^":@L+EO MCYX+TUO*F*0>+[6W0E4?[L=_CL#\J/CC(1NI8G^K.!<_5.?]F8E^Y/X;]&]U MZ/\ /U/XNXWR)U(?VEAOCC\5NJ6S]5^7H?H!_P $SOV^=&_X*"_LWV/BBV^S MV?B730MEXBTQ'R;*[ ^\HZ^5( 70GME>FOW4_A\N\?ET[KT9[/ M"O$"S'#\M1_O8;^?][Y]>S]4=#1117R9]4?G;^U+>/XF_P""E5K:M\T=KJVD M6J#_ &=L#G_QYFK]"M6TN'7-*N;*ZC\RWO(FAE0_Q*P((_(U\/\ BCX(>+/$ M?_!1H>(6\-ZO_8*Z[!+]N-N?)V1(@W[NF,IUK[HKX7@_#U/;X^I5BUSU96NM MU=]]UJ?J7B%BZ3PN54:$TW3H1O9IV=E>]MG='YG_ 2\9S?L5_M,>,K&_P!O M_$OL=0LE#DQK2/,*)CJ?G%>Q?\$G?ARUX/%7CJ\5I+F[E_LV"5CD MGD2S'ZDF/GVK+_X*,?LH^*/&OQGM/$7A;0KS6(=6LU2[^RKN:*:+Y'/#PC\N:SM%>Y]6G?+R$_P# F(^@ [5\_P -Y#B: M6 M3MKNGY'!_P#!2+1UU3]D3Q%*PRUA-:7"?7[3&A_1S7(?\$FKUKCX :Q$3Q;Z MW(![9AB/]:]5_;-\)7WCG]F/Q9I>F6DU]?W5O'Y,$*[I)66:-\ ?\!KS+_@F M'X \0_#?X;^)-/\ $&C:CH\TFI)<0K=0F/S%,04D9ZX*_P J^@Q5"HN*Z-91 M?*Z33=M+WEN]NQ\I@<52EP'B,/*:YU732NKV:@KI;VW/"?\ @K!_R<5IO_8# MA_\ 1LU?H)X7_P"19T[_ *]8O_0!7Q+_ ,%*O@AXO^(_QUT^^T'P[JVK6<>D M10M-;0&1%<2RDKD=\$?G6#:_%O\ :JLK:.&.W\1K'"H1!_PC]H< # _Y8UX& M$S?^RLZQU2M0J2522LXQOM?NUWZ7/JLPX?6?<.992PV)HPE2C+F4YV?O7'C;QW^Q3JP\7V][-XPU#2=3@DAEM4@FD8^G1J0?))WG%)=K*S>NNQ\)C^"ZV32H8NMB:-1.I%6ISQ""9_[ M*2?>@.<8D1@.>XYKO_\ A#U=8@5YQR"*YS]MCX2>/OV@_VIHX;7PWK3Z#9>1I=M=+ ?)" M$[I)=QX^\[<^BCTKV,_X@GC\EJ+!T:D93DH6E&SUU;LF]+:7[L^>X4X2IY7Q M)1>88BE*%.+JWC.\;K2*NU'WN:SMV1Z5^PK^R)X1U3]G?2]7\4>&=+U;4M<= M[U)+N#S'2$G;&!GH"J[N./FSWKV+_AC_ .%__0B^&_\ P#6N\\.Z';^&- L= M-M8UCM=/MX[:% .%1%"J/R JY7U67>)@'1<>A"-_VTK]!OA;X]M?BA\--%\0V;*T&KV4=R #G8Q7YE/NK9 M4^X->,?\%(O@9J'QA^#%I=:+8S:AK&A7JRQP0)OEEBD^1PHZ\$JWT4T__@G) M8^)O#'P0NO#_ (FT?5-)FT>\;[(+N(IYD,@W?+GT;?GZCUKYC)\+/+>(J^%A M!JC62DK+1-=.R^UIZ'VW$..I9SPCA,;5J)XC#R<))MH_34O_ $(U^B-?"_[%?P0\7>#/VQ[[6-6\.ZMI^ER"_P!MU/ 5B.]C MMY]^U?=%=/A_1J4LNG&K%Q?M);JW;NR@KIIJ]Y::'P?_ M ,%-OV=9O!GB^V^)&AHT5M?RHFH^4-IMKD8V3#']_&">S+G^*O*_BG\85^.W MQR^'?B)C_ITEMI]K?C^[I:#JUNMQI^ MJ0-!*A[ ]&![,#@@CH0*_-F#]C;Q]\/OCK:6:^&]6U#3]+UB';?PVY:&:)95 M(D!]-O)].:^3XRR+$87%^VP<6Z5>47))-VG%WOIWN_O?D??^'/%.$QN 5#,9 MJ-?#1E&$I-+FIR5K7>[327HH^9^BWQI^'F>)&DT_3[YGTG4UD)VVLR/A78=/E<%2>P M9O>OTQKYO_;/_8*MOV@;E_$7A^:'3?%2Q[95E^6WU$*/EW$ E7QP&Z$8!]:^ MNXMR7%5:M'-,N5ZU%[?S1[?GIU3?4_/N .),#0HXC(\W=L/B%\7\DMD_RUZ- M*^ESZ.BE6>)9(V5T MV+WUO%C_ )YRQG('H ^WVJ]XG_:"_:(_:,T_^R=-\/ZCH]I=K^1M/PJQ7M>:GBZ+H?\ /SG5 MK=[=_*]O/J1_\%-/V@8_BE\1M/\ !FB7'VNP\/2-]I,+;EGO6^4KQP3&,K]6 M<5]?_LE?![_A1OP$T'09DVZ@(C=7WJ9Y#N8'_=R$^B"O'?V-_P#@GBOPDUBU M\5>,I+>^\00_O+6RC/F0V+_WV;^.0=L?*#R">"/JEVV(6Y.!G JN%\IQ;Q=7 M.B\]-=6T9\;Y_@(X"APYDTN>C1UE/\ GGKJO+5N^SOI MHDW^>/[%B?\ "2?\%#-2O_O>7=:M=Y]-WF+_ .U*^U?VE?A6;O:DG 6=/GBR?3>H!]B:^4_^"=_P6\8^$OVDM2USQ%XZW);K:1L#_$Q2X^A"**^S/\ M@FW\*%^'/[-]G?R1[;_Q1*VHS,1SY?W8E^@4;OJYKYK^-'["/BS5?VJ=0L]+ MT2^;POJVJ),NHQH/)MX9B'DYSQL+.,'^Z/6OT,T?2;?0-)M;&SB6&TLH4@AC M'2-% 51^ %>7P/E.+AC)3QL6EATZ<+IJ]Y-MKOII==&CW?$[B# 5,NA3RV2 M;Q![K;\D-W=Q$^A=(B/\ T U[ MQ^Q;KB^(/V5_ ]PO\&FK;GZQ,T1_5*\]_P""FWPRUSXF_"'0[?0=)O=7O+75 MQ(\5M$9'1##("V!VS@?C6M^SK:>)?A-^P9:0_P!BZ@OB;3;&^\C3VB/G^:UQ M,8_EZ_Q*WTKUL/&I0XGQ5>47R.DG>SLVN567=VOH>!C)TL5P3@<+&*M$U+3&L;,Q6C7L6QI M)93AF&>20H89_P!OWK[>K+@S*57HULPQ]).=:;=I1NTNFZ[W^5C?Q&S^6&Q. M'RG*J[5+#TXQO"32W=K)%;W M4-J%>WD*D*X/L<&OD7_@FQX]F^%/[3-UX7U0-:_VY')ITL4AQY=U$2R@CURK MK]6%?HM7Y^_M4_LY>-/!G[74_BCPCX=U34K.6Z@UF&6R@+*DN074D=#O5C]& M%9\79:L%7PN:8&EK3G:2C'>+\DO)KYFW &+G+:2VLY/N MT[?W3[T\/?\ 'A)_U\W'_HYZ*K^![YM3\-0W+120-<22RF.1=KQEI6.TCL1G M!%%?HT7=71^/2BT[,F\4>'X?%6@W&GW,=O-;W0"RQ7$(FAF3()1T/#*P!!!X M()KA?^&4? ?_ $(?PU_\)6W_ ,:**UA5G#X6UZ,QE2A/XDG\@_X91\!_]"'\ M-?\ PE;?_&G1_LJ^!8GW+X%^&ZMZCPK;@_SHHJOK-;^9_>R?J]+^5?1J7_ #]V/_@(W_QRBBLI2;=V:QBD MK(/(U+_G[L?_ $;_P".4>1J7_/W8_\ @(W_ ,.12Q/JQ)HHK:CB*M&7-2DXONFU^1C6P]*K M'EJQ4EYI/\SD=*_X(X_L]Z/=+-'\+?!+NI##SK.>5<_1IR*]X^'GPFTSX1Z MNE>%=*\+^&]-4Y%KIFCK:PYZ9VHX!/N>:**TKX[$UE:M4E+U;?YF='!8>B[T M:<8^B2_(WO(U+_G[L?\ P$;_ ..4>1J7_/W8_P#@(W_QRBBN4Z@\C4O^?NQ_ M\!&_^.5G^*?!:^.="N-+UJWT'6--NAMFM+[3/M$$P]&1W*G\11134FG=":35 MF> >(_\ @D#^S_XJU&2ZNOA9X%2:5MS?9]/EMUS[+',%'X"MGX;?\$P/@E\) M=5COM#^&/P]M[R/E)I]%-TR'U'FRM@^XYHHKMEFF-E'D=65NW,[?F<4JJ, "S8 #_OY3O(U+_G[L?_ 1O_CE%%<)W'SI MXX_X)(? OXD>,M4\0:Y\._"NH:QK5U)>WMS)!<[KB:1BSN<3@9+$GBO:/A+\ M'=/^!?P]TWPKX3MM*T7P_I"&.SLX;60I I8L0-TI/4D\GO11756QV(JP5.K4 ME)+9-MI?)G-1P>'I265CU+M%(I8^[9-%%9T<15HRYJ,G%^3:_(NM MAZ59^> ? MA=I_PI\/1Z3X7TWPSX=TN(Y6TTW2!:P@^NQ' S[]:**TKX[$5U:M4E+U;?YD M4,'AZ+O1IQCZ)+\C:\C4O^?NQ_\ 1O_ (Y63X[^'Z?$SP7JWAW7%TW4-%UR MTDL;ZUDM7"W$,BE70XE!P5)'%%%<\9.+NMSHE%-6>Q\_Z/\ \$!?\ @E#\"/AQJT=]I?PM\ ?:H3E'NM)>["G_ '9967]* M**[O[4QG+R>UE;MS.WYG#_9N#YN?V4;]^57_ "/?;'2KS3+*&WMI=,M[>W01 MQ116+(D:@8"J!)@ #@ 5+Y&I?\_=C_X"-_\ '***X3N#R-2_Y^['_P !&_\ MCE^'8KB:3 P,N[%C@ #D]!1151J2B M[Q=B90C)6DKFMX.^'=K\/-+:Q\/V/AO0[)Y#*UOI^DBUB9R "Q5' W$ #/7@ M5K>1J7_/W8_^ C?_ !RBBE*3;NQQBDK(/(U+_G[L?_ 1O_CE+L*4(R5I* MYL>#_A[;?#W2FL?#]CX1J7_ #]V/_@(W_QRN/\ $'[.?A/Q9K$^HZKX M2\ ZGJ%TVZ:YN_#<,TTQZ99V))/U-%%.%24'>+MZ"E3C)6DKE/\ X91\!_\ M0A_#7_PE;?\ QH_X91\!_P#0A_#7_P )6W_QHHK3ZS6_F?WLS^KTOY5]R-;P MY\#O#_@^\6XTGP[X+TNXC.5EL] C@=3[%6!KIO(U+_G[L?\ P$;_ ..445G* M1J7 M_/W8_P#@(W_QRL>\^&ECJ-W)<7&F^&;B>9BSR2:.K.Y/4DE\DT45,Z<9Z25_ M4TIUITW>#:]'8M:+X/\ ^$;\S^SH=#L/.QO^S:9Y6_'3.UQG&:O>1J7_ #]V M/_@(W_QRBBB,5%6BK(F#115;:HDXO_ (91\!_]"'\-?_"5M_\ M&NK\+>"8_ NBQZ;HEMH&CZ?"6:.UL=+^SPH6.20B.%&223QR3116DJU22M*3 M?S,XT81=XQ2^1H^1J7_/W8_^ C?_ !RCR-2_Y^['_P !&_\ CE%%9F@>1J7_ M #]V/_@(W_QRCR-2_P"?NQ_\!&_^.444 'D:E_S]V/\ X"-_\1J7_ #]V/_@(W_QRCR-2_P"?NQ_\ M!&_^.444 'D:E_S]V/\ X"-_\1J7_ #]V/_@(W_QRCR-2_P"?NQ_\!&_^.444 'D:E_S]V/\ X"-_ M\1J7_ #]V/_@(W_QR MCR-2_P"?NQ_\!&_^.444 'D:E_S]V/\ X"-_\1J7_ #]V/_@(W_QRCR-2_P"?NQ_\!&_^.444 'D: ME_S]V/\ X"-_\1F5=H)9RQP,GU]:*** /_V0$! end GRAPHIC 15 cstl-20211231_g11.jpg GRAPHIC begin 644 cstl-20211231_g11.jpg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end GRAPHIC 16 cstl-20211231_g12.jpg GRAPHIC begin 644 cstl-20211231_g12.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1#R17AI9@ 34T *@ @ ! $[ ( M - (2H=I 0 ! (6)R= $ : 0T.H< < @, /@ M &UL;G,Z9&,](FAT=' Z M+R]P=7)L+F]R9R]D8R]E;&5M96YT#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@ M96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8 M%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4 M"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ_\ $0@!GP5S P$B (1 0,1 ?_$ !\ $% 0$! 0$! M ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" P $ M$042(3%!!A-180'EZ@X2%AH>( MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! M @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$' M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66 MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F MY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ]1\5_$/7=(\?1^%/#'@__A(; MMM,&I.W]II:[$\UHR/G4@X(7OGYNG%5O^$V^)W_1(_\ RY;;_P")H_YNF_[D MS_V]KTF@#S;_ (3;XG?]$C_\N6V_^)H_X3;XG?\ 1(__ "Y;;_XFO2:* /-O M^$V^)W_1(_\ RY;;_P")H_X3;XG?]$C_ /+EMO\ XFO2:* /-O\ A-OB=_T2 M/_RY;;_XFC_A-OB=_P!$C_\ +EMO_B:])HH \V_X3;XG?]$C_P#+EMO_ (FC M_A-OB=_T2/\ \N6V_P#B:])HH \V_P"$V^)W_1(__+EMO_B:/^$V^)W_ $2/ M_P N6V_^)KTFB@#S;_A-OB=_T2/_ ,N6V_\ B:/^$V^)W_1(_P#RY;;_ .)K MTFB@#S;_ (3;XG?]$C_\N6V_^)H_X3;XG?\ 1(__ "Y;;_XFO2:* /-O^$V^ M)W_1(_\ RY;;_P")H_X3;XG?]$C_ /+EMO\ XFO2:* /-O\ A-OB=_T2/_RY M;;_XFC_A-OB=_P!$C_\ +EMO_B:])HH \V_X3;XG?]$C_P#+EMO_ (FC_A-O MB=_T2/\ \N6V_P#B:])HH \V_P"$V^)W_1(__+EMO_B:/^$V^)W_ $2/_P N M6V_^)KTFB@#S;_A-OB=_T2/_ ,N6V_\ B:/^$V^)W_1(_P#RY;;_ .)KTFB@ M#S;_ (3;XG?]$C_\N6V_^)H_X3;XG?\ 1(__ "Y;;_XFO2:* /-O^$V^)W_1 M(_\ RY;;_P")H_X3;XG?]$C_ /+EMO\ XFO2:* /-O\ A-OB=_T2/_RY;;_X MFC_A-OB=_P!$C_\ +EMO_B:])HH \V_X3;XG?]$C_P#+EMO_ (FC_A-OB=_T M2/\ \N6V_P#B:])HH \V_P"$V^)W_1(__+EMO_B:/^$V^)W_ $2/_P N6V_^ M)KTFB@#S;_A-OB=_T2/_ ,N6V_\ B:/^$V^)W_1(_P#RY;;_ .)KTFB@#S;_ M (3;XG?]$C_\N6V_^)H_X3;XG?\ 1(__ "Y;;_XFO2:* /-O^$V^)W_1(_\ MRY;;_P")H_X3;XG?]$C_ /+EMO\ XFO2:* /-O\ A-OB=_T2/_RY;;_XFC_A M-OB=_P!$C_\ +EMO_B:])HH \V_X3;XG?]$C_P#+EMO_ (FC_A-OB=_T2/\ M\N6V_P#B:])HH \V_P"$V^)W_1(__+EMO_B:/^$V^)W_ $2/_P N6V_^)KTF MB@#S;_A-OB=_T2/_ ,N6V_\ B:/^$V^)W_1(_P#RY;;_ .)KTFB@#S;_ (3; MXG?]$C_\N6V_^)H_X3;XG?\ 1(__ "Y;;_XFO2:* /-O^$V^)W_1(_\ RY;; M_P")H_X3;XG?]$C_ /+EMO\ XFO2:* /-O\ A-OB=_T2/_RY;;_XFC_A-OB= M_P!$C_\ +EMO_B:])HH \V_X3;XG?]$C_P#+EMO_ (FC_A-OB=_T2/\ \N6V M_P#B:])HH \V_P"$V^)W_1(__+EMO_B:/^$V^)W_ $2/_P N6V_^)KTFB@#S M;_A-OB=_T2/_ ,N6V_\ B:/^$V^)W_1(_P#RY;;_ .)KTFB@#S;_ (3;XG?] M$C_\N6V_^)H_X3;XG?\ 1(__ "Y;;_XFO2:* /-O^$V^)W_1(_\ RY;;_P") MH_X3;XG?]$C_ /+EMO\ XFO2:* /-O\ A-OB=_T2/_RY;;_XFC_A-OB=_P!$ MC_\ +EMO_B:])HH \V_X3;XG?]$C_P#+EMO_ (FC_A-OB=_T2/\ \N6V_P#B M:])HH \V_P"$V^)W_1(__+EMO_B:/^$V^)W_ $2/_P N6V_^)KTFB@#S;_A- MOB=_T2/_ ,N6V_\ B:/^$V^)W_1(_P#RY;;_ .)KTFB@#S;_ (3;XG?]$C_\ MN6V_^)H_X3;XG?\ 1(__ "Y;;_XFO2:* /-O^$V^)W_1(_\ RY;;_P")H_X3 M;XG?]$C_ /+EMO\ XFO2:* /-O\ A-OB=_T2/_RY;;_XFC_A-OB=_P!$C_\ M+EMO_B:])HH \V_X3;XG?]$C_P#+EMO_ (FC_A-OB=_T2/\ \N6V_P#B:])H MH \V_P"$V^)W_1(__+EMO_B:/^$V^)W_ $2/_P N6V_^)KTFB@#S;_A-OB=_ MT2/_ ,N6V_\ B:/^$V^)W_1(_P#RY;;_ .)KTFB@#S;_ (3;XG?]$C_\N6V_ M^)H_X3;XG?\ 1(__ "Y;;_XFO2:* /-O^$V^)W_1(_\ RY;;_P")H_X3;XG? M]$C_ /+EMO\ XFO2:* /-O\ A-OB=_T2/_RY;;_XFC_A-OB=_P!$C_\ +EMO M_B:])HH \V_X3;XG?]$C_P#+EMO_ (FC_A-OB=_T2/\ \N6V_P#B:])HH \V M_P"$V^)W_1(__+EMO_B:/^$V^)W_ $2/_P N6V_^)KTFB@#S;_A-OB=_T2/_ M ,N6V_\ B:/^$V^)W_1(_P#RY;;_ .)KTFB@#S;_ (3;XG?]$C_\N6V_^)H_ MX3;XG?\ 1(__ "Y;;_XFO2:* /-O^$V^)W_1(_\ RY;;_P")H_X3;XG?]$C_ M /+EMO\ XFO2:* /-O\ A-OB=_T2/_RY;;_XFC_A-OB=_P!$C_\ +EMO_B:] M)HH \V_X3;XG?]$C_P#+EMO_ (FC_A-OB=_T2/\ \N6V_P#B:])HH \V_P"$ MV^)W_1(__+EMO_B:/^$V^)W_ $2/_P N6V_^)KTFB@#S;_A-OB=_T2/_ ,N6 MV_\ B:/^$V^)W_1(_P#RY;;_ .)KTFB@#S;_ (3;XG?]$C_\N6V_^)H_X3;X MG?\ 1(__ "Y;;_XFO2:* /-O^$V^)W_1(_\ RY;;_P")H_X3;XG?]$C_ /+E MMO\ XFO2:* /-O\ A-OB=_T2/_RY;;_XFC_A-OB=_P!$C_\ +EMO_B:])HH M\V_X3;XG?]$C_P#+EMO_ (FC_A-OB=_T2/\ \N6V_P#B:])HH \V_P"$V^)W M_1(__+EMO_B:/^$V^)W_ $2/_P N6V_^)KTFB@#S;_A-OB=_T2/_ ,N6V_\ MB:/^$V^)W_1(_P#RY;;_ .)KTFB@#S;_ (3;XG?]$C_\N6V_^)H_X3;XG?\ M1(__ "Y;;_XFO2:* /-O^$V^)W_1(_\ RY;;_P")H_X3;XG?]$C_ /+EMO\ MXFO2:* /-O\ A-OB=_T2/_RY;;_XFC_A-OB=_P!$C_\ +EMO_B:])HH \V_X M3;XG?]$C_P#+EMO_ (FC_A-OB=_T2/\ \N6V_P#B:])HH \V_P"$V^)W_1(_ M_+EMO_B:/^$V^)W_ $2/_P N6V_^)KTFB@#S;_A-OB=_T2/_ ,N6V_\ B:/^ M$V^)W_1(_P#RY;;_ .)KTFB@#S;_ (3;XG?]$C_\N6V_^)H_X3;XG?\ 1(__ M "Y;;_XFO2:* /-O^$V^)W_1(_\ RY;;_P")H_X3;XG?]$C_ /+EMO\ XFO2 M:* /-O\ A-OB=_T2/_RY;;_XFC_A-OB=_P!$C_\ +EMO_B:])HH \V_X3;XG M?]$C_P#+EMO_ (FC_A-OB=_T2/\ \N6V_P#B:])HH \V_P"$V^)W_1(__+EM MO_B:/^$V^)W_ $2/_P N6V_^)KTFB@#S;_A-OB=_T2/_ ,N6V_\ B:/^$V^) MW_1(_P#RY;;_ .)KTFB@#S;_ (3;XG?]$C_\N6V_^)H_X3;XG?\ 1(__ "Y; M;_XFO2:* /-O^$V^)W_1(_\ RY;;_P")H_X3;XG?]$C_ /+EMO\ XFO2:* / M-O\ A-OB=_T2/_RY;;_XFC_A-OB=_P!$C_\ +EMO_B:])HH \V_X3;XG?]$C M_P#+EMO_ (FC_A-OB=_T2/\ \N6V_P#B:])HH \V_P"$V^)W_1(__+EMO_B: M/^$V^)W_ $2/_P N6V_^)KTFB@#S;_A-OB=_T2/_ ,N6V_\ B:/^$V^)W_1( M_P#RY;;_ .)KTFB@#S;_ (3;XG?]$C_\N6V_^)H_X3;XG?\ 1(__ "Y;;_XF MO2:* /-O^$V^)W_1(_\ RY;;_P")H_X3;XG?]$C_ /+EMO\ XFO2:* /-O\ MA-OB=_T2/_RY;;_XFC_A-OB=_P!$C_\ +EMO_B:])HH \V_X3;XG?]$C_P#+ MEMO_ (FC_A-OB=_T2/\ \N6V_P#B:])HH \V_P"$V^)W_1(__+EMO_B:/^$V M^)W_ $2/_P N6V_^)KTFB@#S;_A-OB=_T2/_ ,N6V_\ B:/^$V^)W_1(_P#R MY;;_ .)KTFB@#S;_ (3;XG?]$C_\N6V_^)H_X3;XG?\ 1(__ "Y;;_XFO2:* M /-O^$V^)W_1(_\ RY;;_P")JM/\4/&.D:KHL'B?X5L [$0DX 8]AQC(S7J5>;?&3_F0O^QST[_VI0!Z31110!YM_P W3?\ DUYM_S=-_W)G_ +>UZ30 4444 %%%% !1110 4444 %%%>(Z)+KWQB\:^ M)'?Q1JV@>'M%NC96MOHUQY$LS@D&1WP>,#..>HZ8Y /;J*\YU?Q9N #TJBO+O#?QLM/%VI^&M.\/:2;J\U6)YM M1B-UM_LM$.&+':=_.<#Y<_+TW5:^/6JZAHWP?U.]TB^N+"Z26 +/;2M&Z@RJ M#AE((R.* /1Z*\=^&7C>[T+PWXMTKQIJ$][>^%'>X-Q)]:O[F/5-%?4Q92W#M#"))%,>U"<+\A&, 8SB@#Z+H MKS33OC -0^"][X_&B&,6K,OV#[7G=APG^LVS]VN8UG5I=2_:*^'>J6UN0 M]YH,UPMMYG4M!.P3=TZX&<>] 'N5%>._"GX@>.O$WC#7;#7]"WV%MJ?$C2_!?PNT>\T[0[P:1J&OO97,MYJ0E:T+;3 MYF1$NX8R<8'W3R_$#5/"FA>#;G4[C3+E(YYTO4CC2$XS(2R\'GA!DG!Y&*R_A_ MKEAI^K?$V\T;1-6NKNUUM_/MDN%N&N9/,=L-XSM?#/BCP7/H=_J-O+-IX.HQSK.44MM8J $)"GKGFL#X:_$OQGJ_B+Q*G MBK1@ND:=?W"W5T;N #2%C5V\G:J@S8*A=X^M 'M-%>20?'.8VUGKE[X-OK/P MC>W(MX=:DNXR02Q4,T(&Y5R#SGMQFO4M1NSI^EW5XMM/=&WA>46]NFZ27:I. MU!W8XP!ZF@"S17F5O\6-7M/%>CZ3XN\$76@6^MS&"QNGOXYBS\8#HHRG)4I'&(ES\Y)7(8[6P@#$[3S0!ZQ17#P M_$>;5OA_I/B3PIX:O]:EU5BD5E&ZQ^4R[@WF2-PJAD(W=SCUKFKWXC7'BCP; M\0?#VMZ!+H&N:3HEP\]JUTEPI5X&((=0 >"IZ?Q#F@#UVBO$?AY\0#X3\ _# M;2[[3FELM=\RU_M#S\"WD$I"*5VG.20.HP,]<5T6M_&>TT35O%L,ND33V'AB M&#SKN*;)FGE*A8@A7 Y)RQ;^$\4 >F45P>B?$>]E\.ZEK/B_PQ<>'K2QM%O$ MF6Z2[CN(B#]QTP-_ ^7K\PK)TGXR7D^H:(WB#P==Z+HOB"58M,U.2\CE\UG& M8]\8&8]W&,D]<].: /4J*\T7XM7U_P"--3T?P]X/N]5L=(NQ::A>QW<:21-N MVDK ?F=00>0>U=KXI\0VOA/PMJ&NWZ226]C"972(99NP ^I(% &M17F%KXYU MGQ=X"UV74_"=QHMK/HD]U9W8O$N8IT,9 !9 -C\YVGG@^E<#\-OBK>^!_A#X M<;4_"E]+X?2>2VFUK[0@"LT\A&R+EF4 XR<#*D"@#Z-HK@/$_P 3+K3O&1\* M>$_#-QXEUJ*V%U<0I=);1P1G&-SL",\CC'<>M8EQ\=[>'P+<>(!X>N!<:;JB M:=JVGRW 5[,G(+A@IW@,-N,#)STQR >M45P%[\5[&T^,&F^!5M!*+ZV$WV\3 MX".59E39MYR%7G=_$.*X7XB_$'3O&'PM\42:CH=V=)TO6X]/CEM=06-[ID?) M<$Q,%'W3C#9W=10![S17FNM?%.ZT;QM;^$-&\*W6LWLVEI=VWE7:IN))&URP MPBA5)+DGG QSFC2_C/87/P^U[Q)JVDW.FSZ!.;6^T\N)&6;<%55? !RS 9P, M<_B >E45Y;H7Q7\2:EX^T[PQJW@!]*DOK?[8)GU:.39!S\^T( 3G@KG"X;WPK#Y1DF"SZCNC;[-R-J^6ZG?ORPR/N[?>@#U"BOG_XLZ[KC MW_PUU76_#D^F:C#KI@45Y$OQVE-C%XA?P=?1^#9; MG[.NN-=)N'S[-Y@QNV[N,Y]NO%>E>(=>M?#GAF_UR\#R6UE;M.XB&68 9P/K M0!IT5YGHGQ,\3^(/#UUJ-KX!N(5DL&O=,E&I1/%=*&4;6?&(GP^[:PYVMZ5A M?#?XH^+;OX4ZCXD\4Z-]N@T^TGN8M3^U11_;61C^Z\I$S'@#&[!SCWH ]IHK MRW3?C0\W@VY\6ZUX6O-+\/Q6JRP7;7*2-CT5X])\<]2EM M_$$^D^!+N_A\/78"5R6.&)0 X SGFMS5?BW&FF^&&\,:%< MZWJ7B:)IK&P,Z6^$1=S[W;(!']#S0!Z+17A&L_&GQCJ'PZ\2ZGI'A Z-<:/= MK93W3:C%,;60']X3&T8W;3L7&#G?D?=-97Q9U_Q#KW[.MC?^)=(.E737]J8W M%VDWVI3"6$WR !-Q)^7J,4 ?1E%>=:'\4[N]^(%IX6\1>$[W0)M2MVN-.DGN M$D,ZJ"Q#JO\ JVPK<9)&,'%95W\<+CR=1U?1O!M[J?A?2[@V]WK"7<:$%2 S M)$1EUY'.1UYQ0!ZU17G'B/XN#2?%&BZ+HF@7&O2:YI_VVQ:VG5#(3DJN&& N MT%BQ/ '2M/X>_$(^-I-8L;[1IM%U?19UAO;*282A-V[:0X !SM;MV[YH [2B MN'\9_$=_#GB33_#6A:%/X@U^_B:>.RBG6!4C&?F>1LA<[6QQV^F>9U#XM:EJ M_@'QA%8^'+C3O$VAVSB\L9+M ;9&1OWZ28 <( 6P "<#'4&@#UZBO'/V;M+- MMX%EU.70WL9=1VN^H/?^?_:.UI/WGEY_=$;BN._6I+/6],TOX[?$&ZAL+QM1 ML-&BN)G>\!AF5(8V"K'LRAY R6;N<#- 'K]%>,Q_M 7 \/Z;XDN_!%];^'+J M58)]3^UHPBDR0VQ,;G4$$;OE!((ZUT_BKXFW.D>-HO"?ACPU<>(]7^S?:[F* M*Y2!8(L]=S @GIQQU7G)Q0!W]%?/?PE\;6/AGPO\0_%.M17,$":V\S6S+^^W MN3B,CLV2 ?3GTKO=!^*=_<^*=,T7Q;X1N?#;:U&\FES27:3K<;0&*L% \ML$ M<'G) [T >CT5XX/CQJ-UINKW^E> [R]MM$N)(]1G6^1(X8T.-RDKEVP"2H'R MC&370:M\7;&WT/P[<^']+N=:U+Q*F[3M.CD6-FP,MOAT5 MYG!\8&7P[XHFU;P[-INN^&8EEN])ENE?>'Y MM3\&WVG:'K\L<%IJ=(_(!&<(K#]XV#]T$$G('0UP'P;\;V?@7X OJNHQ37>)I?#OBWPM/X*OB<='UK2M#\,Z%/XBUK5+;[7#:1SK;JD/.'=V!"Y MP<<=OIFOJOQ6N-+TK18I/">H'Q-K,LD-OH32HC!HSAF,I^4)T(;'(.<8S0!Z M+17'>!_'S>*M0U71]6T>;0M=TAD%W82S+,%5QE661M1>-OB+_ ,(O MKFF>']'T6?7M?U16>WL89EA 1W8]* .VHKR>3XM:IJ?AKQ796_A MBXT_Q7H=MOGTV6]3Y$8?ZY)<88(IW8P,\ =:R_V9]-=?!MQK%QHLEM-?G)U5 M[\S?VD1+*"3%G]T4P%S_ !=: /;**\-U.RU3QA^TCKGAM_%GB+2-.M=(CNXH M]*U%H '_ '2].1@^82>,YQS6IX+\4:SX5^(WB#P1XPUE]5LM/T_^T[/4KE1Y MHA&W$/"UQXEU.R@6>^"7:6R6ZL 0-S Y;!!QQU MXSS@ ]"HKR"36M.O?VA?#%Q>Z3J=EJ=QX;:=1-'[B=X(]6%Y&Y5E!.9(1\T8.,9)(Y% 'I5%>+> ? M%WAWPOHOQ%UU[:^MK>PUR9[H372SF:0MM'E@(FWHRQK4L_C-?P:CHO M_"6>"KS0=*UV1(K#4&O$FW,^-GF( #'G(ZG/MP: /5:*\KO_ (Q:F/$WB+0] M \$W6LW>A./-:.]2.-H]N2Y++\I]% 8G!KF_BC\1)_$GP4\-^(_"U]J.BG4M M9CMY3;7#12H-DRNFY2,C&^,XO$'P7;2O$5AXOUK7-%EODM MM1LM;N!Z_X5T_5M3TS^RKB\B$QLS-YIB4\KEMJ M\E<$C'&<=J\,^,NM^+;+XL7!\,ZW?VL>D:''JALHKEUAF"38?<@."-I).>H7 M% 'T517CGQ0\$_#&G>"K^>RO?$Z_:Q<6\A62"UCC\R0[AR#V[?=855\ M _$V3P[\ ]&UKQ%)?ZYJ5[>R6=K$93)/:6?Q& MO-7FUKPOXI\-S>&M;729;V&W>[2Y2:'!7S45P'B?XF76G>,CX4\)^&;CQ+K45L+JXA2 MZ2VC@C.,;G8$9Y'&.X]:S?\ A=MJ?AEKOBA=$GCO]!N4M;[29YPC)(TBQXWA M3QECSMZJ1@4 >HT5Y#/\=;NQU/2XM1\":K!:ZY&6T>59XVEO&XVJ8_X,EEZM MD!@<8K?\)?$ZXU_4O$.D:SX9N](UK0HQ-+8).MRTJ%=R[&4 %CQQT.X8)[ ' M?T5Y@/BWK&G^(M'LO%G@6[T.PUJZ6UL[R2_BE8NQ 4/$HRG)&^U[5V86EG'N<(,LQ) 50/4D@#ZT :]%>56?QFOX-1T7_A+/!5YH.E: M[(D5AJ#7B3;F?&SS$ !CSD=3GVX-:.E?%JVNM-\:3ZIIAT^X\)2R)/;?:-YF M50VQ@=HQO*D <]N>: /1**\O;XQ7,FD>&TT_PK/?>(O$5LUW;Z1%>*JQPC)# MO,R@ %1D?+ZCZI+\:4M_ 'B+6[OP_-;:OX6Y&5:2144B4*05^8D M';SM/UH ]1HKEO _BW4_%]I/?WGAJXT;3G2.73Y[BX1VO(VW?,4',>, X/4, M"*X+4?B'X^MOCU-X=T_P]]MT]++?'I_VV"/S$\S'VOS"N1QQY>S45YE< M_%K4G^(>K^$-!\&W&K7FF/$6ECO4C0Q,H+NQ9<*1N "Y);GIBF>*/BUKOA>. M\U.[^'NH?\([93^3-J4U[%$Y_>; ZP$%BI)&#D9!'2@#U"BO/O%/Q3.E:YI. MA>%M!G\1ZQJEK]MCMH[A;=4@()#L[ @9P>/;KR,^2^&]5CO]/^-VH:QIU[#% M-Y33V)F$4\>3."F[:P!'3."..E 'TW17S_J/C_Q5X=TOX9V7@O1I3I6H6L 2 M.>]@9[X[5'V!/[;T>\LMH(\-L M3'*6C90G[PC:PW!E'0X.* /7**\ENOC=>S0ZKJ?AKP5>:QX=TB9XKS51>QQ8 MVSTJW\(7.E:-=:Q!XI24VZP2!9490FU-I!!)9PI M^8!<$\T >ET5Y_X5^)]QK>L:[HFN>&+O1]:T6W^TO8I.MT9HR,C8R@ L/> 6/\ PTG\11DX,5MD9_V%KKO'/Q#_ .$2U+2]&TO1YM=UW5F;[)80RK%E M5&69G;(4?AV/I0!V=%>"_%'6]2UJ/P!\!AF5(8V"K'LRAY R6;N<#- 'K] M%>,Q_M 7 \/Z;XDN_!%];^'+J58)]3^UHPBDR0VQ,;G4$$;OE!((ZUHB_P!( MM_VFK[SK>ZCO8?#V^2[:['D"(,I(\K9D'WWX_P!GO0!ZK17FWA?XK:IXLOK: MYTOP1J#>&KJY-O%K/VE"USPQ'-JFI?#W48O#L%Q MY+ZC->Q)+][:&$'WL'C!)&IT5XWJ\XE_:X\,20N3%+X<9@0>&!:X(_I7 MI/BK7+_0=*CGTG0;S7;N:80QVMJRI@E6.YW;A$^7&X]R!WH VZ*\\\-?%*YU M75]MTT5Y]XF^*,^F^,8/"_A7PW<>)=4:T^VSQ MQ7*6ZPP^NY@-[MX9H#<:Y)*89QAXRV3M8=F'0^X MH ]IHKSSQ=\4I_#7Q"M?".G^&KG6;Z]T\7=L+>X5"[EW78P8850$9BY/'I2> M&?BN^OZ/KYE\,W]OKF@RB*ZT:%UGE9F.%V, 1D')Q@ 9Z4 >B45YKI?Q3UA MO&=KX9\4>"Y]#O\ 4;>6;3P=1CG6T/=86U[/K0![717S-\*OB;J/@7X.VUS+X2O; M_0[6]=;O4UN4C6+>XP$0Y+\G!^Z,G&:]<\5?$\:/K6E:%X;T2X\1:WJMO]K@ MM(IE@58<$AWD;AT5XMXE^(J^,?A1X[TN_TF?1-^# MT/I0!Z_17GGA[XM0WUQK]AXIT2X\/:MX?M&O;RS>9;@&!5W%T='H1\/)8K/Q')C3KF75XQYJ#!+%=AVD*<[203VS0![%17FVG_ M !AMY_"_C#4]3THV%YX5GDAGLC<[_-(R(R&VC&]@5Z'&,\UU>D:]J&K^ ;?7 MH]&*7]U8_:H=,-P 68IN2,R%0 3P,D<9]J -ZBOFOX07VI2>(O%?C'4?"-_J MFHPW4Z&\M]0\R17+(/L@ASA@-V=_0!:].T3XHZI-X[L/"WB[P?/X=N]3BDEL M7-_'IP7* M*0XQN\N(C,F,]CTP>]8WA_XA^/K[XX:YX?G\/>=IMM);H]K]M@7^SHF"YGW[ M=TNY3OV9R,X[4 >S45Y3??&B^EFUBX\*>"[S7=&T.5XK_4A>)"%*]2Z[\;['3M/\(WVD:+=:O#XH686Z12!)8Y$VJ(]N"&)=]IY&,$\T >H MT5YAJGQ8UK3;[1M"'@B63Q1J4$EP^E'5(42"-7=1^_(VN2$+ =_6O0=%U"; M5=%M;VZL)].FFC#26EP/GA;NI_Q[T 7J*** "BBB@ HHHH **** "O-OC)_S M(7_8YZ=_[4KTFO-OC)_S(7_8YZ=_[4H ])HHHH \V_YNF_[DS_V]KTFO-O\ MFZ;_ +DS_P!O:])H **** "BBB@ HHHH **** "O&['PSXX^&7C77[SP=H-O MXGT/7+C[5]E^WI:RVLA))&7X(^8CC.0%Z.]5U3PKXXATG3 MGU_1I)A/HR7>%>)R0H65OEWA2+_ (=^-="URUC_ +375K=H MO$B>;&IMG=]^]+?A;J&D>'[7[7?S20M'#YB MIN"R*3RQ Z ]Z[VB@#PGXG_"3Q#XC\::5=>'E,=CJEI#8:^R3(NV..1&W$$Y M8X4?=S_JQZ\]59>"]5L_VAI/$4-@L>@C0ULXIED3"N"N$V9W=!UQCWKTRB@# MYSC\ ?$S3/A;K7P[L=!L+BR>=Y8=4:_13/'N5@BQ]0Q*]6( !(]#77Q>!?$* M_%CX>ZRUB!8:+H9M+Z;SD_=2^1(FW;NRW+#D CWKUVB@#ROP+X?\6^$/B9XE MAFT6&YT#7=4FU'^UEO$4P!@[!/*^\QR57/ ')YKG/#7PEUUOV<=8\(ZY8+;: MO+,M1UYQIWC#7HA; MP2B=6\M(X@J'>A.TDDC(.1@&N,T?X/\ BJ/Q)X/U'_A"8],FTO4[>35;Y]:6 MYDO0KJS3;"VU -I^49;YNAKZ=HH \V\">$M:T;XM>.M:U*S$.GZK+"UE-YJ- MYH4-GY025QD=0*Y2+X<>-H]'^*$6G#^S;S7M6-SILHN5!GA\YW(W*24W*V.< M'G!KW2B@#YT\'?"KQ#IOQ1\+Z]'X(C\/6-F9!?\ _$X%Y([^6P\ULMP&+8"I MG&#GM73Z+X)\5Z=XF\<:#=:1#+X>\6W%W.=92\0&V6:.3"^3]YCEE'8#D\U[ M)10!\SZ!\$]0M([;2-:^&6FWUPDNV77W\02I"Z;OO>0C!L[>. .G2O?_ !?8 M:GJO@W5K'0;K[)J5Q:O';3[BNQR./F'(],CIUK9HH ^8M'^#_BJ/Q)X/U'_A M"8],FTO4[>35;Y]:6YDO0KJS3;"VU -I^49;YNAKT?P?X*U[2O%'Q/O+^R$4 M&O2AM.;SD;SAB;G )*_?7[V.M>K44 ?/\WPT\:K\#O".@II[33:;>32:KHB: M@L!NXFF=@OFJVWHWK_%GJ*@\*?"GQ)I5WXYEB\+0Z)::SX=GM-/L8M26Y$/J%W9Z@P1+F-I,;<]%)4%E[ M M7KNOZ!IOBC0[C1]B(HP /H!0!X5X;^$GB*ZT/QG87&GKX5TK6K58['16U'[8L$ZD-YA<9 M !*]N<-TX%5/!?PCO+'5]&BU3X8Z?:SV$T3W&N/K\LBR[""72!7X8XS@_+GM MCBOH>B@#P;QMX \8>)/&WVK2?"=CHVHQZAYD/BNRU,1[K<,=OF0?>9]NW)[D M8'!KV+Q5#?7'A:_ATFPL]2NI(]JV=\<0S@D;D;ZKD#/&<9K7HH \)\'?#GQ/ M8ZAXINH?#Z^%M*U'1YK6+0UU1;M9;EEP) ?NJ.HYQC..F:9??#7Q7-^RWIOA M"/3 VNPW!DDM?M$7R@W$C_?W;?NL#UKWFB@#R76_#7B_PM\8=1\;>$=$M_$5 MOK%DEOG!-?2?A9K-[\//&\?B86ZZWXLE>Z^S0N M&CMW&6A3=T)#]3].>]>Q44 ?-UG\)_'G_"$2ZY%-.L/M&O/<)=W4/GQJ=[.6;+E@I*@@ M9SSBO=Z* /,(O!VN)^T#8>)#9C^R(-!%H]SYJ<2Y/R[<[N_7&/>O/_&N@:KX M4^&?Q-?6H(K1=?\ $/FV&]DE^T1M/O& I.TX&1G!&.U?1]9^N:#I?B329=,U MVQAOK.7!:&5*O^&/A9X+\&Z@;[PYH,-K=X*B=Y))G0$8.TR,Q7(XXQ76T >/>*M \:^- MM1^'^K7OAN/39]*UH7-_;+?Q2^1"LD9W[LC=D(QPN2*U)_ ^JW_QOU[5[FW\ MO1-2\--IJW8D0GS&9,C9G=T!.<8]Z]-HH ^9-&^".J:?;IH^J_#73=6N5D(. MOOX@EBA9"Q(+0(P;@'' '0=\FOH;Q!;W9\*WMOHUE:7ES]G*0VEY_J9>,;&] MB,BM6B@#Q3X<_#_Q#IGC[4=5.@)X-T.YL6@DTJ/4Q>+/.3_K0!PHQVX(Q@<$ MXA\*^$/'.E_!WQ#X"U'P] @2RNDL;Z*_C87LDC$JH3C8.3RQ';@ENFD8(P!BB#D#+8/SYP,]\5[K10!XWX8\ ^)-.\'_$^QO- M/$=QKT]ZVG)Y\9\\21N$.0V%R6'WL8[XK@_$VB:Y:77PT\*P6=W)K^GZ3/)) M9Z;J,=G*_AYX5\;M"WBC1H;Z2%=L//&7P*LO#UQX7CLM5L+JVB2W74(7\Z*.(J9=V0JY)^[DGZUZ MYX:\(Z#X.TXV/AK3(=/@8[G$>2SGIEF)+,?J36S0!YYXC\+:Q?\ QT\'>(K2 MT\S2],MKI+N?S4'EL\3JHVD[CDL.@->3VGP-U'0KB]TVY^'=CXH5[AC9ZPVO M26BQQ'[HDB5@3CO@=SR>M?3=% 'E,_@+5X/C-X$U6PT^)-$T/2'LYY(IQMA( MAE144.V]A\R@'GCJ:T_ 7A;6-$^)GC_5M3M/)LM8N;9[*7S4;S519-QP"2N- MPZ@5Z'10!Y;XU\+>)[#XK:;X^\'Z9!K;16)L;K39+I;=V&6(97;Y?XN_IT.> M,[3? ?BJ_L/B'XB\06<%KKGBC39+2UTN"X5Q"! 8T5I.%+'Y1G..,]^/8Z* M.1^%6A:AX:^%^B:1K4'V>^M866:(.K["78XRI(/!'0UR$O@7Q"_Q7^(>M"Q' MV#6=$%I8R^F!M=AN#) M):_:(OE!N)'^_NV_=8'K70>(O#7B_0/C3)XW\'Z+;Z[#J.G"QN;:2]6W:$@K MA\MU'[M.F3]X8'!KUFB@#Y^LO@[XKU+X=^-M'UI+6TU/5-574+61)0T,K [C MC!+*I)8#<,]#BKGP]^&4^G>+]*O;SX8V/A_[ 2\VHG7I;II&", 8H@Y RV#\ M^<#/?%>ZT4 ?+O@@>-[[PKX\T3PEH-IJ=GJVIW5I+<27BPO:,Z[78JWWU*,, M8.00>M=-XK^"&HGPOX+2RL;;Q#)H%N\%]IDETUL+L.=QV29&W#%L9([>XKV7 MP]X5T7PK#=Q:!9"T2]N6NK@"1WWRMC+?,3CIT''M6O0!X7IWPQOXOA]XQATW MP):>&KW5+%+>TLX]8:[EE(+%M[NWEJ/NXQCOD]*T-;\ ^)+OX=_#;2[?3P]Y MHE_93:A'Y\8\A(UPYR6PV#_=)SVS7LE% 'CTWAKQUX0^*WB/6_"&B66LV7B- M(SYMQ>+#]CE48W.#RRY+'"C)&.1CGEH/@CXDG^!Z^';JWMUU6PUQ[Z&WEG'E MW<6T)CX$D=I]HBY N8W^_NV?=4GK M7O-% 'C^O>#_ !;HGCOP]XU\+:3!K4]KI":;>Z9)=K _ /S+(WR]_?[O0YXS M_B+\//%/CJ'P[XAU7P]I][?V#3+>: E^T:RPLV443@CYP!R<@9/IQ7N%% 'F M7PD\$GPU"K7PG]I2*.*WCU62^E< L6+L6* ?=QMYZY[4SQ[X4\2P_$ M_0_'WA#3X-8GL+1[*YTV6Y%NTB'>0RNWR@_O&Z^@X/./4** /(M$\%>*M1U# MQKXK\2V,%AJFO:8UA9Z5#<++Y*B/: T@^4DD+SGUZ=*Z?X/>'M3\*?"?1M&U MZW^S7]MYWFPB17V[IY''S*2#PPZ&NVHH \9U?1O'/A_X\ZOXP\.^$!KUE>Z8 MEE'_ ,3.&VP?W9+?,2>#'C&!G/6K?A_X;:]K6J^+/$?CQK:TU+Q#IKZ7!:6C M^8MG R;3ENA/"GCW]<#UNB@#YGT#X)ZA:1VVD:U\,M-OKA)=LNOOX@E2%TW? M>\A V\< =.E=YJ'ASQGX0^+NL^*_"6@V_B*RUZ"-)K=[Y+9[:1 !G+\%?E MSQD\XXQSZY10!Y0_A3Q=>_'+PYXLOK"U2*VT V]Y-#,#%'+'^*FDZ]%X3L_!RVTC-JUS8:F)(=2!_A6 ?#ZYZBO=Z* /"; M/X1^(-2\#_$+1=1BCT^?6=8:\TZ2257615DWJ6V$E0V,<\C.<<59N?#7Q"\= MKX7T/Q/X>M-!TK0[N&ZNKQ;])VNVB4J/+1>4R"?O>N<\8KVVB@#S#PAX.US2 M_B9\0=6OK,166L>7]AE\U&\["MG@$E<9'W@*X6]^%_C,_L\^'/#L&B^;K6GZ MV;R:S^UPC$?[[G>6V_QKT)/-?1-% 'C>N>'O'GQ5U'2;+Q7X>M?"_AZQO$N[ MF$Z@EW-=%00%!3@#!(Y]<\XQ53XE_#'Q-\3_ !5JMQ=Q_P!G6&DV/EZ%F:,F M[N"0S.V"2JG;M^;'\)]:]OHH \[B^'NG_$'PSHUU\5?#G_$]M+?R)4%XR@$' MEAY,FTAL!O;.*K/X$O9/CDVJ/IRMX;;PT=,,C2J06WX\O:3N/R]\8]Z]-HH M\&^&7PC\2^']6UZ;Q&GF1V6GS:7H)>:-]T3N[%QM/R\G^+!_>$=JIM\&?$FH M_ ?0-%NK&!-9TC4)+I]/N+@;+B-G;,?F1L0"00<@^O(-?0M% 'B?@7X;S6&H M:C?+\.;3PHQTR>WB/]N27LTLK@ ?,45,;LYYSCMFL4?##QQ%\$_#6AC3FEE ML=0EFU31$U!8#>0M(Q"^:K;>GO\ Q9ZC%?0U% '@'@7X6^(=$USQA=#PQ#H= MCJVA26UC91:BMR(Y6 'EEV;<22"23\OS<'L)K[X:^*YOV6]-\(1Z8&UV&X,D MEK]HB^4&XD?[^[;]U@>M>\T4 >2ZWX:\7^%OC#J/C;PCHEOXBM]8LDM[FS:] M6UDB= BA@S\$8C7\STX)P[WX7>++GX2>-Q=6\$WB;Q5?Q7AL()E"0JLZ/LWL M0N0-_.>PY)KW:B@#R/Q'X%\0W^M?"B:TL1)%X=Q_:;><@\C"P#NNT4 ?+MG\'?% MO]I>&[L^"H[*]T_4H)-2U-];%Q)>J'!:4(6VHHV]!\QR,#K7NOQ0\(3>.OAU MJ>@VV+?I.UVT2E1Y:+RF03][USGC%4OBA\+/%FL_$2\F\*0*=$\306T.LR" M:-/), YUOQ5H>NZ3X?M_$-CI]D+"?1 MI+XVA>-2QC*2 C&-Y[]AP<\9\_PLU,_!OQ9IVA^";70-2UA[3R=.AU5KIW6* M97R\LC[ 0"Y&W'OVKWJB@#,\-6<^G>$])LKM=D]M90PRJ"#AE0 C(Z\BO/O$ M_A_Q;IOQLL_&7AG18=;M9M+&G3Q->);M;GS"V\[OO#&#@9)Y''!KU2B@#S;P MCX2UK2_C=XT\07UF(M,U..!;2?S4;S2JJ&^4'<,$=P*\F\1_!SQMJJ:[%?>% MX]9UB>[>:U\12ZWM_=;@1$D!; ) (^; &[V!KZBHH \7U#P9XQ\/^,/"OB[P MUHT&L7%GH<6EW^G27B0,C*N-P<_+C)[9^[TYR,W3OAUXV.B_%(ZMIEN+_P 3 M)#)9I;7*&.1_WC.@);(VEPN6QG&1Q7O5% 'BNM^!/%D7@KX;W&D:7%>ZMX5: M*2ZTU[I(S)A4W*)"=O!7&D):6MEIDJ:@%NHW% MM*\'K+4]/U&:86NLMJ"1B". M50F7B;YF( SQT/\ >%:5]\+-:T^\^%-II<2WUMX9FD;4;D2J@3!FO::* /*;WP5XGF^*?C;6--'V*'5-!%GI]_P"9V?P=\6_P!I>&[L^"H[*]T_4H)-2U-];%Q)>J'!:4(6VHHV]!\QR,#K7U%1 M0!YMX1\):UI?QN\:>(+ZS$6F:G' MI/YJ-YI55#?*#N&".X%0_$7PGXC;XA^ M&_'7A"P@U:[TB.6";3I;@0&5'5AE7;@'#OU]NM>GT4 >.^,_#OCGQM;^$+R_ MT&VL[FQUY+J>U@O$?[-;#;RSD@.W#9V9[8%2R^!?$+_%?XAZT+$?8-9T06EC M+YR?OI?(C3;C=E?F4C+ "O7:* /!K[X:^*YOV6]-\(1Z8&UV&X,DEK]HB^4& MXD?[^[;]U@>M=+?> ]7U/X[:MK$]MY>AWWAY]/\ M8E0GS&P"-F=W3)SC''6 MO5** /(OAGIOQ&\%Z9IW@ZZ\-Z>^EV5P^[6O[0!5H6D9V"Q#Y]WS'!.!TR*\ MSUSX,>.-2T[4X+_PLFK:ZUR94\1RZWS-'NSL2 M@$\\MC _"OJFB@#RE/!6O M#XY>%O$)LA_9>G^'ELKF?SD^28"4;=N=Q^^O(&/>M'XS^&/$7BCPS86_AI&N MT@ODEOM.6[^S&]A .8_,R /Q]<]0*]%HH \!^'OPOU_0?'>O:I_PBD/A_2]0 MT"6UMK./4A=>5,S1X1G9MQ)V$Y^Z,@9J7_A6OBO_ (9:_P"$1_LL?V[]I\S[ M)]HBZ?:=_P!_=L^[SU_7BO>:* /']6\+>,?#7Q:3QEX3T2WUR.^TE-/N[:2] M6W:%AL^?+=1^[3IDGGCH:T_@UX0\1>%#XG?Q5;00W&I:F;I&MY T7OAGQWJ\C0Z-XD\331-!9P7(/DQ(^2AE4XRRDKD'''.,G'K\WA M71;CQ=;^*)K(-K-M;&UANO,?Y(B6.W;G;_$W.,\]:UZ /G3P=\*O$.F_%'PO MKT?@B/P]8V9D%_\ \3@7DCOY;#S6RW 8M@*F<8.>U=CX1\-^+_"WC[Q9:-HD M%UH?B"_N+]=56]13#O5V5/*/S,=Q5<\ TTA--O=+DNU M@OT4 >(/\ #SQ?K&B?$#7M:L8+?7O$]JD%KI4%PC^2 MB* JM)D*6PJC.<<9[X!+\/?%VC)\/O$VAZ;;W^L>'-,%E>:3+=+$7!C*G;)R MN1O<9SCIC->WT4 >%:GH?B*&V\>_$/QM;6FASWF@R:;::=YJW0BC( ^=E&UB M6"@?[QR*X_P)(O@[4O!>K^,?#>N/;W(CMM)N[C7([J&!Y5 +QVRJ&C4YS@DX M]R!7T[?V%IJNGSV.I6T=U:W"%)895#*ZGL17):'\'O 7AS6$U72/#EO%>1MO MCDDEDE\MNH*J[$*1V('':@#R/XL^$+FY^.=AH^F7 2Q\:+ =2MU."1 X+-[? M*N0>YW5]'QQI%&L<:A40!54#@ =JR)/"6B3>,(O%,MB'UJ&W^S1W32.=D?/ M7.T?>;G&>3S6S0!X7HWPY\;6?PL\;Z1:#^R]6U35WN;)AL;,R"__ .)P+R1W\MAYK9;@,6P%3.,' M/:OHNB@#Q?P?X>^(?PWNM7T'0?#NGZKI=_J;WEOJDU^L:P*X5?GC^^V%4<+W MSR:U%\/^+?#_ ,>M4\0Z7HL.J:-X@CM89[C[8D+6*HJ(S%3R_"D@*.%O#7AZSU?3]8NYI[756U!(OLHE0)EXVY8@*.!W!ZU* M_P )]P>&[F>;4[A9558S))'(2 Q!89#@8!/ S7M]% 'E7Q@\ M,:QXGFCMK3P/8^([4VNVWO!J M+JQN"S9; M;?&3_F0O^QST[_VI7I->;?&3_F0O^QST[_VI0!Z31110!Y3JNMZ5H/[3BW6N M:G9Z;;OX/$:RWEPL*,QO"0H+$#. 3CV-=E_PL?P1_P!#EX?_ /!I!_\ %5QN MJZ+I6O?M.+:ZYIEGJ5NG@\2+%>6ZS(K"\(# ,",X)&?'_\ P:0?_%4?\+'\$?\ 0Y>'_P#P:0?_ M !5'_"N/!'_0F^'_ /P5P?\ Q-'_ KCP1_T)OA__P %<'_Q- !_PL?P1_T. M7A__ ,&D'_Q5'_"Q_!'_ $.7A_\ \&D'_P 51_PKCP1_T)OA_P#\%<'_ ,31 M_P *X\$?]";X?_\ !7!_\30 ?\+'\$?]#EX?_P#!I!_\51_PL?P1_P!#EX?_ M /!I!_\ %4?\*X\$?]";X?\ _!7!_P#$T?\ "N/!'_0F^'__ 5P?_$T '_" MQ_!'_0Y>'_\ P:0?_%4?\+'\$?\ 0Y>'_P#P:0?_ !5'_"N/!'_0F^'_ /P5 MP?\ Q-'_ KCP1_T)OA__P %<'_Q- !_PL?P1_T.7A__ ,&D'_Q5'_"Q_!'_ M $.7A_\ \&D'_P 51_PKCP1_T)OA_P#\%<'_ ,31_P *X\$?]";X?_\ !7!_ M\30 ?\+'\$?]#EX?_P#!I!_\51_PL?P1_P!#EX?_ /!I!_\ %4?\*X\$?]"; MX?\ _!7!_P#$T?\ "N/!'_0F^'__ 5P?_$T '_"Q_!'_0Y>'_\ P:0?_%4? M\+'\$?\ 0Y>'_P#P:0?_ !5'_"N/!'_0F^'_ /P5P?\ Q-'_ KCP1_T)OA_ M_P %<'_Q- !_PL?P1_T.7A__ ,&D'_Q5'_"Q_!'_ $.7A_\ \&D'_P 51_PK MCP1_T)OA_P#\%<'_ ,31_P *X\$?]";X?_\ !7!_\30 ?\+'\$?]#EX?_P#! MI!_\51_PL?P1_P!#EX?_ /!I!_\ %4?\*X\$?]";X?\ _!7!_P#$T?\ "N/! M'_0F^'__ 5P?_$T '_"Q_!'_0Y>'_\ P:0?_%4?\+'\$?\ 0Y>'_P#P:0?_ M !5'_"N/!'_0F^'_ /P5P?\ Q-'_ KCP1_T)OA__P %<'_Q- !_PL?P1_T. M7A__ ,&D'_Q5'_"Q_!'_ $.7A_\ \&D'_P 51_PKCP1_T)OA_P#\%<'_ ,31 M_P *X\$?]";X?_\ !7!_\30 ?\+'\$?]#EX?_P#!I!_\51_PL?P1_P!#EX?_ M /!I!_\ %4?\*X\$?]";X?\ _!7!_P#$T?\ "N/!'_0F^'__ 5P?_$T '_" MQ_!'_0Y>'_\ P:0?_%4?\+'\$?\ 0Y>'_P#P:0?_ !5'_"N/!'_0F^'_ /P5 MP?\ Q-'_ KCP1_T)OA__P %<'_Q- !_PL?P1_T.7A__ ,&D'_Q5'_"Q_!'_ M $.7A_\ \&D'_P 51_PKCP1_T)OA_P#\%<'_ ,31_P *X\$?]";X?_\ !7!_ M\30 ?\+'\$?]#EX?_P#!I!_\51_PL?P1_P!#EX?_ /!I!_\ %4?\*X\$?]"; MX?\ _!7!_P#$T?\ "N/!'_0F^'__ 5P?_$T '_"Q_!'_0Y>'_\ P:0?_%4? M\+'\$?\ 0Y>'_P#P:0?_ !5'_"N/!'_0F^'_ /P5P?\ Q-'_ KCP1_T)OA_ M_P %<'_Q- !_PL?P1_T.7A__ ,&D'_Q5'_"Q_!'_ $.7A_\ \&D'_P 51_PK MCP1_T)OA_P#\%<'_ ,31_P *X\$?]";X?_\ !7!_\30 ?\+'\$?]#EX?_P#! MI!_\51_PL?P1_P!#EX?_ /!I!_\ %4?\*X\$?]";X?\ _!7!_P#$T?\ "N/! M'_0F^'__ 5P?_$T '_"Q_!'_0Y>'_\ P:0?_%4?\+'\$?\ 0Y>'_P#P:0?_ M !5'_"N/!'_0F^'_ /P5P?\ Q-'_ KCP1_T)OA__P %<'_Q- !_PL?P1_T. M7A__ ,&D'_Q5'_"Q_!'_ $.7A_\ \&D'_P 51_PKCP1_T)OA_P#\%<'_ ,31 M_P *X\$?]";X?_\ !7!_\30 ?\+'\$?]#EX?_P#!I!_\51_PL?P1_P!#EX?_ M /!I!_\ %4?\*X\$?]";X?\ _!7!_P#$T?\ "N/!'_0F^'__ 5P?_$T '_" MQ_!'_0Y>'_\ P:0?_%4?\+'\$?\ 0Y>'_P#P:0?_ !5'_"N/!'_0F^'_ /P5 MP?\ Q->?_'+P5X5TCX,:[?:5X:T>QNXOL_EW%M811R)FXC!PRJ",@D?0T >@ M?\+'\$?]#EX?_P#!I!_\51_PL?P1_P!#EX?_ /!I!_\ %4?\*X\$?]";X?\ M_!7!_P#$UY_\'_\ P:0?_%4?\+'\$?\ 0Y>'_P#P:0?_ !5'_"N/ M!'_0F^'_ /P5P?\ Q-'_ KCP1_T)OA__P %<'_Q- !_PL?P1_T.7A__ ,&D M'_Q5'_"Q_!'_ $.7A_\ \&D'_P 51_PKCP1_T)OA_P#\%<'_ ,31_P *X\$? M]";X?_\ !7!_\30 ?\+'\$?]#EX?_P#!I!_\51_PL?P1_P!#EX?_ /!I!_\ M%4?\*X\$?]";X?\ _!7!_P#$T?\ "N/!'_0F^'__ 5P?_$T '_"Q_!'_0Y> M'_\ P:0?_%4?\+'\$?\ 0Y>'_P#P:0?_ !5'_"N/!'_0F^'_ /P5P?\ Q-'_ M KCP1_T)OA__P %<'_Q- !_PL?P1_T.7A__ ,&D'_Q5'_"Q_!'_ $.7A_\ M\&D'_P 51_PKCP1_T)OA_P#\%<'_ ,31_P *X\$?]";X?_\ !7!_\30 ?\+' M\$?]#EX?_P#!I!_\51_PL?P1_P!#EX?_ /!I!_\ %4?\*X\$?]";X?\ _!7! M_P#$T?\ "N/!'_0F^'__ 5P?_$T '_"Q_!'_0Y>'_\ P:0?_%4?\+'\$?\ M0Y>'_P#P:0?_ !5'_"N/!'_0F^'_ /P5P?\ Q-'_ KCP1_T)OA__P %<'_Q M- !_PL?P1_T.7A__ ,&D'_Q5'_"Q_!'_ $.7A_\ \&D'_P 51_PKCP1_T)OA M_P#\%<'_ ,31_P *X\$?]";X?_\ !7!_\30 ?\+'\$?]#EX?_P#!I!_\51_P ML?P1_P!#EX?_ /!I!_\ %4?\*X\$?]";X?\ _!7!_P#$T?\ "N/!'_0F^'__ M 5P?_$T '_"Q_!'_0Y>'_\ P:0?_%4?\+'\$?\ 0Y>'_P#P:0?_ !5'_"N/ M!'_0F^'_ /P5P?\ Q-'_ KCP1_T)OA__P %<'_Q- !_PL?P1_T.7A__ ,&D M'_Q5'_"Q_!'_ $.7A_\ \&D'_P 51_PKCP1_T)OA_P#\%<'_ ,31_P *X\$? M]";X?_\ !7!_\30 ?\+'\$?]#EX?_P#!I!_\51_PL?P1_P!#EX?_ /!I!_\ M%4?\*X\$?]";X?\ _!7!_P#$T?\ "N/!'_0F^'__ 5P?_$T '_"Q_!'_0Y> M'_\ P:0?_%4?\+'\$?\ 0Y>'_P#P:0?_ !5'_"N/!'_0F^'_ /P5P?\ Q-'_ M KCP1_T)OA__P %<'_Q- !_PL?P1_T.7A__ ,&D'_Q5'_"Q_!'_ $.7A_\ M\&D'_P 51_PKCP1_T)OA_P#\%<'_ ,31_P *X\$?]";X?_\ !7!_\30 ?\+' M\$?]#EX?_P#!I!_\51_PL?P1_P!#EX?_ /!I!_\ %4?\*X\$?]";X?\ _!7! M_P#$T?\ "N/!'_0F^'__ 5P?_$T '_"Q_!'_0Y>'_\ P:0?_%4?\+'\$?\ M0Y>'_P#P:0?_ !5'_"N/!'_0F^'_ /P5P?\ Q-'_ KCP1_T)OA__P %<'_Q M- !_PL?P1_T.7A__ ,&D'_Q5'_"Q_!'_ $.7A_\ \&D'_P 51_PKCP1_T)OA M_P#\%<'_ ,31_P *X\$?]";X?_\ !7!_\30 ?\+'\$?]#EX?_P#!I!_\51_P ML?P1_P!#EX?_ /!I!_\ %4?\*X\$?]";X?\ _!7!_P#$UY_\)_!7A74?^$U_ MM#PUH]W]F\6W]O!Y]A$_E1+LVQKE?E49. .!F@#T#_A8_@C_ *'+P_\ ^#2# M_P"*H_X6/X(_Z'+P_P#^#2#_ .*H_P"%<>"/^A-\/_\ @K@_^)KS_P"$_@KP MKJ/_ FO]H>&M'N_LWBV_MX//L(G\J)=FV-@?\ "Q_!'_0Y M>'__ :0?_%4?\+'\$?]#EX?_P#!I!_\51_PKCP1_P!";X?_ /!7!_\ $T?\ M*X\$?]";X?\ _!7!_P#$T '_ L?P1_T.7A__P &D'_Q5'_"Q_!'_0Y>'_\ MP:0?_%4?\*X\$?\ 0F^'_P#P5P?_ !-'_"N/!'_0F^'_ /P5P?\ Q- !_P + M'\$?]#EX?_\ !I!_\51_PL?P1_T.7A__ ,&D'_Q5'_"N/!'_ $)OA_\ \%<' M_P 31_PKCP1_T)OA_P#\%<'_ ,30 ?\ "Q_!'_0Y>'__ :0?_%4?\+'\$?] M#EX?_P#!I!_\51_PKCP1_P!";X?_ /!7!_\ $T?\*X\$?]";X?\ _!7!_P#$ MT '_ L?P1_T.7A__P &D'_Q5'_"Q_!'_0Y>'_\ P:0?_%4?\*X\$?\ 0F^' M_P#P5P?_ !-'_"N/!'_0F^'_ /P5P?\ Q- !_P +'\$?]#EX?_\ !I!_\51_ MPL?P1_T.7A__ ,&D'_Q5'_"N/!'_ $)OA_\ \%<'_P 31_PKCP1_T)OA_P#\ M%<'_ ,30 ?\ "Q_!'_0Y>'__ :0?_%4?\+'\$?]#EX?_P#!I!_\51_PKCP1 M_P!";X?_ /!7!_\ $T?\*X\$?]";X?\ _!7!_P#$T '_ L?P1_T.7A__P & MD'_Q5'_"Q_!'_0Y>'_\ P:0?_%4?\*X\$?\ 0F^'_P#P5P?_ !-'_"N/!'_0 MF^'_ /P5P?\ Q- !_P +'\$?]#EX?_\ !I!_\51_PL?P1_T.7A__ ,&D'_Q5 M'_"N/!'_ $)OA_\ \%<'_P 31_PKCP1_T)OA_P#\%<'_ ,30 ?\ "Q_!'_0Y M>'__ :0?_%4?\+'\$?]#EX?_P#!I!_\51_PKCP1_P!";X?_ /!7!_\ $T?\ M*X\$?]";X?\ _!7!_P#$T '_ L?P1_T.7A__P &D'_Q5'_"Q_!'_0Y>'_\ MP:0?_%4?\*X\$?\ 0F^'_P#P5P?_ !-'_"N/!'_0F^'_ /P5P?\ Q- !_P + M'\$?]#EX?_\ !I!_\51_PL?P1_T.7A__ ,&D'_Q5'_"N/!'_ $)OA_\ \%<' M_P 31_PKCP1_T)OA_P#\%<'_ ,30 ?\ "Q_!'_0Y>'__ :0?_%4?\+'\$?] M#EX?_P#!I!_\51_PKCP1_P!";X?_ /!7!_\ $T?\*X\$?]";X?\ _!7!_P#$ MT '_ L?P1_T.7A__P &D'_Q5'_"Q_!'_0Y>'_\ P:0?_%4?\*X\$?\ 0F^' M_P#P5P?_ !-'_"N/!'_0F^'_ /P5P?\ Q- !_P +'\$?]#EX?_\ !I!_\51_ MPL?P1_T.7A__ ,&D'_Q5'_"N/!'_ $)OA_\ \%<'_P 31_PKCP1_T)OA_P#\ M%<'_ ,30 ?\ "Q_!'_0Y>'__ :0?_%4?\+'\$?]#EX?_P#!I!_\51_PKCP1 M_P!";X?_ /!7!_\ $T?\*X\$?]";X?\ _!7!_P#$T '_ L?P1_T.7A__P & MD'_Q5'_"Q_!'_0Y>'_\ P:0?_%4?\*X\$?\ 0F^'_P#P5P?_ !-'_"N/!'_0 MF^'_ /P5P?\ Q- !_P +'\$?]#EX?_\ !I!_\51_PL?P1_T.7A__ ,&D'_Q5 M'_"N/!'_ $)OA_\ \%<'_P 31_PKCP1_T)OA_P#\%<'_ ,30 ?\ "Q_!'_0Y M>'__ :0?_%4?\+'\$?]#EX?_P#!I!_\51_PKCP1_P!";X?_ /!7!_\ $T?\ M*X\$?]";X?\ _!7!_P#$T '_ L?P1_T.7A__P &D'_Q5'_"Q_!'_0Y>'_\ MP:0?_%5Y_P#\(5X5_P"&DO[,_P"$:T?^S_\ A$OM'V3[!%Y7F_;-OF;-N-VW MC.,XXKT#_A7'@C_H3?#_ /X*X/\ XF@ _P"%C^"/^AR\/_\ @T@_^*H_X6/X M(_Z'+P__ .#2#_XJO/\ _A"O"O\ PTE_9G_"-:/_ &?_ ,(E]H^R?8(O*\W[ M9M\S9MQNV\9QG'%>@?\ "N/!'_0F^'__ 5P?_$T '_"Q_!'_0Y>'_\ P:0? M_%4?\+'\$?\ 0Y>'_P#P:0?_ !5'_"N/!'_0F^'_ /P5P?\ Q-'_ KCP1_T M)OA__P %<'_Q- !_PL?P1_T.7A__ ,&D'_Q5'_"Q_!'_ $.7A_\ \&D'_P 5 M1_PKCP1_T)OA_P#\%<'_ ,31_P *X\$?]";X?_\ !7!_\30 ?\+'\$?]#EX? M_P#!I!_\51_PL?P1_P!#EX?_ /!I!_\ %4?\*X\$?]";X?\ _!7!_P#$T?\ M"N/!'_0F^'__ 5P?_$T '_"Q_!'_0Y>'_\ P:0?_%4?\+'\$?\ 0Y>'_P#P M:0?_ !5'_"N/!'_0F^'_ /P5P?\ Q-'_ KCP1_T)OA__P %<'_Q- !_PL?P M1_T.7A__ ,&D'_Q5'_"Q_!'_ $.7A_\ \&D'_P 51_PKCP1_T)OA_P#\%<'_ M ,31_P *X\$?]";X?_\ !7!_\30 ?\+'\$?]#EX?_P#!I!_\51_PL?P1_P!# MEX?_ /!I!_\ %4?\*X\$?]";X?\ _!7!_P#$T?\ "N/!'_0F^'__ 5P?_$T M '_"Q_!'_0Y>'_\ P:0?_%4?\+'\$?\ 0Y>'_P#P:0?_ !5'_"N/!'_0F^'_ M /P5P?\ Q-'_ KCP1_T)OA__P %<'_Q- !_PL?P1_T.7A__ ,&D'_Q5'_"Q M_!'_ $.7A_\ \&D'_P 51_PKCP1_T)OA_P#\%<'_ ,31_P *X\$?]";X?_\ M!7!_\30 ?\+'\$?]#EX?_P#!I!_\51_PL?P1_P!#EX?_ /!I!_\ %4?\*X\$ M?]";X?\ _!7!_P#$T?\ "N/!'_0F^'__ 5P?_$T '_"Q_!'_0Y>'_\ P:0? M_%4?\+'\$?\ 0Y>'_P#P:0?_ !5'_"N/!'_0F^'_ /P5P?\ Q-'_ KCP1_T M)OA__P %<'_Q- !_PL?P1_T.7A__ ,&D'_Q5'_"Q_!'_ $.7A_\ \&D'_P 5 M1_PKCP1_T)OA_P#\%<'_ ,31_P *X\$?]";X?_\ !7!_\30 ?\+'\$?]#EX? M_P#!I!_\51_PL?P1_P!#EX?_ /!I!_\ %4?\*X\$?]";X?\ _!7!_P#$T?\ M"N/!'_0F^'__ 5P?_$T '_"Q_!'_0Y>'_\ P:0?_%4?\+'\$?\ 0Y>'_P#P M:0?_ !5'_"N/!'_0F^'_ /P5P?\ Q-'_ KCP1_T)OA__P %<'_Q- !_PL?P M1_T.7A__ ,&D'_Q5'_"Q_!'_ $.7A_\ \&D'_P 51_PKCP1_T)OA_P#\%<'_ M ,31_P *X\$?]";X?_\ !7!_\30 ?\+'\$?]#EX?_P#!I!_\51_PL?P1_P!# MEX?_ /!I!_\ %4?\*X\$?]";X?\ _!7!_P#$T?\ "N/!'_0F^'__ 5P?_$T M '_"Q_!'_0Y>'_\ P:0?_%4?\+'\$?\ 0Y>'_P#P:0?_ !5'_"N/!'_0F^'_ M /P5P?\ Q-'_ KCP1_T)OA__P %<'_Q- !_PL?P1_T.7A__ ,&D'_Q5'_"Q M_!'_ $.7A_\ \&D'_P 51_PKCP1_T)OA_P#\%<'_ ,31_P *X\$?]";X?_\ M!7!_\30 ?\+'\$?]#EX?_P#!I!_\51_PL?P1_P!#EX?_ /!I!_\ %4?\*X\$ M?]";X?\ _!7!_P#$T?\ "N/!'_0F^'__ 5P?_$T '_"Q_!'_0Y>'_\ P:0? M_%5PGQ/\6>'->NO MKH>OZ7J5PGC#3Y&BL[V.9U4%P6(4DXR0,^XKN_^%<>" M/^A-\/\ _@K@_P#B:X3XG^$_#F@W7@6ZT/0-+TVX?QAI\;2V=E'"[*2Y*DJ M<9 ./84 >OT444 >;?\ -TW_ ')G_M[7I->;?\W3?]R9_P"WM>DT %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YM^ MT'_R0GQ#_P!NW_I3%7I->;?M!_\ )"?$/_;M_P"E,5 'I->;?M!_\D)\0_\ M;M_Z4Q5Z37FW[0?_ "0GQ#_V[?\ I3%0!Z31110 4444 %%%% !1110 445C M^+X+ZY\$:Y!I&_\ M"73KA+7RSAO-,;!,'L=V* .>U'XT?#W2M6?3+WQ/;+= M1L4<1QR2(K#@@NJE01CUKMHI4GA26%P\$Q+:6YCUK2=9#B[FGW '9$"-_)8DGMCTQ5CXL^,;F/5K:VTK4]9T^X@T2& MY-O8ZY#I=K&6!(*JX+3'D#RQS@8% 'T?59]2L8]3CTY[VW6^EC,J6IE42N@. M"P3.2 >^,5\\>*/%FNW?P_\ !FI77BRXM=VEM&QU'XP^#=9U/Q?K-E!JF@0W2W4MXMJS.H51$HY"B0KN:,$Y9VP>: M /H^BOFG5KCQ/<^'_B/XDB\:Z[:MX=\0W$5A9P71$0 F48;/++M( 3(48Z') MKJ-'O-<\*?$[1(]2\5:MK-KKNAS7MY%=.I2*5$W[H4QM0<8"C\2: /;J*^6? M OCG69_B?X8^QZ[K=Q8ZI>*U^%OB+ MQS'XWUU+K1=;DAM;,7&8"AG12'!R7_UG )P ,8H ^G:R]9\2:3X>ETZ/6+O[ M.^IW:65H/+9O,F?[J_*#C/J<#WIEKXHTFZ\0+H*W0&K&Q6_-KL;*PE@N[=C; M]X@8SGVKSKXPZI87'BWP!I%O>P2ZE#XHLYY;..0-+''G[S(.0.1R: .]U_QS MX<\+ZMIVF:[J:6EYJ;[+6,QNV\[@O)4$*,L!EB!^1K3U;5;+0M'NM4U6<6]E M:1&6:4@G:HZG !)^@&37S?XWU8>,_$WCR9/#?B'6%2W32-(O-+T]IH;=X'\Q MR[@C&90IX!.W]=KQA\1%\8?"OP78):7FISZ]/&VJ6>G0&:>2*V8&=508Y+*" M,GIF@#VC2?%^A:YX6;Q'I5^MQI2)([7 C==HCSORI 88P>,9KGM(^-?P\US4 MHK#3O$T!N)F"QK-!+"&8\ !I$49/IFO-O"/B-8KOXE^'FTK4]&MM0LKG6=/L M]5MC;S*'C*S?(2>-V,8/13[XS=8\1>%KW]EO2M!^VV5_K[6T,5G8P.LMS'-Y MH_A4[D.,]<9Z- M;Z:S\,ZU%>W,"[WB\MXVVYP6 =1N&2.1GJ*M3W5IH?P_2Y\8O$8+.QC:_:9 MZEE4;N.Z?XX\?:MXX35-,L]2N]/DL=$T6*\B-UL5#^]E16S MOX/RXX'7H#0!Z1:_%;P1?>*?^$=M?$5M)JAD,2Q!7VL^<;1)C83GC .35^\\ M=^&;#Q5:>&[G6(!K%VVV*S0,[9QG#;00G'3<1FOGBQU+0[WX)^ O#^ERP/XA MB\0Q%[%"/M,;B:3<[+U (*\GC&/3CM?B=JGAK3OC7X!>*^TJTDM;^ZEU1EFC M0PLR0[6FY^4D#@MU H ](\4?$SP?X+OX;+Q+K<-E=3*&6'RWD8*> 2$4[1[G M%='97MMJ5C!>V$\=Q;7""2*:-MRNI&00?2O"_B(#H'C?Q)KVE>*_":1ZUI4< M5Y8ZP[/.(Q'M!@1?O[@,XZ$GD=Z]!^"UA>Z9\&O#MMJ:NEP+=I-KC!5'D9T! M'^ZRT =U1110 4444 %%%% !1110 5YM\&_^9]_['/4?_:=>DUYM\&_^9]_[ M'/4?_:= 'I->;?!O_F??^QSU'_VG7I->;?!O_F??^QSU'_VG0!Z31110 444 M4 %%%% &7XC\2:3X2T.;6/$%W]DL(2JR2^6[X+$*.%!)Y([4W5_$^CZ%J.F6 M.JWGV>YU:;R+*/RW;S7XXRH('4,-"\5: M/\3/ATWBKQC_ ,)&DFL8A3^RXK3R2"F3E"=V>.O3% 'T!17@'A_Q/J$/QT2# M4?%MYJ45]J5Q#;P66HQR6Z( P$,MH0'B92/]9R#COR:Q)/B)=1?!A[*7Q7\CD"KY01 M6P03G.>/3'O7@OQ.\8>*I?BMKNE6NJ7>G0Z;'"+!(O$-OI48+1AM[B;_ %X+ M'H", 8[UL7>GZOXO^*7@B+4=;N-+OKOPIYEY>:3-'O?));RY5W*-QP=RY&.G M!H ]_K+7Q)I+^*W\-+=YU>.T^VM;>6W$.X+NW8V_>(&,Y]JXWX)ZMJ>H^%-7 ML]9U&XU*;1];N=.2ZN6W22)'L(+'J3\W?-N>/:@#W.H;RZ2RL9[J8,8X(VD8*.<*,G'Y5\[7TGB M/1OV<#XR/C/7KK5;^&TQYEV0EN!,H&P#G)7AB2=W.>M=$T.M>$?B;=>'[KQ3 MJVNV6J>&[F[E7490PCG7(W( ,(N ?E'KWXP >K>%/$MGXP\+V6O:9'/%:WJ% MXTN%"N &*\@$CJ/4U%9>,] U#P_J.MV=_P"9IVEM,MW/Y+CRC$,R<%O(]"T+Q5>?"?QUJ&E>,?[.TB*XU0W&E?V7%+YX5 M"7'G,=R[AQQTZB@#Z.T?5['7]'M=5TB?[197<8DAEV,N]3WPP!'XBKM?+NL> M*=5E/"_:9 50#.<=\X]*T!X@\:77@/ MPK;7'B.:UN;SQ/_#T?Q"\3+9^&;..^M9&N\S2R MO!Y@#R8SL!!&P8!SVQ6OK^O:AXR^$/@7PY).7U/Q@\$-W+D!C!'AYY./]U<_ M4T =_;?$S2+3X?:5XI\820^'DU*$2QV\DIF;!Y7;A0SY7!X7C-:/A7Q]X7\; M1RMX7UB&_,(S)&%:.1!G&2C@-CWQBO.?&DNF>'_VB/"5[XC,%IH,6CO!92W. M!!!<*S]SPIVE!D^U0QZCIOB']H^35O!=Q#68 M[/O,2><=@:Z,Z^VK?$_Q)_PD7Q"O?#4VBZC'!IFEQ3K'%/'Q@M"1F;=QTY&< M],4 >RZ_XBTGPMI,FI^(+Z*QLXR%,LI/)/0 #DGV'-9OA_XA>%/%&CWFJ:'K M5O<6=B-UU*X:+R!@G+!P"!@'DC'!I/'OBG0O!GAA];\2(DL5M(#;QE SO/@[ M53/1L;N>PR>E>%7.GPW7PA^(7B"VUC2KKQ%KXBO;K3M+O(YOL-NLZL4.PG)V MLVYO_KD@'N/ACXE^#_&6HS6'AO6X;VZ@4L\7EO&Q4'!*[U&X>XSU%6-*\>>& M-<\377A_1]8@O=3M(C--# &944,%/S@;206 (!R,]*\MLM4T'Q!\:OAPW@Z> MVNHK#2+DW8M"#]GB,!6-9,="&.-IY!/O2>&]8\+V?[4-XFDZCI%OI[^'TLK5 M;6>)86F,T6(4VG!?@_*.?:@#L[[XZ_#G3=1N;&]\1>5P3QW-O'/ VZ.5 Z-C&01D'FO*_B3(?&_Q%T#X=6S;K)&&JZV!T\E M#\D9_P!YNH]U->L !5 48 X ':@ HHHH **** "BBB@#S;_FZ;_N3/\ V]KT MFO-O^;IO^Y,_]O:])H \V_YNF_[DS_V]KTFO-O\ FZ;_ +DS_P!O:])H *** M* "BBB@ HHHH **** .$?XV?#R+6Y=)F\210WD,S02++;S(JNI((+E O4=*_'NB>,O#UA>:/9>&[GQ5331R/>"17C8[ /D MVX"=<'.[M5[7-6\_Q7XNT_6_B%J/A5?#<$46CV5M>"V$X$60S*>9B2%^4<_- MZ8H ^AZX2[^+N@6>DZQJ$EKJ+0Z/J_\ 8\X6)-S3;@N5R_*9/4X/M7FM]XNU MK6[#X;V?BOQ1>>%['5[&:XO]2MIA:O,Z#Y,R'A-PVGT._ITKE5:-_A'XP>&_ M;4HV\;(R7KXSM2O$=>\0:Q#XH^,44.JWL<>FZ1;262+<.!:L;;<6C&?D)/ M.1@YKG_#'B>]3Q1\/KG2?'^H>(;_ %P+'K&DS7(EBMU\L%OW8_U97YN3RVW. M>N0#Z.KF]7\?:#HSZW#-<2S7>AV7VZ\M886WK%C((+84D^F[ZXKP:YO/%:_" MWQ%XYC\;ZZEUHNMR0VMF+C,!0SHI#@Y+_P"LX!. !C%=/XMUF_OM<^*-I->7 M+6,?AB*6&T>9C'$S19)5>@)SR0.: /:-$U6#7M T_5[-)$M]0M8[J)90 ZJZ MA@& )&<'G!-1:]XCTKPS9P76N77V6&XN$M8V\MGW2/\ =7Y0<9QU/%>0?!K6 M-0OO$MAI_B/4+JR>Q\.V1T?2HI2MM]:^N>./#OAOPW;:]K>I"UTVZV>3,8G8OO7,ZC<7<'[07CK['\0[#P23'8[I+VW@E%U_HZ<#S6&-OM_>K3^)'B> MSU?XK:3IC:+JWB31])L)+JZ@T2U^U%Y+B,I'NP0-HC.X'/.[O0!ZM-XT\/P7 MVB6DNHJ)=?0OIF(W*W("AN' VCA@>2,Y%2:CXKT72=;MM(O[WRK^Z@EN(H1$ M[9CC&78E00H !ZD9Z#)KYYL9[[5O@*_EQ3P^(/AUJBW,4=W'Y-?'T2L;&+3?[)TLOU"B+S)O\ Q]AS[F@#K-+^-_PZ MUC4([*R\3P>?*0J">"6%23T&Z1 OZUW%S./7.#[OIN MS2_AK9CQ@T92VTF-=3:Y 9#MB EW#G(X;(YS0!4\-_%#P9XNU>32_#VNPWE[ M&I8PB.1"P'4J64!OPS3$^*W@>3Q5_P (XGB*V.J>;Y(AVOM,F<;/,QLW9XQN MSGBO-O"FJZ-\0_BTOC1=4TO3OL5K)I^@Z6;J);NX.UU,KQ@Y P[ +CI@]LGB M;74='N/V?=!\.6\L+>*AX@ >R!'VGSOM#_,5^\/D*C<>.U 'T=J/CSPQI/B6 MS\/WVL0)JU[((X;10SN6/0-M!V9[;L57\5?$GPCX*NH;;Q/K45E<3KN2+RWD M?;TW$(I('!Y.!Q7F_P 6]2\.:?\ %/P,4O-+M;JWUGS]4(EC1XP5CVO-SD?+ MC!;M[4SX@,-$^(&H>)]&\6^$XEU31DAN;36G+N8"#AX%0Y?>? >PO=.^"N@PZBKI(R2RHCCE4> M5V3\P0?QKT.@ HHHH **** "BBB@ KS;XR?\R%_V.>G?^U*])KS;XR?\R%_V M.>G?^U* /2:*** /-O\ FZ;_ +DS_P!O:])KS;_FZ;_N3/\ V]KTF@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH S?$FK'0/"NK:P(O..GV4UUY><;_+ M0MC\<5X0^H0Q^&-(\3?$/XK^(M$U/7H6NK.WTSS!:Q)D$+Y2(P; 9>I'XXS7 MT)=VL%]9S6EY$LUO<1M%+&XR'5A@@^Q!KR6Z^!^JG09_#.F_$"_M_"TQYTN> MQCG9%W;MJS$A@,]@* +GBWXR0>$=1L=$L;2'6[YK&.[GGNM2ATZ/81P0TO!< MXSL'.#1>_&Q&TOPC=^'?#=UK$GBA;D6]LMPL4D4L. 4.001N)!;(P 6YZ4OB M_P""<'B'6+35M,U>&PO8+*.RD^VZ3!J$4J)T;RY1A6]QV_'.C:_"YH+WP5=2 MZM;F3PL;IF6VTR.VCNS. #A(R%BQCL#F@#$\4_&K5O",B#5O!D4 2WBFN%FU M^VCD5F4%ECC/S2[22N0!D@]JT-5^+E\GB:#0_#'A"ZUVZNM(BU6$)=I#B-SR M'W A<#'.3DD#%9OC/X#1^*_%&L:O%X@2T35T7SXIM*AN71U0*ICE;YHQP,A< M$],],=3H/P[_ +$\/+'S=2;^SY+-=ES?>; N^-C^ZBV#RON\_,VX\\5F6WP9%O\,='\(?V[N&F: MHNH?:_L>/,Q(S[-F_C[V,Y/3I4FN> ]*VM(X5C(MS8; 4 M:3S=V6PK%OE ;C !H [3Q?K;^&_!>L:U%&)9+"REN$1NC,JD@'VSBO//A]X3 M\1:YHNA^,M3\?:Z]_>>5>2V:R+]B:(L&,/DXP,K\NX'@G(%>DG18KKPO_8FK M.U_#)9_9+EY3EIP4VL2?4\G/O7#>&_A;K_AF>RLK/XA:DWAVRG66+3&M(]Y5 M7W",SYW;#T*@ $$CB@#GO"]IK_Q:U+Q%K5UXQUO0[.PU673]/LM)G$*H(PIW M2<'S,AAD'OGG& ,#Q[KD.E_%6ZTOQ?\ $'Q'HMI;:+ T$FE3R1BXN<8),:!E M&[D]O3=7?2_"75-,\0:G?>!_&UYX6(LH[E#(?O-&6(V$^H!/X "M M>U^&UNGB^_UC4;]M2@OM&CTF>UN8MS2!<9D9\_,6QR,=3G- #_A)>>(+_P"% MVCW?BYI'U*:-G+R@!WC+'RV;'-M:U'Q'JFI M[O[(,@%I':9)),*C"JO"EFSD!CQBO4/ 'A.X\$>$XM!FU5M4AMI7^RR/#Y;1 MQ$Y6,_,=V"3SQQ@8&*XB'X0>+=/\6:MX@TCXD?9;S4Y"9))="BN'5,Y6,.[D MA0,# P.!QP* ,G7I/$/C'Q/X_N+;Q5JNB6WA*%1I]MIT_E)+*(FD9IL#YP2O M3T/MRSQQKWBG4_V<;'QA;>([G3)TL;=YX[%!$]Q*TT<9ZGX@U?4="\7W6B1:_!'#K%M'9I*+H*NW*L2#&2">1GJ?7%3>,?A1 M=^(/ ^G^$-"\2G1-#MK=8)[9K!+@W.QE9&+EE92"F3@\D\T 9GQ0EU^;P+X2 MDTA_$KK)/[B#5;%SLU&/3(@DD6 !&\!) M5L <'.:N^ O 4?@FWU&274I]6U/5;G[3?7TR!#*_L@X4.9_ >BZ=>6>C_VQ17(.XJ1U3'.. MO6@#KZ*Y70/%.KRV-Q<^.] @\(JDJ10?:-6AG6DZK97TENVV9+:X20Q'T8*3@_6@"_17GWC'XFV^DZKX=L?#=]I.HS7^O M6^F7\8F$KV\O(H UZ*H:IKVD:' D^MZK9:=%(<))=W"1*Q]BQ&:R_$7BP:3IFE7VE M166IPZC?Q6JN^IQ6Z;'S\Z._$A&.$7ENW2@#HZ*R+OQ9X=L))([[7]+MGCE$ M#K->QH5DQG803PV"#CK63KWQ-\,>&_%FF^']7U"*"XU"-Y//>:-8;=57<#*S M,"F[HO!R: -6[\(>&[_4/M]]X>TJYO,Y^TS64;R9_P!XKFIK_P .:)JES!<: MGHVGWDUN,0RW%JDC1#T4D$C\*LP:C975Y6\US:%1<0QRJSP[AE=Z@Y7 M(Y&>M>=^,?C+#X.^)5EX8N]%>:TFBAEN-26YVBV623R]S)MY4';D[AU_, [: MX\)>'+NSM;2[\/Z7/;68Q;0R64;)!_N*1A?PJQ>Z#I&I/:OJ.E65VUFP:V:> MV1S 1T*9'RG@=/2N$^*OQAA^&EQ9VT6C/K%Q/"UQ,BW'DBWB#! Y.UNK' Z= M.M=SJ?B'1=$DACUG5[#3WG.(EN[E(C(?]D,1G\* ^'=%:UO;5M'L#;ZA(9; MR(VJ;+ER?R%WPH>"JMC*CV'%'M*@N%E\X3164:N),$;\A<[L$\] M>34K>&]";2[C3&T73S87,AEGM#:IY4KY#;F3&&.0#DC.0*B?Q=X;CG2%_$&E M++),T"1F]C#-*IPR ;N6!X(ZBK&K:_H^@QI)KFK6.FI(<(UY.PJ MG_PFGA;["M[_ ,)+H_V5Y/*6?[?%L9_[H;=C/MUH T=/TRPTFV-OI=E;V4!< MN8K:)8UW$Y)PH R>YJK8^%] TNZ2YTS0]-L[A P66WM(XW4,&ZMTGMI4FAD7H(X(H M JW6B:5>WRWM[IEG<72PM L\MNKR"-LADW$9VG)R.AR:J:;X.\,Z-="YTCP[ MI-A<#I+:V,43C\54&N0\)_%74?&.I13:3X.NW\-S736T>L"\C8AA_$\ ^95] M\]Z[";Q=X;MY/+N/$.E1/]H:UVO>QJ?.7&Z/!;[XR,KU&10!HWMC::E92V>H MVL-W:S#;)!/&'1QZ%3P:R].\%^%M(OH[W2?#6CV-W'G9<6UA%'(F00<,J@C( M)'T-6]5U_1]"6-M;U6QTY93MC-YM_J>IV=G9OC;<7 M%PD<;9Y&&) YH B@\-Z%;:N^JVVBZ?#J,F=]Y':HLS9ZY<#)_.JU_P""/"FJ M7TE[J?AC1KRZE(,D]QI\4CN<8Y8J2> !5:]\81VOB;2K&);"73;ZUFNGU!M4 MA3RD1=V5B)W2*>[+PHY->?:+\:-7U?\ MS4[6U\.W.EV=Y]EM+0ZNEK=,/," MB61Y#LV,"2N ,D8&>M 'J-UX6\/WUW!=7NA:;<7%LH2":6SC=XE'0*Q&0!Z" MM6L_4=?T?1YX(=6U:QL9;@[88[FY2-I3Z*&(S^%9OCOQE:> _"5QKM_!)>NZY4+N+1C.7 7G(SQS0!= MHK#D\;^%(HS)+XGT9$"ERS:A$ %#["<[N@;Y<^O'6K&J^(+#2[?#7EF;R:WE MFM+66[2)KKRT+G:6/0#DMT Y/% &I16!X<\5VFM:;IK7DMA9ZG?VWVA=/BU" M*Y;9D@LC(<2+Q]Y>*L7'BWPY9PSS7>OZ7!%;SFWF>6]C58I1UC8D\,/[IYH MUZ*X3QU\0&T+1O#FH^&9=/U*#5];MM.:;?YL?E2!]S(R,!N^48.2/:N[H *\ MV^#?_,^_]CGJ/_M.O2:\V^#?_,^_]CGJ/_M.@#TFO-O@W_S/O_8YZC_[3KTF MO-O@W_S/O_8YZC_[3H ])HHHH **\WUOXE>(H/B!J/A;PKX(_M^73H(IIIO[ M6CM<"101PZ^^.":ZT>*M,LK&%O$E]I^BWPM8[B[L[F^CS;;N,%L@$!LJ&Z$C MB@#;HJC+K>E0:0-5GU.SBTXJ'%X]P@A*GH=Y.W'OFN.T#XDQ:KX^\6Z?<7>E MIH.B6]I-!J"2C:ZRQ[V9I"VS:#P",?C0!VNHZ98:Q8O9:O8VU]:R$%X+J%98 MVPGW]Q:W%_8VUS-9OYEM)-"KM W]Y"1E3[BH+3Q#HM_J,FG MV&L6%S>Q+NDMH;I'D1?4J#D#D4Q_$^@1ZP-)?6]-74B<"S-W&)B?]S.[]* ' M6_AS1+35I-4M='T^'49<^9>1VJ+,^>N7 R?SJ*;PEX&-!UZ1'US1- M-U)XQA&O+2.8J/8L#BIHM$TJ"ZMKF#3+..>T@^S6\J6Z!H8O^>:$#*K_ +(X MKGO#/Q1\*^*[C5H=.U."-M+FECE\^>(>;'']Z=,.VL5U93 MQW%O,H>.6)PZ.IZ$$<$>] $5CIEAI:3+IEE;6:SRM/*+>)8Q)(WWG; &6.!D MGDXJM9>&M"TR.YCTW1=.M$O 1N\ ?-U/6O*M+^/>IW.C6'B#5/ MD]GX;O+D6PU*'4XYRC%BO,6U6QD'KCVS7JVH>(]$TF\AM-5UC3[*YG_U4-S= M)&\G;Y58@G\* '2^']>5='FTBQDTM0 MB]LA@ !R (\;>#STJ6;2=.N-0% M]<:?:RWBPF 7#PJT@C/5-Q&=I[CI4>IZ[I&B"(ZSJMEIXF;;%]KN$B\P^@W$ M9/TIZZQICWD]HFHVC7-M&)IX1.I>)",AF7.0I'<\4 26-A9Z78QV>F6D%G:Q M#$<%O&(T09SPHP!R:AAT32K:PN;&WTRSBM+HNUQ;QVZ+',7&'+J!AMPZYZ]Z MA;Q1H"V=M=MKFFBVNP[6TQNX]DP0$L4;.&P 2<=,5$WC'PPL:NWB/20CJCJQ MOHL,KDA"/FZ-@X]<<4 3S^&]#NM(BTJYT;3YM.A $=G):HT* =,(1@?E4<'A M3P[;6MO;6V@Z9#!:W NK>*.SC589ATD4 85_]HF$SN/Y5'>^*O#VF2W$6I:]IEI);,BSI/>1QF(N,H&!/REAR,]1TH M L_V+I9N;RY_LVS\^_01W +2W^(=GXDCEBB MM=.TTV&GZ9#;"..U+-EI%(.,D';@ <5OW^MZ5I6GK?ZGJ=G9V;XVW%Q<)'&V M>1AB0.:CO?$>AZ;I\-_J.LZ?:6<^/*N9[I$CDSTVL3@_A0!8U'2M/UBT-KJ] MA;7UN3DPW4*RH?\ @+ BF:=HVEZ/9FTTC3;2PMB23#:P+$ASU^50!5F">&ZM MTGMI4FAD7H(X(KS;P]\3_$_B?Q!=6VC^ O.TFRU=],NM3_MB)?*V M. [^4R!CA6#8&<] 5$^2VY4QA3DDY MSDFG7/A[1KS58M3N](L)[^''E79/+E:TLXXBZ_W25 R/8U(/$>B-K)TA=8T\ZF.MD+I/.'_ #.[]*S/'WC M6U\!>%GUB[MI+MC,D$%O&P4R2.> 6/"C@DGVH U-*\.Z+H;2MHFCV&G-,/3H5='!R&#!<@@\YZYJCH' MC*^FTN^N_'&A_P#"("S,9:2\OHI(&5SA2)AA>N 1V)'K70MJ^FI?QV+ZA:K= MRQ&:.W,RB1XQU<+G)7WZ4 $&DZ;;:G<:E;:?:Q7UT%6XNHX5668 8 9P,M@ M8R>U6ZPSXX\)K$9&\3Z,(UB$Q/I MT-_'-P*'YTR<;P,&GW'C'PS:VIN;KQ%I,, E: RR7T2KYBXW)DMC<,C M(ZC- &S17$>+?'4NDZEX/30FL;VSU_4UM))\F0>61]Z-E8#/OR/:NWH **** M /-O^;IO^Y,_]O:])KS;_FZ;_N3/_;VO2: /-O\ FZ;_ +DS_P!O:])KS;_F MZ;_N3/\ V]KTF@ HHKC/B'X[O/!?]C0Z7H7]MWNL7GV2"W^V+;_-C(^9E(YZ M,/"VD>&K[2M3AU M2_DM;YHIA,T&U0<#8V%;)_BSTZ5U$WB[PW;R>7<>(=*B?[0UKM>]C4^ M"WWQD97J,B@#8HK/U;7]'T&-)-30!L6.F6&EK.NFV-M9BXF:>86\*Q^;( MV-SM@#+' R3R<56U'PUH6L745UJVBZ=?7$/^KFNK1)'3Z%@2*BE\7>&X)O*G M\0:5')]H:UV/>Q@^"WWQD97J,UEZC\2_#.E>.X?"=_J$4%_+#YID>:- M8HB<;8W)8$.P((7'((]: -[4]$TK6K5+;6=,L]0MT8,L5U;I*JD=" P(!J)_ M#.@R6LMM)HFG-;S2K-+$UI&4DD4 *[#&"P &">1@5;M]1LKNYN;>TO+>>>T8 M)<112JS0L1D!P#E21S@UYYXA^*.O:=XXU7P[X=\$MKO]E6T=ST/7;."*WL;S6K0VUQ?QVRF1AMVJ7(P7VCH"?RI/" MW@S2?"^EZ?%!963ZC:6,-G+J*6B1S3B-%3)(R>=N<$G%0^'O'^B:]X#L?%DU MU%I6G78/S7\RQ"-E=D*EB4_6MN/6-,ETG^U(M1M'T_87^UK.IBVCOOSC' MOF@"!O#>A-I=QIC:+IYL+F0RSVAM4\J5\AMS)C#'(!R1G(%/DT#1YI;J2;2; M&22\A$%R[6R$SQ@8".UMKJ#7=-DM[R<6UM*EY&4GE/2- M"#AF/]T26R M--&!G 5R-PZGH>]0CQ9X=.[&OZ6=LZVYQ>1\2L"5CZ_>(!(7J<&FR>+O#<.D MQ:I+X@TI-/F8I'=M>QB)V!P0'W8)!!&,T ,U'P7X6U>^DO=6\-:/?7L=&TO3)YI]-TVTLY9U19I+>!8VD"#:@8@]1V/B+1-4M;BYTS6+"\M[8D3RV]TD MB18Y.X@D+^-.TK7=(UV%Y=$U2RU*.-MKO9W"2A3Z$J3@T 5-.\&>%](NUNM) M\-Z18W"_=FMK&*-Q^*J#6K=6MO?6DMK>P1W%O,A26&5 Z2*1@J5/!!'8UPWC M'XB:QH/C:Q\,>'/"?_"07UY9M> ?VBEKM56*D?.I!Z9ZBN@@\66=II=M)XMG ML/#VHO;_ &B>PNM0B)@7=M)W9 9:=X7T6TNH3NC MG@T^)'0^H8+D5:3PWH<6LMJ\6BZ>FIMG=>K:H)CGK\^-WZTEUXFT&RO+>TO= M;TZWN;H P0RW<:/,#T*J3EL^U2:IX@T;0_*_MO5['3O..(OM=RD6\^@W$9_" M@"IJ'@KPKJ]_)?:KX:T>^NY<>9<7-A%)(^ ,LRDG 'T%2W7A3P]?2VTM[H M.F7$EH@CMWFLXW,*CHJ$CY0/05H374,%C)=NX,$<9E+KR-H&O%9>G>-K:;4=5M]:;3=+BL]1%A;2MJL,ANG() *@YC:K96]Q#!]IDAEN$5TAW;?,*DY"YXW=,\5CZMXUTT^"->UOPQJ>FZM M)I=A/<@6]PLR!TC9E#;&Z$KZB@#IZ*P_!6M7/B3P-HVLWR11W-_9QSRK""$# M,H) !)./J36Y0 5YM\9/^9"_['/3O_:E>DUYM\9/^9"_['/3O_:E 'I-%%% M'FW_ #=-_P!R9_[>UZ37FW_-TW_U_L]M.0M=1^\0Z7XJT&WUG0;G[7I]SN\J;RV3=M8H?E M8 CYE(Y':O,?$OB;Q5K_ ,1]4\/^'/$%GH&GZ3I*7TOVFT29KS>,D'<1M4 @ M$J01[YXXWPAXF\0:+\*OA?IOAO5+;33K%W?V\\MU"LD>//DVDYYX+9 !&3@' MCB@#Z2HKP.X^*?BWPCHGC^QU6_M?$&H>')+6.UU(6RPJQG./G1/EROIZ@@DU MT6C:]XQ\.?%30?#7B3Q-9^)[77K2:0XP">OMB@#U#3M4 ML-8LEO-)OK:^M6)"SVLRRH2#@@,I(X-6J^<_#?C/Q5'\+_ 2^';K3]/O-:UF M>TF*Z?"D!4NP!\N-5 QU^7!)')ZU)XJU?QC=>$_B1X2U[Q)%>3^'X[:?[;'I M\<9NX)8RS1%1PG5.1DC!Y- 'T1574=3L-'L7O=7OK:QM8R \]U,L4:Y.!EF( M R3BO./#\?B?3? ?@I#XTTXO<7MHTS7L,Y3 M3[ZVNVM93!<+!,KF&0=4;!^5AZ'FO&_B/H.@^%O'_@.?P7I]EIFNS:S'$\%A M&L7FVQXDWHF!MP<9(Z$U7L_$?BE-!\>/X46RCU2/Q?/:1&&S@25H@>2J8432 MX!/SDLV#S0![M17@.I?%GQ'8_#.P>PU*;4=7NM:?2Y;P:.$NH-JABAM2=IF! M(&T$K[YZ6-.^(GC2U^'_ (CE\43:EI,UG-;)INK:EX>\F>Y\QL,@MP=A8;<# M!(^89H ]VHKP;P5\1?'%['XQTR\N9;G4-,L$GL'US38]-F65N KQJVT DC&3 MSQSSBH[;XJ^*= ^'?BR[UF_?4-=TL6H6UO\ 2Q9RVCS-M)94)1X^048')[@ MB@#WVLO5O$^@Z!)''KNMZ;ICR@M&MY=QPEP.I 8C->9?"GQ=XZU3Q;+I_B>U MUJZTJ6S,\=_JF@C3C%*&'R+L)5E()P2<\51^+44TWQJ\)):^%[;Q5(=/NL:7 M=2Q1I+[EI 5^7KR.U 'L]C?V>J6,=YIEW!>6LHS'/;R"1'&<<,,@\BK%>-:K MJWC&/Q5X0\)>&5LO! U/3[B2XLDMX;I+-D8ME-H"L< \#"_,K:-X>?5)WT)(H2FF^'TO$O)=@+-,VX&%6;.-@/'TY /HFBO O&/Q1\;R^( M],T;1;75=*N#HT&H7<.FZ(NH7 FD&6C:.1EV(IXSUS^GJO@76=7USX=6.H^+ M+.32-3DA<7<VVVIV%[=W5K9 MWUM<7%FP6YABF5G@)&0' .5)]ZM5X/?^(/$U@OQ0O_#D]M!>Z'?VTVZ.Q@5I MX54F02,$R_RY.3DC& 15V^^*=_JEWXEUO1=RWEW!I]C/>7;^7;V\;2RO@G:JC).!ST%0:-K%CX@T:UU72 M)_M%E=H)(9=C+O7UPP!'XBO!_"_CWQ7J]WXM\-^)KO4+R!/#-S?1/JFCIIUP MK !.$1B"A#D@GD^U>C_"34K&T^$_@^TNKRW@N;NRVVT,DJJ\Q7)8(I.6P.3C MI0!VNH:E8Z19O>:K>V]C;)]Z>YE6-%^K,0!2V&HV6JV:7>EWEO>VTGW)K>59 M$;Z,I(-<#\7?!]QXOAT1-+N],;4M/NFNX-,U3YH+]0 &5EZG&1SC'S8.,YKR M3Q9J?]L_"&ZCT:P@\)/I?B%8-5TRTC26"6X)0+)&XX4*5SM7@_J0#ZAHKQ+X M@^*/%OAB;2]!L/&&HWFKQV#W5T=*\-174TX\QE\QE+!(T&-O&2"N3UJE:_%' MQ5K7A/P/(MW/;7&LQ7LE_-I&FK=W/[B0HA6$A@%./F.#[8H ]ZHKY_U;QQ\2 M/"OP]T)=;NKN37O$&H2*KII,3W%G H 5%@4JKR-PV&QC)!Z9KO/A%XB\6:YI M^J0^,K+48VLYU%I>:CIGV"6ZC8'.8@2H((_A)'(H [J'4["XU&YT^WO;:6]M M0IN+9)5:2$,,J64'*Y'(SUJU7EW@S_DXKXD?]<=-_P#2<5F?%[QOK^B^)DTW MPOKFHVTT.G?:YK/3- 2_?&YAYDCNP"1\ 9&2,9/44 >R45X3;_$#QQXE'PYM M-'U:TTR[\26=X;N9[-94#19/F!3SN 4D#(!)YXI)?B?XMT+X;^+1J-]:WVN: M'K0TN+46MUC0JQ $C(/E!'S=L=.O< ]C?Q)I2>*D\-M=XU>2T-ZMMY;VT%U>%A;02RJKSE1E@BDY; ()QTKQKPS::Y M8_M+V]OXFU^#7[Q?"Y(NX;5;?"&^(G_ "6[X6_]=M1_ M]$QT >CV.IV&J+.VFWUM>"WF:"8V\RR>5(N-R-@\,,C(/(S5JO+O@5_R"_&7 M_8VWW_H,=>HT %>;?M!_\D)\0_\ ;M_Z4Q5Z37FW[0?_ "0GQ#_V[?\ I3%0 M!Z37FW[0?_)"?$/_ &[?^E,5>DUYM^T'_P D)\0_]NW_ *4Q4 >DUY5^T#I% MQK/@[1(H-'O]9@AUVWFN[6P@>65H!'*'P%Y'!QG(Y(Y%>JT4 ?/>O:'IVI_! MB_T3P/X"\3:-!_:]M/+9:A9R^9,6(#N@+NQ 5 #@@"NAE\#R:+\:+V/P;HO] ME:=>>$);?[3:VYCMQ]>QT4 ?+NB^%[Q8? 5E;?#?5-,U M31-=M6U;57L0%E7SN6#CYG7^(M]U<=<8INHV4%]K/Q-M%\"7GB+4;W4YK:QO M[:V6868S>;)_>P M20/H,"@#Q&^\,:EX<\2^&M0\9>$+[QCI=KX8BTYK>SMA>FWNP068QL<'@8W> M^>U58?!7B.R^&_A^!M#O(=_CN+4HM.C0RO869# !PN=H!Y/INYP:^BZ* /!K MOX>QZK?_ !=U#5?#$EU>2Q.=(FFM&9G;R'(,!(Y.\+RO.<#VJCJ?AFZLV^%V MNZMX'N]+ MPS<:7(\EKYFJ22.4U/\ =M@H"-HV?=.W.<\\UP_C/P+>>+_B[XAMYK"?[!>^ M$#;07C1'R1>%+O3?L>KI]KCMO#<5K!;KN/* MW"$O*F!R6^4>IR,_5E% 'S;/\-FN_A=\1;R[\*3R^()=>G;3W>R>N*W?$FEW-E\2+3Q!XL\#ZCXNTJ?08;6**VLENS;7 .6W1-]WO M\W;=QWKW6B@#YPM/AUK!\)^!M+UOP_ M>&+B6-/#L,$EVGAV+4;B*<<>2ZS$")0-IW'!!)Z\X]6^">G: MCHWP7T6RU6RN+6^@%P'MKE#&ZG[1(5!#=,@C'L0:] HH ^>K33-2NOB/I.H> M!O!GB7PAJ,FH+)KOVD;-.EASF0 YVR'KC: .>!G!'+W&GQ:FWQ*L8/ 5YK^J MWWB&\@L=3M[=9%M'\S.&;.8\9W9Z-G!-?5M9>C>&])\/2ZC)H]I]G?4[M[V[ M/F,WF3/]YOF)QGT&![4 ?/7C_P #^++7Q%HMS?6FH:E;0^'[:P>>RT.'6"LR M+B0>5*PVY.6WCGGZU<_X12\T;2?A[?:GX9UOQ5H.EV]W'-V7A^6?XE>![BW\)76E:,FF7\V652N %W&,(-1\2> ;_QAIVK6=O#I;6MN)UMBJ;75F)_=9;)W=1G(ZUZ M1XZ\E/ K07OA6X\164FR*ZTVU(>58\?>4=6*D#&"#W!XKK** /GG0_"GB2^\ M(^.=-T/2]>L/#=UIP32=+UYMLXG')5%).U>"!D\Y7GK5_P .R:[KWQ%^&MU- MX1US2K30K*YL[NXO[4HOF?92N1W"D@ ,P&2<#FO=Z* /$OAK\++&^^%NLVVN MZ +'6-2FNX3!SZ#K^@_#7X<^*=)T.^N-<\.8B MN=.2!_/>"4%9%* ;LCCMQN)K)UCPAXBTCX:^%A_PCTFH7FHW5SJ.M7"Z)'J5 MS;33!2N+>0@9(PK9Z;.W0_25% 'S%H/A'Q+;_#?2[.XT+4EN(OB%#>-$; Q, MMOY(S+Y: JB9_N_*#QGBO>/#GB\^(O%'B72H]/,5OH=Q%;+>B7>MS(R;G4#' MRE. 1D]>U=+4%I8VEA&\=A:PVR/(TKK#&$#.QRS$#J2>2>YH GKS;X-_\S[_ M -CGJ/\ [3KTFO-O@W_S/O\ V.>H_P#M.@#TFO-O@W_S/O\ V.>H_P#M.O2: M\V^#?_,^_P#8YZC_ .TZ /2:*** /GGQUX>TR?XVZY?^+_ /B7Q+IDUI;+:2 M:3:3.JN$ ;+(Z ^G4UT:^$K7Q;\=H-3UWPM<2Z(WA6-H5U.S.R&8R#$;YROF MJC-E221R>V:]CHH ^:XO"6NP_!_PQ%>>&-1O[+1O$:-]G;SI;;>Q!$;< MN.3QWW>F339](FM-%^*VJ0>%+SPSI&I:7;/8VMQ:B$ $,-J_*K9!8J#D;A7 MTM5+6-(L=?T>ZTK5X/M%E=QF.:+>R[U/;*D$?@: / O!F@RZIXT\ W/A_P # M7GAU='M6EU75)8%CCO \0QMD4_O=W/)Y&_T!K";P7JS^!KCP?/\ #W49?&LN MH>:/$IME\G_7!S)]JSG[N1CWSUXKZALK.#3["WLK-/+M[:)8HDR3M11@#)Y/ M [U-0!XAXD\.ZU+XI^)LD>F7MPMYX;A@MIDMW*W,@BP50@?,V>PR:KV'@!=% MO/A)>Z1X8>UNUA_XG,T=FP92]NN_SSC@[F'X_#>K?$ M73+[X?74_P!HDO[BSFALA'#<6;#Y;2.9>07& $7@?48KUSP:D(KBRU[4GT[5/-O M?"EVLAC,?F,!)%;@ [QD-SD'.3QD%WQ&\'>(+KXC>(KR]TW6KC3]7$;6MQ8> M&HM4;R_+ V[G=7MV7I\N#Q["OJ.B@#Y^U#P]/H_C+2=0\3>#-6\::0_AJVL+ M<+8K-)!.H&3)$S$1L>$_A'INM>'KR:WM+JX.HV\]J^( M5+97S1CY0<#[W!KJ+7X>Z;$ MM:N-0\-ZMI/A?4=.T*+3I8$TR#1X=6DLY&FD;YK:1MHW*R'(^[C Z5]*T4 < M%\%](DT3X9VEI*-27]_,ZQZG8"RFC!<\>2'8*,Y(YZ'M7)?##X=Z@VM:]K.I MZIXHT5HO$]S-#IT5PUO:WD8*,LC1E?WBMRI8'!"@=J]JHH \+T#X=W%Y9_%" M];0C!X@N]5U!=)O;J HY1U;8T3L. V]AN7UZ\5R_PH\'ZM8_$3PVVIZ?K^GS MZH'H:^BOB28&\(/!J'A6Z\46$\HCN[* MS&Z9(\$^8B\%B&"C (/.0>*ZRB@#YMC\'^*]4^&7CK2M&TS7;;0;A;9M%TO6 MS_I*M'*DDBJI)*KA2 ._'4YKI-*GUKQ1\5M(UM_">N:18P>'[BR+ZC:^63*. M2,#.T$MA=V-V#@<5[=10!XC\.OA597G[/[Z?J>@+IVOZG:7,,\US;&.X#>>Q MBW;AN"@QQ,!TX!]ZQO#FB>*O%.@>*-;\4Z'J%M?Z?X3?0]-M[B!UDN)#"_F2 M*A')9L $==V*^AZ* / -3T?Q+X6\)?#_ ,7>'M#O[K6=.TDZ9>V$5L[3;'A) M3>@&X!),D\=2*S?$G@K7?#W@WP9I=KX>DOMMM++J%]#H46K7$5S*0[*8Y2% MSP6/]WK7TC10!\X>$_"GB*R\,?#VVN]$U&.6P\4RRW*-:,/(CS]]@!A4]_N^ MAKVKPOXN/B;6O$5G%8&&VT6]%FEV)=ZW+A",GK^%=+4%G8VFG6_D M:?:PVL.]G\N",(NYB2QP.,DDDGN30!/1110!YM_S=-_W)G_M[7I->;?\W3?] MR9_[>UZ30!YM_P W3?\ DUYM_S=-_W)G_ +>UZ30 5Y'\>M&?5HO" MIET#4]=TZWU/S+^UTV!Y9##MY'R$$9Z9R/K7KE% '@7B+0['7/A!8Z-X1\#^ M(M)L(?$,'FZ=J%I*)F0Y,D@!9VV?-C=GCGI5[5/ =Y8_$CQ99>#-$.F6&H^# MI(89+: PV[W>\*JAP H'YW\0?#IM/^'6J:'-HLP@UC M4)K#RQ/)Y?W\CYF7*L=[8 W 9Z5BW&GQ:FWQ*L8/ 5YK^JWWB&\@L=3M[=9% MM'\S.&;.8\9W9Z-G!-?5M9>C>&])\/2ZC)H]I]G?4[M[V[/F,WF3/]YOF)QG MT&![4 >+:IXB?#^*ZT:[B6'Q1)>M:HIE_L^WO0Y%:NI^'I;+XD^ M"_$.I>"[G6(9M%BM[TV^G+*T=X H628'[I48&X\@+QTQ7NM% ')>$XH(_%_B MUH?#-QI+O=Q&2^ED=EU(^7_K$!& !T^7(]>+?BUXREM+_ %K1 M4DTN!;.ZM7:&WNY-@!CD;&'7/4 \9KW.B@#YE\2^'O$FK^ O D]GX8O]-M]$ M%Q;W^FPZ.+MHI. )5M9B!,&Y.23C<3G-26_@G6G^#,T=CIFMWT:>)XM0O=)O M=)73I9X%0;UC@5V!4DK@# RIP.*^EJ* /!/$&EO=>&]&U_PC\.M3T>VTOQ/; M:C/I8M1%0%P.O7UJM>Z?K_B&3XJZN/"^L6*ZYI=I]AMKJU/ MG2[$V$;5S\WRY*@DC(S7T)10!X5XO^'-LOPM\#Z9H_A=@TNK:<^K0VUHWF%! M%()&FVC=P7(+-TSU%4/B_P" M0L_%VC7?AO191X>MM/> 6^EZ%!J0@F:1F8_ M97(7Y@5^?MMKZ$HH ^C?#C3KS2-7U#38M7NY;R+4M*-L8$8@@21* MSA$+ D9."#TYQ5W4/ NMK8?%W1/"VC36%K>/8R:9%'"88IP,M.L1P 00"N!Q MSCBOH"B@#YZUCP]-XE^%FLVG@KX=ZCX9O!#:)<+/;K;O?>6Y+(L>?GQ][<<% MNE7?@AX>O;+QY?ZE=6VN6>[3?(:*\\+Q:3;O^\4@CRG*NXP?XD2-"4?S&(C,NT@9ST[U%JOP^CO?C/X M7M]8T^\U_1[#0Y(GO=30W"O*';;YKXVL^#G!^N*]AHH ^5O'G@/7D\>>)!>Z M7K$MAJ,P-I/I?AF'5/W(4!561G5X2HPN%(Z5>^(?@OQ*OC"WOIK35]1TZ71K M:UBN+?P[#JLJLJ .&BD?]RV7;W\ M9W/S%8W0LP0]%ZG%>9>&=)O1\4M*O/ ?A+Q-X2LVG=]=@U!?*L9$Q M_P LU+$,<],<#C KW^B@#YANM,\4VOPTN_ W_"&:Y+=VFN?:WO8K;=;O$9@ M048>B@X')Q@X]'M/!5OJO[0WB/5M?T#[59I8VOV&YNK8M#Y@"[BA(VEAC MMR/:O5Z* /GMO!>O_P#"PI/ ?]DWA\(2>(%UPWOE-]G,7E[S;[L8QOPNW.(/!GC+QEJ7A2277=3%K9VVE:A9EBD$)C+LL38W9;+@=R@X/?(\&>%_$, M;^.Y9=#U2*+4/"EQ%:^9H*:;YTI! C$,.5WYS@9W'KCFOIRB@#S/P/XDNM"L M_ /@J?1YC=WFC&:[:1C&]@L48QOC*Y^9OEY(P?6O3*@6QM$U![Y+6%;R2,1/ M<","1D!)"ENI )) ]S4] !7FWQD_YD+_ +'/3O\ VI7I->;?&3_F0O\ L<]. M_P#:E 'I-%%% 'FW_-TW_DUYM_P W3?\ DT %%%% '!Z3\ M$_A]H6L6VJZ5X?\ (O;202PR_;;AMC#H<&0@_B*UG^'?A:3PM?\ AQM+SI.H MW!NKJW^T2_O)"ZN6W;MP^95. 0.*Z:B@#EM?^&G@_P 4ZC:7^OZ%;WMS:(J1 M2.SCY1R%8 @.!Z-DA:;H5M'IMYS

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end GRAPHIC 17 cstl-20211231_g13.jpg GRAPHIC begin 644 cstl-20211231_g13.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1#R17AI9@ 34T *@ @ ! $[ ( M - (2H=I 0 ! (6)R= $ : 0T.H< < @, /@ M &UL;G,Z9&,](FAT=' Z M+R]P=7)L+F]R9R]D8R]E;&5M96YT#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@ M96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8 M%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4 M"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ_\ $0@!F@(O P$B (1 0,1 ?_$ !\ $% 0$! 0$! M ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" P $ M$042(3%!!A-180'EZ@X2%AH>( MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! M @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$' M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66 MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F MY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^B-0U*QTBPDOM5O+>QM(L>9< M7,JQQID@#+,0!DD#ZFL3_A8_@C_H"/^A-\/_P#@K@_^)H /^%C^"/\ H"/^A-\ M/_\ @K@_^)H_X5QX(_Z$WP__ ."N#_XF@ _X6/X(_P"AR\/_ /@T@_\ BJ/^ M%C^"/^AR\/\ _@T@_P#BJ/\ A7'@C_H3?#__ (*X/_B:/^%<>"/^A-\/_P#@ MK@_^)H /^%C^"/\ H"/^A-\/_\ @K@_^)H_X5QX(_Z$ MWP__ ."N#_XF@ _X6/X(_P"AR\/_ /@T@_\ BJ/^%C^"/^AR\/\ _@T@_P#B MJ/\ A7'@C_H3?#__ (*X/_B:/^%<>"/^A-\/_P#@K@_^)H /^%C^"/\ H"/^A-\/_\ @K@_^)H_X5QX(_Z$WP__ ."N#_XF@ _X6/X( M_P"AR\/_ /@T@_\ BJ/^%C^"/^AR\/\ _@T@_P#BJ/\ A7'@C_H3?#__ (*X M/_B:/^%<>"/^A-\/_P#@K@_^)H /^%C^"/\ H"/^A-\ M/_\ @K@_^)H_X5QX(_Z$WP__ ."N#_XF@ _X6/X(_P"AR\/_ /@T@_\ BJ/^ M%C^"/^AR\/\ _@T@_P#BJ/\ A7'@C_H3?#__ (*X/_B:/^%<>"/^A-\/_P#@ MK@_^)H /^%C^"/\ H"/^A-\/_\ @K@_^)H_X5QX(_Z$ MWP__ ."N#_XF@ _X6/X(_P"AR\/_ /@T@_\ BJ/^%C^"/^AR\/\ _@T@_P#B MJ/\ A7'@C_H3?#__ (*X/_B:/^%<>"/^A-\/_P#@K@_^)H /^%C^"/\ H"/^A-\/_\ @K@_^)H_X5QX(_Z$WP__ ."N#_XF@ _X6/X( M_P"AR\/_ /@T@_\ BJ/^%C^"/^AR\/\ _@T@_P#BJ/\ A7'@C_H3?#__ (*X M/_B:/^%<>"/^A-\/_P#@K@_^)H /^%C^"/\ H"/^A-\ M/_\ @K@_^)H_X5QX(_Z$WP__ ."N#_XF@ _X6/X(_P"AR\/_ /@T@_\ BJ/^ M%C^"/^AR\/\ _@T@_P#BJ/\ A7'@C_H3?#__ (*X/_B:/^%<>"/^A-\/_P#@ MK@_^)H /^%C^"/\ H"/^A-\/_\ @K@_^)H_X5QX(_Z$ MWP__ ."N#_XF@ _X6/X(_P"AR\/_ /@T@_\ BJ/^%C^"/^AR\/\ _@T@_P#B MJ/\ A7'@C_H3?#__ (*X/_B:/^%<>"/^A-\/_P#@K@_^)H /^%C^"/\ H"/^A-\/_\ @K@_^)H_X5QX(_Z$WP__ ."N#_XF@ _X6/X( M_P"AR\/_ /@T@_\ BJ/^%C^"/^AR\/\ _@T@_P#BJ/\ A7'@C_H3?#__ (*X M/_B:/^%<>"/^A-\/_P#@K@_^)H /^%C^"/\ H"/^A-\ M/_\ @K@_^)H_X5QX(_Z$WP__ ."N#_XF@ _X6/X(_P"AR\/_ /@T@_\ BJ/^ M%C^"/^AR\/\ _@T@_P#BJ/\ A7'@C_H3?#__ (*X/_B:/^%<>"/^A-\/_P#@ MK@_^)H /^%C^"/\ H"/^A-\/_\ @K@_^)H_X5QX(_Z$ MWP__ ."N#_XF@ _X6/X(_P"AR\/_ /@T@_\ BJ/^%C^"/^AR\/\ _@T@_P#B MJ/\ A7'@C_H3?#__ (*X/_B:/^%<>"/^A-\/_P#@K@_^)H NZ5XL\.:]=-:Z M'K^EZE<(AD:*SO8YG500"Q"DG&2!GW%:]>4Z5HNE:#^TXUKH>F6>FV[^#S(T M5G;K"C,;P L0H S@ 9]A7JU 'FW[0?\ R0GQ#_V[?^E,5>DUYM^T'_R0GQ#_ M -NW_I3%7I- !1110 4444 %%%% !1110 4444 8GC'Q58^"?"=YXAU:*XEM M+/9YB6RJTAWNJ# 8@=6'?I5+0OB'H6O^ 9?%]L\T&FP1RR3K<(%DB\O.X,H) M&>.@)SD5S_[00S\"?$./^G;_ -*8J\TUK1]5M/'5U\-["*1=(\:75KJCRKD> M3$ 6N@".Y,8XST '>@#VCX?_ !$TGXCZ1=:CHEM>V\5K<&WD2]C5&W;0W 5F M&/F]:Z/4+O[!IEU=E-_V>%Y=F<;MH)QG\*^:M5TRXN/A'\6;;3;5W$/BV9_* MB7.(TF0D@>@'/T&:Z(>*M,\:_&J?6/#[7$^GGP;<0)/);O$KR+(68+N SC>H M)'>@#TCPY\2]*UCPKX:/_9FHQ?984E^W2V^VVFW?PI)GYF'<8XKYFU#0M ?X3_"[7O$EF[Z?'+K3PGJ#:-OT'3EL+IK;SC FQ=O M[N3K\O&&_G0![517B?CW3=<\#0>%_'&O:V_B"\T+4C'>W:626Q-E. C+L0X) M4]/=ZX778Q!\*=.UWQ'ID4\GBW6)]3N9[Z:Y6UM588B$@M_G92O*@>M 'U-6 M7J6N?V=K6EZ=_9>I77]HM(OVFUM]\-KL .9FS\@.<#KD@U\O6$ETW[/^NVC3 M211V_BF%+=8&E58$)0CRO-^=5YRN[GH3SFO2];\)Z5X-^*OPOTS0(9(;5KO4 MIG$DSR%I&ABRQ+$G)QGTZT >U5EZ=XDTG5=;U32+"[\Z^TEHUO8?+8>49%+) MR0 <@'H3[U\G/J(D^)]A?Z=8PZ3J*>(XDND$U\]\BM-@B5G_ '(1L]!\W0=, MUVNG:'HWAWXT>.[73[":#Q-]E>?PL )F_>-:2M*P.2I!) ^?N<#F@#Z0JEK. MK6N@Z'>ZMJ+%+6R@>>4@9.U1DX'<\<5\L?"-Y5^)F@;=8TRQU9Y7&HVV=1^V M7GR,66;S%,)88)X*C/O7K_QVU"]NM%TCP?HMD^H7_B"\ :S281&6WAQ)(N\\ M+G"C)XQF@#L? _CG2_'VCSZAI$-W;"WN&MIK>\C"2Q. #RH)'0CO725\_:/J MVMZ'\4O$-MXC\-GPS%XLTF26VLQ>1W*F>"(@E63 &5W$C&Z=@T#/(/)"YP$Q&!@#H3G- 'U)7,:;XR_M#XDZ MUX3^P^7_ &7:PW'VKSL^;Y@SMV;>,>N3FOF#XJZB#XX\27=G80Z9K%AJ+;)I M)KYKXHK ":,C]PD1'0'G!X[$^MZAX:B\7_%[XD:#<8"WVB6B(S#(1PH*-^#A M3^% 'M=4-&[_4O'JWNI MZ\;^Q/@OPY-IKRP)NG2]CQ">UCL[; M=J5JURMO=/YHR3'.,I+C[VT[3V&!0!]6VT_VFTAG\J2+S45_+E7:Z9&<,.Q' M<5'J.H6FDZ;<:AJ4Z6UI;1F6:5S@(H&2:^:/BC)80>)-&N;B6XO[V/2K1+72 M6%S%(6(!\RTEBRGF<\AQCCOQ7L_Q?T?4?$OPG AE!4Y M!Y!'>OGOQ7\1=$\:?"*/P/X:LKZ]\1W4%M:_V6+*16M61D)+DJ% 7;U!],X% M7+K5+?X=_&"8>)&NME[X7@L+.:*VDF^TSH0I1=H)W$@_IGJ* /9-9\2:3X?E MTZ/6+O[.^IW:65H/+9O-F?[J_*#C/J<#WK4KY-N- TA_@3\-=9U^QE:UM-8> MVU*4>9^[M&NYC(K!.1TZ@;L\ \UL>(7\!)\3)HO$HU%/"/\ PC5F;2*W^T!0 MH4>3Y@7Y^%/&_P#B/- 'TU535=4L]$TBZU/4YO(L[2)IIY=I;8BC). "3QV MKYQMYM4T7X6_#;7?$\=\MAI>O&:669&>2"UW-Y;,.N, X]MH'4"IS!8^/%^, MMY;6=S=P3VUE>6"O%)$\C)#-L<*<,1D9 (Y':@#Z)T[4+75M+M=1T^7SK2\A M2>"3:1O1U#*<'!&01UYJS7F_P''AL?"NR_X12-D!V?VEN$@W7ODQ^<1O]\#Y M?EXXKQ;7/[(F3Q0/$HUL_$S^U)?[($0N/,";@(_*V_)LQG\.G:@#WWQ'X_N- M)\?Z5X2T?09=7O;R 7=RRW*PK:V_F;#)\P.\@@_*,'CWJ;X@_$C2/AOI]G>: MY;7UQ'=RF)!9QJ[ A=Q)W,O&*\T@\&Z?=_M*Z+)KMAYFH?\ ".0:M!(?%MV\T^G7"1/;K;H&DF\P J%4D#.#GD]C6EX5\26?B_P +V6O:9'/' M:WJ%XTN%"N &*\@$CJ#W-?/OA_2]7U'7&\":M'(VF^ /MUV)7Y%P6!^RD^A& MYF'L*SM=;5!\ _ATL83^PB;@ZI]I$_V?[Y\KSO(_>;/O].^* /I;Q%XDTGPG MHDNK^(+O[)8PLJO-Y;/@LP4<*">I':M2ODJXT6/5OV=]?NH;VTUF/2]3CEL$ MTTWACT\-L$B@3JK%=ISSN R3G-7?B+/X/DM/#6G>%]'M3X??3Y9--NM4?4O( M9S/(&CCCB^>M<+\-M,\9^)/@OX6FT3QM+H4L274=P9M-CO&FQ<.J F0Y7:%Q@? MTK(\07'B#Q=\3O$KZ-X2;Q3IVG:<_AXL=0AM%AE< S.-^.@ H ]\AFC MN((YH'$D4BAT=3PP(R"*?7R^=2N/$7PW\!>'=7DN+34-*\6PZ'?"&0I+&!N0 M88'@A&VY'=36T;"V\#:S\3]!T&PO;K2(=+MKE-.CNI20SC#E6R6&=Q)/7 ZX M% 'O.LZC_9&@W^I&+S?L=M)<>7NV[]BEL9[9QUJEX.\1?\);X-TS7OLOV3[? M )O(\S?Y>>V[ S^0KYB^&\Z+XC\01Z3]BATZ[\*WCM%IC7GD22*.K?:?F:09 MP2OR^G4UUH,GA7X8_#?XC6D3R?V)$MMJ"1XS):3$J>O7#'@>K4 ?159=UKGV M7Q)8Z/\ V9J4WVR-W^VPV^ZV@VC.V1\_*3V&.:^:O$6CV]K\,O#VK^*;WR+K M7KR\UJZMKJ*X:SNWEV%$D: [T8+M*<8R7S[]=H=S)<>/?AG.]I>V.?#]Z1!/ M(9)HP%;'S, 3P 1GG&* />Z*^ZU0?:8I-Q=2 M$NHI;?\W3?]R9_[>UZ30!YM^T'_ ,D)\0_]NW_I3%7I->;?M!_\D)\0_P#; MM_Z4Q5Z30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1167XEUZT\+^&K[6M1?9;V<1D8[6;GH!A03R2!T[T :E%>-?#'X ML03^!;WQ-X]\86LJFX$;6XL3"+%SN(B4J,RY4!N,D<\FNXL?BEX+U+PS?>(+ M'78IM-T\ W4BQ2;H7:K\4/'\-WXOO]+L_#3Z)X7O7@FCNC,ES*B_W2&V$X^G M/8T >F>$/!NG^"]/N[;39KFY>]O)+VYN+ME:265\9)*JH[>E=!7"W?Q@\(:- MH^C7?B;4UTJXU:PAOH[5HI)71)%R,[%.!G(R<=#6CJ?Q,\':/8Z9>ZEKUO!: MZM%)+93D,4F6, MR 0",@8."2<#)XH ZFBN8T[XC^$=5\*W7B.QURW?2;0[; MBX8,GE'C@JP# G(P,!AN: M-7^+_@30=2N-/U?Q##;7=M/Y$T)AE9D? /0*>,$?-T]Z .TK"M_"-A;>/+OQ M9'+<&_N[-+.2,LOE!%;((&,YX]<>U4M&^)O@WQ#XB;0M%U^VO-1"EA%&&PX MR=KXVL0.< GH?2LGXM^.=6\#Z7HLFA_V4DVI:G'9/-JV\00JRGYV*L"H! )/ M.!GB@#T"BO"O%OQ<\0^'OA\L]]K_ (5DU;4[W[/8WGA\2W4$,2[?.=MP92Z[ MU^7N&Z'%0'XM75]\0/"OAC3?'$7V=[>!KS4CHY!U*>5QLA\LK^ZW(RG<,!=W M)XQ0![Y17(VGQ5\$7WBC_A';7Q%:R:IYGE"$*^UGSC:),;"<\8!ZT^\^)_@R MP\5#PY=:_;IJQ<1_9PKMAST0L!M#=MI.<\8S0!U=%>:>#?CGX7\6W6M0O.E@ M-->:6-Y"Y6>TC(_T@DHH3.1\A.ZNL\*>.?#?C>"YF\+:I'?I:N$FVQNA0G., MAP#@X.#T.#0!OT444 %%%% !1110 4444 %87C+PE9>-_#4VA:IAW] MO NZ6:VDC1XTF>Y11,&8G M DR4W#C'..?;%1:G\/\ QEXCT?Q]K5[H=MINJ>(K:V@M=(ANXY&'E,N6>7A" M2%ZY]?Q]VHH S] L!IGAW3[(0);F"UCC:., !2% (XXZ^E>):K\#;C7[GQSJ MUYIJPZW-J37>A7+3JZ2H/F"LFXKACQ\XR,^E>^T4 >%^-?#?Q/\ $]QIVEO/I*V]W::;K,-D;>YR=YD8*WF1'(PBD\>ASF70OAQXB@C^$Z:EI"%/#QO MCJ:O-$XMR^#&<;CNY&?ES@CM7M]% 'AGB#X7>)=5T[XAV]G900C4]5M[_38I M94\NZ"OK6GI'AGQCKOQ2;Q-XA\.V_AZVG\/RZ7Y<%['<-$^\ M%6;;C).XXQD * 37L%% 'S[:_#[QY=^#-&^'U]X:TZRL-,OTN'U]+Y'#JLA8 ME(@-X6W&<_+\V/O8YYKV&B@ M#R.U\!ZU::O\);BVTN. :!82Q:N\NG3=8BO+FPEFCB6:)0VY"9#MPWW3P>O0UZ510!XSK7AKQ)XC\ M!V>G67P]M/"LEKKUM=?8;2]MV1XESOER@501P,=3BNGO?"VK7'Q[B\1);E=) M'AMK!KH2+E9C.S;=N=WW2#G&/>N_HH ^:/#7P@\7Z/JVC:7K.DZU?:;I^IQW M N;7Q) EE&!+N\U;5XR^0,D@$$\X(S7<>%_#7C+PGXJU;2T\,:;JFD:KX@_M M4ZS/=H#!&SJQ'E$;S(H4E3T#'/(KU^B@#QK3O"/BW3IOB#HT_ABSU'2]>O;K M4+>YFOU1)_,88@*#YU.,_/Q@CO6O\(/#WBS1)M7?Q-:2V%C*L,=A9W=_'>W$ M2H&R#,BC*#/RJ2=HR/4GTZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@#S;_ )NF_P"Y,_\ ;VO2:\V_YNF_[DS_ M -O:])H \V_:#_Y(3XA_[=O_ $IBH_X9\^&/_0L_^3]S_P#'*/V@_P#DA/B' M_MV_]*8J])H \V_X9\^&/_0L_P#D_<__ !RC_AGSX8_]"S_Y/W/_ ,I7,8=["[U*(LASC ;(#].HH Y?\ X9\^&/\ T+/_ )/W/_QRC_AGSX8_ M]"S_ .3]S_\ '*[N_P!;TK2M/6_U/4[.SLWQMN+BX2.-L\C#$@7;W%W''(^>F% M)!-+J/B70M(F:+5M:TZQD6$3LES=)&1&6VAR&(^7=QGIGB@#B?\ AGSX8_\ M0L_^3]S_ /'*/^&?/AC_ -"S_P"3]S_\DT4 >;?\,^?# M'_H6?_)^Y_\ CE'_ SY\,?^A9_\G[G_ ..5Z310!YM_PSY\,?\ H6?_ "?N M?_CE'_#/GPQ_Z%G_ ,G[G_XY7I-% 'FW_#/GPQ_Z%G_R?N?_ (Y1_P ,^?#' M_H6?_)^Y_P#CE>DT4 >;?\,^?#'_ *%G_P G[G_XY1_PSY\,?^A9_P#)^Y_^ M.5Z310!YM_PSY\,?^A9_\G[G_P".4?\ #/GPQ_Z%G_R?N?\ XY7I-% 'FW_# M/GPQ_P"A9_\ )^Y_^.4?\,^?#'_H6?\ R?N?_CE>DT4 >;?\,^?#'_H6?_)^ MY_\ CE'_ SY\,?^A9_\G[G_ ..5Z310!YM_PSY\,?\ H6?_ "?N?_CE'_#/ MGPQ_Z%G_ ,G[G_XY7I-% 'FW_#/GPQ_Z%G_R?N?_ (Y1_P ,^?#'_H6?_)^Y M_P#CE>DT4 >;?\,^?#'_ *%G_P G[G_XY1_PSY\,?^A9_P#)^Y_^.5Z310!X M!\2_@[X$\/\ _")?V1H7V?\ M'Q-96%U_ID[^9!)OWI\SG&<#D8/H:[;_AGS MX8_]"S_Y/W/_ ,7ORP7& M[!QU]#0!RO\ PSY\,?\ H6?_ "?N?_CE'_#/GPQ_Z%G_ ,G[G_XY6IXK^(@\ M,:9X8O#IGVK^W[ZWM-GVC9Y'FKG=G:=V/3C/J*W[GQ7X>LM473+S7M,M[]B MMI+>1K*2>@V$YY^E '&?\,^?#'_H6?\ R?N?_CE'_#/GPQ_Z%G_R?N?_ (Y7 M87WC'PQIFI-IVI>(])M+U2H:VN+Z*.0%@",J6SR""/J*?-XJ\/6VK#2KC7M, MBU%B%%F]Y&LQ)Z#83G]* .,_X9\^&/\ T+/_ )/W/_QRC_AGSX8_]"S_ .3] MS_\ '*[:[\2Z%87C6E]K6G6URC(C0S7:(ZL_W 5)SEL' [XXKD?BE\3;?P9X M1U*YT*^TF[URR:(&PGF#L@:15):-6#=&]NU %?\ X9\^&/\ T+/_ )/W/_QR MC_AGSX8_]"S_ .3]S_\ '*[/Q5KG_",^$=4UO[/]I_L^UDN/)W[/,VKG;NP< M9]<&N$\._%_4[_6?#]IXE\&3Z);>)(P^F7B:A'=)+E XW!5!3(*]>>>G6@"Q M_P ,^?#'_H6?_)^Y_P#CE'_#/GPQ_P"A9_\ )^Y_^.5V8\5>'CK']DC7M,.I M;]GV,7D?G;O39G=GVQ6'IWQ2\-:QXCUG0=.O87U'2P J2W,2)>-L9V$+;B6V M["&.!M[T 9'_ SY\,?^A9_\G[G_ ..4?\,^?#'_ *%G_P G[G_XY74:'XMM M[[P3:>(M=:PT>*92TF=2BGACPQ Q.IV-G&>/IVK6TW5=.UFT%UI%_:W]N3@3 M6LRRH3_O*2* .!_X9\^&/_0L_P#D_<__ !RC_AGSX8_]"S_Y/W/_ ,W_ (.O M=#L-'\/_ -NWVM3R0PP?;5ML%0#]YE(YSWQTH R_^&?/AC_T+/\ Y/W/_P < MH_X9\^&/_0L_^3]S_P#'*U? WQ"/BN;6K+5]'ET#5-"=%O[:>=94C#ABK"08 M!&%)KI-*U_1]=61M$U6QU%8CMD-GTN1+$9NV2\C(MQZN<_+^.* ML_VUI?VFRM_[2L_/U!#)9Q>>NZY4+N+1C.7 7G(SQS0!P?\ PSY\,?\ H6?_ M "?N?_CE'_#/GPQ_Z%G_ ,G[G_XY78GQAX:#,I\0Z4&59'8?;8\A8\^8?O=% MPFR1V2JUTZ7<9$ 894N<_*".F<9H XK_AGSX8_P#0 ML_\ D_<__'*/^&?/AC_T+/\ Y/W/_P 6XS-;P7*/)$/]I0B7^J2Z;8ZQI]S?PY\VUAND>6/'7* Y'XB@#B/^&?/AC_ M -"S_P"3]S_\*I.78GHJ\9QQ7LE>;?\W3?]R9_[>UZ30!YM^T'_P D)\0_]NW_ *4Q M5Z37FW[0?_)"?$/_ &[?^E,5>DT >1^.O!E_XI^.6BO'D2- M"4?S&(C,NT@9ST[UQWQ6\*>(O^$@ATJPT>_U6U325MH-7;1(=4N;J0;LK-/( M1Y/7[X 8=1FOHVB@#YUD\.ZG8Z+\-=3U_P 'ZEX@TG2].EAOM)CL_.FBE884 MM V,]NO3;SCBK?B7PS;VGB#P)XA@^&5U+I,$=Y'>Z1;V27,R!PWDB1#Q@%MP M!.$Y Z"O?Z* /F_7_#=W:ZEX]T_6_AYJ7B'5M>O)Y-&U>"T6>."-QB+,Q.8M MG''M@\5O:=\.I[OXJ>%K?QCHIU6ST[P=%;SSSPF6V%TLC J6(VLP#' /UKW* MB@#Y]T[P[?V/QU,VD>$-1$$NLRW%W<:AIL9@B0D_OX+Q2'P1R(CE1NQS7T%1 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110!YM\9/^9"_['/3O_:E>DUYM\9/^9"_['/3O_:E>DT %<3\8]/O-4^$ M.OV6F6D]Y=2PH(X+>,R.Y$BG 4_%'P>TK0;?P/J/A#PQ=KJ)U M:S;4'A,\QCCQN=G5F(0!AR<#%9\Q7P/N(#GH0,FOJFB@#P#QC!%J/Q:T[^V?A[K5WIFF)!))>Z9H@ED MU&XV)M\V_T M4 ?*.O\ AGQ;J/C1Y6\)75J\&O+<,MCX=Q*+Q29')SDJ 5[\8X[W3_ M V=#^,/C9&\%W#QZM;B32=3MM/4P6N+:3S0)!]QG9@N%Y8GGUKW&B@#YT/A M?6H/AO\ #.YU/PMJ&KZ=HLER^K:(+]#7:_"'0KNU M\4^+=>@\/7'AG0M5DM_L&EW,0A=2B$.YB'"9)SCW]!7JU% 'CNK>"9;[X]ZS M?VNAHD4>"/!=O)\6O'&MZ[H&9AJ$+ MZ;>7=L>@4DM$S#'4#YE^E2?%[PQ?^)_%?@:"R_M6"WCOIOM-]I>Y9+12BX?S M "$Z8R:]3HH ^=;GP/XHM/ _Q!\&V>G7UWJA*Y( M!.1BOIJB@#Y[T7PW_:?PTU'1-*^&U_HFO0>''L[G4;JW6W%Y,#&2B'.92Y0M MN/W< 9P:N^'9-=U[XB_#6ZF\(ZYI5IH5E1? KPO'X6T VU^IL;K6H(+)7N)BL3%C)$^/-979XGEA"1*TD-?#4.L: M;K^GW.FW@=WC\+0K!WR'ODD#.I&1E@PYZ5]4T4 %%%% !1110!YM_P W3?\ MDUYM_S=-_W)G_ +>UZ30!YM^T'_R0GQ#_ -NW_I3%7I->;?M!_P#) M"?$/_;M_Z4Q5Z30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 >;?&3_F0O\ L<]._P#: ME>DUYM\9/^9"_P"QST[_ -J5Z30 5R'Q5US4?#7PNUO5]%N/LU]:PJT,NQ7V MDR*,X8$'@GJ*Z^N8^(_AJ[\8?#S5M!TV6"*ZO8E2-[AB$!#JW) )[>AH XSP MUXSET#PKJ?B7Q)\1;;QG;6MI%-+8:;9VJ2VA9@.?+?DY./FQT-;'_"Y] _L$ M:J=+UT1S7"V]A =/(FU$E=P:!,_,N.YQ^HI/$'PNL[GX6:CX>\-:;H^F:I?6 M<4$MQ%;B%9&1E)+LB;B,@]0>M5/B3\*KGQOX4T"T@FLC?:+@B&\,GV>X&P*R MLT9#J,J#DZL+RU*746W <#)!4GWKS>W^ ]Y-_$&E?$JTT)/$L/@W2);/SH-3N M-.6Y2ZFSS&S-P@ [\8_$5W.G>,X(]>T3POJ3_:M9OM*%Z]W9J#:OM&'*L6S@ ML"1P>,/O#?COQ!)>Z?HUUX;N-"OXA&T&KVSM);';@M&5!#'JPW=#6*WP MI\2^';CPK?>"-6TV2^T33GTZ&[3PE M+XCN(-12PAU4Z4_[E2XD'5\!N4[^OM5G1/BCIFM>(M.T632-:TNZU."6>U_M M*U6$.(R=RXW%LX&X<8P1SVKD(O@_X@C^'JZ#+J.G37B^)AJYGRZ(\6[UU'Q3\#:MXNL]*O/"MY;6&NZ3=&6WN+DL%V.I5URJL>?E[=J ,V3 MXG6VO:[X;_L._P!1L+2ZUFYT]D-A#*FH>4JY(5']J^T;@OE[=^W/.?O=/RK,@^%5UIT'P[MM.GM!#X6E M>6]W%@9F=1N9 %.3CK7!>)/@#XGUKQ-J.H& M_P!&NC-J'VNWO;N:Z^TK&7!\G:"8U4#.,*3P!P.GJ6@>#[_2OBMXM\37$ULU MEK<=HMO&C,9$,401MP(P,D<8)_"@#LJ*** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH \V_P";IO\ N3/_ &]KTFO-O^;IO^Y,_P#;VO2: /-O MV@_^2$^(?^W;_P!*8J])KS;]H/\ Y(3XA_[=O_2F*C_AGSX8_P#0L_\ D_<_ M_'* /2:*\V_X9\^&/_0L_P#D_<__ !RC_AGSX8_]"S_Y/W/_ ,G?^U*])KP#XE_!WP)X?\ ^$2_ MLC0OL_\ :/B:RL+K_3)W\R"3?O3YG.,X'(P?0UVW_#/GPQ_Z%G_R?N?_ (Y0 M!Z317FW_ SY\,?^A9_\G[G_ ..4?\,^?#'_ *%G_P G[G_XY0!Z317FW_#/ MGPQ_Z%G_ ,G[G_XY1_PSY\,?^A9_\G[G_P".4 >DT5YM_P ,^?#'_H6?_)^Y M_P#CE'_#/GPQ_P"A9_\ )^Y_^.4 >DT5YM_PSY\,?^A9_P#)^Y_^.4?\,^?# M'_H6?_)^Y_\ CE 'I-%>;?\ #/GPQ_Z%G_R?N?\ XY1_PSY\,?\ H6?_ "?N M?_CE 'I-%>;?\,^?#'_H6?\ R?N?_CE'_#/GPQ_Z%G_R?N?_ (Y0!Z317FW_ M SY\,?^A9_\G[G_ ..4?\,^?#'_ *%G_P G[G_XY0!Z317FW_#/GPQ_Z%G_ M ,G[G_XY1_PSY\,?^A9_\G[G_P".4 >DT5YM_P ,^?#'_H6?_)^Y_P#CE'_# M/GPQ_P"A9_\ )^Y_^.4 >DT5YM_PSY\,?^A9_P#)^Y_^.4?\,^?#'_H6?_)^ MY_\ CE 'I-%>;?\ #/GPQ_Z%G_R?N?\ XY1_PSY\,?\ H6?_ "?N?_CE 'I- M%>;?\,^?#'_H6?\ R?N?_CE'_#/GPQ_Z%G_R?N?_ (Y0!Z317FW_ SY\,?^ MA9_\G[G_ ..4?\,^?#'_ *%G_P G[G_XY0!Z317FW_#/GPQ_Z%G_ ,G[G_XY M1_PSY\,?^A9_\G[G_P".4 >DT5YM_P ,^?#'_H6?_)^Y_P#CE'_#/GPQ_P"A M9_\ )^Y_^.4 >DT5YM_PSY\,?^A9_P#)^Y_^.4?\,^?#'_H6?_)^Y_\ CE ! M_P W3?\ DUXWX4\':%X(_:2DTWPQ8_8;27PD9WC\YY,N;Q5)R[$]% M7C..*]DH \V_:#_Y(3XA_P"W;_TIBKTFO-OV@_\ DA/B'_MV_P#2F*O2: . M\9_$76/#_C6Q\,^'?"G_ D%[=V37F/[12UVJK$'[ZD'IGK^%:'@WXCZ5XK\ M'6^OW6W1HYKDVACO9E4><#@*KG ?/;'7D=J\[^,&@VU_\6=&OO$'@_7?$NAQ MZ4\D6TLA67S&*Y*,N,9SC=WZ5@R^#/$EQ\&8M(O-$U/[#)XJCEL=+E5I9 M[6P)/#[,T >\R>+_#4.F+J4WB'2H[%Y#&MTU[&(F<=5#[L9'IFK M%YKVCZ?IB:C?ZK8VMC)C9=3W*)$V>F')P<_6O"?B[\/[ZQ\7Z/>>&=#E7P]! M8-!]GTK0H-2$,Y=BS?9G(7Y@4^?K\M4KKPC+;_"/PW$^C>*+^2TOKN>'.@1- M+;,QX66P=F5HV.2/F&.O>@#US6/'%S:_$WP=H&F?8[G3-?BNY);@9=L11%T, M;!MN">N0L#27UO35U(G LS=QB8G_ ',[OTKR#PYH?B!?%OPG MNM1\.2:;]BMM2%[';0-Y-H71]@8\B/=D':2.3@=,5Q;>"]6?P-<>#Y_A[J,O MC674/-'B4VR^3_K@YD^U9S]W(Q[YZ\4 ?2[:_HZQ7TC:M8B/3FVWKFY3%L?2 M0Y^0_7%/&MZ4T]C -3LS+J*&2RC%PNZZ4+N+1C/S@*.:\1\<>#=?;XE7 M>CZ;87EQH?C..Q&JWL$;%+=H)!YA+ 87#P MCIKZ3833P,B7+-,_[Z,D 2>F:RT\!6VO_ !-^(.HZYX4>2VETNU73#H:CXGDM/%F@Z3:VUKNS.['X5XKX.T'7XM<^#\U_I&H1#3K'4(KQI+5U%KF-U MC$F1\A(P!G&:=\.M#;1?$ATOQ'\/;^ZU]=8ENO\ A(S /)$9)(D^T9R>/X!U MSS@YH [OX:_$0>*?A_I6M^)[C3=.O=2N9+:&)9/*65Q(55$#L2S$#H"2:Z5_ M%WAN.=(7\0:4LLDS0)&;V,,TJG#(!NY8'@CJ*\"^%WA7Q#X5O/!VMZ]H&HWU MFPN+ VLMHYET>5YF(N!'C(5AU8C@=\;13Y_ALUW\+OB+>7?A2>7Q!+KT[:>[ MV3FX>'S(RIBXW%3N?E>#SUQ0!]!:IX@T;0_*_MO5['3O..(OM=RD6\^@W$9_ M"C4?$&C:1'!)JVK6-BEP<0MY\<1ZM=Z=JEU8 MW6D6\"/9^'X=6:)PGSH8Y&'E'=N.X<_-2>)/"5Y:^%/"8M/#WB'5K^TTEH+= M[C0X[B,[I&(AN;=V)@(& )%8D ^U 'T/>^(-&TVZM[;4=7L+2>ZQ]GBGN41I ML]-H)RWX5HU\V^/_ SJTVJ:7<6O@F_NM8?2+2V>W&GI>Z>V%&^,RLP>W*$D M;U8D@#D9)KZ0C+F)#* KE1N / />@!U%%% !1110 4444 %%%% !1110 444 M4 %%%% 'FWQD_P"9"_['/3O_ &I7I->;?&3_ )D+_L<]._\ :E>DT %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% 'FW_-TW_;?\W3?]R9_[>UZ30!YM^T' M_P D)\0_]NW_ *4Q5Z37FW[0?_)"?$/_ &[?^E,5>DT %%%% !117BOASQQK M%]8>';JR\7MKFM7>IB'4-!$5JXBMC(Z.Y6*-9(MB[7WLVW( (.X4 >U45S>N M^-(M DGDN]%U:33K5T2ZU*..,0P;BO.'=9'50P):-&'49)5@(]2\=0V/B"^T M6TT35]4O;&VCNIELHXMHB?=@[I)%7(*8VYW'/RA@&*@'445R\OCW37LM$FTB MUO-7FUR(SV5K9J@D:)5#,[&1T50,J#E@L?VE(/^$C M:TLK&5&:XW-!!MMT0G .XMQD+R6SCYJ /2J*YB'QS:C^TXM3TS4=+O=-LVOI M+.Z6(R20 'YT:.1D89!7&[(/4#(-4(_B?9/)IJ_\(_KR_P!L1&32R;5/]-(" MDJ 'S&<-G,H1<*3NP,T =M161X<\1VWB2RN)K>WN+2:TNI+2ZM;I5$D$J8RK M;693D%6!5B"&'-9VJ>.[73KC45@TK4]2M]*XU&[LDC,=H=H<@[G5G*H0Q$:N M0"._% '445YEJ6OW>K_%JQM+>PUN\TJ#2!?VRZ=?1V\=PS2(1,V)T+H -NU^ MY;Y2#FJ_@3Q=(FCW>M:[9ZY+J&HZI/:6L+W:RI00 M<$&L[Q=X^U70_!&J:M:^%]1MKZR\LB&_6$QA6)_>%HYBK+P055BX)4E<'- ' M=T5S%WXU-I-8V;^'=7?5;V.69--1K8S)%&0&=F\[R\99> Y;YNG7'1V\RW%M M%.BNJR('"R(48 C."IY!]CR* )**** "BBB@ HHHH **** "BBB@ HHHH ** M** /-OC)_P R%_V.>G?^U*])KS;XR?\ ,A?]CGIW_M2O2: "BBB@ HHHH ** M** "BBL_6QK#Z6R>'6LX[YW51+>AC'$I(W-M7ER!G"Y4$XR10!H45ROPSU;4 M=<^'.E:AK5U]KOI5D$T_EK'O*RLH.U0 . .E9_Q/U7Q3HNDPZAX?O+.RL8)[ M=;EWB\V>9I+F*+RU##8B[78ECN). OWJ .ZHK-UC3M0U)8([#6KC2(T8M*] MK!$\LG& H,JNJKR2?E).!@CG.'\--=U'Q#X1:[U69;MHKVXMH+U(P@O(HY"B MS8' W8[8''% '745R.C:C>ZK\0O%#)*[6ND1P6%M;&4K$\Q3SI'8<\_/&N<' M 4XZG-7P+J?B6Y\5>)]-\67UK+-9LK/7F\3:#:0PF/562'Y;ALEX!)"B1R878QP"5WX)Z"N\H ***X6?5 M?%-K\7M*T^^O+--%U&"\:"RMHMS[85AVR22,,[B9&^50 !RW6@#NJ*@O8[F M:PGCL;A;:Y>,K%,\7F"-L<,5R,X],BN,T?4=9T_XK3^&9]9N-?7EYXB\.>.O"UA+XBEUG^V9)TO+.6T MAC2)%CWF6+8H=%5L+AV?(<#)/-:OA_4+J'XA>)M"NIY9XE6WU&T\URQC2561 MXQGHH>(D#MOQVH ZRBBB@ HHHH **** "BBB@#S;_FZ;_N3/_;VO2:\V_P"; MIO\ N3/_ &]KTF@#S;]H/_DA/B'_ +=O_2F*O2:\V_:#_P"2$^(?^W;_ -*8 MJ])H **** "O.K;X>ZI9>!?#MK;3V:^(- OOM5O<;V$3*TK>;&6V[MKQ.RGC MKCTS7HM% 'DGC3X6ZOXC;Q'''9^'[Z75FW6FK:F\C7-@@0 0HOEMM7<#AE<8 MWD[6(P>YT_P_=6GQ"UK7I)(3:ZA96MO$BL=ZM$92Q88QC]X,8)[]*Z*B@#S3 M0_ ?B'PQIWA*YTYM,O-3T73Y=.O+>>XDBAFCD*MN241LP971>"G()Z8&5A^' MVO\ ]G7\]S>:4^1N4<.NX9[-C^&O2J* .%N/">N:Y? M:UJNM?V?9WMUHTNDV=K:W#S1HK_,9))&C0DEL# 3@#J2>+,7A&_2\\#2F:VV M^'8'CN@&;+EK;RAL^7GYN><%M>@U:X6Z6;68\3V;E CJ/W3^:G MRA@-T>"6'?=7I5% ',VWAF>U^($.M1FUCL8M%73EAB4H5<2[_E3& F.!SQTK MF)OAA>3^#=.L+E=*OKS3=:N-22VO%,EKVMAE'!%>FT4 > M>W'P^DN_">H6ECH_AWPS?RSV]S;+I<)>,R02"1/.<)&7!8$8"C:"<$YK1U_1 M/$?B[P3KFD:K'I6G37D CLTM[B2X57'S;I)"B'!(48"<8)RV<#L:* .&\5>' M]>\3Z/:I>:#X?GO(U9D9]1GC>QG# QRP7"0[_P"$$@*AXQN(KK-%LKG3M!L+ M*_O7O[JVMHXIKMQAIW50&DUYM\9/^9"_['/3O_:E>DT %%%% M!1110 4444 %5-3DU&*R+:/:VMU=;AB.ZN6@0CN=ZQN<^VVK=% '#>$-%\7^ M&_A\^B^1HBZC:1/]AF^V330RR,[/^\7RD*J-P'REB>>E3>/M&\3>)/#:Z1I5 MKI+>:UM--<7-])%M>*9)2JHL+Y4[,9+ C/0XY[.B@#B_%^F^,?$&@V-C8PZ7 M:K.[?VO"NIS(7B!XBBG$!(##[S; 0.!UW#H/#L-[:Z3':WVEZ?I:VX$5O;:? M=-/&L8 Y:*/'IC!X YK4HH XKP]')I'Q(\86&Q=VH"WU6T#':L@,8AD&0#T M>(9XX$B\5&5& UNH?)([KCWK MMJ* .+U7P_XEU1=(U:5M)&NZ+J4L]M&C2+;SV[J\9C9B&9',;YW!6 8=,4[3 M] \0VM]K?B*3^RQKVHK!%%:B21[:*&%CA#+M5BS!W^?9\I*_*P7#=E10!Q^C M>'-7?X@7'BS7(M/L96TX:>EI87#SB0>8'\R21HX\D8V@;> 3SS@:^I>#O#&M M7IO-8\.:3?W3 *9[JQBE<@=!N92:V:* ,_2= T?0(9(M"TFQTR.5MTB6=LD( M<],D*!DUR^M:3XNO/'^DZY9:;HK6NDQW4,:RZK*CSK-Y?S$"V(0CR^F6SGKQ M7<44 8EX?%(FUC^SUT=H_LZ?V2)VE!\[!W&? /R9VX"\D9Z=:Q/ NA>(O#T4 MB:OI^F375X3/J&JKJLDT]W/C )0VZ!5[!0V$7 /?MJ* //_ MH7C#3O$-S MK'B+3]$OM2OY!'/?QZK-FVM@V5A@B-OA5'4C>"[ MWAMM)B?'WWC#2RX]@957ZJ?2NTHH **** "BBB@ HHHH **** /-O^;IO^Y, M_P#;VO2:\V_YNF_[DS_V]KTF@#S;]H/_ )(3XA_[=O\ TIBH_P"&?/AC_P!" MS_Y/W/\ \\CD55\H(IP03G.>/3\: MR-=^)>GZ1<^)[*&RN;B^\.:<+^9&*I'*I7] &5_PSY\,?^A9_ M\G[G_P".4?\ #/GPQ_Z%G_R?N?\ XY7;^'-7_P"$@\*Z5K/D?9_[1LH;OR=^ M_P OS$#[=V!G&<9P*TJ /-O^&?/AC_T+/_D_<_\ QRC_ (9\^&/_ $+/_D_< M_P#QRO2:* /-O^&?/AC_ -"S_P"3]S_\DT4 >;?\ #/GPQ_Z%G_R?N?\ XY1_ MPSY\,?\ H6?_ "?N?_CE>DT4 >;?\,^?#'_H6?\ R?N?_CE'_#/GPQ_Z%G_R M?N?_ (Y7I-% 'FW_ SY\,?^A9_\G[G_ ..4?\,^?#'_ *%G_P G[G_XY7I- M% 'FW_#/GPQ_Z%G_ ,G[G_XY1_PSY\,?^A9_\G[G_P".5Z310!YM_P ,^?#' M_H6?_)^Y_P#CE'_#/GPQ_P"A9_\ )^Y_^.5Z310!YM_PSY\,?^A9_P#)^Y_^ M.4?\,^?#'_H6?_)^Y_\ CE>DT4 >;?\ #/GPQ_Z%G_R?N?\ XY1_PSY\,?\ MH6?_ "?N?_CE>DT4 >;?\,^?#'_H6?\ R?N?_CE'_#/GPQ_Z%G_R?N?_ (Y7 MI-% 'FW_ SY\,?^A9_\G[G_ ..4?\,^?#'_ *%G_P G[G_XY7I-% 'FW_#/ MGPQ_Z%G_ ,G[G_XY1_PSY\,?^A9_\G[G_P".5Z310!YM_P ,^?#'_H6?_)^Y M_P#CE'_#/GPQ_P"A9_\ )^Y_^.5Z310!YM_PSY\,?^A9_P#)^Y_^.4?\,^?# M'_H6?_)^Y_\ CE>DT4 >;?\ #/GPQ_Z%G_R?N?\ XY1_PSY\,?\ H6?_ "?N M?_CE>DT4 >;?\,^?#'_H6?\ R?N?_CE'_#/GPQ_Z%G_R?N?_ (Y7I-% 'C?A M3P=H7@C]I*33?#%C]AM)?"1G>/SGDRYO%4G+L3T5>,XXKV2O-O\ FZ;_ +DS M_P!O:])H \V_:#_Y(3XA_P"W;_TIBKTFO-OV@_\ DA/B'_MV_P#2F*O2: /( MOB#JD?@WXU^'/%NMPW"Z%_9LUC->10M(MO(6+#>%!(!R,=SSZ5RMW?CQ9_PM M;Q?I-O<'0[K0EM;6[FB:,7#)%\Q4, <#'ZCUKZ'HH ^:M:;22OP[C^(IOAX+ M/A.V*>3YOE&]V#[WE?-G;MQ_^NL_XJM+_:GAI+MB/":Z'&;)O$8O?+\W<>7^ MS?/YVT+][C'6OJ6B@#YDM])_X22W^$.E:SK+:O9W3W\D[QI$OS6X3]TH4 M+R7XR",+6:2'6-%MY);DF=_M%\JHL?W#][ M3C@=SU)J*\;55\$?$?\ LO[;Y1\<3"_^Q ^;]EW_ #XQSCIG';KQFOI:B@#Y MV\&IH)\<:K)\*/M__"*?\(]/_:!D\_R#=<[<>;SOQC\,X[UB:/X=M-"^'_PR M\96$MY_;=WKUM9S3/=.P:!GD'DAG?^ MU*])KS;XR?\ ,A?]CGIW_M2O2: "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S;_ )NF M_P"Y,_\ ;VO2:\V_YNF_[DS_ -O:])H \V_:#_Y(3XA_[=O_ $IBKTFO-OV@ M_P#DA/B'_MV_]*8J])H **** "O+--\?^)QH/AO7]2?1[BTUK5%L#I]O:2PS MH'D>,.DAF<.5VABNP97=R,5ZG7D6B_#J_P##OA3P]J^DZ);VWBO3;QGO$A,2 M/>V\DK++'(X.U_W;!EW$X*#'/% '?ZEXVT'2;Y[6^NID,']&U2XTV]NYVOK:%;B6VMK*>XD2)LXDVQHQ MV#:06Z*2H)&Y<^?^/_"_BW7K;Q/9+INK:C/>'&DSP:R+:RAA"*=CPB5=S[@_ MWD8$E^, M-#L+'3[N2\:>/4QFR6S@DN9+D;-^Y(XE9F 7DD# XSUKG?"GCZUN]+\4ZSK& MJHVEV.M/;6LICP5B\F$K&%5=S/O=AMP7).WKQ6)X;\,>)/"]AX(U";19M0GT MO2I]-OK""XA\V R%'61"[K&PS&%/S@X88S@TL/A/Q/)8:CJ-QI<<=['XN778 M+ 72-]H@6"--@?[H?AL;L#V]_+'^T37/$>JZ]K,NCS:7YGA^;2;2SN9X6FN)')?>?+=D50<*,MGEB<#&;,/ MAS54OOAU(UKA=%MI$OSYB?N6-IY8'7YOFX^7/Y4 =7HNNZ=XAL&O-)G:6))7 MAD#Q/%)%(APR.C@,C CHP!Z'H15#5?&V@Z+>S6NH7

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end GRAPHIC 18 cstl-20211231_g14.jpg GRAPHIC begin 644 cstl-20211231_g14.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1#R17AI9@ 34T *@ @ ! $[ ( M - (2H=I 0 ! (6)R= $ : 0T.H< < @, /@ M &UL;G,Z9&,](FAT=' Z M+R]P=7)L+F]R9R]D8R]E;&5M96YT#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@ M96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8 M%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4 M"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ_\ $0@ ;@,' P$B (1 0,1 ?_$ !\ $% 0$! 0$! M ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" P $ M$042(3%!!A-180'EZ@X2%AH>( MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! M @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$' M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66 MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F MY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:*YCXC:U>^'? &I:II4BQ7 M<'E>6[(& W2HIX/'0FO"?^%T^-O^@C#_ . L?^%=='"5*T>:-CEK8J%&7+*Y M].T5\Q?\+I\;?]!&'_P%C_PH_P"%T^-O^@C#_P" L?\ A6W]G5NZ_KY&/]H4 M>S/IVBOF,?&KQL#DZA"?8VL?^%:%G\>?%,##[5!872]P8BI/X@TGE]9=@684 M7W/HRBO)="^/ND7;+'KNGS:>QX,L3>:GU(P"/R->G:7J^GZU9+=Z3>0W<#?Q MQ-G'L?0^QKEJ4:E+XT==.M3J? RY1116)J%%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 44$@ DG '4FL6'QCXV@N97M?4LT445(PHHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBO+OC%XWUSPA<:4NA7*0"Y64R;HE? M.TKCJ..IK6E3E5FH1W,ZM14H.S/IJBOGS3_C_K\##^T=.L;M<\[-T;?G MDC]*[WP]\;/#.L.L.H&329VX_P!(YC)_WQT_$"L9X.M!7:OZ&L,91GI>WJ>C M44R*6.>%98)%DC<95T.0P]0:?7(=84444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <3\8O^ M23ZS_P!L/_1\=?+=?4GQB_Y)/K/_ &P_]'QU\MU[V6_P7Z_HCPLQ_BKT_5G> M:/\ ![Q/KFCVNIV1LOL]U&)(]\Q#8/J,5=_X43XO]=/_ / @_P#Q->U?#?\ MY)MH?_7HO]:Z>N2ICZT9M*QUT\#2E!-W/FQ_@7XP5*1DD5D=3@JPP0:T= M!\1ZKX9U%;W1KM[>4$;@#E7'HPZ$5]/^+OA]H?C&V;[?;B&\Q\EY" )%/O\ MWA[']*^;/%_@_4O!FLFQU)=R-EH+A!\DR^H]_4=J]*AB:>(7*]^QYU;#5,.^ M9;=SZ'^'OQ%LO&]B8V"VVJ0KF>WSPP_OIZC^7ZUVE?&>BZQ>:!K%MJ>FRF.X MMW#*>Q]0?4$<&OK;POX@MO%'ARTU:SX2=/G3/,;CAE/T->5C,+[%\T=F>G@\ M3[5K!-1#W&N3RV@;/E+ %5B\-5JU M.:.J.U^%^J7FK_#K3+K469Y]K1EVZN%8J"?7@"NMJ"QL;;3;""RL8EAMX$$< M<:]% J>O,J24IMH]*$7&"3"BBBH+"BBB@ HHHH ^0?&6J7FK^,=3NM1D9Y?M M#H 3]Q58@*/0 "NO^!FJWMMX\73X78VEW"_G1_P@JN0WUR,?C7HWC/X,Z9XH MU:34[*\?3;J8YF CWI(?[V,C!K8\"?#;3/ RRRP2O>7TR[7N9%VX7^ZJ]A^= M>S4Q=&5#E6]MCQZ>$K1K\SVON=C1117C'L!1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %>'?M$?\?6@_P"Y-_-*]QKP[]HC_CZT'_;@\/"LGS=#YN_X43XO]=/\ _ @_ M_$U%-\#O&42Y2"SF/HER!_/%?2U%<']H5O([O[/H^9\B:QX&\2Z C2:IH]S# M$O655WH/^!+D5@5]M$ @@C(/45YKX[^#VE^(89;W0HX].U/!;"#$4Q]&'8^X M_&NJCF*D[5%8YJV7M*]-W/'/!7Q%UCP9=J+>0W.GLW[VSD;Y2.Y7^Z?\%%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <3\8O\ DD^L_P#; M#_T?'7RW7U)\8O\ DD^L_P#;#_T?'7RW7O9;_!?K^B/"S'^*O3]6?6?PW_Y) MMH?_ %Z+_6NGKF/AO_R3;0_^O1?ZUT]>+5_B2]6>S2_AQ]$%%%%9F@5SGCKP MG;^,?"]QI\JJ+A09+64C_5R A]C71T549.$E);HF45*+BSXIG@DMKB2" M="DL3%'4]5(."*]?^ 'B%H=3OM F?]W.GVB 'LZX# ?48/\ P&N6^,6DKI?Q M)O3&NU+Q5N1QW88;_P >!K)^'NHG2OB%HMR&VJ;I(GY_A<[3^C5]'42KX=ON MKGSM-NAB$NSL?6U%%1W%Q#:6TEQ.?#7A] MF35=7MXI5ZQ*V]Q_P%76QZ3Y::N?23?&_P8KX%S M=,/[PMCC]:TM,^*W@W59!'#K$<+DX N4:+]6&/UKY^C^&?C*6(2)X?N]I&?F M 4_D3FL34]%U/19O*U:PN;-ST$\17/TSUK?ZCAY:1EKZHQ^NXB.LHZ>C/LJ. M1)8UDB=71AE64Y!'UIU?*?@KXC:QX,NT$,K7.GEOWMG(V5([E?[I^GXU]-Z! MKMCXDT6#5-+E\RWF'?[R'NI'8BO.Q&%G0>NJ/0P^)C76FC-&BBD9U1&=V"JH MR6)P /6N0ZA:R-8\5Z%H'_(8U6VM6[1O("Y_X".?TKQWXA_&>YNKB72_"$Q@ MME)62^7[\I_V/[H]^I]J\AEEDGE:6:1I)'.6=SDD^I->I1R^4US5'8\RMCXQ M?+35SZ9D^-7@J-RHOYY,'JML^/U%7-/^+/@S49 D>LI Q.,7$;1C\R,?K7RT ML4CC*(S#V%,((Z\5U/+J-M&SE685;ZI'VM;W,%W LUK-'/$PRLD;!E/T(J2O MC_PYXNUKPI>"XT:]>(9R\+',M?3'@'QM!XXT$WD<#V]Q"PCN(B"5 M#8SE6[C]17G8C!SHKFW1Z.'Q<:SY=F7?&.OR>&/"=[J\4"W#VRJ1&S;0V6 Z M_C7D?_#0U_\ ] "V_P# AO\ "O1?BS_R2_5_]Q/_ $8M?*]=6!P]*K3;FKZG M+C:]2G42@[:'V=H]\VIZ'8W[H(VNK>.8H#D*64''ZU *^=O$7BC5O%.HM>: MS=O,V?DCSA(QZ*O0"LJ.*25ML2,Y]%&:]:GEL4KU']QY-3,9-^XCZ-XFVR(R'T8 M8J[HVN:EX?U%+W2+N2VG0]4/##T(Z$>QIU,M@U[C%#,9I^^C[+HKEOA]XR7Q MKX96^:$PW,3>5<( =N_'53Z'].E=37C3BX2<9;H]B,E.*E'9GD?C#XT7GACQ M;?:/%H\%PEJRJ)&F(+94'ICWK9^&WQ,N?'>HWMM<:=%9BVB$@9)"V[)QCD5X MS\6/^2I:S_UT3_T6M==^SU_R']8_Z]4_]"KUZF'I+#33Q%5XGD;TNS MWNBBJVHZC::1ITU]J,ZP6T"[I)'/ '^>U>.DV[(]ANVK+-<[K7C_ ,+Z [1Z MEK%NDJ]8HR9''U"Y(_&O#?'?Q>U7Q)-+::/))IVEY*@(<23#U8CH/8?CFO.< MDGGDUZM'+FU>H[>1Y5;,$G:FKGTN?C?X,#[101WI:^6/!?Q.UOPA/'$)6O=.S\]I,V0!_L'^$_I[5])^'?$6G^*-&B MU+29?,ADX93PT;=U8=B*\O$86=!ZZKN>E0Q,*RTT?8U*@O;ZTTVT>ZU"YBMH M$QNEE<*HSP,DU/7#?&/_ ))=J7^]%_Z,6L:<>>:CW-ZDN2#EV-S_ (3?PM_T M,.F?^!2?XUMQ2QSPI+"ZR1R*&1U.0P/((-?$]>I>-?B?=_V%IWASP]<-!%#9 M0I=W,389V\L913V Z'U/Z^C4R]II0>YYU/,$TW-;'L>M_$+POX>D:+4M7A$R M_>ABS(X^H7./QK"7XW^##)M-S=*/[QMFQ_C7S2J23/A%9V/H,DT2121-ME1D M/HPQ73'+J26K9SRS"JWHD?7NA^,?#_B3C1M4@N),9,6[:X_X"<&MNOBF">6V MG2:WD>*6,[D=&(93Z@BOHGX1_$:7Q3:OI&LN&U.V3OK7 M'B<"Z4>>#NCKP^-567)-69Z;1117FGHA7AW[1'_'UH/^Y-_-*]QKP[]HC_CZ MT'_2>J%%%% 'E'QO\&)J6B?\)'91@7=B +C M:/\ 61>I]U/Z9]*^?*^U+RTBO[&>TN%W13QM&X/<$8-?&>H6CV&IW5G)]^WF M:)OJI(_I7NY=5J:;;:OILUE>IOBE7!]0>Q'N*\O&P=.K)1]3OPU24Z":W(?^$BT7_H+6/\ MX$)_C5RVN[>]A\VSGCGCSC?$X89^HKY_U[1;G0-7EL;H>P5=0U6PTFW$^J7L%G$S;0\\@0$^F36;_PF_A?_H8=,_\ I/\ M:^>_BIXW/B_Q,8[20G3+(F.W /#G^)_QQQ[ 5F> _!]QXT\2Q6,>Y+6/$EU, M!]Q/\3T'_P!:O5C@8JGSU)6/+ECI.IR4U<^K;*^M=2M%NM/N(KF!\[98F#*V M.."*GJ"QLK?3;""RL8EAMX$"1QJ.% J>O+=KZ'IJ]M0HHHI#"H;F\MK.+S+N MXB@3^]*X4?K6!XT\6)X9TY?)"R7L^1$AZ*.[&O(2VL>*-3_Y>+^Y?G YP/Y M?I7+6Q*IOE2NSS\3C8T91[5_PEWA_P S9_:]IG_KH,?G6E:WUI?)NL[J M&X7UBD#?RKQD_#CQ*(?,^Q+TSM\Y<_SK#=-2T+4<.)[*ZC.1U5A_]:L/K52/ MQQ.5YA6IZU*=E\SZ)HK#\(7^IZCX>AN-9@\J8_=;H9%[,1V_R:W*[XRYDFCU MX24XJ2ZA45Q=06L?F74\<*?WI'"C\S7!^,/B*+":33]"*R3J=LEP1E4/HOJ? M?I7G:IK'B2^.T7-_<-U/+8_P%4^$/B+=0745CKKM<0.0 MJ3GET/;/J/UKU:NNE5C55XGHT,1"O'FB%-=UC0M(RHHZEC@"N9\7^-;;PU%Y M$(6XOW&5BSP@]6_P[UY-J&LZQXCO +F::Y=S\D* X'L%%95<3&F^5:LY\1CH M47RK5GMI^$M6$BQKUD3#J/J1G%8_6:JU<-#F>.Q"7-* MGI\SWRBO$?#?CO4]#F2.>1[NSSAH9&R5'^R>WTZ5[-8WL.HV$-Y:L6AF0.A( MP]EO\%^OZ(\+,?XJ]/U9]9_#?\ Y)MH?_7HO]:Z>N8^ M&_\ R3;0_P#KT7^M=/7BU?XDO5GLTOX7:4YCUBS=>JSH1_WT*]%^/=^MSXZM[5#G[+9J&]F9F;^1%< M)X6LVU'Q=I-H@R9KR)?PWC/Z5]+AM,.K]CYS$:XAV[GV+7B?QW\8R(T/A>PE M*AE$UX5/7^ZG]3^%>V5\>^+-5?6O%VJ:A(<^?7E])3J>*/$%MI6GC][.W+D<1J.K'V KZE\)^"](\':3_ B71M-&JZEJE_:6MPQ2"(3S*AV_>;&3W./RKV'_A+/ M#O\ T'=-_P# M/\ &M,=4J2G[-;(SP-.$8<[W9KU3U32;'6M/DLM5M8[JWD& M&21<_B/0^XJI_P )9X=_Z#NF_P#@6G^-'_"6>'?^@[IO_@6G^->:HS3NDST7 M*#5FSYG^(O@Q_!7BA[.,L]E,OFVLC=2N?NGW!X_+UKI/@AXK?2?%7]BW$A^R M:EPH)X24#@_B./RKHOCK?:/J_A[3;C3]1L[JXM[DKMAG5V",O/ /3*BO&-,O M7TW5;6]B.'MYDE7'JI!_I7T%.^(P]I[G@U+8?$7AL?:%>3_'+QA)I>CPZ!82 M%)[]2]PRGE8@<8_X$?T!]:]6BD6:%)4.5=0RGU!KY5^*6J/JOQ)U:1FRD,OV M>,>@0;?Y@G\:\O TE.K=]#T\;4<*5EU.256=PJ LS' &237T#\/?@W8:?8P MZCXJMUN[^0!A:R#,< ]"/XF]<\#]:\[^#6@)K?Q @DN$WP6"&Y8$9!88"_J0 M?PKZF0ER,+/$@21/<,/Y'BM^BO'C.47=,]9QC)6:/ HO@-J \8?99KH'1 M%_>?:QC>RY^YM[-[]._M7N.DZ39:)ID.GZ7;K;VT*X5%'ZGU)]:N45M6Q%2M M93>QE2P].E=Q6YQOQ9_Y)?J_^XG_ *,6OE>OJCXL_P#)+]7_ -Q/_1BU\KUZ MV6_PGZ_Y'E9C_%7H?8GA3_D3-%_Z\(/_ $6M>+?M ZC)+XHT[3LGRH+7SL9X MW.Q'\D%>T^%/^1,T7_KP@_\ 1:UX]^T%HTJ:MINM(A,,D)MG8=%926 _$,?R MKAP=OK.OF=N+O]6T\CS3PGH\?B#Q;INE3N8XKJ=4=AU"]3CWP*^L=(T#2M!M M$MM(L(+6-!CY$&X^Y/4GW-?'ME>W&G7\%Y9R&*XMY!)&XZJP.0:]]\+?'31[ M^VCA\2H^GW8 #2HA>)SZ\O^0_K'_7JG_H M5!2_P!\ M^;/>Z^>/C9XUDU?7CH%E*18V#?OMIXEF[Y]EZ?7->\ZYJ(TG0+_4&Q_HMN\H M![E5) KXVGFDN+B2:9B\DC%W8]R3DFN/+J2E)S?0[,PJN,5!=30\/:!?>)M< MM]+TR/?/,>I^ZB]V)[ 5])>$OA7X>\+V\;/:QZA? 9>YN4#8/^RIX4?K[UR_ MP"T&.WT&]UR1 9KJ7R(V]$7K^;'_ ,=%>NTL;B9.;IQ>B'@L/%0522U8U8HU MCV*BA/[H''Y5S/B7X>>'/%%NZWNGQPW!'RW5NH213]1U^AS7445YT9R@[Q=C MT)0C)6DCY&\:>#K[P7KK6%[^\C<;X)U&%E3U]CZBM7X7>-)/"/BF)9Y#_9MX MPBN4)X7/1_J/Y9KV3XSZ!'K'P_GNP@-QIK">-L<[>CCZ8.?PKYEKZ&A-8JC: M?HSP*\'AJUX>J/MH$$ @Y!Z$5PWQC_Y)=J7^]%_Z,6M'X;:NVM_#S2;N5B\J MP^3(Q[E"5S^E9WQC_P"27:E_O1?^C%KQ:47#$*+Z/]3V:LE*@Y+JOT/EZN^^ M%_PZ/C749+G4"\6E6I E*G#2MUV ]O<_XUP-?5WPQTE-'^'.DPJFUYH1<2>[ M/\W\B!^%>UC:SI4_=W9XV#HJK4][9&YI6@:3HELL&DZ?;VJ+T\N, GZGJ3[F MEU70M+UNU>WU:P@NHW&")$!(^AZ@^XJ_17SW-*][ZGO\L;6MH?+'Q,\#?\(3 MXB6.U9GTZ[4R6S/R5QU0GN1D<^A%9'@O6)-"\::7J$;;1'<*'YQE&.UA^1-> MV?'VT27P3:7)'SP7JA3[,K9_D*^>H#BXC(_O#^=?18:;K4/>]#Y_$05&O[OJ M?:]%-CYC7Z"G5\V?1!7AW[1'_'UH/^Y-_-*]QKP[]HC_ (^M!_W)OYI7;@?] MXC\_R./&_P "7R_,\FT#_D9--_Z^XO\ T,5]E5\:Z!_R,FF_]?<7_H8K[*KI MS/>/S.;+=I!1117DGJA1110 5\E?$2%(/B-KB1C"_;'/YG/]:^M:^/?%M^-3 M\9:M>*=RS73\CR\Q:Y(KS.K^![%?B9 !_%;2@_EG^E? M2]?.7P&LVG\?2W ^[;6;D_4D*/YFOHVLLP?[[Y&N7K]S\SG/&GA=/$FD$1 " M]@!:!SW]5/L?YUX=+$\$SQ2J4="592.01VKZ4KS?XE>$]ZMKFGQ_,/\ CZ11 MU']__'\Z\#%T>9<\=SGS#"\Z]K#=;FE\.?%']K:;_9MX^;NU7Y23S)'V/U'3 M\JY_XU^./['TD>'M.EQ>WR9G93S'%Z?5NGTSZUQ6E:E<:1J<%]:-B6%LCT([ M@^QKL/B;X;M_'?@Z#Q1H<>Z]M8R9$4?,\8^\I]U.2/QKLRNM"=11J=/Z1G1Q M$ZN'<%\2_(\'LK.XU&^AL[.)IKB=PD:*,EB3Q7U9X!\'6_@OPU'9)M>[EQ)= M3#^-_0>PZ#_Z]OUZV.Q'/+V M<=D=.!P_)'VDMV%%%-+A')VP(D:CT&,_P R:[_X<:;!9>$H+B-5\ZZ)>1\6_M4F>W??&6'0_U'M3[#5;#5(A)I]W# M<+_L."1]1U%6Z]/22[GN^[-=T%'9O$VL+; M(Q2%?GGEQ]U?\3VKW#3-*L]'LEM=/@6&-1S@AZ)U<1\)M,66^O-2D7)A M411GT+=3^0_6O4ZY\)27+[1[LX\NH+D]M+=A00""",@]0:**[SUSEG^'VB/X M@_M)H?DQDVH'[LOZX]/;I74*H50J@ 8 Z4M%3&$8_"C.%.%._*K7"BBBJ- M#B?C%_R2?6?^V'_H^.OENOJ3XQ?\DGUG_MA_Z/CKY;KWLM_@OU_1'A9C_%7I M^K/K/X;_ /)-M#_Z]%_K73US'PW_ .2;:'_UZ+_6NGKQ:O\ $EZL]FE_#CZ( M****S- JOJ%_;Z7IMQ?7L@BM[>,R2.>P S4EQ21L*H]2 M:^>/BM\3QXGD.CZ&[+I439DEZ&Y8=/\ @([>O7TKHP]"5:=EMU.?$5XT8W>Y MPGB76Y?$?B6^U:<8:ZE+JO\ =7HH_ "NU^!^A-J?CL7[KF#38C(3_MM\JC] M2?PKSB.-YI5CB4N[D*JJ,DD]!7U1\,_"'_"'^$8K>=0+ZY/G71]&(X7\!Q]< MU[6,J*E1Y5UT/'PE-U:W,^FIU=SG[)-MZ[&Q^5?%LV?/?=UW'-?:_6OCKQ1I MCZ/XLU/3Y!@V]RZCW7/RG\1@UR98U>2]#JS).T7ZF6 3T!HVMZ&O:/V?M2MB MVJZ1.$,S[;B(,!\P'RMCZ96O;?LT'_/&/_O@5O7QWL:C@X_B84<%[6"FI?@? M%6UO0T;6]#7VK]F@_P">,?\ WP*/LT'_ #QC_P"^!6/]I_W?Q_X!M_9O][\/ M^"?%6UO0_E1M/H?RK[5^S0?\\8_^^!1]F@_YXQ_]\"C^T_[OX_\ #^S?[WX M?\$J:"2WAO36;J;2(G_O@5\D^*"Q\7:OOSN^VS9S_OFOL4# P.!7RA\3M-?2 M_B1K$3+A9)S.G'57&[^I'X5&727M)%YA%^SB=Q^SR%_M?6B?O^1&!]-QS_2O M=Z^9?@QX@CT3Q]%#]EO\)^ MO^1X>8_Q5Z'V)X4_Y$S1?^O"#_T6M3ZWHECXAT>?3=5A$UM,,,.A4]B#V(]: M@\*?\B9HO_7A!_Z+6M:O$DVIMKN>S%)P29\X^*/@CK^DS/+H8&JV>_X?E7GE[IU[ILQAU"TGM9 <%)HRA_(U]HU#1&.[MXIT/!65 P/X& MO1IYC.*M-7//J9?!N\'8^+ Q5@5)!'0BNR\+?%+Q)X8FC47CWUFI^:UNF+#' M^R3ROX<>U>T^)_@]X:UZWD:QM5TN]()26V&$S_M)TQ],&OF_5]+N=$UBZTV^ M4+/:R&-P#D9'<>W>O0IUJ6*BU;Y,X*E&KA9)W^:/K;PMXGL/%N@Q:IIC'8_R MR1M]Z)QU4_YY%;%> _L_ZK)#XDU#2RQ,-Q;^<%[!D(&?R8U[]7AXFDJ-5Q6Q M[6&JNK34GN?*WQ8_Y*EK/_71/_1:UUW[/7_(?UC_ *]4_P#0JY'XL?\ )4M9 M_P"NB?\ HM:Z[]GK_D/ZQ_UZI_Z%7L5O]S^2_0\BE_OGS9ZI\2<_\*UUS;_S MZM_2ODROLO7-.&K>'[_3SC_2K=X@3V)4@'\Z^-YX9+>XDAF4I)&Q1U/8@X(K M++9+DDC7,4^>+/IWX-^7_P *OT[R^NZ7=]?,;_ZU=U7D7P!UZ.XT&]T.1P)K M67SXU]8VQG\F'_CPKUVO,Q47&M)/N>EAI*5&+78****YSH,+QOM_X0'7=_W? M[/F_] -?(5?37QFUZ/1_A_<6H<"XU)A;QKGG;U<_3 Q^(KYEKW*>R>:_'?_ ))VG_7['_Z"U?.4/^O3_>%?1OQW_P"2=I_U^Q_^@M7S ME#_KT_WA7T&7_P #YG@X_P#C?(^U8_\ 5)_NBG4V/_5)_NBG5\^>\%>'?M$? M\?6@_P"Y-_-*]QKP[]HC_CZT'_/S.;+=I!1117DGJA1167 MX@\1Z9X8TM[_ %BY6")?NKU:0_W5'YK/\,^'K MOQ1XAM=*L%R\S?,^.(T_B8^P%?186BL/2O+?J?/8FLZ]2T=NA[7\ ]":S\-W MNL3+AKZ41QD]T3//_?1/Y5ZS532M-M]&TFUTZR79!;1B-![ =?J>M6Z\*M4] MK4<^Y[M&G[.FH!6/XHUVVT#1);FY"R,X*10M_P M&(Z?3UK4N;B*TMI+BY<1 MQ1*6=V/ KPGQ;XDE\2:PTYRMM'\L$9_A7U^IK@Q%;V4=-VQB. MV^0L%"[CG"C@5ZGH#1_#[P#=:QKTK*)0)%MB>^/E4#^\W?\ ^M6#\.?"W]JZ MC_:5['FTM6^0,.)'[?@.OY5@?'VYU@^(;.WNEV:2(MUKM/#O_&6_VAT^GUHR MO">UJ*4CR\+3=&F\0UKT_P SV'P;XILO%WAR#4; ",XV309YA<=5_P /:MZO ME/X=>-Y_!7B-)V+/I]QA+N(=U[,/QZ^%Q"K0UW1+7G7Q-TN^U;5-+@TZVDN)/+?(1>G(ZGM7HM%> M?4IJI'E9K7HJM3<&SS7P]\+YX98[K5[UH'4Y$5JV&'U?M^'YUZ1&@CC5 6(4 M LJ:7::SI\EG?Q>9$_P":GL0>QKRK6_AE MJMC(SZ7B^@[ '$@'N._X5[#12JT(5?B(KX6G7^+?N?.,L-[IESMFCFM9E[," MC"NH\/\ Q&U72Y4CU%VOK7H1(AY%7"UL(O:4Y:'L=A?V M^IV$5Y92"2&5=RM_3ZUX?XWS_P )MJ>?^>O]!7;?"6[>32[ZT9B4BD5U![;@ M<_\ H-<_\4=.:U\4"[ _=W<0;/\ M+\I_D/SK3$2=2@IFV,FZ^$C4\_^ >D> M#L?\(;I>W_GW7\^];5<9\,=56]\,_8F;,UFY4C/.UCD'^8_"NSKLHR4J::/4 MP\E.C%KL%%%%:FX5Y3\6\_VQ8>GD''_?1KU:O/\ XL:<9M)L]01<_9Y"CGT# M=/U'ZUS8I-TF<./BY8>5B3X2[?\ A';S'WOM7/\ WRM=Y7E7PHU58-2NM-E; M'VA0\>>[+U'Y']*]5HPTDZ2'@)*6'C;H%%%%=)VA1110 4444 <3\8O^23ZS M_P!L/_1\=?+=?4GQB_Y)/K/_ &P_]'QU\MU[V6_P7Z_HCPLQ_BKT_5GT1X(^ M)OA'2? ^DV&H:N(;FWMPDD?D2':?3(7%;W_"WO __0<7_P !I?\ XFOEFBJE ME]*4G)MZ_P!=A1Q]6,4DEI_7<^GKCXS^"H!E-1EG]HK9_P"H%$4^*"6>01P1O([=%122?PIQR^A'5W8I8^M+1:'0> M*/'FO^+I/^)M>'[.#E;:(;(U_#O]3FN=1&D<(BEF8X R2:[;P]\)/%6ONK- M8G3[8]9KSY./9?O'\J]L\%_"O1/"!2Z*_;]2 _X^9EX0_P"PO1?KR?>G4Q5& MA'EC]R)IX:M7ES2^]G+_ G^%;Z4\7B#Q)#B\QNM;5Q_J?\ ;;_:]!V^O3U^ MBBO"K595I!]UA]UC]1Q^ ]:]T MJ"^L;;4K":ROH5GMYT*21N.&!JJ%9T:BFB:])5H.+/CK1=9O= UBWU/3)?*N M+=]RGL?4$=P1Q7TMX,^*.A>*[:..2>.PU'&'M9GQD_[!/##]:\A\>_"/5/#5 MQ+>:/')?Z426!09D@'HP'4?[0_'%><\CVKVZE*EBXJ29XM.K5PDN5H^VJIZI MJ^GZ)8O>:M=Q6L"#EY&QGV [GV%?(EMXEURSB$=KK%]#&. B7+@#\,U4N[^\ MU"7S+^ZGN7_O32%S^9KD66N^LM#K>9*VD=3T+Q]\7-0U_5H4\.SS6%A:2;XG M4[7EB_G7H_PR^*8\7,NDZM"8]51"PDC3]W,HZG_9/Z>GI7A7AKP=K7 MBR\$&CV;R+G#SL-LT7F2'_='\2_J/>O)W1HW*2*493@JPP0:]^4:.,I_U='A1E5PD_ZL MS[3@NH+J$2VL\K@^-%E%KMT''EF$@> M:1G_ %F?7_9Z8_.O;-/U"UU73X;[3YEGMIU#QR(>"*^0M \-:MXFU!;/1K.2 MXD)^9@,*@]6;H!7T[\/O!O\ PA/AL6#W;W,\C^;,WG8>-*5=JH>A7E5C1O3+/P]^-,)NCQ.&!_$5\6,K(Q5U*LIP01@@TZ.>6+_52NF>NUB* M]&ME\)OF@['GTL?."M)7/K[7O%NB>&K1Y]7U"&':,B(,#(Y] HY-?*GBC6SX MC\47^K-'Y0NIBZIG[J] /R K*9BQRQ)/J:UO#OA?5O%.I+9Z/:O,V1ODQA(Q MZLW05K0PT,,G)LRKXB>(:BD>A? #39)O%=_J&T^5;6OEEL<;G88'Y*:^@:Y[ MP3X1M?!GAR+3K8B24G?<38P97/4_3L*Z&O%Q555:KDMCV,-2=*DHO<^5OBQ_ MR5+6?^NB?^BUKKOV>O\ D/ZQ_P!>J?\ H5F6>LZ;/8:E L]M.NUT;O_ ('WKQ\/7=&?-T/7Q%%5H$]#]UU[J1W!KZ3\)?%+P]XHMHU:ZCL+['SVMPX7G_9 M8\,/U]J\=\=?"/5O#,TEWI,9/YG MC4ZM7"RY6C[9#JRAE8%3R"#Q7->)?B%X=\+VSM?7\1CZ8'3ZG% M?)XN9PFP32!?0,<5'U]ZYXY;%/WI7.B692:]V)T7C7QC?>-->:_O1Y<2#9;P M Y$2>GN3W-:7PP\&2^+O%47G1G^SK-A+=.1P0#PGU/\ +--\%_#/6_&%Q'(D M+6>G9^>\F7 (_P!D?Q']/>OI+PWX;T[PKHL6FZ3%LB3EG/+2-W9CW-:8G$PH M0]G3W_(C#X>=:?M*FWYFL , = *X;XQ_\DNU+_>B_]&+7'6OL;PQ_R*.C_]>,/_ *+%?'(K[&\,?\BC MH_\ UXP_^BQ7J9G\,3S,M^*1J4445XI[)YK\=_\ DG:?]?L?_H+5\Y0_Z]/] MX5]&_'?_ ))VG_7['_Z"U?.4/^O3_>%?09?_ /F>#C_ .-\C[5C_P!4G^Z* M=38_]4G^Z*=7SY[P5X=^T1_Q]:#_ +DW\TKW&O#OVB/^/K0?]R;^:5VX'_>( M_/\ (X\;_ E\OS/(M(GCMM\#_ /0;'_@-+_\ $U2N_C=X M-ME/DW%U=,!P(K[.AYA5[(]FUW]H&XE1H_#NE+!D<3W; M;F'_ $@'0#V%0V.F7VIS"+3K.>ZD)Q MMAC+G]*]$\,_ [7]5=)=<9=)MCR5;#RL/91P/Q/X5LHX?#*^B_,Q5BL8ZWNQT7YGJ87"*E[TM M6%%%9G75J1I0+ M/MEP=&T^3-O"W[]U/WW'\/T'\_I7'Z%HUQKVKPV-J.7.6;LB]R:H?,[]V9C] M237MG@3PP/#^CB6Y3%]<@-+GJ@[+_C[UY4(RQ-6[V/G:4)XVOS2V_3L;^FZ? M;Z5IT-E9IMBA7:/?W/N:R?&OA2V\8^&9]-N-JRXWV\Q'^KD'0_3L?8UT%%>S M!N#3CT/HW"+CR6T/B[4=/N=*U*XL+^(Q7%NYCD0]B*]9^"OQ ^QW"^&-7F_< M3-_H4CG[CG^#Z'M[_6MSXV>!/[2L#XETN+-U:IB[11S)&/XOJO\ +Z5X$K,C MAD)5E.00<$&OHHN&,HZ_\,SP)*>$K:?\.C[9HK@/A3X^7Q=H?V._D_XFUDH$ MN>LR=!(/Y'W^M=_7@5*A^\A->?+$5*>,KT*K]K'W?ZZGT0 M2%4EC@#DD]J\>^)/B*WUC5(+2Q<2PV@8&1>C.<9Q[# KG+G7=9U11!<7]U<* MW'EF0D'\.];WAKX>ZEJTZ3:C&]E9YRQ<8=QZ ?U/ZUG4K2KKD@C"MBIXM>RI M1W.J^%.GO;Z'^%=<\]$8,A, M!;3Q%FYMV%M?@?ZS'RR M>S#^O\Z\MU'PWKF@7&ZXM9H]ARLT62OU#"N)>UPSM:\3RXNO@6U;FC_7W'OM M5-2U6RTBS:YU&X2&-1_$>6]@.YKPI/%6O11^6NK787T,IJ.&SUGQ!<@Q1W5] M*>-QRV/Q/2K>-OI&.IH\TYE:G#4[:V^*K_V_(;FW_P")8Y"HJCYXQ_>]_[BX.,'!&0>>_0UQ/A3X:BSF2]U\I+*IW);*-[#7[=(IY$MK\##1,_P!.M:'B+PS8^)++R;Q=LJ?ZJ91\R'^H]J\E MUKP)K6BR,PMVNH!TF@!;\QU%+/-OFMQ^%,DN]8UV81R2W=\^>$RS_I5?75 M;2.I;S2-M(ZG=ZW\43!K<::,BS64)(E+C'G?3T [&NZT36;;7M+COK+>(V." MKK@JPZCW^HKS;PY\,KR[D2?7/[?[/\Z]4MK:&SM8[>UC6*&)0J M(HP *UP_MI-RGL=&#>)DW.KL^A+11176>B5[ZPM-3LI+/4;>.YMI,;XI5W*V M"",CZ@&L?_A O"G_ $+VG?\ @.M=!15*SAV1A1^"/"\39C\/Z<#_U[+_A6I::=96" MXL;.WMAZ0Q*G\A5FBIYD:3]"\0DMK&DV]Q(1CS=NU_^^EP?UK;HJHR M<7=.PI14E9H\\E^!_@V1RR07<0_NIRM]WDVT2Q)N.3M48&?P%3T45EN:[&%K7@GPYXA8O MJ^D6\\K=90NQS_P)<&N8D^!_@UW)6"\C']U;DX_4&O1**UC6JP5HR9E*C3D[ MRBCAK#X.^"[&0.=,:Y8=/M$[,/RR!^E=C96%IIMJMMI]M#:PKTCA0*H_ 58H MI3J3G\3N5&G"'PJP4445F6<1KGPE\->(=:N-5U%;LW-P07\N;:O X&/05?\ M*?#[1/!MU<7&C"X#W"!'\V7<, Y]*ZBBM76J./*Y:&2HTU+F2U"BBBLC4*YO M6OA]X6U^1I-2T>!IFZRQ9C".&!%CCC4(B*,!0!@ 4^BJT[(_Z=UKH**I3D ME9,EPBW=H ,# HHHJ2@K.U3P_I&MM&=7TZVO3$"(S/&&VYZXS]!6C133:=T) MI-69S_\ P@7A3_H7M._\!UH_X0+PI_T+VG?^ ZUT%%7[2?=D^SAV1S__ @7 MA3_H7M._\!UJ:#P=X;MR##H.G*1_T[(?Z5M44O:3[L/9P[$<,$-M&([>)(D' M144*!^ J2BBH+"BBB@ JC2,,3^)J]12:3W$XJ6C1G1 M^'M'AE62+2[1'0Y5A"N0?6M&BBA)+82C&.R"BBBF4(RJZ,CJ&5A@@C((K _X M0+PI_P!"]IW_ (#K70452E*.S)<8RW1D:?X4T#2KQ;O3-(L[6X4$"6&(*P!Z MC(K7HHI.3EJQJ*6B"BBBD,*:\:2+MD17'HPS3J* (X[>"$YBAC0^JJ!4E%% M;!1110 4444 0M:6S-N:WB+>I09J55"C"@ >@%+10*R"BBB@84444 1R6T$I ?S+#&Y]60&G)&D2XC14'HHQ3J*!604444#"BBB@#_V0$! end GRAPHIC 19 cstl-20211231_g15.jpg GRAPHIC begin 644 cstl-20211231_g15.jpg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cstl-20211231_g16.jpg GRAPHIC begin 644 cstl-20211231_g16.jpg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cstl-20211231_g17.jpg GRAPHIC begin 644 cstl-20211231_g17.jpg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end GRAPHIC 22 cstl-20211231_g18.jpg GRAPHIC begin 644 cstl-20211231_g18.jpg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end GRAPHIC 23 cstl-20211231_g19.jpg GRAPHIC begin 644 cstl-20211231_g19.jpg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

  •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cstl-20211231_g2.jpg GRAPHIC begin 644 cstl-20211231_g2.jpg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end GRAPHIC 25 cstl-20211231_g3.jpg GRAPHIC begin 644 cstl-20211231_g3.jpg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end GRAPHIC 26 cstl-20211231_g4.jpg GRAPHIC begin 644 cstl-20211231_g4.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" (O!.@# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4Z*** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@#Y$L?VXO&'BCQ%XCT_P (?!'4_%-KHM[)9RW= MIJI'1F"EE%N=I8*3MR<>M==\-?VU-$\3>,K;P=XT\,ZM\-/%5T0MM9ZTI\J9 MF.%42%4(+'.-R@'H#D@'BO\ @GW_ ,ACXT?]C'_6:NH_X*$> ]-\2?L]ZGK\ MT"#5_#LT%U970 $B!YHXI$W==I#YQW*+Z4 ?35%>*Z#\<%\-_LGZ5\2]>W7< MUOH$%S/EMIN;C:L8&<<>9*0,X.-W>O#O!?AWXV?'7PK;>.M1^-D'@6;4%-SI MV@:?"ODI"3F,2$2+@'KR)#M(R<\4 ?;=%?.W['_QT\0_%"R\6^%_&;6]QXN\ M(7WV&\OK4*([M2SJ' 4!$=._: _:@\*'Q MY!X]A^&^G3(TFB:+IL!*W.W(W3/NW!688RV_N0@&,^I?L@_&[Q%\;/@O>W^L M1P2^+=(NIM.E=@(DN9%16CD8*,)G=M; ZJ2 ,XH ^@:*^4IO@7^T/XTM7UK6 MOC1'X7UD[I(-#T2R)LH^ZQM(&4D#H25D^K56^!OC+QY^U1\ ]5TFZ\8W'@OQ MGHVL?8KC7M-ME,DT: -\R*R $DD'81]P'N10![G\$/CEX>^/WA:]U_PU#?P6 M-I?2:>ZZA$L;F1$1R0%9AM(D7'.>O KT.OS?_89^"_C3QYX%N]/_B;^U1\6O%OAGX?^*Q\/ M_ WA>;['=:Q;P":YNYMS*"AR#@E'P%90%P6Y(% 'V-7SC^TI\6O%7@'XU?!' M0M"U/[%I7B+5S:ZG;^1&_P!HC,UNF-S*2O$C_=(Z^PQY[-XZ^*'[)OQ6\(:+ MXZ\8_P#"P? 7B:?[&FI7< BN+67>+/C?I_P8^%M];Z)J8MA>:WKTT8D-I$5#!5! M! ^1E.0,DR( 5P37%?$S3_CC^R7H]OXY'Q+F^)?ANWN8TU?3=6M?**QNP52I M+R$ L0NY6!!9?E89H ^VJ*^3OCQ^T'XG\4:Y\+_ _P +K]-%U'QU9QZHVKW$ M2L]M:2#*A0<@-A9"W&1M &":\;^._A+XR? _Q=X&T^Y^./B#5-(\37PL6U"/ MS(Y+5MZ!B8?-(88DR,.,[2#MX) /KKXG?%7QEX.^*G@7PYH7@2[\0Z#K4RQZ MEK4*R%+!3(%+,54JNU27.XC(&!ZUZW7RA\9?%WC#X<_&?]GGPI!XLO[J"ZD2 MSU:;A!J9!BC:25>C6>H^-5^)?@&^$JZA=:A$L%U8L$ M9E)_!-WX M"U!;IX$TR\N1.[QA5(EW;$P"688(_@/J*^7/V0_VK_A5\,_V?_#/ASQ+XL33 M-:LVN?/M6L;F39ON9'7YDB*G*L#P>]?5GA?XH>'_ (F> ;OQ-X0U5=4TWRYE MCNDB>/$B Y!5U# @XZB@#LJ*_/3]FY?CW^TKX6O''Q1OO"_A_2+F2.+5/)\Z MYO;@X8QD[E8H@(R2V!N4!6YQ]&>//A_\@%9&6/@(IPK#:R_>/)Z ]_HKXTT3Q1\3OV;_VA/!/@CQ;XYE^(7A3 MQ;NABNKVV$<\,Q.T8)9F&&*?Q%2K'@'!%?\ :,^(WQ:M?VLM!\%?#;6OL\VJ M:(J1VEUM-I$S&4O<,K C$/ MA-\-IH+'QAXD'VB;4[A XL[8%AN ((SB.5B<$A4X!)! !]+U\X^"_BUXJU;] MN#Q]X NM3\WPGI>A17=II_D1CRY2EFQ;>%WGF:3@L1\WL,9&C_"G]H'X4^*M M O\ 3_B/_P +-T6XO8HM9TW5X%@:&!F >2)G=N%7%_^$0\!W?CF"\^RB0_98QMP3L4[=VXX9OE&PYZUX-= M>(/BI^RK\9O &D^*/'TWQ%\'^,+O[#*U];^5+;2ET4LN6)?A_'\,CX=UFZT@WWB*.&Z^S-M\Z/CY&]5Y/'0T ?3=%?*'[2GQ M.\9ZI\??!WP?\+^*HO %KK-B;RYUYHU:5F)E"QIDC',6!M92S/C/KZ+\&?A] M\2_A9JVKKXT^(\/CCPBMGYEO/>VYBO(9@V79C\W[O9GJ[= H8H^!\QV%CD\AD898$$ 'U? M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 ?&?[ VJ6=AK7QG6YNX+9CXBR!-(JDC=-SR:O?MO?&32?%O M@E/A-X-NX/%'B_Q+>06SV>F2K,;>-)5D^=E.%8LB#:3PNXG QGO-8_83^$.N M:U?:G<:)>+<7L[W,RQ:A,J%W8LV!NX&2>*[WX8_L\_#SX.32W'A+PQ:Z;>R@ MJ]Z[//<$'J!)(S,H.!E00..E 'F7[07PGO\ 3/V(=2\%Z:OVV^T?1K,-Y0_U MWV9XI)F ]Q&[ 5Y'^SK^SW\ /BS\)]"U>YD/]N1VJ1ZK;OK#1217"C:[-'N^ M4,06';!K[MKPKQ-^Q%\'/%&M3ZI/X4%E(F^&5Y:7\TDD4.IR6NI_;2C*&*(?F(7[S?7OTX\G_9<_Y.X_ M:!_Z_%_]&M7T=\-/A'X0^#^CRZ7X/T.#1;.9_,E$;.[RL!@%W,\5% MX3^$'A?P3XT\2^*M(L'M]:\1.LFH3-.[K(P).0I.%R23Q0!\Z_\ !2K_ ))C MX-_[&*+_ -%25[)^UE_R;?\ $+_L%2?S%=-\4?@_X6^,FE6&G>*K![^TL;M; MV%$G>+$B@@9*D9&&/%;?C#PEIGCSPOJ?A[68&N=+U&!K>XB5V0LA]&!!!H \ MV_8__P"39_A]_P!@T?\ H;5\]?L:^*+SP3^SW\:?$&GP+<7VEW]]>P1N"5+Q MV^Y=P'49'/MFOLSP7X.TKX?^%=,\.Z);M:Z5IT(@MXF=G*J.>68DDY)K$^&O MP;\*?"73-5T_PUIS6EGJET]Y=133/,'=@ 1\Y.!@8Q0!\5?"KX7^%OCQ\*#\ M2OBW\9-;:^DEG>YMX=7AMXM/"R,HC,;*V"P 954*,.H"GC/??\$RH[:+P'XZ M2R=I;-=;Q!))]YH_+&TG@:UI%>3I;%LY_U M8? &?X1A>V,<5Z+\,?@[X3^#MKJMMX3TS^R[;4KLWD\*RLR!R,84$G:H'11P M* /F/_@F[XHT?P[\'?%&GZKJMEIM[!XDD:2"[N$B9=\,")D,1U9&4>I&*J_L M/>)-.^%?C[XI?#7Q->P:3KT>LFXM1>.(OMBCIPIY:7\$KP3[>RED(W =@V<9XQ0!\[?MN>(--^+WCSX8?"_P MS>P:MKLVL"YN_L3B;[%'@#+E MZ_"K]G7X??!>>>Y\*>'H;&_N%V2WTTCSW#+D$J'%O$&N6+W6J>&;DW6FRK.Z"*0LC9*J0&^:-#SZ>A- 'R_\ V]9_!W_@ MHIXAU+Q1/'I>E>+-#C@L-0NG"0[MEO\ ><\#Y[5TY[E?6NR_;T^)_AVU^ .L M>&8=3M;[7M?DMK>RT^UE665\3I(S[5)(7$9&?4J*]O\ B=\'O!WQDTB+3?%^ MAV^L6\+%H7\8_$OPY>^)?AE;Z;]G ML!%;BXMK>X8,&WQM\C-N^;!Y(VD9V 5Q7QX\??"+XW>%4\&_"'X:B_\ &]_/ M"UM?:7H4=D;50X+EG4 D$94[OD 8L2-HH ]<_:N_Y.I_9Z_["9_]'15D^']> ML/A/_P %$/&?_"374>E6GBC1XUTV\NF$<64#J17T!IOP M&T;5K'X::AXMBDU;Q9X-L;>.&_6YD :X2.,/(0"-^73=\U;/Q4^"'@GXU:?; M6OC#0H=5%J2UO/O:*:$GKMD0A@#@97.#@9'% "ZE\;/!.E^.-%\'OX@M9_$> MKLRVUC:MYSC:A?,FS(C! XW8SVSSB/X__P#)!_B1_P!BUJ7_ *2R5D_"W]F/ MX;_!W4VU/PSXB MZG#]HT[4K66SN80Q7?%(A1UR"",JQ&0(OV9_">H:KX2T/4 M[^9KOS+J\TV&65\74H&6923@ #GL!7T5TT>QW^3%)*TC N[.Q+,23EF)_& MNAN+>.ZMY895WQ2*4=?4$8(H ^5O^":__)OU_P#]C!=?^BX:Y3XT^(-7^+W[ M6TGPFU;QM?> _!=C81S*MA<"VDU21HDD*ASP3ER #N4>4<+DFOJCX6_"?PU\ M&O#+:!X5LGL=-:X>Z:.29Y6,C GQW7V9O.4(H9$4!C\V5R2..F>??!_PM MJ'Q2L/B'/8._BJQM&LH+KSW"K&0X/R9VDXD<9QW]A0!\[?\ !3S_ )('H/\ MV,UO_P"DMU69\=-6M?A=^W?\,/&7B"5;'PW>:5)8_P!H3?+%%*5GB(+= %,T M1)/ #Y/2OISXK?"#PO\ &KP[;Z'XML7U#38+M+V...=X2)55E!RA!^Z[C'OZ MX-6_B)\,?"_Q8\/-H?BS1K?6=-+B18YMRM&X! 9'4AD;!(RI!P2.AH S/&'Q MT\">!IM(@U7Q+9+=:MD_X*%?ZKX2?]C/'_[+7T5\0OA!X7^*-]X=O/$5 M@]Y<:!>"^L&2=X_+DRIY"D;AE%X/I]:/B1\(/"_Q:&BCQ-8/>C1[Q;^TV3O' MME'KM(R.G!]* //?C;X0^#7QW\02>!_%VJ62ZU2%/+2_MYI()MO96*,-P' M;<#CMBM/X5? OP1\%;.Z@\(:%#I;71!N+@N\L\V.@:1R6Q_L@@#)XH ^%/V/ M?@A\(_B/X=UK1/'HDLO'>DZC+#-87&H/:2&$!0"J9&2KB16QD@@9QD5]2?"' MX$? WX?_ !.6?P==6=SXRLK61Q;+K!N9H(FPCN8]YQPX7)'\5=/\2OV4?AA\ M6->$O M#L6G:A<1^3->R323S.F02NYV.T$@$A< D#TH ])HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $90RE6 *D8(/0U';VL% MHI6"&.%2HB[P0H4D#+$T;NR]?E_P[0=+O\ K^M3V>BN'FT'P]\&?"/B76O#^B0V-O:V M4E[)IUFYAMW\F-F 2,92,GD$JO/&$[75]5M M_!$-_H.E(\TTLFL+%>31(-SO#"L3JW ) >5"<=!4W7*IO9W_ =OZ_X#'9\S M@MU;\5<]%HKSKQQ\8XO"VB^#=2TW1;OQ''XHNXK6T@M'5)?WEO)-&V&XP=@! MR5"ABQ/RX-CPU\1-4N/&C>%?$V@P:%JLUBVI6;V6H&\M[B%'5)!O,4961"Z9 M7:1AAACS56=W'JK_ (*[_#4FZLG\_O=E^)WM%>/M\=-9OO#^H>+='\&?VGX' ML6E+:@=2$=[45=!M8C=*C,!D#D9Z+Q!\5!'>Z!I?A?3E\2:SK= MFVHVL37/V:WCM %_?S2[7**3(B@*C,2W3 )"_K]?T?W/LQ[;_P!?UI]Z.^HK MR]?C-=:7%XLL?$'AY=*\2>'])?6OL,%]]HMKVV"OAX9_+4XW(4;=&I4D<$$5 MK^*/B>,-;T3PSX9@UI=!,*ZE+=:H+23?+&)%2!/ M+<2'85.7:-%=21;C0M+T>;Q! M+8R#=%-Q4]0*]2DT73IM0M[]["U>^ME9(+IH5,L2D8( M5L94$=<41U2EWO\ @VOS0/1\O:WXJ_Y,NT5YQX+^)&H^)/A!J'BNYM[6/4+< M:D5BB5A$?L\TR)D%B>1&N>>I.,5YGXBU+QGXP\>? [6K'5]#TR;5=,N;N.*X MT>:X6&5[%'EW8NTWJ=V%'RE<9)?I26M[=+?C>WY,;5M_/\+7_,^DZ*Y'7+?Q MY,;6'1M0\.V82W4W%[?6$]QYTW\02!9H_+3H03*YYQCC)X>7XV:Q'\!/%/C% MM,LX_$?A]KVTN+-69[9[BVF:)BO*ML;;D D$9QGC-/37R_(+/3ST^9[-17D] MWXZ\<^%=0\+WWB2UT,:-KNHPZ;)I]@DINM.DF!$3-.SE)QN"JP$:8W9!8#E\ M?C;QGX[\1^)K7P:=#TW2O#]V=.>[UJVFN6O;I45Y$18Y8_*1=ZKO.\DY^7CD M_2_X6O\ FOO%Y]_UO_D_N/5:*\?A^.EWK'@CPQ#_'7A[0/%[Z/JEEXA::"RU31[26 MS\FYCC,ODRQ22RY#(CD.''*8*\@T^MOZ[_UWVW#9?UZ?HST^BO./!?Q(U'Q) M\(-0\5W-O:QZA;C4BL42L(C]GFF1,@L3R(USSU)QBN?7XM>(=M>;0^/O%'B?XB>)M M"T*Y\/Z>OAZ>&*33=5BE>[OD>))#,KI(HAC^7+DHW3I5?:Y1=+GJM%>; MZUXR\3:]X_U+PKX0;2;$Z/:07.HZEJ]M+'BRS\$?$#4=4T?2['6?#.MVVE);Q.\T,BR"UW2%LJ3GSV9>%P-H(R#E M1][1?UJE^;_78'I_7E?\CW>BN,^(GC2]\(WW@V&TB@E76MXEGNXHU+$&X$B+ M$Y .!Y4@!QR:GF23D]E^B3_4?*VU%;O]6U^AZ517DWCSXN:UI^@_#J_\*Z3: M:A/XMO8;=+;4)6C$<?$JS^(@\!RVWAV^U*\ MT\:I;Z]#!-#:VT"OY(JCXA\>?$;P-X//C;7;7P_-HEO&EUJ.@V4$XO+.W)&]ENFE*3/&IW% M?)0-M(!Z4ORT_';^NG6P]?GK^&_]=>A[+17%>&O'%UKGQ,\5^'VCM_[.TJST M^YMIHPWF.9Q,6W'."!Y:XP!U/6N0UCXW:EH_@_QQJ\MI8A]%\2C0K>64O';Q M1,UN@N+ALD[4\YF8C PO;K1UY>O_ 4OS:'TO_6U_P D>R45SO@UO$36DK:_ M?Z-JJOM>UOM&MY+=)%(R08WDEQCC#"0[L]%QST5-Z$[A1112&%%%% !1110 M4444 8'B/X@>%_!]S;6^O>)-(T2XN?\ 41:E?Q6[R]OE#L"WX5N1R)-ⅅ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ଧ_@W44F\5>)#JUY;1ZMH\_@>>ST^U@F^_+!=>2& BR#ND=@P M!/%5'WFHKJH_^3;?UTZDR]U-OS_!*_Y_/H?43:UIZZPFDM?VRZJ\)N5L3,OG MM$&"F0)G<5!(&[&,D"KM?,/C#PCXHU/]LJQ_L_QY>Z/YOA:6YB\K3K27R(%N MHE:W&^,Y5F^;<)OB!XUTS2=7\2^'[#P[=_V;:CP_X/DU ME;F=8U9WN)!#(%7

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cstl-20211231_g5.jpg GRAPHIC begin 644 cstl-20211231_g5.jpg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end GRAPHIC 28 cstl-20211231_g6.jpg GRAPHIC begin 644 cstl-20211231_g6.jpg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�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end GRAPHIC 29 cstl-20211231_g7.jpg GRAPHIC begin 644 cstl-20211231_g7.jpg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end GRAPHIC 30 cstl-20211231_g8.jpg GRAPHIC begin 644 cstl-20211231_g8.jpg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cstl-20211231_g9.jpg GRAPHIC begin 644 cstl-20211231_g9.jpg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end XML 32 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Cover Page - USD ($)
    $ in Billions
    		 12 Months Ended
    Dec. 31, 2021
    Feb. 21, 2022
    Jun. 30, 2021
    Cover [Abstract]      
    Document Type 10-K    
    Document Annual Report true    
    Document Period End Date Dec. 31, 2021    
    Current Fiscal Year End Date --12-31    
    Document Transition Report false    
    Entity File Number 001-38984    
    Entity Registrant Name CASTLE BIOSCIENCES, INC.    
    Entity Incorporation, State or Country Code DE    
    Entity Tax Identification Number 77-0701774    
    Entity Address, Address Line One 505 S. Friendswood Drive    
    Entity Address, Address Line Two Suite 401    
    Entity Address, City or Town Friendswood    
    Entity Address, State or Province TX    
    Entity Address, Postal Zip Code 77546    
    City Area Code 866    
    Local Phone Number 788-9007    
    Title of 12(b) Security Common Stock, $0.001 par value per share    
    Trading Symbol CSTL    
    Security Exchange Name NASDAQ    
    Entity Well-known Seasoned Issuer Yes    
    Entity Voluntary Filers No    
    Entity Current Reporting Status Yes    
    Entity Interactive Data Current Yes    
    Entity Filer Category Large Accelerated Filer    
    Entity Small Business true    
    Entity Emerging Growth Company false    
    ICFR Auditor Attestation Flag true    
    Entity Shell Company false    
    Entity Public Float     $ 1.5
    Entity Common Stock, Shares Outstanding   25,410,602  
    Documents Incorporated by Reference Portions of the registrant’s definitive proxy statement to be filed with the Securities and Exchange Commission, or SEC, subsequent to the date hereof pursuant to Regulation 14A in connection with the registrant’s 2022 Annual Meeting of Stockholders, are incorporated by reference into Part III of this Annual Report on Form 10-K. The registrant intends to file such proxy statement with the SEC not later than 120 days after the conclusion of its fiscal year ended December 31, 2021.    
    Entity Central Index Key 0001447362    
    Document Fiscal Year Focus 2021    
    Document Fiscal Period Focus FY    
    Amendment Flag false    

    XML 33 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Audit Information
    		 12 Months Ended
    Dec. 31, 2021
    Audit Information [Abstract]  
    Auditor Name KPMG LLP
    Auditor Location San Diego, CA
    Auditor Firm ID 185
    XML 34 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
    CONSOLIDATED BALANCE SHEETS - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Current Assets    
    Cash and cash equivalents $ 329,633 $ 409,852
    Accounts receivable, net 17,282 12,759
    Inventory 2,021 2,217
    Prepaid expenses and other current assets 4,807 4,766
    Total current assets 353,743 429,594
    Long-term accounts receivable, net 1,308 1,096
    Property and equipment, net 9,501 7,102
    Operating lease assets 7,383 0
    Intangible assets, net 88,922 0
    Other assets – long-term 1,715 1,536
    Total assets 462,572 439,328
    Current Liabilities    
    Accounts payable 2,546 2,098
    Accrued compensation 15,483 9,108
    Medicare advance payment 0 6,615
    Operating lease liabilities 1,179 0
    Other accrued and current liabilities 5,678 3,055
    Total current liabilities 24,886 20,876
    Contingent consideration 18,287 0
    Noncurrent operating lease liabilities 6,900 0
    Noncurrent portion of Medicare advance payment 0 1,735
    Deferred tax liability 635 0
    Other liabilities 124 1,026
    Total liabilities 50,832 23,637
    Commitments and Contingencies (Note 12)
    Stockholders’ Equity    
    Preferred stock, $0.001 par value; 10,000,000 shares authorized as of December 31, 2021 and 2020; no shares issued and outstanding as of December 31, 2021 and 2020. 0 0
    Common stock, $0.001 par value; 200,000,000 authorized as of December 31, 2021 and 2020, respectively; 25,378,520 and 24,812,487 shares issued and outstanding as of December 31, 2021 and 2020, respectively. 25 25
    Additional paid-in capital 505,482 478,162
    Accumulated deficit (93,767) (62,496)
    Total stockholders’ equity 411,740 415,691
    Total liabilities and stockholders’ equity $ 462,572 $ 439,328
    XML 35 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
    CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
    Dec. 31, 2021
    Dec. 31, 2020
    Statement of Financial Position [Abstract]    
    Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
    Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
    Preferred stock, shares issued (in shares) 0 0
    Preferred stock, shares outstanding (in shares) 0 0
    Common stock, par value (in dollars per share) $ 0.001 $ 0.001
    Common stock, shares authorized (in shares) 200,000,000 200,000,000
    Common stock, shares issued (in shares) 25,378,520 24,812,487
    Common stock, shares outstanding (in shares) 25,378,520 24,812,487
    XML 36 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
    shares in Thousands, $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Income Statement [Abstract]    
    NET REVENUES $ 94,085 $ 62,649
    OPERATING EXPENSES AND OTHER OPERATING INCOME    
    Cost of sales (exclusive of amortization of acquired intangible assets) 15,822 9,685
    Research and development 29,646 13,256
    Selling, general and administrative 86,738 48,132
    Amortization of acquired intangible assets 1,958 0
    Other operating income 0 (1,882)
    Total operating expenses, net 134,164 69,191
    Operating loss (40,079) (6,542)
    Interest income 68 373
    Interest expense (1) (2,634)
    Loss on extinguishment of debt 0 (1,397)
    Loss before income taxes (40,012) (10,200)
    Income tax (benefit) expense (8,720) 84
    Net loss (31,292) (10,284)
    Comprehensive loss $ (31,292) $ (10,284)
    Loss per share attributable to common stockholders:    
    Basic (in dollars per share) $ (1.24) $ (0.54)
    Diluted (in dollars per share) $ (1.24) $ (0.54)
    Weighted-average shares outstanding:    
    Basic (in shares) 25,137 18,929
    Diluted (in shares) 25,137 18,929
    XML 37 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
    CONSOLIDATED STATEMENTS STOCKHOLDERS’ EQUITY - USD ($)
    $ in Thousands
    Total
    Cumulative Effect, Period of Adoption, Adjustment
    Preferred Stock
    Common Stock
    Additional Paid-in Capital
    Accumulated Deficit
    Accumulated Deficit
    Cumulative Effect, Period of Adoption, Adjustment
    Beginning balance (in shares) at Dec. 31, 2019     0 17,130,907      
    Beginning balance at Dec. 31, 2019 $ 85,113   $ 0 $ 17 $ 137,308 $ (52,212)  
    Increase (Decrease) in Stockholders' Equity [Roll Forward]              
    Stock-based compensation expense $ 8,309       8,309    
    Exercise of common stock options (in shares) 460,207     459,074      
    Exercise of common stock options $ 1,593     $ 1 1,592    
    Exercise of common stock warrants (in shares)       241,052      
    Exercise of common stock warrants 0            
    Public offering of common stock, net of underwriting discounts, commissions and offering costs (in shares)       6,900,000      
    Public offerings of common stock, net of underwriting discounts, commissions and offering costs 329,664     $ 7 329,657    
    Issuance of common stock under the employee stock purchase plan (in shares)       81,454      
    Issuance of common stock under the employee stock purchase plan 1,296       1,296    
    Net income (loss) (10,284)         (10,284)  
    Ending balance (in shares) at Dec. 31, 2020     0 24,812,487      
    Ending balance at Dec. 31, 2020 $ 415,691 $ 21 $ 0 $ 25 478,162 (62,496) $ 21
    Increase (Decrease) in Stockholders' Equity [Roll Forward]              
    Accounting Standards Update [Extensible Enumeration] Accounting Standards Update 2016-02            
    Stock-based compensation expense $ 21,740       21,740    
    Exercise of common stock options (in shares) 414,890     416,037      
    Exercise of common stock options $ 4,234       4,234    
    Net settlement of vested stock awards (in shares)       39,548      
    Issuance of common stock from vested restricted stock units and payment of employees’ taxes (781)       (781)    
    Public offerings of common stock, net of underwriting discounts, commissions and offering costs 39       39    
    Issuance of common stock under the employee stock purchase plan (in shares)       110,448      
    Issuance of common stock under the employee stock purchase plan 2,088       2,088    
    Net income (loss) (31,292)         (31,292)  
    Ending balance (in shares) at Dec. 31, 2021     0 25,378,520      
    Ending balance at Dec. 31, 2021 $ 411,740   $ 0 $ 25 $ 505,482 $ (93,767)  
    XML 38 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
    CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    OPERATING ACTIVITIES    
    Net loss $ (31,292) $ (10,284)
    Adjustments to reconcile net loss to net cash (used in) provided by operating activities:    
    Depreciation and amortization 3,407 472
    Stock-based compensation expense 21,740 8,309
    Amortization of debt discounts and issuance costs 0 839
    Deferred income taxes (8,736) 0
    Loss on extinguishment of debt 0 1,397
    Other 0 (16)
    Change in operating assets and liabilities:    
    Accounts receivable (4,631) 1,663
    Prepaid expenses and other current assets 617 (2,815)
    Inventory 327 (980)
    Operating lease assets 931 0
    Other assets (180) (1,401)
    Accounts payable (182) 169
    Operating lease liabilities (852) 0
    Accrued compensation 6,208 3,329
    Medicare advance payment (8,350) 8,350
    Other accrued liabilities 2,286 561
    Other liabilities (276) 272
    Net cash (used in) provided by operating activities (18,983) 9,865
    INVESTING ACTIVITIES    
    Purchases of property and equipment (3,483) (4,751)
    Asset acquisitions, net of cash and cash equivalents acquired (63,184) 0
    Proceeds from sale of property and equipment 10 3
    Net cash used in investing activities (66,657) (4,748)
    FINANCING ACTIVITIES    
    Proceeds from public offerings of common stock, net of underwriting discounts, commissions and offering costs 0 330,041
    Payment of common stock offering costs (336) 0
    Repayment of term debt 0 (27,359)
    Proceeds from exercise of common stock options 4,234 1,593
    Payment of employees’ taxes on vested restricted stock units (781) 0
    Proceeds from contributions to the employee stock purchase plan 2,312 1,615
    Repayment of principal portion of finance lease liabilities (8) 0
    Net cash provided by financing activities 5,421 305,890
    NET CHANGE IN CASH AND CASH EQUIVALENTS (80,219) 311,007
    Beginning of year 409,852 98,845
    End of year 329,633 409,852
    SUPPLEMENTAL DISCLOSURE OF CASH PAID FOR:    
    Interest 1 1,978
    Income taxes 16 102
    DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
    Accrued purchases of property and equipment 33 58
    Property and equipment acquired with tenant improvement allowance 54 714
    Asset acquisition, receivable for purchase price adjustment 519 0
    Asset acquisition, liability for contingent consideration 18,287 0
    Common stock offering costs incurred but not paid 0 377
    Cashless exercise of common stock warrants $ 0 $ 250
    XML 39 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Organization and Description of Business
    		 12 Months Ended
    Dec. 31, 2021
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    Organization and Description of Business Organization and Description of Business
    Castle Biosciences, Inc. (the ‘‘Company’’, “we”, “us”, or “our”) was incorporated in the state of Delaware on September 12, 2007. We are a commercial-stage diagnostics company focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. We are based in Friendswood, Texas (a suburb of Houston, Texas) and laboratory operations are conducted at our facilities located in Phoenix, Arizona and in Pittsburgh, Pennsylvania.
    Impact of COVID-19 Pandemic
    Since the COVID-19 pandemic began in March 2020, we have maintained uninterrupted business operations with normal turnaround times for delivery of test reports, but have experienced declines in test report volume in certain periods, which we believe is linked to delays and/or cancellations in patient visits in response to COVID-19, resulting in reduced diagnostic biopsies and thus reduced diagnoses of cutaneous melanoma. The extent to which COVID-19 may further impact our business, consolidated results of operations, consolidated financial condition and consolidated cash flows will depend on future developments, which are highly uncertain and cannot be predicted with confidence.
    XML 40 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Summary of Significant Accounting Policies
    		 12 Months Ended
    Dec. 31, 2021
    Accounting Policies [Abstract]  
    Summary of Significant Accounting Policies Summary of Significant Accounting Policies
    Basis of Presentation
    Our consolidated financial statements include the accounts of Castle Biosciences, Inc. and our wholly owned subsidiaries and have been prepared in conformity with accounting principles generally accepted in the United States of America (‘‘U.S. GAAP’’). All intercompany accounts and transactions have been eliminated in consolidation.
    Reclassification
    Certain prior year amounts in our consolidated statements of operations and comprehensive loss have been reclassified to conform to the current year presentation. Specifically, we no longer present gross margin on our statements of operations and comprehensive loss and therefore the cost of sales line is now presented within the operating expenses section. This reclassification had no impact on operating loss, loss before income taxes, net loss, comprehensive loss or loss per share.
    Use of Estimates
    The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include revenue recognition, the valuation of stock-based compensation, assessing future tax exposure and the realization of deferred tax assets, the useful lives and recoverability of long-lived assets, the valuation of acquired intangible assets, the valuation of contingent consideration and other contingent liabilities. We base these estimates on historical and anticipated results, trends, and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. We have considered the potential impact of the COVID-19 pandemic on our estimates and assumptions. The extent to which the COVID-19 pandemic may impact our estimates in future periods is uncertain and subject to change.
    Operating Segments
    Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment. All revenues are attributable to U.S.-based operations and all assets are held in the United States.
    Cash and Cash Equivalents including Concentrations of Credit Risk
    Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less. Our cash equivalents consist of money market funds, which are not insured by the Federal Deposit Insurance Corporation (“FDIC”), that are primarily invested in short-term U.S. government obligations. Cash deposits at financial institutions may exceed the amount of insurance provided by the FDIC. Management believes that we are not exposed to significant credit risk on our cash deposits due to the financial position of the institutions in which deposits are held. We have not experienced any losses on our cash or cash equivalents.
    Revenue Recognition
    Revenue is recognized in accordance with Financial Accounting Standards Board (‘‘FASB’’) Accounting Standards Codification (‘‘ASC’’) Topic 606, Revenue from Contracts with Customers (‘‘ASC 606’’). In accordance with ASC 606, we follow a five-step process to recognize revenues: (1) identify the contract with the customer, (2) identify the performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenues when the performance obligations are satisfied. We have determined that we have a contract with the patient when the treating clinician orders the test. Our contracts generally contain a single performance obligation, which is the delivery of the test report, and we satisfy our performance obligation at a point in time upon the delivery of the test report to the treating physician, at which point we can bill for the report. The amount of revenue recognized reflects the amount of consideration to which we expect to be entitled, or the transaction price, and considers the effects of variable consideration. See Note 3 for further details.
    Accounts Receivable and Allowance for Credit Losses
    We classify accounts receivable balances that are expected to be paid more than one year from the consolidated balance sheet date as non-current assets. The estimated timing of payment utilized as a basis for classification as non-current is determined by analyses of historical payor-specific payment experience, adjusted for known factors that are expected to change the timing of future payments.
    We accrue an allowance for credit losses against our accounts receivable based on management’s current estimate of amounts that will not be collected. Management’s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of customers’ financial condition and generally do not require collateral. Historically, our credit losses have not been significant. The allowance for credit losses was zero as of December 31, 2021 and 2020. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.
    Inventory
    We carry inventories of test supplies in our laboratory facilities. The inventories are carried at the lower of weighted average cost and net realizable value and expensed through cost of sales as the supplies are used.
    Property and Equipment
    Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between five and ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Our leasehold improvements primarily relate to our office and laboratory facilities in Friendswood, Texas and Phoenix, Arizona, and are generally being amortized through the end of the lease terms in 2025 and 2033, respectively. Maintenance and repairs are charged to expense as incurred, and material improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss in the period realized.
    Intangible Assets
    Our intangible assets, which are comprised primarily of acquired developed technology, are considered to be finite-lived and are amortized on a straight-line basis over their estimated useful lives.
    Long-Lived Assets
    We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than the carrying amount. Impairment, if
    any, would be calculated based on the excess of the carrying amount of the long-lived asset over the long-lived asset’s fair value. There were no impairment charges recognized for the years ended December 31, 2021 and 2020.
    Acquisitions
    We assess acquisitions under ASC 805, Business Combinations, to determine whether a transaction represents the acquisition of assets or a business combination. Under this guidance, we apply a two-step model. The first step involves a screening test where we evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single asset or a group of similar assets. If the screening test is met, we account for the set as an asset acquisition. If the screening test is not met, we apply the second step of the model to determine if the set meets the definition of a business based on the guidance in ASC 805. If so, the transaction is treated as a business combination. Otherwise, it is treated as an asset acquisition. Asset acquisitions are accounted for by allocating the cost of the acquisition, including transaction costs, to the individual assets acquired and liabilities assumed on a relative fair value basis without recognition of goodwill. Business combinations are accounted for using the acquisition method. Under the acquisition method, goodwill is measured as a residual amount equal to the fair value of the consideration transferred less the net recognized fair value of the identifiable assets acquired and the liabilities assumed, as of the acquisition date, and transaction costs are expensed as incurred.
    Contingent Consideration
    Under the terms of business combinations or asset acquisitions, we may be required to pay additional consideration if specified future events occur or if certain conditions are met. With respect to the additional consideration that may be payable in connection with the Cernostics, Inc. (“Cernostics”) asset acquisition, we account for the contingent consideration as liability in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), under the guidance for obligations that must or may be settled by issuance of a variable number of shares. In accordance with ASC 480, we record the contingent consideration initially and subsequently at fair value with changes in fair value recorded in the statements of operations and comprehensive loss each period. For additional information on the contingent consideration, see Notes 5 and 11.
    Other Operating Income
    On April 10, 2020, we received an automatic payment of $1.9 million from the U.S. Department of Health and Human Services (“HHS”) pursuant to the Coronavirus Aid, Relief and Economic Security Act enacted on March 27, 2020, also known as the CARES Act, out of relief funds allocated by HHS to healthcare providers to reimburse healthcare related expenses or lost revenues attributable to COVID-19. This automatic payment was calculated by HHS in proportion to the providers’ share of Medicare fee-for-service reimbursements in 2019 and was applicable to all facilities and providers that received Medicare fee-for-service reimbursements in 2019. In the second quarter of 2020, based on guidance issued by HHS at the time that stated any reasonable method could be used to calculate lost revenues attributable to COVID-19, we concluded it would qualify to retain the relief funds and recognized the funds received as other operating income during the three months ended June 30, 2020. On September 19, 2020, HHS issued a notice of reporting requirements that changed the methodology for determining lost revenues to be based on a patient care operating income metric, as defined by HHS. Due to this change in methodology and uncertainty in its application, we determined that it was no longer reasonably assured of keeping the funds. Therefore, in the three months ended September 30, 2020, we reversed the previously recognized income. However, in the fourth quarter of 2020, a legislative change was enacted affecting the program, under which we concluded it is reasonably assured we will qualify to retain the funds. Accordingly, we recognized the income again in the fourth quarter of 2020.
    Leases
    Effective January 1, 2021, we account for leases in accordance with ASC 842, Leases. We categorize leases at their commencement as either operating or finance leases based on the criteria in ASC 842. Under ASC 842, we record right-of-use (“ROU”) assets and lease liabilities for each lease arrangement identified, except that we have elected the short-term lease exemption for all leases with a term of 12 months or less. Lease liabilities are recorded at the present value of future lease payments discounted using our incremental borrowing rate for the lease established at the commencement date and ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. For our operating leases, we recognize a single lease cost over the lease term on a straight-line basis. We have elected the practical expedient of not separating nonlease components from lease components in all leases. Periods prior to January 1, 2021 have not been restated for the adoption of ASC 842 and continue to reflect the accounting treatment of leases in accordance with the prior lease accounting guidance, ASC 840, Leases. Under ASC 840, landlord/tenant incentives, rent holidays and escalations in the base price of rent payments under operating leases were recognized on a straight-line basis over the lease term. Deferred rent balances were classified as current or non-current in the consolidated balance sheets based upon the period when reversal of the liability was expected to occur. See Note 9 for details on our leases.
    Cost of Sales (exclusive of amortization of acquired intangible assets)
    Cost of sales is expensed as incurred and includes material and service costs associated with testing samples, personnel costs (including salaries, bonuses, benefits and stock-based compensation expense), electronic medical records, order and delivery systems, shipping charges to transport samples, third-party test fees, and allocated overhead including rent, information technology costs, equipment and facilities depreciation and utilities.
    Research and Development
    Research and development costs are charged to operations as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on behalf of us will be expensed as services are rendered or when the milestone is achieved.
    Research and development costs include, but are not limited to, payroll and personnel-related expenses, stock-based compensation expense, materials, laboratory supplies, and consulting costs.
    Selling, General and Administrative Expenses
    Selling, general and administrative (“SG&A”) expenses are attributable to sales, marketing, executive, finance and accounting, legal and human resources functions. These expenses consist of personnel costs (including salaries, employee benefit costs, bonuses and stock-based compensation expenses), customer services expenses, direct marketing expenses, educational and promotional expenses, market research, audit and legal expenses, and consulting. We expense all SG&A costs as incurred.
    Accrued Compensation
    We accrue for liabilities under discretionary employee and executive bonus plans. These estimated compensation liabilities are based on progress against corporate objectives approved by our board of directors, compensation levels of eligible individuals, and target bonus percentage levels. The board of directors reviews and evaluates the performance against these objectives and ultimately determines what discretionary payments are made. We also accrue for liabilities under employee sales incentive bonus plans with accruals based on performance achieved to date compared to established targets. As of December 31, 2021 and 2020, we accrued approximately $12,071,000 and $7,175,000, respectively, for liabilities associated with these bonus plans. These amounts are classified as current or noncurrent accrued liabilities in the balance sheets based on the expected timing of payment.
    Retirement Plan
    We have an Internal Revenue Code (“IRC”) Section 401(k) profit sharing plan (the “Plan”) for eligible employees. The Plan is funded by employee contributions and provides for discretionary contributions in the form of matching and/or profit-sharing contributions. For the years ended December 31, 2021 and 2020, we provided a discretionary matching contribution of $2,036,000 and $789,000, respectively. The higher amount for the year ended December 31, 2021 reflects both an increase in the number of employees and a higher matching contribution rate compared to the year ended December 31, 2020.
    Income Taxes
    We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the statutory enactment date. Valuation allowances are established to reduce deferred tax assets when it is more likely than not that some portion or all of the deferred tax assets will not be realized.
    Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50% likely to be realized upon settlement. A liability for unrecognized tax benefits is recorded for any tax benefits claimed in our tax returns that do not meet these recognition and measurement standards.
    Our policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of tax expense. No material amounts of tax-related interest or penalties were recorded during the years ended December 31, 2021 and 2020.
    Stock-Based Compensation
    Stock-based compensation expense for equity instruments issued to employees is measured based on the grant-date fair value of the awards. The fair value of employee stock options and offerings under the 2019 Employee Stock Purchase Plan (the “ESPP”) are estimated on the date of grant using the Black-Scholes option-pricing valuation model. For restricted stock units (“RSUs”), the fair value is equal to the closing price of our common stock on the date of grant. We recognize compensation costs on a straight-line basis for all employee stock-based compensation awards over the requisite service period of the awards. For options and RSUs, the requisite service period is generally the awards’ vesting period (typically four years). For the ESPP, the requisite service period is generally the period of time from the offering date to the purchase date. Forfeitures are accounted for as they occur.
    Comprehensive Loss
    Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive loss was the same as our reported net loss for all periods presented.
    CARES Act Payroll Tax Deferral
    The CARES Act permits employers to defer the payment of the employer share of social security taxes due for the period beginning March 27, 2020 and ending December 31, 2020. Of the amounts deferred, 50% were required to be paid by December 31, 2021 and the remaining 50% are required to be paid by December 31, 2022. We began deferring payment of the employer share of social security taxes in May 2020. Of the $551,000 originally deferred, 50% was repaid during the year ended December 31, 2021. As of December 31, 2021, the remaining $276,000 of such taxes was classified as a current liability on the consolidated balance sheet.
    Recently Adopted Accounting Pronouncements
    We were previously an emerging growth company (“EGC”) within the meaning of the Jumpstart Our Business Startups Act, as amended, (the “JOBS Act”) and elected to delay the adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements were made applicable to private companies, as permitted under the JOBS Act. Because the market value of our common stock held by non-affiliates exceeded $700.0 million as of June 30, 2021, we ceased to be an EGC effective December 31, 2021. Accordingly, we are no longer permitted to delay the adoption of new or revised accounting pronouncements and as such we adopted the pronouncements discussed below in the fourth quarter of 2021 effective as of the dates noted.
    In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which supersedes ASC 840, Leases. ASU 2016-02 establishes ASC 842, Leases, and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized based on an effective interest method for finance leases or on a straight-line basis over the term of the lease for operating leases. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of classification. Leases with a term of 12 months or less may be accounted for similar to existing guidance for operating leases. We adopted ASU 2016-02 and ASC 842 using the modified retrospective approach with an effective date of January 1, 2021. Periods prior to January 1, 2021 have not been restated for the adoption of ASC 842 and continue to reflect the accounting treatment of leases in accordance with ASC 840. In connection with the adoption, we elected the package of practical expedients to not reassess prior conclusions about lease identification, lease classification and capitalized indirect costs. We did not elect the use of hindsight practical expedient. Upon adoption, effective January 1, 2021 we recognized operating lease right-of-use assets of $5,405,000, operating lease liabilities of $6,076,000, reductions to noncurrent liabilities of $751,000, reductions to current assets of $59,000 and a credit to accumulated deficit of $21,000. See Note 9 for disclosures about our leases.
    In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement of expected credit losses for financial instruments carried at amortized cost, such as accounts receivable, held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. We adopted the standard effective January 1, 2021 using the modified retrospective approach. The adoption of this standard had no impact on our consolidated financial statements.
    In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which eliminates certain exceptions to the general principles in Topic 740 and simplifies other areas of the existing guidance. The adoption of ASU 2019-12 effective January 1, 2021 had no impact on our consolidated financial statements.
    XML 41 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Revenue
    		 12 Months Ended
    Dec. 31, 2021
    Revenue from Contract with Customer [Abstract]  
    Revenue Revenue
    All of our revenues from contracts with customers are associated with the provision of diagnostic and prognostic testing services. Most of our revenues are attributable to DecisionDx®-Melanoma for cutaneous melanoma. We also provide a test for uveal melanoma, DecisionDx®-UM. We launched a test for patients with cutaneous squamous cell carcinoma, DecisionDx®-SCC in August 2020 and launched a test for use in patients with suspicious pigmented lesions, DecisionDx® DiffDx™-Melanoma in November 2020. We began offering a test for difficult-to-diagnose melanocytic lesions, myPath Melanoma, following an asset acquisition completed in May 2021 and began offering the TissueCypher® Barrett’s Esophagus Assay for patients with BE following an asset acquisition completed in December 2021. Information on the disaggregation of revenues is included below.
    Once we satisfy our performance obligations and bill for the service, the timing of the collection of payments may vary based on the payment practices of the third-party payor and the existence of contractually established reimbursement rates. Most of the payments for our services are made by third-party payors, including Medicare and commercial health insurance carriers. Certain contracts contain a contractual commitment of a reimbursement rate that differs from our list prices. However, absent a positive coverage policy, with or without a contractually committed reimbursement rate, with a commercial carrier or governmental program, our diagnostic tests may or may not be paid by these entities. In addition, patients do not enter into direct agreements with us that commit them to pay any portion of the cost of the tests in the event that their insurance provider declines to reimburse us. We may pursue, on a case-by-case basis, reimbursement from such patients in the form of co-payments and co-insurance, in accordance with the contractual obligations that we have with the insurance carrier or health plan. These situations may result in a delay in the collection of payments.
    The Medicare claims that are covered by policy under a Local Coverage Determination (‘‘LCD’’) are generally paid at the established rate by our Medicare contractor within 30 days from receipt. Medicare claims that were either submitted to Medicare prior to the LCD coverage commencement date or are not covered by the terms of the LCD but meet the definition of being medically reasonable and necessary pursuant to the controlling Section 1862(a)(1)(A) of the Social Security Act are generally appealed and may ultimately be paid at the first (termed ‘‘redetermination’’), second (termed ‘‘reconsideration’’) or third level of appeal (de novo hearing with an Administrative Law Judge (“ALJ”)). A successful appeal at any of these levels results in payment.
    In the absence of LCD coverage or contractually established reimbursements rates, we have concluded that our contracts include variable consideration because the amounts paid by Medicare or commercial health insurance carriers may be paid at less than our standard rates or not paid at all, with such differences considered implicit price concessions. Variable consideration attributable to these price concessions is measured at the expected value using the ‘‘most likely amount’’ method under ASC 606. The amounts are determined by historical average collection rates by test type and payor category taking into consideration the range of possible outcomes, the predictive value of our past experiences, the time period of when uncertainties expect to be resolved and the amount of consideration that is susceptible to factors outside of our influence, such as the judgment and actions of third parties. Such variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. Variable consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in the absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Variable consideration for Medicare claims that are not covered by an LCD, including those claims subject to approval by an ALJ at an appeal hearing, is deemed to be fully constrained due to factors outside our influence (i.e., judgment or actions of third parties) and the uncertainty of the amount to be received is not expected to be resolved for a long period of time. Variable consideration is evaluated each reporting period and adjustments are recorded as increases or decreases in revenues. Included in revenues for the years ended December 31, 2021 and 2020 were $3,324,000 and $176,000, respectively, of revenue increases associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. These amounts include (i) adjustments for actual collections versus estimated amounts and (ii) cash collections and the related recognition of revenue in current period for tests delivered in prior periods due to the release of the constraint on variable consideration.
    Because our contracts with customers have an expected duration of one year or less, we have elected the practical expedient in ASC 606 to not disclose information about our remaining performance obligations. Any incremental costs to obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of our contracts. Contract balances consisted of accounts receivable (both current and noncurrent) as of December 31, 2021 and 2020 and the Medicare advance payment (discussed further below) as of December 31, 2020.
    Medicare Advance Payment
    On April 16, 2020, we received an advance payment of $8.3 million (the “Advance Payment”) from the Centers for Medicare & Medicaid Services (“CMS”) under its Accelerated and Advance Payment Program, which was expanded to provide increased cash flow to service providers during the COVID-19 pandemic. CMS began recoupment of the Advance Payment in April 2021 by applying 25% of the Medicare payments otherwise owed to us against the balance of the Advance Payment. Recoupment of the full amount of the Advance Payment was complete by December 31, 2021.
    DecisionDx-Melanoma Claims Consolidation
    In June 2017, we submitted to the Office of Medicare Hearings and Appeals (‘‘OMHA’’) a formal request to participate in a program that OMHA developed with the intent of providing appellants a means to have large volumes of claim disputes adjudicated at an accelerated rate. The program consolidates outstanding claims at the ALJ level and uses a statistical-sampling approach where five ALJs will determine reimbursement results for a sample of claims which are then extrapolated to the universe of claims. The consolidation includes 2,698 DecisionDx-Melanoma claims dating from 2013 through spring 2017. Hearings were held in April 2019 with a supplemental hearing in May 2019. On March 12, 2020, OMHA issued a decision denying payment on all claims in the consolidation. We have filed an appeal to the decision, although no ruling on such appeal has been issued to date. In accordance with ASC 606 and consistent with prior periods, we have not recognized (fully constrained the variable consideration) any revenues attributable to these claims in our consolidated financial statements pending the outcome of this matter.
    Disaggregation of revenues
    The table below provides the disaggregation of revenue by type (in thousands):
    Years Ended December 31,
    20212020
    Dermatologic$85,753 $57,646 
    Other8,332 5,003 
    Total net revenues$94,085 $62,649 
    Payor Concentration
    We rely upon reimbursements from third-party government payors (primarily Medicare) and private-payor insurance companies to collect accounts receivable related to sales of our diagnostic tests.
    Our significant third-party payors and their related revenues as a percentage of total revenues and accounts receivable balances are as follows:
     Percentage of Revenues
    Percentage of
     Accounts Receivable
     (current)
    Percentage of
     Accounts Receivable
     (non-current)
     Year Ended December 31,As of December 31,As of December 31,
     202120202021202020212020
    Medicare57 %58 %24 %15 %— %— %
    Medicare Advantage plans28 %29 %40 %40 %— %25 %
    BlueCross BlueShield plans7 %6 %22 %26 %58 %44 %
    XML 42 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Loss Per Share
    		 12 Months Ended
    Dec. 31, 2021
    Earnings Per Share [Abstract]  
    Loss Per Share Loss Per Share
    Basic loss per share is computed by dividing net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options or purchases under the 2019 Employee Stock Purchase Plan (“ESPP”). The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. However, potentially dilutive shares are excluded from the computation of diluted loss per share when their effect is antidilutive.
    Due to us reporting a net loss for all periods presented, all potentially dilutive securities are antidilutive and are excluded from the computation of diluted loss per share for such periods.
    The table below provides the weighted-average number of potential common shares associated with outstanding securities not included in our calculation of diluted loss per share for the years ended December 31, 2021 and 2020 because to do so would be antidilutive (in thousands):
    Years Ended December 31,
    20212020
    Stock options and restricted stock units3,459 2,789 
    Common stock warrants— 35 
    Employee stock purchase plan62 100 
    Total3,521 2,924 
    In addition, in connection with the acquisition of Cernostics, we may issue shares of our common stock to satisfy the contingent consideration obligation, pending the outcome of certain commercial milestones, as discussed in Note 5.
    XML 43 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Asset Acquisitions
    		 12 Months Ended
    Dec. 31, 2021
    Business Combination and Asset Acquisition [Abstract]  
    Asset Acquisitions Asset Acquisitions
    Myriad myPath, LLC
    On May 28, 2021, we completed the acquisition of all of the equity of Myriad myPath, LLC, a laboratory in Salt Lake City where the myPath Melanoma test for difficult-to-diagnose melanocytic lesions was developed and offered, for a cash purchase price of $32,500,000. Following the completion of the acquisition, we became the sole provider of the myPath Melanoma test. Based on the guidance in ASC 805, we concluded that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset and therefore the transaction represents an asset acquisition. We incurred $684,000 of direct transaction costs that were included in the cost of the acquisition. The allocation of the acquisition to individual assets resulted in an intangible asset representing developed technology of $33,054,000 and inventory of $130,000. The intangible asset has an estimated useful life of 12 years and is being amortized on a straight-line basis.
    Cernostics, Inc.
    On December 3, 2021, we completed the acquisition of Cernostics, Inc., which offers the TissueCypher® Barrett’s Esophagus Assay for patients with BE. We acquired Cernostics for an upfront cash purchase price of $30,732,000, including $653,000 of direct transaction costs. A portion of the upfront cash consideration is being held in escrow for a specified period following closing to secure post-closing adjustments and indemnification claims, if any. Our consolidated balance sheet at December 31, 2021 reflects a receivable of $519,000 for the post-closing purchase price adjustment, representing the difference between actual and estimated cash and working capital at closing, among other things. We have also agreed to pay up to an additional $50.0 million in cash or shares of our common stock, at our sole discretion, based on the achievement of certain commercial milestones relating to the year ending December 31, 2022 (“Earnout Payments”). The portion of any Earnout Payments that may be settled in shares of our common stock is subject to certain limitations and the aggregate number of shares that may be issued for the Earnout Payments may not exceed 5,034,653 shares. Any Earnout Payments in shares of our common stock will be based on the volume weighted-average price of our common stock for the 15 trading days ending December 30, 2022. The Earnout Payments represent contingent consideration. ASC 480, Distinguishing Liabilities from Equity, provides guidance on accounting for certain obligations that must or may be settled by issuance of a variable number of shares. In accordance with that guidance, we recognized a liability of $18,287,000, which represents the fair value of the obligation as of the acquisition date. See Note 11 for additional information on the measurement of the contingent consideration. Based on the guidance in ASC 805, we concluded that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset and therefore the transaction represents an asset acquisition.
    The cost of the acquisition, which is comprised of the cash consideration, transaction costs and contingent consideration, was allocated to the assets acquired and the liabilities assumed as follows (in thousands):
    December 3, 2021
    Cash and cash equivalents$1,251 
    Accounts receivable104 
    Prepaid expenses and other current assets198 
    Property and equipment455 
    Intangible assets57,827 
    Accounts payable(655)
    Accrued compensation(167)
    Other accrued and current liabilities(386)
    Finance lease liabilities(237)
    Deferred tax liabilities(9,371)
    Total cost allocated$49,019 
    The intangible assets were comprised of developed technology of $57,264,000 with an estimated useful life of 15 years and a developed workforce of $563,000, with an estimated useful life of five years, and each is being amortized on a straight-line basis.
    XML 44 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Property and Equipment, Net
    		 12 Months Ended
    Dec. 31, 2021
    Property, Plant and Equipment [Abstract]  
    Property and Equipment, Net Property and Equipment, Net
    Property and equipment, net consisted of the following (in thousands):
    As of December 31,
     20212020
    Leasehold improvements$5,044 $1,388 
    Lab equipment(1)
    		3,727 2,037 
    Computer equipment2,457 1,305 
    Furniture and fixtures1,288 436 
    Construction-in-progress27 3,590 
    Total12,543 8,756 
    Less accumulated depreciation(1)
    		(3,042)(1,654)
    Property and equipment, net$9,501 $7,102 
    (1)    Includes lab equipment under a finance lease of $237 thousand and accumulated depreciation of $8 thousand.
    Depreciation expense was recorded in the consolidated statements of operations and comprehensive loss as follows (in thousands):
    Years Ended December 31,
     20212020
    Cost of sales (exclusive of amortization of acquired intangible assets)$478 $341 
    Research and development248 31 
    Selling, general and administrative722 100 
    Total$1,448 $472 
    XML 45 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Intangible Assets, Net
    		 12 Months Ended
    Dec. 31, 2021
    Goodwill and Intangible Assets Disclosure [Abstract]  
    Intangible Assets, Net Intangible Assets, Net
    Our intangible assets, net consist of the following (in thousands):
    December 31, 2021
     Gross carrying valueAccumulated amortizationNetWeighted-Average Remaining Life (in years)
    Developed technology$90,317 $(1,949)$88,368 13.2
    Assembled workforce563 (9)554 4.9
    Total intangible assets, net$90,880 $(1,958)$88,922 

    There were no intangible assets as of December 31, 2020.

    The estimated future aggregate amortization expense as of December 31, 2021 is as follows (in thousands):
    Years Ending December 31,
    2022$6,681 
    20236,681 
    20246,700 
    20256,681 
    20266,672 
    Thereafter55,507 
    Total$88,922 
    Amortization expense of intangible assets was $2.0 million for the year ended December 31, 2021. No amortization expense was recorded for the year ended December 31, 2020.
    XML 46 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Other Accrued and Current Liabilities
    		 12 Months Ended
    Dec. 31, 2021
    Payables and Accruals [Abstract]  
    Other Accrued and Current Liabilities Other Accrued and Current Liabilities
    Other accrued liabilities consisted of the following (in thousands):
    As of December 31,
     20212020
    Accrued service fees$1,905 $1,543 
    Clinical studies1,655 348 
    Employee stock purchase plan contributions760 536 
    Payroll tax liabilities695 276 
    Accrued payor refunds386 — 
    Other277 352 
    Total$5,678 $3,055 
    XML 47 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Leases
    		 12 Months Ended
    Dec. 31, 2021
    Leases [Abstract]  
    Leases Leases
    Operating Leases
    We lease office space in Friendswood, Texas (the “Friendswood Lease”) for use as our corporate headquarters. The Friendswood Lease commenced in late 2020 under a 60-month term and a renewal option for one additional five-year term.
    We lease two facilities in Phoenix, Arizona for laboratory and office space. For both leases, the current term extends until April 2033 with options to renew for two additional five-year terms.
    We have not included the optional renewal periods in the measurement of the lease obligations because it is not reasonably certain that we will exercise these renewal options.
    Our other operating leases primarily consist of office equipment.
    Finance Lease
    In connection with the December 2021 acquisition of Cernostics, we assumed a finance lease for laboratory equipment.
    Discount Rates
    We discount our lease obligations using our incremental borrowing rate at the commencement date. The incremental borrowing rate is the rate of interest we would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. We primarily consider industry data, our credit rating and the lease term to determine our incremental borrowing rate.
    Lease Balances and Costs
    Lease balances reflected in the consolidated balance sheet were as follows (in thousands):
    Lease BalanceClassificationDecember 31, 2021
    Lease Assets
    OperatingOperating lease assets$7,383 
    FinanceProperty and equipment, net$229 
    Lease Liabilities
    Current
    OperatingOperating lease liabilities$1,179 
    FinanceOther accrued and current liabilities$105 
    Noncurrent
    OperatingNoncurrent operating lease liabilities$6,900 
    FinanceOther liabilities$124 
    Costs associated with our leases were included in the consolidated statement of operations and comprehensive loss as follows (in thousands):
    Lease CostYear Ended December 31, 2021
    Operating lease cost(1)
    		$1,450 
    Finance lease cost
    Amortization of lease assets8 
    Interest on finance lease liabilities1 
    Short-term lease cost29 
    Total lease cost$1,488 
    (1)    Includes variable lease cost of $187 thousand for the year ended December 31, 2021.
    Other Information
    Supplemental cash flow information on leases is as follows (in thousands):
     Year Ended December 31, 2021
    Cash paid for amounts included in the measurement of lease liabilities
    Operating cash flows from operating leases$1,145 
    Operating cash flows from interest paid on finance leases$1 
    Financing cash flows from finance leases    $8 
    During the year ended December 31, 2021, we recorded $2.9 million in lease liabilities arising from obtaining ROU assets.
    Information regarding the weighted-average lease term and weighted-average discount rate is presented below:
     December 31, 2021
    Weighted-average remaining lease term (years)
    Operating leases9.1
    Finance leases2.3
    Weighted-average discount rate
    Operating leases4.9 %
    Finance leases5.0 %
    The following is a maturity analysis of our operating lease and finance lease liabilities as of December 31, 2021 (in thousands):
    Operating leasesFinance leases
    Years Ending December 31,
    2022$1,258 $108 
    20231,287 108 
    20241,302 26 
    20251,218 — 
    2026689 — 
    Thereafter4,609 — 
    Total lease payments10,363 242 
    Less: Interest component(2,284)(13)
    Present value of lease payments$8,079 $229 
    As of December 31, 2021, we have no material leases that have not yet commenced.
    Disclosures Under ASC 840
    Future non-cancellable commitments under all operating leases were as follows as of December 31, 2020 (in thousands):
    Years Ending December 31,
    2021$1,164 
    20221,148 
    20231,142 
    20241,154 
    20251,119 
    Thereafter1,037 
    $6,764 
    Rent expense was $548,000 for the year ended December 31, 2020.
    Leases Leases
    Operating Leases
    We lease office space in Friendswood, Texas (the “Friendswood Lease”) for use as our corporate headquarters. The Friendswood Lease commenced in late 2020 under a 60-month term and a renewal option for one additional five-year term.
    We lease two facilities in Phoenix, Arizona for laboratory and office space. For both leases, the current term extends until April 2033 with options to renew for two additional five-year terms.
    We have not included the optional renewal periods in the measurement of the lease obligations because it is not reasonably certain that we will exercise these renewal options.
    Our other operating leases primarily consist of office equipment.
    Finance Lease
    In connection with the December 2021 acquisition of Cernostics, we assumed a finance lease for laboratory equipment.
    Discount Rates
    We discount our lease obligations using our incremental borrowing rate at the commencement date. The incremental borrowing rate is the rate of interest we would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. We primarily consider industry data, our credit rating and the lease term to determine our incremental borrowing rate.
    Lease Balances and Costs
    Lease balances reflected in the consolidated balance sheet were as follows (in thousands):
    Lease BalanceClassificationDecember 31, 2021
    Lease Assets
    OperatingOperating lease assets$7,383 
    FinanceProperty and equipment, net$229 
    Lease Liabilities
    Current
    OperatingOperating lease liabilities$1,179 
    FinanceOther accrued and current liabilities$105 
    Noncurrent
    OperatingNoncurrent operating lease liabilities$6,900 
    FinanceOther liabilities$124 
    Costs associated with our leases were included in the consolidated statement of operations and comprehensive loss as follows (in thousands):
    Lease CostYear Ended December 31, 2021
    Operating lease cost(1)
    		$1,450 
    Finance lease cost
    Amortization of lease assets8 
    Interest on finance lease liabilities1 
    Short-term lease cost29 
    Total lease cost$1,488 
    (1)    Includes variable lease cost of $187 thousand for the year ended December 31, 2021.
    Other Information
    Supplemental cash flow information on leases is as follows (in thousands):
     Year Ended December 31, 2021
    Cash paid for amounts included in the measurement of lease liabilities
    Operating cash flows from operating leases$1,145 
    Operating cash flows from interest paid on finance leases$1 
    Financing cash flows from finance leases    $8 
    During the year ended December 31, 2021, we recorded $2.9 million in lease liabilities arising from obtaining ROU assets.
    Information regarding the weighted-average lease term and weighted-average discount rate is presented below:
     December 31, 2021
    Weighted-average remaining lease term (years)
    Operating leases9.1
    Finance leases2.3
    Weighted-average discount rate
    Operating leases4.9 %
    Finance leases5.0 %
    The following is a maturity analysis of our operating lease and finance lease liabilities as of December 31, 2021 (in thousands):
    Operating leasesFinance leases
    Years Ending December 31,
    2022$1,258 $108 
    20231,287 108 
    20241,302 26 
    20251,218 — 
    2026689 — 
    Thereafter4,609 — 
    Total lease payments10,363 242 
    Less: Interest component(2,284)(13)
    Present value of lease payments$8,079 $229 
    As of December 31, 2021, we have no material leases that have not yet commenced.
    Disclosures Under ASC 840
    Future non-cancellable commitments under all operating leases were as follows as of December 31, 2020 (in thousands):
    Years Ending December 31,
    2021$1,164 
    20221,148 
    20231,142 
    20241,154 
    20251,119 
    Thereafter1,037 
    $6,764 
    Rent expense was $548,000 for the year ended December 31, 2020.
    XML 48 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Long-Term Debt
    		 12 Months Ended
    Dec. 31, 2021
    Debt Disclosure [Abstract]  
    Long-Term Debt Long-Term DebtWe had a Loan and Security Agreement with Oxford Finance LLC (“Oxford”) as collateral agent, and Oxford and Silicon Valley Bank as equal syndicated lenders (the “2018 LSA”). The 2018 LSA consisted of a $25.0 million secured term loan credit facility (the “Term Loan”). The Term Loan bore interest at a floating rate equal to the greater of (1) 8.55% and (2) the 30-day U.S. LIBOR rate as reported in The Wall Street Journal on the last business day of the month that preceded the month in which the interest was to accrue, plus 6.48%. We were permitted to make interest-only payments on the Term Loan through May 31, 2020. As required, we began to repay the principal in 30 equal monthly installments of $833,333 each beginning on June 1, 2020. All unpaid principal and accrued and unpaid interest were to be due at maturity on November 1, 2022. However, on December 21, 2020, we terminated the 2018 LSA and repaid in full all amounts due, which totaled $21.6 million as of such date, including the outstanding principal balance, the final payment amount, early termination and prepayment fees and accrued interest. The termination of the 2018 LSA resulted in the recognition of an extinguishment loss of $1.4 million, which was reflected in our statement of operations and comprehensive loss for the year ended December 31, 2020.
    XML 49 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Fair Value Measurements
    		 12 Months Ended
    Dec. 31, 2021
    Fair Value Disclosures [Abstract]  
    Fair Value Measurements Fair Value Measurements
    Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used in measuring fair value. There are three levels to the fair value hierarchy based on the reliability of inputs, as follows:
    Level 1 – Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
    Level 2 – Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.
    Level 3 – Unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions.
    Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or amounts recorded may not be indicative of the amount that us or holders of the instruments could realize in a current market exchange.
    The table below provides information (in thousands), by level within the fair value hierarchy, of our financial assets and liabilities that are accounted for at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):
     
    As of December 31, 2021
     Quoted Prices in Active Markets for Identical Items (Level 1)Significant Other Observable Inputs
    (Level 2)    		Significant Unobservable Inputs
    (Level 3)    		Total
    Assets:    
    Money market funds(1)
    		$327,721 $— $— $327,721 
    Liabilities:
    Contingent consideration$— $— $18,287 $18,287 
    As of December 31, 2020
    Quoted Prices in Active Markets for Identical Items (Level 1)Significant Other Observable Inputs
    (Level 2)    		Significant Unobservable Inputs
    (Level 3)    		Total
    Assets:
    Money market funds(1)
    		$409,480 $— $— $409,480 
    (1) Classified as “Cash and cash equivalents” in the consolidated balance sheets.
    Contingent Consideration
    In connection with our acquisition of Cernostics, we have recorded a contingent consideration liability for the Earnout Payments. This liability is classified as a Level 3 fair value measurement due to the use of significant unobservable inputs and a Monte Carlo simulation to determine its fair value. The Monte Carlo simulation uses projections of the commercial milestones for the applicable period as well as the corresponding targets and approximate timing of payment based on the terms of the arrangement. The analysis also uses assumptions for expected volatility of the financial metrics and a risk-adjusted discount rate, which were 20.0% and 16.1%, respectively, at initial measurement on December 3, 2021. The contingent consideration liability is remeasured at fair value at each reporting period taking into account any updated assumptions or changes in circumstances. Any change in the fair value is recorded as a gain or loss in our consolidated statement of operations and comprehensive loss. There was no change in fair value from the initial recognition on December 3, 2021 through December 31, 2021.
    The following table discloses the summary of changes in the contingent consideration liability measured at fair value using Level 3 inputs during the year ended December 31, 2021 (in thousands):
     Year Ended
    December 31, 2021
    Balance at beginning of period$— 
    Acquisition of Cernostics18,287 
    Change in fair value— 
    Balance at end of period$18,287 
    XML 50 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Commitments and Contingencies
    		 12 Months Ended
    Dec. 31, 2021
    Commitments and Contingencies Disclosure [Abstract]  
    Commitments and Contingencies Commitments and ContingenciesFrom time to time, we may be involved in legal proceedings arising in the ordinary course of business. We believe there is no threatened litigation or litigation pending that could have, individually or in the aggregate, a material adverse effect on our financial position, results of operations or cash flows.
    XML 51 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stockholders’ Equity
    		 12 Months Ended
    Dec. 31, 2021
    Equity [Abstract]  
    Stockholders' Equity Stockholders’ Equity
    Capital Stock
    The Company’s Amended and Restated Certificate of Incorporation, dated July 29, 2019, authorizes the Company to issue up to 200,000,000 shares of common stock with a par value of $0.001 per share. The Company is also authorized to issue up to 10,000,000 shares of preferred stock with a par value of $0.001 per share. No dividends were declared or paid during the years ended December 31, 2021 or 2020.
    On June 29, 2020, we issued and sold 2,000,000 shares of our common stock in a follow-on public offering at a price of $37.00 per share. We received $69,079,000 in net proceeds, after deducting underwriting discounts, commissions and offering costs. In connection with the offering, we granted the underwriters a 30-day option to purchase up to 300,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. On July 2, 2020, we issued and sold an additional 300,000 shares of common stock pursuant to the underwriters’ exercise in full of their option to purchase additional shares, which resulted in an additional net proceeds to us of $10,425,000. On December 18, 2020, we issued and sold 4,600,000 shares of our common stock in a follow-on public offering, including 600,000 shares associated with the full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $58.00 per share. We received $250,201,000 in aggregate net proceeds, after deducting underwriting discounts and commissions and offering costs.
    Common Stock Warrants
    The Company issued an aggregate of 209,238 shares and 31,814 shares of common stock December 11, 2020 and December 29, 2020, respectively, pursuant to net exercises by the holders of common stock warrants outstanding. In accordance with the net exercise provisions of the warrants, shares of common stock were withheld to satisfy the cost of these exercises.
    There were no common stock warrants outstanding as of December 31, 2021 or 2020.
    The common stock warrants were classified as stockholders’ equity and no adjustments were recorded for changes in fair value.
    XML 52 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stock Incentive Plans and Stock Based Compensation
    		 12 Months Ended
    Dec. 31, 2021
    Share-based Payment Arrangement [Abstract]  
    Stock Incentive Plans and Stock Based Compensation Stock Incentive Plans and Stock-Based Compensation
    Stock Incentive Plans
    Our stock incentive plans provide for the granting of options to purchase common stock and other equity-based awards to our employees, directors and consultants. On September 6, 2008, we adopted the 2008 Stock Plan (the “2008 Plan”), on August 15, 2018, we adopted the 2018 Stock Plan (the “2018 Plan”) and on July 24, 2019, we adopted the 2019 Equity Incentive Plan (the “2019 Plan”). Following the adoption of the 2018 Plan, no additional stock awards were granted under the 2008 Plan and following the adoption of the 2019 Plan, no additional stock awards were granted under the 2018 Plan.
    Options under the plans may be granted as incentive stock options (“ISOs”) or non-statutory stock options (“NSOs”). ISOs may only be granted our employees (including directors who are also considered employees). NSOs may be granted our employees, directors and consultants. Options may be granted for terms up to ten years from the date of grant, as determined by the Board of Directors; provided, however, that with respect to an ISO granted to a person who owns stock representing more than 10% of the voting power of all classes of stock of ours, the terms shall be for no more than five years from the date of grant. The exercise price of options granted must be no less than 100% of the fair market value of the shares on the date of grant, provided, however, that with respect to an ISO granted to an employee who at the time of grant of such options owns stock representing more than 10% of the voting power of all classes of stock of ours, the exercise price shall not be less than 110% of the fair market value of the shares on the date of grant. Options generally vest over four years (generally 25% after one year and monthly thereafter), subject to the option holder’s continued service with us. We issue new shares to satisfy option exercises.
    As of December 31, 2021, 46,741 shares remained available for grant under the 2019 Plan. On January 1, 2022, an additional 1,268,926 shares became available under the 2019 Plan pursuant to an automatic annual increase.
    Stock Options
    Stock option activity under our stock plans for the years ended December 31, 2021 and 2020 is set forth below:
      Weighted-Average 
     Stock Options
    Outstanding    		Exercise
    Price    		Remaining
    Contractual
    Term (Years)    		Aggregate
    Intrinsic
    Value
    (in thousands)
    Balance as of January 1, 20202,637,966 $13.30 
    Granted1,286,065 $49.63 
    Exercised(460,207)$3.53 
    Forfeited/Cancelled(94,322)$27.51 
    Balance as of December 31, 20203,369,502 $28.11 
    Granted841,336 $48.97 
    Exercised(414,890)$10.13 
    Forfeited/Cancelled(209,260)$33.97 
    Balance as of December 31, 20213,586,688 $34.75 8.3$45,970 
    Exercisable at December 31, 2021(1)
    		1,332,487 $23.31 7.5$28,845 
    (1)Vested and exercisable options. Additionally, outstanding unvested options to purchase an aggregate of 10,255 shares of common stock with a weighted-average exercise price of $2.39 per share may be exercised prior to vesting as of December 31, 2021 under early-exercise provisions. In the event of such exercise, the shares obtained upon exercise would be restricted and subject to forfeiture prior to vesting. No such early exercises have occurred as of December 31, 2021.
    Restricted Stock Units
    RSUs represent the right to receive shares of our common stock at a specified future date, subject to vesting. Our RSUs generally vest annually from the grant date in four equal installments subject to the holder’s continued service with us. We issue new shares to satisfy RSUs upon vesting.
    The following table summarizes our RSU activity for the years ended December 31, 2021 and December 31, 2020:
    Restricted Stock Units OutstandingWeighted-Average Grant Date Fair Value
    Balance as of January 1, 2020— $— 
    Granted161,477 $59.16 
    Vested— $— 
    Forfeited/Cancelled— $— 
    Balance as of December 31, 2020161,477 $59.16 
    Granted958,361 $43.05 
    Vested (1)
    		(56,002)$61.07 
    Forfeited/Cancelled(13,662)$62.80 
    Balance as of December 31, 20211,050,174 $44.31 
    (1)The aggregate number of shares withheld upon vesting for employee tax obligations was 16,440 for the year ended December 31, 2021.
    RSU Awards to Related Parties
    On October 1, 2021, the Audit Committee of our Board of Directors approved, at the recommendation of our Compensation Committee, a one-time award of RSUs to three employees who are the children of our Chief Executive Officer (“CEO”) which we have determined to be outside the ordinary course of business. Under the Internal Revenue Code (“IRC”), those owning more than a specified percentage of a company’s stock are not eligible to receive certain preferential tax benefits that are afforded to qualifying stock compensation arrangements. In determining eligibility under the Code, when calculating the number of shares of common stock owned, an individual must attribute all shares owned by specified family members. Because
    of the stock ownership of our CEO and this attribution requirement, the three children have not been eligible to participate in the ESPP and, at times, have not qualified to receive stock option grants on terms as favorable as those received by other similar employees. Our Compensation Committee recommended, and our Audit Committee approved, a one-time grant of restricted stock units designed to compensate the three children for these differences. The aggregate number of shares underlying the restricted stock units granted to the three children was 17,275 which are included in the table above. The awards had an aggregate grant date fair value of $1,129,000, vested immediately upon grant and was recognized as stock-based compensation expense, included in selling, general and administrative expenses, during the year ended December 31, 2021.
    Employee Stock Purchase Plan
    The ESPP became effective July 24, 2019. Offerings under the ESPP are generally 24 months in length with four six-month purchase periods unless terminated earlier, as described below. Eligible employees who enroll in an offering are able to purchase shares of our common stock at a discount through payroll deductions, subject to certain limitations. The purchase price of the shares of common stock is the lesser of (i) 85% of the fair market value of such shares on the offering date and (ii) 85% of the fair market value of such shares on the purchase date. A new offering begins approximately every six months. Offerings are concurrent, but in the event the fair market value of a share of common stock on the first day of any purchase period during an offering (the “New Offering”) is less than or equal to the fair market value of a share of common stock on the offering date for an ongoing offering (the “Ongoing Offering”), then the Ongoing Offering terminates immediately following the purchase of shares on the purchase date immediately preceding the New Offering and the participants in the terminated Ongoing Offering are automatically enrolled in the New Offering. In such case, we account for this event as a modification of the Ongoing Offering. Notwithstanding the above, our Board of Directors (or an authorized committee thereof) may modify the terms of or suspend any future offerings prior to their commencement.
    As of December 31, 2021, 639,466 shares remained available for issuance under the ESPP. The ESPP provides for certain automatic increases in the number of shares of common stock reserved for issuance, which resulted in an additional 253,785 shares becoming available under the ESPP effective January 1, 2022. We issue new shares to satisfy ESPP purchases.
    Determining Fair Value - Summary of Assumptions
    We use the Black-Scholes option pricing model to estimate the fair value of stock options and purchase rights granted under the ESPP at the date of grant, start of the offering or other relevant measurement date. Set forth below is a description of the significant assumptions used in the option pricing model:
    •Expected term. The expected term is the period of time that granted options are expected to be outstanding. For stock options, we have set the expected term using the simplified method based on the weighted average of both the period to vesting and the period to maturity for each option, as we have concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate the expected term. For the ESPP, the expected term is the period of time from the offering date to the purchase date.
    •Expected volatility. Previously, because of the limited period of time our stock had been traded in an active market, we calculated expected volatility by using the historical stock prices of a group of similar companies looking back over the estimated life of the option or the ESPP purchase right and averaging the volatilities of these companies. In the third quarter of 2021, we adjusted this calculation to include our own stock price on a relative basis to the peer group in the calculation of expected volatility, as our common stock has now been traded in an active market for more than two years.
    •Risk-free interest rate. We base the risk-free interest rate used in the Black-Scholes valuation model on the market yield in effect at the time of option grant and at the offering date for the ESPP, provided from the Federal Reserve Board’s Statistical Releases and historical publications from the Treasury constant maturities rates for the equivalent remaining terms.
    •Dividend yield. We have not paid, and does not have plans to pay, cash dividends. Therefore, we use an expected dividend yield of zero in the Black-Scholes option valuation model.
    The fair value of our common stock is also an assumption used to determine the fair value of stock options. Prior to our initial public offering of common stock on July 29, 2019 (the “IPO”), our common stock was not publicly traded, therefore we estimated the fair value of our common stock. Following the IPO, the fair value of our common stock is the closing selling price per share of its common stock as reported on the Nasdaq Global Market on the date of grant or other relevant determination date.
    We use the Black-Scholes option pricing model to estimate the fair value of each option grant on the date of grant or any other measurement date. The following table sets forth the assumptions used to determine the fair value of stock options:
     Years Ended December 31,
    20212020
    Average expected term (years)
    6.1
    6
    Expected stock price volatility
    66.50% - 68.83%
    59.57% - 67.02%
    Risk-free interest rate
    0.51% - 1.48%
    0.28% - 1.76%
    Dividend yield
    —%
    —%

    The following table sets forth assumptions used to determine the fair value of the purchase rights issued under the ESPP:
     Years Ended December 31,
    20212020
    Average expected term (years)
    1.2
    1.2
    Expected stock price volatility
    61.13% - 86.50%
    56.80% - 100.49%
    Risk-free interest rate
    0.06% - 0.20%
    0.12% - 0.95%
    Dividend yield
    —%
    —%
    We use the closing price of our common stock on the date of grant to determine the fair value of RSUs.
    Stock-Based Compensation Expense
    Stock-based compensation expense is included in the consolidated statements of operations and comprehensive loss as follows (in thousands):
     Years Ended December 31,
     20212020
    Cost of sales (exclusive of amortization of acquired intangible assets)$2,058 $1,049 
    Research and development4,522 1,492 
    Selling, general and administrative15,160 5,768 
    Total stock-based compensation expense$21,740 $8,309 
    For the years ended December 31, 2021 and 2020, the weighted-average grant date fair value of stock options was $29.89 and $28.95 per option, respectively, and the weighted-average grant date fair value of the purchase rights granted under the ESPP was $27.60 and $17.43 per share, respectively. As of December 31, 2021, the total unrecognized stock-based compensation cost related to outstanding awards was $99,251,000, which is expected to be recognized on a straight-line basis over a weighted-average period of 3.3 years. The total unrecognized compensation cost will be adjusted for forfeitures in future periods as they occur. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2021 and 2020 was $27,191,000 and $18,377,000, respectively. The aggregate intrinsic value of shares issued under the ESPP was $6,341,000 and $1,797,000 during the years ended December 31, 2021 and 2020, respectively. The aggregate fair value of restricted stock units that vested during the year ended December 31, 2021 was $2,698,000. No tax benefits related to stock-based compensation were recorded in the consolidated statements of operations and comprehensive loss during the years ended December 31, 2021 and 2020 due to the valuation allowance on net deferred tax assets.
    XML 53 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Income Taxes
    		 12 Months Ended
    Dec. 31, 2021
    Income Tax Disclosure [Abstract]  
    Income Taxes Income Taxes
    The components of income tax expense (benefit) are as follows (in thousands):
    Years Ended December 31,
    20212020
    Current tax expense
    U.S. Federal$— $— 
    State and local16 84 
    Total current16 84 
    Deferred tax (benefit) expense
    U.S. Federal(8,726)— 
    State and local(10)— 
    Total deferred(8,736)— 
    Total income tax (benefit) expense$(8,720)$84 
    The differences between income taxes expected at the U.S. federal statutory rate (21%) and the reported income tax expense (benefit) are summarized as follows (in thousands):
    Years Ended December 31,
    20212020
    Pre-tax loss$(40,012)$(10,200)
    U.S. federal taxes at statutory rate(8,402)(2,142)
    State income taxes(1,764)(311)
    Non-deductible meals— 235 
    Research and development (“R&D”) tax credit(1,658)(703)
    Change in valuation allowance2,570 2,784 
    Stock-based compensation(880)(781)
    Non-deductible officers’ compensation1,571 963 
    Other(157)39 
    Total income tax (benefit) expense$(8,720)$84 
    Significant components of deferred tax assets and liabilities are as follows (in thousands):
    As of December 31,
    20212020
    Deferred tax assets:
    Net operating loss (“NOL”) carryforwards$24,316 $13,720 
    Accrued liabilities4,168 2,730 
    Lease liabilities2,114 — 
    Intangible assets— 46 
    Stock-based compensation2,202 761 
    R&D tax credit3,670 1,777 
    Other240 — 
    Total deferred tax assets36,710 19,034 
    Less valuation allowance(17,774)(15,204)
    Deferred tax assets, net$18,936 $3,830 
    Deferred tax liabilities:
    Prepaid expenses$(330)$(289)
    Property and equipment(2,285)(776)
    Intangible assets(12,913)— 
    ROU assets(2,166)— 
    Section 481(a) adjustment (cash to accrual)(1,877)(2,765)
    Total deferred tax liabilities(19,571)(3,830)
    Net deferred tax asset (liability)$(635)$— 
    At December 31, 2021, we had NOL carryforwards for federal income tax purposes of approximately $99,365,000 of which $43,513,000 will begin to expire in 2030 if not utilized to offset taxable income, and $55,852,000 may be carried forward indefinitely. Future changes in ownership, as defined by Section 382 of the IRC, could limit the amount of NOL carryforwards used in any one year. Also, as of December 31, 2021, we had state net operating loss carryforwards of approximately $67,453,000, which begin to expire in 2028 if not utilized to offset state taxable income. Our R&D tax credit carryforwards of $3,670,000 at December 31, 2021 will begin to expire in 2034 if not utilized to offset federal income tax.
    In general, under Section 382 and 383 of the IRC, a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change NOLs and certain tax credits, to offset future taxable income and tax. In general, an ownership change occurs if the aggregate stock ownership of certain stockholders changes by more than 50 percentage points over such stockholders’ lowest percentage of ownership during the testing period (generally three years). We performed a Section 382 analysis from inception through the year ended December 31, 2021 and concluded we had experienced an ownership change in 2011, 2014 and 2020. These changes in ownership did not result in the expiration of any NOLs or R&D credits. However, future changes in ownership may further limit the ability of us to utilize our NOL carryforwards and R&D tax credit carryforwards.
    During the year ended December 31, 2021, in connection with the acquisition of Cernostics, we recorded additional net deferred tax liabilities of $9,371,000, primarily due to book-tax differences related to the acquired intangible assets. As a result of these additional deferred tax liabilities, we determined that $8,726,000 of our existing valuation allowance should be reduced, which was reflected in our income tax benefit for the year ended December 31, 2021. At December 31, 2021 and 2020, we placed a valuation allowance of $17,774,000 and $15,204,000, respectively, against our net deferred tax asset balances, as we have determined that it is more likely than not that they will not be realized.
    We assessed whether we had any significant uncertain tax positions related to open tax years and concluded there were none. Accordingly, no reserve for uncertain tax positions has been recorded as of December 31, 2021 and 2020. We are generally no longer subject to tax examinations for U.S. federal income tax purposes for fiscal years prior to 2018 and fiscal years prior to 2017 for multiple state jurisdictions. However, since we have been in an NOL position since 2008, our 2008 to 2017 federal tax returns and our 2008 to 2016 state tax returns are potentially subject to examination adjustments to the extent of those NOL carryforwards.
    XML 54 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Summary of Significant Accounting Policies (Policies)
    		 12 Months Ended
    Dec. 31, 2021
    Accounting Policies [Abstract]  
    Basis of Presentation Our consolidated financial statements include the accounts of Castle Biosciences, Inc. and our wholly owned subsidiaries and have been prepared in conformity with accounting principles generally accepted in the United States of America (‘‘U.S. GAAP’’).
    Consolidation All intercompany accounts and transactions have been eliminated in consolidation.
    Reclassification Certain prior year amounts in our consolidated statements of operations and comprehensive loss have been reclassified to conform to the current year presentation. Specifically, we no longer present gross margin on our statements of operations and comprehensive loss and therefore the cost of sales line is now presented within the operating expenses section. This reclassification had no impact on operating loss, loss before income taxes, net loss, comprehensive loss or loss per share.
    Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include revenue recognition, the valuation of stock-based compensation, assessing future tax exposure and the realization of deferred tax assets, the useful lives and recoverability of long-lived assets, the valuation of acquired intangible assets, the valuation of contingent consideration and other contingent liabilities. We base these estimates on historical and anticipated results, trends, and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. We have considered the potential impact of the COVID-19 pandemic on our estimates and assumptions. The extent to which the COVID-19 pandemic may impact our estimates in future periods is uncertain and subject to change.
    Operating Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment. All revenues are attributable to U.S.-based operations and all assets are held in the United States.
    Cash and Cash Equivalents Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less. Our cash equivalents consist of money market funds, which are not insured by the Federal Deposit Insurance Corporation (“FDIC”), that are primarily invested in short-term U.S. government obligations.
    Concentrations of Credit Risk Cash deposits at financial institutions may exceed the amount of insurance provided by the FDIC. Management believes that we are not exposed to significant credit risk on our cash deposits due to the financial position of the institutions in which deposits are held. We have not experienced any losses on our cash or cash equivalents.
    Revenue Recognition, Cost of Sales (exclusive of amortization of acquired intangible assets) Revenue is recognized in accordance with Financial Accounting Standards Board (‘‘FASB’’) Accounting Standards Codification (‘‘ASC’’) Topic 606, Revenue from Contracts with Customers (‘‘ASC 606’’). In accordance with ASC 606, we follow a five-step process to recognize revenues: (1) identify the contract with the customer, (2) identify the performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenues when the performance obligations are satisfied. We have determined that we have a contract with the patient when the treating clinician orders the test. Our contracts generally contain a single performance obligation, which is the delivery of the test report, and we satisfy our performance obligation at a point in time upon the delivery of the test report to the treating physician, at which point we can bill for the report. The amount of revenue recognized reflects the amount of consideration to which we expect to be entitled, or the transaction price, and considers the effects of variable consideration.Cost of sales is expensed as incurred and includes material and service costs associated with testing samples, personnel costs (including salaries, bonuses, benefits and stock-based compensation expense), electronic medical records, order and delivery systems, shipping charges to transport samples, third-party test fees, and allocated overhead including rent, information technology costs, equipment and facilities depreciation and utilities.
    Accounts Receivable We classify accounts receivable balances that are expected to be paid more than one year from the consolidated balance sheet date as non-current assets. The estimated timing of payment utilized as a basis for classification as non-current is determined by analyses of historical payor-specific payment experience, adjusted for known factors that are expected to change the timing of future payments.
    Allowance for Credit Losses We accrue an allowance for credit losses against our accounts receivable based on management’s current estimate of amounts that will not be collected. Management’s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of customers’ financial condition and generally do not require collateral. Historically, our credit losses have not been significant. The allowance for credit losses was zero as of December 31, 2021 and 2020. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.
    Inventory We carry inventories of test supplies in our laboratory facilities. The inventories are carried at the lower of weighted average cost and net realizable value and expensed through cost of sales as the supplies are used.
    Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between five and ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Our leasehold improvements primarily relate to our office and laboratory facilities in Friendswood, Texas and Phoenix, Arizona, and are generally being amortized through the end of the lease terms in 2025 and 2033, respectively. Maintenance and repairs are charged to expense as incurred, and material improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss in the period realized.
    Intangible Assets Our intangible assets, which are comprised primarily of acquired developed technology, are considered to be finite-lived and are amortized on a straight-line basis over their estimated useful lives.
    Long-Lived Assets We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than the carrying amount. Impairment, if any, would be calculated based on the excess of the carrying amount of the long-lived asset over the long-lived asset’s fair value.
    Acquisitions, Contingent Consideration
    We assess acquisitions under ASC 805, Business Combinations, to determine whether a transaction represents the acquisition of assets or a business combination. Under this guidance, we apply a two-step model. The first step involves a screening test where we evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single asset or a group of similar assets. If the screening test is met, we account for the set as an asset acquisition. If the screening test is not met, we apply the second step of the model to determine if the set meets the definition of a business based on the guidance in ASC 805. If so, the transaction is treated as a business combination. Otherwise, it is treated as an asset acquisition. Asset acquisitions are accounted for by allocating the cost of the acquisition, including transaction costs, to the individual assets acquired and liabilities assumed on a relative fair value basis without recognition of goodwill. Business combinations are accounted for using the acquisition method. Under the acquisition method, goodwill is measured as a residual amount equal to the fair value of the consideration transferred less the net recognized fair value of the identifiable assets acquired and the liabilities assumed, as of the acquisition date, and transaction costs are expensed as incurred.
    Contingent Consideration
    Under the terms of business combinations or asset acquisitions, we may be required to pay additional consideration if specified future events occur or if certain conditions are met. With respect to the additional consideration that may be payable in connection with the Cernostics, Inc. (“Cernostics”) asset acquisition, we account for the contingent consideration as liability in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), under the guidance for obligations that must or may be settled by issuance of a variable number of shares. In accordance with ASC 480, we record the contingent consideration initially and subsequently at fair value with changes in fair value recorded in the statements of operations and comprehensive loss each period.
    Leases Effective January 1, 2021, we account for leases in accordance with ASC 842, Leases. We categorize leases at their commencement as either operating or finance leases based on the criteria in ASC 842. Under ASC 842, we record right-of-use (“ROU”) assets and lease liabilities for each lease arrangement identified, except that we have elected the short-term lease exemption for all leases with a term of 12 months or less. Lease liabilities are recorded at the present value of future lease payments discounted using our incremental borrowing rate for the lease established at the commencement date and ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. For our operating leases, we recognize a single lease cost over the lease term on a straight-line basis. We have elected the practical expedient of not separating nonlease components from lease components in all leases. Periods prior to January 1, 2021 have not been restated for the adoption of ASC 842 and continue to reflect the accounting treatment of leases in accordance with the prior lease accounting guidance, ASC 840, Leases. Under ASC 840, landlord/tenant incentives, rent holidays and escalations in the base price of rent payments under operating leases were recognized on a straight-line basis over the lease term. Deferred rent balances were classified as current or non-current in the consolidated balance sheets based upon the period when reversal of the liability was expected to occur.
    Research and Development
    Research and development costs are charged to operations as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on behalf of us will be expensed as services are rendered or when the milestone is achieved.
    Research and development costs include, but are not limited to, payroll and personnel-related expenses, stock-based compensation expense, materials, laboratory supplies, and consulting costs.
    Selling, General and Administrative Expenses Selling, general and administrative (“SG&A”) expenses are attributable to sales, marketing, executive, finance and accounting, legal and human resources functions. These expenses consist of personnel costs (including salaries, employee benefit costs, bonuses and stock-based compensation expenses), customer services expenses, direct marketing expenses, educational and promotional expenses, market research, audit and legal expenses, and consulting. We expense all SG&A costs as incurred.
    Accrued Compensation, Stock-Based Compensation We accrue for liabilities under discretionary employee and executive bonus plans. These estimated compensation liabilities are based on progress against corporate objectives approved by our board of directors, compensation levels of eligible individuals, and target bonus percentage levels. The board of directors reviews and evaluates the performance against these objectives and ultimately determines what discretionary payments are made. We also accrue for liabilities under employee sales incentive bonus plans with accruals based on performance achieved to date compared to established targets. As of December 31, 2021 and 2020, we accrued approximately $12,071,000 and $7,175,000, respectively, for liabilities associated with these bonus plans. These amounts are classified as current or noncurrent accrued liabilities in the balance sheets based on the expected timing of payment.Stock-based compensation expense for equity instruments issued to employees is measured based on the grant-date fair value of the awards. The fair value of employee stock options and offerings under the 2019 Employee Stock Purchase Plan (the “ESPP”) are estimated on the date of grant using the Black-Scholes option-pricing valuation model. For restricted stock units (“RSUs”), the fair value is equal to the closing price of our common stock on the date of grant. We recognize compensation costs on a straight-line basis for all employee stock-based compensation awards over the requisite service period of the awards. For options and RSUs, the requisite service period is generally the awards’ vesting period (typically four years). For the ESPP, the requisite service period is generally the period of time from the offering date to the purchase date. Forfeitures are accounted for as they occur.
    Retirement Plan We have an Internal Revenue Code (“IRC”) Section 401(k) profit sharing plan (the “Plan”) for eligible employees. The Plan is funded by employee contributions and provides for discretionary contributions in the form of matching and/or profit-sharing contributions.
    Income Taxes
    We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the statutory enactment date. Valuation allowances are established to reduce deferred tax assets when it is more likely than not that some portion or all of the deferred tax assets will not be realized.
    Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50% likely to be realized upon settlement. A liability for unrecognized tax benefits is recorded for any tax benefits claimed in our tax returns that do not meet these recognition and measurement standards.
    Our policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of tax expense.
    Comprehensive Loss Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources.
    Recently Adopted Accounting Pronouncements
    Recently Adopted Accounting Pronouncements
    We were previously an emerging growth company (“EGC”) within the meaning of the Jumpstart Our Business Startups Act, as amended, (the “JOBS Act”) and elected to delay the adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements were made applicable to private companies, as permitted under the JOBS Act. Because the market value of our common stock held by non-affiliates exceeded $700.0 million as of June 30, 2021, we ceased to be an EGC effective December 31, 2021. Accordingly, we are no longer permitted to delay the adoption of new or revised accounting pronouncements and as such we adopted the pronouncements discussed below in the fourth quarter of 2021 effective as of the dates noted.
    In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which supersedes ASC 840, Leases. ASU 2016-02 establishes ASC 842, Leases, and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized based on an effective interest method for finance leases or on a straight-line basis over the term of the lease for operating leases. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of classification. Leases with a term of 12 months or less may be accounted for similar to existing guidance for operating leases. We adopted ASU 2016-02 and ASC 842 using the modified retrospective approach with an effective date of January 1, 2021. Periods prior to January 1, 2021 have not been restated for the adoption of ASC 842 and continue to reflect the accounting treatment of leases in accordance with ASC 840. In connection with the adoption, we elected the package of practical expedients to not reassess prior conclusions about lease identification, lease classification and capitalized indirect costs. We did not elect the use of hindsight practical expedient. Upon adoption, effective January 1, 2021 we recognized operating lease right-of-use assets of $5,405,000, operating lease liabilities of $6,076,000, reductions to noncurrent liabilities of $751,000, reductions to current assets of $59,000 and a credit to accumulated deficit of $21,000. See Note 9 for disclosures about our leases.
    In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement of expected credit losses for financial instruments carried at amortized cost, such as accounts receivable, held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. We adopted the standard effective January 1, 2021 using the modified retrospective approach. The adoption of this standard had no impact on our consolidated financial statements.
    In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which eliminates certain exceptions to the general principles in Topic 740 and simplifies other areas of the existing guidance. The adoption of ASU 2019-12 effective January 1, 2021 had no impact on our consolidated financial statements.
    XML 55 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Revenue (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Revenue from Contract with Customer [Abstract]  
    Schedule of Disaggregation of Revenue
    The table below provides the disaggregation of revenue by type (in thousands):
    Years Ended December 31,
    20212020
    Dermatologic$85,753 $57,646 
    Other8,332 5,003 
    Total net revenues$94,085 $62,649 
    Schedules of Concentration of Risk, by Risk Factor
    Our significant third-party payors and their related revenues as a percentage of total revenues and accounts receivable balances are as follows:
     Percentage of Revenues
    Percentage of
     Accounts Receivable
     (current)
    Percentage of
     Accounts Receivable
     (non-current)
     Year Ended December 31,As of December 31,As of December 31,
     202120202021202020212020
    Medicare57 %58 %24 %15 %— %— %
    Medicare Advantage plans28 %29 %40 %40 %— %25 %
    BlueCross BlueShield plans7 %6 %22 %26 %58 %44 %
    XML 56 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Loss Per Share (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Earnings Per Share [Abstract]  
    Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
    The table below provides the weighted-average number of potential common shares associated with outstanding securities not included in our calculation of diluted loss per share for the years ended December 31, 2021 and 2020 because to do so would be antidilutive (in thousands):
    Years Ended December 31,
    20212020
    Stock options and restricted stock units3,459 2,789 
    Common stock warrants— 35 
    Employee stock purchase plan62 100 
    Total3,521 2,924 
    XML 57 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Asset Acquisition (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Business Combination and Asset Acquisition [Abstract]  
    Asset Acquisition
    The cost of the acquisition, which is comprised of the cash consideration, transaction costs and contingent consideration, was allocated to the assets acquired and the liabilities assumed as follows (in thousands):
    December 3, 2021
    Cash and cash equivalents$1,251 
    Accounts receivable104 
    Prepaid expenses and other current assets198 
    Property and equipment455 
    Intangible assets57,827 
    Accounts payable(655)
    Accrued compensation(167)
    Other accrued and current liabilities(386)
    Finance lease liabilities(237)
    Deferred tax liabilities(9,371)
    Total cost allocated$49,019 
    XML 58 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Property and Equipment, Net (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Property, Plant and Equipment [Abstract]  
    Property, Plant and Equipment
    Property and equipment, net consisted of the following (in thousands):
    As of December 31,
     20212020
    Leasehold improvements$5,044 $1,388 
    Lab equipment(1)
    		3,727 2,037 
    Computer equipment2,457 1,305 
    Furniture and fixtures1,288 436 
    Construction-in-progress27 3,590 
    Total12,543 8,756 
    Less accumulated depreciation(1)
    		(3,042)(1,654)
    Property and equipment, net$9,501 $7,102 
    (1)    Includes lab equipment under a finance lease of $237 thousand and accumulated depreciation of $8 thousand.
    Depreciation expense was recorded in the consolidated statements of operations and comprehensive loss as follows (in thousands):
    Years Ended December 31,
     20212020
    Cost of sales (exclusive of amortization of acquired intangible assets)$478 $341 
    Research and development248 31 
    Selling, general and administrative722 100 
    Total$1,448 $472 
    XML 59 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Intangible Assets, Net (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Goodwill and Intangible Assets Disclosure [Abstract]  
    Schedule of Finite-Lived Intangible Assets
    Our intangible assets, net consist of the following (in thousands):
    December 31, 2021
     Gross carrying valueAccumulated amortizationNetWeighted-Average Remaining Life (in years)
    Developed technology$90,317 $(1,949)$88,368 13.2
    Assembled workforce563 (9)554 4.9
    Total intangible assets, net$90,880 $(1,958)$88,922 

    There were no intangible assets as of December 31, 2020.
    Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
    The estimated future aggregate amortization expense as of December 31, 2021 is as follows (in thousands):
    Years Ending December 31,
    2022$6,681 
    20236,681 
    20246,700 
    20256,681 
    20266,672 
    Thereafter55,507 
    Total$88,922 
    XML 60 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Other Accrued and Current Liabilities (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Payables and Accruals [Abstract]  
    Schedule of Accrued Liabilities
    Other accrued liabilities consisted of the following (in thousands):
    As of December 31,
     20212020
    Accrued service fees$1,905 $1,543 
    Clinical studies1,655 348 
    Employee stock purchase plan contributions760 536 
    Payroll tax liabilities695 276 
    Accrued payor refunds386 — 
    Other277 352 
    Total$5,678 $3,055 
    XML 61 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Leases (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Leases [Abstract]  
    Schedule of Lease Balances
    Lease Balances and Costs
    Lease balances reflected in the consolidated balance sheet were as follows (in thousands):
    Lease BalanceClassificationDecember 31, 2021
    Lease Assets
    OperatingOperating lease assets$7,383 
    FinanceProperty and equipment, net$229 
    Lease Liabilities
    Current
    OperatingOperating lease liabilities$1,179 
    FinanceOther accrued and current liabilities$105 
    Noncurrent
    OperatingNoncurrent operating lease liabilities$6,900 
    FinanceOther liabilities$124 
    Schedule of Lease Cost
    Costs associated with our leases were included in the consolidated statement of operations and comprehensive loss as follows (in thousands):
    Lease CostYear Ended December 31, 2021
    Operating lease cost(1)
    		$1,450 
    Finance lease cost
    Amortization of lease assets8 
    Interest on finance lease liabilities1 
    Short-term lease cost29 
    Total lease cost$1,488 
    (1)    Includes variable lease cost of $187 thousand for the year ended December 31, 2021.
    Supplemental cash flow information on leases is as follows (in thousands):
     Year Ended December 31, 2021
    Cash paid for amounts included in the measurement of lease liabilities
    Operating cash flows from operating leases$1,145 
    Operating cash flows from interest paid on finance leases$1 
    Financing cash flows from finance leases    $8 
    Information regarding the weighted-average lease term and weighted-average discount rate is presented below:
     December 31, 2021
    Weighted-average remaining lease term (years)
    Operating leases9.1
    Finance leases2.3
    Weighted-average discount rate
    Operating leases4.9 %
    Finance leases5.0 %
    Schedule of Operating Lease, Liability, Maturity
    The following is a maturity analysis of our operating lease and finance lease liabilities as of December 31, 2021 (in thousands):
    Operating leasesFinance leases
    Years Ending December 31,
    2022$1,258 $108 
    20231,287 108 
    20241,302 26 
    20251,218 — 
    2026689 — 
    Thereafter4,609 — 
    Total lease payments10,363 242 
    Less: Interest component(2,284)(13)
    Present value of lease payments$8,079 $229 
    Schedule of Finance Lease, Liability, Fiscal Year Maturity
    The following is a maturity analysis of our operating lease and finance lease liabilities as of December 31, 2021 (in thousands):
    Operating leasesFinance leases
    Years Ending December 31,
    2022$1,258 $108 
    20231,287 108 
    20241,302 26 
    20251,218 — 
    2026689 — 
    Thereafter4,609 — 
    Total lease payments10,363 242 
    Less: Interest component(2,284)(13)
    Present value of lease payments$8,079 $229 
    Schedule of Future Minimum Payments for Operating Leases
    Future non-cancellable commitments under all operating leases were as follows as of December 31, 2020 (in thousands):
    Years Ending December 31,
    2021$1,164 
    20221,148 
    20231,142 
    20241,154 
    20251,119 
    Thereafter1,037 
    $6,764 
    XML 62 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Fair Value Measurements (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Fair Value Disclosures [Abstract]  
    Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
    The table below provides information (in thousands), by level within the fair value hierarchy, of our financial assets and liabilities that are accounted for at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):
     
    As of December 31, 2021
     Quoted Prices in Active Markets for Identical Items (Level 1)Significant Other Observable Inputs
    (Level 2)    		Significant Unobservable Inputs
    (Level 3)    		Total
    Assets:    
    Money market funds(1)
    		$327,721 $— $— $327,721 
    Liabilities:
    Contingent consideration$— $— $18,287 $18,287 
    As of December 31, 2020
    Quoted Prices in Active Markets for Identical Items (Level 1)Significant Other Observable Inputs
    (Level 2)    		Significant Unobservable Inputs
    (Level 3)    		Total
    Assets:
    Money market funds(1)
    		$409,480 $— $— $409,480 
    (1) Classified as “Cash and cash equivalents” in the consolidated balance sheets.
    Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation The following table discloses the summary of changes in the contingent consideration liability measured at fair value using Level 3 inputs during the year ended December 31, 2021 (in thousands):
     Year Ended
    December 31, 2021
    Balance at beginning of period$— 
    Acquisition of Cernostics18,287 
    Change in fair value— 
    Balance at end of period$18,287 
    XML 63 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stock Incentive Plans and Stock Based Compensation (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Share-based Payment Arrangement [Abstract]  
    Schedule of Share-based Payment Arrangement on Stock Option Activity
    Stock option activity under our stock plans for the years ended December 31, 2021 and 2020 is set forth below:
      Weighted-Average 
     Stock Options
    Outstanding    		Exercise
    Price    		Remaining
    Contractual
    Term (Years)    		Aggregate
    Intrinsic
    Value
    (in thousands)
    Balance as of January 1, 20202,637,966 $13.30 
    Granted1,286,065 $49.63 
    Exercised(460,207)$3.53 
    Forfeited/Cancelled(94,322)$27.51 
    Balance as of December 31, 20203,369,502 $28.11 
    Granted841,336 $48.97 
    Exercised(414,890)$10.13 
    Forfeited/Cancelled(209,260)$33.97 
    Balance as of December 31, 20213,586,688 $34.75 8.3$45,970 
    Exercisable at December 31, 2021(1)
    		1,332,487 $23.31 7.5$28,845 
    (1)Vested and exercisable options. Additionally, outstanding unvested options to purchase an aggregate of 10,255 shares of common stock with a weighted-average exercise price of $2.39 per share may be exercised prior to vesting as of December 31, 2021 under early-exercise provisions. In the event of such exercise, the shares obtained upon exercise would be restricted and subject to forfeiture prior to vesting. No such early exercises have occurred as of December 31, 2021.
    Schedule of Share-based Payment Arrangement on Restricted Stock Units
    The following table summarizes our RSU activity for the years ended December 31, 2021 and December 31, 2020:
    Restricted Stock Units OutstandingWeighted-Average Grant Date Fair Value
    Balance as of January 1, 2020— $— 
    Granted161,477 $59.16 
    Vested— $— 
    Forfeited/Cancelled— $— 
    Balance as of December 31, 2020161,477 $59.16 
    Granted958,361 $43.05 
    Vested (1)
    		(56,002)$61.07 
    Forfeited/Cancelled(13,662)$62.80 
    Balance as of December 31, 20211,050,174 $44.31 
    (1)The aggregate number of shares withheld upon vesting for employee tax obligations was 16,440 for the year ended December 31, 2021.
    Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions The following table sets forth the assumptions used to determine the fair value of stock options:
     Years Ended December 31,
    20212020
    Average expected term (years)
    6.1
    6
    Expected stock price volatility
    66.50% - 68.83%
    59.57% - 67.02%
    Risk-free interest rate
    0.51% - 1.48%
    0.28% - 1.76%
    Dividend yield
    —%
    —%
    Schedule of Share-based Payment Award, ESPP, Valuation Assumptions
    The following table sets forth assumptions used to determine the fair value of the purchase rights issued under the ESPP:
     Years Ended December 31,
    20212020
    Average expected term (years)
    1.2
    1.2
    Expected stock price volatility
    61.13% - 86.50%
    56.80% - 100.49%
    Risk-free interest rate
    0.06% - 0.20%
    0.12% - 0.95%
    Dividend yield
    —%
    —%
    Schedule of Share-based Payment Arrangement, Expensed and Capitalized, Amount
    Stock-based compensation expense is included in the consolidated statements of operations and comprehensive loss as follows (in thousands):
     Years Ended December 31,
     20212020
    Cost of sales (exclusive of amortization of acquired intangible assets)$2,058 $1,049 
    Research and development4,522 1,492 
    Selling, general and administrative15,160 5,768 
    Total stock-based compensation expense$21,740 $8,309 
    XML 64 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Income Taxes (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Income Tax Disclosure [Abstract]  
    Schedule of Components of Income Tax Expense (Benefit)
    The components of income tax expense (benefit) are as follows (in thousands):
    Years Ended December 31,
    20212020
    Current tax expense
    U.S. Federal$— $— 
    State and local16 84 
    Total current16 84 
    Deferred tax (benefit) expense
    U.S. Federal(8,726)— 
    State and local(10)— 
    Total deferred(8,736)— 
    Total income tax (benefit) expense$(8,720)$84 
    Schedule of Effective Income Tax Rate Reconciliation
    The differences between income taxes expected at the U.S. federal statutory rate (21%) and the reported income tax expense (benefit) are summarized as follows (in thousands):
    Years Ended December 31,
    20212020
    Pre-tax loss$(40,012)$(10,200)
    U.S. federal taxes at statutory rate(8,402)(2,142)
    State income taxes(1,764)(311)
    Non-deductible meals— 235 
    Research and development (“R&D”) tax credit(1,658)(703)
    Change in valuation allowance2,570 2,784 
    Stock-based compensation(880)(781)
    Non-deductible officers’ compensation1,571 963 
    Other(157)39 
    Total income tax (benefit) expense$(8,720)$84 
    Schedule of Deferred Tax Assets and Liabilities
    Significant components of deferred tax assets and liabilities are as follows (in thousands):
    As of December 31,
    20212020
    Deferred tax assets:
    Net operating loss (“NOL”) carryforwards$24,316 $13,720 
    Accrued liabilities4,168 2,730 
    Lease liabilities2,114 — 
    Intangible assets— 46 
    Stock-based compensation2,202 761 
    R&D tax credit3,670 1,777 
    Other240 — 
    Total deferred tax assets36,710 19,034 
    Less valuation allowance(17,774)(15,204)
    Deferred tax assets, net$18,936 $3,830 
    Deferred tax liabilities:
    Prepaid expenses$(330)$(289)
    Property and equipment(2,285)(776)
    Intangible assets(12,913)— 
    ROU assets(2,166)— 
    Section 481(a) adjustment (cash to accrual)(1,877)(2,765)
    Total deferred tax liabilities(19,571)(3,830)
    Net deferred tax asset (liability)$(635)$— 
    XML 65 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Summary of Significant Accounting Policies - Narrative (Details)
    		 12 Months Ended
    Apr. 10, 2020
    USD ($)
    Dec. 31, 2021
    USD ($)
    segment
    Dec. 31, 2020
    USD ($)
    Jan. 01, 2021
    USD ($)
    Class of Stock [Line Items]        
    Number of operating segments | segment   1    
    Allowance for doubtful accounts   $ 0 $ 0  
    Long-lived assets, impairment charges   0 0  
    Other operating income (loss), CARES Act $ 1,900,000      
    Accrued bonuses   12,071,000 7,175,000  
    Discretionary matching contributions   2,036,000 789,000  
    Deferred payroll taxes, CARES Act   276,000 551,000  
    Operating lease assets   7,383,000 0  
    Operating lease liabilities   8,079,000    
    Current assets   353,743,000 429,594,000  
    Accumulated deficit   $ (93,767,000) $ (62,496,000)  
    Accounting Standards Update 2016-02 | Cumulative Effect, Period of Adoption, Adjustment        
    Class of Stock [Line Items]        
    Operating lease assets       $ 5,405,000
    Operating lease liabilities       6,076,000
    Noncurrent liabilities       (751,000)
    Current assets       (59,000)
    Accumulated deficit       $ 21,000
    Stock options and restricted stock units        
    Class of Stock [Line Items]        
    Service period   4 years    
    Minimum        
    Class of Stock [Line Items]        
    Property, plant and equipment, useful life   5 years    
    Maximum        
    Class of Stock [Line Items]        
    Property, plant and equipment, useful life   10 years    
    XML 66 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Revenue - Narrative (Details)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    USD ($)
    claim
    Dec. 31, 2020
    USD ($)
    Apr. 16, 2020
    USD ($)
    Revenue from Contract with Customer [Abstract]      
    Number of days contract with customer is generally paid 30 days    
    Variable consideration adjustments included in revenue $ 3,324 $ 176  
    Amount received from CMS under its accelerated and advance payment program     $ 8,300
    Number of claims in adjudication process | claim 2,698    
    XML 67 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Revenue - Disaggregation of Revenue (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Disaggregation of Revenue [Line Items]    
    Total net revenues $ 94,085 $ 62,649
    Dermatologic    
    Disaggregation of Revenue [Line Items]    
    Total net revenues 85,753 57,646
    Other    
    Disaggregation of Revenue [Line Items]    
    Total net revenues $ 8,332 $ 5,003
    XML 68 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Revenue - Payor Concentration (Details) - Third-Party Payor Concentration Risk
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Medicare | Percentage of Revenues    
    Disaggregation of Revenue [Line Items]    
    Concentration risk percentage 57.00% 58.00%
    Medicare | Percentage of Accounts Receivable (current)    
    Disaggregation of Revenue [Line Items]    
    Concentration risk percentage 24.00% 15.00%
    Medicare | Percentage of Accounts Receivable (non-current)    
    Disaggregation of Revenue [Line Items]    
    Concentration risk percentage 0.00% 0.00%
    Medicare Advantage plans | Percentage of Revenues    
    Disaggregation of Revenue [Line Items]    
    Concentration risk percentage 28.00% 29.00%
    Medicare Advantage plans | Percentage of Accounts Receivable (current)    
    Disaggregation of Revenue [Line Items]    
    Concentration risk percentage 40.00% 40.00%
    Medicare Advantage plans | Percentage of Accounts Receivable (non-current)    
    Disaggregation of Revenue [Line Items]    
    Concentration risk percentage 0.00% 25.00%
    BlueCross BlueShield plans | Percentage of Revenues    
    Disaggregation of Revenue [Line Items]    
    Concentration risk percentage 7.00% 6.00%
    BlueCross BlueShield plans | Percentage of Accounts Receivable (current)    
    Disaggregation of Revenue [Line Items]    
    Concentration risk percentage 22.00% 26.00%
    BlueCross BlueShield plans | Percentage of Accounts Receivable (non-current)    
    Disaggregation of Revenue [Line Items]    
    Concentration risk percentage 58.00% 44.00%
    XML 69 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Loss Per Share - Schedule of Antidilutive Securities (Details) - shares
    shares in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
    Antidilutive securities excluded from computation of earnings per share, amount (in shares) 3,521 2,924
    Stock options and restricted stock units    
    Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
    Antidilutive securities excluded from computation of earnings per share, amount (in shares) 3,459 2,789
    Common stock warrants    
    Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
    Antidilutive securities excluded from computation of earnings per share, amount (in shares) 0 35
    Employee stock purchase plan    
    Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
    Antidilutive securities excluded from computation of earnings per share, amount (in shares) 62 100
    XML 70 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Asset Acquisitions - Narrative (Details)
    $ in Thousands
    Dec. 03, 2021
    USD ($)
    day
    shares
    May 28, 2021
    USD ($)
    Dec. 31, 2021
    USD ($)
    Dec. 31, 2020
    USD ($)
    Asset Acquisition [Line Items]        
    Asset acquisition, receivable for purchase price adjustment     $ 519 $ 0
    Asset acquisition, liability for contingent consideration $ 18,287   18,287 $ 0
    Myriad myPath, LLC        
    Asset Acquisition [Line Items]        
    Payments to acquire productive assets   $ 32,500    
    Asset acquisition, transaction costs   684    
    Inventory   130    
    Myriad myPath, LLC | Developed technology        
    Asset Acquisition [Line Items]        
    Intangible assets acquired   $ 33,054    
    Finite-lived intangible asset, useful life   12 years    
    Cernostics, Inc.        
    Asset Acquisition [Line Items]        
    Asset acquisition, transaction costs 653      
    Cash purchase price 30,732      
    Asset acquisition, receivable for purchase price adjustment     $ 519  
    Additional consideration payable based on achievement of certain commercial milestones $ 50,000      
    Maximum number of shares payable in earnout payment (in shares) | shares 5,034,653      
    Number of trading days to determine volume weighted-average price of common stock | day 15      
    Intangible assets $ 57,827      
    Cernostics, Inc. | Developed technology        
    Asset Acquisition [Line Items]        
    Intangible assets $ 57,264      
    Estimated useful life (in years) 15 years      
    Cernostics, Inc. | Assembled workforce        
    Asset Acquisition [Line Items]        
    Intangible assets $ 563      
    Estimated useful life (in years) 5 years      
    XML 71 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Asset Acquisitions - Assets Acquired and Liabilities Assumed (Details) - Cernostics, Inc.
    $ in Thousands
    Dec. 03, 2021
    USD ($)
    Asset Acquisition [Line Items]  
    Cash and cash equivalents $ 1,251
    Accounts receivable 104
    Prepaid expenses and other current assets 198
    Property and equipment 455
    Intangible assets 57,827
    Accounts payable (655)
    Accrued compensation (167)
    Other accrued and current liabilities (386)
    Finance lease liabilities (237)
    Deferred tax liabilities (9,371)
    Total cost allocated $ 49,019
    XML 72 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Property, Plant and Equipment [Line Items]    
    Total $ 12,543 $ 8,756
    Less: accumulated depreciation (3,042) (1,654)
    Property and equipment, net 9,501 7,102
    Finance lease assets 229  
    Leasehold improvements    
    Property, Plant and Equipment [Line Items]    
    Total 5,044 1,388
    Lab equipment    
    Property, Plant and Equipment [Line Items]    
    Total 3,727 2,037
    Finance lease assets 237  
    Finance lease, right-of-use asset, accumulated amortization 8  
    Computer equipment    
    Property, Plant and Equipment [Line Items]    
    Total 2,457 1,305
    Furniture and fixtures    
    Property, Plant and Equipment [Line Items]    
    Total 1,288 436
    Construction-in-progress    
    Property, Plant and Equipment [Line Items]    
    Total $ 27 $ 3,590
    XML 73 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Property and Equipment, Net - Summary of Depreciation Expense (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Property, Plant and Equipment [Line Items]    
    Depreciation and amortization $ 1,448 $ 472
    Cost of sales (exclusive of amortization of acquired intangible assets)    
    Property, Plant and Equipment [Line Items]    
    Depreciation and amortization 478 341
    Research and development    
    Property, Plant and Equipment [Line Items]    
    Depreciation and amortization 248 31
    Selling, general and administrative    
    Property, Plant and Equipment [Line Items]    
    Depreciation and amortization $ 722 $ 100
    XML 74 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Intangible Assets, Net - Summary of Intangible Assets (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Finite-Lived Intangible Assets [Line Items]    
    Gross carrying value $ 90,880  
    Accumulated amortization (1,958)  
    Net 88,922 $ 0
    Developed technology    
    Finite-Lived Intangible Assets [Line Items]    
    Gross carrying value 90,317  
    Accumulated amortization (1,949)  
    Net $ 88,368  
    Weighted-Average Remaining Life (in years) 13 years 2 months 12 days  
    Assembled workforce    
    Finite-Lived Intangible Assets [Line Items]    
    Gross carrying value $ 563  
    Accumulated amortization (9)  
    Net $ 554  
    Weighted-Average Remaining Life (in years) 4 years 10 months 24 days  
    XML 75 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Intangible Asset, Net - Future Amortization (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Goodwill and Intangible Assets Disclosure [Abstract]    
    2022 $ 6,681  
    2023 6,681  
    2024 6,700  
    2025 6,681  
    2026 6,672  
    Thereafter 55,507  
    Net $ 88,922 $ 0
    XML 76 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Intangible Assets, Net - Narrative (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Goodwill and Intangible Assets Disclosure [Abstract]    
    Amortization of acquired intangible assets $ 1,958 $ 0
    XML 77 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Other Accrued and Current Liabilities (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Payables and Accruals [Abstract]    
    Accrued service fees $ 1,905 $ 1,543
    Clinical studies 1,655 348
    Employee stock purchase plan contributions 760 536
    Payroll tax liabilities 695 276
    Accrued payor refunds 386 0
    Other 277 352
    Other accrued and current liabilities $ 5,678 $ 3,055
    XML 78 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Leases - Narrative (Details)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    renewal_option
    facility
    Dec. 31, 2020
    USD ($)
    Operating Leased Assets [Line Items]    
    Operating leases, rent expense | $   $ 548
    Office Space    
    Operating Leased Assets [Line Items]    
    Lease arrangement, term of contract 60 months  
    Lease arrangement, number of renewal options 1  
    Lease arrangement, renewal term 5 years  
    Office and Laboratory Facility    
    Operating Leased Assets [Line Items]    
    Lease arrangement, number of renewal options 2  
    Lease arrangement, renewal term 5 years  
    Number of facilities leased | facility 2  
    XML 79 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Leases [Abstract]    
    Operating lease assets $ 7,383 $ 0
    Finance lease assets 229  
    Operating lease liabilities 1,179 0
    Finance lease liabilities 105  
    Noncurrent operating lease liabilities 6,900 $ 0
    Finance lease liability, noncurrent $ 124  
    Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Property and equipment, net  
    Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other accrued and current liabilities  
    Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other liabilities  
    XML 80 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Leases - Lease Cost (Details)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    USD ($)
    Leases [Abstract]  
    Operating lease cost $ 1,450
    Amortization of lease assets 8
    Interest on finance lease liabilities 1
    Short-term lease cost 29
    Total lease cost 1,488
    Variable lease cost $ 187
    XML 81 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Leases - Other information (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Cash paid for amounts included in the measurement of lease liabilities    
    Operating lease liabilities $ 1,145  
    Operating cash flows from interest paid on finance leases 1  
    Repayment of principal portion of finance lease liabilities 8 $ 0
    Operating lease assets in exchange for operating lease liability $ 2,900  
    Weighted-average remaining lease term (years)    
    Operating leases 9 years 1 month 6 days  
    Finance leases 2 years 3 months 18 days  
    Weighted-average discount rate    
    Operating leases 4.90%  
    Finance leases 5.00%  
    XML 82 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Leases - Operating Lease and Finance Lease Maturity (Details)
    $ in Thousands
    Dec. 31, 2021
    USD ($)
    Operating leases  
    2022 $ 1,258
    2023 1,287
    2024 1,302
    2025 1,218
    2026 689
    Thereafter 4,609
    Total lease payments 10,363
    Less: Interest component (2,284)
    Operating lease liabilities 8,079
    Finance leases  
    2022 108
    2023 108
    2024 26
    2025 0
    2026 0
    Thereafter 0
    Total lease payments 242
    Less: Interest component (13)
    Present value of lease payments $ 229
    XML 83 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Leases - Future Minimum Lease Payments (Details)
    $ in Thousands
    Dec. 31, 2020
    USD ($)
    Leases [Abstract]  
    2021 $ 1,164
    2022 1,148
    2023 1,142
    2024 1,154
    2025 1,119
    Thereafter 1,037
    Total $ 6,764
    XML 84 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Long-Term Debt - Narrative (Details)
    		 12 Months Ended
    Dec. 21, 2020
    USD ($)
    Nov. 30, 2018
    USD ($)
    installment
    Dec. 31, 2021
    USD ($)
    Dec. 31, 2020
    USD ($)
    Debt Instrument [Line Items]        
    Loss on extinguishment of debt     $ 0 $ 1,397,000
    2018 Loan and Security Agreement | Notes Payable to Banks        
    Debt Instrument [Line Items]        
    Debt instrument, face amount   $ 25,000,000    
    Number of equal monthly installments | installment   30    
    Debt Instrument, monthly installments principal amount   $ 833,333    
    Repayments of debt $ 21,600,000      
    Loss on extinguishment of debt       $ 1,400,000
    2018 Loan and Security Agreement | Notes Payable to Banks | London Interbank Offered Rate (LIBOR)        
    Debt Instrument [Line Items]        
    Basis spread on variable rate   6.48%    
    2018 Loan and Security Agreement | Notes Payable to Banks | Minimum        
    Debt Instrument [Line Items]        
    Debt instrument, interest rate, stated percentage   8.55%    
    XML 85 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Fair Value Measurements - Summary of Financial Assets and Liabilities at Fair Value (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 03, 2021
    Dec. 31, 2020
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
    Asset acquisition, liability for contingent consideration $ 18,287 $ 18,287 $ 0
    Fair Value, Recurring      
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
    Money market funds 327,721   409,480
    Asset acquisition, liability for contingent consideration 18,287    
    Fair Value, Recurring | Quoted Prices in Active Markets for Identical Items (Level 1)      
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
    Money market funds 327,721   409,480
    Asset acquisition, liability for contingent consideration 0    
    Fair Value, Recurring | Significant Other Observable Inputs (Level 2)      
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
    Money market funds 0   0
    Asset acquisition, liability for contingent consideration 0    
    Fair Value, Recurring | Significant Unobservable Inputs (Level 3)      
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
    Money market funds 0   $ 0
    Asset acquisition, liability for contingent consideration $ 18,287    
    XML 86 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Fair Value Measurements - Changes in the Level 3 Fair Value Assets and Liabilities (Details)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    USD ($)
    Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
    Balance at beginning of period $ 0
    Acquisition of Cernostics 18,287
    Change in fair value 0
    Balance at end of period $ 18,287
    XML 87 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Fair Value Measurements - Narrative (Details) - Valuation, Income Approach
    		 12 Months Ended
    Dec. 31, 2021
    Measurement Input, Discount Rate  
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
    Asset acquisition, contingent consideration liability, measurement input 16.10%
    Measurement Input, Price Volatility  
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
    Asset acquisition, contingent consideration liability, measurement input 20.00%
    XML 88 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stockholders’ Equity - Narrative (Details) - USD ($)
    $ / shares in Units, $ in Thousands
    		 12 Months Ended
    Dec. 18, 2020
    Jul. 02, 2020
    Jul. 02, 2020
    Jun. 29, 2020
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 29, 2020
    Dec. 11, 2020
    Class of Stock [Line Items]                
    Common stock, shares authorized (in shares)         200,000,000 200,000,000    
    Common stock, par value (in dollars per share)         $ 0.001 $ 0.001    
    Preferred stock, shares authorized (in shares)         10,000,000 10,000,000    
    Preferred stock, par value (in dollars per share)         $ 0.001 $ 0.001    
    Common stock, dividends declared (in dollars per share)         0 0    
    Common stock, dividends paid (in dollars per share)         $ 0 $ 0    
    Common stock, shares issued (in shares)         25,378,520 24,812,487    
    Warrants outstanding (in shares)         0 0    
    Common Stock                
    Class of Stock [Line Items]                
    Common stock, shares issued (in shares)             31,814 209,238
    Follow On Public Offering                
    Class of Stock [Line Items]                
    Common stock issued and sold (in shares) 4,600,000   300,000 2,000,000        
    Common stock offering price (in dollars per share) $ 58.00     $ 37.00        
    Proceeds from sale of stock $ 250,201   $ 10,425 $ 69,079        
    Over-Allotment Option                
    Class of Stock [Line Items]                
    Common stock issued and sold (in shares) 600,000              
    Common stock option period       30 days        
    Option to purchase, number of shares (in shares)   300,000            
    XML 89 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stock Incentive Plans and Stock Based Compensation - Narrative (Details)
    		 12 Months Ended
    Jan. 01, 2022
    shares
    Oct. 01, 2021
    USD ($)
    employee
    shares
    Dec. 31, 2021
    USD ($)
    purchase_period
    $ / shares
    shares
    Dec. 31, 2020
    USD ($)
    $ / shares
    shares
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Unrecognized compensation expense | $     $ 99,251,000  
    Unrecognized compensation expense, period for recognition     3 years 3 months 18 days  
    Options exercised, intrinsic value | $     $ 27,191,000 $ 18,377,000
    Tax benefits related to stock-based compensation | $     $ 0 $ 0
    2019 Equity Incentive Plan        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Number of shares available for grant (in shares) | shares     46,741  
    2019 Equity Incentive Plan | Subsequent Event        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Increase in number of shares authorized for issuance (in shares) | shares 1,268,926      
    Employee stock purchase plan        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Options granted, weighted average grant date fair value (in dollars per share) | $ / shares     $ 27.60 $ 17.43
    Stock options        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Term of awards     10 years  
    Percentage of share price at grant date     100.00%  
    Vesting period     4 years  
    Options granted, weighted average grant date fair value (in dollars per share) | $ / shares     $ 29.89 $ 28.95
    Stock options | First Year of Vesting        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Vesting period     1 year  
    Vesting percentage     25.00%  
    ISOs        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Term of awards     5 years  
    Percentage of voting power ownership     10.00%  
    Percentage of share price at grant date     110.00%  
    Employee stock purchase plan        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Aggregate intrinsic value of shares issued under the ESPP | $     $ 6,341,000 $ 1,797,000
    Employee stock purchase plan | Employee stock purchase plan        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Number of shares available for grant (in shares) | shares     639,466  
    Increase in number of shares authorized for issuance (in shares) | shares 253,785      
    Offering period     24 months  
    Number of offering periods | purchase_period     4  
    Purchase period     6 months  
    Purchase price of common stock, percentage of fair market value     85.00%  
    Restricted Stock Units (RSUs)        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Vesting period     4 years  
    Granted (in shares) | shares     958,361 161,477
    Aggregate fair value of restricted stock units vested | $     $ 2,698,000  
    Restricted Stock Units (RSUs) | Immediate Family Member of Management or Principal Owner        
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
    Granted (in shares) | shares   17,275    
    Grant date fair value of awards granted | $   $ 1,129,000    
    Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Employees To Receive Awards | employee   3    
    XML 90 R59.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stock Incentive Plans and Stock Based Compensation - Activity Under Stock Incentive Plan (Details) - USD ($)
    $ / shares in Units, $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Stock Options Outstanding    
    Beginning balance (in shares) 3,369,502 2,637,966
    Granted (in shares) 841,336 1,286,065
    Exercised (in shares) (414,890) (460,207)
    Forfeited/Cancelled (in shares) (209,260) (94,322)
    Ending balance (in shares) 3,586,688 3,369,502
    Options exercisable, number of options (in shares) 1,332,487  
    Exercise Price    
    Beginning balance (in dollars per share) $ 28.11 $ 13.30
    Granted (in dollars per share) 48.97 49.63
    Exercised (in dollars per share) 10.13 3.53
    Forfeited/Cancelled (in dollars per share) 33.97 27.51
    Ending balance (in dollars per share) 34.75 $ 28.11
    Options exercisable, weighted average exercise price (in dollars per share) $ 23.31  
    Stock Option Activity, Additional Disclosures    
    Options outstanding, weighted average remaining contractual term 8 years 3 months 18 days  
    Options outstanding, aggregate intrinsic value $ 45,970  
    Options exercisable, weighted average remaining contractual term 7 years 6 months  
    Options exercisable, aggregate intrinsic value $ 28,845  
    Options outstanding, nonvested (in shares) 10,255  
    Options outstanding nonvested, weighted average exercise price (in dollars per share) $ 2.39  
    XML 91 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stock Incentive Plans and Stock Based Compensation - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) - $ / shares
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Restricted Stock Units Outstanding    
    Beginning balance (in shares) 161,477 0
    Granted (in shares) 958,361 161,477
    Vested (in shares) (56,002) 0
    Forfeited/Cancelled (in shares) (13,662) 0
    Ending balance (in shares) 1,050,174 161,477
    Weighted-Average Grant Date Fair Value    
    Weighted average grant date fair value at beginning balance (in dollars per share) $ 59.16 $ 0
    Granted (in dollars per share) 43.05 59.16
    Vested (in dollars per share) 61.07 0
    Forfeited / Cancelled (in dollars per share) 62.80 0
    Weighted average grant date fair value at ending balance (in dollars per share) $ 44.31 $ 59.16
    Shares withheld for tax withholding obligations 16,440  
    XML 92 R61.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stock Incentive Plans and Stock Based Compensation - Assumptions Used in Fair Value of Stock Options and ESPP (Details)
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Employee stock purchase plan    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Average expected term (years) 1 year 2 months 12 days 1 year 2 months 12 days
    Expected stock price volatility, minimum 61.13% 56.80%
    Expected stock price volatility, maximum 86.50% 100.49%
    Risk-free interest rate, minimum 0.06% 0.12%
    Risk-free interest rate, maximum 0.20% 0.95%
    Dividend yield 0.00% 0.00%
    Stock options    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Average expected term (years) 6 years 1 month 6 days 6 years
    Expected stock price volatility, minimum 66.50% 59.57%
    Expected stock price volatility, maximum 68.83% 67.02%
    Risk-free interest rate, minimum 0.51% 0.28%
    Risk-free interest rate, maximum 1.48% 1.76%
    Dividend yield 0.00% 0.00%
    XML 93 R62.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Stock Incentive Plans and Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Total stock-based compensation expense $ 21,740 $ 8,309
    Cost of sales (exclusive of amortization of acquired intangible assets)    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Total stock-based compensation expense 2,058 1,049
    Research and development    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Total stock-based compensation expense 4,522 1,492
    Selling, general and administrative    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Total stock-based compensation expense $ 15,160 $ 5,768
    XML 94 R63.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Current tax expense    
    U.S. Federal $ 0 $ 0
    State and local 16 84
    Total current 16 84
    Deferred tax (benefit) expense    
    U.S. Federal (8,726) 0
    State and local (10) 0
    Total deferred (8,736) 0
    Total income tax (benefit) expense $ (8,720) $ 84
    XML 95 R64.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Income Taxes - Income Tax Expense Reconciliation (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Income Tax Disclosure [Abstract]    
    Pre-tax loss $ (40,012) $ (10,200)
    U.S. federal taxes at statutory rate (8,402) (2,142)
    State income taxes (1,764) (311)
    Non-deductible meals 0 235
    Research and development (“R&D”) tax credit (1,658) (703)
    Change in valuation allowance 2,570 2,784
    Stock-based compensation (880) (781)
    Non-deductible officers’ compensation 1,571 963
    Other (157) 39
    Total income tax (benefit) expense $ (8,720) $ 84
    XML 96 R65.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Income Taxes - Deferred Tax Assets And Liabilities (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Deferred tax assets:    
    Net operating loss (“NOL”) carryforwards $ 24,316 $ 13,720
    Accrued liabilities 4,168 2,730
    Lease liabilities 2,114 0
    Intangible assets 0 46
    Stock-based compensation 2,202 761
    R&D tax credit 3,670 1,777
    Other 240 0
    Total deferred tax assets 36,710 19,034
    Less valuation allowance (17,774) (15,204)
    Deferred tax assets, net 18,936 3,830
    Deferred tax liabilities:    
    Prepaid expenses (330) (289)
    Property and equipment (2,285) (776)
    Intangible assets (12,913) 0
    ROU assets (2,166) 0
    Section 481(a) adjustment (cash to accrual) (1,877) (2,765)
    Total deferred tax liabilities (19,571) (3,830)
    Net deferred tax asset (liability) $ (635) $ 0
    XML 97 R66.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Income Taxes - Narrative (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 03, 2021
    Dec. 31, 2021
    Dec. 31, 2020
    Operating Loss Carryforwards [Line Items]      
    Tax credit carryforward   $ 3,670  
    Decrease in valuation allowance   8,726  
    Deferred tax assets, valuation allowance   17,774 $ 15,204
    Cernostics, Inc.      
    Operating Loss Carryforwards [Line Items]      
    Deferred tax liabilities $ (9,371)    
    Domestic Tax Authority      
    Operating Loss Carryforwards [Line Items]      
    Operating loss carryforwards   99,365  
    NOL carryforwards, subject to expiration   43,513  
    NOL carryforwards, not subject to expiration   55,852  
    State and Local Jurisdiction      
    Operating Loss Carryforwards [Line Items]      
    Operating loss carryforwards   $ 67,453  
    XML 98 cstl-20211231_htm.xml IDEA: XBRL DOCUMENT 0001447362 2021-01-01 2021-12-31 0001447362 2021-06-30 0001447362 2022-02-21 0001447362 2021-12-31 0001447362 2020-12-31 0001447362 2020-01-01 2020-12-31 0001447362 us-gaap:PreferredStockMember 2019-12-31 0001447362 us-gaap:CommonStockMember 2019-12-31 0001447362 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001447362 us-gaap:RetainedEarningsMember 2019-12-31 0001447362 2019-12-31 0001447362 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001447362 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001447362 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001447362 us-gaap:PreferredStockMember 2020-12-31 0001447362 us-gaap:CommonStockMember 2020-12-31 0001447362 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001447362 us-gaap:RetainedEarningsMember 2020-12-31 0001447362 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2020-12-31 0001447362 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-12-31 0001447362 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001447362 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001447362 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001447362 us-gaap:PreferredStockMember 2021-12-31 0001447362 us-gaap:CommonStockMember 2021-12-31 0001447362 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001447362 us-gaap:RetainedEarningsMember 2021-12-31 0001447362 srt:MinimumMember 2021-01-01 2021-12-31 0001447362 srt:MaximumMember 2021-01-01 2021-12-31 0001447362 2020-04-10 2020-04-10 0001447362 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001447362 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201602Member 2021-01-01 0001447362 2020-04-16 0001447362 cstl:DermatologicMember 2021-01-01 2021-12-31 0001447362 cstl:DermatologicMember 2020-01-01 2020-12-31 0001447362 us-gaap:ServiceOtherMember 2021-01-01 2021-12-31 0001447362 us-gaap:ServiceOtherMember 2020-01-01 2020-12-31 0001447362 cstl:MedicareMember us-gaap:RevenueFromContractWithCustomerMember cstl:ThirdPartyPayorConcentrationRiskMember 2021-01-01 2021-12-31 0001447362 cstl:MedicareMember us-gaap:RevenueFromContractWithCustomerMember cstl:ThirdPartyPayorConcentrationRiskMember 2020-01-01 2020-12-31 0001447362 cstl:MedicareMember cstl:AccountsReceivableCurrentMember cstl:ThirdPartyPayorConcentrationRiskMember 2021-01-01 2021-12-31 0001447362 cstl:MedicareMember cstl:AccountsReceivableCurrentMember cstl:ThirdPartyPayorConcentrationRiskMember 2020-01-01 2020-12-31 0001447362 cstl:MedicareMember cstl:AccountsReceivableNoncurrentMember cstl:ThirdPartyPayorConcentrationRiskMember 2021-01-01 2021-12-31 0001447362 cstl:MedicareMember cstl:AccountsReceivableNoncurrentMember cstl:ThirdPartyPayorConcentrationRiskMember 2020-01-01 2020-12-31 0001447362 cstl:MedicareAdvantagePlansMember us-gaap:RevenueFromContractWithCustomerMember cstl:ThirdPartyPayorConcentrationRiskMember 2021-01-01 2021-12-31 0001447362 cstl:MedicareAdvantagePlansMember us-gaap:RevenueFromContractWithCustomerMember cstl:ThirdPartyPayorConcentrationRiskMember 2020-01-01 2020-12-31 0001447362 cstl:MedicareAdvantagePlansMember cstl:AccountsReceivableCurrentMember cstl:ThirdPartyPayorConcentrationRiskMember 2021-01-01 2021-12-31 0001447362 cstl:MedicareAdvantagePlansMember cstl:AccountsReceivableCurrentMember cstl:ThirdPartyPayorConcentrationRiskMember 2020-01-01 2020-12-31 0001447362 cstl:MedicareAdvantagePlansMember cstl:AccountsReceivableNoncurrentMember cstl:ThirdPartyPayorConcentrationRiskMember 2021-01-01 2021-12-31 0001447362 cstl:MedicareAdvantagePlansMember cstl:AccountsReceivableNoncurrentMember cstl:ThirdPartyPayorConcentrationRiskMember 2020-01-01 2020-12-31 0001447362 cstl:BlueCrossBlueShieldPlansMember us-gaap:RevenueFromContractWithCustomerMember cstl:ThirdPartyPayorConcentrationRiskMember 2021-01-01 2021-12-31 0001447362 cstl:BlueCrossBlueShieldPlansMember us-gaap:RevenueFromContractWithCustomerMember cstl:ThirdPartyPayorConcentrationRiskMember 2020-01-01 2020-12-31 0001447362 cstl:BlueCrossBlueShieldPlansMember cstl:AccountsReceivableCurrentMember cstl:ThirdPartyPayorConcentrationRiskMember 2021-01-01 2021-12-31 0001447362 cstl:BlueCrossBlueShieldPlansMember cstl:AccountsReceivableCurrentMember cstl:ThirdPartyPayorConcentrationRiskMember 2020-01-01 2020-12-31 0001447362 cstl:BlueCrossBlueShieldPlansMember cstl:AccountsReceivableNoncurrentMember cstl:ThirdPartyPayorConcentrationRiskMember 2021-01-01 2021-12-31 0001447362 cstl:BlueCrossBlueShieldPlansMember cstl:AccountsReceivableNoncurrentMember cstl:ThirdPartyPayorConcentrationRiskMember 2020-01-01 2020-12-31 0001447362 cstl:StockOptionsAndRestrictedStockUnitsMember 2021-01-01 2021-12-31 0001447362 cstl:StockOptionsAndRestrictedStockUnitsMember 2020-01-01 2020-12-31 0001447362 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001447362 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001447362 us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0001447362 us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0001447362 cstl:MyriadMyPathLLCMember 2021-05-28 2021-05-28 0001447362 cstl:MyriadMyPathLLCMember us-gaap:DevelopedTechnologyRightsMember 2021-05-28 2021-05-28 0001447362 cstl:CernosticsIncMember 2021-12-03 2021-12-03 0001447362 cstl:CernosticsIncMember 2021-12-31 0001447362 cstl:CernosticsIncMember 2021-12-03 0001447362 2021-12-03 0001447362 cstl:CernosticsIncMember us-gaap:DevelopedTechnologyRightsMember 2021-12-03 2021-12-03 0001447362 cstl:CernosticsIncMember cstl:DevelopedWorkforceMember 2021-12-03 2021-12-03 0001447362 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001447362 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001447362 us-gaap:EquipmentMember 2021-12-31 0001447362 us-gaap:EquipmentMember 2020-12-31 0001447362 us-gaap:ComputerEquipmentMember 2021-12-31 0001447362 us-gaap:ComputerEquipmentMember 2020-12-31 0001447362 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001447362 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001447362 us-gaap:ConstructionInProgressMember 2021-12-31 0001447362 us-gaap:ConstructionInProgressMember 2020-12-31 0001447362 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001447362 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001447362 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001447362 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001447362 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0001447362 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0001447362 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0001447362 us-gaap:DevelopedTechnologyRightsMember 2021-01-01 2021-12-31 0001447362 cstl:AssembledWorkforceMember 2021-12-31 0001447362 cstl:AssembledWorkforceMember 2021-01-01 2021-12-31 0001447362 cstl:OfficeSpaceMember 2021-01-01 2021-12-31 0001447362 cstl:OfficeAndLaboratoryFacilityMember 2021-01-01 2021-12-31 0001447362 cstl:TwoThousandEighteenLoanAndSecurityAgreementMember us-gaap:NotesPayableToBanksMember 2018-11-30 0001447362 srt:MinimumMember cstl:TwoThousandEighteenLoanAndSecurityAgreementMember us-gaap:NotesPayableToBanksMember 2018-11-30 0001447362 cstl:TwoThousandEighteenLoanAndSecurityAgreementMember us-gaap:NotesPayableToBanksMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-11-30 2018-11-30 0001447362 cstl:TwoThousandEighteenLoanAndSecurityAgreementMember us-gaap:NotesPayableToBanksMember 2018-11-30 2018-11-30 0001447362 cstl:TwoThousandEighteenLoanAndSecurityAgreementMember us-gaap:NotesPayableToBanksMember 2020-12-21 2020-12-21 0001447362 cstl:TwoThousandEighteenLoanAndSecurityAgreementMember us-gaap:NotesPayableToBanksMember 2020-01-01 2020-12-31 0001447362 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001447362 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001447362 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001447362 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001447362 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001447362 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001447362 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001447362 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001447362 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:IncomeApproachValuationTechniqueMember 2021-01-01 2021-12-31 0001447362 us-gaap:MeasurementInputDiscountRateMember us-gaap:IncomeApproachValuationTechniqueMember 2021-01-01 2021-12-31 0001447362 cstl:FollowOnPublicOfferingMember 2020-06-29 2020-06-29 0001447362 cstl:FollowOnPublicOfferingMember 2020-06-29 0001447362 us-gaap:OverAllotmentOptionMember 2020-06-29 2020-06-29 0001447362 us-gaap:OverAllotmentOptionMember 2020-06-29 2020-07-02 0001447362 cstl:FollowOnPublicOfferingMember 2020-07-02 2020-07-02 0001447362 cstl:FollowOnPublicOfferingMember 2020-12-18 2020-12-18 0001447362 us-gaap:OverAllotmentOptionMember 2020-12-18 2020-12-18 0001447362 cstl:FollowOnPublicOfferingMember 2020-12-18 0001447362 us-gaap:CommonStockMember 2020-12-11 0001447362 us-gaap:CommonStockMember 2020-12-29 0001447362 cstl:IncentiveStockOptionsMember 2021-01-01 2021-12-31 0001447362 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-01-01 2021-12-31 0001447362 cstl:TwoThousandNineteenEquityIncentivePlanMember 2021-12-31 0001447362 cstl:TwoThousandNineteenEquityIncentivePlanMember us-gaap:SubsequentEventMember 2022-01-01 2022-01-01 0001447362 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001447362 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001447362 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001447362 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001447362 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001447362 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2021-10-01 0001447362 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2021-10-01 2021-10-01 0001447362 us-gaap:EmployeeStockMember cstl:EmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0001447362 us-gaap:EmployeeStockMember cstl:EmployeeStockPurchasePlanMember 2021-12-31 0001447362 us-gaap:EmployeeStockMember cstl:EmployeeStockPurchasePlanMember 2022-01-01 2022-01-01 0001447362 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001447362 cstl:EmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0001447362 cstl:EmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0001447362 us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0001447362 us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0001447362 us-gaap:DomesticCountryMember 2021-12-31 0001447362 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 iso4217:USD shares iso4217:USD shares cstl:segment cstl:claim pure cstl:day cstl:renewal_option cstl:facility cstl:installment cstl:employee cstl:purchase_period 0001447362 2021 FY false http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member P5Y http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2021-01-31#OtherAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent P4Y 10-K 10-K true 2021-12-31 --12-31 false 001-38984 CASTLE BIOSCIENCES, INC. DE 77-0701774 505 S. Friendswood Drive Suite 401 Friendswood TX 77546 866 788-9007 Common Stock, $0.001 par value per share CSTL NASDAQ Yes No Yes Yes Large Accelerated Filer true false true false 1500000000 25410602 Portions of the registrant’s definitive proxy statement to be filed with the Securities and Exchange Commission, or SEC, subsequent to the date hereof pursuant to Regulation 14A in connection with the registrant’s 2022 Annual Meeting of Stockholders, are incorporated by reference into Part III of this Annual Report on Form 10-K. The registrant intends to file such proxy statement with the SEC not later than 120 days after the conclusion of its fiscal year ended December 31, 2021. KPMG LLP San Diego, CA 185 329633000 409852000 17282000 12759000 2021000 2217000 4807000 4766000 353743000 429594000 1308000 1096000 9501000 7102000 7383000 7383000 0 88922000 0 1715000 1536000 462572000 439328000 2546000 2098000 15483000 9108000 0 6615000 1179000 0 5678000 3055000 24886000 20876000 18287000 0 6900000 0 0 1735000 635000 0 124000 1026000 50832000 23637000 0.001 0.001 10000000 10000000 0 0 0 0 0 0 0.001 0.001 200000000 200000000 25378520 25378520 24812487 24812487 25000 25000 505482000 478162000 -93767000 -62496000 411740000 415691000 462572000 439328000 94085000 62649000 15822000 9685000 29646000 13256000 86738000 48132000 1958000 0 0 1882000 134164000 69191000 -40079000 -6542000 68000 373000 1000 2634000 0 -1397000 -40012000 -10200000 -8720000 84000 -31292000 -31292000 -10284000 -10284000 -1.24 -0.54 -1.24 -0.54 25137000 18929000 25137000 18929000 0 0 17130907 17000 137308000 -52212000 85113000 8309000 8309000 459074 1000 1592000 1593000 241052 0 6900000 7000 329657000 329664000 81454 1296000 1296000 -10284000 -10284000 0 0 24812487 25000 478162000 -62496000 415691000 21000 21000 21740000 21740000 416037 4234000 4234000 39548 -781000 -781000 39000 39000 110448 2088000 2088000 -31292000 -31292000 0 0 25378520 25000 505482000 -93767000 411740000 -31292000 -10284000 3407000 472000 21740000 8309000 0 839000 -8736000 0 0 -1397000 0 16000 4631000 -1663000 -617000 2815000 -327000 980000 -931000 0 180000 1401000 -182000 169000 -852000 0 6208000 3329000 -8350000 8350000 2286000 561000 -276000 272000 -18983000 9865000 3483000 4751000 63184000 0 10000 3000 -66657000 -4748000 0 330041000 336000 0 0 27359000 4234000 1593000 781000 0 2312000 1615000 8000 0 5421000 305890000 -80219000 311007000 409852000 98845000 329633000 409852000 1000 1978000 16000 102000 33000 58000 54000 714000 519000 0 18287000 0 0 377000 0 250000 Organization and Description of Business<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Castle Biosciences, Inc. (the ‘‘Company’’, “we”, “us”, or “our”) was incorporated in the state of Delaware on September 12, 2007. We are a commercial-stage diagnostics company focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. We are based in Friendswood, Texas (a suburb of Houston, Texas) and laboratory operations are conducted at our facilities located in Phoenix, Arizona and in Pittsburgh, Pennsylvania.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 Pandemic</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the COVID-19 pandemic began in March 2020, we have maintained uninterrupted business operations with normal turnaround times for delivery of test reports, but have experienced declines in test report volume in certain periods, which we believe is linked to delays and/or cancellations in patient visits in response to COVID-19, resulting in reduced diagnostic biopsies and thus reduced diagnoses of cutaneous melanoma. The extent to which COVID-19 may further impact our business, consolidated results of operations, consolidated financial condition and consolidated cash flows will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</span></div> Summary of Significant Accounting Policies<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the accounts of Castle Biosciences, Inc. and our wholly owned subsidiaries and have been prepared in conformity with accounting principles generally accepted in the United States of America (‘‘U.S. GAAP’’). All intercompany accounts and transactions have been eliminated in consolidation. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts in our consolidated statements of operations and comprehensive loss have been reclassified to conform to the current year presentation. Specifically, we no longer present gross margin on our statements of operations and comprehensive loss and therefore the cost of sales line is now presented within the operating expenses section. This reclassification had no impact on operating loss, loss before income taxes, net loss, comprehensive loss or loss per share.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include revenue recognition, the valuation of stock-based compensation, assessing future tax exposure and the realization of deferred tax assets, the useful lives and recoverability of long-lived assets, the valuation of acquired intangible assets, the valuation of contingent consideration and other contingent liabilities. We base these estimates on historical and anticipated results, trends, and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. We have considered the potential impact of the COVID-19 pandemic on our estimates and assumptions. The extent to which the COVID-19 pandemic may impact our estimates in future periods is uncertain and subject to change.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Segments</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment. All revenues are attributable to U.S.-based operations and all assets are held in the United States.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents including Concentrations of Credit Risk</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less. Our cash equivalents consist of money market funds, which are not insured by the Federal Deposit Insurance Corporation (“FDIC”), that are primarily invested in short-term U.S. government obligations. Cash deposits at financial institutions may exceed the amount of insurance provided by the FDIC. Management believes that we are not exposed to significant credit risk on our cash deposits due to the financial position of the institutions in which deposits are held. We have not experienced any losses on our cash or cash equivalents. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized in accordance with Financial Accounting Standards Board (‘‘FASB’’) Accounting Standards Codification (‘‘ASC’’) Topic 606, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(‘‘ASC 606’’). In accordance with ASC 606, we follow a five-step process to recognize revenues: (1) identify the contract with the customer, (2) identify the performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenues when the performance obligations are satisfied. We have determined that we have a contract with the patient when the treating clinician orders the test. Our contracts generally contain a single performance obligation, which is the delivery of the test report, and we satisfy our performance obligation at a point in time upon the delivery of the test report to the treating physician, at which point we can bill for the report. The amount of revenue recognized reflects the amount of consideration to which we expect to be entitled, or the transaction price, and considers the effects of variable consideration. See Note 3 for further details.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify accounts receivable balances that are expected to be paid more than one year from the consolidated balance sheet date as non-current assets. The estimated timing of payment utilized as a basis for classification as non-current is determined by analyses of historical payor-specific payment experience, adjusted for known factors that are expected to change the timing of future payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue an allowance for credit losses against our accounts receivable based on management’s current estimate of amounts that will not be collected. Management’s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of customers’ financial condition and generally do not require collateral. Historically, our credit losses have not been significant. The allowance for credit losses was zero as of December 31, 2021 and 2020. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry inventories of test supplies in our laboratory facilities. The inventories are carried at the lower of weighted average cost and net realizable value and expensed through cost of sales as the supplies are used.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczNGMzNzFhNjVjNTQ4YmM5Nzg3OGU1NDRmODBiNjlhL3NlYzo3MzRjMzcxYTY1YzU0OGJjOTc4NzhlNTQ0ZjgwYjY5YV8yNzEvZnJhZzo0OTIzMzQ4MDk1ZWI0NGIwODMzY2ZkYjJlMmIzZGNkNC90ZXh0cmVnaW9uOjQ5MjMzNDgwOTVlYjQ0YjA4MzNjZmRiMmUyYjNkY2Q0XzE0Nzc0_3e0430f3-04d8-4721-babc-1d66164f2e3c">five</span> and ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Our leasehold improvements primarily relate to our office and laboratory facilities in Friendswood, Texas and Phoenix, Arizona, and are generally being amortized through the end of the lease terms in 2025 and 2033, respectively. Maintenance and repairs are charged to expense as incurred, and material improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss in the period realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets, which are comprised primarily of acquired developed technology, are considered to be finite-lived and are amortized on a straight-line basis over their estimated useful lives. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than the carrying amount. Impairment, if </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any, would be calculated based on the excess of the carrying amount of the long-lived asset over the long-lived asset’s fair value. There were no impairment charges recognized for the years ended December 31, 2021 and 2020.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess acquisitions under ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to determine whether a transaction represents the acquisition of assets or a business combination. Under this guidance, we apply a two-step model. The first step involves a screening test where we evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single asset or a group of similar assets. If the screening test is met, we account for the set as an asset acquisition. If the screening test is not met, we apply the second step of the model to determine if the set meets the definition of a business based on the guidance in ASC 805. If so, the transaction is treated as a business combination. Otherwise, it is treated as an asset acquisition. Asset acquisitions are accounted for by allocating the cost of the acquisition, including transaction costs, to the individual assets acquired and liabilities assumed on a relative fair value basis without recognition of goodwill. Business combinations are accounted for using the acquisition method. Under the acquisition method, goodwill is measured as a residual amount equal to the fair value of the consideration transferred less the net recognized fair value of the identifiable assets acquired and the liabilities assumed, as of the acquisition date, and transaction costs are expensed as incurred.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of business combinations or asset acquisitions, we may be required to pay additional consideration if specified future events occur or if certain conditions are met. With respect to the additional consideration that may be payable in connection with the Cernostics, Inc. (“Cernostics”) asset acquisition, we account for the contingent consideration as liability in accordance with ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASC 480”), under the guidance for </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligations that must or may be settled by issuance of a variable number of shares. In accordance with ASC 480, we record the contingent consideration initially and subsequently at fair value with changes in fair value recorded in the statements of operations and comprehensive loss each period. For additional information on the contingent consideration, see Notes 5 and 11.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Operating Income</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 10, 2020, we received an automatic payment of $1.9 million from the U.S. Department of Health and Human Services (“HHS”) pursuant to the Coronavirus Aid, Relief and Economic Security Act enacted on March 27, 2020, also known as the CARES Act, out of relief funds allocated by HHS to healthcare providers to reimburse healthcare related expenses or lost revenues attributable to COVID-19. This automatic payment was calculated by HHS in proportion to the providers’ share of Medicare fee-for-service reimbursements in 2019 and was applicable to all facilities and providers that received Medicare fee-for-service reimbursements in 2019. In the second quarter of 2020, based on guidance issued by HHS at the time that stated any reasonable method could be used to calculate lost revenues attributable to COVID-19, we concluded it would qualify to retain the relief funds and recognized the funds received as other operating income during the three months ended June 30, 2020. On September 19, 2020, HHS issued a notice of reporting requirements that changed the methodology for determining lost revenues to be based on a patient care operating income metric, as defined by HHS. Due to this change in methodology and uncertainty in its application, we determined that it was no longer reasonably assured of keeping the funds. Therefore, in the three months ended September 30, 2020, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we reversed the previously recognized income. However, in the fourth quarter of 2020, a legislative change was enacted affecting the program, under which we concluded it is reasonably assured we will qualify to retain the funds. Accordingly, we recognized the income again in the fourth quarter of 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2021, we account for leases in accordance with ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We categorize leases at their commencement as either operating or finance leases based on the criteria in ASC 842. Under ASC 842, we record right-of-use (“ROU”) assets and lease liabilities for each lease arrangement identified, except that we have elected the short-term lease exemption for all leases with a term of 12 months or less. Lease liabilities are recorded at the present value of future lease payments discounted using our incremental borrowing rate for the lease established at the commencement date and ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. For our operating leases, we recognize a single lease cost over the lease term on a straight-line basis. We have elected the practical expedient of not separating nonlease components from lease components in all leases. Periods prior to January 1, 2021 have not been restated for the adoption of ASC 842 and continue to reflect the accounting treatment of leases in accordance with the prior lease accounting guidance, ASC 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 840, landlord/tenant incentives, rent holidays and escalations in the base price of rent payments under operating leases were recognized on a straight-line basis over the lease term. Deferred rent balances were classified as current or non-current in the consolidated balance sheets based upon the period when reversal of the liability was expected to occur. See Note 9 for details on our leases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales (exclusive of amortization of acquired intangible assets)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales is expensed as incurred and includes material and service costs associated with testing samples, personnel costs (including salaries, bonuses, benefits and stock-based compensation expense), electronic medical records, order and delivery systems, shipping charges to transport samples, third-party test fees, and allocated overhead including rent, information technology costs, equipment and facilities depreciation and utilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to operations as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on behalf of us will be expensed as services are rendered or when the milestone is achieved.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs include, but are not limited to, payroll and personnel-related expenses, stock-based compensation expense, materials, laboratory supplies, and consulting costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (“SG&amp;A”) expenses are attributable to sales, marketing, executive, finance and accounting, legal and human resources functions. These expenses consist of personnel costs (including salaries, employee benefit costs, bonuses and stock-based compensation expenses), customer services expenses, direct marketing expenses, educational and promotional expenses, market research, audit and legal expenses, and consulting. We expense all SG&amp;A costs as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for liabilities under discretionary employee and executive bonus plans. These estimated compensation liabilities are based on progress against corporate objectives approved by our board of directors, compensation levels of eligible individuals, and target bonus percentage levels. The board of directors reviews and evaluates the performance against these objectives and ultimately determines what discretionary payments are made. We also accrue for liabilities under employee sales incentive bonus plans with accruals based on performance achieved to date compared to established targets. As of December 31, 2021 and 2020, we accrued approximately $12,071,000 and $7,175,000, respectively, for liabilities associated with these bonus plans. These amounts are classified as current or noncurrent accrued liabilities in the balance sheets based on the expected timing of payment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retirement Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an Internal Revenue Code (“IRC”) Section 401(k) profit sharing plan (the “Plan”) for eligible employees. The Plan is funded by employee contributions and provides for discretionary contributions in the form of matching and/or profit-sharing contributions. For the years ended </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021 and 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we provided a discretionary matching contribution of $2,036,000 and $789,000, respectively. The higher amount for the year ended </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reflects both an increase in the number of employees and a higher matching contribution rate compared to the year ended December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the statutory enactment date. Valuation allowances are established to reduce deferred tax assets when it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50% likely to be realized upon settlement. A liability for unrecognized tax benefits is recorded for any tax benefits claimed in our tax returns that do not meet these recognition and measurement standards.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of tax expense. No material amounts of tax-related interest or penalties were recorded during the years ended December 31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for equity instruments issued to employees is measured based on the grant-date fair value of the awards. The fair value of employee stock options and offerings under the 2019 Employee Stock Purchase Plan (the “ESPP”) are estimated on the date of grant using the Black-Scholes option-pricing valuation model. For restricted stock units (“RSUs”), the fair value is equal to the closing price of our common stock on the date of grant. We recognize compensation costs on a straight-line basis for all employee stock-based compensation awards over the requisite service period of the awards. For options and RSUs, the requisite service period is generally the awards’ vesting period (typically four years). For the ESPP, the requisite service period is generally the period of time from the offering date to the purchase date. Forfeitures are accounted for as they occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive loss was the same as our reported net loss for all periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CARES Act Payroll Tax Deferral</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act permits employers to defer the payment of the employer share of social security taxes due for the period beginning March 27, 2020 and ending December 31, 2020. Of the amounts deferred, 50% were required to be paid by December 31, 2021 and the remaining 50% are required to be paid by December 31, 2022. We began deferring payment of the employer share of social security taxes in May 2020. Of the $551,000 originally deferred, 50% was repaid during the year ended December 31, 2021. As of December 31, 2021, the remaining $276,000 of such taxes was classified as a current liability on the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were previously an emerging growth company (“EGC”) within the meaning of the Jumpstart Our Business Startups Act, as amended, (the “JOBS Act”) and elected to delay the adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements were made applicable to private companies, as permitted under the JOBS Act. Because the market value of our common stock held by non-affiliates exceeded $700.0 million as of June 30, 2021, we ceased to be an EGC effective December 31, 2021. Accordingly, we are no longer permitted to delay the adoption of new or revised accounting pronouncements and as such we adopted the pronouncements discussed below in the fourth quarter of 2021 effective as of the dates noted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 842) (“ASU 2016-02”), which supersedes ASC 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-02 establishes ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized based on an effective interest method for finance leases or on a straight-line basis over the term of the lease for operating leases. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of classification. Leases with a term of 12 months or less may be accounted for similar to existing guidance for operating leases. We adopted ASU 2016-02 and ASC 842 using the modified retrospective approach with an effective date of January 1, 2021. Periods prior to January 1, 2021 have not been restated for the adoption of ASC 842 and continue to reflect the accounting treatment of leases in accordance with ASC 840. In connection with the adoption, we elected the package of practical expedients to not reassess prior conclusions about lease identification, lease classification and capitalized indirect costs. We did not elect the use of hindsight practical expedient. Upon adoption, effective January 1, 2021 we recognized operating lease right-of-use assets of $5,405,000, operating lease liabilities of $6,076,000, reductions to noncurrent liabilities of $751,000, reductions to current assets of $59,000 and a credit to accumulated deficit of $21,000. See Note 9 for disclosures about our leases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires the measurement of expected credit losses for financial instruments carried at amortized cost, such as accounts receivable, held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. We adopted the standard effective January 1, 2021 using the modified retrospective approach. The adoption of this standard had no impact on our consolidated financial statements.</span></div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2019-12”), which eliminates certain exceptions to the general principles in Topic 740 and simplifies other areas of the existing guidance. The adoption of ASU 2019-12 effective January 1, 2021 had no impact on our consolidated financial statements.</span> Our consolidated financial statements include the accounts of Castle Biosciences, Inc. and our wholly owned subsidiaries and have been prepared in conformity with accounting principles generally accepted in the United States of America (‘‘U.S. GAAP’’). All intercompany accounts and transactions have been eliminated in consolidation. Certain prior year amounts in our consolidated statements of operations and comprehensive loss have been reclassified to conform to the current year presentation. Specifically, we no longer present gross margin on our statements of operations and comprehensive loss and therefore the cost of sales line is now presented within the operating expenses section. This reclassification had no impact on operating loss, loss before income taxes, net loss, comprehensive loss or loss per share. The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include revenue recognition, the valuation of stock-based compensation, assessing future tax exposure and the realization of deferred tax assets, the useful lives and recoverability of long-lived assets, the valuation of acquired intangible assets, the valuation of contingent consideration and other contingent liabilities. We base these estimates on historical and anticipated results, trends, and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. We have considered the potential impact of the COVID-19 pandemic on our estimates and assumptions. The extent to which the COVID-19 pandemic may impact our estimates in future periods is uncertain and subject to change. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one operating segment. All revenues are attributable to U.S.-based operations and all assets are held in the United States.</span> 1 Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less. Our cash equivalents consist of money market funds, which are not insured by the Federal Deposit Insurance Corporation (“FDIC”), that are primarily invested in short-term U.S. government obligations. Cash deposits at financial institutions may exceed the amount of insurance provided by the FDIC. Management believes that we are not exposed to significant credit risk on our cash deposits due to the financial position of the institutions in which deposits are held. We have not experienced any losses on our cash or cash equivalents. <span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized in accordance with Financial Accounting Standards Board (‘‘FASB’’) Accounting Standards Codification (‘‘ASC’’) Topic 606, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span>(‘‘ASC 606’’). In accordance with ASC 606, we follow a five-step process to recognize revenues: (1) identify the contract with the customer, (2) identify the performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenues when the performance obligations are satisfied. We have determined that we have a contract with the patient when the treating clinician orders the test. Our contracts generally contain a single performance obligation, which is the delivery of the test report, and we satisfy our performance obligation at a point in time upon the delivery of the test report to the treating physician, at which point we can bill for the report. The amount of revenue recognized reflects the amount of consideration to which we expect to be entitled, or the transaction price, and considers the effects of variable consideration.Cost of sales is expensed as incurred and includes material and service costs associated with testing samples, personnel costs (including salaries, bonuses, benefits and stock-based compensation expense), electronic medical records, order and delivery systems, shipping charges to transport samples, third-party test fees, and allocated overhead including rent, information technology costs, equipment and facilities depreciation and utilities. We classify accounts receivable balances that are expected to be paid more than one year from the consolidated balance sheet date as non-current assets. The estimated timing of payment utilized as a basis for classification as non-current is determined by analyses of historical payor-specific payment experience, adjusted for known factors that are expected to change the timing of future payments. We accrue an allowance for credit losses against our accounts receivable based on management’s current estimate of amounts that will not be collected. Management’s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of customers’ financial condition and generally do not require collateral. Historically, our credit losses have not been significant. The allowance for credit losses was zero as of December 31, 2021 and 2020. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses. 0 0 We carry inventories of test supplies in our laboratory facilities. The inventories are carried at the lower of weighted average cost and net realizable value and expensed through cost of sales as the supplies are used. Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczNGMzNzFhNjVjNTQ4YmM5Nzg3OGU1NDRmODBiNjlhL3NlYzo3MzRjMzcxYTY1YzU0OGJjOTc4NzhlNTQ0ZjgwYjY5YV8yNzEvZnJhZzo0OTIzMzQ4MDk1ZWI0NGIwODMzY2ZkYjJlMmIzZGNkNC90ZXh0cmVnaW9uOjQ5MjMzNDgwOTVlYjQ0YjA4MzNjZmRiMmUyYjNkY2Q0XzE0Nzc0_3e0430f3-04d8-4721-babc-1d66164f2e3c">five</span> and ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Our leasehold improvements primarily relate to our office and laboratory facilities in Friendswood, Texas and Phoenix, Arizona, and are generally being amortized through the end of the lease terms in 2025 and 2033, respectively. Maintenance and repairs are charged to expense as incurred, and material improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss in the period realized. P10Y Our intangible assets, which are comprised primarily of acquired developed technology, are considered to be finite-lived and are amortized on a straight-line basis over their estimated useful lives. We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than the carrying amount. Impairment, if any, would be calculated based on the excess of the carrying amount of the long-lived asset over the long-lived asset’s fair value. 0 0 <div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess acquisitions under ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to determine whether a transaction represents the acquisition of assets or a business combination. Under this guidance, we apply a two-step model. The first step involves a screening test where we evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single asset or a group of similar assets. If the screening test is met, we account for the set as an asset acquisition. If the screening test is not met, we apply the second step of the model to determine if the set meets the definition of a business based on the guidance in ASC 805. If so, the transaction is treated as a business combination. Otherwise, it is treated as an asset acquisition. Asset acquisitions are accounted for by allocating the cost of the acquisition, including transaction costs, to the individual assets acquired and liabilities assumed on a relative fair value basis without recognition of goodwill. Business combinations are accounted for using the acquisition method. Under the acquisition method, goodwill is measured as a residual amount equal to the fair value of the consideration transferred less the net recognized fair value of the identifiable assets acquired and the liabilities assumed, as of the acquisition date, and transaction costs are expensed as incurred.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of business combinations or asset acquisitions, we may be required to pay additional consideration if specified future events occur or if certain conditions are met. With respect to the additional consideration that may be payable in connection with the Cernostics, Inc. (“Cernostics”) asset acquisition, we account for the contingent consideration as liability in accordance with ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASC 480”), under the guidance for </span>obligations that must or may be settled by issuance of a variable number of shares. In accordance with ASC 480, we record the contingent consideration initially and subsequently at fair value with changes in fair value recorded in the statements of operations and comprehensive loss each period. 1900000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2021, we account for leases in accordance with ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We categorize leases at their commencement as either operating or finance leases based on the criteria in ASC 842. Under ASC 842, we record right-of-use (“ROU”) assets and lease liabilities for each lease arrangement identified, except that we have elected the short-term lease exemption for all leases with a term of 12 months or less. Lease liabilities are recorded at the present value of future lease payments discounted using our incremental borrowing rate for the lease established at the commencement date and ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. For our operating leases, we recognize a single lease cost over the lease term on a straight-line basis. We have elected the practical expedient of not separating nonlease components from lease components in all leases. Periods prior to January 1, 2021 have not been restated for the adoption of ASC 842 and continue to reflect the accounting treatment of leases in accordance with the prior lease accounting guidance, ASC 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases. </span>Under ASC 840, landlord/tenant incentives, rent holidays and escalations in the base price of rent payments under operating leases were recognized on a straight-line basis over the lease term. Deferred rent balances were classified as current or non-current in the consolidated balance sheets based upon the period when reversal of the liability was expected to occur. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to operations as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on behalf of us will be expensed as services are rendered or when the milestone is achieved.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs include, but are not limited to, payroll and personnel-related expenses, stock-based compensation expense, materials, laboratory supplies, and consulting costs.</span></div> Selling, general and administrative (“SG&amp;A”) expenses are attributable to sales, marketing, executive, finance and accounting, legal and human resources functions. These expenses consist of personnel costs (including salaries, employee benefit costs, bonuses and stock-based compensation expenses), customer services expenses, direct marketing expenses, educational and promotional expenses, market research, audit and legal expenses, and consulting. We expense all SG&amp;A costs as incurred. We accrue for liabilities under discretionary employee and executive bonus plans. These estimated compensation liabilities are based on progress against corporate objectives approved by our board of directors, compensation levels of eligible individuals, and target bonus percentage levels. The board of directors reviews and evaluates the performance against these objectives and ultimately determines what discretionary payments are made. We also accrue for liabilities under employee sales incentive bonus plans with accruals based on performance achieved to date compared to established targets. As of December 31, 2021 and 2020, we accrued approximately $12,071,000 and $7,175,000, respectively, for liabilities associated with these bonus plans. These amounts are classified as current or noncurrent accrued liabilities in the balance sheets based on the expected timing of payment.Stock-based compensation expense for equity instruments issued to employees is measured based on the grant-date fair value of the awards. The fair value of employee stock options and offerings under the 2019 Employee Stock Purchase Plan (the “ESPP”) are estimated on the date of grant using the Black-Scholes option-pricing valuation model. For restricted stock units (“RSUs”), the fair value is equal to the closing price of our common stock on the date of grant. We recognize compensation costs on a straight-line basis for all employee stock-based compensation awards over the requisite service period of the awards. For options and RSUs, the requisite service period is generally the awards’ vesting period (typically four years). For the ESPP, the requisite service period is generally the period of time from the offering date to the purchase date. Forfeitures are accounted for as they occur. 12071000 7175000 We have an Internal Revenue Code (“IRC”) Section 401(k) profit sharing plan (the “Plan”) for eligible employees. The Plan is funded by employee contributions and provides for discretionary contributions in the form of matching and/or profit-sharing contributions. 2036000 789000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the statutory enactment date. Valuation allowances are established to reduce deferred tax assets when it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50% likely to be realized upon settlement. A liability for unrecognized tax benefits is recorded for any tax benefits claimed in our tax returns that do not meet these recognition and measurement standards.</span></div>Our policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of tax expense. P4Y Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. 551000 276000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were previously an emerging growth company (“EGC”) within the meaning of the Jumpstart Our Business Startups Act, as amended, (the “JOBS Act”) and elected to delay the adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements were made applicable to private companies, as permitted under the JOBS Act. Because the market value of our common stock held by non-affiliates exceeded $700.0 million as of June 30, 2021, we ceased to be an EGC effective December 31, 2021. Accordingly, we are no longer permitted to delay the adoption of new or revised accounting pronouncements and as such we adopted the pronouncements discussed below in the fourth quarter of 2021 effective as of the dates noted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 842) (“ASU 2016-02”), which supersedes ASC 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-02 establishes ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized based on an effective interest method for finance leases or on a straight-line basis over the term of the lease for operating leases. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of classification. Leases with a term of 12 months or less may be accounted for similar to existing guidance for operating leases. We adopted ASU 2016-02 and ASC 842 using the modified retrospective approach with an effective date of January 1, 2021. Periods prior to January 1, 2021 have not been restated for the adoption of ASC 842 and continue to reflect the accounting treatment of leases in accordance with ASC 840. In connection with the adoption, we elected the package of practical expedients to not reassess prior conclusions about lease identification, lease classification and capitalized indirect costs. We did not elect the use of hindsight practical expedient. Upon adoption, effective January 1, 2021 we recognized operating lease right-of-use assets of $5,405,000, operating lease liabilities of $6,076,000, reductions to noncurrent liabilities of $751,000, reductions to current assets of $59,000 and a credit to accumulated deficit of $21,000. See Note 9 for disclosures about our leases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires the measurement of expected credit losses for financial instruments carried at amortized cost, such as accounts receivable, held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. We adopted the standard effective January 1, 2021 using the modified retrospective approach. The adoption of this standard had no impact on our consolidated financial statements.</span></div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2019-12”), which eliminates certain exceptions to the general principles in Topic 740 and simplifies other areas of the existing guidance. The adoption of ASU 2019-12 effective January 1, 2021 had no impact on our consolidated financial statements.</span> 5405000 6076000 -751000 -59000 21000 Revenue<div style="margin-bottom:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our revenues from contracts with customers are associated with the provision of diagnostic and prognostic testing services. Most of our revenues are attributable to DecisionDx®-Melanoma for cutaneous melanoma. We also provide a test for uveal melanoma, DecisionDx®-UM. We launched a test for patients with cutaneous squamous cell carcinoma, DecisionDx®-SCC in August 2020 and launched a test for use in patients with suspicious pigmented lesions, DecisionDx® DiffDx™-Melanoma in November 2020. We began offering a test for difficult-to-diagnose melanocytic lesions, myPath Melanoma, following an asset acquisition completed in May 2021 and began offering the TissueCypher® Barrett’s Esophagus Assay for patients with BE following an asset acquisition completed in December 2021. Information on the disaggregation of revenues is included below. </span></div><div style="margin-bottom:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once we satisfy our performance obligations and bill for the service, the timing of the collection of payments may vary based on the payment practices of the third-party payor and the existence of contractually established reimbursement rates. Most of the payments for our services are made by third-party payors, including Medicare and commercial health insurance carriers. Certain contracts contain a contractual commitment of a reimbursement rate that differs from our list prices. However, absent a positive coverage policy, with or without a contractually committed reimbursement rate, with a commercial carrier or governmental program, our diagnostic tests may or may not be paid by these entities. In addition, patients do not enter into direct agreements with us that commit them to pay any portion of the cost of the tests in the event that their insurance provider declines to reimburse us. We may pursue, on a case-by-case basis, reimbursement from such patients in the form of co-payments and co-insurance, in accordance with the contractual obligations that we have with the insurance carrier or health plan. These situations may result in a delay in the collection of payments.</span></div><div style="margin-bottom:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare claims that are covered by policy under a Local Coverage Determination (‘‘LCD’’) are generally paid at the established rate by our Medicare contractor within 30 days from receipt. Medicare claims that were either submitted to Medicare prior to the LCD coverage commencement date or are not covered by the terms of the LCD but meet the definition of being medically reasonable and necessary pursuant to the controlling Section 1862(a)(1)(A) of the Social Security Act are generally appealed and may ultimately be paid at the first (termed ‘‘redetermination’’), second (termed ‘‘reconsideration’’) or third level of appeal (de novo hearing with an Administrative Law Judge (“ALJ”)). A successful appeal at any of these levels results in payment.</span></div><div style="margin-bottom:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of LCD coverage or contractually established reimbursements rates, we have concluded that our contracts include variable consideration because the amounts paid by Medicare or commercial health insurance carriers may be paid at less than our standard rates or not paid at all, with such differences considered implicit price concessions. Variable consideration attributable to these price concessions is measured at the expected value using the ‘‘most likely amount’’ method under ASC 606. The amounts are determined by historical average collection rates by test type and payor category taking into consideration the range of possible outcomes, the predictive value of our past experiences, the time period of when uncertainties expect to be resolved and the amount of consideration that is susceptible to factors outside of our influence, such as the judgment and actions of third parties. Such variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. Variable consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in the absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Variable consideration for Medicare claims that are not covered by an LCD, including those claims subject to approval by an ALJ at an appeal hearing, is deemed to be fully constrained due to factors outside our influence (i.e., judgment or actions of third parties) and the uncertainty of the amount to be received is not expected to be resolved for a long period of time. Variable consideration is evaluated each reporting period and adjustments are recorded as increases or decreases in revenues. Included in revenues for the years ended December 31, 2021 and 2020 were $3,324,000 and $176,000, respectively, of revenue increases associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. These amounts include (i) adjustments for actual collections versus estimated amounts and (ii) cash collections and the related recognition of revenue in current period for tests delivered in prior periods due to the release of the constraint on variable consideration.</span></div><div style="margin-bottom:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our contracts with customers have an expected duration of one year or less, we have elected the practical expedient in ASC 606 to not disclose information about our remaining performance obligations. Any incremental costs to obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of our contracts. Contract balances consisted of accounts receivable (both current and noncurrent) as of December 31, 2021 and 2020 and the Medicare advance payment (discussed further below) as of December 31, 2020.</span></div><div style="margin-bottom:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare Advance Payment</span></div><div style="margin-bottom:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 16, 2020, we received an advance payment of $8.3 million (the “Advance Payment”) from the Centers for Medicare &amp; Medicaid Services (“CMS”) under its Accelerated and Advance Payment Program, which was expanded to provide increased cash flow to service providers during the COVID-19 pandemic. CMS began recoupment of the Advance Payment in April 2021 by applying 25% of the Medicare payments otherwise owed to us against the balance of the Advance Payment. Recoupment of the full amount of the Advance Payment was complete by December 31, 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DecisionDx-Melanoma Claims Consolidation</span></div><div style="margin-bottom:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, we submitted to the Office of Medicare Hearings and Appeals (‘‘OMHA’’) a formal request to participate in a program that OMHA developed with the intent of providing appellants a means to have large volumes of claim disputes adjudicated at an accelerated rate. The program consolidates outstanding claims at the ALJ level and uses a statistical-sampling approach where five ALJs will determine reimbursement results for a sample of claims which are then extrapolated to the universe of claims. The consolidation includes 2,698 DecisionDx-Melanoma claims dating from 2013 through spring 2017. Hearings were held in April 2019 with a supplemental hearing in May 2019. On March 12, 2020, OMHA issued a decision denying payment on all claims in the consolidation. We have filed an appeal to the decision, although no ruling on such appeal has been issued to date. In accordance with ASC 606 and consistent with prior periods, we have not recognized (fully constrained the variable consideration) any revenues attributable to these claims in our consolidated financial statements pending the outcome of this matter. </span></div><div style="margin-bottom:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of revenues</span></div><div style="margin-bottom:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides the disaggregation of revenue by type (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermatologic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,753 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,646 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,085 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,649 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payor Concentration</span></div><div style="margin-bottom:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon reimbursements from third-party government payors (primarily Medicare) and private-payor insurance companies to collect accounts receivable related to sales of our diagnostic tests.</span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant third-party payors and their related revenues as a percentage of total revenues and accounts receivable balances are as follows:</span></div><div style="margin-bottom:9pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.825%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percentage of Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percentage of</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accounts Receivable</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(current)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percentage of</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accounts Receivable</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(non-current)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BlueCross BlueShield plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> P30D 3324000 176000 8300000 2698 <div style="margin-bottom:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides the disaggregation of revenue by type (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermatologic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,753 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,646 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,085 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,649 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 85753000 57646000 8332000 5003000 94085000 62649000 <div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant third-party payors and their related revenues as a percentage of total revenues and accounts receivable balances are as follows:</span></div><div style="margin-bottom:9pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.825%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percentage of Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percentage of</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accounts Receivable</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(current)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percentage of</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accounts Receivable</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(non-current)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BlueCross BlueShield plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.57 0.58 0.24 0.15 0 0 0.28 0.29 0.40 0.40 0 0.25 0.07 0.06 0.22 0.26 0.58 0.44 Loss Per Share<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Basic loss per share is computed by dividing net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options or purchases under the 2019 Employee Stock Purchase Plan (“ESPP”). The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. However, potentially dilutive shares are excluded from the computation of diluted loss per share when their effect is antidilutive.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Due to us reporting a net loss for all periods presented, all potentially dilutive securities are antidilutive and are excluded from the computation of diluted loss per share for such periods.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The table below provides the weighted-average number of potential common shares associated with outstanding securities not included in our calculation of diluted loss per share for the years ended December 31, 2021 and 2020 because to do so would be antidilutive (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and restricted stock units</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,789 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,521 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In addition, in connection with the acquisition of Cernostics, we may issue shares of our common stock to satisfy the contingent consideration obligation, pending the outcome of certain commercial milestones, as discussed in Note 5.</span></div> <div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The table below provides the weighted-average number of potential common shares associated with outstanding securities not included in our calculation of diluted loss per share for the years ended December 31, 2021 and 2020 because to do so would be antidilutive (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and restricted stock units</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,789 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,521 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3459000 2789000 0 35000 62000 100000 3521000 2924000 Asset Acquisitions<div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Myriad myPath, LLC</span></div><div style="margin-bottom:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2021, we completed the acquisition of all of the equity of Myriad myPath, LLC, a laboratory in Salt Lake City where the myPath Melanoma test for difficult-to-diagnose melanocytic lesions was developed and offered, for a cash purchase price of $32,500,000. Following the completion of the acquisition, we became the sole provider of the myPath Melanoma test. Based on the guidance in ASC 805, we concluded that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset and therefore the transaction represents an asset acquisition. We incurred $684,000 of direct transaction costs that were included in the cost of the acquisition. The allocation of the acquisition to individual assets resulted in an intangible asset representing developed technology of $33,054,000 and inventory of $130,000. The intangible asset has an estimated useful life of 12 years and is being amortized on a straight-line basis.</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cernostics, Inc.</span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, we completed the acquisition of Cernostics, Inc., which offers the TissueCypher® Barrett’s Esophagus Assay for patients with BE. We acquired Cernostics for an upfront cash purchase price of $30,732,000, including $653,000 of direct transaction costs. A portion of the upfront cash consideration is being held in escrow for a specified period following closing to secure post-closing adjustments and indemnification claims, if any. Our consolidated balance sheet at December 31, 2021 reflects a receivable of $519,000 for the post-closing purchase price adjustment, representing the difference between actual and estimated cash and working capital at closing, among other things. We have also agreed to pay up to an additional $50.0 million in cash or shares of our common stock, at our sole discretion, based on the achievement of certain commercial milestones relating to the year ending December 31, 2022 (“Earnout Payments”). The portion of any Earnout Payments that may be settled in shares of our common stock is subject to certain limitations and the aggregate number of shares that may be issued for the Earnout Payments may not exceed 5,034,653 shares. Any Earnout Payments in shares of our common stock will be based on the volume weighted-average price of our common stock for the 15 trading days ending December 30, 2022. The Earnout Payments represent contingent consideration. ASC 480, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provides guidance on accounting for certain obligations that must or may be settled by issuance of a variable number of shares. In accordance with that guidance, we recognized a liability of $18,287,000, which represents the fair value of the obligation as of the acquisition date. See Note 11 for additional information on the measurement of the contingent consideration. Based on the guidance in ASC 805, we concluded that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset and therefore the transaction represents an asset acquisition.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of the acquisition, which is comprised of the cash consideration, transaction costs and contingent consideration, was allocated to the assets acquired and the liabilities assumed as follows (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(655)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued and current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(386)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:3.6pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost allocated</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,019 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible assets were comprised of developed technology of $57,264,000 with an estimated useful life of 15 years and a developed workforce of $563,000, with an estimated useful life of five years, and each is being amortized on a straight-line basis.</span></div> 32500000 684000 33054000 130000 P12Y 30732000 653000 519000 50000000 5034653 15 18287000 <div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of the acquisition, which is comprised of the cash consideration, transaction costs and contingent consideration, was allocated to the assets acquired and the liabilities assumed as follows (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(655)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued and current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(386)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:3.6pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost allocated</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,019 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1251000 104000 198000 455000 57827000 655000 167000 386000 237000 9371000 49019000 57264000 P15Y 563000 P5Y Property and Equipment, Net<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,044 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,727 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,543 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,756 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,042)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,501 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,102 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.467%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    Includes lab equipment under a finance lease of $237 thousand and accumulated depreciation of $8 thousand.</span></div><div style="margin-bottom:3pt;margin-top:11pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was recorded in the consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization of acquired intangible assets)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,044 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,727 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,543 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,756 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,042)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,501 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,102 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.467%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    Includes lab equipment under a finance lease of $237 thousand and accumulated depreciation of $8 thousand.</span></div><div style="margin-bottom:3pt;margin-top:11pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was recorded in the consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization of acquired intangible assets)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5044000 1388000 3727000 2037000 2457000 1305000 1288000 436000 27000 3590000 12543000 8756000 3042000 1654000 9501000 7102000 237000 8000 478000 341000 248000 31000 722000 100000 1448000 472000 Intangible Assets, Net<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets, net consist of the following </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross carrying value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Remaining Life (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,317 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,949)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled workforce</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,880 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,958)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,922 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no intangible assets as of December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future aggregate amortization expense as of December 31, 2021 is as follows (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,681 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,672 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,922 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Amortization expense of intangible assets was $2.0 million for the year ended December 31, 2021. No amortization expense was recorded for the year ended December 31, 2020. <div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets, net consist of the following </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross carrying value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Remaining Life (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,317 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,949)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled workforce</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,880 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,958)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,922 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no intangible assets as of December 31, 2020.</span></div> 90317000 1949000 88368000 P13Y2M12D 563000 9000 554000 P4Y10M24D 90880000 1958000 88922000 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future aggregate amortization expense as of December 31, 2021 is as follows (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,681 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,672 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,922 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6681000 6681000 6700000 6681000 6672000 55507000 88922000 2000000.0 0 Other Accrued and Current Liabilities<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consisted of the following </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued service fees</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,905 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical studies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payor refunds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,678 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,055 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consisted of the following </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued service fees</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,905 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical studies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payor refunds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,678 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,055 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1905000 1543000 1655000 348000 760000 536000 695000 276000 386000 0 277000 352000 5678000 3055000 Leases<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease office space in Friendswood, Texas (the “Friendswood Lease”) for use as our corporate headquarters. The Friendswood Lease commenced in late 2020 under a 60-month term and a renewal option for one additional five-year term.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease two facilities in Phoenix, Arizona for laboratory and office space. For both leases, the current term extends until April 2033 with options to renew for two additional five-year terms. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not included the optional renewal periods in the measurement of the lease obligations because it is not reasonably certain that we will exercise these renewal options.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other operating leases primarily consist of office equipment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Lease</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the December 2021 acquisition of Cernostics, we assumed a finance lease for laboratory equipment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discount Rates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We discount our lease obligations using our incremental borrowing rate at the commencement date. The incremental borrowing rate is the rate of interest we would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. We primarily consider industry data, our credit rating and the lease term to determine our incremental borrowing rate.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Balances and Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease balances reflected in the consolidated balance sheet were as follows </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:55.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.915%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczNGMzNzFhNjVjNTQ4YmM5Nzg3OGU1NDRmODBiNjlhL3NlYzo3MzRjMzcxYTY1YzU0OGJjOTc4NzhlNTQ0ZjgwYjY5YV8yOTIvZnJhZzo5NmY3MzQyNTMzMWQ0OThhOTM3YmM5YTZlNmM2YWJjZC90YWJsZTo3MmE3NDE4ZTIxZTQ0MjQxOWVhZmVjZWI0N2RjYzA3Ni90YWJsZXJhbmdlOjcyYTc0MThlMjFlNDQyNDE5ZWFmZWNlYjQ3ZGNjMDc2XzQtMi0xLTEtMjY2NzQ_d0fe9d8c-95ce-4528-9592-83958d9ded8f">Property and equipment, net</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczNGMzNzFhNjVjNTQ4YmM5Nzg3OGU1NDRmODBiNjlhL3NlYzo3MzRjMzcxYTY1YzU0OGJjOTc4NzhlNTQ0ZjgwYjY5YV8yOTIvZnJhZzo5NmY3MzQyNTMzMWQ0OThhOTM3YmM5YTZlNmM2YWJjZC90YWJsZTo3MmE3NDE4ZTIxZTQ0MjQxOWVhZmVjZWI0N2RjYzA3Ni90YWJsZXJhbmdlOjcyYTc0MThlMjFlNDQyNDE5ZWFmZWNlYjQ3ZGNjMDc2XzEwLTItMS0xLTI2NjUz_ccb59e92-4356-457e-b2d3-dc5ac905682c">Other accrued and current liabilities</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczNGMzNzFhNjVjNTQ4YmM5Nzg3OGU1NDRmODBiNjlhL3NlYzo3MzRjMzcxYTY1YzU0OGJjOTc4NzhlNTQ0ZjgwYjY5YV8yOTIvZnJhZzo5NmY3MzQyNTMzMWQ0OThhOTM3YmM5YTZlNmM2YWJjZC90YWJsZTo3MmE3NDE4ZTIxZTQ0MjQxOWVhZmVjZWI0N2RjYzA3Ni90YWJsZXJhbmdlOjcyYTc0MThlMjFlNDQyNDE5ZWFmZWNlYjQ3ZGNjMDc2XzEzLTItMS0xLTI2Njkz_13f2223a-580f-4155-aae2-4c3592ae28be">Other liabilities</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with our leases were included in the consolidated statement of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.467%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    Includes variable lease cost of $187 thousand for the year ended </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information on leases is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.888%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from interest paid on finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases    </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we recorded $2.9 million in lease liabilities arising from obtaining ROU assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the weighted-average lease term and weighted-average discount rate is presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.888%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average remaining lease term (years)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average discount rate</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a maturity analysis of our operating lease and finance lease liabilities as of December 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest component</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,079 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we have no material leases that have not yet commenced.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosures Under ASC 840</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future non-cancellable commitments under all operating leases were as follows as of December 31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,764 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense was $548,000 for the year ended December 31, 2020.</span></div> Leases<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease office space in Friendswood, Texas (the “Friendswood Lease”) for use as our corporate headquarters. The Friendswood Lease commenced in late 2020 under a 60-month term and a renewal option for one additional five-year term.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease two facilities in Phoenix, Arizona for laboratory and office space. For both leases, the current term extends until April 2033 with options to renew for two additional five-year terms. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not included the optional renewal periods in the measurement of the lease obligations because it is not reasonably certain that we will exercise these renewal options.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other operating leases primarily consist of office equipment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Lease</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the December 2021 acquisition of Cernostics, we assumed a finance lease for laboratory equipment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discount Rates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We discount our lease obligations using our incremental borrowing rate at the commencement date. The incremental borrowing rate is the rate of interest we would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. We primarily consider industry data, our credit rating and the lease term to determine our incremental borrowing rate.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Balances and Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease balances reflected in the consolidated balance sheet were as follows </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:55.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.915%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczNGMzNzFhNjVjNTQ4YmM5Nzg3OGU1NDRmODBiNjlhL3NlYzo3MzRjMzcxYTY1YzU0OGJjOTc4NzhlNTQ0ZjgwYjY5YV8yOTIvZnJhZzo5NmY3MzQyNTMzMWQ0OThhOTM3YmM5YTZlNmM2YWJjZC90YWJsZTo3MmE3NDE4ZTIxZTQ0MjQxOWVhZmVjZWI0N2RjYzA3Ni90YWJsZXJhbmdlOjcyYTc0MThlMjFlNDQyNDE5ZWFmZWNlYjQ3ZGNjMDc2XzQtMi0xLTEtMjY2NzQ_d0fe9d8c-95ce-4528-9592-83958d9ded8f">Property and equipment, net</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczNGMzNzFhNjVjNTQ4YmM5Nzg3OGU1NDRmODBiNjlhL3NlYzo3MzRjMzcxYTY1YzU0OGJjOTc4NzhlNTQ0ZjgwYjY5YV8yOTIvZnJhZzo5NmY3MzQyNTMzMWQ0OThhOTM3YmM5YTZlNmM2YWJjZC90YWJsZTo3MmE3NDE4ZTIxZTQ0MjQxOWVhZmVjZWI0N2RjYzA3Ni90YWJsZXJhbmdlOjcyYTc0MThlMjFlNDQyNDE5ZWFmZWNlYjQ3ZGNjMDc2XzEwLTItMS0xLTI2NjUz_ccb59e92-4356-457e-b2d3-dc5ac905682c">Other accrued and current liabilities</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczNGMzNzFhNjVjNTQ4YmM5Nzg3OGU1NDRmODBiNjlhL3NlYzo3MzRjMzcxYTY1YzU0OGJjOTc4NzhlNTQ0ZjgwYjY5YV8yOTIvZnJhZzo5NmY3MzQyNTMzMWQ0OThhOTM3YmM5YTZlNmM2YWJjZC90YWJsZTo3MmE3NDE4ZTIxZTQ0MjQxOWVhZmVjZWI0N2RjYzA3Ni90YWJsZXJhbmdlOjcyYTc0MThlMjFlNDQyNDE5ZWFmZWNlYjQ3ZGNjMDc2XzEzLTItMS0xLTI2Njkz_13f2223a-580f-4155-aae2-4c3592ae28be">Other liabilities</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with our leases were included in the consolidated statement of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.467%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    Includes variable lease cost of $187 thousand for the year ended </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information on leases is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.888%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from interest paid on finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases    </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we recorded $2.9 million in lease liabilities arising from obtaining ROU assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the weighted-average lease term and weighted-average discount rate is presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.888%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average remaining lease term (years)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average discount rate</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a maturity analysis of our operating lease and finance lease liabilities as of December 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest component</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,079 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we have no material leases that have not yet commenced.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosures Under ASC 840</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future non-cancellable commitments under all operating leases were as follows as of December 31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,764 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense was $548,000 for the year ended December 31, 2020.</span></div> P60M 1 P5Y 2 2 P5Y <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Balances and Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease balances reflected in the consolidated balance sheet were as follows </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:55.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.915%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczNGMzNzFhNjVjNTQ4YmM5Nzg3OGU1NDRmODBiNjlhL3NlYzo3MzRjMzcxYTY1YzU0OGJjOTc4NzhlNTQ0ZjgwYjY5YV8yOTIvZnJhZzo5NmY3MzQyNTMzMWQ0OThhOTM3YmM5YTZlNmM2YWJjZC90YWJsZTo3MmE3NDE4ZTIxZTQ0MjQxOWVhZmVjZWI0N2RjYzA3Ni90YWJsZXJhbmdlOjcyYTc0MThlMjFlNDQyNDE5ZWFmZWNlYjQ3ZGNjMDc2XzQtMi0xLTEtMjY2NzQ_d0fe9d8c-95ce-4528-9592-83958d9ded8f">Property and equipment, net</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczNGMzNzFhNjVjNTQ4YmM5Nzg3OGU1NDRmODBiNjlhL3NlYzo3MzRjMzcxYTY1YzU0OGJjOTc4NzhlNTQ0ZjgwYjY5YV8yOTIvZnJhZzo5NmY3MzQyNTMzMWQ0OThhOTM3YmM5YTZlNmM2YWJjZC90YWJsZTo3MmE3NDE4ZTIxZTQ0MjQxOWVhZmVjZWI0N2RjYzA3Ni90YWJsZXJhbmdlOjcyYTc0MThlMjFlNDQyNDE5ZWFmZWNlYjQ3ZGNjMDc2XzEwLTItMS0xLTI2NjUz_ccb59e92-4356-457e-b2d3-dc5ac905682c">Other accrued and current liabilities</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczNGMzNzFhNjVjNTQ4YmM5Nzg3OGU1NDRmODBiNjlhL3NlYzo3MzRjMzcxYTY1YzU0OGJjOTc4NzhlNTQ0ZjgwYjY5YV8yOTIvZnJhZzo5NmY3MzQyNTMzMWQ0OThhOTM3YmM5YTZlNmM2YWJjZC90YWJsZTo3MmE3NDE4ZTIxZTQ0MjQxOWVhZmVjZWI0N2RjYzA3Ni90YWJsZXJhbmdlOjcyYTc0MThlMjFlNDQyNDE5ZWFmZWNlYjQ3ZGNjMDc2XzEzLTItMS0xLTI2Njkz_13f2223a-580f-4155-aae2-4c3592ae28be">Other liabilities</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7383000 229000 1179000 105000 6900000 124000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with our leases were included in the consolidated statement of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.467%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    Includes variable lease cost of $187 thousand for the year ended </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information on leases is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.888%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from interest paid on finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases    </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the weighted-average lease term and weighted-average discount rate is presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.888%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average remaining lease term (years)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average discount rate</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 1450000 8000 1000 29000 1488000 187000 1145000 1000 8000 2900000 P9Y1M6D P2Y3M18D 0.049 0.050 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a maturity analysis of our operating lease and finance lease liabilities as of December 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest component</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,079 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a maturity analysis of our operating lease and finance lease liabilities as of December 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest component</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,079 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1258000 108000 1287000 108000 1302000 26000 1218000 0 689000 0 4609000 0 10363000 242000 2284000 13000 8079000 229000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future non-cancellable commitments under all operating leases were as follows as of December 31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,764 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1164000 1148000 1142000 1154000 1119000 1037000 6764000 548000 Long-Term Debt<span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We had a Loan and Security Agreement with Oxford Finance LLC (“Oxford”) as collateral agent, and Oxford and Silicon Valley Bank as equal syndicated lenders (the “2018 LSA”). The 2018 LSA consisted of a $25.0 million secured term loan credit facility (the “Term Loan”). The Term Loan bore interest at a floating rate equal to the greater of (1) 8.55% and (2) the 30-day U.S. LIBOR rate as reported in The Wall Street Journal on the last business day of the month that preceded the month in which the interest was to accrue, plus 6.48%. We were permitted to make interest-only payments on the Term Loan through May 31, 2020. As required, we began to repay the principal in 30 equal monthly installments of $833,333 each beginning on June 1, 2020. All unpaid principal and accrued and unpaid interest were to be due at maturity on November 1, 2022. However, o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">n December 21, 2020, we terminated the 2018 LSA and repaid in full all amounts due, which totaled $21.6 million as of such date, including the outstanding principal balance, the final payment amount, early termination and prepayment fees and accrued interest. The termination of the 2018 LSA resulted in the recognition of an extinguishment loss of $1.4 million, which was reflected in our statement of operations and comprehensive loss for the year ended December 31, 2020</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">.</span> 25000000 0.0855 0.0648 30 833333 21600000 -1400000 Fair Value Measurements<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:131%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used in measuring fair value. There are three levels to the fair value hierarchy based on the reliability of inputs, as follows:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:131%">Level 1 – Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:131%">Level 2 – Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:131%">Level 3 – Unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:131%">Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or amounts recorded may not be indicative of the amount that us or holders of the instruments could realize in a current market exchange.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:131%">The table below provides information (in thousands), by level within the fair value hierarchy, of our financial assets and liabilities that are accounted for at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:131%">As of December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Items (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:131%">As of December 31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Items (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,480 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,480 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.883%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Classified as “Cash and cash equivalents” in the consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Cernostics, we have recorded a contingent consideration liability for the Earnout Payments. This liability is classified as a Level 3 fair value measurement due to the use of significant unobservable inputs and a Monte Carlo simulation to determine its fair value. The Monte Carlo simulation uses projections of the commercial milestones for the applicable period as well as the corresponding targets and approximate timing of payment based on the terms of the arrangement. The analysis also uses assumptions for expected volatility of the financial metrics and a risk-adjusted discount rate, which were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 20.0% and 16.1%, respectively, at initial measurement on December 3, 2021. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability is remeasured at fair value at each reporting period taking into account any updated assumptions or changes in circumstances. Any change in the fair value is recorded as a gain or loss in our consolidated statement of operations and comprehensive loss. There was no change in fair value from the initial recognition on December 3, 2021 through December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table discloses the summary of changes in the contingent consideration liability measured at fair value using Level 3 inputs during the year ended December 31, 2021 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.176%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Cernostics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,287 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:131%">The table below provides information (in thousands), by level within the fair value hierarchy, of our financial assets and liabilities that are accounted for at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:131%">As of December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Items (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:131%">As of December 31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Items (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,480 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,480 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.883%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Classified as “Cash and cash equivalents” in the consolidated balance sheets.</span></div> 327721000 0 0 327721000 0 0 18287000 18287000 409480000 0 0 409480000 0.200 0.161 <span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table discloses the summary of changes in the contingent consideration liability measured at fair value using Level 3 inputs during the year ended December 31, 2021 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.176%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Cernostics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,287 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 18287000 0 18287000 Commitments and ContingenciesFrom time to time, we may be involved in legal proceedings arising in the ordinary course of business. We believe there is no threatened litigation or litigation pending that could have, individually or in the aggregate, a material adverse effect on our financial position, results of operations or cash flows. Stockholders’ Equity<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Stock</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s Amended and Restated Certificate of Incorporation, dated July 29, 2019, authorizes the Company to issue up to 200,000,000 shares of common stock with a par value of $0.001 per share. The Company is also authorized to issue up to 10,000,000 shares of preferred stock with a par value of $0.001 per share. No dividends were declared or paid during the years ended December 31, 2021 or 2020.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2020, we issued and sold 2,000,000 shares of our common stock in a follow-on public offering at a price of $37.00 per share. We received $69,079,000 in net proceeds, after deducting underwriting discounts, commissions and offering costs. In connection with the offering, we granted the underwriters a 30-day option to purchase up to 300,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. On July 2, 2020, we issued and sold an additional 300,000 shares of common stock pursuant to the underwriters’ exercise in full of their option to purchase additional shares, which resulted in an additional net proceeds to us of $10,425,000. On December 18, 2020, we issued and sold 4,600,000 shares of our common stock in a follow-on public offering, including 600,000 shares associated with the full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $58.00 per share. We received $250,201,000 in aggregate net proceeds, after deducting underwriting discounts and commissions and offering costs.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issued an aggregate of 209,238 shares and 31,814 shares of common stock December 11, 2020 and December 29, 2020, respectively, pursuant to net exercises by the holders of common stock warrants outstanding. In accordance with the net exercise provisions of the warrants, shares of common stock were withheld to satisfy the cost of these exercises.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no common stock warrants outstanding as of December 31, 2021 or 2020. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common stock warrants were classified as stockholders’ equity and no adjustments were recorded for changes in fair value.</span></div> 200000000 0.001 10000000 0.001 0 0 0 0 2000000 37.00 69079000 P30D 300000 300000 10425000 4600000 600000 58.00 250201000 209238 31814 0 0 Stock Incentive Plans and Stock-Based Compensation<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plans</span></div><div style="margin-bottom:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock incentive plans provide for the granting of options to purchase common stock and other equity-based awards to our employees, directors and consultants. On September 6, 2008, we adopted the 2008 Stock Plan (the “2008 Plan”), on August 15, 2018, we adopted the 2018 Stock Plan (the “2018 Plan”) and on July 24, 2019, we adopted the 2019 Equity Incentive Plan (the “2019 Plan”). Following the adoption of the 2018 Plan, no additional stock awards were granted under the 2008 Plan and following the adoption of the 2019 Plan, no additional stock awards were granted under the 2018 Plan. </span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options under the plans may be granted as incentive stock options (“ISOs”) or non-statutory stock options (“NSOs”). ISOs may only be granted our employees (including directors who are also considered employees). NSOs may be granted our employees, directors and consultants. Options may be granted for terms up to ten years from the date of grant, as determined by the Board of Directors; provided, however, that with respect to an ISO granted to a person who owns stock representing more than 10% of the voting power of all classes of stock of ours, the terms shall be for no more than five years from the date of grant. The exercise price of options granted must be no less than 100% of the fair market value of the shares on the date of grant, provided, however, that with respect to an ISO granted to an employee who at the time of grant of such options owns stock representing more than 10% of the voting power of all classes of stock of ours, the exercise price shall not be less than 110% of the fair market value of the shares on the date of grant. Options generally vest over four years (generally 25% after one year and monthly thereafter), subject to the option holder’s continued service with us. We issue new shares to satisfy option exercises.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, 46,741 shares remained available for grant under the 2019 Plan. On January 1, 2022, an additional 1,268,926 shares became available under the 2019 Plan pursuant to an automatic annual increase. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under our stock plans for the years ended December 31, 2021 and 2020 is set forth below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,637,966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286,065 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460,207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,369,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841,336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(414,890)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586,688 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332,487 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,845 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Vested and exercisable options. Additionally, outstanding unvested options to purchase an aggregate of 10,255 shares of common stock with a weighted-average exercise price of $2.39 per share may be exercised prior to vesting as of December 31, 2021 under early-exercise provisions. In the event of such exercise, the shares obtained upon exercise would be restricted and subject to forfeiture prior to vesting. No such early exercises have occurred as of December 31, 2021.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs represent the right to receive shares of our common stock at a specified future date, subject to vesting. Our RSUs generally vest annually from the grant date in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjczNGMzNzFhNjVjNTQ4YmM5Nzg3OGU1NDRmODBiNjlhL3NlYzo3MzRjMzcxYTY1YzU0OGJjOTc4NzhlNTQ0ZjgwYjY5YV8zMTMvZnJhZzpmYmQyNTQ5NjhlMWE0MzExOGM0ZWI5NGY4ODhmYzdlNy90ZXh0cmVnaW9uOmZiZDI1NDk2OGUxYTQzMTE4YzRlYjk0Zjg4OGZjN2U3XzIxOTkwMjMyODI5Mzk_08b9f5f5-7999-4c0e-829d-27aa32cfea82">four</span> equal installments subject to the holder’s continued service with us. We issue new shares to satisfy RSUs upon vesting. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU activity for the years ended December 31, 2021 and December 31, 2020:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958,361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,002)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050,174 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.31 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.883%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The aggregate number of shares withheld upon vesting for employee tax obligations was </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16,440 for the year ended December 31, 2021.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSU Awards to Related Parties</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, the Audit Committee of our Board of Directors approved, at the recommendation of our Compensation Committee, a one-time award of RSUs to three employees who are the children of our Chief Executive Officer (“CEO”) which we have determined to be outside the ordinary course of business. Under the Internal Revenue Code (“IRC”), those owning more than a specified percentage of a company’s stock are not eligible to receive certain preferential tax benefits that are afforded to qualifying stock compensation arrangements. In determining eligibility under the Code, when calculating the number of shares of common stock owned, an individual must attribute all shares owned by specified family members. Because </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the stock ownership of our CEO and this attribution requirement, the three children have not been eligible to participate in the ESPP and, at times, have not qualified to receive stock option grants on terms as favorable as those received by other similar employees. Our Compensation Committee recommended, and our Audit Committee approved, a one-time grant of restricted stock units designed to compensate the three children for these differences. The aggregate number of shares underlying the restricted stock units granted to the three children was 17,275 which are included in the table above. The awards had an aggregate grant date fair value of $1,129,000, vested immediately upon grant and was recognized as stock-based compensation expense, included in selling, general and administrative expenses, during the year ended December 31, 2021.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP became effective July 24, 2019. Offerings under the ESPP are generally 24 months in length with four six-month purchase periods unless terminated earlier, as described below. Eligible employees who enroll in an offering are able to purchase shares of our common stock at a discount through payroll deductions, subject to certain limitations. The purchase price of the shares of common stock is the lesser of (i) 85% of the fair market value of such shares on the offering date and (ii) 85% of the fair market value of such shares on the purchase date. A new offering begins approximately every six months. Offerings are concurrent, but in the event the fair market value of a share of common stock on the first day of any purchase period during an offering (the “New Offering”) is less than or equal to the fair market value of a share of common stock on the offering date for an ongoing offering (the “Ongoing Offering”), then the Ongoing Offering terminates immediately following the purchase of shares on the purchase date immediately preceding the New Offering and the participants in the terminated Ongoing Offering are automatically enrolled in the New Offering. In such case, we account for this event as a modification of the Ongoing Offering. Notwithstanding the above, our Board of Directors (or an authorized committee thereof) may modify the terms of or suspend any future offerings prior to their commencement. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, 639,466 shares remained available for issuance under the ESPP. The ESPP provides for certain automatic increases in the number of shares of common stock reserved for issuance, which resulted in an additional 253,785 shares becoming available under the ESPP effective January 1, 2022. We issue new shares to satisfy ESPP purchases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Determining Fair Value - Summary of Assumptions</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes option pricing model to estimate the fair value of stock options and purchase rights granted under the ESPP at the date of grant, start of the offering or other relevant measurement date. Set forth below is a description of the significant assumptions used in the option pricing model:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The expected term is the period of time that granted options are expected to be outstanding. For stock options, we have set the expected term using the simplified method based on the weighted average of both the period to vesting and the period to maturity for each option, as we have concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate the expected term. For the ESPP, the expected term is the period of time from the offering date to the purchase date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Previously, because of the limited period of time our stock had been traded in an active market, we calculated expected volatility by using the historical stock prices of a group of similar companies looking back over the estimated life of the option or the ESPP purchase right and averaging the volatilities of these companies. In the third quarter of 2021, we adjusted this calculation to include our own stock price on a relative basis to the peer group in the calculation of expected volatility, as our common stock has now been traded in an active market for more than two years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We base the risk-free interest rate used in the Black-Scholes valuation model on the market yield in effect at the time of option grant and at the offering date for the ESPP, provided from the Federal Reserve Board’s Statistical Releases and historical publications from the Treasury constant maturities rates for the equivalent remaining terms.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have not paid, and does not have plans to pay, cash dividends. Therefore, we use an expected dividend yield of zero in the Black-Scholes option valuation model.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The fair value of our common stock is also an assumption used to determine the fair value of stock options. Prior to our initial public offering of common stock on July 29, 2019 (the “IPO”), our common stock was not publicly traded, therefore we estimated the fair value of our common stock. Following the IPO, the fair value of our common stock is the closing selling price per share of its common stock as reported on the Nasdaq Global Market on the date of grant or other relevant determination date.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">We use the Black-Scholes option pricing model to estimate the fair value of each option grant on the date of grant or any other measurement date. The following table sets forth the assumptions used to determine the fair value of stock options:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.50% - 68.83%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.57% - 67.02%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51% - 1.48%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28% - 1.76%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth assumptions used to determine the fair value of the purchase rights issued under the ESPP:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.838%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.13% - 86.50%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.80% - 100.49%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06% - 0.20%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12% - 0.95%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the closing price of our common stock on the date of grant to determine the fair value of RSUs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is included in the consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization of acquired intangible assets)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,740 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,309 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years ended December 31, 2021 and 2020, the weighted-average grant date fair value of stock options was $29.89 and $28.95 per option, respectively, and the weighted-average grant date fair value of the purchase rights granted under the ESPP was $27.60 and $17.43 per share, respectively. As of December 31, 2021, the total unrecognized stock-based compensation cost related to outstanding awards was $99,251,000, which is expected to be recognized on a straight-line basis over a weighted-average period of 3.3 years. The total unrecognized compensation cost will be adjusted for forfeitures in future periods as they occur. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised during the years ended </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021 and 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $27,191,000 and $18,377,000, respectively. The aggregate intrinsic value of shares issued under the ESPP was $6,341,000 and $1,797,000 during the years ended </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021 and 2020, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The aggregate fair value of restricted stock units that vested during the year ended December 31, 2021 was $2,698,000. No tax benefits related to stock-based compensation were recorded in the consolidated statements of operations and comprehensive loss during the years ended </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span> due to the valuation allowance on net deferred tax assets. P10Y 0.10 P5Y 1 0.10 1.10 P4Y 0.25 P1Y 46741 1268926 <div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under our stock plans for the years ended December 31, 2021 and 2020 is set forth below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,637,966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286,065 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460,207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,369,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841,336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(414,890)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586,688 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332,487 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,845 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Vested and exercisable options. Additionally, outstanding unvested options to purchase an aggregate of 10,255 shares of common stock with a weighted-average exercise price of $2.39 per share may be exercised prior to vesting as of December 31, 2021 under early-exercise provisions. In the event of such exercise, the shares obtained upon exercise would be restricted and subject to forfeiture prior to vesting. No such early exercises have occurred as of December 31, 2021.</span></div> 2637966 13.30 1286065 49.63 460207 3.53 94322 27.51 3369502 28.11 841336 48.97 414890 10.13 209260 33.97 3586688 34.75 P8Y3M18D 45970000 1332487 23.31 P7Y6M 28845000 10255 2.39 <div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU activity for the years ended December 31, 2021 and December 31, 2020:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958,361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,002)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050,174 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.31 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.883%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The aggregate number of shares withheld upon vesting for employee tax obligations was </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16,440 for the year ended December 31, 2021.</span></div> 0 0 161477 59.16 0 0 0 0 161477 59.16 958361 43.05 56002 61.07 13662 62.80 1050174 44.31 16440 3 3 3 3 17275 1129000 P24M 4 P6M 0.85 0.85 P6M 639466 253785 The following table sets forth the assumptions used to determine the fair value of stock options:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.50% - 68.83%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.57% - 67.02%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51% - 1.48%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28% - 1.76%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></div></td></tr></table> P6Y1M6D P6Y 0.6650 0.6883 0.5957 0.6702 0.0051 0.0148 0.0028 0.0176 0 0 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth assumptions used to determine the fair value of the purchase rights issued under the ESPP:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.838%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.13% - 86.50%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.80% - 100.49%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06% - 0.20%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12% - 0.95%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> P1Y2M12D P1Y2M12D 0.6113 0.8650 0.5680 1.0049 0.0006 0.0020 0.0012 0.0095 0 0 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is included in the consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization of acquired intangible assets)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,740 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,309 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2058000 1049000 4522000 1492000 15160000 5768000 21740000 8309000 29.89 28.95 27.60 17.43 99251000 P3Y3M18D 27191000 18377000 6341000 1797000 2698000 0 0 Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income tax expense (benefit) are as follows (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax (benefit) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,726)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,736)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax (benefit) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,720)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between income taxes expected at the U.S. federal statutory rate (21%) and the reported income tax expense (benefit) are summarized as follows (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,012)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,200)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal taxes at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(311)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible meals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development (“R&amp;D”) tax credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,658)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(703)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(880)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(781)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible officers’ compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,571 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax (benefit) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,720)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of deferred tax assets and liabilities are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss (“NOL”) carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,670 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,710 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,034 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,774)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,913)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 481(a) adjustment (cash to accrual)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,571)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,830)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset (liability)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(635)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, we had NOL carryforwards for federal income tax purposes of approximately $99,365,000 of which $43,513,000 will begin to expire in 2030 if not utilized to offset taxable income, and $55,852,000 may be carried forward indefinitely. Future changes in ownership, as defined by Section 382 of the IRC, could limit the amount of NOL carryforwards used in any one year. Also, as of December 31, 2021, we had state net operating loss carryforwards of approximately $67,453,000, which begin to expire in 2028 if not utilized to offset state taxable income. Our R&amp;D tax credit carryforwards of $3,670,000 at December 31, 2021 will begin to expire in 2034 if not utilized to offset federal income tax.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, under Section 382 and 383 of the IRC, a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change NOLs and certain tax credits, to offset future taxable income and tax. In general, an ownership change occurs if the aggregate stock ownership of certain stockholders changes by more than 50 percentage points over such stockholders’ lowest percentage of ownership during the testing period (generally three years). We performed a Section 382 analysis from inception through the year ended December 31, 2021 and concluded we had experienced an ownership change in 2011, 2014 and 2020. These changes in ownership did not result in the expiration of any NOLs or R&amp;D credits. However, future changes in ownership may further limit the ability of us to utilize our NOL carryforwards and R&amp;D tax credit carryforwards.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, in connection with the acquisition of Cernostics, we recorded additional net deferred tax liabilities of $9,371,000, primarily due to book-tax differences related to the acquired intangible assets. As a result of these additional deferred tax liabilities, we determined that $8,726,000 of our existing valuation allowance should be reduced, which was reflected in our income tax benefit for the year ended December 31, 2021. At December 31, 2021 and 2020, we placed a valuation allowance of $17,774,000 and $15,204,000, respectively, against our net deferred tax asset balances, as we have determined that it is more likely than not that they will not be realized. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed whether we had any significant uncertain tax positions related to open tax years and concluded there were none. Accordingly, no reserve for uncertain tax positions has been recorded as of December 31, 2021 and 2020. We are generally no longer subject to tax examinations for U.S. federal income tax purposes for fiscal years prior to 2018 and fiscal years prior to 2017 for multiple state jurisdictions. However, since we have been in an NOL position since 2008, our 2008 to 2017 federal tax returns and our 2008 to 2016 state tax returns are potentially subject to examination adjustments to the extent of those NOL carryforwards.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income tax expense (benefit) are as follows (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax (benefit) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,726)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,736)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax (benefit) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,720)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 16000 84000 16000 84000 -8726000 0 -10000 0 -8736000 0 -8720000 84000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between income taxes expected at the U.S. federal statutory rate (21%) and the reported income tax expense (benefit) are summarized as follows (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,012)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,200)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal taxes at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(311)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible meals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development (“R&amp;D”) tax credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,658)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(703)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(880)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(781)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible officers’ compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,571 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax (benefit) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,720)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -40012000 -10200000 -8402000 -2142000 -1764000 -311000 0 235000 1658000 703000 2570000 2784000 -880000 -781000 1571000 963000 -157000 39000 -8720000 84000 <div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of deferred tax assets and liabilities are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss (“NOL”) carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,670 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,710 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,034 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,774)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,913)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 481(a) adjustment (cash to accrual)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,571)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,830)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset (liability)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(635)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 24316000 13720000 4168000 2730000 2114000 0 0 46000 2202000 761000 3670000 1777000 240000 0 36710000 19034000 17774000 15204000 18936000 3830000 330000 289000 2285000 776000 12913000 0 2166000 0 1877000 2765000 19571000 3830000 635000 0 99365000 43513000 55852000 67453000 3670000 9371000 -8726000 17774000 15204000 EXCEL 99 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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
  •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
  •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�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ࡄ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

    [*D7G= T&+XM"/[[C.,2_:I.:/#K,I I M%2WH:+QJ?15?/11);6VY9U\C$R4U<0!DW_(]S;>*ZYF V8%\YRE$]C6)HL62 MRQ9OQ8)PENNA\F30V"LU5Y,H/7X=:9MU=HOCVU+ICHTIB;QJDL-S7\@S@\ = M3TV;#4R5HM"Y#I)!EZBSG:]%*T8: M4*FI@HORFE-UYR@("5>#+&L1[1X^G12WD$T/W1NS42FG9" -U>E< M5K#71V8"DNG*[:FW\^G,2[:XF$2;E&! :+_>4;!TV+JT2R5ZR#7/W]'7$E"C M5)K8+%D2\.>FA-;=4WN*ZF;%)Q)!S#ESTT0F[+)]M6U>*5@IQJVB1=^[-(,6 MHQRW^#1#"*3Z)%.K066-!.+07;/KY]-SZAVBS/@.UH#): -COXDS4=7[3DB. M 4>YHE3IR,^!T047N>C*![W]S51=U6?G9AAW^6^Q(F^31[D[(QTDL+S9" 4 M3?]Z@/^4YOUO9=(S+FQ:1$^=&H+1SO$URERJ;A[0Q:F7H\JK/7E4H=4A[-"Y MWMPPJ]H/)EO0D@(=!_+F 0(C7^U<$EKG6DW0UW],L42,6S6X'4]K$( M-&\^]IQ18.B5JPS';[O*3;QE'5P.7H_KW]FN9&+6+F NT 95WY#8[I>M;O,& MZ;HU?)7AJL(8CP>?[IK:X;5! +^Y#.%F:.@-7I?7B#$>FU5S%K.%HGG3 M^K):=>0!1U<-U0>:8-6H_41 J:$T9>0Q&WM:$&[=WAVS +ZYSSJ6JKO5 V"* MJ;W*&?TYI8213LJE);/>(ED6VETL7RCC5/+ M*=:]$FE**W+.F+Q29[0ER^E+8SP$D'OQY/;V:"55(@V'UM\0*#\$7"X)=LLJ M0-/UUG!_(DD&YPF(E"OM^_3:TMML3D@7A<-]F F"CUKY@MBE M.R0+&B(Q#RQV&\='N:%V^WQ>/%HS^:-O21D7V@#[@'?U"4^(T0HF):9E%^\( MQ]19#IHT+3$.T\4-L\@S;Q\HI5T7/[!GO$ZI831]&!U"TO@"LG:.V]]>$"'B MWXZK]1'+<=+(.WL64JUM+OXN\?"MXLTL)#5!2E /'F_A-O68OR1#/8K5>9!9 M"WV&UBD&;,+ T!=ML*?Q;0'M\[=7BH](7P*[.%5VQ7MLT MGM3^+(\Z6C#>=(-Z?=%L_K9**X]QH72/6@51'QO_F"'?F8IF@,C:*HHXTO8A MMA; F?EWD 45(&SZZJ<<>:G<(Z96BU"?@OFEY9[!&07>.8U5"@):T5?8Z"B; M\ZH^_8QSZ1YSGN^[8D"W]ON?_W49G?Y)ZL!.:3R$_F%*S85IA&]15U3=A1I6HXCA(G;)G;%%U,TN>]\ <K6"8R[2=;62RH9E:R\N8:P.[L-7Q0.*S1,S\$!W8. M*?Q<<:B+P#5O'*XVW/VID5]D-NO:>RKM7, MK0'&.B.QO;43^(DF]!'YX6:(WNO9POZ_8>C\[C):\)'@CRO-65+4\O+]F9O( M"<7]YG2"TWF1X2^38)1WH;F G(]7?#^>#]2+S*9.#H(8O/KCE#.;@#I:ZV86 MKKS$5#J>F45@?S3:I^R8'Y6&9@H:X;_5DNXKV]5V3=^9&HEJ1IJ%UWUNL^"P M5%"X_R]C_2_ISDZA^WRDXU)=]&X/:-1M2PCL\,XG'YAPB<3V"I+1T$_N#?+O M[0T'Y4Y!("!,CQ)BIQG8'?C(0F=7 =;I*^MALE"V9=':?L38(<[/*?ON2_?J M< =$D&=V4)V/=>\*/.0*EVX5(02P3Y_X41Q3.DGP # &2O5Z//IK[_^A5=SJ MY+@M,Z4Q8_?C@=)/4S',)S2=A@\/AF9';P?$'!HHM*C=.*$1&CR(?(J]I67W MAVJ@4R%VYW<;5<5L=)F'#-G8KQ_$BB/0Z5PO\P;$:R"FD50_6T.__JSA-Z7[ M/EYD(P1:6BO1\7&==F^2O0[/!VN%CQBF$QIOD)C?J!HD267]4+KRD#7.>(>9 MW]ZR\EL0I6T;[9.\5/;F2X_>5:,":E M_QLY_R?S"6AHN!C:AAVJA_,9?1MK&(9Z/(*!PVZE(YF%TJ,N!'63EF+\SGF1 M9 _1%NU;TCFC-@VY!#:(UE_2"7C5W6:PV@[W(M1$5VWRE=/O&72LI=S0NISZ M"'WA#LJ.GD15<\5TA<,\X=OVYB+5Z;%R%8MI?C[[Y W1R4SV$YHG,2!-#8UR MZUQ';$W)J+]@/Q.B4C(M0JV0NA5EGWU"DRE9E#8#P:)?#62XS@#;%STB5GJ' M14Y31GCM D5[>P9+N\8[W8P/)'9BXLZ("GFH4L2\*Z,W466V0S8R1(KM- QFHQ@?ZE);;AX&EV/;& M(0&W26JBI"&4G9F:B^C]+4!?EA88V]B4I__UJYJ]#:;TJVTO6=SQ^R6^_TZ7 ME7L\J\QV["SVZUW+]8025(/XB*@-Z^0[PQXEAO@B6))#Q;#@W5%+\XM!%R(S M*$8VULZ8GY#<8 A N\DI6%?:_1I2ZB_:&R!IF'WM=3WM6M&,EBCA@*;F)=UN[C61*0B0E3>628\7XT"=IOF=F3)A\>@#.*GO33H#FQ_ MBOV7@FTF0M('@<[UY9;9@9"50VW*M'Z/O/*I0OL _#D3.[;%[:2'A!3YW4WO M"S;7(%?3#5YP$Y;Z?Q0):K%PAY?>,B&ATL5[=\;IVGE>>CG6+04_JLBN3@Q* MN!8M=*YTJF!>[A[2-H+KA:538Y[GG3+U9+^U ,4F(>;V,^$#[_O51N*+T_E\ MG8QG1CS])5JC[(DTA'RQ6 6 M1'8MX!SF=SQ/>>E+!-G9800QX8Z?VAZI)A>B_Q +-*??FU88:;Z<+F/OIFTI M>!MM'&'X?-PY#\-2V54X+7FT/'CCVE*_K\#,P*%=+Z'_; H-I0(H3S(2M'95C-.7>0K'N2BY-VZ+5C)>&S3Y)A+L)>*9)M KA(^ M-ZQ$[?,DQ5Z8S64-M/HC[)?ZLNP8_ P:Y5YK![(] M52PS/=!LJ&QC"R?;7-Z?C2[4:@C/O(5,?\TNFANW,LMRR4(;,#2K88?D]" - M4342'?FEU@S7BRI/AX$W\!WI<@B39/MGN87*Q=,J^' Q*7&!^)FZG?R>(.FG M_S3T4^J.=O4'59_'QW-V#A[CPL9?C \5!-9W3'7P;E M-!!%0H.$W[%Z;VWH:U?CE^.$&.^C6O+B!\AH+M>P>.6?V[]'Z7_GTM:?*SYS M2M?8=N/V[CU"34:S7F![?/SZ\/F- 1RGQ6V8?666:R>RAWI#);HL/_\!7AK" M9RC=FZH]R7U\46N^^ MJ>S\1,T.A(W"EBQ,%#SABA;P8Q,T.$([BB1)KSY0")H12B[^.G."^SIQ'__6 M+%BUVGV(P&EO?O>07+%ZMK9_&W7#.E.KD;.4Z+^># & RL,I6U-K.G@_5;Q< MV[-YB7!D0=WN0\7\"QX[_?>6)\0TF'H.QS@:TJ4^QG#A5H)WZT?U5R16#?+; M$NA,0D1'[9E 6R/.KU5S?W- JV2NT;(53]K4;IY1DQ3(KH;&AK#9@_$?_![1:SG%M"ZH, M,;?-B-S%*$TU>7NV9A,IK^(1S;*IX]A<(^$43F_XCVG,CN"T:*F_S MT7J0T_ "0@N;&>^*4T3H -2GL,T_WO]6.,L=!^+X;@BU)J\U1_6IK!UOQ;'@ M/28.8R2'Y+']%&.#:L+LWE5^POR#\@KC8TN6*\Y3CX_$)@(L$K5"CDW@&A/@ M:T,'^FZS50S=0,0!2#7?(G)-]E M*1/,C S!$07LKQ4>?OC:?2Z75RHE*K6-\%[?O*VEN21-ZLIEQ9\F$QF\+2BY MM=3>(5"NQH\A2"!'Q;Y6JFR[8Y4VYAB(>C WQLH_,\E&&"0VX);T?9E]1L_7 M8(+FF[&Y]0I< 3>:==>*8 Y=.=L0#/R6;9Q7XTC?UD&N8)C /)AGFS*MD6"> M_?,W6M!3*'K,SF?><,](S?R9;42(^6+*:2/H0_K,Y,;%]<% OII&9QN=*%R7 M$DLYKY9M\,TRS)Q1KDNH@I_CUD[]/55Y3ET-5L8P@]'G>W;J IHY_6K2:GU> MD^GP/]VH*MSN;6OIH M3?O1-B)[[KNCX'_7DKTS51BZ1$=0N"=XS#9I<7^M=96)[VBQ]G&>F\ZN0R J M:>6PYH3F:9G >=>WB]^=L_]"3U[RE.Q!D>-;]I<$P-'TV-&9XE6]S M%SN/ZBW-Y%96Q&DX@S&@?:#C(2].6E:#5)RS&M^U:#8-FDDQ'K /DSQ01':? M%HN2QC'CA5"J637!2)OF-H3VPK0O+9 C24'\VRY] F*#MKI=Y_GL;3/C!-D4 M3@4U&D"T1CD3D4.ZMOG ,(A6#!MB :9%!!R=KRT M2)5/P%"UR^&DX@G-^L47UYW[#S.[CQ\(-84]EX7\YKE5.=X*G7Q:%=MR>O-? M2[N%=ZTK%$)6-L)^"=SS*VK=?7="DUP2\,!UMQ"@$S-[)#MRO%5TZ,W *!WN M].V\7!A:U#A:7 GL')/:!16]]9KU$HX[K"FHN(4.K->OCU(]P(;.72J^VFU6 M\/FO#%>)HUCPN\/+(P*/+:-+I:EYDUV&^L[N,0QL#Z^@0M]E P"VV&2ZA$-5 MM#9,J)[4D$V)WXE@D':=4H< JKEI/1UDH/VKTFOU!41$VD6'#N_K0(T8#MN^ M:MB]+UK1=W/UA2+'Z)8;+<6+-:QX IF;F<*'0_F>8FZ0LUX\_QU _1=TYW21 M07^FR\XM$^RM.M>>001 7I2"S1*@HHZG4008,(UAOY%8J^9S,%8R-[< *ISR M5V;PTG>4,HN2G0E*=.^I"!F_J='ZH<:XOFP2?5EFM#>$K;1D=(0[1K&B*+>X MP.?JNK" EZODTH>_=O>CJ&?347SIRLK5L,-A>.; ;LH)31)AO!P7D&CN>D*S M&WU"$\>B<]@/WS]K";&>DVK\+F+"%/=Y?-&S*;V#T MN_+)$==N>> ;U,-CX^(=YB2P[2YI[9!367R5=GE M2PA8(>PPTR="=K63 E;+=VS>0NW/?LMV06Z1N/5UN6V0[0XTO46/ C\[F*Q[ MSF0Y?#)BII[0\!J9B1?0-U3\VYE@[3[*=L3C?/VI7U90[/?+#GE6[PP/\OGF MA2H>$VAQ7*" M.T)POT[@&075VM,FR)9Z.FW\G3=8Q09D4E5QKW 3& M#F %%[0,PE7L>1FZT_I2/BZ-QH*4OWS@(L[/+E\(C73TNYJ;N*3W)D_@]@KHA.8F7%SP M)Y<"/G#J1N00DDUE\?"ESVAZ92%.^UHV,=3B.EHG+S4Y#&;66X@&V'J#CC\NXHO=]\(3UQV@53=,K;X7>M*QC(U3TZ)RREL, M18HUZV^YAM>IHML>O;QB40V;%7FW 2?H&]8E_>3P$_?[TAL4(SC\Z]DO'&UC M%)HJ7JIMBYHF' J@)_51I1$_3<>XED\06WJ6UM<9 [5(6[K4)@9FM9D7I'@[(#$"0_ ML1R]$V1-\< VL#N$-D.KX]O?HKFC:5IBX_(EP#:!,ECRIWV]\O5V8%+,@2 MP(ML(L\6JQT%RZ1^>/AI5/]UE'M)NYIAV7B>*[CMR,B/*5LQ]A$%+UVI5TFS'>X,LOKNS%=]L$T19)FJEL[]:;5.E2 >NB M>RBXO*77W [7'R=B!.3);UHEQ;/,FK5$+S@VOZF/L)GAM'%SQB2Y5Z+ATKTD M)6X5_%<#"']:)8^S[R-<%MH4]4+NQ0'IN)1R4>&RMU)KDA45ZK'&PUJT.Y[;FABZNPW:HWK;& ME:.<;*++!?NL.WM0KJ_HL?]XA3CM#.I8[3?VVU*78G16.!I*\7> +^'IRS#' M<7R)#O<,=X#Q'E$W>O]I$Z"?V:Y6J*JA.]IW#"SQ*4_=Y3C""6]+R\,5::<" MMPVJ!OF\$6WR">P%WVT<$LQKQ=ONGP*3#/5VZ4QYH^'[E%DJ@P)'(@9P!(&O M^P2^CK$5GKG_G;Y.@V>]"0.QHWS)^8^],+9=4FMV6>)XH\.O;U'$ZG/BPD%M[ E-R0LZYX(M.DR[PF#'KTD6;7_\C_A= M^F%NK.7*\8W:3=6OS;72.'>?T$2-@C')"\XO'=6P:7^TTQ7!Q)S"[3Y)OJO^$1DNON95?X6&FLK<) M;< WG9W+G%LL>LLX3*X@&ZS;!"_:W^+'$;4U@&]GU.RKO5.A4[R85WW[^U"4 MCYP8IO*Y.U1O8RRQH\A>>-F'<(>0W:3GRBSYE^SB7*-FU?>@1HG MPPRF>@8,M''1E(3.+N2HTE'7S73,YS^CA=.'>%XL!(BF1VJ5:-F!H$BTS=<) MY?N"Y[N?K,'0]M>"%%KMY0067).\J@7THBQM0W\%T:#;O2W9(3>,M=D'<60U ME4<6Q5GG"_@\7/TT"L8 Z(1'C#7$0PTDZ1K$&M2Y](U&-7SEBC\.+3"-2R-Z M1[%[XW -#_A$J/6\DL_UC<$IX[J=NC$A(ZH'/4$TWRQJ*>0B,8JUR'>32617 M#"(-DJSP "&H7WI>WOX$_?9_JC $S<73H\A -1LP%OE;6(!H X.FH:!(NCOO M_4*WQ-/X$-5"9SVQWM<;E_0*N56?YB$9'YE6--=BQ]4MPMV*C6WPL ]93S6#,AKU4=\I6'?)4O_J"ZE?+@>7 ME)U)!]O9;UB:TZ+Y!QAO!;;S9#5_-@BQ]VB5N*)M262 @%+*>-M5T$!TY:0V M"%J*OD1);EDN%?^UB$11&%IQR-6,TVK9Q+?KVF- .0$(_?C,KPME-M9A;L 0-QO8BYR@8NZ*4(A)WVU*17XU, M B,"T(/A?*WU,HBQ0^H60T> >?'ABG#?X-)R5N?LD"5AQ]W!3M71'TI4 ;_; M+MMN4UMRK'0O_MGTGZ?GU!=6C+ZY;ZC%\_VJ:Y8QYE)CJK9-2Z4P:,[-"F=$ MB'%YQ_H<)'/<+@+2^J8R4#,DH>#+79_D9[HVA@K>[S8D@H.1U?/=Z'?\8+.8 MG.2/5PW6XPQF2)ENT? "=P_]+!')%-_"+Y'0J^$S7T]#C^=< ME>>>8A3GGE8]-G\VTN8R#/+8[)>)DGRWTI[CZM7E0D50 7)Y*Y;T@_>_768/ M>/S3E],?'CNM:]251:1.FDW(NZ_3&LUWV9[07$L_M=F_ CNAR:Z.7P>>B];XI<)XQ6)?SBRSMM[UL*\[D+JS;U%H_3"E MV>*[/G^CL\*N4%?*\@T7RX<7X*JNRHL#P*P2K7AEA[=1E,$;X$S&\+W7IC!L M^-:<4N_7]:->DA?V$2A8OBQE[WR;;G![THAXH6L=T"Q8<2A2BTHBK3-)' MI-^NC]^?D-C#Y 3.7*K:;./>Z@*DY_SZ-Y[_) ,Y?RR]K("]5O)-[>'+SX]& MW+\>Y(M/:-ZHKF7J7F$(W _I#22:[,8+3KO0'#'\BZYNJA+Y*ZZ6.W(D&*Q* M*#@^7^/&? CV+NRQ;[/BKL&!$.,JSU#&8#)PARB]B;?15YB,!:6J\[6YZK:Q M D]>U\:>:LV5:#S\U]R#)NN$F$&9R*DG8\#^FVGQ*(L(?(A$T0XFN"C/C. M%5]6)N6^(,6'?CM??SIY..;R0N![P?VOEM-*6I2;^I@ UZR#R@E-RM$/7[ U M,L:;C;FUQZ,G-'MV/Z >Z\9T_V%AG]^G"V:+]0I]>ZB^0+Z.71W([#/9 *M7 MY$-"GH2&1/UGG>3^S^-"]60YV0#!FFAD7IHX0L;HNO3;B4%+Z/HTM1$>N5J ,>N_&Q6]?WRH:5"M>D3FCN.=8Z0X\$6V9/:-8X3FANBQ3LY0]O M7NK ]O2ZAO_ZK=1"W'6U RM1"DEYUY?H'T;+FIW0B+E?6;%+=XO=5UAS.J&Y M(1IZ6&NU+"SR+DHE[P\5(,;NR;W?*+5V,+>>/-LN+;@=OZK#?S3NN'P7((A; MQ8@<33@OD^[F#7QWA^X:]Y"R?56@J\,E!;JM9N\NT/RNJG-E;SA8->$AZZA< M^!;:?_J=2(J-\>'\O.W0F'#"FPYP M]G)%=<5O@![Y#HTQ1W#X.IPD-!U#KU MU<'9@3@DTZ-_)^)IO:_'EZBM4D?':B+'QL/7C.-!QS\.^W([NL=J2^(G\-V% M/3N\;YX\^8KY?Z8_6;_GGVE"1-:.O<->PEY?\+V>2)[IT84%^ 9[R](SQP2V MSDJ0WS6!'3NESC#H023@_*8 )EG?#I-9DKN(AN%I8_&*6L'6U>#,(9O-G#(, M)<80!L:1D*QKD5]:GT_=1MEE8 KS2R(\:<[SJ4!;S MXI4O+R^3[9<8:4MTC&_;FO17\;3-M 1JK8;R=[#GEQR2T:3AP6I#%OE\/>UU MB\M^PHBM@N:[<-%VC@8^JV;TN* M&LF68J'W?C9_X,F\A$TKY$#Z#FGH<>:T;'%P#@/*@U6X(S-:M13K&KF*1QNK,*X)ND1+WFO[0=G%]VZ7V9L*; M(U2HH4"'WQ706" ^$LK>PM\[]L*C<-R>Q%(.RZ>T]O2%3FH0NJ)#8T*L7Q+M:F@=!TCX6_,7OA58]ACD*Q_7N8 MCK(S\17GZ65O&]#URW.LYF!,JTVH$6;_X FXU[L^F'X,8LRBF:C87),SC@WA MJV)B:AN";CRPG?,E/(Q)OJG6P9":W?#_FTVQ2 M"@V<$AM"QD\H!O%] V7=3=@DOE(YKU"HB*R67P(#AV>D$/\OY16N!6(H#:R]-//C;6ZJ0LQM[JKR.-S>"1;UO/V MR4.6?3=@,>)\-1%S00G7(A;4W.2"A?C_OW"O.S=EH MW4[Q==:[A>8T*W0^1#8,.46]KK_P, +-L7MY8@)G+]K07UE>L?%T+4:H2K.T M#W%,Y]HZ5">EY>\2/5B_YTR%-]K_#%>M6_S8T[:@KC'!>$A$#$5!R"SV025+'5=VEZH8^'\0#&) +U;/L2%V=0P7QYN7R&C7+1)"FD5);JT\$ M[11=XPVPEE\3:5+-&NN.MM&R**LL(V:P)4N_P<'%(BTN )3RQQ M;4/K*7,&#R9XNP1%-/"RK-(V*W)_!+'3A9,L'IJ_6'B-N089+Y?GFX6."W@+ M"L3KYM0Z$'5%+MZF.(@G-V+]+#)V797:RTG MG!:J)L++UD_K /M#'!>U&)@CAUPD;I17R0=:$$0K\P6Y"TT_^CPU)P,>Z?7, M?%0R> J2ILKV^X!RXKL,:;VJB\KN9?',.P^?W:.>[?4'-.E+O(>>T"C.M_D4 M\$#FGQ=+2RJ6Z&#KS7MG(GOA;F*\2Z.-[9K9R?_P!I_2=+0+"V%H[OJY55L MJ*H?+V^2RP!G\,^Y;7(WY4V[ R7-E-6_!0^P0=LH04HH1#_1.4FG![6I0HD2 M=1.[BT%>0XF="4+IA/3)FV'H:+Y?OU4G79.L_5&J&]>,#C3@M&[XK>2 THH] M)8UFB[FV0(B^7UKZY*VA2.]_>=:C;W T8N'NK,Z* J'VXC)W?X_1>6KM+?3N M.W1E_\>19BHRD"5VV7[FV^C&G]S$?\ '4 S3NS\[O*K=;P[]W&4P)1X(7O7-*_F]M@Q6J#7&?C^VG>P\)L:O+ M9PKR:W@"W^W$6T'B.Z)6M+=9_:Y\+LBI-0<=*?2H9^WFCFP?_DQ A_M'+76( MN^19#3W?/W+EG'I\H3K ON;BU'5OXPM"0=0$,?%U68"T9#..\GYV!5$5I)?P M"/WA6T&%T$V+$S)\,94:76.]R@H2LW%DCR'$5R'!;0$HW/3T'I# M=>[+VDTB'\Q'';APF#IWY)P\_5;RX[!(.8:S7#FO2F($(6%>F;1O-7$G"U85 M/.2I[0@ U[3:SW=?MBTB8(::JUB3U_QM/OMJOHMC_C.*/,4RVE?>OE_GG+_P M9D#@F% H6ELP^[8YKC_:HJFA#^P_8A:Y:XUA6@U&W;04[;V&X4QR,"DYH3%" M!Z_93W)]NZIQZ"XI MMX7^"-S+UU,-A,PM'0S[,=[+55+R$WE)=0Q 0'0;>0#D#-#%'I&T4' 7[7=@ M2+W<,GS\MJFSJWS--QD,*X/45"2PMN-T$!2;\'I#H3>3!"5-T8 3FK!;7>X0 MM$].1U!O"=X'B-K];!V3XK:54%4<(B'E=T"[Y%+ET[M5(=&C3O!)5/.6GU51 M"-6AE[>BL"32%K.^U;/E[&OK+8=Y1%U:9<= B+[*>M2PGVJX9BX6!]]]C86FM;1 '1 M'56=K@'Z5,;)._1P-M77&&SPF$TV^;"31_>L8UR=2@ MD>7'6_*I#"GARO'0!]%+W>5.#K:M@I*)1M#"X2+-)<81%H@K^AS]M\!*&VM) M\< OW.VJ$ H,GB1,Y-46E!Y$EQ5<3)*;OZXE,ESBOJ41W"XO 7@++E!"-XRF M8C+4$%G-YPP/KP.+)I801P%+N&1$.C>KBVT0%P2$A4BAW,S:LMV&=]U6,;.7 M#D0FCZTTV QJ!)M:2]N=H;0Z$-.]5#YOQ3BJELX]??:+/"G'TM]?B3_U8^IV M8*7_E;WZ5H6S0X*>83%!>_TM %^<%.X0Y'>.9$RT.XX.[^:@E3S^AN_'$8^[ M1QEELS,6X_5^3]]Q2LG_0 TD)G[9B@X_H:'KWM"6.Z%)')]+:,RX[,J!_!T0 M,]N- &?U']-6L 'CKC/F+^1N=PO;*'[!&LU\* ;*\98(B()+NM=SC5*U(;^Y MJ$#0N.8?EFH8&D=>)BQO,ZVE<3:S@)M7/#VKH\KQ0:>G-+P6_8S<+=S%Z!9S MW-:\%&8QM/I5VIOZ![A4B7";)0"K!\WAW#S_I,B9Q8G-#0YQ8XS@6SC M 1%8]B%&7I5UDA)?5P5YP=Z6@M3RI]Y6U0BO_916.F?L%"$YJNR^JYK^D=FT M:#YNN.?2G>,&(P[SCBU76+=_^,%6C]I69JI%DHH%9!,: M9ORJ )-A+ZL^!U@3V<[."@]YK'\N]):GN%UB4FEUU5O$N=VH?K?=6PF:D:ON M8DI%SLWVF7FNC-NN:(&FO?C1>>![MU\GO[T:\=\H-GXWL(*[AB!_Q853!!H$ MJ58<=YJ?M,VF)*3@N"ISZ=%RC>5O(2"[(UH\\*D!33Y^MS$6;%/M@.9(=U3. MDV_:%GJ7;R2^G;_1V [15./GOR%7^R7?&EQ?N7/7\,I9K>Z$YAEEO+(@\!IW9;1A*OEO M//]A*>]U [:CZ%W2'JI.ON>1Y%23PH;.L^/MBAT5KJP3&J8KZ]>?!+9O!TQ= M![[N0WWX(]E/:S:[&.=IIW/5I -J_(HS5VP4SKATCVX?3_T0-U]+ZRHTQL2Y M=(^V\Y=O6SF5/HJ]T_ABI."E1H?_U4%7I+3Z-7:7TDP(D)HZB/^DBP'IC+OM#!H>2O#$1.6A_AA_BGWH;V&T3!@G(6$ MS7N1&8LQ'9PV,ZP:)(E\M"MI>* M/4+@S&-#^=Z>2*UYE*[JRN3PUI.(>\=7IUD2MORP6D65?CTKN1+]9]=BQE2X MY_7 4;;W,L2#6<,'9FBQ&ZYVT6X& :N)?W*)&$Z=/4"-D.]K=JT<&FU3%RR M3]D0E*T@WM7'>'1"\U+U-=PNFQ2[Q@6:K2J9&^'S)1QQV/^\-I\@>*TY"6#6 M5W@C8?1)HU^5)E:NN M\,\GE)8N1%;_\#3;)+F8/F@*J:Z/%;F@F=PR\$BTO)=[K+"QA#Q)5@);U7K(+ P&95Y\",*,SG%5!D]*[1^5O MHJNRW $V^MBZ^&]W>7+$Q0PKN9K"G9N*9"Z;1>N*+,*6:(\B+:"JT,?1Q@(% M=]0J-TQJ'IC.6E?I3]\:>Q+L3&B#SR1J* X;\FFXH4MSP1E0,)]24\GMJ=M[ MVAIGTV&^+*XV$(P1PJXG#LG2"!)P$:4 \G/*LI+EK'XG=;UA&;)J%\X^V)C< M*'4/???H;0?OBG*AN;8IT::KT)P(P0>Z5"R%'5@:QY00^A\;F(HV*+\IP739 MM&EG)+>Z<[ICSD."D[_ZQ30"IWYM$.AB=61QDMZSF5-!J M]@A0L-\]N[L_KO,BQ"&A71%FB]BPDJ[!@OO?K.4$]5G;RGA>^*T >W,5T,6W M'=^D-=Q*KSBXA-CC<[:Y6W< ME=LE=YK[NBF*F0U5YN(\7/4K5S)+,TG1LPD6(ZN12;QX.2!AY'9.^FK\6>UW M(@;KZ7:(D=[\]XWO:O;\^SBOQXPK73UK]\9*CT.]6[P,]V#JI8OAPD%2GHD0 M,5[8KX/YEW^/JQ]4J]1$/60]\S1;).WK5MHOA?H\, M\_%U5G@+X[MA\'L^!$W1S)'8B^1#L.W#/B@:7T(6T'Q#?E_G)WXQ(+(2J"3+ M*'==]Z.A!B?@-; E M0I7HKJ>^W.2/,FCLG..;OG(F/OA'&9?/W:\$@@62[LXH>5\6G60 XVG1-K!> M]-T4'G6'U$=36@(Y:4VH 9(A;X53"O !.*X]Z?WWP0$E MEIR.NZJ5#C=GN7[IB _\40$V[I?&%:UH #_2,5L/.[[QZ&4S\COOWMDI3O& MKLHK&WPXA5-Y2E<[:V$CAYF8J:)-J@(67Z.AL79U25GV7QPVME;+Y0M,)E&)&%4G@_M_>9S16RBE) M@*4UKTH;OP[7P[/Z$(3M;'1W@RPYGE&1 (DOL2D:=)'6DMML:%+D&+58^X1&X'BDTH;F^M].X6<,9*:G@"]:EHR1&06" M\H]S)F&(RCL(5=):7C/0XR%2)[Q4.^Q58'@X"0UXA)9?@6U^60EK,L59LS?S M.[(F[)5@1J)@]%J&G?/:_I0ND<"KAZG#SE9WNB;?HSW?**?)W2-45KAX3;57 M&*&FIU41P3='4[Z[A''*8;F;C9NE^](B\W",9GL(MJ-HD1,$SB_ LK>V=.(U M!,0*C&\(BXQ#;<"8D)((\$%N;GL,*UZ!/SE";&7R?4;2T+-R0[:>F+J9JJH^ MS_%13%?THE?0_)=Y#:8#@QR7IH7;'8)YU)C,401Y5&('*"&78LR#+VU+ C0Z M"/[;QTY_CTX=0Q$0(%(K')0+ XA]_9_TELQ]_;%L0I&_JF'"J0I1=][[:@,L M1O0CR5-\1**LC&@>RW4H:I$E^M+W&_2;RP MM[A6\/G@\PI3@4L5K3Y*1[AIN_[,6%.4GMS^Q20_5FPJ-[M!%3?(9=.Z[IHU MWY-OI..H-1!M):]?1Z8R MG*=OEF"A];B_/'%X%Y5XHY L';"A/J/*QC9LTY/6 =.. *DN_;J*,!:-L[,5 MCV+ W5.[@"L:M8AK][S7+@0PT!Y^&8\1X[G@CWZ"N9#'ZH2(5Y.]2+6+W. : MTKW,5KBFQQ ?;<5,3N8MKJREX\QFZV.T$FU W,%F:=_L60',[&_!^P!BF[T8 M1M?#A .U64_OLQ8>ZB+]].>RMZ)MV,&+AL):ANQE(*BJL79'DZLUOQK M?,DH'S@SE&4W*<_.;M3U[7P88I"#]([(KY0V'LC:978WS@SN-1K ML_+U\+3?-T=J5%EI3&@<6TL'IC&3,MA01=3!8+QUX^*7E(SVPG5Y P[UM;'. M6PE>I;.;?00[0_6F("GQ"F/]+CM'-: [8R<.:1("3,;HJ)_^=B/YGS;['Y]3 ML)<7/?9^KT#H.3\<&4B%9AR17)==[M0R7=E8>1+8P6BT=&T]E/U*S[_$;'^@ M.YCK?N@CHZH/',).=^*E?0S1-I\5!0:"AZ2'(0IXB"0.:P>6J]R^F$YIK=V_I05I_NCOB\A0?H]N3J?_8:!>>2F24GD[1G88C.?SF*A]::PDI0>CS9NZV=[P3A;T+ M9:!"SKN\5%\+15I<\I!+GC,KCK\6]MA*H_._J,7R>W1!9.FJ@&9% M-S[I::HN-R MZ_(^.DA6>C(6-5_R#!P#-',6*%7%&+%3Z]:NYW_9;:'2]WU=:ZJ[I=%L WJ4 MM&7V Q-BZ-!4AP$OU63L;_^U_S\%MCEV /"FJ@C7"<&R,K*1M4M8&W<#@!;G MZ+ X,6. 9@!!W[FCT2H%Y=D4)"83/=:K)L>78'(@/S[R7,M0%T662E#@*M_1 M>_OL^[SJ2Y^6JA?L=W[ZK-TM&9)DAV(W<.\WA.G#$'@SSXS_&^EIP0NW?*' MZP^O"#WV^S1YAC"A\$)\K%5_U!S=EY[KHYM]V^]HU*?9?_IGISQXDOZ=3 M+U*P2U%UZM:9]OGWU]I_:'6I:)TGQIL$;5\LL9YG4W5.#30Q<1Q8CRA^=DB/ M<\:T)%[L@0&0W" U#X-$G7G9%^@$0W(PPQ%[VI'"AS1AWE8 MZ%XI6KI[_Q$!&,!^-[X^4RT_LT(V81M4:+-L(&3PD'J&Q &C++PI/:'Y67A[ MA3(/H$+:1*.27S26C>!7,W7&Q(?+R8U;!!C$D?P$;X!TB1:GA(,WVL7DDWH2 MK@S-AL,/;NOH/-)+=M**3,Z-'9/<5"QQ-AJ\Q*HZ,+V__YSGS5&8[Z_.K9X7 M/--$S654F5_-YK)XA"1=AP_/"+.F\5 )45.V1HTO&,H6)K&S>C=]QTHQ6Y!> MU;;=F*P-@UOJR_1V"JIZTFKNCJK5CA7BRA68R^X!X.%<&V"?3DXF^='^CMDX M>O3E3=NCF/%"_89#7YXBP[7VH]P3&FBE[@IE,,&WL4SCA:!/]8%%W=L-DUHJ M'K@J&81#VQBEQ7N@H4A;6SR+LANZ99*D44YILH$ P%F:O7@6Q3QO;36Q40U; MR5?_]B+QJ?BNBK#3J@(D< M>/;8'6ZO5V[%NU=!F=P5$3[2I"84@VO$OK]%TJ:KK]>$G2_C&'MXGI/VX>TI MP0HIQL @V(L9;_HBU'K3?)L*O[FH/ MGC 51?7@$U>+'KM%X1ZJ>S,T891'>!*N!7U'8(.TAMVU;-:*!9$OEV532C!9 MGWP!$)QB)DY9*UCW+UD36V*EG)4EN3HY<]!(*Y#J.9;;)$.;17.1=>W!M:70 MEOD10*FYUYPWV#@XXKJ@#B8D M(M/_[ %B34&'JOM@A ]UL;=?_X2FO1&\/M-Y17PB^DVG,XK@01[/^75'(?85 MAOK@IZLM!>:UGF8+R>Z3_=RK=/$.((ZX)N[R/ E_N[BBA#GC,V6:B M"P5>/NBYJWGV6MA5;%BF7Z-*D@Z;R'SY0ZD2G'( -AYR:]0Y83JS,CYYXWR_ MZ.=\$U66Z1TW;'T?63VE*EQS/#)=_YF1S8\I04L"(V:1%].V!R8=*+:-#K## MP^8SQ:6E=[.5U.C+,*UM[GDIV![;B!LH39OLV9O5T37G?@KES=9ZTK95ANRZ M"]4I\7T\9WD@M2-AZT"8-JWD_-$598W7CI]>+Q97M$>4VVMV\Q[ MLO1_X[ :TO[-8:7WAPZK4T47!PMFGJ:I.K'>R6I;QE;8&]TVOCF?&Q%_LTCP MGIC[D&ARTZ\5;6B[GK?;!P8VNXM@+<0)S>-F+2P%JX6#H1M30J24T9Y]MX+Q MF[Y*G[ \P>"J @_'? OLA++?!EPTSTZ5#0?P<$23?&TD1O0_&3[C%U%J^,?- M+*Q.:2ZKR*YK4U)X]$=T86MXDZD6RJ%(+TH(.JO>%DW:4C.$APE^M%"_BDM!/FKLUQQG%\JGQJK4U:E/3&9J^4.\*(D=T+CZ&AT_XI!K1YH.X M=H;O7%7_36^!SP9!73 MRC$N!_21-0[/8G^817Q;T(7F7/84JZ/C#"7;V*D34B2R<"N&R,(4:7:V=64; MW1H#N_/(S4 6N%,?T +X2W1#+A-J4$]V^,S'ACN+B['*S/4A]HH1NF1YB)O]R?$/S8YTO=FV#L]JL"=U-WP&#=KCYL2/QZ\(KM]2$;Y MP::&9F>OD FQQF_D2.MZ*8>/Y#W::NXY+KW9:.[4PS3FR^4'./US P__P>_W MO^S_R_Z_[/\OV)F8MY^ZES7VUQ;,CFZ?1GT^H;EXC!W_\6C M'_$:D+CU0F- M[@F-\:[,Q+N?B)Y]1/=TF;8U[P 764-9E84?G8N6*0LSW2_)&&W/">;E5M5+ MOI>$ZZJ%ZR9&>(QHAPQAA[.K* A@Q8^+[DOY5*AC-#,ZFCG/%]WTY.?4^W_= MJWY^6#-V+=?K\B\#G:6P.W6)U-VGA-Y1'P$]_X11?T+)1HF&.E[[/!)*@IW0 M)%3VIJVH%DR:I #UQKS?J"P5V"E.\G'- ]534(:!YT.$S?.9N/TX__W;#O/!IT9EPW72834>U M.Q:L-,"<TC7B]Y[W* M'WJMRQNV(; M)8TU^F1C!O@4&3C.*PC=^=((B=1R2871_TJ\#EAU?_+YN_*7%V4]GDYSN(QJ MOEV;WQ.)J+:M>KD>*47IKZ,+MVD^=&ZG1QQS56GL;CXQ7 M"X1SHXY5(2.PG.TJF22"EK !_EFE"R+]#I/H9,4%J_$JH\$LMYJ.84]' .CS.,),':#J4.&0US M]F[/TP\;)=!-:?D= $A:R8.MUU;79/0'5\=#!YLJ:NIZVOF!E$AC##:K2CD1 M. PMR27I0P=O!N_8X9L.W"O&EM='TSVJ#>X8.L2GXX&'PU$?5>-FVGUR,VUT MS%N]52$V(&UL=!]L^%E1&<;*CN&B[;/(&PRMS(V\37RYM^,4[NGT$_202_^' MO?>.:CKK]L:9&1U%!$>:5!E%>I/>811I06 (A))0!FF&$'JOHX)(1R#T,I00 MDQ"0$DI"&:G2)9!00I'>>^^OS^^]S_U=9YYY;GG7>LM:=Z\%_^2<=?8YNYQ] MSMG?SW9IO_#$AGB8^@@;6%9FS\TKJM7I5I^,;MW=G?\J LGPS1F@'1^O:B]+ M,U?#1RV_,W"A-N>X8F+G-ZCWTM.?<-29CCLG72P7X56OFQE*9GE-B"R)],=2 MJ@+U7LNS^@Y.].Q"L3J_'&"\#,P86Y@/@_B$X:6ZH$A=]V =A>>U+SHX5;H. MZYHTOH8(XLV?5YM9>&AWRQ*!AZ9>9D*FP*'S[E9GV4\;.*9_#5KDN:((F!56Z6"\Z\A>*@2QJ)ID&QF,=<"\K"_\ V M?L0VON[4+ ,NXPQ:AHI*NI4("X.)8XV=>H[T#B#DZR)^Q&')T]J%* ]NZ&8: M8X,Z%KC@G[E\;+D23#76#R0C4\1F$_C/V_0/ABWM7 >7C*E=\2YAC/I6G&*W M4'N:0H$7MADFQ$S+AIP<\4ZAD))%WZ+R>>_J0%;37Y9L.W[_BA4IMXCJJ_;U M=;-6F+C\N5"E_=X^/?&*\=>Y$;9=8L.C/81NK 8,NF0ZS%C:$+(.VP2=@SN" M+1LLPNCVKW;#U3/%?\N$RPJG.!F(R<:T :"EC3Y=Q1)WZLL7N;Q)^L!']491ORTF%J79 MF=T+?7OK#V9[F1V+V(YK%T5XPZZET$B77]Y*([Z^0+WY[O/B>F1[7K_YP>"6>8(76":TC?D^&9Z8N0Y5O'+[LG"JQ_GGUQHOXG,?PD$,I.=KL]ZU-) M 89W?SPP66G!OBF8PA%&([6?IN#!QS%/ 5;"T9C<L]QSMF/ER MUN\.9Y#.IFUG@]+FS5"J%Y?B86!&#\^,C>?L6ZB(ZAY"CWB\\:P\S M*NTE32"B&AD2=7(B6$1IVAJ<4,-R$E+O5+FAPY2U2H3%UQX4$0*&'VTY9H2( M4D7KNC;4T^OR@2F-"T58IMDHBU$20K\5Q),86G-@]R P%.,U7[Y :(B8@ MG BBEU81NM<;P.B1M,/Q_"C!8_>K67^SPE[28'A$0V.YWARSC*J/%LZ?D*;3CA+N7UQ^ M.9FAIO:9VB]IMERQES3A4Y6T%!/BBPZ;W9OII/2I'A=7W& MB,4,S3Y;((+],4*$"AW*0GIIE=X.=P8 _1^M1<-+W,?,PU@8[FP[:1]]@/8^ MREV&:SJE ,L\;N WI+K'3*#M#8C>QGU V%?HH/'T%O'H?WC MSQR,.)+_>5V8_U(-D^_X_.WDQ&K2+7^N[0NY_!QG JOXI[:\ MQ%,$4@1\KQB"P2X="C[S.NH*8%F[7YY<59+F,_@6\=&!S2G5.+E9>",FI W( M__E93-I?YH7\[__X\5]I.Z2SXZ[ZSOU/6:Q'I, R#W F5%\SIL)=Q4D2UQB- M112FHN]074;E,NC19"&&=HA!-8&L"V)9EF)E+W5"]%=UNXK\G*>OV*5PZ Z[ M.]MZ)+%34BD3Z90!&2B[M9<8^W[C62XW^05=T.EHWGI:+4)J^N7,J42\WR@M MI.HMVJO3:_N0'X/!6".BUVI'YQO>A&8:&>&PU?(#,EL@%AS,ZI)&=&:R]'VS MO'2AGWX8Y HR?K#0+M*P M2JH1;Z9U8B3[5JI1=IYEZS4SW0RV2J\\L+<=76&(VNB$/QYCG M!6NJM1@NM%^U S^14E,GA3>_G\ X^'WB-Q_["*"W_>^SM">;.WO.@? M#"VO1H5O'D[-%C_OB&[4VQ]E_ W_0@=H2GA(FH:+A+S5"S%9&=?4T1&Y(V5>BI$%P52-Z PZ]?CDMD<,1MZ M],-S&3,*:"+%'X@,EZRTAP15A&0/ M>S7&YHTG)5S?-;/%(%)RF=V$ -R0 \QI[?-W2U5H:5'3WT3V:U:'5@\JDE?9$V?W8K2EHU@MY+*__?:!_Z?B7,+" M(6>PZ4KFT=+LT!8)LPQ8V)L$[\9>](OIL9%K7Z:-V\5.O;TJ,,=FI9TA6GB/ MV)/5;();F#WTM[TZU]L6P)_ON9WRZ]=#_R=]^'=(EY*[HY5X2@BNS'G+HIJ5 M!?'+H<^QX-OI:H=4H0/VE7T_YM2IK;9 M&]I.36-GO_+<^2T[3)_QE#;M-@53M:_/!86NSNA# 7EME-S*=\EC[X =V(:. M'FAJ97@4CE,?7SZ,C;0)BI#Y5][I']C!W9!!V8H#[1MRS<\JS4K] M[XL2^:< FU: U'CH[X7.PTLP.<4/N&9TJI#$4/#0K3248WS5=110ZI2 EW0 M,)!D%5+%45R?N8V\I-D6;HJ/?YN*V_;O9V';M'; (,Z4$/@GJ^KWQT!?XK18 M@%..G;KZ;U^/K]H?>QKM^NM48)F;!F0/1M>-&W03;4-9,)5#\58H\6II0T:H MF:M_Z[''P/" IB* @EC^-.@?@11<#6')@#ICE(=]*^+DCGG!JN>TC>],8Q^< MO'VP%69CZ=X452=._&V^+FWJL8])"/,Z*DX$ TN&ZP607RZTZZ81JRW7#['P MQFUH>EOSL.\KQD5X'DLKD=6G,8B^*U)*&KV29I[,/82[@ 7)ZA;J88E,9I&*5)LEA?SX'Q<)#^TXMY M:0\S\"D5F2??IK9Y"LPI;LD$GD!-GAV^=H 8DP$>3]O@;8&62KN_KX?M1[5T MJXPM.%N0"4>JE(E2_(.TY^>9#"S6/PIZ&%P?#4U>FBJ-0N(6*X*::(KS-Q#)"20@;QQHLN*05K M?THCV+&UGWB Q!;%=2R!04/4X('<,6-_N7R@/O\6?\*="Q'3SQTLGKT>X8L( MX^QWD\8)8GJ 5<\*O4% 7I!UM@< !'TD5S J=[YPS.. ^ W/4/5!ZKI9D.M6 M%I.=7IY+8F1Z':S>5T7YM M%9[IS+42OFQIOX4HL9-]%4$V$R3;^ !2!&C%B"("G[R-CUYLP\1Q+5PQ.E L MQF==EEMGJLM[+MO9_%.LTR-\=YUU \#GQP.Y]:*Z3!$=;ZZYKS\#9NU8&RZX MI&'-MD^K=$T\BTT.L*=KNN?*VYT8*\!F0KPKP#Y$R96@VS7SRATC[$&8J#BA MI55K^Z,1F$21BD9\3G7N@4WRSVL'*F;-(JY#)<.>J@BY.J2!M;:[RD_^\#V- M5X,4^:I#KQ!=[U5^"J-IZND0O.!BQ76FRH8WXKG+HN<*B+3_)QW\,;FQ_] P M_Y)&(4#@,U6S;UMR*T_I^*J$CY-L6)3AKR>P0US8P(#%;+XVS^]?=I MDAL_ZR$>N44AONL0^-VR[+#B_&[Y@,UTW86S4]/.Z;G42-6]/KN*W_XT*LVW M.1,C\I"@L'3VB JJ>)+'A(9;!&;=!SJ$0XRON77GI:N:4C%93U(]J46U>F9@ MM'ZS6]L@DC$7ZU\)98=:LXR-6VK[7M+(9)<)1(_E&VG)L*K4*OT0\:2."2VJ MZ!',N#TYPR6[>-=M;6VQ"6%ODI\Z^&$F!R!N3/ 7BP8L(,'ZZZXR^?%L@N^& M1&___+4N)UT,U,(R;!1\R"W=A>7NED$J/2A^#!"J-1@]+OG&(&A*W[EW42": M8(P3 J,&*3E0\.&L1I:VZ.?U\YONZ"#KL?"@ABJ8;H#,4F^ FJ[;F68%[6*H M9!V(PC;0#7=S+28TTBO[J]_'M')_3#Q7G69Q,O*1)%VT8XYMG4. I_%/&U56?H#U] MA\XSR^KBF/TWB8>BPS"3P>X=UUO.%+8"EIE5T(!OAXK)LD'*\G*9C>;VMDBA MPJ>AM%OTG0;-(B@V[)=S.K?M7';A!;\?\[Q/H1BK:HG00F4(F_[\0#RW_V"J MVB-KTFYV^=<:X$MDNJ0)4I[:]8L/92PIOJLX>=.^20*[H;-LLT79F@5>K.2? M:(BV>HVL_CV1]MN8[+YF;)FBS4=+(U&2S/,@.ZE:B!T2(Y4J.LHRJ:5M[T!? MC-?_8:)@K8T)[%V -JA""EFGK)71>H7E^3N]=81OFN1:/);VGXT#_&R"40E< MI/53E Q&+5#;KQFOE [)4Z28B[Y6MI M1O9;_Y;_[QJ=>^X:](Z.K4*:/4NZ1]@I?!%:H0A-EC;"1$G]UR M11AOUH 4HC2^HD-+1P?Z&4PM[J?*E+A@QV5)[P816M5P*O%U;W%OP=X\W*[$ M,X?/]1"VD(' %UGWQB]4":)J'#M4/(+DX",V*)[W8Y*0J\EL'9\K7=[/^L; M7W?"8_-N!H44]--FA533T:[:T$G>Z]" HO;X9!320H)\,JPI/6[%*];CH!Q M+3M=/-E29:W5E!\"A,!?^,THI36(L5 KZ,4-#&/(R.7M$6#T9- M_MEN_XJ^H>?>;K)?#SIM?18F1WU>K2:@O@ _W!">0HYR7=)<\#;-O09=TLA2 M0U]D(,!*!AY_@(:^.E,K^EM]P(>AMS:R>JM5#8>">\G>.7,G35C_"Z8JBU+K MNOFCVS-'&I1SNY[E QOY#DJC.+YN[%O(F+R$_^S%1EK*6,O'%H;2QYFPD8U5 MK@^VD:[1.^?K-;[=J.SWCA!_# M,QR*G=/U\("EL=S"NQS"Z#*#AD"3HUV.D%(;ZU0%-Z/,G9F! X?=M;(EDQ;N ML4^A)LGR?,PR#;_]U:3^-^,5?TT7)BDXX<OQ&5MA MH=B%3!$])[:NDZX8S+'#U='^NVG"KF+'8OMK/YXFWNW,X]Q)L*[S*'M[J@>T MY-8H*X]?Z^:+A#\;2C;D!K_ZW@<-WN2O@F0C&3.)?*R["^!OL!&S++]+JNG,) +/(JR\3?6WJA^//_!/Z<\IJQ@QSX6I MS:UZHZ)E"_BHS80]P+!AB 6OT$SUVYXQ%+AD743->:!9X7S<\K".MYDJNYVHV@Q V@TC;$6ZY27**S-LP=?/,*(0;_C2X4![E6,W M>L&4KE0R"6Q/RH'=7;1K:'WE]>NYT(4&[I[-,2W#Y,SD2E(93,$D7USW,< H MI#W+\"/OV,$A*]Z*[IU!CO].NY%'TD9QLK4NN=]C^8_RG2^1[VZ4#*ZTKSUO MUBP^3[""#W?SD3C.ZGRI#<5VTNLUU[$XD2K_\MP4H*2CX!6D3/)59;WP: E&A4=JB%_VV/*#5SWW6]5Q7L51N'@ M0U;T\*D4E_\J9H"6O5H,]A'A"F+%UU(/AEUOQ*_"RM('X]!T2T64"*9>4:=4 M1S]V'T/MQU7+C0V="K-STU$!.\0EQP!XHYTA?=>>K9&/6YO>+5ZN6W9JWVW^ M$]55$T%43_B_$!_VJVDF4 7>UP[BA@5+#%[(2:;^TN9UDXR5XK)67L75)H[,PTM6 $/:Q*4;&"208 M!H1#3M]]?!FJ'?3@J*JJC[ MD3(<\R"^M)3A]L>;GK([WT5;<8,YK3N&M\68 MX-NC-B\(1N9#B\+19( GQE#SX[$9)U;[NI.O4=)B#OLOYZ5PU/J;>"_K&T:I MTIUN?'=Z;PRT!=DSPL9&K1E,#B ;BJW\KFFXF([82(G?UZV#RM9Z%5;D MW"8_4?2M,^;0&-42@:U@O'T/7:J#JO884_7+]HK]9PTH*\P;#N?<-I!<5;J@ MAN25\"+-X[X79 L.A![6PF!,G03<_SA-.@Q:*JUK?V#&^1;U)]%(78OFC+I0 MW0E*".J,NM5N@!P?FU+/?'?N/$O)MA.KFG#[.27:-!=VA_.)WRPAP:-] @A; M0L?VE;!"DR<<>@6HU*&7&UUB G,J[,F=;KD666,+0M,CEL99&UJZ^+D2HUI; M8< 7EZ4+9LT4HM-_7H061IE\^0,+"2,#256' $%KNW\!!J;Y]GTC18 \7*P> MHNJSR_F19/.Y+,*,A[BX,70])NXN'>1B*[)V6':3-;CD#XY2;LRW8_1V]; ; M \NBT5P!9/BNK+.R_L3!T$QB21IC"\X_U#0:-(:>>C]'87^.8T::(@P!:!L* M[@'Y(+[;9(&U]Q?$A&GC M S80GK,87=UL&>?>*W.L0T6L9#5Y\X<'8_A-DO?N(E9!+:2RD)E&J%-(5])/.; M8[6.MZQ/M87 ^UZ<(;+\C71S\;.R9;GDA!*J\=KG2QJ2R3QL SJ35W&?=5;. M&[>#8><6"MQO,R#!SKG5GERL^,L>WLRWM>_Z0PSPGRP"1$-#=IHD:HDDG']2 M]'M32?MP[=BT^VVMY"8? 4^[:KU8\V$TH7AR*E^LI=IZ!YKX/-Q(K'I.\QYS M 6/F'>G(T82^0+5VHO]0Q-TN*P62:^YD=4%>L7U3XM MY5/0L^,(^\,U@ZU>8Q,0L5C5&_$\-X$>!BY.0=RV4I7=XZ[MK-2SW!7$]Y7D MROGY#JT:ASS$7E4XC^+=I45+B:Q+O'/;ZW/B'N\6K\?!09ZVP A=8.:98"66 MG??&'_2">EZ@^./D_*R+%3PH3WLWA[$V/39U$ASBZ$HG)$%\:?DNMVI;]GMF M)QQHV0"-K+MA%6Q PL]?TL3=_34U>>8*_FJVO*?+,H 2Y*GN^K%L%8T"RG# M0UWB^Q:/HK:=.2YIPMU)BG%6Z[K%V7#[K$V4D]BBDW'==2U3JB++]3IXIJL9 MH,_J+Z_K_[% F,XG%49P_1W7? W4KTI)AS#,G36P0#'")F??ZM$7*M<@39 B MT]5M;]JH&"R8#^N%UET2W M.^CTY65+_8&GWHD=RY?G3'=?!-:/N[[?5I8J'W>663;H=.YX!II<#<45CT6: M8#1?;/7NV&?*Y4855MP!!Z$Z8&DCHZ R, FAY..*.L"ZG9V-X%#% 280,N7 R;-+&N.I2QK'BNH<2\F64".K>9ESD&[M M8 )5ES./8<_:KM7*"_$\&,L2E#%)^@WY6C6;3\(*,ZSRG&2,50L949%+ZVXM MA_'?BIXUMY:E9UWSN_W>8COKYO?+@/LLN6UN"2[5;8810LCGK0KO#*U35C_- MM$,SK)T4$>UNZ?I#380R)?*#.[?UED3:/XS!O,/NE-.IZA/ES39*LE;\()%__0CPYS@EVF$ MRLRF5M3O(;*GE*:EI9+M3X4)G[_J:"CQ3%F69]3RUX_!UW%P?SENQUUGLO., M4$C3^"+H>A JHDKQ4)&LBPLL12.AY^"4L@ZU32_#.5^%)LOZ,N.;OH$3"MI< MBEOKOFHN-KJ#$M/HM(-,HHECNH1%-QQJ]YI,-46K,"T8OA^KVS),KZCKKRS[ MLWY_K[93& "IG?W-UWHJN_B.])V./ /9[S6A)E:5G!4#T-;U:%=$8:DD_[EL M]$>,(%*619PXV!R=U4]?!6]OI!R'IA;6HRV'K4K2BO(9+JJVY_2-8VL\/BC6 M=G"![T_*>MP?#*]_V"<[W[=:YN!\<8O6$T3 D$6<_3UKNZJFFUZ+RPPMOK[M MP%SJ)W28A6C>]DD_;U[VS1&?]\P3:E,6]C[NKQ.V[Q3'8G)"GT::X#&-""$0 M>C0K*) U=6\=GL\& 8;;7F_[I9"MJ)"Y+DGW >%6;\3\/,76S_3BI @S.8P6 M1@@(Q*+^5BHY>3&EB.J64SFCVO'UH^^52QI?ON'H,.&IH&=/PFZ(F5^(E8D! M4R9$%K$_UG9U2EU?5]Y D:&Q5.:9L*[=MS9+0K?B?0/S4^.$;+NI0X@V?]1!T[4:3\O3 M@271X)^-<3_^R_@WS/VDSPF*UP[;XB^^?8:R#+8.ZRR)&1&^2#8_V_?_L@L/ MI:*/K6Y]6H]EY/?$?^T($%QL+K*GE)@P!''NKWUWW,/+-4 M[V^X=TGST"*H2J^+RUU=^VOE^]O($X?3'H0%%7?'^/NEA1PC&V(8,5D/>J)W M*W P1MN&\>>9#"LF\"#2.7KO4-BFGW&IT\'B;"NH=(9LUQL=$6SV-KJ#0##0 MO:1A7/ZP. ;(A(583%67CR6C8:]@^9^W@H_47G[37>MUY:M!_]-%FFANI/AE M#J^TUKT^,*5:W5^G]WOC<"-$J "ZOHX5,)A'TA!'/;+WF*-GFE@/BP3. G, M4=E^VL\*;4:FZIXL6(59QW.=(KA<[Y_&@XK3QBM?3[72Z:DD)'CV3?-8]'EB M(;$!.0!A4\\$G\=CV7DF TR:V8)?77U):42:U9HOBAQ-^]>6QOT41=BO<&A$ M^ANQ1UDXE'(F99E?J?E>0 M# Z$@GW4DZ)3+.W+8\RE3]D5.@$2M +1\C^-B;]U\\UR6*$W?2V:??M9M-EE8[A[0K#K%VH;D*PR]1/-H/,C< M4$7=]\_]Z1\N V-;-ZISA3$]."T>V!*1N$%_,CPLWY-A>FA!8MT]"3'^"DW MCV?4E?!X[1^_ZF4P5>FUCW^>5]\PNZN1]K:#586V[@"@MLJH-6WXNGJR S)> MY/*[\".7_X!.L$UTBO-L)Z>-9+YOU(4^97(936KI@139I_HN)]F1$R,AGEH" MZ50RG6AK,5E"9.U@M-SJD'PX(6(LEK)8UZAI,\VNWP9@43RT"9(@Q+1+60'U MV;*IO%W27>K7>G'+PZC>>N+2><_?T)1CGA;W>X8Y ".623,&'FDN9;&04(^YL>3",(>;3M9@TQT6"8>$!([5S4 MW0X=.W!_/S00=V/],[;#@?_+24-S9GF_4YZ>:,+8^M+'YGJI2[[(NJR0V6_5 M!"FJD7A(IRCS20$IMS<>_MDDU9N]NK-2K$;0$W?(&8S^P>GW'.Z1Y%]ZWZR, M(!CLS3Y1MY%:(?A[[904')T^% RLXE_JDH[.YG"',5.&!N>@B=F%@KK-4+3 M*T,[?2_I>774'ZZZO^^[Y>3G4N;L6SB[!_4T$E['BF?Q&EM9:NSYZ&@IYEB7 MCHP[@5&@)Y9/!>[C\?,8/"8I6M$@"FP,B&H3D7@!TT.QA(MHY6@>?@)8C3NQ M!T343OMLML@X8)+;O1V 6:>C-7<7?D@Q&^5?2Z"]\H_E^:]T';&H[6!-ZU5! MO[*=MLK&4>DQ_F[O#;7%2.-%U(*!%=?CYQD!(=72M.V^G 9"Q:1UUVV>+"UC M$^TOYH;II1IX? >$UFGEW.C#O[QXC?5\S7T[-)H;@A,->-8K8O2<7O'=K#!B M"2._>>*LJV6^UQG(OK_)OS67)!@TGE?I)!+D.E%DSQZ"X]1+&!2_'AF_N79W M2KQVUE4O6>=@U>!#!;A.O.0E M\M&!8J9Y5^S8Y&C7YV,!%G)X$E6PS3;.@QS(I$A*]H&5_DNE8&( ,V685JW^ MV>3'+D.N^S]-]#[XPSI\Y[9(*W?CH(/>/ZI0DQ5.V8K,9HO .:8# (P;Y\O*G%_GJFN19BXGGIG+.N M>#SH%421K@VUT">"R2%[C^7@G7M'(,6:.1184P M)//ER:YJB\A&M(\W20X%UG?X7$Q5X3;I8(^YMR$;"3735LR9_F=6*KKZ4-$M M1\]XW+NT!R48@?&IHK.A-WFQB;%5V9SS<>MR1"+"+'VT=+P*:?WU_+YY3QQU MG"M1S?N@0DSP6LP/T&;W#9E^8[K2J5Q[&0?0#.A^Q2&18K"HYOK2L#-+]$TR1@,Z/-B]&F!Y7UW+V% 2@!1.?) M/M+IY2D@O4]BZU1SCA5^_[[EUZL;WNFIS, =;[.S5KQ^HR7V6;5>J?;;*7%# M?EE"KVWYA]!%/Z+E XE)[0C7FC:/13.;QYR:,!OW R,DL,'\4^$=X<&D6. \ MO)[1"KZF78H#>PL!&J"" ^&615/W=9]15_1@LC\=JB_@I_*R2=3Q5P''Z&;D MA-!K*%5E3&EL^USCC:HP SMK^=T58C!UABMTW]T.DS1!619IL:%_;J7/@UI> MSE'7$#$/OJ<=BK7.+*GNG>U+_:AYDEZ0[GQV$9BF7I91'\HPN?[@7$QP[65+ M1D-ETC[0/C1+\FN@,1J:G";'Q57G ?6 H(Z%2 G>>%%_)J^UE!#*@[CF/'IX M0WQ-G<[HKR8O1__>39"X[KR]3Q5?_.+.!,7>)V^%AI55J$JF &S5KF@WKF:- M[8S;4B/S93P=#GKS#*"(P79,I1/&;+J <]N\C]8Q&AFQ8"@_!<1RE&^80"I: MT K\)_,3(C4<.QT&%_T*+S>=20@AOU\."Q,@QOX^VK4F;-EO5+YBF!YQMS=T M'0]WI8P-TCO:W;+GN*8R2D#Q/D,XU.F37,V4'6>3N*+'.##/L.PC1G8RAZ_1 M 1[<*WBER$"3/M'YW0J*++;J5"339$7[8S1*8OY1O6*YY0AK4P1[N(1WB##M MR3H>D#(_USF4L..8JG*D%JR[R_L8\._XI*_(^)*&F%M46KD@9QP2PQ%KX3O_ MLJU\?1_*4DA;JP,=]^-WQA8P1O<$_?A>77)H'XC6?0<*PVF@)T4(>HE2U'WEH#A?*4*"!CT;*K@B6VJX!]O#J4N:5X%9^>TB3^:(=[NX/&Z66>V M8>@ L2B,-W5E"DCFG*:%:T-%/$Y?JPJ]=C5*S#0R(++&'KV+-*.(SO(P+&U+ M:%C.21I9X-6MJ[(^N(X;&_J*U3/&F;B+]71C\X930$7\60K0U3B?[\8>B2IDO+9ME!U3 RY-IOYUFH^\Z;=MG^<<\-8 M)U2TUC,3POBLT[8579.>V!W]^!,&)*P/ PSFKQ6"<0WFP_E"C^L?_+T.P)/8Q%^2$*#29'?+"%?##M@" :EP%F,G;-4(6!UL$^?$HQJ6P0?2 MX82%M!_V6%X7M04KF9R*("H;:I'ASFL0QJSFDCLRPMK99S/^']PKFJ[YEV]'H[Q+"[/-VH$5Q53>MAC'B0^_OV?K,6W <0?MR]I MIGNF?ME1._RNPZWYOHC-+Q5W8:UC%<0SK?EYKQGE):SG6BUQ3=.,J"D; %(= M8R[KH+,,OB50_DG.J[EAKI')/9DZ,I@NT_E[[AM551'Q(SC](;?TOIV)47+.E MJK^-\M2ZI/F,%/'ZN(_,Z]D5 9=]5G9TD'N#M0H6+ SS5GV."03-X$3.P2+?N_@0C]8C[2J%_YMS4IL&)WZ*[LLZ0^\(6%"TWOISM*A)GUK8#Y,/C?M]Q-*N>SIC D*!9/+&:IMR M5Z)'H>YT)6<@4TH>U5*AGD\_T=2R)>L/C(E_,R9@>B'N[Q U6=1N$E1-Z92R MBE.4X"UK]=.)2G[N&X0LI. MP55T!YJ6MR0'"(#+IH3Q*%HUZVUQ>[_D5F/-D4?-I\K$VJ9<$=>U M(MP2?%\JW\V@Q$R@5+Z;7W?:*B;V[[P@([W4J86)8<'FFY_YA7TZVA;/,C\V MO"Q;EDWH-XN_=:[KG(?X=,XP\N&^D\C7L%CL1A_ZJ;?BU'-=;JWO/9:;Y3D& MO0OS'C_-CBIK:SD[)?'L7DTC/JG/[_AN[\_"*=D,2=AT>A+JNJ/>;,)-^T6I M[)2.0R0\G7Y4CS*,Y( =@L)(MZ\@^Q6_SBF]LNXK<''@U[2PR77&9_%4Q:N> MK3/4QFS\+:EI&C?=CCPG:^R]MGBS6#[\]PC["L,AB>)3![,2J;E?#JZ+A3_^-_R_MU2I+A^HZ7%5IZGS$<@6QJCGC"&.X%?&AT0 M.6:E*N2!,M+D;QH _PV+9Q@I+)N$$&IKU]V1H="K%5??76%9!0]']-9GBPOU M J0@7 YW8L'!O3*9$G[M8L,N'7P6@W[Z_43$6[!&$>(VS9XAPJZ M#2#KNDZ]?9Q$!8&8S-@+[I!20 P//9ATQI_KP]*78>&'<-<'Z,Z30*G-+^=< M8> K?[OPA@QOS")T.KCD M\XFBC$FJQ3#"\0]D\9H8?=)5%4L!(^$RA/$-.@. 5L=D]; MA_P,_]3EQD2T*<87C^,7Z8@U6TLY%!IHVJ%S:@8T%,<4WC("EX2ESL\%2IP> M=^6U95KE5N+4S;12FA(+YTYX3NO>T#VH^$,-]6]J_:+9]:5SQ3S*Y/164[); M?EKN04I9)47%=Q8_*MWNQO-X0IR-/5/W^8XP,S"34OPVL$'8Z.E*PH?*+&+P MP[4-YX["3WUZR5F)]:-B;N'V!VELLV,08)IA0;B-A+K09OO#SE__8I+_1T#- MOB86]H-$(L NX(#0I1SQ7-11%>4$^WB]SE.>K?PGZ)O36S31&'D)*$64GVFF M9TOKCK;KCMDE#??[JIH)L.6OF3K9"D:X%:J5AMZ"EVJ+RHO8V[@4EQQV=O:Z\_EM!Y9+S"RBU[XFI]O M+]0ZXW_9[X@8C_Y@Y3',V18@S),_: 5;W232?#?6Q2&)L1,>J-?G,W['BI7^?S1:V-HCFVGATLF^?OC!'M6 MO6R?UMHQ"5-8%B/\4-EEJ?1+&!2 KYYA 0LCD(9PCGT<5FMFTA-ES6CP_R4" M.T-QZ%+'!)"SC"L4,#ES.X>V[4O@H]"I&OE)WTZUK+\_KL^D@^R3+@ MA4>CQRVICQ91:OV@KKK)+[MM\I2]>*(D=KS&^0Q]LK(M:Y)@3VS$*[2LND[( M.B?5)HFS)D=:/GI=5%21/?!N,64V.H@1Q]+]H(Z91%4H!<7.5@9HE7DP1>X. M^EC#$2C1^*+W,)BW_?']*9%70?<$/FZ%5V_4F7$A=/Z(]41FZ!SE';5Q+F6: MX,'N6UII/X7+)A:)]0O0=WD^55-E,@&F%#(G/-/G0!%2SV3*BA%">3] A97Z M'[YL@8=LML0Z7-($>"J$@2@#=<%3POG$(ZF4L T^T4']UG\1==/%(-_;[C+G MG A%YAB368C3T\G)_80[65I3W4;QP/>!,O-"(GU-A67@&D.!GL.)0#Z@V_45 M01C B#KU"=.4W%"#;=C9XE43,_8:P-N_WQ0AA75-C!Y9F_)7/QY!_ $!X+)FIT7MU7FQ;2\E[*5"_&6$G6S*E5D:8FPSLLV! M?)U(X5DY/P$^9IPE!I2_S6F@9[1,2,'--J1#&BEI>AZ&@70;T]%ZN9#:'99$ $O>[L$9Q:0?EH%%\+NBO_ NK(T[NP=75M9C,R>$Y'&Q^^O MQTM]\.Q*;JFR"JH5*HU@M\4GH6[(/O ,WI]/DVKN.KP^<\P+LAMM:FS[L%>G MS?UFI!GTC/3KO^=8_@W=4VZ@9)6:%;BK=KO%:(MSI(E9%>SMW)[&2')'K)C. M-]UK!>)]WTH1'7#%P*;'JCY=Q548K"9UBNGVZ, M#];$&H\0+:H&X8#22*T^J3]R;3Y5V23'VU]=V=J;%:#GI^QLWT.J@<4,(<59 M)TOU"#!RIX[>G(9(XI:6'OUM%<_JTIY>GX8G2B8W?HQ*QRX++LC;WR4<'93L$3CL2Q:=7TVMHN MLVLON9P&N3P&F'T<\Y)0 5Q"$V-=NF1\K5YC>)(_P9,J+/L0@%2Y>SLS^UZR MO?_3'_]*[7XHGXR,9Q[AL&YKDCR2\1(8]&S0X,/>!'FZ^]1$YAS0G;OXG %;JC75EG:@:D2]JYHS:I4Y3MP M78!$KG&$(+)JL6S[^VD)4BX/Q$-9!!7OA5JL\R"4IZS!^B3AG[/"KI5.RS3< MA))KLV#T>&>EGSR"_XEYG-QK1;BGL5YAVWR:):=Q^UYK[-CD6V&3-&"/_YK4 M!'.-=0AY0 @ !:-!2,' %3+J<0J6DA3!IMD%=+N29%Y-'4F"0!:T"1$WAD'3 M<#BM22U:EDU+J X ]->2U(/!J[[\/&+M%WER7YZS=KD$KP1Q3,N2C<#&V]V+ M,&KM[2U; D0& 44JA]4A@&R+RDL794RJC9 M I"SGPM4^D[F!6C:]HS?1\DTJ!0=]Y,DOJF%:H=G"W;N/38Z;IX<-2$D49O\ M+ YJ)()2C>(LE+RIU-''=(YL[.+:18U_GOY_O7CT\_AVN7G9#JM*WQ)'4A01 MHU\G+:05O$B&?7B_+!)+*&X,@<3H$4P26%2XK3K?2L'5*)O;4. M-R!$=\@A"T65K=OKVNO)?;L>7[LCUS$%]T*5QG& K.Q-]*9+VX&O;X5':-;U M W2)K]\F/;%UC.7*TI^^U_[N=AVV*]LK2DGK.*_?4C\=P1V=9VH0$4$,@ED! M)'QJ=PYDS$HIJ6V$%"9C])5EL21[OYZ6>XT. ;)]H%7>3M=ANO6#35D32V+. MY*K0: TMB3D%>=SSG#/OTJ]Y MJ>?:^K8YSS;^ZU6IL*W%S2IW;UORWK6CE!VGZMJUN7@T')YHSMZK:ZN"L!VB M@8V](3 ( M.+UP]9DOF7'P-NRQZHJEQYL4(,'GD(QNK=^5J^O?Q=;O',(GYGO!NXN;F#[C MM,3L]U;:RU2]Y5-N@>**<[%44:FUZJX(G%BZ7XI0>PI$+^==\4G?Y+.>O]>3 M^S\&D5[9<*#>D'/[F/CQDH;V9V^!UHX/L:OS>PV=V;]>\*EQ0''?/JS9E;QE9OKZ\4ZF--IF3P^^N%Q%W_Y>@9W-#]4HN'?4/M\^S3-/#>V3) M/@6\+;W3#\?!9;A PP06&7W!U1A][6WT-%Q?/U'#RK[JL+*D(BO.O\V/#)?T M]%Q%U&?E\I"["CO8VM0B_",\)E/?D!$*9FC802!,I00)4U3;>6W[\F5,A[U= MP%4._UU3E.8O*8M\4+NLQ>=_]F9_2?<*&^77QO,V MR!Z1-^^2IM7O++&K:8'H]DE:"JNMVR?\Z]>]Z].^OZ2Q:Y2Y<'QO6&7$H+"= M<$8>4F\H#2%I+UW2M+6R3LO*\K\J%_;R_@3ID[ X9:8"::^YT9STO'M/XPSMCZZJE#AD6\^8#Q&H)R>LZTH*!$@I[H*N1)K# M2MXXKSIP46_?YN+./:\JV8[FJM=6Q@64'PZ:($O6J$N:[OD'*4.]?X4!_WWE M)0V4<]5YQ)MHSVNH#P.3J_6(/2 LDSZYPP^C'Q+"&OUJD]\4QG7&B+0AU9#4J)2[^J(_:',CFW'DP2 MATT\4":.036^"[XE=.!?3%'BQZR:?AXF\.JEHDK&*;2.ZGM63K:EBU4GFB+G/357$#C7MG>_LG.''3@GM9\;W M>]_U<^RN%0=[VR67*_WTPM7I[OCP?J_G\&O'0UB5T\;3ITCH,WA&XV]K*?&^T>:?EWF-0T !3L%OG#PGC]N[GWRSS%[FZR> M)@%+(FGRZN.<8,]SUB.+<6W9/:C-A+'CI??7( MO3_+;UK*TK,C?3;M3%N@6K-AUD(_:37>7@[Z$9M8>J \=V<]#6;?OE1$]G#Z M/676 (A F8A7K00)DM&/2V #KK+Y?(+XKDS_8L+@6. *"66=\LX48(*ZPR[P M<=!0'>G:P+NT*MM812EF*-3-%PXF35SEZ2QQ2 M'=,4OO%.*"@MT>-YXWHGG*Z.$UAS$SX\&M*=@;6 M*[&3N1:.[V,V,8;T*&@=G[\[O_@[CW#FMJVMF%VL8MN"R#5K4@)D*#T*L=" M2P0D(92$(KV$@ 1"1_96$.D""4B7$B"$4), H;CI'81 **%(+Z%7 97/\_2] MSSD_GO?ZKO>[KF_\7G.M,>8<\YYCS#7F/>4SS18U3B_IP\AYL\I%[C[NLMPC MY?V:AJ-'D>(IB0!O[)%H3'&+;%>MUA;QXD" 5+5,C4+Y="N*,%Z\5E;=\:$( M4O]RB<35<8"J"SPF%Z0P8V84X,1!-.@NK3>8Y%Z7NDP0ZSJX7&_.ZE"^5JS] M<\0_F?PJH%ZFK^C\<'(&<71DJ/+>,.N, -TF^86LCTOQ'[6F&U?,PQ4D,T[= M6A#<'M\J/P8_VIH$6S@[>9R#WT]5K4F]4.A#\_1:)^J!9)\J5?)K(6+H553V(5\ WT[*6,80A=%2609Q.T-3>''9 6/+#%2T7J@B M$-FOR!KJ+#?5^/&U7\S3=BYJ6B]'1G+*8W6<*0 LV0G'Z(<,VUKZ*!BYN5B/ M&1'.J2G?P\%\L6CQGKT;2$MF97[,O$I%1%O2V0Y"K&53;U_!X=_^9./HP>IN M1YQTQ>+E"?RM91 A?8T7I(-M2WOB&Y@\OCG=!AZ'XK5L'EMSRL6NT,:NXKY' M>N)&E\1%!+&!V:66%?OH9<7Y.D+M]"O,1R;(@(<]93-3: D=T?OA/?]_A#<_ MJQWLM7"]\WZ[P%67%SC*71N F'<%WF.]7?6:9I&0M:SI#[/8>(T_YG2W%NL &,5.0XE<^XCMYW*6(H9KNWJ[)A+1RB\X$9A@ M:XU?AP;-9=[_=>1<0?O>JL5(/]T\H+G*Q"A8PTQ0,/;V)4Y,70_[^7C*B_8F M5Y;H/1E(AOVPTO#;@G]?<)')WE02H[<5]HKSIUPK-.V&CGKJ,X@[5BU3S1= M3!4!6+=C_)?BD+-.&SP3F3^LD0@9E;;Q1=6.$M[P;-<@]>*;05=AUM9SX!!R M27HCJGDN4%(P;[3AJ!ID0GW@TX>*2 PKII)I"5T'SDI]RB2>4=C2PIIHW6.KVZ/UQT-ENFUF M((_4>9:T3*>W4'"X5EU43Q <"-27IAMUS. M/3.TCC7)QN6#N=!PK_+)+ TTG440.?\0+^3*"Y*C0RED:.&14P _G?(AKK)6_\[9.?/R0X; MXU5V"5J%4()25<=]K92&$A&^EX=!;34'U_T>U'U>C+MM4N("3,;9_#+?C=93 M]6^[;2X0_$O'TU!:9YV)1/-<8_4]1):0J,CM.L!PEA]&:B #F\!RH)1.E&C) M.'OJ%A]I!$C9'/5K[W27YT'2S.?A'I-9"$.]G9;[^Q8=VN= >;;A^#_3Y'PU M#5KJDQ65[6V+$V1.Q=X*XV9TJPTLS1K(L+'@,2PA+P*<@(#+YR-.)YBJ$T/& M?,G1_)(!5WR,*W>.8_OW7@]\R HLZ3?F1U<\NQW0D_VBOVG63Z%&=.*WE)(6 M!=<6/X]ROEMRN0'E!7M0%LPV&R\=SB>#<)3U2?0XX1AULQN_.YV%QXJ%8/[#F>ISZ'1?=?X*)_TJ$ M#.J^1^@^SG7)Q&(7YX+#??[ -M/$KQ)Y:Y6Z;\?)B1O]XMY4BXSMUR)BDZ0I M60/-H,[5,5FH2?]1A?3@_N?J40M&X4RUX]F.[SCQ#9.Q*S14;EXPH(3/7O.- M?"\;?=EWEL\LPPKQ,F$N'_HT"&^I3X MUXZX)5T 3OZTO/GA]"(J<9=W<]+@$-2:V/BQ,%@3ZIW7NSYUET((=I2'#M0I M#88DWD0? ]$.QB-56)C*=C;Z/O( M]+4M2+#BA?7W104_%C]V6[L;?<^X66[1]/CL4M_O!Y;.BN+D?KDP8"_QH2DV M!99H[O>)L'C1,RS%WC!=[YH/?%^VI>-C:JO5F<)#[SL3@%J?3[1*I>Z-,Q&Q M49,6;8(JY5+?O):V5*7?I_>H7;?%@H&/IG%71T-2(TKTE;SA]E$V1/UDD99 MX%\J/R\GNHX8CT#7%7D]T/O'@6;7'/M2;Q649CV,&)C"@\SSF:PKV:W65& ; M=V[663T48@"GCG,:JB+Q!_AV8A=%;K0".J&XC.]@P\UR_SF1N2_,\/!P=W2' MKJ_G A #(?G*O>"[(;=3<031@2B;!$R"\YU4]Q_IX]^A^".I0K%.MD6UJP@Y MD4O2MZ#?DB#KI'46S#G3R,_I^=V17,U,(GP]@\<$S"PMB#"L!M>K_;)E8\S( M(2DEZ8+IC5Y2(E3-58_T85D4'GG$]55!?4^D4X/OLI!8D/YBV)=K53BT?1V8 MK?"Z0P\=M3QRW[1E37_#+F/8O69R&/L9P9P9G(V CB-P5+)+82*UD K%$22H MA;C"83+*2L_%\@X.&F5\11MD#P#K0]$=M=BIUSXM"9&EE8<[YF%Y(PWCVY$>J&+44C$>^CWN,3$BUD8NV:P&\@0Y7F!8'$Y0GI"%N3RZ\8+LZNJ "RMU& MZ@W.QU;,9B.J$/G4?55\Q-X524RINX*?%TR&;PMP_\[GMP1:+M#\[="8@4J_ MRLM9/J'[0:#/:X3OPKJ'FNK"]KUW,O M+>QRQ[-*SS8,27!8H)Z545@P>*R^B"X;N//9A#NL_^4)9QVK"4HS[X>5+2HWO+ FJ=S!WZ7W/6,.TO0A4_) M>MOZ>"<5[.U-UM1#/1O:VHBA;%P*XJ MG55&V3OH]?@B?1M_GJ6^*W*^=C8^ M/C+F7B#A"EC1X+7'H43AB>=YO*[G/)DQ[E>J-$N8<%RHB!=2[?4V:S5D/')"]>58^XK!44Q6*2"C$GZ7@ MOW8.E@KY6*VTG>>;51DW\B_1]T># #V/]9H*W/Z3PHUST+L]OW8'1?IZH && M5AWO$HR?\R,FLHU8&)Y@E\KK!,LP,VIMYK)D2=0"_>A6D\LHNFC0TW6ZQE3* MNQ!HZZFFC%B=LAN;PSN5S_G&/B_;NA:M<#BTIZBND2_,OT(NWAL'6-OKU6N* MF7DO:VA><'E3>=AUK?9O_T2I_U/N] M/O96"\!XFMEJ0@J+7?J<2[K/EX!*S MKNW#*F4T0430V*WY%DQXR>X0UPG';PO#,7*B57AKP_RJ;17=^PY#0[.H]A;; M"6WG$XXP3K#[RV3J]6&4(.SYV"+8F!<3B]3D\\BZ2/0CH^2*FV2NV["5E7?>)".P1*QY"8^R(&\T;WVQV@H1 M[*_"3/YZ+T^VSC;](V/L10AI(>E:XSWS<'_G7O.W^:>F]-WMH,V#U-8JAIKR MP &BR63B(4.X(K].N:M?]PCA-=L%)>M:\WG-3H'U1'H[S7=X$GDSI17FOOX> M)\+6DD5#F.E!KZ'0W,O M;W8!IMV27FL_&S)OS+M67?+Z*MGDDB5>G]\6?*-N9&92!L?Z\GEK)_KH5/"O1H2@93M7#L05WWKK-%@,8TVXB?WSW\2]^(:%,N MX8K[Y]-+9#+Y8FWIT#95U203&/SNOC9 HM3F%S;B%OQ)GMNU\6KY93T5EN3R M"8<(O*(UU82LW,27K'?..CB5&4UY/F^4P\;/CWM$$$!6B\:]6&S@H\^^>YD" M3HL'3R<[O=8H&R*Q6=AYMD+IW"[8$^^['>P8X)=.[[40'/HO50#6XWW[2W,W MI[A5/Y^+2/?8\COA$"V7?D8ZTK/=&9I]=<(!1>3/>VD\HMW52>[\\YU"IXV> M>^XWS1HLIOYT'/1+=%7;-[C+S0G%^XNW47^_%_#^;MB7!OOU?FEQCS^^WOSM MKRXMJ3IE>SS:?S.U-G83?^9AX)/ &[WU5I#QY/;+,[#IUI2O0U:[(0\ GKTN M?VKV@ZI%^ E'7?K&84V;QCECV&6!C=,R5DE#!W>\2CZC?#V(P=BG7V\EVBBO M8O]S)OSPA7S6XP*Z601-EGCXD=*O@^ "$W00<#!!%XH:H)1D4S2(553QVCNQ M$,WQJH0F_I?ICN M->RE0B**93TC-7?)@:!^W1)-44J^0Y55X2R9]U MMPC97#:]K_4"5;7X/K\)!%P< \"\5M=DS\=,8$XXZ,:-=:2V]"]"!#5_D8@ MV+V/4SII_]/LFRPWI:[HVJY(9V9B$A^6"KBD,,.E>:N5F?)OYAC_G433.&S; M,&IF]DX:HB&_??B16I8R(X6H5]4+E&,TY%7S!?9XRDP(EAT.\R2D[)'1I<71 M^0$H$HS30@!_ZWJPCQ"I$F+YT?@XG-U"=!P2YA:S=:; M3SWZ@HLE3^V,ICYV'9$;1,J9%:W0RD3^ZT*C3P-46R3<>0S\@P:W5+=P.:U M"4H,L2CI:GG*%;A ;F4)>3;$UN?Z/KULXWMX=;]JUDR>CX6;?TP._9E@@[241T'SS'#=U8Q8!!29[.1,D"2K#C2G#XP2#E:C<5%U* MHC31)E$Z!P6A]\\"&H$ N;2,"SR=F^ZG!C;UIC^F+FA4?/;[RP=>QWR>*O>N M^SIS3R,534'>O):YHW!\P.4^L!H3?,)Q96K[D<0)1\K:A[]U=Y(%Q90*_]SZ MQVUS_J\QGQF'*0WW^Q\KS;9J[)@\_;9??:![,^>$@^?R]C6=X*[]%[/7)-X, MIOSQ+ZW\^YOBA(9?W%AU9;VJX>14H;F;%N\VB:CAZO-L:Z(LJ/CMGPPDN_8< M!%/2Z'J(_-C6M1N>_?WUA-!/V$;OP^@2-4>MX)!"L7FWX@7)W)(T]TJ761#= M/#[4Z<6%O.&DVB_Y'V&N&3I_.;IRNG7*_H0#TS)25S'-]F_7;@P,'F=)G\)P MPJW4N5T; ]'5KE5#0O(#<0X3LL>1XB6/]S#"N.6E+8G"K9>-QO3JB>E)"R0C M0]W#(L%B,(MG+INQ^?JKA;.(2TVITR_)K]Y8P0W=[L-SX'?D/G?8=;X=ILE7AVZR$E+F[EH7"VG#NGIC)#W!;4J\^7F9\2>\: M*K=(L7!]L!HIO^T&A";EQS9PYIN3=F.QCI=D] SJL*K0Z3U_4 "8M "'L6 MWCV]9\G2LM]AE;]>GZ+B._-:!*K M^?Y<$,^CO_^WX"W.$XYLJZ]Y.C_%!'^Q^N9XPM'?L?/[U)?\;\BOU5X#'&(? M_UO#?F_O[@8Y9FWW/JVW UWE73\\,L^0[-I&U5!=3F6T.4;,59>G;8JXW]]( MG/H]D0\\]78[GJ'S]Y\4NZ-CYE,3L/**5T2LLNOSDE(^Y[0,4 M$>1[)7I&NLL>)@/I=D@SMU_D9;PU3?+RD[= /C*<)J <^"7(S?TJ8):NO<28 M$N0N*81D, 3AC+-ROHB(6.]*?))_-&QLOM(].MYU8WZW+/J&_[M9FL':XDM, M4/NVYI5@OB=O,,+=8;>6XF?4!M^5YZC,7A76L6ZF-[_9^)[5=W73_[TTK1!' MEAP7;(Z*XKV%^"8N!D^'>+VS)N4PV1HS M/@SJ!=H&)!J'HIP]6V9?+<7/1R6IV268+^WG"-G](U)R*H_'?\VN7%S,=_XF M, 69P'TKI!VJ:S1KE^# M_'VKYY-7HN>E7LSW2EA9UQ>GO_Y0N%;/DR=[P:L,5[0R?0#F;%LE#/=3!OTM M!A+^:J%/CW7%_J7$$:48YI REOW3R#O!%=%'X?95N]1'-69N'X>L@/L"2[0, MZX7$O%QM+$@;+]A2OBW@W))E)3^?7FR-4I43"9ZR,03!$W.!KHDFQPN.J.38B?H:A;4V0.9]3 MO'MJ 5^%G\C&FT=@-AP[ERN7):P[^GFW(8YW:-P5#]EL=9@;&33N[%@:&W1) MTQ!DQFCKPBG;5B:JZ@X+O]3\+\M_7:S1#D#?9&7RUZ!J18Z%)N=[!L8F/";, M^!!YMD?'PV,Y;[>C.^Z/ L-62_DC"G6B[>T'+4'A,'4 M_!D_7AXMF_ NY7" M,GH5-"LN?\JHZ9S!)=,!/71@+]JMS5TJD1TK7_(+9@T(-J:MR^_0:L9\9V_8 M=DB0U2/3'Z@ON^[>"^@R!^U.IEK%UUC)3M14RM8XUDBKURC[M&^KUH238JJ- M".\2CP.UH..2FC']YV@S#:^X:-D/WS!7NV#=#Z?,2XG MQ*:^RQU/VZ=MH6FLYL+1&-N 5,O!;MGS\20?8]-.@]4[U5NF"8^;9KF*9\P-[+#]OW/"1Y5]1&TFJ:VBX(1CX($M]]$\9V1ALN&VVZT_'V=0'XXV MCV6I02:J+GU_T$PJRLH:Q>HR@;CB "W(]5*3H-CZ)%V5%SB6V"8?@>'"MA+ZJ0F=116U]L=F[!_K,HN=!@!VP=(IA &S!J7U>F;RN^P[: MO7U890%-E,PJ]NWP;(78FB^G0E0Q/F<87]M\-VPG$#W[1:/J=7>+5'U,P2F# MI/W2OCK=RD4S@G&X/2M1V0/._36%K97B,G\^W>6U'55"RM^C<+=N']J[['!VT*F*0GN3FC0?MX:6O9CJ%ALF?$>JR\V5!8RK MM7 6$@B6H29XUHQ;$/C"3DNZZZ4"B_J91Y[J9%+^WPJBEM_\[HX][5%_VT MECF2LL+OT\+50ID?&0"9#MP:40B=A%Y+=?E8,#!C]K0)%U>TB4R_3@=00)5= M4>YGBI1/5=YA#=E23,Z3,4D7^YZNFW0G7I*K=H8%]IQPF,E_OA(8H0?@8B \ M]-D*L"ZY;U\O4F<(L'B"9F_2WO/@,)'.F=1PTU0AJ\39:\/8UO*H2"&Z\JUD M-_,BGYKT//_Y5O]RVT[S]JNV[49OMKE,?J&3FD.'6\ #]?%6Q(>A3NO&(6(7 M[S;D,@5;'QNQAW. 1[ TQQBE/,9VOU^F0P =..QAC \5D9Z) 6 MUKD=65M#.%#Z(PEXG&C_4K_&8NZ#PG+P'PO=15PN66 M.L$+Y_L'D^WE^56B'U)LXI]FW'CH#(R0A9S#B,AE#,LT/T\RU3^*HDS:&W:N MIWCF !3&IV-D7KFC_%SZ\XY^%RQ*GB'0!-XAVFCYZ+ZPF'MB-M+!4RP2SO*UJ1 MP*&@OOI7D3=!$H;Q;K(AN"PEY8<>.#L&=?'G@%34NMY#"JHNZ?9H266-:^OK MR,"P_FM\HU>OCO&9KRK 5L#"EKGJ!M<2'>$FR[,$FV+PU8VX[F]ROK6.:6ID MD_N,+6)0-@LS"?$G%[8)CBUC&!";XL3U;@D)=%MPI1#04LD?&:6P*Y=7@A[(6D1-=]*=7M'8".\I4'V#N+U9>U1I$T#2KP,M2D/Y'4"HG4'5XK\!U] MK9&&'J=?4D83!-V&T-E$Z=L=CI180:#O4#3!?VT,<\1H^43@M9;8JIW5,X3D M36?O"A%G3J,%,B%CO3.SMFE?.24,7V20M2<;U6\<# 2M"@.>I6&;ZR6=]*\L M'[JH8X/T!Q@N^0;])E4IIOO>NR;!QNX.2B(WQ.J@3U]BX/"%-@RZI/,0MG6! MRP$5=#LD\#[=W0W4K)KRZI%M34+,Z96""UTL;H>.7JUL" M5GHT<\*1Y^NHSTM>7[DJ+ M@^/B\:>;BN66-UU3H)^J*\F**7IA-VUFH@N+0=(O\='\,FVI_;LS.+['\5>I)6S"#H\9003/GU]5"3/G .DK]E('4J MIDVIM^]SZ>=6AR^GAT8L5)+X?KI+/#N%!!8K^935O*=-6T8$[1J?KY,?-3@G M 0>8!U_I\JC=X2EU>(==X'X0:<]=8%)S:F5RWCP,0QV_\?A-N5GA0-B56;37 MUBUG2'0A'CR AU+R ;)/2NYV>/(=:J' 7K*2+N7YT#0:^%IDH^X.9EMN#.6" MENL]MC-;,"26HRP>O1V'T3O(=MJ],\ZER!)XHNP0]4'/@ MZ;]0&_^7_/R##WTVMM%T_W+'N/>9"$NE.;1/V1!O;"")J_-)N!+ZFTW_XRP@ MR]V]SLUCZ'.:A\F-:,9DI7Z23_.Q5:#0T4Z8S\X>*62=[!$\\$#$$N>_J*=5 M"/D9+U$^']=UPC$#;'0/G3=SO[%=:#I,\2C[,&'U<1!'0%FB7<'ISOHAN5NX M=/\KR%]-.#XXBOSM7ZCX/>\ZNZ;1MN(, LR.CB52#26-O,LZ18.NYN:1=:IK,_4 X&%\O:S*['+P5?;(6%\ H%-X$^&K M'I-KJ7AMG5[%:%$O(YP9],EIC@R=,@F\1NUQ)ZZ[<#X2"3:CAN1H>4Q4Y$VV MT0NLD:<35]L96 M/*BW6S8*?9RI)5'1Y#!^$\2O,O]%7G9%WHM9P+BD:Y(5A/+*Z9VUQ(.A* >@ M&/KZ?JUB3IDM+1"L[_7ISV:I%0&/5(/LIA] >?FLYL22-:1#]G=@1VB-;)/>-=QYN-%:KO79Y3<9B$;SC2 M#.+3Q6U?$8U]Y<^"DJBUPEP *L][#['P,=F0,9OB(N;!6VJ7\VJ(-YCJ_TZ1 M3V&W#$HR-G6-:- 44^Z\/@LH#-XQ2:WA>7?8Y'.AT:)EKUCI>+=!?M Y,NX2 M,TD\+ZW><@ILYK:%ZW6HY[D#/^>F"M\V!<-,KF_ /FLV? D+Y57-YF)U$,?OKR3.\X(<'Z^'O7'G% K[5"L/W!.[R(::?#8O,]5% M-*AX>["CLL;,&W9:YSVM0\CX]S7_Y8'_WY'R.P:L!@>H"._XQ'V[^G[)(#SV M%>]PUW) @O(/7\"!2@PK.NG;VS/\^6_X/;63DXN-HV$G),KAX6^EUS M#AL 3@J/5<@&48;$-7NGV-67> %C(O+94YENF*7&<;@SXO8U\=TC%:O@:]%V MA:,+_I<67E2#P=LO S<3UR26O<0[#.,A&;E3/@E6S:]>;V>]FTLS+LMGRW_: M9M.JN73,5FM%0/]N>/6_3>L'51R%%IIH!\"DV/L M/^,'U"<[?$(*#5OOE):\Z%HMCK!!UZ/.PZ[:JN'+1%4CG0>)5*)\L^,H-YQ8 M'A 5IIIS(:IP)354!Q*7WYLI9<\3DJ5$%=?]>TS2$P9V*3KA>+PBJ6Y"6'=! M.#+E6OYW[S3Y,:7W@MJB M']JNLW_,C>@'#61PH_ V7F]G"D%I8M3C2%P?+MY-NS6YP=W'JZ?85J=HY$GKA+V>=_T,N\X^;OQJ@ M_]B!W/\T\KF7D_,)^;,'*"&0O3?*2?J#;EKV[FQRG%7:P[KS3Y1*B.J2B('O M:X)>"=@);4'>N'^*@#F.[*R:!CQ4@KW68!I_'SU4UF":QX(<9U +2&CS ^BP MSW*!Z8<^PR/>FKM%A@-CRRI?XOU[/ N-%H;OGY.Y4LTY]6.ZF*E23XGDS$H> MFLKJNLHK MLVZ\+:DV>N/;6)?W@K5?;YEJL^HZT-,_Z,:KZ/%G==KOX&%"K\<#O?NY( 0G M]I496MG7DCR9VF)FC!X6;,1^H,T+CTJ\3"&)KO3L M@F&82-V6(FZ!+WV^K)8@/1(:V^J7,37N@N1_PZ05+(8 %\]$!?!=,D$JIL![(BP:*I+@..-:3(1G_DJ2@"F:2E45 MUA9YBCCCVT,6X8;RD+(5JJI@9UK-[,T+GI>X7:KG$Z:(<>;N1A5%7]6EO!OU M7-><%7(,7=OJ"N*C==*'MI[/UANT19\R4,M=[A\R#J!X\MN=<*24O.Y\:^!N M_3PAG1>M2QS >!)D9=MQI7^&@$?:@>ZCJI;?MFYD]M#&@+'A?8>I0<<1E MVAHG'&\V#F_A@WN\I]X[V!O')*3!_^Q3/_B!.+^U?8>MGF>93MD"'K,W#TD% MP0'FQ[FQ_2<3N0MUJAWM-L#2W_!I3U?64+B0F=/^_G?[ M3N:?O_RCN^JU U LJPNOS]I7;S#\/-7.7>2K_\E/E_2FR&=V MOS^B1;3C3)@*U3EPT7MY&F]A??Z#"U,5?W^/1M@O3VB@1*>4.CZL;@S#T+HC MGU>:WVY+_S&0EQ,2JG*=]O:+V=OYNY4W$K@AET305:& "P^)"&,*T=">]Z'^ M-3T]-;X /A1>?@#I^R=&NTS#F>#_'-L;C$Y+:X^:4/I:@'8\RT2 J501\^%J M=V3*G'Y[>4W.Q?Z]T=)QZ$#S:JP$G4 @Z,N?EYU\A-VQ)*&_)R)6HNT5Z ?8 M3;7L*+;QO*]KE,F3W,TH$R1*2#-RQ,8SZD"B'?B"-]4XE$\M4K \82G*6"9A M17>ZUM^X.V?SEJMWH_H=NLNNDAVL3%UVS=D0Z<1A'6Q8]U<@?4[J!.X8X#V)SHFK'6!X C_-Z MMTDUD%3^Y#%+&%ZRT/V*L6MN:V5D*=]'*'RZ$(I6W$*PT+/ MSR!K-4!_)7#QOW\F_%_E?!S.7#M]$&0%HLDWO:GU[[Q^<(.J]RUZH5H^QC/S MC+M>@EW"OJ[3V\:!'H;YLP/NP!JH\VRT1Q6E)MYH1[>R:B)K^O7KPY@AQ^1< MC8.(_HW;S#&Y*46X;HEFWXV#5*%M;%@X?7:Q*S_>WO.$8TR\ZT-\@*21^5>O M3U\ORQ&FUI!DXZ=).F\Y.)1K/>^TE[+72(!F]X,BI&AIC\V\;?M65Q%;<+_' M(ZI$ !5:N.'Z M@XH:#R51R;],N,Y#+!R7^EGV"95C N[:S=WR!+;PI5+WS3T(A+F90W"XDF MQ]X>1DV.S-?1WG:!JTMW$HM,G*B\4GGI#M6H&I5\ 7_-5N@7(%-P\,O-+D]. M=IVJB+/W_CZFI3]A91ZO(>RO%OX DW#ZW< M6^_"5]<_7/H"79CB\:.&*&9XD)[;L(0FQWTWK*3NB1A/I%EO:&PX7Y!M6 \/ M3YB%BN]=#P$]L=-.F"ZNO>LR+VT2ENFR1A5MO9$%7E^;,0.Q(-,GBB5_8VYVU^C#1F6*3;G!A MF,KG!+ HA0"*>45-SXCM6AK4,_BT8GK?RMP-M:J3AUA?X4GY<)>LEW\Y1&FF M6K7Y_;=NG3X%!NS/.+@UV9XA:TJO2/6+Q0OAZEJ66ND5FC3[9UYCP.GB\^%8/\V;LV[Y[4>K MKAD=HM10^C[^)2P:3LLK+^%DF*,.>P *N]GU1$\ZP?-;[WB ;<_H.H]3<#+: M."CET0F'=\EE9.0\01^2DY([G+T8%3 1W:/2T<+IOM/#:,=TS.(^9@:+=!CG M^A\N-QP).4/JQW!\13_ Z#H$F2TUU@@[DVA"E-'W/.'OEKZ2*GH*' M5"%7;[!TWE53L#19/F)D"WF19I"Q4'UJH+83I1_M%JC0"LDV]&V%$//#)!K6 M0!6LC;'@CZEX!0N?7H$7/((*JNUN?-XTA9ZQC1P9Y14/3CD23K-P(Y'-,T>< M&\B@U9")=(79OO';V40W_#%L,UBV=)+.*/IUBL.T0[W97#?-?%K5:+B1?8E,]=HU"D-]+$$;&X&L M5;"?-G%V:7:9CPQ.9\)$S\LOC0]$!_BU$LY]1T>J.'4@I46>&=/H'_N7HX"7 MY\'@JP2R[L-?4H@HN!.. ,B' \ E8!$ 085)/>"0F\,(V4%>GW!,PCZ!8U4N MKC55B#Y,Y=R?:TZZJH\*\)#CL8)/9+,_D@Q)B)0X $J 3*%;S7L N;< M&<2?=\[OS)@9Z02D@&6ZBT6XTRS\H^7;F<=J7L=](7_2A#-KXC>I$XX?]L.F M!Z5-]TI4NF@;0HX)AZY]^&)*.?36_J2UL[=4:!X%P1VQ MMSM V17JA(MI%:%@H]"K>CZP%B$Z91J!*Q@T9:0A@EI+'5+,IZ[1/REG6+R< M0FZ[^UH:!#=O2!U/E5EX=!75J+=\\*^\MB'29*%^'JXNM 99=K?D4=BLSO\R MH:,%J;Z3Z&-I#U26S%Y:6?5R&UBB/*?['DPYG9&/MS$X+OZB85TK? MWXFR^[S6*;AXLWV+G<8"'K7X5MX/-SXF9VR@7\@WCF)^!^16=:TJA2$\Y*!P M\ !>36+@/]'=F:BE*\<881C8&J3+]N(1% DMZCDP5S8C*GO,F4S,H^55IX!X M6+9CKZIGGY9]?30.96 ZR&4P[F'T7.\5IR=%\7>,O)SS:?4_N5A3[71CAOQK MO,LJ(2\_3JAU>;4QYR(:5"I>?20#K)S-Q/76O'>"V/O*'QX-\1[478O0O9:1 M,/-E64M!)0_T',G5S!.8=*0CK3DL[C-Q-Z$EB6? _/#+E#O!E%# MS7\92/WP[/#G"W.^)2HII$'0U@R=R)2LN<\EL@1#Q )#"3H>%( \X=>H)JEN M3&J8<[(A\>&TOUE+D?^PK 6G3::LF/D'V:X=%!:;R,RWG-AIU)T>/&0L&YRN M[E\]TQCT;X#G*W;+3[LM1MSZJH*8L.+IRP5;"D^/TMV X" MT];SR:QD!WJ"B;),/R\H$V!E9+N4>Y2=N@)('\\<\^]5>"SUZNG^,<42:RER M3X9LHO]HWL/4T6'26IITF82=6.%(3N2=2LV!@(' M7RLI.'>J6@Z"WE!XY04M\TC7U;-IL.A6]SCCC]^ICCS%H%E)05E>P_?[*MN6 M5<-'2FM/VX;4['MQ?,U$D?4#_PYW1?-(X9H)F8LOCSV2?>JFW#WG)]P54ZFM MC^+7>53)O0$E/57FCF"L?NU.%S*FJI ()J,0"5@5KR5&M(2A(>%ZO.Z=>.15 M75==T.,W4 (87P@FFRG#$] T%KJ.3-NG34DZ+=]9OK'G&73_2RR ^HBEI)@?G/6Y4_W:N2[[588QT' MF%;F1=8?448FX15RC>MN[9Z71GT]X_G]9]_8[R^8NS.M=;>_>,P)-TE, <3C M!)T\KI.?JT3JS],S@8D6[]INU)6F[!K-]XC79^ [1,I69>D^A@XJCO=B;),@ MYX )KW;EA?MX03%A73Q4M(*E]^9Z<*O^'-]T6N93.U=3;\V,R:9C8:VYRK/1 MJVJG[5U8TA],*;G!]"C-49!HG/1SI)%V 25K10NO;4.%8O5C>W8)4[9!G&Q= M#23Y^H%H37VBQ=T $X5[#36.A+T7AH5K 2C>]8D6_WE>^0]GQG?[V^)1MHN- MI@1AT4+T7\.D[YC5I>(E:0=(DL2UTXZQ]5+AC,7>MX,Z3ZT?.[MW)LO V.@W M_;9WQQ)G(Z%/0T2I9&>PD&%4OLA9T87)OSRF.R/&DU+[+ WE?4;J0,VK*XQM2A@H6A: S@QK?5P[L&E]1%YP0>L; M-K>V+BNH[CX<\PY45+F:]V[ZOE^:TOC"R*C]QIF0I!)=[*,!'Y=GPQ)1<5PK M;I)V?BIX&BQT[:C%IX29?;2X?(S;,HCKE,H)DZWY#5.2J3SF&:.[>IP([:E_ MG.\A=6E8NF::^> MV-%=6)\.];A.#TRFLJ"^_M5U)021$!."3HGR?EXO%MC7*.O2ZWQ__X*]DNW* M,QJ(MI6PV_/NF6/W68[='MG*_=._CXT=8UUJ=C[W-C-Y+3)EFMV?B,8, ">[ M@%>3W3*!47E-TL#%-P5H\,,@GWM3):RPQL%?[P/N%8>/U# M7[$DVU+G$S;VW'CBCV3>=='!%-V$WUR[^%VUNTM'J7"GK]=^]"3&G6N#AG93 MP9&238_KX_$K@2\7GRS*EZ>F(5ZU7MWSFGJ?LDZ.S08;+H!>)_>M44%Z$'E: M@W*1V$U#0W_Q^MDQNLTLR%.V^X>_@,4/O!;#5?ODZ9: _0<.O^OZ%2<%343; MDISA]CIMTRTPLR%B"2A?XJ]?G M>6OAY"=^7&9JZ(6C(2MDF\!UEY[ZAQF?UY^7;=U\.:R<9P4)?KJ\K'JDY ]X M&O*\-J_:6T6H[J5IIQ>@Q3KAVX#9!]*ZV'^<<-P4]'L/Z&=\ MTY),\_NOFFY4[1O2SER#9]\"-K?Y*] MF9M)"]7$SEK1Q_E9[[-#I^PYPW'+96.0[(WHX>RYIMQW0<&%VQ% Y95HG\]9TM=3V !*XLKF"[C3A#UD@_NOSF4 L%NQ5X.:9YK^CE+F6WQ*@Y:KM.:)KJ''V91$UO:_"JM\ & MJ#W'Y)\9;?A:9V8-SO3VC) #>K8("3UG]DV/L97*N@!*LS>&"FINT(?.N\6.W*WZAI 5,^_ M,$;N:R-,#IS0WXXB!''O//#-8*9&'UQQ-[I5]H6[?U:L+Q02KGWJXRSX:IN M+5S.LRGR9K/-6 H1O^DIA95 6UWJ%J[AJN!<47B;N$NW5=F[]

    •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end XML 100 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 101 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 102 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 138 503 1 false 59 0 false 12 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.castlebiosciences.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0002002 - Document - Audit Information Sheet http://www.castlebiosciences.com/role/AuditInformation Audit Information Notes 2 false false R3.htm 1001003 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Uncategorized 3 false false R4.htm 1002004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Cover 4 false false R5.htm 1003005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 5 false false R6.htm 1004006 - Statement - CONSOLIDATED STATEMENTS STOCKHOLDERS??? EQUITY Sheet http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENTS STOCKHOLDERS??? EQUITY Statements 6 false false R7.htm 1005007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101101 - Disclosure - Organization and Description of Business Sheet http://www.castlebiosciences.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 8 false false R9.htm 2102102 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2105103 - Disclosure - Revenue Sheet http://www.castlebiosciences.com/role/Revenue Revenue Notes 10 false false R11.htm 2110104 - Disclosure - Loss Per Share Sheet http://www.castlebiosciences.com/role/LossPerShare Loss Per Share Notes 11 false false R12.htm 2113105 - Disclosure - Asset Acquisitions Sheet http://www.castlebiosciences.com/role/AssetAcquisitions Asset Acquisitions Notes 12 false false R13.htm 2117106 - Disclosure - Property and Equipment, Net Sheet http://www.castlebiosciences.com/role/PropertyandEquipmentNet Property and Equipment, Net Notes 13 false false R14.htm 2121107 - Disclosure - Intangible Assets, Net Sheet http://www.castlebiosciences.com/role/IntangibleAssetsNet Intangible Assets, Net Notes 14 false false R15.htm 2126108 - Disclosure - Other Accrued and Current Liabilities Sheet http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilities Other Accrued and Current Liabilities Notes 15 false false R16.htm 2129109 - Disclosure - Leases Sheet http://www.castlebiosciences.com/role/Leases Leases Notes 16 false false R17.htm 2137110 - Disclosure - Long-Term Debt Sheet http://www.castlebiosciences.com/role/LongTermDebt Long-Term Debt Notes 17 false false R18.htm 2139111 - Disclosure - Fair Value Measurements Sheet http://www.castlebiosciences.com/role/FairValueMeasurements Fair Value Measurements Notes 18 false false R19.htm 2144112 - Disclosure - Commitments and Contingencies Sheet http://www.castlebiosciences.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 19 false false R20.htm 2145113 - Disclosure - Stockholders??? Equity Sheet http://www.castlebiosciences.com/role/StockholdersEquity Stockholders??? Equity Notes 20 false false R21.htm 2147114 - Disclosure - Stock Incentive Plans and Stock Based Compensation Sheet http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensation Stock Incentive Plans and Stock Based Compensation Notes 21 false false R22.htm 2154115 - Disclosure - Income Taxes Sheet http://www.castlebiosciences.com/role/IncomeTaxes Income Taxes Notes 22 false false R23.htm 2203201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPolicies 23 false false R24.htm 2306301 - Disclosure - Revenue (Tables) Sheet http://www.castlebiosciences.com/role/RevenueTables Revenue (Tables) Tables http://www.castlebiosciences.com/role/Revenue 24 false false R25.htm 2311302 - Disclosure - Loss Per Share (Tables) Sheet http://www.castlebiosciences.com/role/LossPerShareTables Loss Per Share (Tables) Tables http://www.castlebiosciences.com/role/LossPerShare 25 false false R26.htm 2314303 - Disclosure - Asset Acquisition (Tables) Sheet http://www.castlebiosciences.com/role/AssetAcquisitionTables Asset Acquisition (Tables) Tables http://www.castlebiosciences.com/role/AssetAcquisitions 26 false false R27.htm 2318304 - Disclosure - Property and Equipment, Net (Tables) Sheet http://www.castlebiosciences.com/role/PropertyandEquipmentNetTables Property and Equipment, Net (Tables) Tables http://www.castlebiosciences.com/role/PropertyandEquipmentNet 27 false false R28.htm 2322305 - Disclosure - Intangible Assets, Net (Tables) Sheet http://www.castlebiosciences.com/role/IntangibleAssetsNetTables Intangible Assets, Net (Tables) Tables http://www.castlebiosciences.com/role/IntangibleAssetsNet 28 false false R29.htm 2327306 - Disclosure - Other Accrued and Current Liabilities (Tables) Sheet http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesTables Other Accrued and Current Liabilities (Tables) Tables http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilities 29 false false R30.htm 2330307 - Disclosure - Leases (Tables) Sheet http://www.castlebiosciences.com/role/LeasesTables Leases (Tables) Tables http://www.castlebiosciences.com/role/Leases 30 false false R31.htm 2340308 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.castlebiosciences.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.castlebiosciences.com/role/FairValueMeasurements 31 false false R32.htm 2348309 - Disclosure - Stock Incentive Plans and Stock Based Compensation (Tables) Sheet http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables Stock Incentive Plans and Stock Based Compensation (Tables) Tables http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensation 32 false false R33.htm 2355310 - Disclosure - Income Taxes (Tables) Sheet http://www.castlebiosciences.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.castlebiosciences.com/role/IncomeTaxes 33 false false R34.htm 2404401 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 34 false false R35.htm 2407402 - Disclosure - Revenue - Narrative (Details) Sheet http://www.castlebiosciences.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 35 false false R36.htm 2408403 - Disclosure - Revenue - Disaggregation of Revenue (Details) Sheet http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails Revenue - Disaggregation of Revenue (Details) Details 36 false false R37.htm 2409404 - Disclosure - Revenue - Payor Concentration (Details) Sheet http://www.castlebiosciences.com/role/RevenuePayorConcentrationDetails Revenue - Payor Concentration (Details) Details 37 false false R38.htm 2412405 - Disclosure - Loss Per Share - Schedule of Antidilutive Securities (Details) Sheet http://www.castlebiosciences.com/role/LossPerShareScheduleofAntidilutiveSecuritiesDetails Loss Per Share - Schedule of Antidilutive Securities (Details) Details 38 false false R39.htm 2415406 - Disclosure - Asset Acquisitions - Narrative (Details) Sheet http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails Asset Acquisitions - Narrative (Details) Details 39 false false R40.htm 2416407 - Disclosure - Asset Acquisitions - Assets Acquired and Liabilities Assumed (Details) Sheet http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails Asset Acquisitions - Assets Acquired and Liabilities Assumed (Details) Details 40 false false R41.htm 2419408 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details) Sheet http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails Property and Equipment, Net - Summary of Property and Equipment (Details) Details 41 false false R42.htm 2420409 - Disclosure - Property and Equipment, Net - Summary of Depreciation Expense (Details) Sheet http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofDepreciationExpenseDetails Property and Equipment, Net - Summary of Depreciation Expense (Details) Details 42 false false R43.htm 2423410 - Disclosure - Intangible Assets, Net - Summary of Intangible Assets (Details) Sheet http://www.castlebiosciences.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails Intangible Assets, Net - Summary of Intangible Assets (Details) Details 43 false false R44.htm 2424411 - Disclosure - Intangible Asset, Net - Future Amortization (Details) Sheet http://www.castlebiosciences.com/role/IntangibleAssetNetFutureAmortizationDetails Intangible Asset, Net - Future Amortization (Details) Details 44 false false R45.htm 2425412 - Disclosure - Intangible Assets, Net - Narrative (Details) Sheet http://www.castlebiosciences.com/role/IntangibleAssetsNetNarrativeDetails Intangible Assets, Net - Narrative (Details) Details 45 false false R46.htm 2428413 - Disclosure - Other Accrued and Current Liabilities (Details) Sheet http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails Other Accrued and Current Liabilities (Details) Details http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesTables 46 false false R47.htm 2431414 - Disclosure - Leases - Narrative (Details) Sheet http://www.castlebiosciences.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 47 false false R48.htm 2432415 - Disclosure - Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details) Sheet http://www.castlebiosciences.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details) Details 48 false false R49.htm 2433416 - Disclosure - Leases - Lease Cost (Details) Sheet http://www.castlebiosciences.com/role/LeasesLeaseCostDetails Leases - Lease Cost (Details) Details 49 false false R50.htm 2434417 - Disclosure - Leases - Other information (Details) Sheet http://www.castlebiosciences.com/role/LeasesOtherinformationDetails Leases - Other information (Details) Details 50 false false R51.htm 2435418 - Disclosure - Leases - Operating Lease and Finance Lease Maturity (Details) Sheet http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails Leases - Operating Lease and Finance Lease Maturity (Details) Details 51 false false R52.htm 2436419 - Disclosure - Leases - Future Minimum Lease Payments (Details) Sheet http://www.castlebiosciences.com/role/LeasesFutureMinimumLeasePaymentsDetails Leases - Future Minimum Lease Payments (Details) Details 52 false false R53.htm 2438420 - Disclosure - Long-Term Debt - Narrative (Details) Sheet http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails Long-Term Debt - Narrative (Details) Details 53 false false R54.htm 2441421 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities at Fair Value (Details) Sheet http://www.castlebiosciences.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesatFairValueDetails Fair Value Measurements - Summary of Financial Assets and Liabilities at Fair Value (Details) Details 54 false false R55.htm 2442422 - Disclosure - Fair Value Measurements - Changes in the Level 3 Fair Value Assets and Liabilities (Details) Sheet http://www.castlebiosciences.com/role/FairValueMeasurementsChangesintheLevel3FairValueAssetsandLiabilitiesDetails Fair Value Measurements - Changes in the Level 3 Fair Value Assets and Liabilities (Details) Details 55 false false R56.htm 2443423 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 56 false false R57.htm 2446424 - Disclosure - Stockholders??? Equity - Narrative (Details) Sheet http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails Stockholders??? Equity - Narrative (Details) Details 57 false false R58.htm 2449425 - Disclosure - Stock Incentive Plans and Stock Based Compensation - Narrative (Details) Sheet http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails Stock Incentive Plans and Stock Based Compensation - Narrative (Details) Details http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables 58 false false R59.htm 2450426 - Disclosure - Stock Incentive Plans and Stock Based Compensation - Activity Under Stock Incentive Plan (Details) Sheet http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails Stock Incentive Plans and Stock Based Compensation - Activity Under Stock Incentive Plan (Details) Details 59 false false R60.htm 2451427 - Disclosure - Stock Incentive Plans and Stock Based Compensation - Restricted Stock Units Activity (Details) Sheet http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails Stock Incentive Plans and Stock Based Compensation - Restricted Stock Units Activity (Details) Details 60 false false R61.htm 2452428 - Disclosure - Stock Incentive Plans and Stock Based Compensation - Assumptions Used in Fair Value of Stock Options and ESPP (Details) Sheet http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails Stock Incentive Plans and Stock Based Compensation - Assumptions Used in Fair Value of Stock Options and ESPP (Details) Details 61 false false R62.htm 2453429 - Disclosure - Stock Incentive Plans and Stock Based Compensation - Stock-based Compensation Expense (Details) Sheet http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails Stock Incentive Plans and Stock Based Compensation - Stock-based Compensation Expense (Details) Details 62 false false R63.htm 2456430 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details) Sheet http://www.castlebiosciences.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails Income Taxes - Components of Income Tax Expense (Benefit) (Details) Details 63 false false R64.htm 2457431 - Disclosure - Income Taxes - Income Tax Expense Reconciliation (Details) Sheet http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails Income Taxes - Income Tax Expense Reconciliation (Details) Details 64 false false R65.htm 2458432 - Disclosure - Income Taxes - Deferred Tax Assets And Liabilities (Details) Sheet http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails Income Taxes - Deferred Tax Assets And Liabilities (Details) Details 65 false false R66.htm 2459433 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.castlebiosciences.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 66 false false All Reports Book All Reports cstl-20211231.htm cstl-20211231.xsd cstl-20211231_cal.xml cstl-20211231_def.xml cstl-20211231_lab.xml cstl-20211231_pre.xml exhibit1011non-employeedir.htm exhibit211subsidiaries.htm exhibit23consent10-k2021.htm exhibit311yearend2021.htm exhibit312yearend2021.htm exhibit321yearend2021.htm cstl-20211231_g1.jpg cstl-20211231_g10.jpg cstl-20211231_g11.jpg cstl-20211231_g12.jpg cstl-20211231_g13.jpg cstl-20211231_g14.jpg cstl-20211231_g15.jpg cstl-20211231_g16.jpg cstl-20211231_g17.jpg cstl-20211231_g18.jpg cstl-20211231_g19.jpg cstl-20211231_g2.jpg cstl-20211231_g3.jpg cstl-20211231_g4.jpg cstl-20211231_g5.jpg cstl-20211231_g6.jpg cstl-20211231_g7.jpg cstl-20211231_g8.jpg cstl-20211231_g9.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 105 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cstl-20211231.htm": { "axisCustom": 0, "axisStandard": 28, "contextCount": 138, "dts": { "calculationLink": { "local": [ "cstl-20211231_cal.xml" ] }, "definitionLink": { "local": [ "cstl-20211231_def.xml" ] }, "inline": { "local": [ "cstl-20211231.htm" ] }, "labelLink": { "local": [ "cstl-20211231_lab.xml" ] }, "presentationLink": { "local": [ "cstl-20211231_pre.xml" ] }, "schema": { "local": [ "cstl-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 609, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 6, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 10 }, "keyCustom": 56, "keyStandard": 447, "memberCustom": 19, "memberStandard": 38, "nsprefix": "cstl", "nsuri": "http://www.castlebiosciences.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.castlebiosciences.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105103 - Disclosure - Revenue", "role": "http://www.castlebiosciences.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110104 - Disclosure - Loss Per Share", "role": "http://www.castlebiosciences.com/role/LossPerShare", "shortName": "Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113105 - Disclosure - Asset Acquisitions", "role": "http://www.castlebiosciences.com/role/AssetAcquisitions", "shortName": "Asset Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117106 - Disclosure - Property and Equipment, Net", "role": "http://www.castlebiosciences.com/role/PropertyandEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121107 - Disclosure - Intangible Assets, Net", "role": "http://www.castlebiosciences.com/role/IntangibleAssetsNet", "shortName": "Intangible Assets, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126108 - Disclosure - Other Accrued and Current Liabilities", "role": "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilities", "shortName": "Other Accrued and Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129109 - Disclosure - Leases", "role": "http://www.castlebiosciences.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137110 - Disclosure - Long-Term Debt", "role": "http://www.castlebiosciences.com/role/LongTermDebt", "shortName": "Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139111 - Disclosure - Fair Value Measurements", "role": "http://www.castlebiosciences.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2144112 - Disclosure - Commitments and Contingencies", "role": "http://www.castlebiosciences.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0002002 - Document - Audit Information", "role": "http://www.castlebiosciences.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2145113 - Disclosure - Stockholders\u2019 Equity", "role": "http://www.castlebiosciences.com/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2147114 - Disclosure - Stock Incentive Plans and Stock Based Compensation", "role": "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensation", "shortName": "Stock Incentive Plans and Stock Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2154115 - Disclosure - Income Taxes", "role": "http://www.castlebiosciences.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Revenue (Tables)", "role": "http://www.castlebiosciences.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - Loss Per Share (Tables)", "role": "http://www.castlebiosciences.com/role/LossPerShareTables", "shortName": "Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314303 - Disclosure - Asset Acquisition (Tables)", "role": "http://www.castlebiosciences.com/role/AssetAcquisitionTables", "shortName": "Asset Acquisition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318304 - Disclosure - Property and Equipment, Net (Tables)", "role": "http://www.castlebiosciences.com/role/PropertyandEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322305 - Disclosure - Intangible Assets, Net (Tables)", "role": "http://www.castlebiosciences.com/role/IntangibleAssetsNetTables", "shortName": "Intangible Assets, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327306 - Disclosure - Other Accrued and Current Liabilities (Tables)", "role": "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesTables", "shortName": "Other Accrued and Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001003 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "cstl:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2330307 - Disclosure - Leases (Tables)", "role": "http://www.castlebiosciences.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "cstl:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2340308 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.castlebiosciences.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2348309 - Disclosure - Stock Incentive Plans and Stock Based Compensation (Tables)", "role": "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables", "shortName": "Stock Incentive Plans and Stock Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2355310 - Disclosure - Income Taxes (Tables)", "role": "http://www.castlebiosciences.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "role": "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "cstl:ContractWithCustomerCustomerPaymentTerms", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Revenue - Narrative (Details)", "role": "http://www.castlebiosciences.com/role/RevenueNarrativeDetails", "shortName": "Revenue - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "cstl:ContractWithCustomerCustomerPaymentTerms", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Revenue - Disaggregation of Revenue (Details)", "role": "http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails", "shortName": "Revenue - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ia6b3ef0da1d9401595e4971679879e53_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i5f7541c4257c461a9a2822805ca54eb9_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Revenue - Payor Concentration (Details)", "role": "http://www.castlebiosciences.com/role/RevenuePayorConcentrationDetails", "shortName": "Revenue - Payor Concentration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i5f7541c4257c461a9a2822805ca54eb9_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - Loss Per Share - Schedule of Antidilutive Securities (Details)", "role": "http://www.castlebiosciences.com/role/LossPerShareScheduleofAntidilutiveSecuritiesDetails", "shortName": "Loss Per Share - Schedule of Antidilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "cstl:AssetAcquisitionPostClosingPurchasePriceAdjustmentReceivable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415406 - Disclosure - Asset Acquisitions - Narrative (Details)", "role": "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails", "shortName": "Asset Acquisitions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "id7131c5ed1354809a68f77297569a41c_D20210528-20210528", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PaymentsToAcquireProductiveAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesOutstanding", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AssetAcquisitionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i7a2d9fe1e1ae42789204c737065835e6_D20211203-20211203", "decimals": "-3", "first": true, "lang": "en-US", "name": "cstl:AssetsAcquisitionsCash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416407 - Disclosure - Asset Acquisitions - Assets Acquired and Liabilities Assumed (Details)", "role": "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails", "shortName": "Asset Acquisitions - Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AssetAcquisitionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i7a2d9fe1e1ae42789204c737065835e6_D20211203-20211203", "decimals": "-3", "first": true, "lang": "en-US", "name": "cstl:AssetsAcquisitionsCash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419408 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)", "role": "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails", "shortName": "Property and Equipment, Net - Summary of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420409 - Disclosure - Property and Equipment, Net - Summary of Depreciation Expense (Details)", "role": "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofDepreciationExpenseDetails", "shortName": "Property and Equipment, Net - Summary of Depreciation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423410 - Disclosure - Intangible Assets, Net - Summary of Intangible Assets (Details)", "role": "http://www.castlebiosciences.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails", "shortName": "Intangible Assets, Net - Summary of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424411 - Disclosure - Intangible Asset, Net - Future Amortization (Details)", "role": "http://www.castlebiosciences.com/role/IntangibleAssetNetFutureAmortizationDetails", "shortName": "Intangible Asset, Net - Future Amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425412 - Disclosure - Intangible Assets, Net - Narrative (Details)", "role": "http://www.castlebiosciences.com/role/IntangibleAssetsNetNarrativeDetails", "shortName": "Intangible Assets, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428413 - Disclosure - Other Accrued and Current Liabilities (Details)", "role": "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails", "shortName": "Other Accrued and Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ia9f207c1f6cc4e19b1797b53ae3a0016_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431414 - Disclosure - Leases - Narrative (Details)", "role": "http://www.castlebiosciences.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ia9f207c1f6cc4e19b1797b53ae3a0016_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432415 - Disclosure - Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details)", "role": "http://www.castlebiosciences.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails", "shortName": "Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cstl:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433416 - Disclosure - Leases - Lease Cost (Details)", "role": "http://www.castlebiosciences.com/role/LeasesLeaseCostDetails", "shortName": "Leases - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "role": "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434417 - Disclosure - Leases - Other information (Details)", "role": "http://www.castlebiosciences.com/role/LeasesOtherinformationDetails", "shortName": "Leases - Other information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435418 - Disclosure - Leases - Operating Lease and Finance Lease Maturity (Details)", "role": "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails", "shortName": "Leases - Operating Lease and Finance Lease Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i49e48de81474496492891aee8311b855_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436419 - Disclosure - Leases - Future Minimum Lease Payments (Details)", "role": "http://www.castlebiosciences.com/role/LeasesFutureMinimumLeasePaymentsDetails", "shortName": "Leases - Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i49e48de81474496492891aee8311b855_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438420 - Disclosure - Long-Term Debt - Narrative (Details)", "role": "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails", "shortName": "Long-Term Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ifaa6f78708294c729a7c1e496ba95a69_I20181130", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441421 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities at Fair Value (Details)", "role": "http://www.castlebiosciences.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesatFairValueDetails", "shortName": "Fair Value Measurements - Summary of Financial Assets and Liabilities at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ibd767cd51bf74ffeb826a86ccc5f72b8_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i49e48de81474496492891aee8311b855_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442422 - Disclosure - Fair Value Measurements - Changes in the Level 3 Fair Value Assets and Liabilities (Details)", "role": "http://www.castlebiosciences.com/role/FairValueMeasurementsChangesintheLevel3FairValueAssetsandLiabilitiesDetails", "shortName": "Fair Value Measurements - Changes in the Level 3 Fair Value Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i49e48de81474496492891aee8311b855_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i129d090af8f249329594d5b1eb9535aa_D20210101-20211231", "decimals": "3", "first": true, "lang": "en-US", "name": "cstl:AssetAcquisitionContingentConsiderationLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443423 - Disclosure - Fair Value Measurements - Narrative (Details)", "role": "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails", "shortName": "Fair Value Measurements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i129d090af8f249329594d5b1eb9535aa_D20210101-20211231", "decimals": "3", "first": true, "lang": "en-US", "name": "cstl:AssetAcquisitionContingentConsiderationLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446424 - Disclosure - Stockholders\u2019 Equity - Narrative (Details)", "role": "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails", "shortName": "Stockholders\u2019 Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockDividendsPerShareDeclared", "us-gaap:CommonStockDividendsPerShareCashPaid", "us-gaap:CommonStockDividendsPerShareCashPaid", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449425 - Disclosure - Stock Incentive Plans and Stock Based Compensation - Narrative (Details)", "role": "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails", "shortName": "Stock Incentive Plans and Stock Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i49e48de81474496492891aee8311b855_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450426 - Disclosure - Stock Incentive Plans and Stock Based Compensation - Activity Under Stock Incentive Plan (Details)", "role": "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails", "shortName": "Stock Incentive Plans and Stock Based Compensation - Activity Under Stock Incentive Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie3686b1c9d3744038937264a46a295eb_I20191231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i83e849c831714d2b8965add319400189_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004006 - Statement - CONSOLIDATED STATEMENTS STOCKHOLDERS\u2019 EQUITY", "role": "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY", "shortName": "CONSOLIDATED STATEMENTS STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i83e849c831714d2b8965add319400189_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i088e45d64c384a3f84ad367f18550700_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451427 - Disclosure - Stock Incentive Plans and Stock Based Compensation - Restricted Stock Units Activity (Details)", "role": "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails", "shortName": "Stock Incentive Plans and Stock Based Compensation - Restricted Stock Units Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i67e45811404345c99e42d3379531b334_I20191231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i282be5fa1fc546f282691ba282c69f59_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452428 - Disclosure - Stock Incentive Plans and Stock Based Compensation - Assumptions Used in Fair Value of Stock Options and ESPP (Details)", "role": "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails", "shortName": "Stock Incentive Plans and Stock Based Compensation - Assumptions Used in Fair Value of Stock Options and ESPP (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i282be5fa1fc546f282691ba282c69f59_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453429 - Disclosure - Stock Incentive Plans and Stock Based Compensation - Stock-based Compensation Expense (Details)", "role": "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails", "shortName": "Stock Incentive Plans and Stock Based Compensation - Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456430 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)", "role": "http://www.castlebiosciences.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails", "shortName": "Income Taxes - Components of Income Tax Expense (Benefit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossAttributableToParent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2457431 - Disclosure - Income Taxes - Income Tax Expense Reconciliation (Details)", "role": "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails", "shortName": "Income Taxes - Income Tax Expense Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458432 - Disclosure - Income Taxes - Deferred Tax Assets And Liabilities (Details)", "role": "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails", "shortName": "Income Taxes - Deferred Tax Assets And Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:TaxCreditCarryforwardAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459433 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.castlebiosciences.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "i70bebb2490274d139831aa81792e205c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:TaxCreditCarryforwardAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization and Description of Business", "role": "http://www.castlebiosciences.com/role/OrganizationandDescriptionofBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cstl-20211231.htm", "contextRef": "ie38b5c83696c42db93ff770f9934d2cb_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 59, "tag": { "cstl_AccountsReceivableCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Current [Member]", "label": "Accounts Receivable, Current [Member]", "terseLabel": "Percentage of Accounts Receivable (current)" } } }, "localname": "AccountsReceivableCurrentMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/RevenuePayorConcentrationDetails" ], "xbrltype": "domainItemType" }, "cstl_AccountsReceivableNoncurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Noncurrent [Member]", "label": "Accounts Receivable, Noncurrent [Member]", "terseLabel": "Percentage of Accounts Receivable (non-current)" } } }, "localname": "AccountsReceivableNoncurrentMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/RevenuePayorConcentrationDetails" ], "xbrltype": "domainItemType" }, "cstl_AccruedClinicalStudiesCurrent": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Clinical Studies, Current", "label": "Accrued Clinical Studies, Current", "terseLabel": "Clinical studies" } } }, "localname": "AccruedClinicalStudiesCurrent", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cstl_AccruedPayorRefundsCurrent": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Payor Refunds, Current", "label": "Accrued Payor Refunds, Current", "terseLabel": "Accrued payor refunds" } } }, "localname": "AccruedPayorRefundsCurrent", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cstl_AssembledWorkforceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assembled Workforce", "label": "Assembled Workforce [Member]", "terseLabel": "Assembled workforce" } } }, "localname": "AssembledWorkforceMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cstl_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Assets Acquired and Liabilities Assumed, Net", "label": "Asset Acquisition, Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total cost allocated" } } }, "localname": "AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "cstl_AssetAcquisitionContingentConsiderationArrangementsRangeOfOutcomesValueHighShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Contingent Consideration Arrangements, Range Of Outcomes, Value, High, Shares", "label": "Asset Acquisition, Contingent Consideration Arrangements, Range Of Outcomes, Value, High, Shares", "terseLabel": "Maximum number of shares payable in earnout payment (in shares)" } } }, "localname": "AssetAcquisitionContingentConsiderationArrangementsRangeOfOutcomesValueHighShares", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "cstl_AssetAcquisitionContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Contingent Consideration, Liability, Measurement Input", "label": "Asset Acquisition, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Asset acquisition, contingent consideration liability, measurement input" } } }, "localname": "AssetAcquisitionContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "percentItemType" }, "cstl_AssetAcquisitionEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Earnout Payments, Number Of Trading Days To Determine Volume Weighted-Average Price", "label": "Asset Acquisition, Earnout Payments, Number Of Trading Days To Determine Volume Weighted-Average Price", "terseLabel": "Number of trading days to determine volume weighted-average price of common stock" } } }, "localname": "AssetAcquisitionEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "cstl_AssetAcquisitionInventory": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Inventory", "label": "Asset Acquisition, Inventory", "terseLabel": "Inventory" } } }, "localname": "AssetAcquisitionInventory", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cstl_AssetAcquisitionPostClosingPurchasePriceAdjustmentReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Post-Closing Purchase Price Adjustment, Receivable", "label": "Asset Acquisition, Post-Closing Purchase Price Adjustment, Receivable", "terseLabel": "Asset acquisition, receivable for purchase price adjustment" } } }, "localname": "AssetAcquisitionPostClosingPurchasePriceAdjustmentReceivable", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails", "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisitions, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "label": "Asset Acquisitions, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Additional consideration payable based on achievement of certain commercial milestones" } } }, "localname": "AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cstl_AssetsAcquisitionsAccountsPayable": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 8.0, "parentTag": "cstl_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Assets Acquisitions, Accounts Payable", "label": "Assets Acquisitions, Accounts Payable", "negatedTerseLabel": "Accounts payable" } } }, "localname": "AssetsAcquisitionsAccountsPayable", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "cstl_AssetsAcquisitionsAccountsReceivable": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 7.0, "parentTag": "cstl_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets Acquisitions, Accounts Receivable", "label": "Assets Acquisitions, Accounts Receivable", "terseLabel": "Accounts receivable" } } }, "localname": "AssetsAcquisitionsAccountsReceivable", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "cstl_AssetsAcquisitionsAccruedCompensation": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "cstl_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Assets Acquisitions, Accrued Compensation", "label": "Assets Acquisitions, Accrued Compensation", "negatedTerseLabel": "Accrued compensation" } } }, "localname": "AssetsAcquisitionsAccruedCompensation", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "cstl_AssetsAcquisitionsCash": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "cstl_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets Acquisitions, Cash", "label": "Assets Acquisitions, Cash", "terseLabel": "Cash and cash equivalents" } } }, "localname": "AssetsAcquisitionsCash", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "cstl_AssetsAcquisitionsDeferredTaxLiabilities": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "cstl_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Assets Acquisitions, Deferred Tax Liabilities", "label": "Assets Acquisitions, Deferred Tax Liabilities", "negatedTerseLabel": "Deferred tax liabilities" } } }, "localname": "AssetsAcquisitionsDeferredTaxLiabilities", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.castlebiosciences.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cstl_AssetsAcquisitionsFinanceLeaseLiability": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 10.0, "parentTag": "cstl_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Assets Acquisitions, Finance Lease Liability", "label": "Assets Acquisitions, Finance Lease Liability", "negatedTerseLabel": "Finance lease liabilities" } } }, "localname": "AssetsAcquisitionsFinanceLeaseLiability", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "cstl_AssetsAcquisitionsIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "cstl_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets Acquisitions, Intangible Assets", "label": "Assets Acquisitions, Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "AssetsAcquisitionsIntangibleAssets", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cstl_AssetsAcquisitionsOtherAccruedAndCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "cstl_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Assets Acquisitions, Other Accrued And Current Liabilities", "label": "Assets Acquisitions, Other Accrued And Current Liabilities", "negatedTerseLabel": "Other accrued and current liabilities" } } }, "localname": "AssetsAcquisitionsOtherAccruedAndCurrentLiabilities", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "cstl_AssetsAcquisitionsPrepaidExpensesAndOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 9.0, "parentTag": "cstl_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets Acquisitions, Prepaid Expenses And Other Current Assets", "label": "Assets Acquisitions, Prepaid Expenses And Other Current Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "AssetsAcquisitionsPrepaidExpensesAndOtherCurrentAssets", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "cstl_AssetsAcquisitionsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "cstl_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets Acquisitions, Property, Plant and Equipment", "label": "Assets Acquisitions, Property, Plant and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "AssetsAcquisitionsPropertyPlantAndEquipment", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "cstl_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Lessee", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Schedule of Lease Balances" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "cstl_AuditInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit Information [Abstract]", "label": "Audit Information [Abstract]" } } }, "localname": "AuditInformationAbstract", "nsuri": "http://www.castlebiosciences.com/20211231", "xbrltype": "stringItemType" }, "cstl_BlueCrossBlueShieldPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BlueCross BlueShield Plans [Member]", "label": "BlueCross BlueShield Plans [Member]", "terseLabel": "BlueCross BlueShield plans" } } }, "localname": "BlueCrossBlueShieldPlansMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/RevenuePayorConcentrationDetails" ], "xbrltype": "domainItemType" }, "cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination And Asset Acquisitions, Policy", "label": "Business Combination And Asset Acquisitions, Policy [Policy Text Block]", "terseLabel": "Acquisitions, Contingent Consideration" } } }, "localname": "BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cstl_CashFlowLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Flow, Lessee", "label": "Cash Flow, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "CashFlowLesseeAbstract", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOtherinformationDetails" ], "xbrltype": "stringItemType" }, "cstl_CentersForMedicareAndMedicaidServicesAcceleratedAndAdvancedPaymentProgramPaymentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Centers For Medicare And Medicaid Services, Accelerated And Advanced Payment Program, Payment Received", "label": "Centers For Medicare And Medicaid Services, Accelerated And Advanced Payment Program, Payment Received", "terseLabel": "Amount received from CMS under its accelerated and advance payment program" } } }, "localname": "CentersForMedicareAndMedicaidServicesAcceleratedAndAdvancedPaymentProgramPaymentReceived", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cstl_CernosticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cernostics, Inc.", "label": "Cernostics, Inc. [Member]", "terseLabel": "Cernostics, Inc." } } }, "localname": "CernosticsIncMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails", "http://www.castlebiosciences.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cstl_ContractWithCustomerCustomerPaymentTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract With Customer Customer, Payment Terms", "label": "Contract With Customer Customer, Payment Terms", "terseLabel": "Number of days contract with customer is generally paid" } } }, "localname": "ContractWithCustomerCustomerPaymentTerms", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/RevenueNarrativeDetails" ], "xbrltype": "durationItemType" }, "cstl_DebtInstrumentNumberOfMonthlyInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Number Of Monthly Installments", "label": "Debt Instrument, Number Of Monthly Installments", "terseLabel": "Number of equal monthly installments" } } }, "localname": "DebtInstrumentNumberOfMonthlyInstallments", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "cstl_DeferredPayrollTaxesCARESAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Payroll Taxes, CARES Act", "label": "Deferred Payroll Taxes, CARES Act", "terseLabel": "Deferred payroll taxes, CARES Act" } } }, "localname": "DeferredPayrollTaxesCARESAct", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cstl_DeferredTaxAssetsLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Lease Liabilities", "label": "Deferred Tax Assets, Lease Liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "DeferredTaxAssetsLeaseLiabilities", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cstl_DeferredTaxLiabilitiesChangeInAccountingMethod": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Change In Accounting Method", "label": "Deferred Tax Liabilities, Change In Accounting Method", "negatedTerseLabel": "Section 481(a) adjustment (cash to accrual)" } } }, "localname": "DeferredTaxLiabilitiesChangeInAccountingMethod", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cstl_DeferredTaxLiabilitiesRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Right-Of-Use Asset", "label": "Deferred Tax Liabilities, Right-Of-Use Asset", "negatedLabel": "ROU assets" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAsset", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cstl_DermatologicMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dermatologic", "label": "Dermatologic [Member]", "terseLabel": "Dermatologic" } } }, "localname": "DermatologicMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "cstl_DevelopedWorkforceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Developed Workforce", "label": "Developed Workforce [Member]", "terseLabel": "Assembled workforce" } } }, "localname": "DevelopedWorkforceMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "cstl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officers' Compensation, Amount", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officers' Compensation, Amount", "terseLabel": "Non-deductible officers\u2019 compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "cstl_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan [Member]", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "Employee stock purchase plan" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cstl_ExerciseOfCommonStockWarrantsNoncash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Exercise Of Common Stock Warrants, Noncash", "label": "Exercise Of Common Stock Warrants, Noncash", "terseLabel": "Cashless exercise of common stock warrants" } } }, "localname": "ExerciseOfCommonStockWarrantsNoncash", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "cstl_FollowOnPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Follow On Public Offering", "label": "Follow On Public Offering [Member]", "terseLabel": "Follow On Public Offering" } } }, "localname": "FollowOnPublicOfferingMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "cstl_IncentiveStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive Stock Options [Member]", "label": "Incentive Stock Options [Member]", "terseLabel": "ISOs" } } }, "localname": "IncentiveStockOptionsMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Assets", "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Assets", "negatedTerseLabel": "Operating lease assets" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "cstl_LeaseArrangementRenewalTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Arrangement, Renewal Term", "label": "Lease Arrangement, Renewal Term", "terseLabel": "Lease arrangement, renewal term" } } }, "localname": "LeaseArrangementRenewalTerm", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "cstl_LeaseArrangementTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Arrangement, Term Of Contract", "label": "Lease Arrangement, Term Of Contract", "terseLabel": "Lease arrangement, term of contract" } } }, "localname": "LeaseArrangementTermOfContract", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "cstl_LeasesWeightedAverageDiscountRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leases, Weighted Average Discount Rate", "label": "Leases, Weighted Average Discount Rate [Abstract]", "terseLabel": "Weighted-average discount rate" } } }, "localname": "LeasesWeightedAverageDiscountRateAbstract", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOtherinformationDetails" ], "xbrltype": "stringItemType" }, "cstl_LesseeOperatingLeaseNumberOfFacilitiesLeased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Facilities Leased", "label": "Lessee, Operating Lease, Number Of Facilities Leased", "terseLabel": "Number of facilities leased" } } }, "localname": "LesseeOperatingLeaseNumberOfFacilitiesLeased", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cstl_LesseeOperatingLeaseNumberOfOptionsToRenew": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Options To Renew", "label": "Lessee, Operating Lease, Number Of Options To Renew", "terseLabel": "Lease arrangement, number of renewal options" } } }, "localname": "LesseeOperatingLeaseNumberOfOptionsToRenew", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "cstl_MedicareAdvantagePlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare Advantage Plans [Member]", "label": "Medicare Advantage Plans [Member]", "terseLabel": "Medicare Advantage plans" } } }, "localname": "MedicareAdvantagePlansMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/RevenuePayorConcentrationDetails" ], "xbrltype": "domainItemType" }, "cstl_MedicareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare [Member]", "label": "Medicare [Member]", "terseLabel": "Medicare" } } }, "localname": "MedicareMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/RevenuePayorConcentrationDetails" ], "xbrltype": "domainItemType" }, "cstl_MyriadMyPathLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Myriad myPath, LLC", "label": "Myriad myPath, LLC [Member]", "terseLabel": "Myriad myPath, LLC" } } }, "localname": "MyriadMyPathLLCMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "cstl_OfferingCostsIncurredButNotYetPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Offering Costs Incurred But Not Yet Paid", "label": "Offering Costs Incurred But Not Yet Paid", "terseLabel": "Common stock offering costs incurred but not paid" } } }, "localname": "OfferingCostsIncurredButNotYetPaid", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "cstl_OfficeAndLaboratoryFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office And Laboratory Facility [Member]", "label": "Office And Laboratory Facility [Member]", "terseLabel": "Office and Laboratory Facility" } } }, "localname": "OfficeAndLaboratoryFacilityMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cstl_OfficeSpaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office Space [Member]", "label": "Office Space [Member]", "terseLabel": "Office Space" } } }, "localname": "OfficeSpaceMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cstl_OperatingExpensesNetOfOtherOperatingIncome": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Expenses, Net Of Other Operating Income", "label": "Operating Expenses, Net Of Other Operating Income", "totalLabel": "Total operating expenses, net" } } }, "localname": "OperatingExpensesNetOfOtherOperatingIncome", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "cstl_OperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards, Not Subject To Expiration", "label": "Operating Loss Carryforwards, Not Subject To Expiration", "terseLabel": "NOL carryforwards, not subject to expiration" } } }, "localname": "OperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cstl_OperatingLossCarryforwardsSubjecttoExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards, Subject to Expiration", "label": "Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "NOL carryforwards, subject to expiration" } } }, "localname": "OperatingLossCarryforwardsSubjecttoExpiration", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cstl_OtherOperatingIncomeLossCARESAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Operating Income (Loss), CARES Act", "label": "Other Operating Income (Loss), CARES Act", "terseLabel": "Other operating income (loss), CARES Act" } } }, "localname": "OtherOperatingIncomeLossCARESAct", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cstl_PaymentsForAssetAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for Asset Acquisitions", "label": "Payments for Asset Acquisitions", "terseLabel": "Cash purchase price" } } }, "localname": "PaymentsForAssetAcquisitions", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cstl_PaymentsToAcquireAssetAcquisitionsNetOfCashAcquired": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Asset Acquisitions, Net Of Cash Acquired", "label": "Payments To Acquire Asset Acquisitions, Net Of Cash Acquired", "negatedTerseLabel": "Asset acquisitions, net of cash and cash equivalents acquired" } } }, "localname": "PaymentsToAcquireAssetAcquisitionsNetOfCashAcquired", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "cstl_PropertyAndEquipmentAcquiredWithTenantImprovementAllowance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Property And Equipment Acquired With Tenant Improvement Allowance", "label": "Property And Equipment Acquired With Tenant Improvement Allowance", "terseLabel": "Property and equipment acquired with tenant improvement allowance" } } }, "localname": "PropertyAndEquipmentAcquiredWithTenantImprovementAllowance", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "cstl_RevenueFromContractWithCustomerRevenueNotYetRecognizedNumberOfClaimsInAdjudicationProcess": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Disputed Claims", "label": "Revenue From Contract With Customer, Revenue Not Yet Recognized, Number Of Claims In Adjudication Process", "terseLabel": "Number of claims in adjudication process" } } }, "localname": "RevenueFromContractWithCustomerRevenueNotYetRecognizedNumberOfClaimsInAdjudicationProcess", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/RevenueNarrativeDetails" ], "xbrltype": "integerItemType" }, "cstl_SaleOfStockOptionToPurchaseSharesNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale Of Stock, Option To Purchase Shares, Number Of Shares", "label": "Sale Of Stock, Option To Purchase Shares, Number Of Shares", "terseLabel": "Option to purchase, number of shares (in shares)" } } }, "localname": "SaleOfStockOptionToPurchaseSharesNumberOfShares", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "cstl_SaleOfStockSellingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale Of Stock, Selling Period", "label": "Sale Of Stock, Selling Period", "terseLabel": "Common stock option period" } } }, "localname": "SaleOfStockSellingPeriod", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "durationItemType" }, "cstl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssuedDuringThePeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Aggregate Intrinsic Value, Issued During The Period", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Aggregate Intrinsic Value, Issued During The Period", "terseLabel": "Aggregate intrinsic value of shares issued under the ESPP" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssuedDuringThePeriod", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cstl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period, Grant Date Fair Value", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period, Grant Date Fair Value", "terseLabel": "Grant date fair value of awards granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cstl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesToReceiveAwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Employees To Receive Awards", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Employees To Receive Awards", "terseLabel": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Employees To Receive Awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployeesToReceiveAwards", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "integerItemType" }, "cstl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Purchase Periods", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Purchase Periods", "terseLabel": "Number of offering periods" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "integerItemType" }, "cstl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period", "terseLabel": "Offering period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "cstl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOwnership": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement, By Share-Based Payment Award, Percentage Of Voting Power Ownership", "label": "Share-Based Compensation Arrangement, By Share-Based Payment Award, Percentage Of Voting Power Ownership", "terseLabel": "Percentage of voting power ownership" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfVotingPowerOwnership", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "cstl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPriceOfCommonStockPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Price Of Common Stock, Percentage", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Price Of Common Stock, Percentage", "terseLabel": "Percentage of share price at grant date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPriceOfCommonStockPercentage", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "cstl_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Purchase Period", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Purchase Period", "terseLabel": "Purchase period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "cstl_StockIssuedDuringPeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Warrants Exercised", "label": "Stock Issued During Period, Value, Warrants Exercised", "terseLabel": "Exercise of common stock warrants" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "cstl_StockIssuedDuringPeriodWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Warrants Exercised", "label": "Stock Issued During Period, Warrants Exercised", "terseLabel": "Exercise of common stock warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodWarrantsExercised", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "cstl_StockOptionsAndRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options and Restricted Stock Units", "label": "Stock Options and Restricted Stock Units [Member]", "terseLabel": "Stock options and restricted stock units" } } }, "localname": "StockOptionsAndRestrictedStockUnitsMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/LossPerShareScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "cstl_ThirdPartyPayorConcentrationRiskMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third-Party Payor Concentration Risk [Member]", "label": "Third-Party Payor Concentration Risk [Member]", "terseLabel": "Third-Party Payor Concentration Risk" } } }, "localname": "ThirdPartyPayorConcentrationRiskMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/RevenuePayorConcentrationDetails" ], "xbrltype": "domainItemType" }, "cstl_TwoThousandEighteenLoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Eighteen Loan And Security Agreement [Member]", "label": "Two Thousand Eighteen Loan And Security Agreement [Member]", "terseLabel": "2018 Loan and Security Agreement" } } }, "localname": "TwoThousandEighteenLoanAndSecurityAgreementMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "cstl_TwoThousandNineteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Nineteen Equity Incentive Plan [Member]", "label": "Two Thousand Nineteen Equity Incentive Plan [Member]", "terseLabel": "2019 Equity Incentive Plan" } } }, "localname": "TwoThousandNineteenEquityIncentivePlanMember", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cstl_WeightedAverageRemainingLeaseTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Remaining Lease Term", "label": "Weighted Average Remaining Lease Term [Abstract]", "terseLabel": "Weighted-average remaining lease term (years)" } } }, "localname": "WeightedAverageRemainingLeaseTermAbstract", "nsuri": "http://www.castlebiosciences.com/20211231", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOtherinformationDetails" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r626", "r627", "r628" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r622" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.castlebiosciences.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r57", "r59", "r109", "r110", "r259", "r296" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/RevenuePayorConcentrationDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r116", "r123", "r129", "r204", "r401", "r402", "r403", "r436", "r437", "r462", "r465", "r467", "r468", "r634" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY", "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r116", "r123", "r129", "r204", "r401", "r402", "r403", "r436", "r437", "r462", "r465", "r467", "r468", "r634" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY", "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r116", "r123", "r129", "r204", "r401", "r402", "r403", "r436", "r437", "r462", "r465", "r467", "r468", "r634" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY", "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r258", "r295", "r362", "r363", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r598", "r600", "r619", "r620" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r258", "r295", "r362", "r363", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r598", "r600", "r619", "r620" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails", "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r184", "r339", "r342", "r553", "r597", "r599" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r184", "r339", "r342", "r553", "r597", "r599" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r258", "r295", "r350", "r362", "r363", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r598", "r600", "r619", "r620" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails", "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r258", "r295", "r350", "r362", "r363", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r598", "r600", "r619", "r620" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails", "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r58", "r59", "r109", "r110", "r259", "r296" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/RevenuePayorConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r117", "r118", "r119", "r120", "r198", "r199", "r201", "r202", "r203", "r204", "r205", "r206", "r243", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r436", "r437", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r532", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r632", "r633", "r634", "r635", "r636" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting Standards Update [Extensible Enumeration]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Other Accrued and Current Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r43", "r538" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r10", "r30", "r187", "r188" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetNoncurrent": { "auth_ref": [ "r30", "r187", "r576", "r587" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent.", "label": "Accounts Receivable, after Allowance for Credit Loss, Noncurrent", "terseLabel": "Long-term accounts receivable, net" } } }, "localname": "AccountsReceivableNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrentAndNoncurrent": { "auth_ref": [ "r577", "r592" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.", "label": "Accrued Bonuses", "terseLabel": "Accrued bonuses" } } }, "localname": "AccruedBonusesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r13", "r14", "r45" ], "calculation": { "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Employee stock purchase plan contributions" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r14", "r45" ], "calculation": { "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Payroll Taxes, Current", "terseLabel": "Payroll tax liabilities" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r13", "r14", "r45" ], "calculation": { "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued service fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Estimated useful life (in years)" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r31", "r404", "r538" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r113", "r114", "r115", "r401", "r402", "r403", "r467" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r117", "r118", "r119", "r120", "r129", "r198", "r199", "r201", "r202", "r203", "r204", "r205", "r206", "r243", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r434", "r435", "r436", "r437", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r532", "r555", "r556", "r557", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r632", "r633", "r634", "r635", "r636" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r366", "r393", "r406" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r193", "r207", "r208", "r209" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r88", "r278", "r285", "r286", "r505" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discounts and issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r88", "r213", "r221" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 5.0, "parentTag": "cstl_OperatingExpensesNetOfOtherOperatingIncome", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of acquired intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.castlebiosciences.com/role/IntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LossPerShareScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LossPerShareScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LossPerShareScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LossPerShareScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails", "http://www.castlebiosciences.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "auth_ref": [ "r450", "r451", "r452", "r453" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "terseLabel": "Asset acquisition, transaction costs" } } }, "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionContingentConsiderationLiability": { "auth_ref": [ "r449" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized from contingent consideration in asset acquisition.", "label": "Asset Acquisition, Contingent Consideration, Liability", "terseLabel": "Asset acquisition, liability for contingent consideration" } } }, "localname": "AssetAcquisitionContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails", "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.castlebiosciences.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r449" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent.", "label": "Asset Acquisition, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration" } } }, "localname": "AssetAcquisitionContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails", "http://www.castlebiosciences.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Asset Acquisition [Line Items]", "terseLabel": "Asset Acquisition [Line Items]" } } }, "localname": "AssetAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionTable": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset acquisition.", "label": "Asset Acquisition [Table]", "terseLabel": "Asset Acquisition [Table]" } } }, "localname": "AssetAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionTableTextBlock": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of asset acquisition.", "label": "Asset Acquisition [Table Text Block]", "terseLabel": "Asset Acquisition" } } }, "localname": "AssetAcquisitionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AssetAcquisitionTextBlock": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for asset acquisition.", "label": "Asset Acquisition [Text Block]", "terseLabel": "Asset Acquisitions" } } }, "localname": "AssetAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_Assets": { "auth_ref": [ "r105", "r167", "r176", "r182", "r200", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r454", "r457", "r485", "r536", "r538", "r571", "r588" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r11", "r12", "r55", "r105", "r200", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r454", "r457", "r485", "r536", "r538" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "terseLabel": "Current assets", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r367", "r395" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails", "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]", "terseLabel": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r7", "r112", "r159" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Organization and Description of Business" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/OrganizationandDescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r93", "r94", "r95" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Accrued purchases of property and equipment" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r8", "r39", "r90" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Money market funds" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r20", "r91" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r84", "r90", "r96" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "End of year", "periodStartLabel": "Beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r84", "r494" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET CHANGE IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails", "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r317", "r365" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "verboseLabel": "Warrants outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r50", "r239", "r578", "r591" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies (Note 12)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r236", "r237", "r238", "r240", "r615" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Common stock, dividends paid (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Common stock, dividends declared (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r113", "r114", "r467" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY", "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r29", "r309" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r29" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "terseLabel": "Common stock, $0.001 par value; 200,000,000 authorized as of December\u00a031, 2021 and 2020, respectively; 25,378,520 and 24,812,487 shares issued and outstanding as of December\u00a031, 2021 and 2020, respectively." } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Accrued Compensation, Stock-Based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r61", "r63", "r64", "r71", "r580", "r594" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r153", "r154", "r186", "r482", "r483", "r614" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/RevenuePayorConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r153", "r154", "r186", "r482", "r483", "r613", "r614" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/RevenuePayorConcentrationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r153", "r154", "r186", "r482", "r483", "r613", "r614" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/RevenuePayorConcentrationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r149", "r584" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r153", "r154", "r186", "r482", "r483" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/RevenuePayorConcentrationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r153", "r154", "r186", "r482", "r483", "r614" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/RevenuePayorConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r98", "r456" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction-in-progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r319", "r320", "r340" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Medicare advance payment" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r319", "r320", "r340" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Noncurrent portion of Medicare advance payment" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": { "auth_ref": [ "r327" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.", "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period", "terseLabel": "Variable consideration adjustments included in revenue" } } }, "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r73", "r553" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "cstl_OperatingExpensesNetOfOtherOperatingIncome", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales (exclusive of amortization of acquired intangible assets)" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales (exclusive of amortization of acquired intangible assets)" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofDepreciationExpenseDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Current tax expense" } } }, "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r106", "r431", "r440" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "U.S. Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r106", "r431", "r440", "r442" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r106", "r431", "r440" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State and local" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r101", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r272", "r279", "r280", "r282", "r289" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Long-Term Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r22", "r23", "r24", "r104", "r111", "r255", "r256", "r257", "r258", "r259", "r260", "r262", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r283", "r284", "r285", "r286", "r506", "r572", "r574", "r586" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r255", "r283", "r284", "r504", "r506", "r507" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "verboseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r47", "r256" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, interest rate, stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r48", "r104", "r111", "r255", "r256", "r257", "r258", "r259", "r260", "r262", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r283", "r284", "r285", "r286", "r506" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Debt Instrument, monthly installments principal amount" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r48", "r104", "r111", "r255", "r256", "r257", "r258", "r259", "r260", "r262", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r281", "r283", "r284", "r285", "r286", "r310", "r313", "r314", "r315", "r503", "r504", "r506", "r507", "r583" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r106", "r432", "r440" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "U.S. Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Deferred tax (benefit) expense" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r88", "r106", "r432", "r440", "r441", "r442" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.castlebiosciences.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes", "totalLabel": "Total deferred" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.castlebiosciences.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r26", "r27", "r421", "r573", "r585" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r413", "r414" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r106", "r432", "r440" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State and local" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r422" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r424" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred tax assets, net" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r429", "r430" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss (\u201cNOL\u201d) carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r429", "r430" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r427", "r429", "r430" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "R&D tax credit" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r429", "r430" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r429", "r430" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r423" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Less valuation allowance", "terseLabel": "Deferred tax assets, valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails", "http://www.castlebiosciences.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r414", "r424" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred tax asset (liability)" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r429", "r430" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "negatedTerseLabel": "Intangible assets" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.", "label": "Deferred Tax Liabilities, Prepaid Expenses", "negatedTerseLabel": "Prepaid expenses" } } }, "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r429", "r430" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedTerseLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Discretionary matching contributions" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r88", "r227" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation and amortization" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofDepreciationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r88", "r165" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails", "http://www.castlebiosciences.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails", "http://www.castlebiosciences.com/role/RevenuePayorConcentrationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r339", "r342", "r343", "r344", "r345", "r346", "r347", "r348" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails", "http://www.castlebiosciences.com/role/RevenuePayorConcentrationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock Incentive Plans and Stock Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Loss per share attributable to common stockholders:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r72", "r121", "r122", "r123", "r124", "r125", "r130", "r132", "r134", "r135", "r136", "r140", "r141", "r468", "r469", "r581", "r595" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r72", "r121", "r122", "r123", "r124", "r125", "r132", "r134", "r135", "r136", "r140", "r141", "r468", "r469", "r581", "r595" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r137", "r138", "r139", "r142" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "auth_ref": [ "r407", "r416" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount", "terseLabel": "Stock-based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r394" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation expense, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r393" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, Tax Benefit", "terseLabel": "Tax benefits related to stock-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee stock purchase plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LossPerShareScheduleofAntidilutiveSecuritiesDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options", "verboseLabel": "Stock options and restricted stock units" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails", "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Lab equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r66", "r67", "r68", "r113", "r114", "r115", "r118", "r126", "r128", "r144", "r204", "r309", "r316", "r401", "r402", "r403", "r436", "r437", "r467", "r495", "r496", "r497", "r498", "r499", "r500", "r603", "r604", "r605", "r636" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r470", "r471", "r472", "r480" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r270", "r283", "r284", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r359", "r471", "r540", "r541", "r542" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r470", "r471", "r474", "r475", "r481" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r270", "r351", "r352", "r357", "r359", "r471", "r540" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Items (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r270", "r283", "r284", "r351", "r352", "r357", "r359", "r471", "r541" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r270", "r283", "r284", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r359", "r471", "r542" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "verboseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsChangesintheLevel3FairValueAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r476", "r480" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r477" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsChangesintheLevel3FairValueAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "auth_ref": [ "r478" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases", "terseLabel": "Acquisition of Cernostics" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsChangesintheLevel3FairValueAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r476" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsChangesintheLevel3FairValueAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r270", "r283", "r284", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r359", "r540", "r541", "r542" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r479", "r481" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r515", "r520", "r530" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesLeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on finance lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r517", "r524" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows from interest paid on finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOtherinformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r513", "r529" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Present value of lease payments" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of Finance Lease, Liability, Fiscal Year Maturity" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance lease liability, noncurrent" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r529" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r529" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails_1": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r529" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails_1": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r529" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails_1": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r529" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails_1": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r529" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails_1": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r529" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails_1": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r529" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: Interest component" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r516", "r524" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Repayment of principal portion of finance lease liabilities", "terseLabel": "Repayment of principal portion of finance lease liabilities" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.castlebiosciences.com/role/LeasesOtherinformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r512" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance lease assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails", "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": { "auth_ref": [ "r515", "r520" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization", "terseLabel": "Finance lease, right-of-use asset, accumulated amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r515", "r520", "r530" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of lease assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r527", "r530" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOtherinformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r526", "r530" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOtherinformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-lived intangible asset, useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r220" ], "calculation": { "http://www.castlebiosciences.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/IntangibleAssetNetFutureAmortizationDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IntangibleAssetNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r222" ], "calculation": { "http://www.castlebiosciences.com/role/IntangibleAssetNetFutureAmortizationDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IntangibleAssetNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r222" ], "calculation": { "http://www.castlebiosciences.com/role/IntangibleAssetNetFutureAmortizationDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IntangibleAssetNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r222" ], "calculation": { "http://www.castlebiosciences.com/role/IntangibleAssetNetFutureAmortizationDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IntangibleAssetNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r222" ], "calculation": { "http://www.castlebiosciences.com/role/IntangibleAssetNetFutureAmortizationDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IntangibleAssetNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r222" ], "calculation": { "http://www.castlebiosciences.com/role/IntangibleAssetNetFutureAmortizationDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IntangibleAssetNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r214", "r217", "r220", "r223", "r554", "r558" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails", "http://www.castlebiosciences.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r220", "r558" ], "calculation": { "http://www.castlebiosciences.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross carrying value" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r214", "r219" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails", "http://www.castlebiosciences.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r220", "r554" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.castlebiosciences.com/role/IntangibleAssetNetFutureAmortizationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.castlebiosciences.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net", "totalLabel": "Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.castlebiosciences.com/role/IntangibleAssetNetFutureAmortizationDetails", "http://www.castlebiosciences.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Weighted-Average Remaining Life (in years)" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r215" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Intangible assets acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r88", "r287", "r288" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 4.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on extinguishment of debt", "terseLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember": { "auth_ref": [ "r533", "r534" ], "lang": { "en-us": { "role": { "documentation": "Family member whom a principal owner or a member of management might control or influence, or by whom they might be controlled or influenced, because of the family relationship.", "label": "Immediate Family Member of Management or Principal Owner [Member]", "terseLabel": "Immediate Family Member of Management or Principal Owner" } } }, "localname": "ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r88", "r226", "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment, Long-Lived Asset, Held-for-Use", "terseLabel": "Long-lived assets, impairment charges" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r225", "r233" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeApproachValuationTechniqueMember": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach converting future amounts to single current discounted amount.", "label": "Valuation, Income Approach [Member]", "terseLabel": "Valuation, Income Approach" } } }, "localname": "IncomeApproachValuationTechniqueMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossAttributableToParent": { "auth_ref": [ "r68", "r74" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.", "label": "Income (Loss) Attributable to Parent, before Tax", "terseLabel": "Pre-tax loss", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r232", "r235" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofDepreciationExpenseDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofDepreciationExpenseDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r107", "r417", "r419", "r426", "r438", "r443", "r445", "r446", "r447" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r108", "r127", "r128", "r166", "r415", "r439", "r444", "r596" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.castlebiosciences.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax (benefit) expense", "totalLabel": "Total income tax (benefit) expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.castlebiosciences.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails", "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r65", "r411", "r412", "r419", "r420", "r425", "r433" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r416" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r416" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "U.S. federal taxes at statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment": { "auth_ref": [ "r416" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount", "terseLabel": "Non-deductible meals" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r416" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r416" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State income taxes" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r416" ], "calculation": { "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "negatedTerseLabel": "Research and development (\u201cR&D\u201d) tax credit" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesIncomeTaxExpenseReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r87" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r87" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r87", "r550" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Medicare advance payment" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r87" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r87" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r87", "r524" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r87" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "terseLabel": "Other accrued liabilities" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r87" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r87" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r87" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets, Net" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IntangibleAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r69", "r164", "r502", "r505", "r582" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r83", "r85", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r9", "r53", "r538" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r16", "r54", "r99", "r143", "r210", "r211", "r212", "r551" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r76", "r163" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Operating leases, rent expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r528", "r530" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r529" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r529" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r529" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r529" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r529" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r529" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r529" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r529" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: Interest component" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r44", "r105", "r177", "r200", "r244", "r245", "r246", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r455", "r457", "r458", "r485", "r536", "r537" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r35", "r105", "r200", "r485", "r538", "r575", "r590" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r46", "r105", "r200", "r244", "r245", "r246", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r455", "r457", "r458", "r485", "r536", "r537", "r538" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r17", "r18", "r19", "r24", "r25", "r105", "r200", "r244", "r245", "r246", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r455", "r457", "r458", "r485", "r536", "r537" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "terseLabel": "Noncurrent liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r48", "r242" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Measurement Input, Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Measurement Input, Price Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r84", "r86", "r89" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r6", "r60", "r62", "r68", "r70", "r89", "r105", "r117", "r121", "r122", "r123", "r124", "r127", "r128", "r133", "r167", "r175", "r178", "r181", "r183", "r200", "r244", "r245", "r246", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r469", "r485", "r579", "r593" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "netLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesPayableToBanksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a bank.", "label": "Notes Payable to Banks [Member]", "terseLabel": "Notes Payable to Banks" } } }, "localname": "NotesPayableToBanksMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES AND OTHER OPERATING INCOME" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r167", "r175", "r178", "r181", "r183" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r521", "r530" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r513" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOperatingLeaseandFinanceLeaseMaturityDetails", "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r513" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.castlebiosciences.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r513" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Noncurrent operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.castlebiosciences.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r518", "r524" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOtherinformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r512" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.castlebiosciences.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails", "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r527", "r530" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOtherinformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r526", "r530" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOtherinformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r508", "r509" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r508", "r509" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r508", "r509" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2025" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r508", "r509" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r508", "r509" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r508", "r509" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r508", "r509" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r13", "r14", "r15", "r45" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued and current liabilities", "totalLabel": "Other accrued and current liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets \u2013 long-term" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r89" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "cstl_OperatingExpensesNetOfOtherOperatingIncome", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "negatedLabel": "Other operating income" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherSundryLiabilitiesCurrent": { "auth_ref": [ "r45", "r241" ], "calculation": { "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.", "label": "Other Sundry Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherSundryLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r82" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedTerseLabel": "Payment of common stock offering costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r80" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Payment of employees\u2019 taxes on vested restricted stock units" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r78", "r450", "r451", "r452" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "terseLabel": "Payments to acquire productive assets" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/AssetAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r78" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy": { "auth_ref": [ "r360", "r361", "r364" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for plans, other than pension plans, that provide postretirement benefits (including both defined benefit and defined contribution plans). This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Nonpension Benefits, Policy [Policy Text Block]", "terseLabel": "Retirement Plan" } } }, "localname": "PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r367", "r395" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r28", "r293" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r28", "r293" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValueOutstanding": { "auth_ref": [ "r28" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.", "label": "Preferred Stock, Value, Outstanding", "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized as of December\u00a031, 2021 and 2020; no shares issued and outstanding as of December\u00a031, 2021 and 2020." } } }, "localname": "PreferredStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r11", "r37", "r38" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassification" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r79" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from public offerings of common stock, net of underwriting discounts, commissions and offering costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r77" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r79", "r396" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of common stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r79" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from contributions to the employee stock purchase plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r229", "r515", "r520" ], "calculation": { "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "negatedTerseLabel": "Less: accumulated depreciation" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r56", "r230", "r520" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r21", "r228", "r512" ], "calculation": { "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "terseLabel": "Total" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r41", "r230" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesNarrativeDetails", "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r234", "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/PropertyandEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofDepreciationExpenseDetails", "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r40", "r230", "r616", "r617" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r21", "r230" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/PropertyandEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r21", "r228" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesNarrativeDetails", "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, plant and equipment, useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r36", "r195" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "terseLabel": "Allowance for Credit Losses" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r358", "r533", "r534" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r358", "r533", "r535", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r81" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Repayments of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfSecuredDebt": { "auth_ref": [ "r81" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.", "label": "Repayments of Secured Debt", "negatedLabel": "Repayment of term debt" } } }, "localname": "RepaymentsOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r410", "r552", "r621" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 4.0, "parentTag": "cstl_OperatingExpensesNetOfOtherOperatingIncome", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofDepreciationExpenseDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r32", "r316", "r404", "r538", "r589", "r607", "r612" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r113", "r114", "r115", "r118", "r126", "r128", "r204", "r401", "r402", "r403", "r436", "r437", "r467", "r603", "r605" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r161", "r162", "r174", "r179", "r180", "r184", "r185", "r186", "r338", "r339", "r553" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "netLabel": "Total net revenues", "terseLabel": "NET REVENUES" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r153", "r186" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Percentage of Revenues" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/RevenuePayorConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r100", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r349" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition, Cost of Sales (exclusive of amortization of acquired intangible assets)" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r321", "r322", "r323", "r324", "r325", "r326", "r328", "r329", "r341", "r349" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r525", "r530" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating lease assets in exchange for operating lease liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesOtherinformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Proceeds from sale of stock" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Common stock issued and sold (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Common stock offering price (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LossPerShareScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r366", "r392", "r406" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Arrangement, Expensed and Capitalized, Amount" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r470", "r471" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r214", "r219", "r554" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r214", "r219" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Future Minimum Payments for Operating Leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]", "terseLabel": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r41", "r230" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofDepreciationExpenseDetails", "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r367", "r395" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r372", "r383", "r386" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Arrangement on Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, ESPP, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Arrangement on Restricted Stock Units" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r51", "r102", "r145", "r146", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r298", "r302", "r307", "r310", "r311", "r312", "r313", "r314", "r315", "r316" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails", "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r152", "r153", "r154", "r155", "r482", "r484" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedules of Concentration of Risk, by Risk Factor" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r168", "r169", "r170", "r171", "r172", "r173", "r185" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Operating Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "cstl_OperatingExpensesNetOfOtherOperatingIncome", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/PropertyandEquipmentNetSummaryofDepreciationExpenseDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "Selling, General and Administrative Expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ServiceOtherMember": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, financial service, and other financial service, classified as other.", "label": "Service, Other [Member]", "terseLabel": "Other" } } }, "localname": "ServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r87" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited/Cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited / Cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Stock Units Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted average grant date fair value at ending balance (in dollars per share)", "periodStartLabel": "Weighted average grant date fair value at beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected stock price volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected stock price volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "verboseLabel": "Increase in number of shares authorized for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Stock Option Activity, Additional Disclosures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Options exercisable, number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r385" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Options exercised, intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Forfeited/Cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited/Cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Options granted, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r395" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Options outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r374", "r395" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Stock Options Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r365", "r370" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails", "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche One [Member]", "terseLabel": "First Year of Vesting" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "terseLabel": "Aggregate fair value of restricted stock units vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Term of awards" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r389", "r405" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Average expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r395" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Options exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options exercisable, weighted average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "terseLabel": "Options outstanding, nonvested (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "terseLabel": "Options outstanding nonvested, weighted average exercise price (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options outstanding, weighted average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase price of common stock, percentage of fair market value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "terseLabel": "Shares withheld for tax withholding obligations" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r522", "r530" ], "calculation": { "http://www.castlebiosciences.com/role/LeasesLeaseCostDetails": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r97", "r112" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r52", "r66", "r67", "r68", "r113", "r114", "r115", "r118", "r126", "r128", "r144", "r204", "r309", "r316", "r401", "r402", "r403", "r436", "r437", "r467", "r495", "r496", "r497", "r498", "r499", "r500", "r603", "r604", "r605", "r636" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r113", "r114", "r115", "r144", "r553" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r28", "r29", "r309", "r316" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under the employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r28", "r29", "r309", "r316" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Public offering of common stock, net of underwriting discounts, commissions and offering costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r28", "r29", "r309", "r316" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Net settlement of vested stock awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r28", "r29", "r309", "r316", "r376" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)", "terseLabel": "Exercise of common stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY", "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r28", "r29", "r309", "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under the employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r28", "r29", "r309", "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Public offerings of common stock, net of underwriting discounts, commissions and offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r309", "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of common stock from vested restricted stock units and payment of employees\u2019 taxes" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r52", "r309", "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of common stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r29", "r33", "r34", "r105", "r196", "r200", "r485", "r538" ], "calculation": { "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r103", "r294", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r308", "r316", "r318" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r501", "r539" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r501", "r539" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r501", "r539" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH PAID FOR:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforward" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r189", "r190", "r191", "r192", "r194", "r197" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r117", "r118", "r119", "r120", "r129", "r198", "r199", "r201", "r202", "r203", "r204", "r205", "r206", "r243", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r434", "r435", "r436", "r437", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r532", "r555", "r556", "r557", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r632", "r633", "r634", "r635", "r636" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Accounting Standards Update [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r147", "r148", "r150", "r151", "r156", "r157", "r158" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r424" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "negatedTerseLabel": "Decrease in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r523", "r530" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Common stock warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/LossPerShareScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r131", "r136" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r130", "r136" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Weighted-average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.castlebiosciences.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" } }, "unitCount": 12 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r234": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r289": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r318": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL108322424-203045" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r349": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/subtopic&trid=2235172" }, "r361": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/subtopic&trid=2235116" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r364": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/subtopic&trid=2235144" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944" }, "r408": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r447": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r531": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(9))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r622": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r623": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r624": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r625": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r626": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r627": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r628": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r629": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r630": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r631": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.20)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" } }, "version": "2.1" } ZIP 106 0001447362-22-000045-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001447362-22-000045-xbrl.zip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b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

    /E9_ UG8>'O*)6YM[0+]GD&"K&4@;L M],#GH?6O*_B1H]_-^U!:L3%<#R^O9EZ4D:YC&?2G=*_+\3B:V+J>UKR9^\8+ X;+Z7 MLL+!1CO9=Q:***Y3T HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /%_VC/V7- _: M4_X1[^W-6U+2_P"Q?M'D_P!GF/Y_.\K=NWJ>GE+C'J:\?C_X)B>!-R^;XN\4 M2QYY3S8!G_R'7V117HTLPQ5""ITYM)'GU2G&R/E'Q/_P3W\-3^([G5_!WB[7? ;73%I;7 M39,Q#)R0F"K*/;)%=Y\#?V1?!WP1U:778)KSQ%XGE!#:QJS!Y$S][8 /ESSD M\GGK7N5%=<\PQ52'LY3;7]==SEA@,-3G[2,$G_738\O^.7[.G@_]H#2(+7Q) M:R1WEKG[+J5FP2X@SU 8@@J?[I!%>%:;_P $V?#IOK?^W?'?B'7-)MVS'ISE M8UP/X2V6X^@%?0GQO\4:OX2\&QW>B2K%?R7D4"EE# [L\<^^*U/A;XND\:># M;.]N0%U"/-O=IC&)DX;CMGK^-<5'.JU&L\#3FTTK^7R/2K9#3K899C4@G%OE M\[^:[' ?&K]EW2/B]X9\(:%%JDWA_3_#4Z26J0Q";$?CKJ5IK-Q>WV@^(K:)85U+3R,R*OW=ZGJ1V((/O5[4?BIK=U\9K+1]/D5 M/#RW@L)CL!\R4*6< ^W K0U+5/&7B+XFZYH>BZY;Z7:6$$4H6:W$F=P&>?K7 M#3X@G&WL7)N,G%6MN]7N]5IU/2J<,I_Q^6*G!3=[Z).RO9.SUZ'F_P -?V ? M"?@[Q=9^)/$'B'5O&NH63B2WCU'"PJPY4LN6+8/(&<<=*]%^-/[.MG\9O&7@ MGQ!<:U/I_6NJ\/Z5XOT5;^XUS7[;5(5MV,4< M-MY95P,YS4OPE\17WBKP+8ZEJ,@ENY6D#,JA0<.0.!["NV.<8BM7@ZEU.SM> MVB5D]KK6YYL\EH4G*0_%KX-^%OC9X7?0O%-A]JML[ MX9XSLFMW_O1OV/Z'O7S=!_P36\/FX2WO/B!XDO-!1]PTPE%X]-W(_$**^Q+B MXCM8))I7$<4:EW9N@ &2:\A^&?Q6U;Q%XVFL]6C$&FZK')=DF_1,] \ _#_0/ MACX7M/#_ (;T^/3=+MA\L48Y9CU9CU9CW)KBO@-^SOHOP C\0IH^I7^HC6KI M;N;[=L^1@&X7:HX^8]:M?'#Q9XA\,6>AIX<=1?7MV8=C(&W_ "Y"\^]=3\/_ M !G;^.O#-OJ<(\N;_5W$'>*4?>4_YZ$5SQS+FKU,)S/F=F[]>N_E?7U.F>4R MAA:6/Y5RZI6WCTU72]G;T.-^/'[/&B_'Z+P_'K&I7^G#1;HW9;64-L)GV'[I^_X)F^![[4KN\_X2WQ)"]S*TS+&T M +$G'^K]ZU/"_\ P3:^%^BWR76IWNN>(MISY-]P%+I/!?@V[OK8;K^0K;VB8R6F#9+O6Y5EOX[R6!F50H&W'''N37G5JU"MBXX>JN::][R7_!._#T M,5A\#/%T9@XSBN(\5_% MS4M(^)$<5NJGPI8W$5CJ,VT'$T@8YSV"X'Y5[)790S!8F,\/"6D'MY]UY;KY M'!BLKE@W3Q%2*O4CNNV]GYZI^C0M%%%;'(%%%% !1110 4444 %%%% !1110 M 4444 %%%% 'G_[0G_) _B7_ -BSJ?\ Z2R5\=?L-_LW^ /BU\);K5_$^BKJ M%^E_)")2Y'R@# K[%_:$_P"2!?$O_L6=3_\ 262O"/\ @FE_R0F]_P"PI)_( M5]!AJDZ67594W9\RV/!Q%.%7,*<:BNN5[^HWXJ?\$]O"6I:/->> 9;CPUXC@ M4R6V)SY4CCD*?[N3WK3_ &'?CMK7Q T;6/!GB^1W\5>&W\F22;_621@E?F_V M@00?I7U-7P=\#]2AM?VV_B[JVGX?2[.*\EN#']TLK$_S#4Z-:ICL-5IUWS.* MNF]UKM?S)K4:>"Q-*I17*I.S2V>F]O(^TO%WC[PWX!LUN_$>N:?HENW"R7UP MD08^@W$9J+P=\2/"WQ!@DF\->(-.UQ(_O_8;E)2GU"DXK\_OA?XP^&?QD\?> M)O&_QG\26LL@NF@TO1;V;$4<()P=O0C&./4FCXN>*OA=\*_'/A+QG\%]>L[> M^2[$.H:7I\O[J2$D<[!QC&?R%:?V2N;V/O<_>WNW[7_4C^U7R^V]WD[7]ZW> MWZ'Z0W%Q%:6\D\\BPPQJ6>20@*H'4D]A7#V/QX^'.IZO_9=KXWT&XU MM%O' MJ$18MZ ;N37R]^U?XNUGXS?%3X>?"'1K^32],UV&&_U!XFP7C<;@#ZA55SCU MQ7H.L?\ !/?X67OAM+"QM;S3=0C"[=3CN&:7<.I()PK4E'#034=&V[7?9&I^V9X;\+>)/!_AT>*?&EQX-M(]30PW%NK- MYS[6.S [X!(/M7MNH:_H_@OP[%=ZOJUOI^G01JIO+Z98U/'!+,1R:^._V_/" ML'@GX$?#S0K6>>Y@L-8BA26Y236)^W#.(_B_\.AXQCOI/ALMJAN%M M=VTOD[^G\6-OX5UTL&L32HPYW9N?3M;;S?J*RNTE=1ZD YQ7CWQ(\*>%K[]JGP7J5]XVN]-\ M0QP VV@(K;+D L <] #SD>U\K4=-4R#2K>\(+M MCAF0G/'.1T/>J/QF_P"3_?A;_P!> _\ 0I*SI4(4Z\HTI27N2W5GML:5*TZE M",JJB_>CL[K?<^N]8UK3_#^GS7^J7MOI]E",R7%U((XT'J6)P*Y?PM\:O ?C M;4#8:#XOT;5;W./L]K>QO(?HH.37R5XNT^\_:\_:LU7P3J6H7%KX&\)Q&2:U MMY"GGL"H)X[EG SV -==\:_V'?!6D^ [[6O T%QX=\1:1";JWGAN&._8,X;G MKQUK-8/#T^6G7J-3DD]%HK[7-'C,14YIT()PBVM7J[;V/K#5M8L=!T^:_P!2 MO(-/LH1F2XN9!'&@SCEB<#DUS7B#XQ>!O"VGV=]JWBW1["TO$$EM-->QJLRG M^)#GYA[BOE#4?B[>_&'_ ()\^)M4U.0R:M9*MC(_'$=SKNHZE;#R!)<,$MH ,1J@![*!0L!2HTY5,3)KEERV2O M?03QU6M4C##13YH\UV]M3[)\/^)-*\6:7%J6C:C:ZI82?G]JP?R:N2_9$TNX^$?[47Q'^&=G>2W'AZ"U^U01R,3M8-'M/ MUQ(PKKO^"DW_ "06T_["T'\FK7#X=8;,J4(NZ;33\F9U\0\3E]64E9JZ:\T: MO@']BWX2ZYX#\/WUWX:5[JZT^":602$$LT8)/YFO(/CS^R[?_LUPK\2OA1J= M[9V^FN)+S3GE+;4SRP/=>Q'O7VA\*O\ DF7A3_L%VW_HI:S_ (Z3V=M\'_%\ ME^56T&FS;R_3[O'ZXK*EF&)CB.64G*+=FGJFKFE7 8>6'YHQ49)736C3L9WP M<^-6D_$GX2Z+XQN[NWTU+E/+N?/D5%CF'#+DG\?QKT6TO(+^UCN;::.XMY%W M)+$P96![@CJ*^0/V!/"$?BW]F#5-)UJ$RZ=>ZE.(PW4?*GS+Z$'!!]14D>N> M-_AOX?\ &'PMTMOM>OB!FT29C]Y&ZA3V.#D?C7DXZ*P^8/#+2#=D^S\S*GF% M2G3I3K1]V:WZ\W:WGT\SZHT?QGH'B#4+JQTO6M/U&]M<^?;VMRDDD6#@[E!R M.>.:V*\1_9G^"=K\ ?AG)-?_ +_Q!?1F^U:[/S.S8+;,]PO/XDUO>.O& \>? M!W7;_P '7+W4QA*CR@1(/[PQU!QFL\7*E0G*--\R5[=W8]%8EPH\]56G9OE6 M^AW$'C30+G4O[.AUK3Y;_=M^RI"UCUZ 1R2)(WEW32J06SW89!K4US36^,'QCO_ ]? MR2CPSX>AC>2U1BJW$S#/S8Z@=*\R.)FX*5DV]%9_GZ''#'5)4E.T9.32C9^5 M]=-+'KFD^+M#U^9X=,U>QU"5?O);7"2$?4 UZ1 M87;V.G:<['R@J]7*]R:MU:L;0<5S/;73U-98C$4[4Y07/)Z6>EENWI?3\3VO M1_$6E^((FDTO4;748U^\UK,L@'UP:T:X?0_@WX9\,^*(-S.F7$<;1F&U8 MI$^1C)4<&NXKJIN;7[Q6?D=]%U7']\DGY.X4445H;A1110 4444 %%%% !11 M10 4444 %%%% !1110!\X?\ !03QYXA^&O[,6OZ[X7U>YT36(;FU2.\M'VR* M&E4, ?<5\^_#/]G[]IOXE?#CP]XNLOVB[NU76+&*^BM+A)"8PZA@K,.N,^E> MR?\ !3S_ )-!\2_]?EG_ .CEKU7]D[_DVCX9?]@"T_\ 18KT(S=/#J44KW[> M1S./-4L^Q\?ZI^T5^T?^Q?KVFK\9K6U^(/@&ZF$']NZ>BB2+/I(JK\^.=LB_ M-@X:OJ;XW:IXV^,'[.J:M\"->MX=:U9+>[L;XR*GF6['+JK,"$?''/3!'!K8 M_:R\+Z9XP_9M^(VGZM''):KHMS:/J>C^(/LEC>VLA62.)YH695/IF1Q^)K2*5:,:D4E)-+R?R);=- MN+=U;YGZ :#J?C3X=_LW?VCXTNK?5/'&CZ#-$O^%S>/YM2\1^-6\0/<6]S->NJQ-"R,I*@X8EL\'C& * M]0^(W@[X@?&C]C;P9XDT_P")FI>&Y[;PG)?:RJ(9#J^ZV5BLAW#KM;GG[QKY M_P#V&OV=_BG\2O@3#K/A'XWZKX"TAM1N(AI%G;ET#J5W/D..6R.W:J@E&E-\ MUFWY^>@I.\XJUU8Z'X?_ ITK]MO]LSXU_\ "R[F_P!2T+P?=/I^G:7#=/"B M()Y(DY4@@ 1%B!C+-DUL_M1:E\0]!_:B^&'P6^&/CS4? NB7>A6UG;K#(6CC MV&559AU8[8U&?:O)?V3/@=\1?&'[07QGTG0?BYJ7AC5-"U7R]5U2W@+/K#"Y MG4LXWC!+(S=3]\U[7^T AC_X*??!-7;>RZ?""Q[G-QS6\M*O*G=*.W;0R6L+ MVU;_ %-;4/V8_P!KGPS&;[0?C_%KMY'\RV>H(RI)[?.CK^=;/[-/[;GBJX^* MG_"GOCGH:>&O'9;R[/4$010WC8)567[H+ ':ZG:W0 'K]LU^&/C1X)U_5+_ ,+67DMXC\)O*6MO+P,R!,<*P)5L?=.U MO6N0^('[57BG]KKXC>"_AS\!-:O] LY88]5\1>(X%*/91E1NA)_V-V"!]YRH MS@&L(X:4DI)Z=7V]31U5%M/<_02O(OVE/$VK>%_">G3Z/?S6%Q)>"-I(6P2N MUCC\Z](T>&W\/Z39:;)J4EW):PI$UQ?3[YY2 !O=CU8]3]:\C_:JD2;P7H[H MRNIU!<,IR/NM7SN;3<<%5<'9I=#Z?(*:GF="-2-TWUVV9H?LZ^/M1\3:9JVD M:Y%7\21 M7BNM#_A5WQQT+6E_=:5X@A6&?LHWTX1QJ.RK H _(5*NO>(OC9XLU6UTK7F\->%]-D\DS6YQ+ M<-DC.<@\XSUP 1UK++L3+"471G><^>45KJ[6OJ]D;9O@X9AB8XBFHTJ?LXR; MMHN9NVB6K9[[7AOQ!8C]I+P.,G'V?IG_ *ZUG:IJ7B+X%^(M'EG\23>)?#-_ M-Y$R79#20GCD')[9/!YP$K.I&:G"=*I9JZVBTTT]4T>Z45YQ\0?"/BSQ-KD:VGBI?#W MAM809/LZ[9O,SSELCC&.X^E>HSB"X@GD#O%RHSU M./O9!!'0@UZ-?,'AY?O*;4$[1A&+'0+N16NX=HM&;]U)(SE5+#OC(_*L_Q]X)\<^!- M!E\5P^.;S4+VU*R7-NRE8L$@':N2" 3T('%95^-!TCX.Z=XI$"-J>H1K'#!_#YQR M&/T&"?RK!T?X5^._%FEQ:QK'CJ^TW4;A!-':VP(2+(R 0&4#MP!Q6TLP4I*& M'@YMI/2RLGM=OJ^QST\I<82JXNHJ45)QUNVVM[))Z+JSW6BO&OA3\0-?M?&= M_P"!?%TJW6IVRE[:] \Y0 <'@9RIR#UX.:Y#PGJWC?X@>-/%/AVT\0SV&G0 MW3M+>-\\D,8=E6./IC/U'"UD\UIN,.2#;DVK:7371FZR&JI5%4J1C&"4N;6S MC+9JRN_3?H?2E%?,NM:IXZ^#_C2W\/VFNR>($UB,):-?98I(S; W)."I]\&M M'Q]X0\<_#?0_^$K@\;7FI75NZM=6\H(BP2!PI)!&2!C X-9?VL^6;]C+W/BV MT_'7370W_L"/-37UF-JOP:2][\/=UTU/HFBN&;5M>\=_#"RU'PW=0:9J]]!' M())EW*F>' X.#UP<&O-O$G@+Q!X9TFYU2+XH7$NM6L;3&WFF"QR%1DJ 6/OC M(YKKK8Z5-*=.FY1M>]TM/F]7Y'GX;+(5I.G5K*$[\MK2;NN]E9+S/H*BN+^$ M'C2?Q[X#L-5NU5;PEH9RHP&=3@L![\'\:[2N^C5C7IQJPVDKGE8BA/"UIT*G MQ1;3^04445L,_#_\ ;!^&GQ+\0:3H^CZG M?+=ZMY@T]KW3I[>*[9 2RQR.H5B,'@'M74^(OCQX,\*_$[0_A_J6J&#Q1K,? MFVEKY3%6!W8W.!A2=C8!/.*U=.I?E:9BJE.W,FCOO)6HI]/M[K'G0QRXZ;T! M_G7E_P 3_P!I_P "?"'Q,F@^(KG4(]1:S_M I9Z=-HJ"W_:O\"W/A#4/$JIKRZ;8W,5K- MYFBW*2[Y 2NV,IN8?*Y[G#90VZE8HUC4G.%4#^52"$+TKS'5/VE/ FC>$O$WB2[U&:+2?#^J2:-> M2_9G+->(P0Q1+C,AW, -O'-:_P +?C+H/Q=L[^?18-4M6L95AN+?5=/EM)8V M*[A\K@9R.>,]:ATY)7:T+4X-I)ZG;2V\<\;1RHLD;<%6&0?PJ&STNTT^/9:V M\-LF<[88PH_05Y%XS_:X^'W@7QMJWA/4)=7GUK2O+^UPV&DSW*Q>9&LB9:-2 M.58&K_Q+_:<\$_"O6K/1]6;5+O5KJS_M#[#I>G2W4L5MDCS9%0?*N01SSQ5^ MRJ:*SU)]K2UU6AZOL&W%5IM+M;B022P1RNOW6= 2/I7G?CS]H[P/\.?#&B:Y MK&H7"PZXJMIEI;VDDEW=[E##9"!OZ,,Y QGGFH_!?[2W@3Q[X/\ $/B/2]1G M%KX?C>75;6YM7ANK0(I8[XF&[HIQCKBDJTA7]?2/P^_:M^'/Q.OKBQT;4[M+V&Q;4Q;WUA-;/-;+]Z6/>HW@> MQK2F_:(\$6OPIT[XCO?SCPKJ$D<4%R+9R[,\IB7*8W#YACI7L9?C9Y:VXT5* M?1O=7T/F,XRE9SRQEB7"EUBK6DO-[G5?#KPA;> _!NEZ%:X:.SA5&DQCS'ZL M_P"+9/XU\]?MD>!_$'B_7/#=9N?LEF%B:0LXQDG:.%&Y!D5-\5OC9X1^#.BVNI^ M)]0:W2\E$%I;V\33SW,AYVQQKDL]L_(O(;"%)(Y4PZ,% (.>7UO8>&U+ZK;WEA+#% M;&Y\$037DJR^,L_V,/(8^=^[63YN/D^5AU]:\^JISFY26K9ZV'C2HTXTX-:) M+[M#N/)7.:&A5NM>/VG[6'@'4/B _A&SEU2\O4U#^R6O;?3)GLENP<&$SA=H M8'@]O?'->JZMK5GH>DW>I7THM[*UA:>:9NB(H)8GZ 5G*$HZ21T1E"2]UEQ8 M@G2H;C3X+K'FQ(^.1O4''YUQ7PS^./A#XN>";CQ9X;U(W.B6SR1SSS1F(Q-& MH9PRM@C"D'GL:Y_X9_M3>!OBUXA32/#[:L\DT4D]K=76ES0VUU'&<.T4K+M8 M X].HJN2<;NST)-D\,Z1+J MMW<2W4EE#?KIDWV*:>,$NBS[=I(P>>G'6NB\0?'KP9X7^)^B?#_4M3,'B?68 M_-M+7RF*L/FQN<#"D[&P"><>])TYWY6M=P4Z;C=/38]!'%+7F=_^T5X&TF\\ M:6FH:JVGW/A"%;C58KJ%D9(F&5= 1^\5N "N>2!WKN/"_B*U\7>'=.UJR29+ M._@2YA%Q$8I-C %2RGE201P>:3C**NT6IQD[)FI1114%A1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 >7?M#?\B;IW_85MO_ $(USFM>)1\& M/&7B<,-MCK5H=1LE_A^U#Y64>Y)S^5>J>-?!MKXXTN"QNYI8(X;F.Y#0XR60 MY Y'2J_C/X>:5XZDTI]15BVG3B>/9CYNF5/L<#\J\#%8.O4JSK4=)>[RO[T_ MP9]7@,PPM*A3PV)3YEZ\KC;YQ^X\FM?#+^%[KX61W /V^[OY+R[9OO&61 M0QS[C@?A5Z7PSJ'B;XW>*X[#7[S06CM;=F>T )D&!P>:]3\0>#;7Q#K.AZC- M+)%+I,QFA2/&UB1C!XZ?2N<\1?!V'7/$UYKD'B#5]'NKI%24:?/Y8(48'09K MFGETZ:Y81O%23M>S:4.7?U.VGG%*H^>I/EDX25^7F2;J1@]ZSO@%_R2_2_]^7_ -&-5SPS\,Y/#UY/-+XG MUO5DE@:$P7]R9$&[^(#U%8-E\!%TRW%O9>,?$5G;J25A@N]B+DYX %=,:=>G M4IU*=+1*2MS7>K3W?H<4JV%K4JM&K7UE*+NH66BDFK)*VZ)OV@/$TVE^$%TB MQ6674M8D%M'';J6D\OJY4#J<')$>.>YLV1 M/) PX9NV. M@KK=>T.S\2:/=Z9?Q":UN4*.I_F/<=:M82M4YZLO=G[K7JHV?R>S\C-X_#4? M9T(-RI>]&72\7*Z?JM&O,^>/L$^K? ?QL+0&0IKTTY"<[D5XR>GMS^%?0?AC M5[/7O#]A?6#J]K-"I38>%X^[]1T_"LGP!\.[#X?>'I]'M99;RUFF>9_M0!)W M*JD<#&,+^MNT$C%9X;#XG!J-10YFX MI-75U9MJS>CW=S;&8O!Y@YTI5.1*;E&33:::2::6J?NJVCZE3XES1ZQ\5/ F ME69$FH6MP]Y/LY,<0 Y/IG!KE;GPO)XJNOBI#; B_M;^&\M&7[PE16(Q[D9' MXUZMX(^&NE^!Y+BZADGU#5+GB?4+U]\SCTSV%7?#W@NU\.:UKFIP32R2ZM,L MTJ28VH0",+Q[TI9?4Q$N>LKSP[;Y(I1;7Q/VBF].B MW27;U/+M#\3+\:/&7A@+\UAH]H-1O5'W?M1^54_ \_G5CX8^)H?!_P )?$6K MSX(MM1NF53_$^5"K^)Q7H7@OX=Z5X$?5&TU&!U"X,\F['R^B#V&3^=8DGP6T MN7P['HCWUVVGC43J,D>5_>L3]QN/NUG#!XRG:L[.I:5_5\JC\K*YK4S#+ZM\ M,KQHIPLK:V7,Y?-N5E\CRK2-2:3X6ZCHE]X6\076IZH9+J:\6Q8JTS'8+JCB66U;'EJX_B7C.3S^==6'P-7"582C+FC;E>EM-T_/7\SAQ M>9X?'T*L)PY).7.M6]=FO)6_)'2T445[I\N%%%% !1110 4444 %%%% !111 M0 4444 %%%% ' ?M" M\ _B4 ,D^&=3_ /262OAW]CG]K/P;\#/ACMA<71IT)8>M!M-IZ.VQY6)PM:I7C7HS2:36JO MN?)?CK]O#6?B%;OX<^$?A/4KK6KX&*/4)HB3%GC^MV[=V.E@Y^T]MB)\TEMI9+T1^;7PQM? 7[/7 MCSQ)X+^,?@JRNK>2[:?3=62< L1]TC'T(->EV_P 0_@3XD^)&@^&O M _PJTKQ5]KEQOL#Q-X+T#QG:BWU[1;#68%^ZE];)*%^ MFX''X5'X7\ ^&O!,;)H&@:;HRM][[#:I$6^I49-=53,J=6]2<9<[725HW[]_ MDVL"?ZN M)<@# Z HSKGMQ7::C_P4-^&4'AM;VR.H7^J.HVZ6L!63<>H)[8]:^G9H([J% MXIHUEB<%7C=0RL#U!!ZBN0M/@QX"L=4_M&W\&:##?9W"=-.B# ^H^7@USQQ= M"I3A#$P;<=$T[779F\L+7IU)SPTTE+5IJ]GW1\I_M]^*(O&OP'^'FN06\]I% M?:O#,L-PFV1,PR\$5ZE\&IM0T.\M%EFOI[836P) P MI!W>_I7N7B?P3H'C2S@M->T>RU>V@D$L4-Y"LBHX! 8 C@X)J3Q#X/T+Q;9+ M9ZWH]CJUJOW8;VW255^@8''X4HXNCR4ZV_& M3/\ PWW\+,]?L S_ -]25]4>%_A[X8\$A_\ A'_#VF:,7&&:QM4B9AZ$J,FI MK[P3H&I>(K37KO1[.XUJT79;W\D*F:(<\*W4=3^==,\SA*:M%V47'5W>O=G/ M#+9QB[R5W)2T5EIV1\9>-+K4?V1?VIM4\>7>FW-_X%\51&.YGMD+&!CM)_$% M ?<$UTWQD_;D\)>(O U[H/@%;S7_ !'J\)M8(DMR!'O&"3[\]*^N-2TNRUJS MDL]0M(+ZTD&'@N8UD1A[J1@US_AWX4^#/"-Z;S1?"NCZ7=DY\^ULHT?\& R* MR6-P]3DG7IMSBDM'H[;7-7@Z]/FA0J)0DV]5JK[V/DW5OA!>?!W_ ()]^)=( MU%"NK7B)?74?=&>6(!?P 'YU[_\ LDJ5_9S\!@C!_LR+K_NUZIJ6FV>L6,(B#T"C@"N>MC7 M7I2A-:N7-?Y6L=%'!JA54X/11Y;?.Y\??"5&'_!0KXE,5(!TL\X]X*V?^"DB MEO@+:X4M_P 36$\#/9J^GX/#NE6NK3:I#IEG#J3>0+*F1WPP(S6BQR^LTJ_+\"2^Y&7U)_5ZE#F M^-M_>?)'@O\ X*"_#CP[X)T33);;6)+RRL8;=U6T."RH%.#]17!^//BQ\0OV MV+F/P;X,\/77A_P=)*IO[^Y!!=0?XFZ8_P!D=:^V5^%?@M&#+X0T%6'0C3(, M_P#H-=%9V-MIUNL%I;Q6L"\+'"@11] *U6-PM&7M:%+W^C;O;Y6,G@\36C[. MM5]SJDK7^9YA"F@_LO\ P6LM/MU\R'38/*@C_BN9SD_J46/P1\2_$KX M7^*_$EWJ$]AXS\10%[.9#M:*/JJ#NH; Z=L5]0ZEH^GZPB)?V-M?(ARJW,*R M!3ZC(.*MJHC4*H"J!@ # %?/M3EBEB9N_+JO7NS:I@%6J)S?N15DO/:_W;=C MYH_8]^.ES\0/#]YX#\7H8O&.@*;:>*X'-S"OR[N>I'0^Q%>]>(]:M/ ?A>>^ M2Q=[2S3BVLX^0/8#M5F#PGHEKK#ZM#HVGPZJ^=U]':HL[9&#EP-QXXZUJ$!@ M01D5V8J<*U1SI1Y;_.S_ ,CIHT:E.CR2E>2T3M]USY9^+6L^#OB/9:OUKN-=DO/@_\3+KQ5<6TUYX?UJWBBOI(%+& MWF08W8]#U_&O9+72;&RF::WLK>"5OO211*K'ZD"K,D:R(4=0ZL,%6&0:\581 MWZU MZ\NYE0QVT9'E*3RS'V]*YCP_KO\ PH?Q5K>E:Y;SKX:M>[OZGG^A_&S2O%GBRUT;0K2ZU.%U+3WT:%8H M!CC)/7->BU7L]/M=/C,=K;0VT?7;#&$'Y"K%=%-32]]W9W48U8Q?M97?DK!1 M116IN%%%% !1110 4444 %%%% !1110 4444 %%%% 'RE_P4\_Y-!\2_]?EG M_P"CEK)_9U_;1^"G@WX!^ ]'UGX@Z98ZII^C6\%U:NLA>.18P&4@(>0?2OJ+ MQW\/_#OQ.\-SZ!XJTBWUO1IV5Y+.Z!*,5.5)P>Q%>6K^P[\!E8,/A?H.0<\Q M,1^6ZNR%2E[+V=2^]]#"49\_-$^3_P!I[]M*7]J'3Y?@U\!])U+Q#=:X1!J& MK_9S%&(-PW*@/*J^"TE6YO+9[2>_N$^ M[+=27*-(1_L@G:/917VSX)^&_A7X;Z>;'PKX=TWP]:-RT6G6J0AL>NT<_C4O MCKP#X>^)GANY\/\ BC2;?6M&N"K2V=T"4'> _\ E'[IO_8A'_TD-<5_P2E_Y-.MO^PS>?S2OJJT\%:'8^#T\*V^ MF01>'4M/L"Z*J_#[X;>&/A3X>70O"6BVV@Z0LK3"SM 0@= ML;FY)Y.!6;JIPE'N[EJ#YD^R/B?]@#_D[;]J/_L-M_Z6W=<]^UMXQT;X?_\ M!1_X2^(/$-_%I>C6.FQ2W-Y-G9$NZX&3@$]2*^[O!_PA\&^ /$6OZ]X=\/6> MDZQKTOGZG>6ZD/=/N9]SY/7<['\36-\1_P!G#X9_%W6H=7\9>#=-\0ZE#"+> M.YO$8LL8)(48(XR3^=;+$0]JYM:-6_"QG[*7)RK>YYSXB_X*'? +P[ILMW_P MGMMJ;("5MM.MY997/H!M _,@5\IZ+:^*O^"E'[1WA_Q;<:'=:!\'/"OVII/[&7P/T2\2ZM/ACX>6=#E6DM?-P?HY(KV" MRL;?3;2*UM+>*UMHE"1PPH$1%'0 #@"I5:G23=)._=]!N$Y_&]#Y'_;X_:,N MO!^AV?PA\#VXU;XB^-4^P1VD:!_LMM+^[+,#T9P2%ST 9CT&?G3X?:'XC_X) M>_%_07\33)K/PZ\:6L%MJ>HV\/\ QYW:C+8/7]VS,0/XD).,K7Z(6GP.\!V/ MQ&F\>P^%[$>,9MV_664M/RNTX))Q\O'';BM;X@?#?PQ\5/#SZ%XMT2TU_2&D M68VEXFY-Z_=8>A&3R/4TX8B$(JG;W7O_ %Y!*G*3YKZ]#E=<^"OA#XC:B?$D MEQ=7/]H)',LUITBP\PVEO?X3S6W-R& M)R?J:]N\)^$M(\"^';'0=!L8]-T>Q3R[:TB)*1+DG:,DG&2:=XA\+:3XKM8[ M?5[&*_@C?S$28$@-C&:^8Q>6T:M*JJ$5&4^OSOJ?58#.J]"O1EB9N5.F[\M^ MRMH>?_'3P@?%7PK,T*9O=-C6\B(ZX5?G _X#G\A7&?L\07_CSQ?J?C75SYLE MM!'8P'MN"*&(_P" C\W-?0C6\;6Y@* Q%=A0CC;C&/RJEH/AW3?#%@++2K.* MQM=Q?RH1@;CU-14RU5,9#$WT6Z[M?"_E=ETD]'VB[F>,M<\.^.WFT^[CGS:7)G,44B9/4].1@@ MGU-?4B^$M'C\1-KJZ?"-79=AO,'>5QC'Y5!XH\":!XTC1=:TN"^*<([@AU^C M#!%<53*)3O/W7)3E))ZIJ5M']QZ='B"%.U/WHQ=.$&XM*2<+ZKRUV=CPZ]\& M_!ZW\0Z9H\-Q>:G>7LHC7[%=-,L9/0L1TR?3-;7CY!'^TAX$1>BVV!_Y%KT[ MPO\ #/PQX-F,^D:/!:7!&/.Y=\>@9B2/PK1O/"ND:AKEIK%S813:G:KM@NF! MWQCG@?F?SK6.63]G:T8OFB_=6EHN]K]?N,)9U3]MS7;3IT._#\0X>BZ4_?2C'EY$TH7M:_G?>S6_4\R^+'_)?OA[_P !_P#1AKO_ M (W?\DI\2_\ 7K_[,*Z'4/">CZMK%EJMW80SZA9_\>]PX.Z/!SQ^-7-4TNTU MO3Y[&_@6ZM)UVR0R?=8>AKUU@YI8A77[R]O+W;:GS\LQIN6#?*_W-K^=I.6A M\V>(/#5YKG[-GA>]LHVF?2W-S)&HR2FY@3CVR#],UZ_X2^,WA36_#5M>RZS: M6,JQ+Y]O<2A'C8#D8/49Z$=:[+2='LM#TV+3["VCM;*(;4A0?*H/./UKE-2^ M"7@C5KYKNX\/V_G,=S>66C5C[JI KFIX+$X62GAW%MQC&2=[>ZK)IH[:N98/ M'1E2Q<9)*GSN>9^!;H_$WX_WWBK3XW&B:=#Y*7#*0)#LV ?4 MY8_0"KG[/?\ R/\ \1/^OS_VI)7M>DZ/8Z#8QV6G6D-E:Q_=AA0*HJKHWA/1 M_#]Y>W6G6$-I<7K;[B2,',C9)R?Q)_.BCELZ=2G5E)-J4I2]9*VGH+$9S2K4 MJU&,&HN$(1ZV47?7S?D>/_%[_DNWP\_WU_\ 1M=Q\>O^21^(O^N2?^C$KJ-2 M\)Z1K&K66IWEA#<:A9G-O<.#NCYSQ^-6]7T>SU[39K#4+=+NSF $D,GW6 (/ M/X@5T?4I\N)5U^\O;R]VVIR_VE3YL'+E?[FU_.TN;0^;/&/B#5-'^ W@2WLK MF:QLKT>5=W$.0P7G"Y'KR??;6EXC\(_";PSX(N;J":'6=1DMR+5A>-)-+*1A M3M5N.3GI7NS>$M&D\/KH;Z;;OI*KL6T9*=@ M5WMN62Y5'WKOELK/E6VN_0]>&>X=0TYX-3E+W6ES MW=TI/=6VZZ'+?LP?\DIM_P#K[F_F*]:K-T#PWIGA:P^Q:39QV-IN+^5%G;N/ M4UI5[N#HRP^'IT9.[BDCY?,<3'&8NKB(*RDV]?,****[#S@HHHH **** "BB MB@ HHHH **** "JVH(TEE,J@LQ0@ =>E6:*8GJK'YH_LX_"?X@:'KGP@ \(^ M.(M2T#4;A]2B\3VP31;&VEW[WM5;#"4J1R.V^O07NC:??V\ZZN8-/8B#R%Q@+(&8E2/F/X5^B-%>@\;)RYK*__ ;GFQP, M5'DYF?#OQP^&?Q+^+'Q.N/$/A:+6O"MQ=?#DH7:SPLUPTNYM/D9Q\CD,1Q@C M%&K_ B\4^(_#_[-MAX0TSQ#X%?1X+Z*YNY[(R3:1(;8KF8.N,.X8 D#<&R. MU?<5%0L7**22V_RL:/!P=VWO_P /^A^>.L_";Q?%^QK9^'4\(>)QXOL_&B7N MKQVMN\EU=2"1C)>6YV@%2NTJP& 1^-?3_P"S'K&H7OAG4]-O]+\?6[V8#\L;#JJ;/3C>/6O;Z*BIB'4BXM=;E4\*J"_ MA'J-AKVDW>D7K^(-1N%M[R%HW,;S$H^".A'(-'PA\'ZUI/[4GQLUJ^TF[M=( MU)=+%C>S0LL5SLM]K[&/#;3P<=*^@J*R=5MR?\QJJ*2BOY3PO]IKP-HUW\(+ M_2E\ ZIXET^XOTN9K'PJ$AO(9#)N:ZC Y:0'YL $L3SP37,_L9I\0UB\81^* MD\3_ /")1W,/_".-XTA\K5MFUO-$H/S8!V8+>^*^FJ*I5G[-TVKB=!>U51,^ M#/'GA_Q7X7_:V^(_B8:!\4I-%OI=+DM)O!%OFVOA%:Q!TF+#YU# K@'^\*W/ MVI]*U/5O&%AXG\.^!OB5I?C$Z%''IOB'PG'YBL[%G%I>1+G:JDC<6QU(Z 5] MKT5K]9]Z,G'96,7A=)1YMW<^,O%'AWXG>%/%GP=^+.O>$KWQIJ>CZ#)INOZ3 MH\:RW5M/(O\ KX8QPSP_JBOOI^MK'R5\$?V8= M2T#P=HWB_P 2ZQK.K^*+7PD^E6.CWEND*Z:LD7S0A54,S9^7+'->%W'[*7CF MW_9+\*W"ZAXZN]=2[MFE\#2NS6MNHNSD_9]NY=J_/STSFOTIHIK&5%)R\[_G M_F)X*DTH^5CXE^/_ ,&?B/\ M#_&#Q:EAI-E9>'-%T+^QM/N/$4$RII1%W'C@>O%.ZTWXDOI_P "OBCJG@36==U+PC;76EZYX?%LWV]6($2W M<4;++"*PN3,ROO0HH#!1^[0,V> />J7@FW\'O''A_XZV\GPU\&?$'P;/?\ B8W&NV.H*)?#=Q:M(?-N%D^Z M'9?FPI)&<#H*^@OVP]-\6^)OA"?!_@[3;J\U/Q1>PZ5/TC3O"WASX@ M>'OAO'97)UC0_&L0-K:3%28X[&1L;AOQR.Q.:^ZJ*OZTWS.2NV9K"*/*E+8^ M!OAGX=\<>%_CAH%M\/O!_P 0/!6@3:M+-XDT7Q @DT*.W9LM);2GY2[#) 0D MY('2L;XC?!SXR?$C4/'WQ/L-!ALKV'78+[1M/O[:==7\FQRL(@3H X9VP>6) M/M7Z)452QDD^9178CZE&UG)]SY ^/7P=D^,/Q/\ @?XF;PEJB0:BPC\30B%U M$5L@2>*&[&. LN1\W<>U?75O&(H515"*HP% P /2I:*Y:E1U%&+V1UTZ*IMR M6["BBBL3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "N-\;>)M= MQ[>E=E7#>*O^2J>!/^N6H_\ HN.N+&2E&E[KM=Q7WR2?X'I9=&$J[YXII1F[ M/:ZA)K\4'F?$K_GAX5_[_7/_ ,11YGQ*_P">'A7_ +_7/_Q%=S12^JO_ )^2 M^_\ X!7UY?\ /F'W/_,X;S/B5_SP\*_]_KG_ .(H\SXE?\\/"O\ W^N?_B*[ MFBCZJ_\ GY+[_P#@!]>7_/F'W/\ S.&\SXE?\\/"O_?ZY_\ B*/,^)7_ #P\ M*_\ ?ZY_^(KN:*/JK_Y^2^__ ( ?7E_SYA]S_P SAO,^)7_/#PK_ -_KG_XB MCS/B5_SP\*_]_KG_ .(KN:*/JK_Y^2^__@!]>7_/F'W/_,X;S/B5_P \/"O_ M '^N?_B*/,^)7_/#PK_W^N?_ (BNYHH^JO\ Y^2^_P#X ?7E_P ^8?<_\SAO M,^)7_/#PK_W^N?\ XBCS/B5_SP\*_P#?ZY_^(KN:*/JK_P"?DOO_ . 'UY?\ M^8?<_P#,X;S/B5_SP\*_]_KG_P"(H\SXE?\ /#PK_P!_KG_XBNYHH^JO_GY+ M[_\ @!]>7_/F'W/_ #.&\SXE?\\/"O\ W^N?_B*/,^)7_/#PK_W^N?\ XBNY MHH^JO_GY+[_^ 'UY?\^8?<_\SAO,^)7_ #P\*_\ ?ZY_^(H\SXE?\\/"O_?Z MY_\ B*[FBCZJ_P#GY+[_ /@!]>7_ #YA]S_S.&\SXE?\\/"O_?ZY_P#B*/,^ M)7_/#PK_ -_KG_XBNYHH^JO_ )^2^_\ X ?7E_SYA]S_ ,SAO,^)7_/#PK_W M^N?_ (BCS/B5_P \/"O_ '^N?_B*[FBCZJ_^?DOO_P" 'UY?\^8?<_\ ,X;S M/B5_SP\*_P#?ZY_^(H\SXE?\\/"O_?ZY_P#B*[FBCZJ_^?DOO_X ?7E_SYA] MS_S.&\SXE?\ /#PK_P!_KG_XBCS/B5_SP\*_]_KG_P"(KN:*/JK_ .?DOO\ M^ 'UY?\ /F'W/_,X;S/B5_SP\*_]_KG_ .(H\SXE?\\/"O\ W^N?_B*[FBCZ MJ_\ GY+[_P#@!]>7_/F'W/\ S.&\SXE?\\/"O_?ZY_\ B*/,^)7_ #P\*_\ M?ZY_^(KN:*/JK_Y^2^__ ( ?7E_SYA]S_P SAO,^)7_/#PK_ -_KG_XBCS/B M5_SP\*_]_KG_ .(KN:*/JK_Y^2^__@!]>7_/F'W/_,X;S/B5_P \/"O_ '^N M?_B*/,^)7_/#PK_W^N?_ (BNYHH^JO\ Y^2^_P#X ?7E_P ^8?<_\S@KB[^) M5K"\WV#PS=^6-WD07%P)),?PJ67 )[9XKHO"?BRR\8:6+RS+1NC&*XM9AMEM MY!]Z-U[$5MUQ/BSPG>VFJ'Q/X8"QZVBA;FS8[8M1C'\#^CC^%^W0\=,Y0JX; M]Y&3FNJ>_JO\NO37?2%2AC%[*<53ET:T7I+79]'T>^FW3:\=371[HZ,+5M35 M"8%O WE,P_A;:<@'ID=.N#TKR/P;\0OB;XR^W6\-EX1L=4T^7R;S3;V6ZCN( M&[$J%8%6'(8$@CO7J/A/Q99>,-+%Y9EHW1C%<6LPVRV\@^]&Z]B*PO'_ ( G MUJ[M_$/AZX32_%U@I%O=,/W=S'U-O.!]Z,_FIY%:5+U8QJT977EU7^9\UC\- MB*=3=IQT<=K^GG^#_$H>9\7?^?;P5_X$7G_Q%'F?%W_GV\%?^!%Y_P#$5M^ M/'\'C6TN(9K=]+UVP81:CI4Y_>6\GK_M(>JL."*ZRKC34X\T9NQE3HQJQ4X5 M9-/S_P" ><>9\7?^?;P5_P"!%Y_\11YGQ=_Y]O!7_@1>?_$5Z/15>Q_OO[S7 MZJ_^?DOO_P" ><>9\7?^?;P5_P"!%Y_\11YGQ=_Y]O!7_@1>?_$5Z/11['^^ M_O#ZJ_\ GY+[_P#@'G'F?%W_ )]O!7_@1>?_ !%'F?%W_GV\%?\ @1>?_$5Z M/11['^^_O#ZJ_P#GY+[_ /@'G'F?%W_GV\%?^!%Y_P#$4>9\7?\ GV\%?^!% MY_\ $5Z/11['^^_O#ZJ_^?DOO_X!YQYGQ=_Y]O!7_@1>?_$4>9\7?^?;P5_X M$7G_ ,17H]%'L?[[^\/JK_Y^2^__ (!YQYGQ=_Y]O!7_ ($7G_Q%'F?%W_GV M\%?^!%Y_\17H]%'L?[[^\/JK_P"?DOO_ . ><>9\7?\ GV\%?^!%Y_\ $4>9 M\7?^?;P5_P"!%Y_\17H]%'L?[[^\/JK_ .?DOO\ ^ ><>9\7?^?;P5_X$7G_ M ,11YGQ=_P"?;P5_X$7G_P 17H]%'L?[[^\/JK_Y^2^__@'G'F?%W_GV\%?^ M!%Y_\11YGQ=_Y]O!7_@1>?\ Q%>CT4>Q_OO[P^JO_GY+[_\ @'G'F?%W_GV\ M%?\ @1>?_$4>9\7?^?;P5_X$7G_Q%>CT4>Q_OO[P^JO_ )^2^_\ X!YQYGQ= M_P"?;P5_X$7G_P 11YGQ=_Y]O!7_ ($7G_Q%>CT4>Q_OO[P^JO\ Y^2^_P#X M!YQYGQ=_Y]O!7_@1>?\ Q%'F?%W_ )]O!7_@1>?_ !%>CT4>Q_OO[P^JO_GY M+[_^ ><>9\7?^?;P5_X$7G_Q%'F?%W_GV\%?^!%Y_P#$5Z/11['^^_O#ZJ_^ M?DOO_P" ><>9\7?^?;P5_P"!%Y_\11YGQ=_Y]O!7_@1>?_$5Z/11['^^_O#Z MJ_\ GY+[_P#@'G'F?%W_ )]O!7_@1>?_ !%'F?%W_GV\%?\ @1>?_$5Z/11[ M'^^_O#ZJ_P#GY+[_ /@'G'F?%W_GV\%?^!%Y_P#$4>9\7?\ GV\%?^!%Y_\ M$5Z/11['^^_O#ZJ_^?DOO_X!YQYGQ=_Y]O!7_@1>?_$4>9\7?^?;P5_X$7G_ M ,17H]%'L?[[^\/JK_Y^2^__ (!YQYGQ=_Y]O!7_ ($7G_Q%'F?%W_GV\%?^ M!%Y_\17H]%'L?[[^\/JK_P"?DOO_ . ><>9\7?\ GV\%?^!%Y_\ $4>9\7?^ M?;P5_P"!%Y_\17H]%'L?[[^\/JK_ .?DOO\ ^ ><>9\7?^?;P5_X$7G_ ,11 MYGQ=_P"?;P5_X$7G_P 17H]%'L?[[^\/JK_Y^2^__@'G'F?%W_GV\%?^!%Y_ M\14,?Q"\2>#=8M+?Q]8Z7::7?L(K?5](EE>WAFSQ'/Y@!7=V;IZ^WIM5-6TF MSU[3;G3]0MH[RRN4,QI.E):QF[^>Q,L/4BKTZCOYZKYZ%JN1^*U] MXSTOP5?7O@.RTW4_$-N/,BL-4WB.X4 Y165EP_IDX)&#C.1RVDZM>_!C4[;0 MM=N9+SP=H MZ=P2"#76^?\ M%_\^7PO_P# S4?_ (U4GQ0^%^M:#XH?XE?#5(X_%J(JZKHK MMY=MX@MU_P"6;]EG49\N7_@)R#QW'PO^*&B_%KPNFL:.\D;([6]Y872^75=3^?49!KVZM2/+[6E3CR^FJ?9Z_<^OJ#OBKI>E:%J>JSUS?Q"^ M'NA_%#PK>>'O$-F+S3[D9X.V2)Q]V2-NJNIY##^617F'P]^(6N?##Q59_#;X MDWAO);D^7X;\6R#;'JZ#I!.>BW2C Y^_U'/WJE".(CSTE:2W7ZK]5\UIM"G+ M#RY:CO%[/]'^C^3UW]HU07ITVY_LUK=;_8?(-TK&+?V#;2#CZ?K7B7A'XD_% M7Q7JFJ:1_9_@[3-;TQ]MSIM_-=I-M/W95"JP:-NS GWZBO>*XCXC?#G_ (2[ M[)JVDW?]C>+=,RVGZH@SCUBE'\<3="IZ9R.X.V"K487IUHK79M7L_/R[]5NN MSXLRP^(J*:7,O)O:2Z='L[7NLCS?C+_ ,^W@7_P(O?_ (W1YOQE M_P"?;P+_ .!%[_\ &ZU_AS\1O^$N^UZ3JUI_8WBW3,+J&ENFK:-;-/5,\Q\WXR M_P#/MX%_\"+W_P"-T>;\9?\ GV\"_P#@1>__ !NO3J*R^N+_ )]1^Y_YG1_9 MS_Y_S^]?Y'F/F_&7_GV\"_\ @1>__&Z/-^,O_/MX%_\ B]_^-UZ=11]<7_/ MJ/W/_,/[.?\ S_G]Z_R/,?-^,O\ S[>!?_ B]_\ C='F_&7_ )]O O\ X$7O M_P ;KTZBCZXO^?4?N?\ F']G/_G_ #^]?Y'F/F_&7_GV\"_^!%[_ /&Z/-^, MO_/MX%_\"+W_ .-UZ=11]<7_ #ZC]S_S#^SG_P _Y_>O\CS'S?C+_P ^W@7_ M ,"+W_XW1YOQE_Y]O O_ ($7O_QNO3J*/KB_Y]1^Y_YA_9S_ .?\_O7^1YCY MOQE_Y]O O_@1>_\ QNCS?C+_ ,^W@7_P(O?_ (W7IU%'UQ?\^H_<_P#,/[.? M_/\ G]Z_R/,?-^,O_/MX%_\ B]_^-T>;\9?^?;P+_X$7O\ \;KTZBCZXO\ MGU'[G_F']G/_ )_S^]?Y'F/F_&7_ )]O O\ X$7O_P ;H\WXR_\ /MX%_P# MB]_^-UZ=11]<7_/J/W/_ ##^SG_S_G]Z_P CS'S?C+_S[>!?_ B]_P#C='F_ M&7_GV\"_^!%[_P#&Z].HH^N+_GU'[G_F']G/_G_/[U_D>8^;\9?^?;P+_P"! M%[_\;H\WXR_\^W@7_P "+W_XW7IU%'UQ?\^H_<_\P_LY_P#/^?WK_(\Q\WXR M_P#/MX%_\"+W_P"-T>;\9?\ GV\"_P#@1>__ !NO3J*/KB_Y]1^Y_P"8?V<_ M^?\ /[U_D>8^;\9?^?;P+_X$7O\ \;H\WXR_\^W@7_P(O?\ XW7IU%'UQ?\ M/J/W/_,/[.?_ #_G]Z_R/,?-^,O_ #[>!?\ P(O?_C='F_&7_GV\"_\ @1>_ M_&Z].HH^N+_GU'[G_F']G/\ Y_S^]?Y'F/F_&7_GV\"_^!%[_P#&Z/-^,O\ MS[>!?_ B]_\ C=>G44?7%_SZC]S_ ,P_LY_\_P"?WK_(\Q\WXR_\^W@7_P " M+W_XW1YOQE_Y]O O_@1>_P#QNO3J*/KB_P"?4?N?^8?V<_\ G_/[U_D>8^;\ M9?\ GV\"_P#@1>__ !NCS?C+_P ^W@7_ ,"+W_XW7IU%'UQ?\^H_<_\ ,/[. M?_/^?WK_ "/,?-^,O_/MX%_\"+W_ .-T>;\9?^?;P+_X$7O_ ,;KTZBCZXO^ M?4?N?^8?V<_^?\_O7^1YCYOQE_Y]O O_ ($7O_QNCS?C+_S[>!?_ (O?_C= M>G44?7%_SZC]S_S#^SG_ ,_Y_>O\CS'S?C+_ ,^W@7_P(O?_ (W1YOQE_P"? M;P+_ .!%[_\ &Z].HH^N+_GU'[G_ )A_9S_Y_P _O7^1YCYOQE_Y]O O_@1> M_P#QNCS?C+_S[>!?_ B]_P#C=>G44?7%_P ^H_<_\P_LY_\ /^?WK_(\Q\WX MR_\ /MX%_P# B]_^-U5F^(WC#P#?VDWQ TW1XO#UTWDG5M"EFD2RD) 4SB10 M0C9QN' .,]:]8J"^L;?5+.>SO(([FUG0QRPRJ&1U(P00>H(JHXNG)VJ4H\O6 MUT_D[[D2P%:*YJ.(ES+:[37S5EH^MFGV=R6.19HU=&#HPW*RG((/0@TZO&[6 MZN_V?M0BL+^66\^&]S($M+Z0EY-%=CQ%*>I@).%<_=Z'C!KV*.19HU=&#HPW M*RG((/0@USXC#^QM*+YH2V??_)KJOTLSKPF+6(3A-:[Q?1]?)II. MHHHKD.\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KAO%7_ "53 MP)_URU'_ -%QUW-<-XJ_Y*IX$_ZY:C_Z+CKAQO\ "7^*'_I<3U,N_C2_P5/_ M $W([FBBBNX\L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKR M+]J/XY6_P$^$NI:ZKHVM7'^AZ5;MSON6!PQ'=4 +G_=QU(H Q?B)^VQ\*/AG MXJOO#NK:W<3:K8OY5U%964DJQ/C)0N!M)&>0"<'(/((KM?@[\>/!WQVTN^OO M"&H2WL=C(L5RD]L\+QLP)7A@,Y /0GI7X^7GP]US4/A=??$[499&L[C7H]+2 M6?)>[GDBFFEDW'KM\M03W+GT-?;?_!*W_D5OB#_U^VG_ *!)0!]U4444 %%% M% !1110 4444 %%%% !1110 4444 <3XL\)WMIJA\3^& L>MHH6YLV.V+48Q M_ _HX_A?MT/'3;\)^+++QAI8O+,M&Z,8KBUF&V6WD'WHW7L16W7$^+/"=[:: MH?$_A@+'K:*%N;-CMBU&,?P/Z./X7[=#QT\Z<)8>3JTE>+^*/ZKS[KKZ[^O3 MJ0QD%0KNTEI&3_\ 29>79_9_P[-\?^ )]:N[?Q#X>N$TOQ=8*1;W3#]WC/YJ>15SP!X_@\:VEQ#-;OI>NV#"+4=*G/[RWD]?]I#U5AP16CX3\66 M7C#2Q>69:-T8Q7%K,-LMO(/O1NO8BL+Q_P" )]:N[?Q#X>N$TOQ=8*1;W3#] MWC/YJ>16B::]O0U3_'S7G^9\]B,/5P=64HQU^U'OYKS_/[F=Q17 M)^ /'\'C6TN(9K=]+UVP81:CI4Y_>6\GK_M(>JL."*ZRNJ,E./-'8VIU(U8J M<'=,****LT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@"MJ6IVFBZ? .YKY<\;?\ !2+X5>%[ MZ2TTJ/6/%#H=IN-/MEC@)'7#2LK'ZA2#ZU[7\?\ X=ZA\6/@[XG\):5@4#M0!]*T444 %%%% !1110 4444 %%%% ! M1110 4444 5-6TFSU[3;G3]0MH[RRN4,QKS+2=6O?@QJ=MH6NW,E MYX.N7$6EZU,O:;65RACE@E&5= M3V-85*;D^:.DE_5GY'+6HN;52F[36S_1^7Y;HM5XS\4/A?K6@^*'^)7PU2./ MQ:B*NJZ*[>7;>(+=?^6;]EG49\N7_@)R#Q?TG5KWX,:G;:%KMS)>>#KEQ%I> MM3'+63'[MM<-_=[*Y^A]O5ZZ,-B7%MI:[-/\GY?UN9QE'%1<9*TE]Z?=?H]F MOFCD?A?\4-%^+7A=-8T=Y(V1VM[RPNE\NYL;A>'@F0\JZG\^HR#77UXQ\4/A M?K6@^*'^)7PU2./Q:B*NJZ*[>7;>(+=?^6;]EG49\N7_ ("<@\=Q\+_BAHOQ M:\+IK&CO)&R.UO>6%TOEW-C<+P\$R'E74_GU&0:ZJM*/+[6E\/XI]G^CZ^II M2JRYO95?B_!KNOU73T.OHHHKD.H**** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "LKQ/XITCP7H5WK6NZC;Z5I5HN^>[NG"(@S@_M[EI[S=L\M"=PPH))P<@="0 M.1UH \G\5?\ !3+X8:+>/;Z3IVN^(54X^U0VZ00L/5?,%+RX<1Q2:O&@MV8]!YJ,P7ZN%'O6!X9_X)E_#33='$&LZI MKFLZDRX>\CG2V0-CJD84X'LQ:O@?]HCX2I\#_B_KW@^&];4;6R:.2WN) [1 M21K(H8#C< V#C )&<#.* /VUHKR3]DOQ!J'B?]G'P%J&IR/->-IPA:23)9UC M=HT8D]2513GOG->MT %%%% !1110 4444 %%%% !1110 4444 %#MDB0P_ED5TE%5&4H-2B[-$RBIIQDKIG MAGP]^(6N?##Q59_#;XDWAO);D^7X;\6R#;'JZ#I!.>BW2C Y^_U'/WO_$+7/AAXJL_A MM\2;PWDMR?+\-^+9!MCU=!T@G/1;I1@<_?ZCG[W;**Q*=2FK26Z[^:_5?-:; M<<9/#M0F[Q>S[>3_ $?R>N_>?$;X<_\ "7?9-6TF[_L;Q;IF6T_5$&<>L4H_ MCB;H5/3.1W!/AS\1O^$N^UZ3JUI_8WBW3,+J&EN+ZKINNJ?+B,/4H5'BL*KM_%'^;S7::Z/9K1]''MZ*XCX<_$;_A+OM> MDZM:?V-XMTS"ZAI;G./26(_QQ-U##IG![$]O7)6HSH3=.HK/^OO3Z,]##XBG MBJ:JTG=/^FFNC6S3U3"BBBL3H"BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@#R/XK?M6?#+X-WCV'B'Q)&=60?-IMA&US<+WPX0$(< M=G*]:\PTW_@I1\(;Z^2"9/$&GQ,<&YN=/4QK[D)(S8^BUYGI/_!-K4?&7CKQ M)KWCKQ1]AL[[5+FYAM=) EN)4>5F#O(XVH2#G&UNO..E>:?M??L1Z5\ _!EI MXL\,:W?ZAIGVI+2ZM=4\MI4+ABKJZ*H(RN"-N>0<]: /TF\&>-M!^(?AZVUS MPWJEOK&DW _=W-LV5R.JD=58=U(!'<5N5^;O_!+CQ=J,/Q$\6^&!*[:3<:5_ M:1B))5)HYHHPP'8E9B#Z[5]!7Z14 %%%% !1110 4444 %%%% !1110 4444 M %%%% $%]8V^J6<]G>01W-K.ACEAE4,CJ1@@@]017D5K=7?[/VH16%_++>?# M>YD"6E](2\FBNQXBE/4P$G"N?N]#Q@U[)4%]8V^J6<]G>01W-K.ACEAE4,CJ M1@@@]0179A\1[*].HKP>Z_5=FNC^3T/.Q>$=9JK2?+4CL_T?>+ZKYJS29+'( MLT:NC!T8;E93D$'H0:=7C=K=7?[/VH16%_++>?#>YD"6E](2\FBNQXBE/4P$ MG"N?N]#Q@U[%'(LT:NC!T8;E93D$'H0:6(P_L;2B^:$MGW_R:ZK]+,K"8M8A M.$URU(_%'MYKO%]'U\FFDZBBBN0[PHHHH **** "BBB@ HHHH **** "BBB@ M HHHH *X;Q5_R53P)_URU'_T7'7U?E5^T%XXU;]LO]I?3O"?A:3S]%MK@Z;I;#)BV MYN+QO]DA2W^XB=Z_0/\ :EU*\TC]G?X@W5@[Q72Z1,H>/[RJPVL0>V%+<]J_ M)?X+_'+Q%\!] ]* M^&/[)?@CPMHL7DZ;IFO6L$>0-SG[+=EG;U9F)8GU8U6_X)6_\BM\0?\ K]M/ M_0)*^4OC/^UIX]^/'A>UT#Q3)ISZ?;WBWR"SM/*?S%1T&3D\8D;CZ5+^S7^T MAXP^!^KC2_#:64UGK-_;?:X;FW,C28;;M4@@C(8B@#]DJ*** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@#B?%GA.]M-4/B?PQMCUM%"W-FQVQ:C&/X' M]''\+]NAXZ;GA/Q99>,-+%Y9[XW1C%<6LPVRV\@^]&Z]B*VJXGQ9X3O;35#X MG\,!8];10MS9L=L6HQC^!_1Q_"_;H>.GG3A+#R=6DKQ?Q1_5>?==?7?UZ=2& M,@J%=VDM(R?_ *3+R[/[/^'9OC_P!/K5W;^(?#UPFE^+K!2+>Z8?N[F/J;>< M#[T9_-3R*N> /'\'C6TN(9K=]+UVP81:CI4Y_>6\GK_M(>JL."*TO"?BRR\8 M:6+RSWQNC&*XM9AMEMY!]Z-U[$5@^/\ P!/K5W;^(?#UPFE^+K!2+>Z8?N[F M/J;><#[T9_-3R*T337MZ&J?X^:\_S/GL1AZN#JRE&.OVH]_->?Y_NV#"+4=*G/[RWD]?]I#U5AP1765U1DIQYH[&U.I&K%3@[ MIA1115F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\#^ M/_\ @IGJWA?Q=XAT.R\!V:5(4+*@:1@H+$@ <]R2 /K7*:G\'_ 'K5S"?#M]<7+M)/-1ZEHMM;!H=0BD5UNRY+O-N4D M'@8QAL>NX M]S0!]V4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %35M)L]>TVYT M_4+:.\LKE#'+!*,JZGL:\RTG5KWX,:G;:%KMS)>>#KEQ%I>M3'+63'[MM<-_ M=[*Y^A]O6*J:MI-GKVFW.GZA;1WEE>#KEQ%I>M3'+63'[MM<-_=[*Y^A M]O5ZZ,-B7%MI:[-/\GY?UN9QE'%1<9*TE]Z?=?H]FOFCD?A?\4-%^+7A=-8T M=Y(V1VM[RPNE\NYL;A>'@F0\JZG\^HR#77UXQ\4/A?K6@^*'^)7PU2./Q:B* MNJZ*[>7;>(+=?^6;]EG49\N7_@)R#QW'PO\ BAHOQ:\+IK&CO)&R.UO>6%TO MEW-C<+P\$R'E74_GU&0:ZJM*/+[6E\/XI]G^CZ^II2JRYO95?B_!KNOU73T. MOHHHKD.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BNK M@6MK-,5+"-"Y5>IP,XJ6HIKB&!HDEE2-I6V1J[ %VP3@>IP"<>@- 'YVZI_P M50U^:UF73O .FVMP0?+DN;^29%],J$0G\Q7S=X;5/VC/C%/J/C_QUIWAF75; ME9;O4M01U##A0D>%V+A0JC>RJ !R<8K]<+WX&_#C48I([GP#X9F63.[=H]OD MY[YV=?>OS(_;M^#7ACX,_%^TLO"D8LM/U/3UOWTT.7%LYD="%R20C;,@'HSLI9"25A,<<@CR>REFQZ!@.@%?65 !1110 44 M44 %%%% !1110 4444 %%%% !1110 5S?Q"^'NA_%#PK>>'O$-F+S3[D9X.V M2)Q]V2-NJNIY##^617245492@U*+LT3**FG&2NF>&?#WXA:Y\,/%5G\-OB3> M&\EN3Y?AOQ;(-L>KH.D$YZ+=*,#G[_4<_>]SKF_B%\/=#^*'A6\\/>(;,7FG MW(SP=LD3C[LD;=5=3R&'\LBO,/A[\0M<^&'BJS^&WQ)O#>2W)\OPWXMD&V/5 MT'2"<]%NE&!S]_J.?O=LHK$IU*:M);KOYK]5\UIMQQD\.U";O%[/MY/]'\GK MOWGQ&^'/_"7?9-6TF[_L;Q;IF6T_5$&<>L4H_CB;H5/3.1W!/AS\1O\ A+OM M>DZM:?V-XMTS"ZAI;G./26(_QQ-U##IG![$]O7$?$;X<_P#"7?9-6TF[_L;Q M;IF6T_5$&<>L4H_CB;H5/3.1W!JC6A5@J&(=E]F7\OKWB^JZ;KJGRXC#U*%1 MXK"J[?Q1_F\UVFNCV:T?1Q[>BN(^'/Q&_P"$N^UZ3JUI_8WBW3,+J&EN*IJK2=T_Z::Z-;-/5,** M**Q.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^;?VE_V MTM._9Q\::=XNH&:*[6!45I)(PO*-DYB8_B*^(OVFOVR=<_:4 ML[#P_#I$'AOP]#7!56DE(50H#'C SDDX&/T]\;?!OP/\2+^" M]\4>%=+UV\@B\F*XOK99'6/).T$\XR2<>Y]:^7/VQ/V._ASI/PAU[QAX9TF+ MPOK&CQ+<_P"B.PM[A-ZJ8VC)*@X)P5 .<9R* .A_X)^_ ?3/AOX-O_%?]O:7 MXAUK6U2)Y-)N5N(;.)?F\G>.LA)!?TVJ!TR?K2OR*_8/^(VK^"?VA?#^FV5Q M)_9>O2&PO[/<=DH*,4?']Y&P0>N-PZ$U^NM !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 07UC;ZI9SV=Y!'16MU=_ ML_:A%87\LMY\-[F0):7TA+R:*['B*4]3 2<*Y^[T/LE07UC;ZI9SV=Y!' MA!IU>-VMU=_L_:A%87\LMY\-[F0):7TA M+R:*['B*4]3 2<*Y^[T/L4A!I8C#^QM*+YH2V??_ M ":ZK]+,K"8M8A.$URU(_%'MYKO%]'U\FFDZBBBN0[PHHHH **** "BBB@ H MHHH **** "BBB@ KAO%7_)5/ G_7+4?_ $7'75T#T=F=+1110 4444 M%%%6=]?T^Q34+E/(81)$[ */,Q@L=P./3/H:.M@Z7.H MFACN89(9HUEBD4H\;J"K*1@@@]16+_P@/AC_ *%S2?\ P!B_^)K>HH ^1/\ M@H1\*9-8^"FE)X0\(&\U&+7H)9DT73=\RP_9[@%B(UW;=S)GMDBN>_X)O_"S M4?#_ (=\7W/BOPE<:;<->VS64FL:"5Y'>OMRB@ HHK/U;Q! MI>@FS&IZE9Z<;R=;6V^USI%Y\S?=C3<1NCK;^M-0Z7_K>QZ#17)_ M#CXG:%\5M(OM3\/RSSV5G?3:>\D\#1;I8\;BH8VFJ'Q/X8"QZVBA;FS8[8M1C'\#^CC^%^W0 M\=-OPGXLLO&&E_:[,O'(C&*XM9AMEMY!]Z-U[$5MUQ/BSPG>VNJ?\)/X8VQZ MVBA;FS8[8M1C'\#^CC^%^W0\=/.G"6'DZM)7B_BC^J\^ZZ^N_KTZD,9!4*[M M):1D_P#TF7EV?V?\.S?'_@"?6KNW\0^'KA-+\76"D6]TP_=W,?4V\X'WHS^: MGD5<\ >/X/&MI<0S6[Z7KM@PBU'2IS^\MY/7_:0]58<$5H^$_%EEXPTO[99[ MXY$8Q7%K,-LMO(/O1NO8BL+Q_P" )]:N[?Q#X>N$TOQ=8*1;W3#]WC/YJ>16B::]O0U3_'S7G^9\]B,/5P=64HQLU\4>_FO/\_N9W%% M-;2XAFMWTO7;!A%J.E3G]Y;R>O\ M(>JL."*ZRNJ,E./-'8VIU(U8J<'=,** M**LT"BBB@ HHHH **** "BBB@ HKFO'GQ(\+_#'1_P"U/%6N6>AV).U)+J3! MD;^ZBCYG/LH)KE/ ?[37PR^)6O+HGA_Q7;W6KN-T=G<6\UK)+QGY!,B;^,GY M<\"A>\[('HKL]0HHHH **** "BBN6^)7Q)T3X3>$;KQ)XAEFATRW>.-C;PM* MY9V"J J\G)(I#2OL>??M@?"S7?C!\#-6T#PTJ2ZRL\%W!;O((_.\MP2@8\ D M9QG R!R.M?GBOQ__ &C?@G%_8=YK/B+1UA_=K#K>GI<$ = CW$;G;Z;3C'2O MUTMYUNK>*9 P210X#*5.",\@]#4E5MH2G=71^+7_ C7Q@_:<\6)?2Z?KWB_ M5)0(A>31%8(5S]W>0L<2Y).,J,D]S7Z9_LC_ +.:_LZ_#N2PO)X[SQ'JDJW. MIW$.?+5@,)$A(!*H">3U+,>A 'N5%(84444 %%9^A^(-+\36(O='U*SU6RWM M']HL9TFCW*<,NY21D$$$=B*T* "BBN$^-_Q3B^"_PSU;Q;)IYU5K,Q)%8K-Y M)GDDD6-5W[6QRV>AZ4F[#2;=D=W17&>(/BKHWA/7/"&AZOY\&M>)Y&ALK6"% MI@'50S[F P%7%%%%(84444 %%%% !1110 4444 5-6T MFSU[3;G3]0MH[RRN4,QKS+2=6O?@OJ=MH6NW,EYX.N7$6EZU,O:;65RACE@E&5=3V-85*;D^:.DE_ M5GY'+6HN;52F[36S_1^7Y;HM5XS\4/A?K6@^*'^)7PU2./Q:B*NJZ*[>7;>( M+=?^6;]EG49\N7_@)R#Q>TG5KWX+ZG;:%KMS)>>#;EQ%I>M3'+63'[MM<-_= M[*Y^A]O6*Z,-B7%MI:[-/\GY?UN9QE'%0<9*TE]Z?=?H]FOFCD?A?\4-%^+7 MA=-8T=Y(V1VM[RPNE\NYL;A>'@F0\JZG\^HR#77UXQ\4/A?K6@^*'^)7PU2. M/Q:B*NJZ*[>7;>(+=?\ EF_99U&?+E_X"<@\=Q\+_BAHOQ:\+IK&CO)&R.UO M>6%TOEW-C<+P\$R'E74_GU&0:ZJM*/+[6E\/XI]G^CZ^II2JRYO95?B_!KNO MU73T.OHHHKD.H**** "BBB@ HHHH **** "BBN1^(?Q:\'_">QAN_%OB"ST2 M*8XA2=BTLI'79&H+OC_9!ZTKI;CLWL==17G/P[_:(^'7Q7U672_"_B>WU#4X ME+M8RPRVTY4=2(YD1F ]0#BO1JJS6Y-PHHHI#"BBB@ KYJ_;M^#_ (M^+'PU MT9_!<3W6L:)J0O\ [+#+Y4SIY;+NB.1EU)! R"><&=,U M:6=;WQ%?#3]/C@@:3?*<72LUU?W@7:)[EP-[ M =E "J.^U1GG->F444 %%5]0U"UTFQN+V^N8;*RMXVEFN+B01QQ(!DLS$X MZDT:?J%KJUC;WME.5&&596'!!!R".M %BBBB@ HKS[XJ? M%D?#?5O!.F1:4=6O?$^LQZ5'&+CRO)0@L\WW6W!0!\O&<]16I_PM#0F^)Q\! M++%;SP]XALQ>:?#MDB0P_ED5YA\/?B%KGPP\56?PV^)-X;R6Y/E^&_%L@VQZN@Z03GHMTHP. M?O\ 4<_>[91CB8N=-6DMUW\U^J^:TVXXR>':A-WB]GV\G^C^3UW[SXC?#G_A M+OLFK:3=_P!C>+=,RVGZH@SCUBE'\<3="IZ9R.X)\.?B-_PEWVO2=6M/[&\6 MZ9A=0TMSG'I+$?XXFZAATS@]B>WKB/B-\.?^$N^R:MI-W_8WBW3,MI^J(,X] M8I1_'$W0J>FWKDK49T)NG45G_ %]Z?1GH8?$4\5356D[I_P!--=&MFGJF%%%%8G0%%%% M!1110 4444 %%%% !14-Y>6^GVLMS=3QVUM$I>2:9PB(HZDD\ 5SWA_XH^#/ M%VH-8:'XNT+6KY02UKI^I0SRC'7*HQ-'D'F=/1110 4444 %174;36TL:.8W M="H<=5)'6I:RO%'BG2/!>@W>M:[J$&E:5:*&GN[E]J("0!D^Y('U-*]MQ[Z( M_*.'XK?'_P#9'U!_#U[>:EIUE$Y2*UU6 75E(/6!W!&T]?W;#WYS7,?%/]JC MXH_'K3XO#^M:J9]-DD5O[*TNU6))W!RNX*-SX(!"DD9 .,BOV,BDL=?TN*5? M)OM/NHED0D!XY48 J>>"""#4>G>'M*T>0O8:99V3L,%K>W2,D?4"JVT9.^J/ M@_\ 8-_9%\1>'?%UO\1_&FG3:*MG&XTG3;I=D[R.A0S2(>44*S *PR2+-;2YET[3U0R16:*\SEG5%5 MS*"26'4BDW8:3;LCJZ*Y[4?'^@:+=:!::IJ4.EW^NMY>GV=TX6:=]H)15YR1 MD9[9(KH:JQ*:>J"BBBD,**** "BBB@ HHHH **** (+ZQM]4LY[.\@CN;6=# M'+#*H9'4C!!!Z@BO(K6ZN_V?M0BL+^66\^&]S($M+Z0EY-%=CQ%*>I@).%<_ M=Z'C!KV2H+ZQM]4LY[.\@CN;6=#'+#*H9'4C!!!Z@BNS#XCV5Z=17@]U^J[- M='\GH>=B\(ZS56D^6I'9_H^\7U7S5FDR6.19HU=&5T8;E93D$'H0:=7C5K=7 M?[/NH16%_++>?#>YD"6E](2\FBNQXBE/4P$G"N?N]#Q@U[''(LT:NC*Z,-RL MIR"#T(-+$8?V-I1?-"6S[_Y-=5^EF/"8M8A.$URU(_%'MYKO%]'U\FFDZBBB MN0] **** "BBB@ HHHH **** "BBB@ KAO%7_)5/ G_7+4?_ $7'7Z;IEM C:M/$L^JZBPW37ETPW2.[G MEOF)QD\"O)_@?;VNE_M;?'5M(1+70(8;!KJ.$!8OM9CW.V!QN_UF? M?M!76B1:.OPJTC3M;\L0-X@NO$4+V ;&/.$" RD=]GZFK^@_!/5?A3\!_&>E MZ)*_B?Q_KMO=W=WJ#LD+7M_,A&07(554G@$CH3WK2I)J4JL>B=O.^VG9+\;& M5.*<8TY=6K^5M6_6_P"IY=\/?B%\:_C!\+/$OC6W\86/@W0;&6_NM.NY-(AN M9[R*-G*H0P")$@4)NPSL0Q)Z5VY_:2UW3?V8_!?B^;38+[QUXH\C3].L,%(I M[R5F5'(!R$PN\@'OC(SFM#6/A7XF\._L:_\ " >'-.%WXH.@1Z<;59XXQYL@ M47!WLP7C?()'$$8+ M(WRJV5R">.2?8U)1BW"_NIP5^MKM2?W681;DE.VK4W;ST<5]]TGHGQ)^)7B[ MQ%\5K;X6_#R[L]*U2&Q&I:UXBO;87*Z?"QVQI'$2%>5CSAN #^7EOB*3QU\2 MOVK/A)9^,=-M/#MG8K=ZU%X=M;L7CVZQ)A9IY5 5F:3 484+U))KN/$'A'X MB_#']H#Q1X\\)>$K?Q[I'BBQM8+BS&J16%Q9RP*%!!E^5D(&>.>?;F5JH\VS M3_)C>\E'=)?>WK_ .2V_-$_@'QKX^\$_M")\,_&/B6W\;V6I:*V ML66K+IL=C<0,DFQHW2/Y2IP>>O2M#X6_%[6?$%Q\:/$6K7ZS>%_#>JSV6F0> M2B")+6',QW!0S;FP?F)QVQ4GPM^&?BW_ (3KQ)\4O',%I'XNU"Q&GZ9H=A/Y ML6G6BG<(C*==G)?/$6F_"_X;KHNGVK_$/QY';165M=K[/,E\E=M][2NE MY:VM8RCS.*E]KE;^>EEVTL_PONFOX?\.SZ ME!H=C/\ :4TX3,85$DN 'E;)8D # 4#.*^J_$,NIPZ#J$FBP6]SJZP.UI#=N M4A>4*=BNP!(4G&2*F]J:;ZW?XVM^'XCM>HTNR7SWO^*^X^8?#/Q*^(GQE^(' MC+3M%^).C^ M4T+5)K*S\'7FD13S74,1&)IGD(DVOSS%PH_6G^T'X5\7^/?V MG/AOX8L?'3Z;"L4VO0PQZ5!*FER01A5F&_F4N^X .<+GBM+Q1\/?B#\=?'G@ MG4=<^&NF_#J?P_J<.H7/B1=8@O+N>./G[/#Y*AMK'_GH0!Z>O1^,/"GQ!\/_ M +44?CO0_"4'B[1;O08]%5VU6*S.GGS][NP<$L._R GG\U"/\-/HW^$='Y7E M;?9^0Y/XVNWYO5>=H_>7->\7>,?#/Q>^$'P\3Q.^KW%Y#>WWB#4)+&")[R") M/DRBKB(%SCY,'@(/B%K\W[4GA7P/I=\(-$AT*YUC6+<0QL9LOY4(+%2R MX;GY2,YYS7.?$KPG\0O#_P"T=IWQ$\+>$[?QKIS>'FT4VCZI%8O9R&8R>9F0 M'*G@?*">3Z#*_ ?X5^/-+^,WQ#\*+GP-XL MM/ ?@S0;Z32[2\;2H[^;5;B/'F.1(0$B!( V\GU].:_9Y\3:KI/@GXY_%+Q' M+9S:U_:%Q'+<62D6\OV"WV*8PW.TMG -/^&G@GXV_"OP'K/PYT3POIB1_;+N M6S\:3:K&5\J5BP86P&\S9.S2%]K80D'!.>V:BSY'RO5Q2\[RM=^236O8UT]HN;92;\N57MZWN MK=2_J7[1>O?#3]F?P%KVOW=CJ7CWQ4D,5K-JACM+59)LN)9RH54CCC9BZ7 D.F0;.W_: ^">LZQ_PK+5O"^@Z=XL7P7(\T^$-SXCW7L-]\)M.^&UD(MT?V?4[:=IY,\*4MTP%QGYBV?;TVYH^TE-= MWIY=%VU^_IV,+/V<8O=K\=?GIIY'F7B3XH>,O''Q^\3> -*^(6G?"[^QX[<: M;;W>EQ75QK32)N9U,Q V \;4^8U]'>&X=4M_#^G1:Y<6]WK"6Z+>7%I&8XI) M0HWLBDY )S@5\P?%[P3\4?VA-"M_"NN_"O1/#M]'MHH6YLV. MV+48Q_ _HX_A?MT/'3;\)^+++QAI?VRSWQR(QBN+68;9;>0?>C=>Q%;=<3XL M\)WMKJG_ D_AC;'K:*%N;-CMBU&,?P/Z./X7[=#QT\Z<)8>3JTE>+^*/ZKS M[KKZ[^O3J0QD%0KNTEI&3_\ 29>79_9]-F^/_ $^M7=OXA\/7":7XNL%(M[I MA^[N8^IMYP/O1G\U/(JYX \?P>-;2XAFMWTO7;!A%J.E3G]Y;R>O^TAZJPX( MK1\)^+++QAI?VRSWQR(QBN+68;9;>0?>C=>Q%87C_P 3ZU=V_B'P]<)I?BZ MP4BWNF'[NYCZFWG ^]&?S4\BM$TU[>AJG^/FO/\ ,^>Q&'JX.K*48Z_:CW\U MY_G]S.XHKD_ 'C^#QK:7$,UN^EZ[8,(M1TJ<_O+>3U_VD/56'!%=975&2G'F MCL;4ZD:L5.#NF%%%%6:!1110 4444 %%%% 'R_\ W3;?XY_&SQ]\2=?B74; M;P_JC^'O#EM<#?%:+#@RS*IXWL2IW=1D^U2?MO6,$T7PJFLXE7Q2?&%E%IUP M@Q,JDL9 #UVY"$CITJ+P7X1^*G[.7B+Q=IWAGP3:_$/PAK6JRZO9R0ZQ#87- MF\N-T<@FX8< KZ9[X'4>#_A5XP\??%+3OB-\3XK'37T:-TT#PMI\YN8[%G& M'GFEP!)*1P-HP, ]J*>U+M'E;]59OYMW^^^P3WJ>=TO1W2^25ON[F=\7OB=\ M0V_:'\-?#SX?3V<1GT6:_P!2EOH%E@ME:38DS\;CL"MM164,SKGBK'P=\;>- M]-^.'CCP!XO\46_B^QT?3+;4X]6&G16+P-)UB98_EQC)!.3@=:W_ (>_#[7K M;]H?XF>-];L1:V-[;V.FZ+(9HW,EO&A,K85B5!DQPP!]JS?AO\*/$'_"6?&S M6_$%M_9=QXLO/L>G2>#KSPWIGAO3M!T^YAE\ M6#54G-U"SMM6WMT&Y9'+A=SD8R3C.!7<:O\ +7M:_9.^&FA>&UMAXB\.MI^ MN16=XWEQ7$R R/$S=LF1NO&1SCK6EDN9)^[[J\[-ZR];+;IKH3=WC=:^\_+1 M:1]+M:_CV@^)FK?'7X1_#6?XE:MX]TB\EL?)N+[PA'HD26BH\BJ8DN=WFDKN MZD\X_/OOC#\4M=L=5^#^E>&;K^S+SQ;K,+70:%)6^PI'YDZ8=2!PRC<.1V(K MF?%OA;XI?M(1Z9X;\7>$+7X<^"H[J*[U=3J\6H76HB-@RP1^4-J(6 )+'/ ] M,'L/$'PYUS7OVGO!WB-]/5/"/AO0[I8+KS8\?;9F\LH(]V[B, [L8[9IQW2> MW-?Y)7L_\35M?U)?PNV]OQ>B^[=V_0Y7XD?$OXCZK^TI;?#KP!>65I9QZ!]K MU*[OK99HK)WEP)B,!G8( %C#!29,MP*N_!7XA>+['XG?$_P=XU\2V_BFQ\*P MVMVFN"PCLF198C(T;I'\OR@?7@\\\;_PE^'VO:5\9OBQXRU^Q%FNM7=K:Z4? M.CD+V<$6T/A6.T,QSAL'CI6#\._@WXBGTGXWR^((%TC5O&^I7D5HYF24K9^2 M8K9R48XX8G'4>@K).4876KY6_FVFEZI/UT:V-6E*=GHN9+Y):OT=O35/*O%5RD^H:M<7-Q$L<*QI#!YS+'&H4#( 7@G+'/)-?.WC MJ\^,'PV_9+O_ EJGAG3?"6G:+IO]G7'B!=5CN7OXV81HEO"@RC2;P"SD8!8 M@9QCZU^#GA4>!_A1X0T'9L?3]*MX)%QCYQ&-_P#X]FMDHKGY=4K)?C=^NB]. MR3UQ;;Y.;1N[?RMIZ:OUTUN>"=&TO6+/PA:^(KZ2VN_%FHV MHN(--5$# ;6(3_%.TU2>TMFU'3?$= MCH]NLDD"Q[C$T>3$=[?*'4< YZ]-[XK:U\07U+4M#M/A+I?Q"\*7D*B*2?68 M+M?#FQGM;GQ/?.UTMG'.1;Q!KA9 M6M8W?HH4$9. 23V.:YY)RI37?_@=/+?3=:==>B-E4A?Y_CK?\+=-^A;_ &9? M!OB3X+_ >S\1:SXREO\ P_'X?DU5/#S:;!$EI(Z_:&8S@>8YY8?,)=/_8_/Q"\47ZWGB'^Q;G5!.T$<8R=[6Z[%4+T,8Z<]\UHZQX?\;?%# M]G'Q+X:O?#$/@;Q!=:=)IUEI[ZG'=KM$:@%I(QM4-\RX&<#!/I7CWCKX>?'# MXH? _0_A_P#\(=8^#M*L([&QO8EU>"YGU".-D4LNTA(XE"F0@LSDA0!UK>M> MI*I".E[)/LFY7=_+2_4QI>[&$Y]+M^;5OSU\CO-6^-'C/PO\%_A?91M;ZU\4 M_&\<$%M)>1+'#&[H))9Y$C"C;&K#@ =NO-<)\9O"OQ+A\5?##P1XL\\WZ):I?.V_=VZ6): M<:?*_P"6WS>C^Z_W+S.P;XAZ[J7[5?\ PAME?"+PSI/AK^T=1M_)C/F7,DVV M/+E=RX3G (![YKQR^_:F M:&5LI&3]T*NXUZY\,_AGKUO\6/C#XI\06GV!/$$]O8Z7()HY&:SAA*"0!6.W M).<-@\=*\L^$/PY\>?!;0K7PO+\#- \87.G3RBW\61ZK96YN(VD9E9Q(AE4@ M-CH>@K"*NDGVO\VV_P#R5-*S_0UEHY-=[?)*WXM7NOU-27]H[QYI7[(=EX_U M#38(?$=Q=+:"^FM'6!(&F*+?/".0NW#8Z$D'H<5ZA\$[?QA<,VK:C\4M+^)? MA>\MLV]Q9Z9#:O%/N&=K0L59,9R&^8''O6C\2?$GQ T7^S?^$?\ A]8^-=/N M;=DU&R_M>.UEAD..%,RA)(\;@>A/H.EZT445!04444 %%%% !1110 4444 5-6TFSU[3;G3]0MH[RRN$,QKS+2=6O?@OJ=MH6NW,EYX-N7$6EZS, MO:;7;>(+=?^6;]EG49\N7_@)R#Q?TG5 MKWX+ZG;:%KMS)>>#;EQ%I>LS'+63'[MM<-_=[*Y^A]O5ZZ,-B7%MI:[-/\GY M?UN9QE'%0<9*TE]Z?=?H]FOFCD?A?\4-%^+7A=-8T=Y(V1VM[RPNE\NYL;A> M'@F0\JZG\^HR#77UXQ\4/A?K6@^*'^)7PU2./Q:B*NJZ*[>7;>(+=?\ EF_9 M9U&?+E_X"<@\=Q\+_BAHOQ:\+IK&CO)&R.UO>6%TOEW-C<+P\$R'E74_GU&0 M:ZJM*/+[6E\/XI]G^CZ^II2JRYO95?B_!KNOU73T.OHHHKD.H**** "BBB@ MHHHH ;)(L,;.YPJ@L3["OF/]E'28?BUK/B?XT^((5O\ 5=3U*:RT3[0-XT^P MA;:JQ _=).[)')P?4Y^FIX5N(9(G&4D4JP]B,&OESX5^'OC!^S;H][X*TGP! M:?$/PU#>37&E:I;:Y!821QR,6V3)*,Y!)Y7/4]:47:;;[:>MU?\ #]1RU@DN M^OI9_K;\"U^T[8P'X_? *;3HEC\22:W(&GB&)&LU53*K$:I>627(LIG!D9HTX,DK!E4*S; $8XS73_ M R^$?B?4_B9/\3_ (E2V)\2+:FQTC1=-_A_K_A/4OB3KWB6P^PZKXD\1SWD,7G1RDV:@+;Y*,0.,\$Y&>0*<5RI*73 MFE\W9)?=[WK<4G>[C_=7W7;?_MOH [^2+^W M8;-+5KB)8B[J8T^4,N ./[V.:YR'Q=\:M<^%MY\7_P#A+='\-Z6EI)J]IX.N M-)2:%[)5+J)KG/FB1T&?EXR1QS@7O!_P!\4ZA^S7\1O#NLPQZ/XQ\8W^H:C+ M').DBI)*X,2L\988*HN<$X#'Z5YE\>M4^+H_9MT_PEK/A>Q\$62BPT*22/4X M[RXU60LD:1PI&,1(0I=MS$X&T#DFH?-)67Q6@EVNU9^6]OT+7*I:_#>5_1/3 MSM:^OXGJ4/QZ\7>&?V>_AS?7*0^(OB9XV:.WTV&XC6&$R3$NLDBQA0(XXV3. M,$\<\DU3\>>(_B]\ KKPAK_B#Q]8^-=)U;6;;2=0T4:)%9B'SB?F@E0[VVX. M-_7C/I71?&CX0>)XY/A5X@\"V%KK5_X"D*KHEU.< M]L&'_A!_B#\=?'_A;5_'WAVU\#^$O#%T-2M]"748[^YOKU1B.21XQL5$Z@ D MGGUXW]UU&UMS?^2Z?FK^=_0PU]FD]^7_ ,FU_+3R.EUKXA:]'? ^F7P MAT*W\/W&L:O;B%&,Q:3RH07*EEPW/RD9SSFN"T7QY\5_BY\9OB7X=\*^(+/P MYX1T.]BLDUBXTZ.ZDMY$CQ)%"AP'9GR6:0L% 7 YKN_A_P##_P 06?[0GQ.\ M;ZS8>19WMO9:;HK>=&YE@C0F0X5B4!DQPV#5;]G/P#XG^'/PEUZ76M,$/C'6 M-2U#69[$3QN3-(Q\M/,5BG(5.=V!GG%8+2*D];1;^;E=+U4?NV9L]9-1ZM+Y M7<6M3>$=5O=.74+6!;?^TA$56,A%^569W"\ M#'2N<\8>*/CIX.^#M[\5M2\::-9,+07K>#WT9/(MXYIPV5+<' MBIX_V:_%-Y^Q2W@!HX;3QI>8VD4E3E0%R"1G'..:Y']H_ M4OBA\1?#7@3PMXH\-V?@72]9U^QTV738=22^N;]\[F;,8VQPH%+8R6)V],5; MBY2Y+^][L;].B;[.[_+S$I**YK>[[S\[+5+NM/\ @['UM\,9]8NOASX8N/$% MR;S7)M-MY;Z";SX0:'JUG=/-#IWB2XUN'[/;(Q(CN#"R>V,U MVEJU^((RN5DD.T8/]X]#WQ6S^T)X)\<_%WX*Z(+'P_;6OB:UU2TU6Y\-RZ@C MI*L3L3!Y^ A)RISTX/)XR22]])[R2;_N^[JO_)MM@BW>#:VBW;SUT?X+7]-+ M7[07Q"\5?#/X!Z;<:;J(3QQJ$VGZ7!>F"-MUU*R"1A&5*<@2'&W ]*3XJ_$; MQ==_$3P]\*_ E[:V'B2\L3J>JZ_>6PG73K13L#K%PK2._ !X'''.1QOBKP+\ M6OC/\4?AIK'B;PY9^&/".B:K]OFT:'4HKN6-XT+)-,XP&)8!56,-@%BQ&:W/ M&7@_XA^!_P!HV_\ B#X2\)V_C;3=:T2+2Y[9]4BL9+.2-PP;,@.4.!PH)Y/I MR]W>763^[ETVV7-_P1+2-HZVBOO?M>>"O#?C+Q-9^, M(?#.DWFO6^HPV"V*,9W!4;8N7"EBI;'-,L,,L2@D$XW>V*B7,H>:B_OV^,'A73];NMLVG?#G2+&WU*60,PV032!C,)2#\V H! MXX[>L?'+XV>*?#4WPQT0:I9?#9O%4+2:GXCU*U%S%ILJQ*WV=0Y";BS%:]9ZO9!0H #2(D49D;/)"G'7!/>M?XM:E M\1-2O-9\.1_"#2/'OA>[15M;JXUJ"&,909\^&5#MDB0P_ED5T=%5&4H-2B[-$RBIIQDKIGAGP^^( M.N?##Q59_#;XDWAO)+D^7X;\6R#;'JR#I!.>BW2C Y_UG4<_>]SKG/B#\/M# M^*'A6\\/>(;,7FG7(SP=LD3C[LD;=5=3R&'\LBO+_A]\0=<^&'BJS^&WQ)O# M>27)\OPWXMD&V/5D'2"<]%NE&!S_ *SJ.?O=LHK$IU*:M);KOYK]5\UIMQQD M\.U";O%[/MY/]'\GKOWGQ&^'/_"7?9-6TF[_ +&\6Z9EM/U1!G'K%*/XXFZ% M3TSD=P3X<_$;_A+OM>DZM:?V-XMTS"ZAI;G./26(_P <3=0PZ9P>Q/;UQ'Q& M^'/_ EWV35M)N_[&\6Z9EM/U1!G'K%*/XXFZ%3TSD=P:HUH58*AB'9?9E_+ MZ]XOJNFZZI\N(P]2A4>*PJNW\4?YO-=IKH]FM'T<>WHKB/AS\1O^$N^UZ3JU MI_8WBW3,+J&EN,CT)%9G[:GPO\ "'@/X/P^+/#' MA_3?#/BG1=2LWTN]T>TCM9=YE5=F8P-PP2<'/2K>@W'B?]FWXR?$BZO? WB+ MQ=X5\77ZZK9ZEX8L_MLL$A!WQ2Q A@ 6X/L.N>-6_P!!\6?M/^.O#5UKOA?4 M/!?PT\.WBZFMCK@6._U:[3_5AX03Y4:Y/#')R?7Y53U5/ETV;?G=.7ZI>5EL M5)VE-RUW27E:R^_=^=S:^,/Q\\3^ _B)X \'>&_#MOXCUGQ!:7$\]G(S1LA5 M0(V\S.(T#;V=BK?*A &:L?#'XM^/)_C9JOPX\>Z=X?6]BT=-:MKWPX\YB$9D M$9CD$O);)Z@#ITYX;X9\,ZKK7[7GB_Q1?Z5=V^DZ/H%KI&F7EQ R13M(QFE: M)B,-M/RDKG&<4GPI\,ZO??M&_%[Q?JFF7EA;,MEHVE374#1K-#''ND>,L!N0 MOCYAQ3B]FUNI-^EVH_G'Y$27*G%=.5+UT;_"Y6G^,?Q$^)7C'Q'IGPITCPX^ MB^&[DV-YK/B:6?R[N[49>&!8>1MZ%VR.>GJGPF_:4U#Q%X%^(?C'QSIEGX;T MCPM?26)ALW,S[X8U\X%]VV0F1MJ[0O4#D\UYC\*/&7CCX#_"CQ/X0;XMO_;LD#,%:[+78E*Y/&6C5<9ZG%2O@;3Z1U\Y6UMV24ORWN:-+VB3_F?W M*_Y^[]_:QW>K?&CXX0_#VY^)4'A#PG8>$8;8ZB-#U"YN3JSV8&[>77$2L4^; M:0FVD>EZ_;?:8!%,!(S-'D!F0 8[ M X.*Y;QUX\\9_'KP#_PKWPO\-_%'A*?5XDL]5U;Q-8BSM-/MN!+Y9+9F8@%0 M%'0YK>\4?#F\;XX_!'P_I^E7K^$?!VG7-W)?&!C;K(L*PP(TF-N_Y=VW.>QC=\O-UY7?U=E'\;_ "W+OQ:^.WB7P3\8_"WPZ\&> M&K/7[W4]+ENFMY6:%8,-LB9I <1Q*%D9OE8G"JN":N?"/XM^-=4^+7BKX>^/ M-/T&/4])L(-3AOO#S3?9VBD(&QQ*2VX9Z\=#Q4/P[\,ZKJ?[4WQ-\7:GI=W9 MV%K86.BZ3-@HWL6(=]P<%EP#C@" MOG;P[\2O&WPA_93O/!UO\.O$&B>(=!T^[CO=:U.W6#38%+NQGBF+?OG.\;50 M'+'K@<_1_P"R[X5/@S]GWP)IC)LE_LR*YE'?S)OWK9_%S6L4ES6=TK*_>]]? MP_&W:*_[0'QEO\ X60^%],T2RL+KQ#XFU$:;8R:O.8; M*!L9,DS+R1R %')SQZ&G=>)/C#X?^'/C"_U^W\$VNMZ7 +NQO[5KI[":%07F M\R(D2*RJIQ\V"2.P-5/CYXHTB\DG\)>+?A'XH\=:!/"DT%YHNFB^B,O((RKJ M\+KV;CJ>1W\\T/X<_$;2?V+_ !MX?EL]0FUN^6Z_L?1;JX^T7=I8.RA+=FSR MXCW_ "@_Q =>*YY7]E4:WZ?AIZWN_-?(WBE[2FGMI?\ '7TM9>3)?V/8_'W@ MWX/IXD\0S^'1X.OK6\\0/Y4=Q_:;2R,9-TC%O+VE03P,XV^]>D> OC5K&J?L MPGXG>([.QM=0_LNZU3[+:HZ0[$,AB&&9F^953//?C%\/>'/" M'B#P[JMKH']CVUAKUF+2:=E@56\M2V2"-R@D#)KR?Q_K7Q \=_LVZ'\.O"7P MS\4:%;QVMAI6K76KV!A?:#&C)!&,NZD@LTA"J$4YZUO65Y3IT_[JCZ/F5_E[ MIC2>D*D_-R_#\]3VC4/VB-7\-_ _P+X@U#18-4\>>+TMX=-T*P+0Q2W$R[E& M69BJ*I!8DG\,\>7?'34?BOK]QX#\ >/M*\,-8>*?$-GB\\-SSXC2&022PR1S MHKMOCQX9U?P;\1O@UXMTOPSJOBGPWX3%U:76GZ);_ &BYA\R! M8XI%B!RP&WMTQ6?IJ^-_BY^U-X+\1:SX.U3PSX,T'3+R[T^/4HL2&:0"+=,5 MRD#!H6C7\&D:!)K4FJ7=IYEY9RO*(D6"0G]WN ^;C)'>N:O/CKX\^(- M_P"(;CX:V/A6P\):#<26<_B/QA<3)#>3Q_ZP0K$1A%/&]C@]JN_"[PIK6J?' M+XU>*=0T^\TM;MK71M)GNX'C$D,4)W21E@-R%R#N'!Q7S]\(_A7X.\!Z);:) M\0/V?O%WB+QI93RI/JECI3WME>@R,4=9#*(L;2!@@#BL(WDHKRO\VVU]RM=? MY&LM&VNZ7W+7[W?7_-'M"[^_23PYXM[M?Y;YNZC'^O/\ +1_YGT+1114%!1110 4444 %%%% M!1110!!?6-OJEG/9WD$=S:SH8Y895#(ZD8((/4$5Y#:W5W^S[J$5A?RRWGPW MN9 EI?2$O)HKL>(I3U,!)PKG[O0\8->RU!?6-OJEG/9WD$=S:SH8Y895#(ZD M8((/4$5V8?$>RO3J*\'NOU79KH_D]#SL7A'6:JTGRU([/]'WB^J^:LTF2QR+ M-&KHRNC#,&O8XY%FC5T971AN5E.00>A!I8C#^QM*+YH2V??\ R:ZK]+,>$Q:Q M"<)KEJ1^*/;S7>+Z/KY--)U%%%!/^N6H_P#HN.NYKAO%7_)5/ G_ %RU'_T7'7#C?X2_Q0_]+B>IEW\:7^"I M_P"FY'@7[6ES"6 # '!4@@#(93TKN:*35QWL>?7/$5\;N[,(.1$&P J9YPH'0>@KT>BBJN38****0PKSWXG?!7 M3?B=J&FZD^O>(O#.KZ>CQ0:CXW6T84/(<< = !7?4455[DA1112&%%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '$^+/"=[:Z MI_PD_AC;'K:*%N;-CMBU&,?P/Z./X7[=#QTV_"?BRR\8:7]LL]\Z8?N[F/J;><#[T9_-3R*N> /'\'C6TN(9K=]+UVP81:C MI4Y_>6\GK_M(>JL."*T?"?BRR\8:7]LL]\WH:I_CYKS_ #/G ML1AZN#JRE&.OVH]_->?Y_NV#"+4=*G/[RWD]? M]I#U5AP1765U1DIQYH[&U.I&K%3@[IA1115F@4444 %%%% !1110 54U;2[; M6]+O-.O$,MI=PO!,@8J61E*L,@@C@GD M*/&?B;0;.598/#NM:VT^GH4.4!C"@LJX& S$<5[FJA5 P!P *6BJN[6)LKW M"BBBD,*S_$.@V?BC0=1T?48VEL+^WDM;B-'9"T;J58!E((X)Y!K0HI-)JS&F MT[H\0TS]DKPU#?Z=)K/BCQEXOTW39EN+31O$.LMTVYT_4+:.[LKA#'+!*,JZGL:\RTG5KWX+ZG;:%KMS)>># M;EQ%I>LS'+63'[MM<-_=[*Y^A]O6*J:MI-GKVFW.GZA;1W=E<(8Y8)1E74]C M6%2FY/FCI)?U9^1RUJ+FU4INTUL_T?E^6Z+5>,_%#X7ZUH/BA_B5\-4CC\6H MBKJNBNWEVWB"W7_EF_99U&?+E_X"<@\7])U:]^"^IVVA:[RN?H?;U>NC#8EQ;:6NS3_)^7];F<91Q4'&2M)?>GW7Z/9KYH MY'X7_%#1?BUX736-'>2-D=K>\L+I?+N;&X7AX)D/*NI_/J,@UU]>,?%#X7ZU MH/BA_B5\-4CC\6HBKJNBNWEVWB"W7_EF_99U&?+E_P" G(/'%M1\ M/ZL)CI]]'Y9HI!@@AE=2""" 1]*\V\-_LN^'](\1:5K.L>)?%OC>?29/ M/TZ#Q1JYNX+24=)$0*H+#L6R1]17LE%"]U\RW!ZJSV"BBB@ HHHH YGXB?#_ M $SXF^%Y]"U66]M[>22.9+C3[EK>XAD1@R.CKT8$ ]Q[5Q?@O]FS0?"OBRR\ M2ZCK_B?QKK>GHR6%UXIU,WGV+<,,8E"JH)'&X@GWKUJBA>Z[H'[RLPHHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N<^(/P^ MT/XH>%;SP]XALQ>:=YU MSGQ!^'VA_%#PK>>'O$-F+S3KD9X.V2)Q]V2-NJNIY##^617E_P /OB#KGPP\ M56?PV^)-X;R2Y/E^&_%L@VQZL@Z03GHMTHP.?]9U'/WNV48XE.I35I+==_-? MJOFM-N.,GAVH3=XO9]O)_H_D]=^\^(WPY_X2[[)JVDW?]C>+=,RVGZH@SCUB ME'\<3="IZ9R.X)\.?B-_PEWVO2=6M/[&\6Z9A=0TMSG'I+$?XXFZAATS@]B> MWKB/B-\.?^$N^R:MI-W_ &-XMTS+:?JB#./6*4?QQ-T*GIG([@U1K0JP5#$. MR^S+^7U[Q?5=-UU3Y<1AZE"H\5A5=OXH_P WFNTUT>S6CZ./;T5Q'PY^(W_" M7?:])U:T_L;Q;IF%U#2W.<>DL1_CB;J&'3.#V)[>N2M1G0FZ=16?]?>GT9Z& M'Q%/%4U5I.Z?]--=&MFGJF%%%%8G0%%%% !1110 4444 %-==Z,N2N1CP;2K<7TL!/,3WN=Q!'!;;DC MCIQ7N>AZ+9>&]%L-)TZ!;73[&!+:WA7HD:*%5?P %7J*K96!ZNX4444@"JFK M6)U32[RR%S/9FXA>$7-J^R6+_6\$=K!'#"BQ MQ1J$1%& J@8 'X5)157TL3;6X4444AA1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110!!?6-OJEG/9WD$=S:SH8Y895#(ZD8((/4$5Y# M:W5W^S[J$5A?RRWGPWN9 EI?2$O)HKL>(I3U,!)PKG[O0\8->RU!?6-OJEG/ M9WD$=S:SH8Y895#(ZD8((/4$5V8?$>RO3J*\'NOU79KH_D]#SL7A'6:JTGRU M([/]'WB^J^:LTF2QR+-&KHRNC#I@).%<_=Z'C!KV..19HU=&5T8;E93D$'H0:6(P_L;2B^ M:$MGW_R:ZK]+,>$Q:Q"<)KEJ1^*/;S7>+Z/KY--)U%%%IEW\:7^"I_Z;D=S1117<>6%%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% '$^+/"=[:ZI_PD_AC9'K:*%N;-CMBU&,?P/Z M./X7[=#QTV_"?BRR\8:7]KM-\3JTE>+^*/ZKS[KKZ[^O3J0 MQD%0KNTEI&3_ /29>79_9]-F^/\ P!/K5W;^(?#UPFE^+K!2+>Z8?N[F/J;> M<#[T9_-3R*N> /'\'C6TN(9K=]+UVP81:CI4Y_>6\GK_ +2'JK#@BM'PGXLL MO&&E_:[3?'(C&*XM9AMEMY!]Z-U[$5A>/_ $^M7=OXA\/7":7XNL%(M[IA^[ MN8^IMYP/O1G\U/(K1-->WH:I_CYKS_,^>Q&'JX.K*48Z_:CW\UY_G]S.XHKD M_ 'C^#QK:7$,UN^EZ[8,(M1TJ<_O+>3U_P!I#U5AP1765U1DIQYH[&U.I&K% M3@[IA1115F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5-6TFSU[ M3;G3]0MH[NRN$,QKS+2=6O?@OJ=MH6NW,EYX-N7$6EZS,O:;7;>(+=?^ M6;]EG49\N7_@)R#Q?TG5KWX+ZG;:%KMS)>>#;EQ%I>LS'+63'[MM<-_=[*Y^ MA]O5ZZ,-B7%MI:[-/\GY?UN9QE'%1<9*TE]Z?=?H]FOFCD?A?\4-%^+7A=-8 MT=Y(V1VM[RPNE\NYL;A>'@F0\JZG\^HR#77UXQ\4/A?K6@^*'^)7PU2./Q:B M*NJZ*[>7;>(+=?\ EF_99U&?+E_X"<@\=Q\+_BAHOQ:\+IK&CO)&R.UO>6%T MOEW-C<+P\$R'E74_GU&0:ZJM*/+[6E\/XI]G^CZ^II2JRYO95?B_!KNOU73T M.OHHHKD.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N<^(/P^T/ MXH>%;SP]XALQ>:=#MDB0P_ED5Y?\/OB#KGPP\56 M?PV^)-X;R2Y/E^&_%L@VQZL@Z03GHMTHP.?]9U'/WNV48XE.<%:2W7?S7ZKY MK3;CC)X=J$W>+V?;R?Z/Y/7?O/B-\.?^$N^R:MI-W_8WBW3,MI^J(,X]8I1_ M'$W0J>F+=,RVGZH@SCUBE'\<3="IZ9R.X-4:T*L%0Q#LOL MR_E]>\7U73==4^7$8>I0J/%857;^*/\ -YKM-='LUH^CCV]%<1\.?B-_PEWV MO2=6M/[&\6Z9A=0TMSG'I+$?XXFZAATS@]B>WKDK49T)NG45G_7WI]&>AA\1 M3Q5-5:3NG_3371K9IZIA1116)T!1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110!!?6-OJEG/:7<$=S:SH8Y895#(ZD8*D'J"*\BM;J[_9^U"*QOI9;S MX;W,@2TOI"7DT5V/$4IZF DX5S]WH>,&O9*@OK&WU2SGM+N".YM9T,+ZKYJS29 M+'(LT:NC*Z,-RLIR"#T(-.KQNUNKO]G[4(K&^EEO/AO3178\12G MJ8"3A7/W>AXP:]BCD6:-71E=&&Y64Y!!Z$&EB,/[&THOFA+9]_\ )KJOTLQX M3%K$)PFN6I'XH]O-=XOH^ODTTG4445R'H!1110 4444 %<-XJ_Y*IX$_ZY:C M_P"BXZ[FN&\5?\E4\"?]$?@;XEU/P/ M#<3>)D6"*U%I;&XE7S)XXW9(P#E@C,1P<=>U $?QP_:>\!_ &VC'B34)+C5) M0&BT?3566[=3_$5+ (ONY .#C)JG^S[^U1X4_:/GUJ'PYI^KV$NDK$\XU2&) M PD+A=I21\_<.]D,@8 MF69R?E/R_=R6YYVXQ7NG_!*O_D.?$;_KWL?_ $*>@#]#:\?^/?[4G@G]GJV@ M37[B:]UBY3?;Z1IZJ]PRYQO;) 1,]V/.#@'!KUF^O(=.L[B[N'\N""-I9'/\ M*J,D_D*_%R6XUG]J7]HA//N&COO%.KB-7D^?[+ S8 [B.(<#N$H ^O(?^"J M>D-?[)OAY>I99_UR:HC28]=AB S[;J^I_@E\?O"'Q^\.R:IX7O':2W(6[T^Z M4)<,"5.#SD$#Q#X@?\$[/AE+\-=0M/#.GWMEXHM[1GM-3DOI9 M'GF52561"?+PQ&#M5<9XKXN_8E^(=U\/OVC?"OERLEGK,XT>[B!P)%F.U,_2 M3RV_"@#]4/BQ\9O"/P3\/+K'B[55TZWD8QP1*IDFN' SMC1>2?4]!D9(KY1U M[_@J?X>MKQDT;P%J6H6H/$M]?QVKGWVJDG\Z]L_:?_9:A_:6U#P8+S79-&T_ M1)+EKE8(0\LZ2B+A"3A2#%U(/WNAKGKS_@G;\&IO#6UWX3UN[<1VT=\RR6\[GI&LJXPQ M/0,JY. "2<5].5^"6MZ;-X9\17^GF;-QI]U) 9HB1\T;E=RGZC-?N1\,]6N] M>^&_A34]0)-_>Z3:7-P2,$R/"C-^I- '2T444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% '$^+/"=[:ZI_PD_AC9'K:*%N;-CMB MU&,?P/Z./X7[=#QTV_"?BRR\8:7]KM-\3JTE>+^*/ZKS[KK MZ[^O3J0QD%0KNTEI&3_])EY=G]GTV;X_\ 3ZU=V_B'P]<)I?BZP4BWNF'[NY MCZFWG ^]&?S4\BKG@#Q_!XUM+B&:W?2]=L&$6HZ5.?WEO)Z_[2'JK#@BM'PG MXLLO&&E_:[3?'(C&*XM9AMEMY!]Z-U[$5A>/_ $^M7=OXA\/7":7XNL%(M[I MA^[N8^IMYP/O1G\U/(K1-->WH:I[KOYKS_,^>Q&'JX.K*48Z_:CW\UY_G]S. MXHKD_ 'C^#QK:7$,UN^EZ[8,(M1TJ<_O+>3U_P!I#U5AP1765U1DIQYH[&U. MI&K%3@[IA1115F@4444 %%%% !117BW[7'QNU/X!_""?Q'HUG!=ZI/=QV$!N MLF.%G5SYA4?>P$.!D?$+XL>$/A1I\%[XM\06>AP3MLA^TN=\I'7:@ M!9L=\#C/-)\.?BUX1^+>GW5[X0URWURVM9!%.\"LOEL1D A@#R*_(?XO>$?B MCJNB6GQ,^(BWQ36KG[-:S:HVR:7Y6<%(O^6<0 XX4M?B9JG@G6H_ M!%GXVU /]@U;4)K2WFF)+W$D:AI7R>H!<#/<[O0U^B__ 2__P"2!:__ -C- MM=%T+QKI]]JETVR"UQ)&TK8SM7>H!/'2O4Z_%_] MD;_DY7X>?]A1/Y&OV@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@"IJVDV>O:;9:3JU[\%] M3MM"UVYDO/!MRXBTO69CEK)C]VVN&_N]E<_0^WK%5-6TFSU[3;G3]0MH[NRN M$,QK"I3S7S1R/PO\ BAHOQ:\+IK&CO)&R.UO>6%TOEW-C<+P\$R'E74_G MU&0:Z^O&/BA\+]:T'Q0_Q*^&J1Q^+415U717;R[;Q!;K_P LW[+.HSY'@F0\JZG\^HR#755I1Y?:T MOA_%/L_T?7U-*567-[*K\7X-=U^JZ>AU]%%%0>)/^"??BKXN?&[QMXF\4^(H=$T*]U6:>S:$?:K MJ> MF,8R%C4+M49)(VXVXP:\M_:N_86][$JRQ M%\A9%9>"N0%(P",CKS@ _2SP7XZ\/_$308=:\-:O:ZUIDIPMQ:2!@&'56'56 M&1E2 1Z4GC;QUH'PX\.W&N^)=3ATC28"JR74^< L0J@ DDD] *_,O\ X)P^ M/-3\/_'Z'PY#.YTKQ!:3QW%OGY/,BC:5),?WAL9?HYKZT_X*,?\ )L]__P!A M*T_]#- '8_\ #:GP3_Z'ZQ_[\3__ !NE7]M+X*,0/^$_L>?6"FDZ79V,;,\=K"D*L MW4A5 !/Y5;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ KG/B#\/M#^*'A6\\/>(;,7FG7(SP=LD3C[LD;=5=3R&'\LBNC MHJHR<&I1=FB914TXR5TSPSX??$'7/AAXJL_AM\2;PWDER?+\-^+9!MCU9!T@ MG/1;I1@<_P"LZCG[WN=#MDB M0P_ED5Y?\/OB#KGPP\56?PV^)-X;R2Y/E^&_%L@VQZL@Z03GHMTHP.?]9U'/ MWNV45B4YP5I+==_-?JOFM-N.,GAVH3=XO9]O)_H_D]=^\^(WPY_X2[[)JVDW M?]C>+=,RVGZH@SCUBE'\<3="IZ9R.X)\.?B-_P )=]KTG5K3^QO%NF874-+< MYQZ2Q'^.)NH8=,X/8GMZXCXC?#G_ (2[[)JVDW?]C>+=,RVGZH@SCUBE'\<3 M="IZ9R.X-4:T*L%0Q#LOLR_E]>\7U73==4^7$8>I0J/%857;^*/\WFNTUT>S M6CZ./;T5Q'PY^(W_ EWVO2=6M/[&\6Z9A=0TMSG'I+$?XXFZAATS@]B>WKD MK49T)NG45G_7WI]&>AA\13Q5-5:3NG_3371K9IZIA1116)T!1110 4444 %% M%% !5#7->TWPSI5QJ>L:A:Z7IUNNZ:[O)EBBC'JS,0!6'\5O'D?PO^''B+Q9 M+:-?KI%G)=?95?892HX7=@X!..<''H:_*3XO?$+XN?M*Z#K'CG6K:Y7P/HCH M?+MP8=/M6>18E5 3^]DW2*"?F8 ]AQ0!^K/@[XM^"OB%>SV?AGQ7H^O7<$?F MR6^GWL0&4ME?QKY,_;&_:F^(%O\3+SX M0_#JQN;74%6&.>^T]&EOKEI8EE"0@#]V KC+#YL@X*@<_!'C3PSK'@WQ5J6C M>((6M]:M)=MW$\@D99" Q!8$@GGDY/- '[P0S)<1)+$ZR1NH970Y# \@@]Q3 MZQO!?_(GZ%_UX0?^BUK9H **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH @OK&WU2SGM+N".YM9T,16MU=_L_:A%8WTLMY\-[F0):7TA+R:*['B*4]3 2<*Y^[T/LE07UC;ZI M9SVEW!'=B\(ZS56D M^6I'9_H^\7U7S5FDR6.19HU=&5T8;E93D$'H0:=7C=K=7?[/VH16-]++>?#> MYD"6E](2\FBNQXBE/4P$G"N?N]#Q@U[%'(LT:NC*Z,-RLIR"#T(-+$8?V-I1 M?-"6S[_Y-=5^EF/"8M8A.$URU(_%'MYKO%]'U\FFDZBBBN0] **** "N&\5? M\E4\"?\ 7+4?_1<==S7#>*O^2J>!/^N6H_\ HN.N'&_PE_BA_P"EQ/4R[^-+ M_!4_]-R.YHHHKN/+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y4_P"" ME'_)N*_]AJU_]!EKQW_@E7_R'/B-_P!>]C_Z%/7L7_!2C_DW%?\ L-6O_H,M M>._\$J_^0Y\1O^O>Q_\ 0IZ /M7XZ7#V?P2^(,\1*R1>'M0=67J"+:0BORT_ M83A2X_:L\"*XRH>\?\193D?J!7ZP?$C0G\4?#OQ3HT8+2:CI5U9JHZDR0L@_ MG7Y!_LD^)H/!G[27@/4;R06\ U#[([RXUV&]F5?\ GG')YTG_ (ZC4 ?M37CW[4/[0&G? ML_?#6[U1Y8Y/$-XC6^D6)(+2SD??*_W$R&8_0=6%;_QQ^-OA_P" O@6Y\1Z] M+O/^JL[&-@);R;&5C3T]2W0#)]C^6*Q_$/\ ;<^-K'_CYU"Z/)Y%II=H#_XZ MBY^K,>[-0!E_LX_!+5?VA_BM9Z0HF;35E%WK.H<_NH-V7.[^^YRJ^YST!Q^S M]K:Q6-K#;P1K%!"@CCC48"J!@ >P%>?? GX&>'O@#X'A\/:#&996(EOM0E4" M6\FQ@NWH.RKT4>IR3Z-0 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110!Q/BSPG>VNJ?\)/X8V1ZVBA;FS8[8M1C'\#^ MCC^%^W0\=-OPGXLLO&&E_:[3?'(C&*XM9AMEMY!]Z-U[$5MUQ/BSPG>VNJ?\ M)/X8V1ZVBA;FS8[8M1C'\#^CC^%^W0\=/.G"6'DZM)7B_BC^J\^ZZ^N_KTZD M,9!4*[M):1D__29>79_9]-F^/_ $^M7=OXA\/7":7XNL%(M[IA^[N8^IMYP/ MO1G\U/(JYX \?P>-;2XAFMWTO7;!A%J.E3G]Y;R>O^TAZJPX(K1\)^+++QAI M?VNTWQR(QBN+68;9;>0?>C=>Q%87C_P!/K5W;^(?#UPFE^+K!2+>Z8?N[F/J M;><#[T9_-3R*T337MZ&J>Z[^:\_S/GL1AZN#JRE&.OVH]_->?Y_NV#"+4=*G/[RWD]?\ :0]58<$5UE=49*<>:.QM3J1JQ4X. MZ844459H%%%% !574-+LM6BCBOK."]CCD65$N(ED"NIRK $<$'H>HJU10!\4 M_P#!4G_DEW@[_L,M_P"B'JG_ ,$L?^1%\=?]A*#_ -%&KG_!4G_DEW@[_L,M M_P"B'JG_ ,$L?^1%\=?]A*#_ -%&@#[?EE2&-Y)'6.- 69V. H'4D^E?E/\ M&/Q9J_[;?[4%CX>\.R,=#BF.GZ:^"8XK93F>[8?[6TOV) 1>M?-+G3I6@N)HX+-I$."(Y9XXY!^*,R_P# J_-C]G?]I"^_9RU#5M1TCPYI M>KZGJ$:P&[U R;X8@!.^!''EF/=F.6)[DDUZ-_P2__ .2!:_\ ]C-)KCR8#MP=N%V*W(]: /J3_ (*!?M ?\*O^&O\ PB>DW/E^ M)/$T;1%HVP]O9])7]B_^K'UMFCT M]9%^:"RZ[QZ&4@'_ '53'WC7R3^U[XJN=8_:F\776K1_VC!IVHI:I9S.RH8( M0H$?!RJL 2<=W)ZFO5X_^"G7C.#3ULH/!GANWMDB\F..(3JJ*!@ #?P .U ' MB7[(W_)ROP\_["B?R-?M!7X4?#/QY=_##Q]H?BNQMX;N[TFX%S%!<9\MR 1A ML$''/:OU[_9;^--]\>_A+:^*M2T^WTR]:ZFMI(;4L8CL;AEW$GH1W/(- 'KE M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 5-6TFSUW3;G3]0MH[NRN$,QKS+2=6O?@OJ5OH6NW$EYX-N7$6 MEZS,NZ;,_%#X7ZUH/BA_B5\-4CC\6HBKJ MNBNWEVWB"W7_ )9OV6=1GRY?^ G(/%_2=6O?@OJ5OH6NW$EYX-N7$6EZS,%TUC1WDC9':WO+"Z7R[FQN%X>"9#RKJ?SZC(-=?7C'Q0^%^M:# MXH?XE?#5(X_%J(JZKHKMY=MX@MU_Y9OV6=1GRY?^ G(/'5=3^?49!KJJTH\OM:7P_BGV?Z/KZFE*K+F M]E5^+\&NZ_5=/0Z^BBBN0Z@HHHH **** "BBB@ KX6_X*8?&JPMO#6G?#2PG M6?5+J>/4-2"'/V>% 3$C>C.Q#8Z@(#_$*]C_ &N/VKM._9[\-?8-.:&_\;ZA M$396;?,MNIR/M$H_N@YVK_$1Z D?!/[//[/?BO\ :T^(5[K&L7MTNBK<^=K. MO3_,\KGDQ1D\-(1^" @G^%2 >O?\$SO@W>ZCXQU+XCWL+1:7IT,EA8,RX\ZX M< 2,OJ$3*GWD'H:^@/\ @HQ_R;/?_P#82M/_ $,U]#^$O">D^!?#>G:!H=E' MI^DZ?$(;>WB'"J/U))R23R223R:D\1^&-'\8:3+I>NZ59ZSILI4R6=_ LT3% M2""58$'! (^E 'Y1_LS?ME7?[-WA'5-#MO"T.NB^OOMIGEO3#L_=JFW:$;/W M(=4@L?%_AJZ\+1RL$&H6US]L@3)ZN-BLH]P&KZ:;X" M_#1[4VQ^'GA7[.1CRQHML!_Z!7YB_MU?"'PY\&_C7'I_A: 66F:CIL6HFQ5R MRVTC22HRKDDA3Y88#MN('&* /UOL[R#4+."ZM9H[FVG198IHF#)(C#*LI'!! M!!S4U?.W[ >N7NM_LP^&OMKO(;.6YM(9'.28DF;:/HH.T>RBOHF@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG/ MB#\/]#^*'A6\\/>(;,7FG7(SP=LD3C[LD;=5=3R&%='151DX-2B[-$RBIIQD MKIGAGP^^(.N?##Q59_#;XDWAO)+D^7X;\6R#;'JR#I!.>BW2C Y_UG4<_>]S MKG/B#\/]#^*'A6\\/>(;,7FG7(SP=LD3C[LD;=5=3R&%>7_#[X@ZY\,/%5G\ M-OB3>&\DN3Y?AOQ;(-L>K(.D$YZ+=*,#G_6=1S][ME%8E.<%:2W7?S7ZKYK3 M;CC)X=J$W>+V?;R?Z/Y/7?O/B-\.?^$N^R:MI-W_ &-XMTS+:?JB#./6*4?Q MQ-T*GIG([@GPY^(W_"7?:])U:T_L;Q;IF%U#2W.<>DL1_CB;J&'3.#V)[>N( M^(WPY_X2[[)JVDW?]C>+=,RVGZH@SCUBE'\<3="IZ9R.X-4:T*L%0Q#LOLR_ ME]>\7U73==4^7$8>I0J/%857;^*/\WFNTUT>S6CZ./;T5Q'PY^(W_"7?:])U M:T_L;Q;IF%U#2W.<>DL1_CB;J&'3.#V)[>N2M1G0FZ=16?\ 7WI]&>AA\13Q M5-5:3NG_ $TUT:V:>J84445B= 4444 %%%% %+6=&L/$6E7>F:I9PZAIUW&T M,]K<('CE0C!5E/!!KP+]N+2[/1?V/_&-AI]I!86-NMA'#;6T8CCC47UOA54 M #V%?15?/_[>W_)I_CC_ +@#)M?"6B6/B*]U^WTBQAUR]18KG4DMU%Q M,B@!5:3&X@ #C/85^.W[7?\ R16MU=_L_:A%8WTLMY\-[ MF0):7TA+R:*['B*4]3 2<*Y^[T/LE07UC;ZG9SVEW!'3178\12GJ8" M3A7/W>AXP:]BCD6:-71E=&&Y64Y!!Z$&EB,/[&THOFA+9]_\FNJ_2S'A,6L0 MG":Y:D?BCV\UWB^CZ^332=1117(>@%<-XJ_Y*IX$_P"N6H_^BXZ[FN&\5?\ M)5/ G_7+4?\ T7'7#C?X2_Q0_P#2XGJ9=_&E_@J?^FY'BX/BX)#]B^R!3+CSX_ M-V!N,^7YG].:],HH _)SQQX+_:E^)6B?V/XGT?Q7K.F>:LWV:Y@4KO7(#< < MC)_.LSX??"?]I'X4RWLOA+PUXGT*2]5%N&M8 /,"Y*@YSTW'\Z_7:B@#Q3]D M63XCR_"7=\4!>CQ%_:$WE_V@JK/]GPFW'O'.J M>*/ FCW'B#PYJD[W366G1F2YL97.YT\H?,R;B2I4' X(& 3^F]% 'XWZE?\ M[0?Q$T>/PC?1>.M:T\;4.G2VMRX8*1@2?+E@"!]\D# /:OLW]AS]C_4?@[-/ MXU\9QQP^)[J V]GIRL'^PQ-C>SL"09&P!@?=7/)+$#[#HH ^&?\ @HI\&_'_ M ,3_ !/X.NO"V@7VOZ9:6<\;I9@/Y,S.I)*YR-RA>?\ 9KY7T']GKX_>%O._ ML7PKXLTCSL>;]@:2#S,9QNVL,XR>OJ:_8ZB@#\A_^%3_ +3?_0/\>_\ @;/_ M /%U^C'[)>D^+]$^ GANS\N$TOQ=8*1;W3#]WC/Y MJ>15SP!X_@\:VEQ#-;OI>NV#"+4=*G/[RWD]?]I#U5AP1765X[\8=O\ PF&@ M?\(IN_X6/N7R?)_U?V/8ZE:RR,&52HV[9%P,'WK]DZ* /'_ ($^*)?VB_V?-&U;QUH6GSMK M*S+>:<]L3:RK'<.J-Y _"W@RZ\)>$=/T0S7EPEU-I=DL6X;$*ARH_WL9]Z['_@F[\+ M?#NI_"F[\2:SX7L;C7[7Q%,;'4[RS4SQHMO;E3&[#( "]'ATG0-+M-&TR$LT=G8PK%$I8DL0JC&2236K10 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 5-6TFSUW3;G3]0MH[NRN$,QKS+2=6O?@OJ5OH6NW$EYX M-N7$6EZS,P=I+KTMV?E^6Z-6O&?BA\+]:T M'Q0_Q*^&J1Q^+415U717;R[;Q!;K_P LW[+.HSY6%TOEW-C<+P\$R'E M74_GU&0:Z^OFCQMG_AI[1O\ A5G_ "-W[O\ X3;;_P @W^S\'9]JQ_R]?\\M MOS8SN^6OI>NK$4HTW&4=I*]GNOZZ/JB\/5E44HRWB[7Z/^NJZ,****Y#J"BB MB@ HHHH _#_XY:AKWB#XP^,K[75NI-4?5;A91.K;D"R%50 ]%50J@=@!76^" M_P!K;XO_ [\,V7A_P .:^FE:/9ILAMH=&L\#G)))A)9B559=R0AAD$\@@BOI_] MOKQ]\1OAGH/@[7_ 5YJ%A;VUU<'4I[. 2Q ;$\KSE*E=O^L^\,9]\5]74E ' MY6Q_\%*/B\EA]G*>'GEVX^U-I[^9GUP)-N?^ XKR[0?!_P 3OVMOB1/>QPW? MB'5KR11=ZK.FRUM5Z#>X&V-5'11SQ@ FOU]N_A?X-U"Z-U=>$M"N;DG/G3:; M"[Y]=Q7-=!9V5OI]NEO:P16UN@PL4*!%7Z <"@#E?@_\-;'X/_#70/!^GR&> M#2[?RVG9=IFD9B\DF.VYV9L=LXKL:** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG/B#\/]#^*'A6\\/> M(;,7FG7(SP=LD3C[LD;=5=3R&%='151DX-2B[-$RBIIQDKIGAGP^^(.N?##Q M59_#;XDWAO)+D^7X;\6R#;'JR#I!.>BW2C Y_P!9U'/WO?M^]CVS\VZNVK%5:7UA*SO9KHWW7ZKI\[+CI2=* MI[!NZM==TNS_ $?7Y7>S\1OAS_PEWV35M)N_[&\6Z9EM/U1!G'K%*/XXFZ%3 MTSD=P3X<_$;_ (2[[7I.K6G]C>+=,PNH:6YSCTEB/\<3=0PZ9P>Q/;UXU\?/ MLO\ :&@?V%YW_"S/-']C?8<>9Y>?WGGYX^SXSG=QGIWK?"_[6EA:G_;K_EZZ M_P!WJ^VZZI^=CE_9[ECJ/ES1_GZ*W]_HOYOA?1KV6BJ^G_:O[/MOMWD_;?*7 MS_L^?+\S W;<\[-IOAO\,?%'BF MWM%OY](T^:\CMV)"NR*2 2.<>OMFOS1^-'[?'B;XU?#76/!FH>&=)T^SU+R= M]S;22F1/+F248#'')C ^AK]69H8[F&2*:-98I%*O&X!5E(P00>HK%_X0/PS_ M -"[I/\ X Q?_$T ?CG^SM^T!JG[.?B_4/$&E:7::K/>6+6#0WC,JJID1]PV MG._ MX0/PS_T+ND_^ ,7_ ,36EINDV.CP[*WL86;>8[:)8U+=,X '/ _*@#XW_ M &F/V\/$7P/^+VJ>#],\+Z;?VME# XNKR20/(9(ED) 4@8&['X&OS]^*'CZY M^*/Q USQ7>6T5G=:M<&XDMX"2B$@# SSCBOW!U'POHVL7'GW^D6-[/@+YMQ; M)(V!T&2,XJM_P@?AG_H7=)_\ 8O_ (F@#X6^"?\ P4.\3^)_''@GP9<>$]+2 MROKRTTEKB"67S45V6+>,DCC.X_0U^@U8]IX/T'3[F.XM=$TVVN(SE)8;2-'4 M^H(&16Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% $%]8V^IV<]I=P1W-K.ACEAE4,CJ1@@@]017D5 MK=7?[/VH16-]++>?#>YD"6E](2\FBNQXBE/4P$G"N?N]#Q@U[)5'7/[._L:^ M_M?[/_9?DO\ :OM6/*\K!W;\\;<9SFNW#U_9WIS7-"6Z_5=FNGW/0\W&87VM MJU.7+4CM+\U+O%]5\U9I,N1R+-&KHRNC#W]:]FMFNCT+P.*^N M8>-?EM?_ (:Z?5/=/JK,]AKAO%7_ "53P)_URU'_ -%QUW-<-XJ_Y*IX$_ZY M:C_Z+CKQL;_"7^*'_I<3Z/+OXTO\%3_TW([FBBBNX\L**** "BBB@ HHHH * M2EKG?B-]O_X5]XF_LM6;4_[,N?LJQ_>,OE-LQ[YQ6=27)!R[(N$>:2CW/%+# MXE?$#]H3Q5KEK\-]7LO!O@?1;EK&3Q1<6*WUQJ%ROWUMXG(01C^\V./ L.MR?$'QMI7B718(UFMM6:P33IX@-QE\\*?*" ;2&&/XLXXKB/V& M+_2)OV9?"L6FSQ-):K,E^BL-\5QYKLX<=CR#SV(K$_:TU^Q\86OPM\,QZG!- MX3\3^*(K34[JVG#0S11-DP%U./F<8(SU3VK>473DJ<=6VE?S;2OZ=5;H91DI MISEHM7]VMO736_4[_P /?M7_ F\5>)+;0=,\9VD^I74GDVZO#-%%.^<;8Y7 M01N2> %8Y[5U_C/XJ>$_AW?Z=9^)-;M]'FU".>6W^TA@C)"H:5F?&U 1]XC M)( R>*\._;&MM-U;P_X!^&NB06X\1ZEKMF=.LK5 &L[>(DR3A1]Q%48SQQGT M-)XM\*Z=\7_VU-+T_5K=-0TGP3X>6_:VE :-KN:7Y PZ'"A6P>ZBHC[UDNK: M^2C>_P"EK_,I^[=OLG]\K6_4](T/]J7X5>(M.UB^LO&E@+72$5[Q[I9+"](^)W[;'CKQ'?V45W!X-L+"PM5= 4^U.A?S".[("P&>F0>P MK5^ ,L.J?&OX^>-#MCLEU2#25<<+_HD&)6_,BB,E;FE_*Y?KM?+7[K6.^\2?M.?#'PB^I1ZMXMMK2;3KQ]/N(/(F>43HH9U5%0LX4, MN60%1G!.:AUO]J?X4^'M#TO5[WQI8BQU2$W%HT"2SR/&&*ES'&C.H# @EE&" M".H->0_LMZ5I?AWX,^./C-J-I')K7B&;4]7DNIE!=;5'D*Q*3T4E23CKD9Z" MLCX2^#])^"_["OB#Q5+90C6==T*XO;JXD0%G\Y66"+/]P!T^7IEB>]1)RA"3 MEO%)OU:>GX;]-M=RXI2FHK9MI>B>_P"*];WT/I[Q!X[T1?AC?^*X?$$-EH3: M<]W'KD49G2*,H2LP0#+XR#MQDXQ7B'Q*_:&3]G3X"Z"7\4'QOXTU"TCN-,OM M4TR>--0624'S)$3'EA8WX1G#':!RX\(_L0^!/ L99-2\0?V3HH7O MYDSK+(/T85V/[1MG!J'CSX#_ _B"I:3Z\-0>/H#%90[@OX[OTK:4+5'!/3G M4?NU?X-?CY-90G[D9M?9/-<\(S_$+7O#=IH/A:]BU"QT+PCILD,;31C$>Z M65RRHO\ =48(].*RO@9>:=KOQN^-_CSQ%<6\5[HFI#1+>:\<*-/L84.2"?N* MY!8GO@^]&FU[6NWZ*R_-]]%KY!KO;LOF[_HOOT\P\)>,M%^-G[75AKGAW5(= M9\/^'?"3/%+/C!\0M)M8[;3-;U];2S\N(1AXH(Q^\QCJYD MW'ODG/->I_'SX:6OQG^'>H>"7UE=&O;_ &7%M)A7.Z&17!,9(WIG:&'N*4KQ MIP272_\ X$^;RVOY7L-6E4DV]+V^Y*/XV'?#K]H;X>_%C6)]*\*^)(M4U&&( MSM;FWF@8Q@@%U\Q%WKDCE6 M)#'%(^1TX9N??-9&F?LW_$3Q5\*]-^'FK^(/!F@> /)A$T?A73)GN;N-2KY, MDSE0SD!C( 3DYYZ5O)>_)1VB[>O^6EN]S&,KPC)[RU]/\]?0]^^(GQ>\'_"? M3;6^\5Z[;Z3!=-LMU97EDG/?9'&&=\9'0'&1ZU;^'_Q'\-_%+P^-;\+:K%J^ MF&1H3-&K(5=<91E++VZU3_A&/#&R36W4->)GR0]6WLEW?E_PRU#Q9XLO;K5 M/^$8\,;)-;=0US>,-T6G1G^-_5S_ IWZGCKM^$_"=EX/TO[):;Y)'8RW%U, M=TMQ(?O2.W/_ !_/HMW; M^'O#UNFJ>+K]2;>U8_N[:/H;BMV'C_ ,?SZ+=V_A[P];IJGBZ_4FWM6/[NVCZ& MXG(^[&/S8\"KG@#P!!X*M+B::X?5-=OV$NHZK./WEQ)Z?[*#HJC@"CP!X @\ M%6EQ--VK;]%_+_P>[^2\^/\ BU\3])^#O@'5?%>LEFM;)!L@C_UD\K'"1+[LQ ]N M3VKRK0/#OQ[^(6CQ>(;[Q]IWP[EO$$]MX;L]!BOA A&56>65MQ?&-P7&#^0R M/VXKB.UM?A3-JAV>%XO&%G)JLC?ZM$&=I?\ V?O]:^CKS7M-TZS@N[O4+6UM M9V1(IYIU1)&<@(%8G!+$C '7/%=$5=.3[V_!/\;_ ('?)V:CY7_%K\+?B<7J MGQ/T_P"$?@72KWXI>(](T[57013S6BR".XF'7R8L&1N,' !QFK7PU^-G@CXO MQWA\(^((-7>S(%Q!YA:.15< XZXQ7D/P_BM?'?[97Q*O\ 7/+N+SPE M965CHEK/@_9XY4WRS(IZ$M@;AV;%1>![ZR\6?MC>/?%^C/&_A_0/#L>CW^H0 M8\J>\\P2,-PX8HB[2>VT"FI)VE+:2;]%9M?HNEF["E'EO&/1I>K=O\_.]KGI M?B3]ISX8^$7U*/5O%MM:3:=>/I]Q!Y$SRB=%#.JHJ%G"AERR J,X)S4.M_M3 M_"GP]H>EZO>^-+$6.J0FXM&@26>1XPQ4N8XT9U 8$$LHP01U!KR']EO2M+\. M_!GQQ\9M1M(Y-:\0S:GJ\EU,H+K:H\A6)2>BDJ2<=*I;*$:SKNA7%[=7$B L_G*RP19_N .GR],L3WJ).4(2M[Z'U3=_$+PY8^!9/& H M)/'8#/;&:XT?M2?"MO$MAH \961U6]>.*&(1RE/,< K&\FS8CG(^5F!!X(S7 MB/Q4T:Y\)?L.^!O L+-'J?B$:5HJC^(23NLL@_1A6C^TY\,]"T_X?_"?X0:) M:)8V.K>)+6VQ"H$@AC1C-+GNY!R6ZDDUM*/+4E%;_* MY/[M/R9[+I_[2GPRU;QQ#X0LO%]C=:_-*T$4$2R-')(.J+-M\LMVVALYXI/B MUJ0N/%'@/PY:^.Y_!^K:AJ1N8[2VL3#_" MK2>R7%U+C\S'4QM)Q]7\^57O;U3778N6BEZ+_P F=OR=^AG>*OVU_"_AWXZ6 M_A,W\2>&[.TN/[7OFTJ]EGCO%DV)#&$3E>"2^UE/9JE^)W[9WASP/\6_#/A6 MWO8O[.9IF\0W-QI=Y)+:((@T(B")\S,S8)"N%Z'!JU\#W7Q7^TM\;?$S,&%C M-9^'[;)Y58HR9!]"^#1X3=?%W[;/CB_=@T?A7PY9Z5$I/1[A_.8C\,BIIW?L MT^J;?W-K]%\TM>KG9>T:Z67Y1?W._P!QZCXG^-7@GP7X1TWQ-KNOP:5H^I1I M+9R74S 5T_BCP#XB^"/P[^+WQ0U;Q!'KGC_5])V-<:?:?9;:T M5$V1B-,DDKN#;F.?E'OF7)*FZK6EFU^GK=>EOS?*W-4UO=+_ #]+?.YZ7K'[ M4WPJT'Q1-X=OO&EA#JL,GDRIMD:&.3^X\P4QJV1C!8'/%*=;O]9VLQ?<>@4>U?1'P6\*CP/\(_!VA;-CV.E6\4B_]-/+!?\ \>)K;EY) M5$]6K1\N[_)&7-S1@UL[O[M%_P"E/[@^)'QD\&?".WM)?%NO0:0;MBMO"4>: M:;'79%&K.P&1D@8&17/^+/C%X4U[X'ZSXNT;QQ%HNBRPM;Q>)(+22X-G,S"- M6\C -^+WC*V^,OPH^#%E9Z5_8X\?>([.YNM/ &1$C&6FQJWR.ZV2;]>57?IKIU.E^-/[2$7[.OA/PEX<.N M+XB\9SFRCGN]4TZX99;9B5ENF$0 W85B(PQ;D<'OZ[8?&KP5J'P_;QN-=BM/ M"REE.H:A#+:+E6VD;955LY& ,:U]O^'7[0_P\^+& MK3:7X6\2PZCJ44?G&T>":WD:/^^JRHI=>1RN1S5/Q;^T_P#"[P-XFE\/ZWXO MM+35865)H5BEE6!CT$LB(4C/LQ%<_P"%?@[XD'Q,M/B;\3/%&DW>IZ/836ME M9Z-9FTLK2-P?,=Y)&+OP3]X@#K7GEY;:W^RSXV6W(TKQE\._B)XFVO:S)MU* MWN+H\XZK/$/<9Z=,\M:RC'O^=[)>5UZZZ"VC)]ORM=OY/_,^LXY%EC5T8.C# M*LIR"#WIU( % & *6D'J%%%% PHHHH **** "BBB@ HHHH **** "BBB@ H MHHH ***J:MJUGH.FW.H:AL/NW-PO\ M=[JA^I]S2=)O?C1J=MKNNV\EGX-MG$NEZ-,,->L/NW-PO]WNJ'ZGW]7KE2>( M=W\/Y_\ _,\Y)XQ\TOX?1?S>;\NRZ[O0*\9^*'Q0UK7O%#_ U^&KQR>+71 M6U76G7S+;P_;M_RT?LT[#/EQ?\"; ')\4/BAK6O>*'^&OPU>.3Q:Z*VJZTZ^ M9;>'[=O^6C]FG89\N+_@38 Y[CX7_"_1?A+X731]'221G=KB\O[IO,N;ZX;E MYYG/+.Q_+@# %>U"$3ITW9+=_HO/N^GKL?"_X M7Z+\)?"Z:/HZ22,[M<7E_=-YES?7#A\/12Z?&W7RFG+><1V+#\,UWOCGXW>$/A M'9::GCGQ'8Z7J=S$I^S6Z2322L!\S1PHK2;,YP.8[:&:54>9@"2J G+' )P.PKYR_9=-EXJ\?_&+QWK3PR>(X?$5QI DN"-]C M8P "-!G[BGDGH#M]JF]VXK16;^ZR_5=1VLE)ZO;[[O\ 1GM_P[^*/A7XL:*V MK>$M:M]:L4?RI'AW*T;XSM=& 9#CLP%)?&-S:1-K_B+1;K4;VZF0%Y6G#"&,D_P MX=/EZ98GO42ERP<[:**?S:NE^#_ N,;S4.\FODMW\FT>Z>)OVI?A5X173VU/ MQK81B_@CN8/(62X_=/C8[^6K>6IR,%\5V/BCXB>'/!OAF'Q#J^J1VVC3/"D5 MVBM*LAF8+%M" D[BPY Q@YZ5\L>(O FF? W]@.^LK:QC&LZYI=M'=R,@,L]U M=,BX)ZG8'PH[!*W/VB/!L>L>'?@1\'9G=H-0U"VCO C89K:SMAYO/;((YK:4 M;3<%TDE][U^Y:W\[V,HRO!3?6+?W+3[^WEN>O:3^TY\+=<\6-X;L?&>GSZJ! M(0OSK"WE@E]LY41-@ DX8]#5GP3^T5\./B-XID\.>'/%5KJFL)&THMXXY%$B M+]YHW90L@'^P3TS7CGQ]^'V@^//CE\$_AJ--MXM!T^*\U6YLH(PB+;1HJI%@ M=$9EVD=Q6]K%G!K?[;7@VPLH(X+?PEX4N;MQ"@54\]_)2/ Z +R!4QM+E\^; M\$]?O5K?B5+2_E;\6E;[FG?\#O?%&K)J'QN\-:/:^/)M(N--T^?5;[PO!8&1 M=0MR?+622?[J!6_AZGVZUYKX2_;:\+>)OC3J_AL7\:^&$BM;?3+J/2;XW-W> MR-AU;Y"$09 ^9%R>/SI MO['++XAT_P"(_C1F#2^(O%EY(C=Q!$1'$I^@W?G2IZ\M]N5R^]I+\&GY/[@J M?:MO=1^Y7?XIKT^\S;_]MSPK9_'2;PNVH1KX4L]/875\-)OI+DZ@)M@A0(A^ M3:"=VP@]FKV'XB_&[P/\)UM/^$K\0V^E2W8W06VR2:XD'JL4:LY'OMQ7F'[- M[KXI^,GQR\7LP8R:Y%H&;SP;#? M?V[-HAF\16US<7MC;P':B1+&ZJB$$$@_>*G-3&[C!=>7F?SLU_Z4EZ?BY64I M/I>WSZ_D_7RZ?5W@/XF>%_B=X=_MWPOK-OJ^EAFC>>+*^6RC)5U8!D(!!PP! MP0:\L\;?M@?"ZWT'Q1::5XSL;K6K/3[IX(T60133)$Q"1S%1&[9 P%8DUYG\ M:?A[J'P#_9K\: ^()-3\1>-=;A_MG6$@%M&GVB15DV1J2$38&7KSN/T&G^UX M/"?A/X(>&_A)I%O9?VCK5W8Z=I5@B*SPQB5 UQCMGE=_4ESUYI3C[1.*ZVC\ MVE?Y*_;7RL5"7)).72[^2>GWV^7S/7/V5?##>$?V>? MA(")WTY+R7=UWS$S M-GWS)6S\2/COX#^$=Q:VWBSQ%!I=W=*9(K58I9YF0?Q^7$K,%X/S$8X/I7:Z M;8Q:7I]K90+L@MXEAC4=E4 ?D*^:_C=I.O_ K\8:W\>?!FJ:+K%G'IJV6L MZ/JAP'AB?!^S3J?D?(QL/!(/4X%:UIIU'+:+;^2U_P" O(RHQ?(HO65E\WU_ M5^9Z'\3OB1H7B#X-PZOH?Q 7PO::_-!9Z9XDL[)[QA*\H 5(@,[FVLO.-O). M,5PWQ8_:TTCX0^/O!W@@ZHE]<1S"+Q)>WFFW4LD$"PJPD3RE >1R1]P.%YR! M6?\ %'5K7XD>,OV=-#L;#^S;'5;X^*I;#8%\E(8/.4,!QG=(<^IS6W;.OB[] MN2]9V!A\(^$UC12>D]S+DL/^V9Q0HM3MM[TONBK_ )IIV#F7)??W5_Y,[?E9 MK_@GJVJ_&+P;H/@2T\9:IKL&F>'+N-9;>\O4>$RAAE0L;J'+$<[=N?:JGPU^ M.W@3XO3WMOX3\0PZI=68#3VS0RP3(IZ-Y*HYI+*K&_\1ZAIJZ)&NEVWV*SM(&<':I9BSN7(PS'/..>*E:KFMH[V^5TO6[7 M9%2T?+?72_SLW]R9NI^U%\+)/&*>%X_&-G)K+W(LUCCCE:$SDX$?GA/*W9XQ MNZUZG7RC\,8]?_9P\>>#_@SK<6D>+/"6M27,^B:A!#Y=]:M&3,3<\8'U=3TY4UK_786O,TPHHHI#"BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH *YSX@_$'0_A?X5O/$/B&\%GIUL,<#=)*Y^['&O5G8\!1_+)H^( M/Q!T/X7^%;SQ#XAO!9Z=;#' W22N?NQQKU9V/ 4?RR:\O^'WP^USXG^*K/XD M_$FS-G);'S/#?A*0[H])0])YQT:Z88//^KZ#G[O72I)KVM72*^]OLOU?3[D^ M6K5:?LZ>LG]R7=_HNOWM'P^^'VN?$_Q59_$GXDV9LY+8^9X;\)2'='I*'I/. M.C73#!Y_U?0<_=]SHKB/B-\1O^$1^R:3I-I_;/BW4\KI^EH<9]993_!$O4L> MN,#N0_WF,J*$%Z+HE^B6[;]69RE2P-)U*C]7U;_5O9)>B#XC?$;_ (1'[)I. MDVG]L^+=3RNGZ6AQGUEE/\$2]2QZXP.Y"_#GX<_\(C]KU75;O^V?%NIX;4-4 M<8SZ11#^")>@4=<9/8 ^'/PY_P"$1^UZKJMW_;/BW4\-J&J.,9](HA_!$O0* M.N,GL!VU:UJT*4'0P[NG\4OYO+_"NBZ[OHERX?#U*]18K%*S7PQ_E\WWF^KV M2T75RS_$&O6'A?0[_6-5NH[+3;&%KBXN)#A8XU&23^ KPCP[\5OC)\8M//B' MP#X:\,>'_" M4I/H[?@FW^*M\SV9:+U8[Y M9+5 KE5D$K8PK !L'D;L'FM#POXZ\->-HYI/#OB'2M?CA.)6TN]BN0A]&*,< M?C7@7C+2[;XW_M9IX+\1(+WPAX1T5-6;1Y>8;R\E<*KRIT=44\ \9SV)!IQ^ M%=#T']N/P[:>"M+L]&6T\-7$VOPZ5 L$)5VQ )%0!=V[8>1G&WTJHOG<;_:Y MK?\ ;M_SY7_6A,O=3MTM^-OT:_K4^B-2\>>&=&;45U#Q%I-BVF^6;T7-]%&; M7>"8_-RPV;@"1NQG'%17'Q&\)V?AZ#7KCQ1HL&A3G$6IR:A"MM(?192VT]#T M/:OFGX%_#+P_\7?B=\5?B9XILH-UU;2YKG5+O2=-U"(2VFG62N^[RHFRJLQ0Y M8#.%4#OG+FM#G?\ *I??;3YW_!FG+[W*OYN7\_\ (^R[;6=/O-*74[>^MI]- M:+SUO(YE:$QXSO#@XVXYSG%8DGQ0\&12:9&_B[0DDU-5>P5M2A!NU;[IB&[Y MP>Q7.:^6?">H7/PT_P"";T]W(S)//#-CX@AT&Y\1:3;ZY/CRM,EOHEN9,]- ML1;O@EX8\"^&?A9X=TK3X9_%VK>+K!9?$,R!]0N'!+SSO,?G.3SC.!D8Z M"O0/'_\ Q6'[9/PVT4?/!X:T6^UV9>P>4B"//N",THI-Q5_M-?\ @*4ORT$V MU%NWV;_>W%?C]QT'C+]J;P=X-^+6A>";C5M%VW4=R^IZE<:S#!'I31+E8Y0> M-[GC:64CKS1\2/VIO!WP_P#&'A#0!J^BW[ZW<[+NX;6888]-M_*$BSRGD88, MNT$J&SP:X+P?X%\-?$+]L+XGW]YX>TJ]T_0=,LM.,*M%D\/IKRZQ8-H;Q"9=36Z0 MVQC/1Q+G;M]\XJ'PSXW\.^-H)9O#NOZ7KT,+;9)-,O([E4/H2C'!^M?*7QK_ M +:\V0 M=C1/A_XB^$=_\0?C-JN@>'O!;6WAF:WM/"_AL[XF:/\ >"6X8(BL^5"_*O3Z MZGO M+A=T*1RGYD(9D4!",8)]:]R_98\*GP;^SUX$TUDV2G3([J4'KOFS*V?Q>M5% MQE-2WC9>5V[_ (D6$9 M>ZOITAB7/3+,0!65<>-M)U/P7J.O:'X@T6YLHK>5X]4:\1[&-U4D-)*I(" X MW'/ KR+]I[X7^)/%7B'P7XMT?0M.\<:?X9:XEN_"&J2"..]WJ )$W H9$P^'XO#"^.=4@TQM/A@6$B[>98I5*I\N=L3#*\ M$<]2:QUG%I;[+YNR^3[K8UTC*+>V[?IJ_N7WGJ?B_P#: ;X&? W3M>\;:OX? M\2^,9K=9HK/2+];>'4]\H"M;E@6,:HZDN%(X)XS7K'A/QUH/C;1#JFBZUI>K M6D?RSSZ;?1W,4,@4,R&1"1D CKC@@U\^?M,^#='U;7O@5X"_LVTN'N-:B4O) M K.+&TBW21[B,["-N1T.*SOVKK:YM=5^'OPJ\$^&+:2P\17=QJ&I:)IL\>E) M?PVZJS0M*%PH;DL<9.P"M&T[VZR:7HK._I:]_0S5[1OI:-W^*_-:>I](^'_B M-X3\6:A/8Z'XHT;6;V 9EMM/U"&>2,#@EE1B1^-+KWQ$\*>%=0@L-:\3:/H] M]<8\FUO[^*"63/ VJ[ G\*^>_!?P%\1ZW\6/!OBR\\"^%OA1I/ACSF2QT&=; MB\OBZ; DLD<:)Y8Z\Y/)]5_T\T'1OM_P;^MOU\F?9BL& M4$'(/((I:AL[.'3[."UMHUAMX(UBCC7HJJ, #Z 5-0[7T!7MJ%%%%(84444 M%%%% !1110 4444 %%%% !1110 4444 %%%07U];Z79SW=W/';6L"&26:5@J M(H&2Q)Z "FDV[(3:BKL+Z^M]+LY[N[GCMK6!#)+-*P5$4#)8D] !7D5K:W?[ M0.H17U]%+9_#>VD#VEC("DFM.IXEE'40 C*H?O=3Q@46MK=_M ZA%?7T4MG\ M-[:0/:6,@*2:TZGB64=1 ",JA^]U/&!7L4<:PQJB*J(HVJJC '0 5ZVF7JR M_B_^D?\ VW_I/^+;P4GFSN_X"_\ *GF_[G9?;_P_$1QK#&J(JHBC:JJ, = M!13J*\@]\*X;Q5_R53P)_P!_9)^ M$?B77[K6;[P7:F_NG,EPUO<3V\*.148D\G*\YKK=?^#O@KQ/X'A\': MEX:T^?PS %$&FK%Y<<.,X,>W!0\GE2#R>>378T4K+EY>@[N_-U//OAQ\ O ' MPEO)[SPKX:M]-OIE\M[R266XG*_W1)*S,%X' ..!70:/X!T'0?%FN^)K&P$. MN:X(5U"[,LCF81+MC&UF*J .R@9[YKH:*J[W)LMCGO"_@#0?!NHZ[?Z/8"TO M-5OEV]-$5=WOYW^??U.33X5^%X_AQ_P ( M$FEB/PG]C-A_9Z3RC]P>J>8&W\\\[L\]:=X@^%WACQ3X"7P7J>EBX\,+##;C M3UFDC7RXBIC7DU7X(^!M<^']IX)O_#EK=^&+0#[/8RLY\H@ MDAE?=O#?,WS;LG)YY-=S10];WZZ_,%I:W0\]^'?[/_@'X4:E+J/A?0%T^_DB M,#7,MW/62"5#2NQ ) Z8Z54\1?LT_#+Q9XRD\5:OX0LK[6Y2K332/)Y#/ NA?#W2IM-\/:>NG64US+>21+([ M[II&W.V6)/)[9P.@P*R/B5\%_!?Q>BLD\6Z''JQL69K:7SI8)8=V-VV2-E8 MX&1G' KMJ*G>U^@]MC@](^!?@30? >I^#=-\.V]CX=U-&CO;6WDD1[@,,-OE M#>8Q(XR6SCO6QJWPX\-:]X%/@W4-)ANO#/V:.S_L^0ML$2 !%!SN!&U<'.<@ M'.:Z2BF_>O?K^FP+W;6Z'#>&_@CX'\)>![[P?IOAZW3PW?%FNK"X>2X68L " M6:5F8\*N.>-HQC%87@W]EKX7_#_7;36="\++::A:-OMY);VYG6%L$91))&53 MR>@XKU:BG=WYNHK*W+T/*_%O[+GPN\<^)KGQ!K?A*WO-5NF5[B5;B>))V'0R M1HX1SQ_$IKTO3M-M-'T^WL;&VAL[*WC6*&W@0)'&@& JJ. .PJS126BY5L- MZN[W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***XGQ9XLO;K5 M/^$8\,;)-;=0US>,-T6G1G^-_5S_ IWZGCKA6K1HQYI?)=6^R.G#X>>)GR0 M]6WLEW?E_P ,M0\6>++VZU3_ (1CPQLDUMU#7-XPW1:=&?XW]7/\*=^IXZ[? MA/PG9>#]+^R6F^21V,MQ=3'=+<2'[TCMW)H\)^$[+P?I?V2TWR2.QEN+J8[I M;B0_>D=NY-87C_Q_/HMW;^'O#UNFJ>+K]2;>U8_N[:/H;B/_ !_/HMW;^'O# MUNFJ>+K]2;>U8_N[:/H;B / $'@JTN)IKA]4UV_82ZCJLX_> M7$GI_LH.BJ. */ '@"#P5:7$TUP^J:[?L)=1U6VK;]%_+_P>[^2\RBBBND[C+\3>%])\9Z'=Z-KNG6^ MJZ7=+LFM+J,.CCJ.#W!P0>H(R*\Z\(_LI?"CP/K5KJVD>#K:*_M7\RVDN;B> MZ$# Y#1K+(RH0>05 Q7K-%"]UW6X/56>QYO\1/V<_AS\5M9CU?Q/X8AU#5(X M_*^V13S6TK(.BLT3J7'LV:Z/0_AOX9\,^#I/"ND:-;:7X?DA>![*S!B#*X*O MEE(;<0>6SN]ZZ6BE96<>C'=W4NJ.33X5^%X_AQ_P@2:6(_"?V,V']GI/*/W! MZIY@;?SSSNSSUIWB#X7>&/%/@)?!>IZ6+CPPL,-N-/6:2-?+B*F-=RL&P"B] M^<>'O%]QH$VKZ% MO"O@V3PIIFBVUOX>E22.6P8&1)5DSOW[B2V[/.2:Z>BE96<>C'?5/JCQ_3_V M1/A#I>GWEE;>"K58+K8)=]S.[[5D$@57:0LB[E!*J0#C!!%>OJ H P!P*6B MJN]B?,\H\1?LJ_"KQ9XFNO$&J^#[6ZU2ZE\^X;[1.D4\F<[I(E<1N2>NY3GO M78ZA\-?#6J:]X:UBXTJ,W_AM9%TEHW>-+02($8+&I"'Y0 ,@XQQBNFHI+W4D MN@WJVV<#\2/@3X$^+M]I]YXM\/Q:M=Z>&6WG\^6%T4G)4F-U++_LMDAUK0/"5O::I!GR+B:>:Y,&>OEB5V$?\ P$"O4:*J[OS=2>G+T"BBBD,* M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBJFK:M9Z#IMSJ&H7,=I96Z M&26>4X5%'C3##7K#[MS<+_=[JA^I]S2=)O?C1J=MKNNV\EGX-MG M$NEZ-,,->L/NW-PO]WNJ'ZGW]7KE2>(=W\/Y_P# _,\Y)XQ\TOX?1?S>;\NR MZ[O0*\9^*'Q0UK7O%#_#7X:O')XM=%;5=:=?,MO#]NW_ "T?LT[#/EQ?\"; M')\4/BAK6O>*'^&OPU>.3Q:Z*VJZTZ^9;>'[=O\ EH_9IV&?+B_X$V .>X^% M_P +]%^$OA=-'T=))&=VN+R_NF\RYOKAN7GF<\L['\N , 5[4(1P\54J*[>R M_5^79=?3?24I5Y.G3=DMW^B\^[Z>NQ\+_A?HOPE\+IH^CI)(SNUQ>7]TWF7- M]<-R\\SGEG8_EP!@"NOHHKCG.523E)W;.R,8PBHQ5D@KG?'GP[\-_$[07T7Q M3HUKK6FLP?R;E?NL.C*PPRMR>5(/)KHJ*S:3T9:;6J/-/ '[-WPV^&&L)JWA MSPM;V>J1J4CO)YIKJ:)2,$(\SN4X)'RXX)%5?&'[+/PL\>^)+C7];\(6]UJM MP0;B>*XG@$Y'>1(W57/NP.:]5HI[V;Z"VO8YV_\ A[X*/ *^"M3TM;CPPL,-N-/6:2-?+B*F M-=RL&P"B]^<,/AWX>\?:38Z9KVG+?V%E=0WD%O MYKQJLL1S&QV,-P!_A.0>X-.U+P#H.L>,='\57E@)]>T>*:&QNFED'D+*,2 ( M&VDD#&2"?0UT-%'G_6UORT] Z6_KN<\W@#06\=KXS:P#>)5L/[,6^,LAVV^_ M?L";M@^;G.W/OBC3_ .@Z7XTU7Q9;6 C\0ZI!%;7=Z99&,D^:Z&BC:UNGZ[_F&][]?Z_1'/>$? .@^!7UA]#L!9/K%_)J=\WFR2&:XDQO< MEV.,X' P!V KG_!OP!\ ?#[Q=?\ B?P]X.;'PY#;>*+B1YI+U)I<&1U*N M_E;_ "PQ#-E@N>3ZUE>+OV6?A;XX\27.OZOX4BEU>Z.;BXMKNXM?./JZQ2*K M'W()->K44K;>6P[O5]SE[[X8>%=2\!_\(5%O(6V&F,I\L(#D ($1LTC.6<+N.%8E1 MG.*]3HJKN_-U)Z:8V[2DY+&WW^43 MG_8KURBEL[K7#>1SRV\ZKG.WS(G5BN2> M"<5V95 M]@0.*]#HHJKM[DV2"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** " MN<^(/Q!T/X7^%;SQ#XAO!9Z=;#' W22N?NQQKU9V/ 4?RR:/B#\0=#^%_A6\ M\0^(;P6>G6PQP-TDKG[L<:]6=CP%'\LFO+_A]\/M<^)_BJS^)/Q)LS9R6Q\S MPWX2D.Z/24/2><=&NF&#S_J^@Y^[UTJ2:]K5TBOO;[+]7T^Y/EJU6G[.GK)_ M&_"4AW1Z2AZ3SCHUTPP>?]7T M'/W?BZ)?HENV_5FN,#N0OPY^'/_"(_:]5U6[_MGQ;J>&U#5'&,^D40_@B7 MH%'7&3V /AS\.?\ A$?M>JZK=_VSXMU/#:AJCC&?2*(?P1+T"CKC)[ =M6M: MM"E!T,.[I_%+^;R_PKHNN[Z)%]0\.^(;&/4=(OH_+GMY"1GG(((Y!! ((Y! KR?2/V1?#^G M0V]A=>,_'>L^'[@:AK[FQ"J?EC*(JLR# ^4L17NE%"]UW0/569Y7\1_V M=?#_ ,1/%=KXHCU?Q!X2\2V]O]C.K>&;_P"R32P9R(WRK*R@^V?R%;/PQ^"_ MASX3V>HKHRWESJ6IOYNH:SJ5P;F^O'Q@-)*W7&> ,GCDUW=%+9-+J#UW." M\"?!G1?AW\,Y_!&E7>H'3YUN1)>SRHUV6G+%WW! NX;N#M[#@U%9_!'0M.^" MI^&%IE>A44Y>\FGU_3;\QIM--; MK7[]SSKQ5\"?#OB[X6DA*$%3M&[ !.."* MT_B%\*](^)=YX7GU:>\1?#VJ1ZO;06SJL5OEKI^+.-\6?"S2?&7CCPCXHU">\^V>&))YK*VC=1 [RH$+2* M5))4#Y<,,'UI=+^%NDZ7\4=:\>I/>3:WJEC#ISQS.IAAAC.0(U"@C)Y.6//3 M%=C126EK>?X[C>N_]6=_S/+(/V=]#L?BO?>/=/USQ'I5]J$T5Q?Z78ZCY5A> MR1KM5I8PNYOINP>>.31X@_9WT/7/BF/'T&N>(]"UF2.&*\AT?4?L]O?I$046 M90I9AP 0&&17J=%"]VUNFP/6]^NYY9\1OV=]"^(7BZW\51:UXA\)>)8K;[&^ MJ>&=0^RS3PYR(Y,JRL ?;T]!C>\._"K3]&\%ZGX9U'5=;\5V.I+)'=S>(M0> M[FD1TV,@;@*N.R@#))ZUVM%*RY7'HQW=U+JCYYE_8?\ !%[X7?P_J.O^+M7T MJ./RK"VU#5A-'IBY_P"7>,IL4XRN65B 3@CK7O\ 8V<6G65O:0+L@@C6*-?1 M5& /R%3T55V39'DOC;]G/3O&GB34=87QGXU\/_VD%%[I^B:VT%K<80)DH5;; ME0 =I7-7;S]G?PA<:%X(T2UAN=,T;PAJ,>IV%C:2CRY)DW%3,65F<99F/()) MSFO3:*2]U)+I;\-ONZ#?O;_U?<\X^+7P+T7XO7V@:C>ZIK6@:QH^(VC^'+:_U'7+/5/#P']F^(+#4&CU M*$[0K,9B#N+!1N+ Y->FT4K:6\[_ #'?6_R^1YWX/^"]OX5T[5[.\\6^+O%2 M:I;FUE;7]8> W>]UT55[/F6Y/2P4444AA1110 4444 %%%% ! M1110 4444 %%%% !1110 445!?7UOI=G/=W<\=M:P(9)9I6"HB@9+$GH *:3 M;LA-J*NPOKZWTNSGN[N>.VM8$,DLTK!410,EB3T %>16MK=_M ZA%?7T4MG\ M-[:0/:6,@*2:TZGB64=1 ",JA^]U/&!1:VMW^T#J$5]?12V?PWMI ]I8R I) MK3J>)91U$ (RJ'[W4\8%>Q1QK#&J(JHBC:JJ, = !7K:9>K+^+_ .D?_;?^ MD_XMO!2>;.[_ ("_\J>;_N=E]O\ P_$1QK#&J(JHBC:JJ, = !3J**\@]\* M*** "N&\5?\ )5/ G_7+4?\ T7'7,-T6G1G M^-_5S_"G?J>.N%:M&C'FE\EU;[(ZR7=^7_#+4/%GBR]NM4_X M1CPQMDUMU#7-XPW1:=&?XW]7/\*=^IXZ[?A/PG9>#]+^R6F^21V,MQ=3'=+< M2'[TCMW)H\)^$[+P?I?V.SWR2.QEN+J8[I;B0_>=V[DUA>/_ !_/HMW;^'O# MUNFJ>+K]2;>U8_N[:/H;BMV'C_ ,?SZ+=V_A[P];IJGBZ_4FWM6/[NVCZ&XG(^ M[&/S8\"KG@#P!!X*M+B::X?5-=OV$NHZK./WEQ)Z?[*#HJC@"CP!X @\%6EQ M--VK M;]%_+_P>[^2\RBBBND[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M ***J:MJUGH.FW.H:AL/NW-PO]WNJ' MZGW-)TF]^-&IVVNZ[;R6?@VV<2Z7HTPPUZP^[(=W\ M/Y_\#\SSDGC'S2_A]%_-YOR[+KN] KQGXH?%#6M>\4/\-?AJ\U"$3ITW9+=_HO/N^GKL?"_X7Z+ M\)?"Z:/HZ22,[M<7E_=-YES?7#G6PQP-TDKG[L<:]6=CP%'\LFO+_A]\/M<^)_BJS^)/Q)LS9R6Q\SPWX2D. MZ/24/2><=&NF&#S_ *OH.?N]=&BFO:U=(K[V^R_5]/N3Y:M5I^SIZR?W)=W^ MBZ_>T?#[X?:Y\3_%5G\2?B39FSDMCYGAOPE(=T>DH>D\XZ-=,,'G_5]!S]WW M.BN(^(WQ&_X1'[)I.DVG]L^+=3RNGZ6AQGUEE/\ !$O4L>N,#N0_WF,J*$%Z M+HE^B6[;]69RE2P-)U*C]7U;_5O9)>B#XC?$;_A$?LFDZ3:?VSXMU/*Z?I:' M&?664_P1+U+'KC [D+\.?AS_ ,(C]KU75;O^V?%NIX;4-4<8SZ11#^")>@4= M<9/8 ^'/PY_X1'[7JNJW?]L^+=3PVH:HXQGTBB'\$2] HZXR>P';5K6K0I0= M##NZ?Q2_F\O\*Z+KN^B7+A\/4KU%BL4K-?#'^7S?>;ZO9+1=7(HHHKSCV HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***@OKZWTNSGO+R>.VM8$ M,DLTK!410,DDGH *:3;LA-J*NPOKZWTNSGO+R>.VM8$,DLTK!410,DDGH *\ MAM;6[_:"U"*_OHI;+X;VT@>TL9 4DUIU/$LHZB $95#][J>,"BUM;O\ :"U" M*_OXI;/X;VT@>TL9 4DUIU/$LHZB $95#][J>,"O8XXUAC5$5411M55& .@ M KUM,O5E_%_](_\ MO\ TG_%MX*3S9W?\!?^5/-_W.R^W_A^(CC6&-4151%& MU548 Z "G445Y![X4444 %%%% !7#>*O^2J>!/^N6H_^BXZ[FN&\5?\E4\" M?]IEW\:7^"I_Z;D=S1117<>6%%%% !1110 4 M444 %%%% !1110 4444 %%%,FFCMXFDED6*-1EG<@ ?4F@!]%06M];7Z%[:X MBN$!P6B<,!^53T %%%% !115.36=/CG\E[ZV2;./+:90V?3&: +E%%-DD2&- MI)&5(U!9F8X ZDF@!U%<)/\>OAI:WYLIOB%X7BNPVTPOK-N&!]"-_7VKM+* M^M]2M8KJTGBNK:5=TH(X(H GHHKG?%7Q&\*>!MG_"1^)M'T$N,J-2 MOHKX1CC\:Z*@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH ***XGQ9XLO;K5/\ A&/#&V36 MW4->)GR0]6WLEW?E_PR MU#Q9XLO;K5/^$8\,;9-;=0US>,-T6G1G^-_5S_"G?J>.NWX3\)V7@_2_L=GO MDD=C+<74QW2W$A^\[MW)H\)^$[+P?I?V.SWR2.QEN+J8[I;B0_>=V[DUA>/_ M !_/HMW;^'O#UNFJ>+K]2;>U8_N[:/H;BMV'C_ ,?SZ+=V_A[P];IJGBZ_4FWM M6/[NVCZ&XG(^[&/S8\"KG@#P!!X*M+B::X?5-=OV$NHZK./WEQ)Z?[*#HJC@ M"CP!X @\%6EQ--VK;]%_+_P>[^2\RBBBND[@HHHH **** "BBB@ HHK.U[Q)I/A7 M3WO]:U2STBQ3AKJ_N$@B7ZLQ H T:*\KC_:H^$,EX+8?$7P_YF[;N:]4)_WV M?EQ[YKTO3=3L]9L8;W3[N"^LYEW17%M(LD;CU5@2"/I0!9HHHH ***S=:\3: M/X;2)]6U6QTM921&U[<)"'(ZXW$9H TJ*K:=J5GK%G'=V%U!>VDGW)[>02(V M#@X8'!YJS0 45SGC+XD>%?AY;)/XG\1Z7H$<@)C_ +0NTA,F.NP,-M02PT3QSH=_?2-MCM5O4660^B(Q!8_0&@#T*BBHYYX[6&2::1888 MU+/)(P554'A.#M/EWR2*#Z%E)4?G7?Z! MXDTGQ7IL>HZ)JEGK&GR<)=6%PD\38ZX920: -&BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH ***J:MJUGH.FW.H:AL/NW-PO\ =[JA^I]S2=)O?C1J=MKNNV\EGX-MG$NEZ-,,->L/NW-P MO]WNJ'ZGW]7KE2>(=W\/Y_\ _,\Y)XQ\TOX?1?S>;\NRZ[O0*\9^*'Q0UK7 MO%#_ U^&KQR>+716U76G7S+;P_;M_RT?LT[#/EQ?\"; ')\4/BAK6O>*'^& MOPU>.3Q:Z*VJZTZ^9;>'[=O^6C]FG89\N+_@38 Y[CX7_"_1?A+X731]'221 MG=KB\O[IO,N;ZX;EYYG/+.Q_+@# %>U"$3ITW M9+=_HO/N^GKL?"_X7Z+\)?"Z:/HZ22,[M<7E_=-YES?7#>(MHT5'!/'=0QS0R++#(H9)(V#*P/(((ZBI* "BBJFJ:M8Z'8RWNI7M MOI]E$,R7%U*L4:#U+,0!0!;HKRR3]J;X0QWOV4_$7P]YN<;EOD,?_?8.W]:] M&T?6M.\1:;#J&E7]KJ=A,-T5U9S++$X]5920?PH NT5#>7D&GVLMS=3QVUM$ MI>2:9PB(HZDD\ >]<[_PM+P9_P!#=H/_ (,X?_BJ .HHKE_^%I>#/^ANT'_P M9P__ !5=+#-'<0I+$ZRQ2*&1T(*L",@@CJ* 'T55U+5+/1;&:^U"[@L+*!=\ MMS'?.W;=WV]/+S_UTSMQ[YH M]2HJKINJ6>M6,-]I]W!?64Z[XKBVD62.1?564D$?2K5 !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %"STZV&.!NDE< M_=CC7JSL> H_EDT?$'XA:'\+_"MYXA\0W@L].MAC@;I)7/W8XUZL['@*/Y9- M>7_#[X?:Y\3_ !59_$GXDV9LY+8^9X;\)2'='I*'I/..C73#!Y_U?0<_=ZZ- M%->UJZ17WM]E^KZ?I8]<8'B#XC?$;_A$?LFDZ3:?VSXMU/*Z?I:'&?664_P $2]2QZXP.Y"_#GX<_ M\(C]KU75;O\ MGQ;J>&U#5'&,^D40_@B7H%'7&3V /AS\.?^$1^UZKJMW_;/ MBW4\-J&J.,9](HA_!$O0*.N,GL!VU:5JT*4'0P[NG\4OYO+_ KHNN[Z)!M-O#:7GC/P]:W0.#!-JD"/GTVE\UTEAJ%KJEK'=65S#>6T@R MDUO('1OH1P: +%%(S!023@#DDUR=Y\7? NGW9M;KQKX=MKI3@PS:K C@^FTO MF@#K:*AM+R#4+:.XM9X[FWD&Y)87#(P]01P:FH **H:SKVF>';,W>K:C::9: MKUGO)UA0?\"8@5G>'_B%X5\63F'1/$NCZS,.L>GW\4[#\$8T =!1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445!?7UOI=G/>7D\ M=M:P(9)9I6"HB@9))/0 4TFW9";45=A?7UOI=G/>7D\=M:P(9)9I6"HB@9)) M/0 5Y#:VMW^T%J$5_?Q2V?PWMI ]I8R I)K3J>)91U$ (RJ'[W4\8%%K:W?[ M06H17]_%+9_#>VD#VEC("DFM.IXEE'40 C*H?O=3Q@5[''&L,:HBJB*-JJHP M !T %>MIEZLOXO\ Z1_]M_Z3_BV\%)YL[O\ @+_RIYO^YV7V_P##\1'&L,:H MBJB*-JJHP !T %.HHKR#WPHHHH **** "BBB@ KAO%7_ "53P)_URU'_ -%Q MUW-<-XJ_Y*IX$_ZY:C_Z+CKAQO\ "7^*'_I<3U,N_C2_P5/_ $W([FBBBNX\ ML**** "BBB@ HHHH **** "OCO\ :B_;Z'P;\9W/@_PGHMKK6L6(7[=>7[M] MGA<@,(E1""[ $9.X 'CDYQ]B5\G^'?V&1I_[3%[\3]7\0VFLZ9-JEWJB:/-8 M$G?+O,:EBY'[MG!!QR4' [ ''_ /_@I%;^,O%%MH/Q"TFQ\/_;'$<&L6,CK; M)(> LJN244]-^X@'&0!DCUG]JC]KZR_9KF\.VL6A1^)[[5DEF:!=0%L;>)"@ M5S^[?((BUOE[>:$&5X4?P!F1 @/3=R0.U ' MV-XT^/\ IG@/X!VGQ/U33;G[-E?F- M\>OVB/B1^T-:SZOJL=S8>"K:Z6"*QL5<6,,K LBR/_RTEVJ3EO0D!1Q7ZR>. M/ACX:^(W@U_"FOZ8EYH#>3FS21XE B960 H00 5'0].*^8/^"BGAS2_"7[,> MAZ3HNG6VE:9;:_;)#:6D0CC0>1<= /\ )H X;_@E+_K/B?\ 33/_ &[K] :_ M/[_@E+_K/B?]-,_]NZ_0&@ HHJAKVN6/AG1;_5]3N4L].L8'N;FXD.%CC12S M,?H : /G/]O']H _!_X6MHFDW7E>*/$BO;0-&V'MK?&)IN.AP=BGU8D?=-?E M7JFBW^CQV,E];R6XOK<7=OY@P9(BS*'QZ$HV/4<]"*^C-)M-9_;P_:JDGN!- M;Z"7\R49_P"/'3(F^5 >SMG''\K^,_B M%J7P^T:_DMO"VBR?9[N.W?'VVZ'^L\PCJJ-\@7IN4GGC'W9^RW_R;G\.?^P) M;?\ H K\FOAN_P#PL+]H?PQ)?KYHUOQ1;/<*_.X37:E\^OWC0!ZY9_\ !.KX MK7G@-?$0&DQW;V_VE-"DN'%Z5VY"$;-@D/\ =+>Q(/%4/V)?V@]8^$?Q6TGP M[=WLI\)ZY=I97=C,QV6\SG:DR@_<(8C=CJN<] 1^M=?B/\>K+_A%/V@/'<-E M^X%GXAO'@"_P#SV9 /H,?E0!^I7[7WQVE^ ?PANM6TXQ_P#"0ZA*+#3!( P2 M5@2TI4]0BJQYXW;0>#7YL?!WX!_$#]K'Q-K5_9WLZ10);_6+F:1L"I Z]P03^H_P"RK\9I/CK\%](\1WGEC6(V>QU)8P O MVB/&6 '3"-4*@S6VJ36RMW"R1;B/SA7\J9_P M2QU.2;P+XZTXG]U;ZE!<*/\ :DB*G_T4M 'W#1110 4444 %%%% !1110 44 M44 %%%% !117$^+/%E[=ZH?#'AC;)K;J&N;QANBTZ,_QOZN?X4[]3QUPK5HT M8\TODNK?9'3A\//$SY(>K;V2[OR_X9:AXL\67MUJG_",>&-LFMNH:YO&&Z+3 MHS_&_JY_A3OU/'7;\)^$[+P?I?V.SWR2.QEN+J8[I;B0_>=V[DTOA/PG9>#] M+%G9AY'=C+<74QW2W$A^]([=R:P?'_C^?1;NW\/>'K=-4\77ZDV]JQ_=VT?0 MW$Y'W8Q^;'@5RP@X/ZQB/BZ+MY+NWU?7T-,;C:5"E[&CI36[ZS?33_TF/3UN MP\?^/Y]%N[?P]X>MTU3Q=?J3;VK']W;1]#<3D?=C'YL>!5SP!X @\%6EQ--< M/JFNW["74=5G'[RXD]/]E!T51P!1X \ 0>"K2XFFN'U37;]A+J.JSC]Y<2>G M^R@Z*HX KK*Z(0E*7M*F_1=O^">)2I2G+VU;?HOY?^#W?R7F4445TG<%%%% M!1110 5SOQ#\=:9\,O!.L^*=9=DTW2[=KB7RP"[XX5%!_B9B%'N1715Y[\?/ MA*OQR^%>L>#&U5M%&H&%OMJP>=L,);%=U M[IMQ< *4_P">T3-C*8]3N))K^XN+ M%8EN%9%01M&6?*A5Z$G[Q]:^8_BA_P $P;J\\27%WX"\2V-GI$[EUT_6!)NM ML_P+(@;>H[;@#CJ3U(!ZI\%?VW9_C%\?KSP':>&[5-$#W?V;5X+QG9XX=VR0 MKMQAP!QGC<.3W\9^/O[,?Q@_:*_:,\4,D4EKX8LIHX;#4-9F:.SCA\I#B!0" M6R]U-==\57T/V=[J.(QPV\.0QCC!))RRJ M2QQG: .<^C?&/\ :"\%? >'2I/&&HS6/]J-(MJL-L\S/Y87>?E!P!O3KZT M?G'\=/V"_&7P3\$7'BLZMIWB#2K,K]M6T5XY8%9@H?:PPRY(!(.1G.,9(W_^ M"<7Q:UCP[\98/ YNI9M!\00SD6CL2D-Q%$THE4?PDK&RG'7*Y^Z,=[^UA^WE MX2^('PQU3P9X(M[Z]EU95BNM1NX/)BBA#!F"*3N9CMV\@ DY)JK_P $\OV: M?$=CXXC^)7B+39](TVSMI(]*CNT,M?LUXL^&' MA3QWK&BZIXAT&SUF^T5I'L)+Q/,$#/MW$*?E)^1#R#@J",5^?O\ P5(_Y*IX M0_[ I_\ 1[T ?3G_ 3Y_P"36O#/_7Q>_P#I3)7JWQN^)UM\'/A7XB\7W"+, M=-MBT$#G EG8A(D/L790<=!DUY3_ ,$^?^36O#/_ %\7O_I3)7)?\%-M8EL/ M@)I-G$<+?:]!'+[HL,SX_P"^E4_A0!\.>!_!/C[]L3XO749U 7VM72-=WNI: M@Y$-M"I Z '"@LJJBCN!P,D;7[1G['_BK]G'3].U>_O[/6M%O)OLPO;(.AAF MVE@CJPXR%8@@G[ISCC/T-_P2JTN+;\1]1909@;"W1LW M\.Z.$&H)"V!>71 8AR.JQ@@;>FX,3G"X@_X)?:C)#\;O$=D#^YN/#\DC#_:2 MX@ _1VKP#Q+*?'7[0^IO>?/_ &OXHD$H/(Q)=D$?3#8H ]M\(?\ !.'XA>*_ MA_:^(6U72M,O[RV%U;:/=&3S2K#D2WHT_7M-F.$V!]CLR]GC.6!Z_*1G!-?L< % & .@K\8_VOM+BT?] MI?XA6\2A$?4FN"!_>E19&/XES0!^SM%<]\.]2DUCX?\ AB_E.Z6ZTNUG<^K- M$K'^==#0 4444 %%%% !1110 4444 %%%% !1110 4454U;5K/0=-N=0U"YC ML[*V0R2SRG"HH[FDW978FU%78:MJUGH.FW.H:A_&C4[;7==MY+/P;;.)=+T:88:]8?=N;A?[O=4/U/N:3I-[\9]3MM=UVVDL M_!ULXETO19AAKUA]VYN%_N]U0_4^_J],_%#XH:UKWBA_AK\-7CD\6NBMJNM.OF6WA^W;_EH_9IV&?+B_X$ MV .3XH?%#6M>\4/\-?AJ\7]TWF7-]<-R\\SGEG8_EP!@"O:A".'BJE17;V M7ZOR[+KZ;Z2E*O)TZ;LEN_T7GW?3UV/A?\+]%^$OA=-'T=))&=VN+R_NF\RY MOKAN7GF<\L['\N , 5U]%%<?.W^[YGF_>QWQCV[5]M?M/?L]K^TCX#L/#C:^WA MXVFHIJ"W(M/M(8K'(FTIO3M(3G/:K'P]_9R\,^#_ (%VWPPU.&#Q#I'E2)>2 MS6XB-T[NSF3 )*L"1M(8E=JX/ H SO@_^U=X(^+'PVNO%7]H6^B3:;"TFJ:; M>W"B2T*KDG)QN0X^5P.>F 00.'_9._;%U']I'QAKFCW?A:WT2"PL_MB7$%VT MVC^+=4N+34+JV^UQPP6DDW[HLRAB5! R58?A7Q3^V9^V9H7QR\ M*VG@CP38WTUE)>1W%U?7W4MWI,-B=5L5E8L+4K*D:K;>@*D]SG]!Z^*/^"=_P"S?X@^ M&ZZQXZ\56$ND7VIVJV-A87*[9U@+K(\DBGE=S)& IP?E)(Y%?:] !7Y__M0? ML[_%_P#:(_:-UFQL$E@\%V$5K]@O-4G:*PB#0(9#&H!+N9#)DJI/ !(&*_0" MB@#\G?CE^P5XQ^"O@6X\6'5].\0:;9E?MJ6BO'+ K,%#A6'S*"0#@Y&),:?9V^?F*[E::3']U4&,_WG7UKX>_8.^&-[\0?V@]$OXX M6.E^'6_M2\GQ\JE<^2N?[S2;>/16/:@#] OVW6*_LL^/2"0?L\ X_P"OF*OS M+^!/[,_B_P#:'76V\*OIJ#2#"+G^T+AHO];YFW;A6S_JVS^%?IG^V]_R:SX] M_P"O>W_]*H:^$OV+?VI/#7[-L/C!?$&F:KJ+:RUF8/[-CB8+Y7G;M^]UQGS5 MQC/0]* -#_AVI\7?^>_AW_P/?_XU7Z3?"KPM=>!_ACX2\.7TJ3WNDZ3:V,\D M1)1GBA5&*D\XRIQGM7AG@3_@HC\)/&>I16-W<:IX7EE;8DNM6RK"2>F9(W<* M/=L#WKZ'\0:TNF^%=2U:V=)EM[*6ZC=2"KA8RP(/<'% 'Y6?MG_'S6OC;\7+ M[PUIES-+X8TB]-AI^GVY)6ZG5MC3$#[[,V0OHN,_#W7/B=XJL_B3\2;,VLG]R7=_HNOWM'P^^'VN?$_Q59_$GXDV M9LY+8^9X;\)2'='I*'I/..C73#!Y_P!7T'/W?I8]<8'&U#5'&,^D40_@B7H%'7&3V [:M*U:%*#H8=W3^*7\WE_A71==WT2YHL5BE9KX8_R^;[S?5[):+JY%%%%><>P%%%% !1110 4444 %>1_M)?M& MZ)^SCX-@U;4;635-2OI##I^F1.(VG8 %BSD':B@C)P?O*,K>&;O2_$-GI$6E0S1/#>1.P/F,IW+M[_ "@8]AS0!X;X;_X*F:I_;D7] MO>![,Z.SX?\ LZZ<7$:YZC>-KD>GRY]17V%XB_: \+Z7\$+WXH:;=1ZSH$-I M]IB$4@C:5B0HB.?NOO(4@C(/&*Y?QY^Q_P"!/'7PBT_P4^FVNEW.FVL<5EK% MC;(D\,JJ 9#W<,1EE8_-G.@#[;_9C_ &D;;]I3PUJ^K6^@S:#_ &==BU:*6X$X?*!@0P5? M7IBOAK]K3]J3Q/\ '#XBW/@3P7=72>%X[O\ LVWM=/8A]7FW;-S%>61FX5.F M,$C)X^Q=+^&5G^R7^R?XNLM(NVNM2L]+O=0GU$KL,UXT)"N!GY5!5% ST4$OAO\:K#Q7XRNC;:9I%K<7$(6%I6DN"GEHJJ!RWSDC/ VYR, M9H ]Q\-_\$N?%FHZ'#Y$9(^ZT@91D=]H(]":^D?V,? MV;O%/[.-IXQL?$&J6&I6NI7%O)9?8))&4;%D#LRNJ[6.Y!QG[O7I7#3?\%1/ MA\M_LC\+>))+/./.*VX?'KL\W'_CU?1WP=^.7@_XZ^'Y-6\)ZE]J6%@ES:3) MY=Q;,'?BY\5OB]I7@3P9::M>>'&TF*ZF@M6, M-FTK2RJS3RDA#@*H"L>,<#)Y\#\ ]7@\,ZR?$^O75K)!:VMM:RK&KNI4/([JHVC. M2 23C&.S2>&]=OHM/O=.9R8LRL$695Z*ZLR MG(Y(!'>OU-^+GQ'LOA'\-_$'B[4%\R#2[8RK#NV^;(2%CCSVW.RKGWK\MOV+ M/@1KOQ3^,'A[64L)H_#&A7T>H7FHNA$1:)@Z0JW1F9@H('0$FOL#_@IIKDNF M_ '3;&(D#4=<@BEYZHL4TF/^^E3\J /AJVA^)?[9GQ:>(3MK.MW"O-MFD,=I M86X(S@ MC1:I^RWXFGD0-)I]Q9W46>S&YCC)_P"^9&_.@#/_ &#_ -H34?C;\-[[3_$- MS]K\2>'I(X)KIOOW,#@^5(WJWR.I/?:">2:^G*_,S_@EWJDD/QF\4:<#^YN- M :=AG^*.XA4?I*U?IG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !114%]?6^EV<]Y>3QVUK ADEFE8*B*!DDD] !32;=D)M15V%]?6^EV<]Y> M3QVUK ADEFE8*B*!DDD] !7D-K:W?[06H17]_%+9_#>VD#VEC("DFM.IXEE' M40 C*H?O=3Q@4MK:W?[0.H17]_%+9_#>VD#VEC("DFM.IXEE'40 C*H?O=3Q M@5[%'&L,:HBA$4;551@ #H *];3+U9?Q?_2/_MO_ $G_ !;>"D\V=WI0_P#3 MGF_[G9?;_P /Q$<:PQJB*J(HVJJC '0 4ZBBO(/?"BBB@ HHHH **** "BB MB@ KAO%7_)5/ G_7+4?_ $7'7V$VIPV+0H+2!PC2-)*L M8^8@@ ;L_A7YX?M4?ML:;^T1\-[7PQ:>%KK198=2BOS<37:RJ0D,IP7B@$;"/Z%Y$)_W![UX7 M\??VT?BYX5^.GB[2]%\3KIVDZ3JDUG;6*6-N\>R-ROS%D+,6QDY/?C'%?='Q M;_9^\+?M'>'O#J^,[>\BGL%,\7V&?RFC:1%\Q3D'(RJ_]\B@#X6_9+_:P^'/ M[./@>[L[OPYKFH^)-2G\V_OK9(-A51]YV[8KR?\ :N^-FE?' MSXK'Q3H]C>:?9_88;7R;X)YFY"V3\K$8^8=Z^\/^';/P@]?$'_@P7_XW7PW^ MV'\'M ^!_P 8#X:\-_:O[-_L^"Y_TR42/O>' M_#GPOM].U&UUG1]#7S+F=4\B;RMB,%(8M_%D9 X!K\^O@FY\-_'[P(;S]W]A M\2V(FS_#MND#?R-?HQ^Q7^SAX.\$^#?"WQ&T]+U_$FL:'&+AI[C=$OF['?8F M!CE1W/&:^'_VQOA%J?P9^.VLW,<$UOI&KW;ZKI5Y&"$^=M[(K=FC=Y.S/7G9NQ[UX[^QK\&=6^-WQPT[5[R":XT/1[Q=4U M6^E!*O(K;TB+=V=P,C^[N/:@#U7_ (*?:1)IWB+X<2,/W?\ 9<]L&'0M&Z9_ M]#'YU[Y_P3?OX[S]FV&)#EK75KJ%_9CL?^3BF?\ !0WX-W_Q.^$-IK.C6CWN MK>&;AKHP1*6=[5U F"@=2"L;_1&KXR_92_:^OOV;(]7TV?1O^$@T#4I%N#;+ M<>3)!,%VET.U@=RA001_"N",8(!]/_\ !4F^CC^%W@ZR+#S9M9:95[E4@<$_ MG(OYU1_X)8:;+%X)\>:@5Q#/J%O K>K1QLS#\I5_.OE?]I3]HS7/VJ/&VCF' M1GL+*S!M=,T>W2?TG_9'^#D_P0^".CZ%?QK'K M5RSZAJ2J<[9Y,?)]418T..,H30![+1110 4444 %%%% !1110 4444 %%%<3 MXL\67MWJA\,>&-LFMNH:YO&&Z+3HS_&_JY_A3OU/'7"M6C1CS2^2ZM]D=.'P M\\3/DAZMO9+N_+_AEJ'BSQ9>W>J'PQX8VR:VZAKF\8;HM.C/\;^KG^%._4\= M=SPGX3LO!^EBSLP\CNQEN+J8[I;B0_>D=NY-'A/PG9>#]+%G9AY'=C+<74QW M2W$A^]([=R:P?'_C^?1;NW\/>'K=-4\77ZDV]JQ_=VT?0W$Y'W8Q^;'@5RP@ MX/ZQB/BZ+MY+NWU?7T-,;C:5"E[&CI36[ZS?33_TF/3UNP\?^/Y]%N[?P]X> MMTU3Q=?J3;VK']W;1]#<3D?=C'YL>!5SP!X @\%6EQ--"K2XFFN'U37;]A+J.JSC]Y<2>G^R@Z*HX KK*Z(0E M*7M*F_1=O^">)2I2G+VU;?HOY?\ @]W\EYE%%%=)W!1110 4444 %%%% !11 M10 4444 %>5_'7]FWPA^T/#HT?BK[>ATEIFMI+"<1,/-";PJ5^ M;_B/]N;XI? [XS>-= U^Q@\0:3;ZQ=?9K+4HS!-%;F5C%Y4JC[A3:065N",4 M =;\:O\ @FOX;TGP5JNL^!M;U2/4]/MI+K[!JCQS17"HI8HK*BE&(!P3D9P. M,Y'S9^R7^T1XC^#?Q*T.RCU&XG\*ZC>1VM_I//!^HZ#H7A2U\,'4('MI[Y[YKN58W!5O+_=H%8@D9.<9XYP M1Y?^QY\!=9^,GQ9T:ZCLY%\-:->17NI7SH?*Q&P<0@]"[D 8'(!)[4 ?L+17 MD7[6?CO6?AK^SUXO\1^'KK[#K%I% D%SL#&/S+B*)F ((SM=L>^*^6_^"?WQ M]^(WQ,^+FKZ+XF\1WFOZ0FCRW92\"MY4BS1*K*P&1P[#&<'/3B@#] :_-7_@ MJ1_R53PA_P!@4_\ H]Z^K/VK/VK$_9CB\,G_ (1EO$DFMFYPOV[[*L(A\K)S MY;Y)\T<8'0U^=/[4G[2!_:4\5:1K)\/?\([_ &?9&S\C[;]J\S]XS[MWEIC[ MV,8/2@#]!O\ @GS_ ,FM>&?^OB]_]*9*XO\ X*?6$EQ\"] N47*V_B"+?[!K M><9_/ _&OGO]GW]OH_ GX6Z9X-_X07^V_L4DTGVW^U_L^_S)6?&SR'QC=C[W M.*^WOC9X)/[2W[-%S:V$'V>_UC3+?5=.BF89CGVK-&A;H,_<)_VB: /FO_@E M3J$?D_$BQ)Q+NT^=1ZKBX4_EQ^=>\_M[:A'8?LK^,5=@'N6LX(P?XF-W"2/^ M^58_A7YP? [XT>)_V6?B;>7\>EE[A$?3]4T:_P!T)=0P)4\91U91@X..1@@F MNN_:<_;+UW]I#2].T0:)%XC27$!7](VKYXU-O^$3^/UV;O]W_ &9XG017R1^WY\$M1^'?QFU+Q1#9N?#?B67[9%=(I*1W+#,T3'LQ8,X]0 MW&=IP ?J]7XR_MB:C%JG[37Q!FB8,JZAY!(_O1QI&P_ J:]J\+_\%-?%>@?# MZUT6Y\*V6J:]:VPMX]:FO&57*KM5Y(0GS-P"<.H)]*\N_9;^#6N_M'?&Z#4= M1AEO-'M[\:IKVHRK\CDN9#&3T+RMD8'."QZ"@#]8?A]I4X5%'_&?4[;7= M=MI+/P=;.)=+T688:]8?=N;A?[O=4/U/OZO7*D\0[OX?S_X'YGG)/&/FE_#Z M+^;S?EV77=Z!7C/Q0^*&M:]XH?X:_#5XY/%KHK:KK3KYEMX?MV_Y:/V:=AGR MXO\ @38 Y/BA\4-:U[Q0_P -?AJ\96=C^7 & *]J$(X>* MJ5%=O9?J_+LNOIOI*4J\G3INR6[_ $7GW?3UV/A?\+]%^$OA=-'T=))&=VN+ MR_NF\RYOKAN7GF<\L['\N , 5U]%%<-^#MSTSVH \9^.'[)/@7]H#Q%8ZWXF.J M1W]G:BR1]/N5B#1AV< @HW(+M^=?)W[3O_!/O1OAG\/-4\8^"]:U">+2T$]W MINJE)"T60&:.157!7.=K Y /.< \[X%_X*'_ !0^&-S<:'XWT>#Q1-9RM%*M M\#97L3 X*,ZJ5X]TS[UD_'[_ (* >(_C1X+N_"NG^'K;PMI5\%6\9;IKJ>5 M0=@?8@520,_+DCC.,Y +/[!/[1'B/PG\5-%\#7VHW&H>%=:.[JSDM_#&@.\J7,J$+=7. MTJB1D_>VD[F(Z;0.IKZ[_;S^*/B7X3_!&WU/PKJ3Z3J5WJ\%D]U$JEUC:.5V M"Y!P28U&>N,T ?1U<+\9OC'X>^!O@>[\2^(KC9#'\EO:QD>==S$';%&.Y..O M0 $G@5\T_P#!.OXS>._BM_PF]OXMUNYUZTTX6CVTUTJEXGD,VY0P )!" X.< M8XQDY^4_VY/B-K7CC]H/Q'I^HW,AT[0;AM/T^SR1'"B@;F _O.WS$]3P.@& M#'UK5OB%^VQ\;$$,'VO4[L[+>U4D6NF6H/=OX47.2QY8GN2!7ZD?L_? G1/V M?O %OX>TD"XNY")M0U%EP]W/C!8^BCHJ]AZDDG\Q_@1^UYK?[/7A^XTWPUX3 M\.37%U)YEWJ5]%.]S<8SM5F64 *H. H '4]22?4(_P#@J)\15D0R>%_"[1Y& MY5BN5)'< ^<<'\#0!^B_CCP3HWQ'\)ZCX;\06GV[1]0C$=Q!YC(6 8,,,I!! M!4'@]J\;C_8+^!D=N8CX*+DC_6-JEYN^O^NJ+]LOXZ>)_@;\+O#_ (G\*Q6Q MN;G5X;>=+Z RQF%H97*, 01ED7D$'CWKYXL?^"JFIQV(2\^'-I/>8YF@U9HH M\^NPPL_;:_9OT;]GOQIHP\.7%P^B:U;R2Q6UT^^2WDC90Z[L:1:-(23Y+6Z.B9_V3*R@=@%': MOACXR_&;QC^U-\1+*ZN['SKPJ++3-&TN)G$:EB=JCEF=B(;BW,#ZW%=LRH2,- M)' 4^5NXR[ 'L>E 'SIJT?\ PFG[0]XEEB4ZMXI<08Y#>;=G;^>X5^W-?E?_ M ,$_?@+J7C[XK6'C6]LW3PQX=E-PMQ(I"7%V!^ZC0]RC$2$CIM4'[PK]4* " MBBB@ HHHH **** "BBB@ HHHH **** "N;^(7Q"T/X7^%;SQ#XAO!9Z?;#' MW22N?NQQKU9V/ 4?RR:/B%\0M#^%_A6\\0^(;P6>GVPQP-TDKG[L<:]6=CP% M'\LFO,/A[\/=<^)WBJS^)/Q)LS9RVQ\SPWX2D.Z/2$/2><=&NF&#S]SH.?N] M=*DFO:U=(K[V^R_5]/N3Y:M5I^SIZR?W)=W^BZ_>T?#WX>ZY\3O%5G\2?B39 MFSEMCYGAOPE(=T>D(>D\XZ-=,,'G[G0<_=]SHKB/B-\1O^$1^R:3I-I_;/BW M4\KI^EH<9]993_!$O4L>N,#N0_WF,J*$%Z+HE^B6[;]69RE2P-)U*C]7U;_5 MO9)>B#XC?$;_ (1'[)I.DVG]L^+=3RNGZ6AQGUEE/\$2]2QZXP.Y"_#GX<_\ M(C]KU75;O^V?%NIX;4-4<8SZ11#^")>@4=<9/8 ^'/PY_P"$1^UZKJMW_;/B MW4\-J&J.,9](HA_!$O0*.N,GL!VU:UJT*4'0P[NG\4OYO+_"NBZ[OHERX?#U M*]18K%*S7PQ_E\WWF^KV2T75R****\X]@**** "BBB@ HHHH **** "BBB@ MHHHH \H_:NMWN?V;_B(B#+#1YW_!1N/Z U^8?[(/PDT#XU?&JQ\-^)7N1I9M M9KEH[641M*T8!"%L$@'G.,'C@BOU\\8>&[?QEX3UO0+LXM=5LIK&4XSA)(V0 MG\FK\1G(-?)__ M 3N\57FA?M+Z1ID$C"UUNTNK2YCS\K!(7G4D>H:(<^Y]:]N_:#_ ."AWA'Q M=\)]8\/>#+#5FU?6[1[*6:_@2%+6*1=LAX=BS[2P&. 3G/&#QW_!-3X,ZEJG MCZZ^(UY;/!HNEV\MK8S.I N+F0;'V>H1"X)]74>N #[@^/?P/TG]H#P(/"^L M7MWIUNMW'>)<66W>KH& 'S @@AVKY2\9?\$M=/&CSR>%?&MU_::*6B@U:W0Q M2MV4NF"F?7:WTK2^/7[;?C3X ?M&Z_X?N='M-=\(I#:R6MG,#;S!6@1G>.8 MYS(9!\RM]W Q@UG^(O\ @J=IW]BRC0O MU_:[(1&VH7B^1&V.&(0;G /;Y<^ MHH ^6/A'^T1\0?V_P##MY,7MW",5D0*21&PP<,O(('4 M9!^Q?^"DEY%XG_9W\%Z]8;I+"XUBWN(W(P?+EM9F0D=N,?G7P3X+\&^)OCO\ M2X]+TR%]0UW6KMYYYMN%3>^Z29R/NH,DD_@.2!7ZL?M'_ UO'G[,]]X)T:,W M%_I=E;OI:G[SR6P7:@]W160>[T ?/7_!*F^C;3_B19YQ*LMA+CU!%P/_ &7] M17NO[>UY'9_LJ^-%=@&F-G$@/A=G=O M=0AKZZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBH+Z^M]+LY[R\ MGCMK6!#)+-*P5$4#)))Z "FDV[(3:BKL+Z^M]+LY[R\GCMK6!#)+-*P5$4#) M))Z "O(K6UN_V@=0BO[^*6S^&]M('M+&0%)-:=3Q+*.H@!&50_>ZGC HM;6[ M_:!U"*_OXI;/X;VT@>TL9 4DUIU/$LHZB $95#][J>,"O8HXUAC5$4(BC:JJ M, = !7K:9>K+^+_ .D?_;?^D_XMO!2>;.[_ ("_\J>;_N=E]O\ P_$1QK#& MJ(H1%&U548 Z "G445Y![X4444 %%%% !1110 4444 %%%% !7#>*O^2J>! M/^N6H_\ HN.NYKAO%7_)5/ G_7+4?_1<=<.-_A+_ !0_]+B>IEW\:7^"I_Z; MD=S1117<>6%%%% !1110 4444 %%%% !1110 4444 9/BGPIH_C;0KK1=?TV MWU;2;K;YUG=('C?:P9<@^C*"/<"O//\ AD_X/?\ 1.]"_P# 85ZS10!Y-_PR M?\'O^B=Z%_X#"MG7KGPG^SC\)=:U+3]+M=&T#1;>6[%E:((U>0]$'^T[E5&> M["O0*H:YH.F>)M+FTW6-.M-6TZ?'FV=] LT,F""-R,"#@@'D=0* /R[_ &0_ M@CJ7[3/QGU'QUXI4S:#8Z@VI:C*RX6\NW?S%@7_9R=S#LN!QN!K]4ZSM!\.: M3X5TU-/T32[+1[!"66UL+=((E)ZD(@ 'Y5HT %<1XT^"/@'XBZJFI^)O".DZ MUJ"1B(75W;*TFP$D*6ZD#)X/K7;T4 5-)TFRT'2[73=-M(;#3[6-88+6WC"1 MQ(HP%51P !V%9GC3P'X=^(VB2:1XFT:SUO37.[R+R(.%;LRGJK:WJ* M /GR/]@GX'QW_P!J'@YF&[<(&U.[,>?IYO3VZ5[7X3\'Z)X%T6'1_#VE6FC: M9#]RULHA&@)ZD@=2>Y/)[UL44 %>+>-?V-O@]X^U.;4=3\&6T-],Q>2;3YI; M3>QZDK$RJ2>I.,FO::H+X@TMM<;11J5H=96W^UG3Q.OV@0[MOF^7G=LW<;L8 MSQ0!Y_\ #7]F;X9?".^6^\+^$[.RU%00M],SW,ZYZ[7E9BN?]G%>GUGZ7X@T MO7)KZ'3M2L]0EL9C;7<=K.DC6\H&3'(%)V-@CY3@\UH4 %%%9\GB#2X=;AT: M34K./6)H6N(M/:=!<21*<,ZQYW%0>"0,4 :%%%% !1110 4444 %%%<3XL\6 M7MWJA\,>&-LFMNH:YO&&Z+3HS_&_JY_A3OU/'7"M6C1CS2^2ZM]D=.'P\\3/ MDAZMO9+N_+_AEJ'BSQ9>W>J'PQX8VR:VZAKF\8;HM.C/\;^KG^%._4\==SPG MX3LO!^EBSLP\CNQEN+J8[I;B0_>D=NY-'A/PG9>#]+%G9AY'=C+<74QW2W$A M^]([=R:P?'_C^?1;NW\/>'K=-4\77ZDV]JQ_=VT?0W$Y'W8Q^;'@5RP@X/ZQ MB/BZ+MY+NWU?7T-,;C:5"E[&CI36[ZS?33_TF/3UNP\?^/Y]%N[?P]X>MTU3 MQ=?J3;VK']W;1]#<3D?=C'YL>!5SP!X @\%6EQ--"K2XFFN'U37;]A+J.JSC]Y<2>G^R@Z*HX KK*Z(0E*7M* MF_1=O^">)2I2G+VU;?HOY?\ @]W\EYE%%%=)W!1110 4444 %%%% !1110 4 M444 %%%% !7*>.OA3X/^)UND/BKPUINNK&,1O>6ZM)&/]A_O+^!%=710!XGI M_P"Q;\%--NUN8? %@\BG(6XGGF3\4>0J?RKU_1]%T_P[IL&G:586VF6$"[8K M6SA6**,>BJH ^E7:* /AO\ X*:?%QM/\.Z%\-M.D+7>K.NH:A''R?(1L0H1 MWW2 M_VR'K7JG[$?[-Y^!?P[;4=8AV>+]>5)KU6ZVL0R8[?ZC)+?[1QSM!KW MZ\\,Z1J.I0:A=Z58W6H08$5U-;(\L>#D;7(R.?0UI4 8'BSP#X8\>16\7B7P M[I/B&.V9FA35+*.Y$1. 2H=3@G SCTKG/^&=_A7_ -$U\(_^".U_^(KT*B@# MSW_AG?X5_P#1-?"/_@CM?_B*[ZWMXK2WB@@C2&")0D<<:A510, #H .U244 M >?_ !"^ /P[^*ES]J\5>$=-U:\VA/MC1F.J-*S%3[C%>HT4 %9^O>']+\5:3<:7K.G6NJ MZ;<#;+:7D*RQ./=6!!K0HH \3?\ 8L^"DE_]L/@"Q$N[=M6><1_]^Q)MQ[8K MU?PSX5T;P9I$.E:#I5GHVFP_L/NW-PO]WNJ'ZGW- M)TF]^,^IVVNZ[;26?@ZV<2Z7HLPPUZP^[(=W\/Y_\ M#\SSDGC'S2_A]%_-YOR[+KN] KQGXH?%#6M>\4/\-?AJ\U"$3ITW9+=_HO/N^GKL?"_X7Z+\)?" MZ:/HZ22,[M<7E_=-YES?7#*O">F: MS'[Q;FU^'^F22J<@7C2W2?]\2NRG\J] MFHH AM+2"PM8K:VACMK>)0D<,*!411T X ]J_/#_@HU\2+[Q]\2/#7PG\/) M)?S63QSW%K;_ #--?3#;#'CU6-L_]MCZ5^BM9O\ PC.D?VP=6_LJQ_M4C!OO MLZ>?TQ]_&[IQUH \R_9=^ MK^S[\+K30\I/K=TWVO5;I.1)<%0-JG^X@ 4>N M">"QKK=>^#/P_P#%6JS:GK7@?PYJ^I38\V\OM)@FFDP !N=D). .3VKLJ* M//?^&=_A7_T37PC_ .".U_\ B*$E93D,-#M@0?7[E>@44 M4M8T73_$&G3:?JEC;:E83#;+:WD*RQ2#T96!!'UKR'4_V+_@KJUT;B?P!IZ2 M$YVVLT]NG_?$UT4 <9X!^#/@;X7[V\*^%M,T29UVO<6T \YE]#(-V,9H T**** "BL_7/$&E^ M&;$WVL:E9Z39!UC-Q?3I#'N8X5=S$#)) [DUH4 %%%% !1110 4444 %"ST^V&.!NDE<_=CC7JSL> H_EDT?$+XA:'\+_"MYXA\ M0W@L]/MAC@;I)7/W8XUZL['@*/Y9->8?#[X>ZY\3O%5G\2?B39FSEMB9/#?A M*0[H](0])YQT:Z88//W.@Y^[UTJ2:]K5TBOO;[+]7T^Y/EJU6G[.GK)_&_"4AW1Z0AZ3SCHUTPP>?N=!S]WW M.BN(^(WQ&_X1'[)I.DVG]L^+=3RNGZ6AQGUEE/\ !$O4L>N,#N0_WF,J*$%Z M+HE^B6[;]69RE2P-)U*C]7U;_5O9)>B#XC?$;_A$?LFDZ3:?VSXMU/*Z?I:' M&?664_P1+U+'KC [D+\.?AS_ ,(C]KU75;O^V?%NIX;4-4<8SZ11#^")>@4= M<9/8 ^'/PY_X1'[7JNJW?]L^+=3PVH:HXQGTBB'\$2] HZXR>P';5K6K0I0= M##NZ?Q2_F\O\*Z+KN^B7+A\/4KU%BL4K-?#'^7S?>;ZO9+1=7(HHHKSCV HH MHH **** "BBB@ HHHH **** "BBB@ HHHH *\Y^*O[/?P_\ C4(W\7>'+?4; MN)-D5]&S0W"+U \Q"&(!R=IR.3Q7HU% 'SKH/[ /P6T.^2Z;PW<:DR-N6._O MYGC!]U# ,/9LBOH#3-+L]%T^WL-/M(;&QMT$<-M;1B..-1T55 P /05:HH X M[XC?!_P9\7-/2S\7^';+6XXP1%).I66+/79*I#IG_9(KQM?^">/P5%UYQT34 M#'G/V$?#UEH<,F/,:W3,LN.F^1 MB7?'^T3775GGQ%I2ZXNBG4[,:PT)N!I_VA/M!B! +^7G=MR0,XQR*T* /'_B M=^R7\+/BYJDNJZ_X8B_M>7F34+&9[:60^K["%<^[ FLGP/\ L1_![P%JD.HV MGA5=1OH6WQ2ZK<27*H1T(C8["0>02I(KW:B@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH ***@OKZWTNSGO+R>.VM8$,DLTK!410,DDGH *:3;LA-J*N MPOKZWTNSGO+R>.VM8$,DLTK!410,DDGH *\BM;6[_:!U"*_OXI;/X;VT@>TL M9 4DUIU/$LHZB $95#][J>,"BUM;O]H'4(K^_BEL_AO;2![2QD!236G4\2RC MJ( 1E4/WNIXP*]BCC6&-410B*-JJHP !T %>MIEZLOXO_I'_ -M_Z3_BV\%) MYL[O^ O_ "IYO^YV7V_\/Q$<:PQJB*$11M55& .@ IU%%>0>^%%%% !1110 M 4444 %%%% !1110 4444 %<-XJ_Y*IX$_ZY:C_Z+CKN:X;Q5_R53P)_URU' M_P!%QUPXW^$O\4/_ $N)ZF7?QI?X*G_IN1W-%%%=QY84444 %%%% !1110 5 M\Z?M#7FK>,/C9\+OAQI7B/6O#EIJ"WNI:K<:#?/:7!@CCQ&-Z\X+;ASQ7T77 MR1J'@.3XZ_M?^.)D\3Z_X9M_".CV>F1WOAV[2WF,DV960NR/\O+9 Y J=YQ M7J_N3_6P]H2?R^]I?E(/VLO"6C:YJMA9:-XG\2V>CRF'5=8T'26NK M&P620,.5')VAL8-20_!O2?@GX%\=:]X;_ +2UGQC=:7<2R:WK%TUYJ%RZ M1,8U,A[ @?*H X'H*\2^'OQZ\$?![]C#3$TC5[/4?%=QI=P_]EVDHENS>OO: M225!EE5"2S,V!M4<]*4IN,'U<5][;DU\DE;[AQBG)=%)_O:QI%O-<6T7V:T0NWE;@;@@R?+!E>6)!Q_#GBLO]F?XX M:]XR^%]O>>-=$\16VH6FFMJ5WX@U+38;6QNT+,Z^048;L1D?P#(7)Z\^9>/+ M&7X8?\$Z=-TI>ROI> M[^5U;\+_ '7+WPI\>>!_AW\!V\=RZYKT7AK5KJ;5/M'BJ83WI>5]HC18\Y!* M#8BY.#GN:T?"7[4/A[Q-XPTGPW?>'/%?A*]U@.=+E\2:2;2&^*C<5C;?LY^#;GQ+#X)T+3H'8ZY=6\4UO!?001^4767]V3NW8W M\?.37J_PW^&V@>*?B!8>)=:^+9^*_B304:2RMXKBTCM['S!M,OV>WZ,1P&8X M_$#&EESNWPIM?):??^EGU(YFX)OXFD_F_P!/^&Z'1^+?VHO"/A'QYJO@V2SU MK5?$M@D#+IVDV/VJ6Z:5"X6)5;)*J-S%@J@,/FYK1\$_M :)\0? NO>)-&T? M7II]$FDM;W0'L0NIQSH 3%Y6_!;D?Q8ZY(P:\[_99T^S\1^-OB]\3)XD>YU+ MQ#/IMK=,.5L[8*HVGL"0,^NP>E8?[/\ K(?BEJFN M'6O#GB:72K_5[MM*U1],@BT[3[*-?EBEF5P3("K \/\ ,0,XZ=AH_P"U=X8\ M1:U;6VE>'O%NHZ)/-S4W4777T3_X?;Y(^OJ\6\4?M7>%]!UC5M/TO0O%'C,:.S)JEYX9 MTHW5M8LHRRR2EE7*CDATW4/@GHFG7/[1EOX>T/4(6:^T&S&GV5U%+*29HVG?,NXDD; MFY(QCC%8J\FTNEOO=_PT-=(I-]7^"W_/\SZE\1?M$>#?#OPHTWXB-=37GAK4 M)(([>6W10[&5]@R'90NT[MV2,!6]*Q-#_:P\(Z[XPT+0ETOQ)8V^O2-#I&N: MAI30:?J#@9 BD8[CGL2H!R.:\\^./P[T&'4?@/\ !C2[3'AV35FO9K-F+;[: MUB+L'/?>9&R>Y)KHOC#&OBC]J#X+>%XE M])2]\07$:C 0(@CA/L-X(K16E/ M39R:7^%*[?RU^:L9NZAKNHW?JVTE\]/O.V^)'[1WA3X6^-+/PKJL.J7>M7EB M;ZVMM-M?M#S_ +SRUB1 VYI&;. !C"L20!3->_:/\.>%O"^A:GJ^E>(+#5M< M9TT_PM)IQ;6)F5B"!;JQQTSDMC!'/-<-\-=-MO'7[8/Q/\53Q+./#%G9Z#82 M,,B-W0R3%?0@Y7Z,?6LBQ\6:#H'[;OC>\\;:K9:-):Z!9P:!+JLZP1&%ANG, M;.0,[]PX.?O>AJ(ZJ">\KOY:M?-JW^6A*+WPS_ &5KWA;Q-:0"[;1_$EA]DN'@) \Q &967)'0]ZX7X4W2>(/VG_C3 MXKF;_1-$M[+089#T4)&99Q^#@5G>!=8M?C%^U1JWQ#T1_M'@SPKH+:+'K"#] MS>W32&23RF_C1%)!(XSCL17%^ /$C^'?V,_BK\0I"8[SQ1>ZKJ$&_VJO#>N^*-%T2^\.>+ M/"YUR3RM*O\ Q!I!M;6^?&0L;[B%9O"_P]_9N\'7>NQ^$ M-"CECDOM9N;=)K>VO(X$>(R))\A!=I.'XZD]*];\!_#?0?&OC[2=9\0_&+_A M:VN:"3>V&G6\]G#;VK<+YYM[?J02 &)P":Z.5*;C]F+Y?E%)??\ AUZF'->" MEUDN;YMO3T_']>X^(G[0WA[X?>)HO#4>EZ[XL\2M#]IDT?PS8&\N((>TD@W* M$![9.3QQR*\Q^"OC'3OC;^U)XO\ &FEK0-#+#-+*TLJ,C#* MNI0J?I6)\!_BKX1\"^(OC=K_ (TURSTSQ1)XIN(9+2YE'VN2VB 6VCBB^_(. M6"A0_WQ^YGT;1110 4444 %%%<3XL\67MYJA\,> M&"LFMNH:YO&&Z+3HS_&_JY_A3OU/'7"M6C1CS2^2ZM]D=.'P\\3/DAZMO9+N M_+_AEJ'BSQ9>WFJ'PQX8*R:VZAKF\8;HM.C/\;^KG^%._4\==OPGX3LO!^EB MSLPTCNQEN+J8[I;B0_>D=NY-'A/PG9>#]+%G9AI'=C+<74QW2W$A^]([=R:P MO'_C^?1;NW\/>'K=-4\77ZDV]JQ_=VT?0W$Y'W8Q^;'@5RP@X/ZQB/BZ+MY+ MNWU?7T-,;C:5"E[&CI36[ZS?33_TF/3UNP\?^/Y]%N[?P]X>MTU3Q=?J3;VK M']W;1]#<3D?=C'YL>!5SP!X @\%6EQ--"K2XFFN'U37;]A+J.JSC]Y<2>G^R@Z*HX KK*Z(0E*7M*F_1=O^"> M)2I2G+VU;?HOY?\ @]W\EYE%%%=)W!1110 4444 %%%% !1110 4444 %<+\ M<_&3_#[X.^,?$,4ODW%AID\D$@.")BI6/'OO*UW5?.W[<VF3>Q_#8/SK.I%RCR1WE9?>[?J:4VHRYI;+7[M3R_Q3X#\2?# M;]F.T^)C?%OQW:^+K?2[74&@U#6WN;*6>38?),$@((._:!GKZ]*]_P!8^/VG M> ? _@V[\3VE]=>*_$%G"\/A[1;0W%[<3&)6D$<61@*2+O'<&F.LMGIWB;51<6<,B_=80HB*2/]K(]JXB'QEX>\/\ [:WC MC4/&NL6&B+I?ART@T635)T@C\E_GF:,N0"=V1QSUK>4DYN*T3;?HDF[>K_"U M^YA&+44WJTOO;:7X;_/H>C^ _P!I[PU\0/'EMX,MM&\1Z5XE>WFN;G3]8T[[ M-)9)'MP9@6_CWC:4W ]R*\TF_:H\23_M&:EH=GX+\:WGAC1]-\F[T>RT:![E MKQY?W=RQ:0,L)C'RG<,YR5J?]GOQ9!\:/VF/B7X\M(9DTC3=.L]#TR2>,HTL M3$RM( 1D!BH89_A=:L?LU^+-$U3XU?&F^OM7L;?Q%J7B3^S+;39[A%NG@M(B MJE(R=Q&-QX'\)]*F.LH-K[+;7SLOP:?EZE2TC-+NE?Y7?XIK_@'?27_A[Q5^ MTM:V2WOB)/$7AC13=/:13(ND[+@E!YJ9W--@Y'8 ]153Q1^U=X7T'6-6T_2 M]"\4>,QH[,FJ7GAG2C=6UBRC++)*6544EV3_\";:\]%OYENT6[][?^ I)_CMY M'U#XD_:0\$^&OAKH'CR:]FN?#FMW,%K:W$**"&D)&YP[+M";6+=QM/!K,\+_ M +4_A7Q1XWT;PT-(\2Z2VN+(VD:GJVE-;6>HA%W'R68[C\O(RHZCU%>;?%7X M;^'S\1/@)\']-L@?#.G37.L3V/*%\_>W.SYSUR:Z7XA*/%W[8_P , M-$4;H/#6CWVNS*.@,F((_P!0#6D>5S5MFY6]$M_6Z?W&;NH:[J*;]6]%^*^3 M,CXM?M,>(O#?[0'AGPAHGA?Q9+C4HXL# MM5/V@M3\&S:]?_$#PO\ %?3?"'Q%\*6DVG2PR7$,JW*(Q3 MP"0,9*7+2@WUNV_*[_\ M?2^FIJX\U2272R7JTG_ )_=V/H'X>>/;/XD>&X] M9L[#4]+4RO!)9:Q:-:W,,B'#*Z'N#Z$CWK+^*'QF\._":'3TU8WE]JFI2&+3 M]&TFV:ZO;QAR1'$O7']3_!OQ9JWCSX6>&/$.NZ>NEZOJ5C'<7%JJE55B M.H!Y (PP!Z9Q7R_XY:]U']L[Q5+=_$VV^&%UINB6D&D75_9VLPN;>1=TPB-S M\JG?NR5^8\CH#6DTXU%3];_)?U\N]C.#4J;G_6K27Y_\,?1/PO\ CUH?Q1US M5-!BTO7/#7B+38DGN-'\16/V6Y$+'"R !F!4G'(/<5QC_MH>"KBVU232=$\4 M^(Y=+FN([VWT;2Q>(9KN&95$,9=;>-8?DC&=IV]>17(^ =.M_@C^P3J&LB)8-4U M'0I]3N9B/GEN+I2(RQ[D!XU_"LYRY8RE_*OO;O;Y66OGL:0CS2C'^9_@K7_% MJQ[;JWQZ\*Z7\%S\4!+:I>$?VB?# MGC+^T[RWT[6[#PW86;WK>*-2L?L^ERHA <1S%OG(R>@P=I()KP?XF>$/[-_9 MG^"'PK8,LOB/4M+LKR,'!\O'GW!_!B*[?]MZ*+1?@?H>FI&;/PJ==TZTU46Z MD)#IX?D$#HH*QC\JVG'EG)+^;E7X:OTYE]QE!\T8M_R\S_'1?<_O-9OVT/!L M,=MJ-SX>\86?A2XF6*+Q9#86$J> M)O%5FDJJF^)?$'BB6VL[2ST>= M+A+2W21'>:0H2(T54[X]NAK4US3EU;]KKX9>&T8S6O@WPS/_LXZ M9;7GP;LUNOVBH/"-GJ,DT^JZ+$FGVEY%.[D2![B7][N.!\Q[8QQBLXW<(Q71 M7_\ FVOPW^2-)64VWWM_P" I)_C>WS9]9M^T%X&C^$T'Q'?5_+\+SIF*9HF M\UY-Q7R1'C<9-P*[1W!["=-^'D/AWQ1X7UCQ1K&GVL-O MXBTMK0W-L9U9Y(SE@0-JY!(/S#BK7Q3\+^%?A/\ $']GCPC)+%IGPZTZ[O;S M[1?SCR7NTC#PO+(WR[B[ELG RQQQ6AXD^)&C_'+]K#X:>'_#MPFK:'X8%YK% MUJ5O\]M-.L>Q5C<<.$8KEER,OCL:TBHRJ1:VYMO*.KO]S^5NY#;C!]^7?S=T MK?A\_0^JX84MX8XHU"QQJ%51T P!3Z**D$K*R"BBB@84454U;5K/0=-N=0U M"YCL[*V0R2SRG"HH[FDW978FU%78:MJUGH.FW.H:A_&?4[;7==MI+/P=;.)=+T688:]8?=N;A?[O=4/U/N:3I-[\9]3MM=UV MVDL_!ULXETO19AAKUA]VYN%_N]U0_4^_J],_%#XH:UKWBA_AK\-7CD\6NBMJNM.OF6WA^W;_EH_9IV&?+B M_P"!-@#D^*'Q0UK7O%#_ U^&KQR>+716U76G7S+;P_;M_RT?LT[#/EQ?\"; M '/?=]/78^%_POT7X2^%TT?1TDD9W:XO+ M^Z;S+F^N&Y>>9SRSL?RX P!77T45QSG*I)RD[MG9&,8148JR04445!04444 M%%%% !1110 4444 %%%% 'D?[6'CJ\^'?P!\6ZMIMU+9ZJT"VEG/ Q61)9G6 M-60CD,-Q((]*\.^-'@OQ-^SW\)])\;:1\4_&UYXLAGLH3I>M:PU]9W\TA421 M"%Q_O$8)X4_4=O\ MFV3>.;KX6_#F.YGM3XD\1I)/+:L%E2W@0M(RD@@$;P0 M2",@<5V7AW]EWPYI?B?3M?UWQ!XH\>ZCIK^;8'Q7JGVJ*TD_OQQJB)N]R#T! MZ@4J?6?]Y?)M2\/Z3I7B"#6-,T M]K^_L[_3_(EM2'V?9W1FW>:>" 5(/WNU>5_#SXB>%O"7[27QTUSQSKMAH>J M6LEG:60U*=8W^PK$6Q"&.6#':2%R22..:T_V3]>/Q(\??&/XF/9SVL&H:G#I MEG%<1E95@MHN 5/()#*2.QXHB^9#_&4OA=;RUTNPM5TBW TF8+BX:\D$FY#N(.-SX4= >* M](\!ZEX<\3_'#XA:U8:AX@?4M#BAT2_AOIT&E1G E)MT!SN&WYF;&,G'4UP7 M[#_BW0M1^'.MWSZS8/XCUK6=2UR_T\7*&YA4R[-M.67^TO%NJ7^I,\8.\6SW"PN?H(UD/TS2DW"-[:J-_F[+]9?=Y%J M/--QOO+E^2O_ )+^F>V:I^V5X,L5N[ZTT3Q9K7ABSE,-SXITS1VETN(AMK$R ME@64'JRJ1Z9KL?B1^T%X.^%ND^&=4UJ]D.F>()0EI=VZ!T">49/-;)!V;MU\CT#P)^TKX=\=>.XO"/]B>)/#N MK7-HU]8CQ!IAM$OH5ZO%EB2,<_,%X%>73?M4>))_VC-2T.S\%^-;SPQH^F^3 M=Z/9:- ]RUX\O[NY8M(&6$QCY3N&E+_-?@>C>//VC-"\$>*7\-6VA>)/%V MOPVZW5WI_AG33>26<3?=:8[E5<]ADGVY%=_X1\3VGC3PUIVN6,=S#:7T(FCC MO(6AF4'LZ-RI'I7R7\:_&?AOP?JFK__%'2E\3W@@MK_PRTT5W'K)C81I M'Y.?-CD [@=!_#DD_7NAWESJ.BZ?=WEJ;*[GMXY9K8G)B=E!9/P)(_"B.L+O M?_A]N^G_ =T$O=DE_72_P"/];G"_$KX]>'?AKK5GH4EIJWB3Q-=QF>+0?#M MD;R\,0.#(R@@(N>[$9[=#3OAW\=_#?Q(T'7]1M(M1TF?0&9-5TS6+4V]W9,J MEL2)DCD D$$C@U\N^$3?:A\>OC)J-Y\8[7X7ZW_;/V)K.\L[-YI[&-0('CDN M>57;V3CH3VKOOB#X?\-_!G]ECXCZ]X;\03>+=0\30LESXBGO$N9+^>9A;@AX M_EPN]@%7I@UG=^QYUNU=>KM9?=^)IRKVJAT3L_1;_CMY'1#]N/P+/X9B\0V> MB>+-2T9$1[^^LM)\V#3-Q&%N) ^P-@@E49B,C//%>D?$CXX>%OA;X.TCQ1K% MQ+)HVJ7-O;6T]LJG/G LLAW,N$"@L3U '0]*\4^.WAB#X3_L7V/@;28$M[O4 M4L-$1$',MQ-(AE8^I;$A/UJ[\;/"]EXD^+'P%^&3Q+3.!@;0?F7CFL31_VMO#%]K^C:;JGAOQ M=X4M]:F6WTW5/$&CFVL[N1ON*K[B06XQN ZURO[7.H65G\0/@E'XCFCM/!/] MOR3ZC/, ^E4_CWXLT?X]>-/A]\.O!FHVOB*>WURWU MW5[W395G@L+2#)^>125#,6P!G/3U%3"TFNSE;Y:7?XM]K+S*E>*?^&_SULOO M5N^IT'QM_P"*J_:6^"GA=?FAL9KSQ%3'MA8_\#S2> R/%G[97Q)UDG=; M^&=$L=#B8] TI,[_ )$8-'@UAXM_;0\?ZL?GM_"WA^ST:-NRR3,9WQ[X!%>9 M^$=0U2X_9C^/OC_21*^I>(]5U2XMI8L[Q;(1""N/[JB0_A62ER0Y^T9R^;?* MOOC_ )FCCSSY.[A'\.;_ -*/7=;_ &Q/!^F2:E/I^A^*O$NA:9(T5]XBT32# M/IMNR_?S,67<%[E0PKM_&/QQ\(>"/ FF^+;[46N-+U01?V:EG$TL]^TJ[HTA MC'+,P/3C'?%?,WPO\!Z%XG^%?AKPM?\ [14$GA6^LX;?_A&=+&G:?*_F ;K9 MG&96)9BI!^9B3GDUU?CYO#G@?]JSX3Z1K5Q9Z#X.T#PW1E_%[XQ:?\ M@^(O#>J77BBTOKS2_$>FM:3/9PJ\A<"ST^V&.!NDE<_=CC7JSL> H_EDT?$+XA:'\+_"MYXA\0W@L]/MAC@;I)7/W M8XUZL['@*/Y9->8?#WX>ZY\3O%5G\2?B39FSEMCYGAOPE(=T>D(>D\XZ-=,, M'G[G0<_=ZZ5)->UJZ17WM]E^KZ? M*K/XD_$FS-G+;'S/#?A*0[H](0])YQT:Z88//W.@Y^[[G17$?$;XC?\ "(_9 M-)TFT_MGQ;J>5T_2T.,^LLI_@B7J6/7&!W(?[S&5%""]%T2_1+=M^K,Y2I8& MDZE1^KZM_JWLDO1!\1OB-_PB/V32=)M/[9\6ZGE=/TM#C/K+*?X(EZECUQ@= MR%^'/PY_X1'[7JNJW?\ ;/BW4\-J&J.,9](HA_!$O0*.N,GL ?#GX<_\(C]K MU75;O^V?%NIX;4-4<8SZ11#^")>@4=<9/8#MJUK5H4H.AAW=/XI?S>7^%=%U MW?1+EP^'J5ZBQ6*5FOAC_+YOO-]7LEHNKD4445YQ[ 4444 %%%% !1110 44 M44 %%%% %?4+Q-.L;F[D#-'!&TK!1DD*"3CWXKYC^&>O?&/]H3P:?'VA?$'2 MO!MA=SS#3?#J:+%>1A(Y"@%S,YWAFV\[,8!R!S@?3&I:QI^CI"VH7MM9)<2K M!$;F58Q)(V<(NX\L<' ')Q7R7\8O",'[,?C[PKXC^&6J3Z5=>)]>AL[[P2LG MF6>H+(?GECA/,;#@;EX&X8QT*BKS2?6R7DV_^&].PY:0;735^:2_KU[GTKJ? MC[3O!,/A:R\5ZC;VNMZW-'I\$=K#*\=Q>%,LJ *2JY!Y? QDU:UWQ_H/AKQ M)H'A_4;\6^L:\\L>G6HBD8DDW=U+D(B*"SN8_X5!.!7O\ \._BEX5^+&@OK/A/68=8 MT])##))&KQM&X&2KHX#*<$'! ZU\^?LWZ7X=\:?'#XS?$W4);.XU*RUI]+M' MFD4FRMH4"&7!^YN"XW>B, >M9OPF\3)H_@?]HKXKV(\C0M4O[NXTEP-JSB") MT$R^SR-U]0:RYN6C=](.7WN]O_)OP-''FJV762C]RM?_ ,E_$]K^#GB*UU#0 M_%/BV3XA-XL\/7>I7$UO>'=7T/\ 9A^ OPYT M^6TLSXJOK=KYM29UMI"X-QY,Q0AMK/(,@$$[:]KA^ OCKQYKGA&?XA:]X;M- M!\+7L6H6.A>$=-DAC::,8CW2RN65%_NJ,$>G%='+RS<7M%\OW)7?X[;]WU,> M:\>:.\DY?>W9?AKT71'J'Q(^-7@GX1QVI\6^(+?29+HGR+?8\T\N.I6*-6<@ M>H&*Y7Q5^U-X T;X3W?CO3]>BU+3KO[9.J6E MK^SSJ=GHS6R-XJU"TTY+BUV[)6FF7>Y9>#E$()K!J4H*V\K6_P"WK6_![]'W ML;1Y54=]HWO\M_ZZKMJ+&TPM_L\T)D13@LAD10X M'JI-)\5?A7IGQ"^$-S\-CJHT5;VRCM;21-I<>3L9<(2-ZC8NX#L>U<%\&/%V MM^)/%?B?X4>/M-TNXUGPSIT4::YX=D>!);:90NT%2'MY2H7(0KTXQ@$[-J52 M2C\O/?[K=OQ,8W5.+E\_+;[[ZZE[X;>#M$M?VG/'^HZ/IL-FNEZ5:6,\R F2 M>ZN'>XE=W.69MHA').!@=*]YKS_P3\"?!WP[U^XUK0K/4K?4;G/GRW&MWUTL MQ*A=SI-,ZLV &(R .#6+^UAXNU'P-^SSXVU?27>'4([,0Q31G#1>;(L1<'L M5#DY[8K&9$,:$'KN88[UV'BSXI^$_ LFD+KVN6VFKJWF?8Y923'((X MS([%P"JJ$&=S$#ISS7SAX/\ V>?B1X@^"^F^ 9_$7@K0? EY:1_:)O#NFSSW MEY&P5V9I)7V;WZEP.IX["KOC3X=Z+X]_:D^''@2YM_MWAOP-X:;4FM)_G5V+ MI#"LF?O?ZM&(/7%:N-I*#>M_P2;>GRTU^[KFI)Q)OVY=:NH$58/ M"WA*"QD*#'[V>7S%4_\ ,\5G?LV>&=/\;?&CXN_%"ZMTN;W^W9-#TV>09\F M&W14=D]"WRC/HI'Y;::-_=+E7WZ,I^[S7[I+YKF_#4];\7?'WP!X$T' M2=8UWQ+;Z?9ZM"L]@K1R-/<1L 0R0JID(P1_#QGFM+X<9 S@UXM^STMIXR^/'QG\7:T8I]>TG5_[$LEG MP6L;*)2 4!^Z'.22.N#[UC?##Q):-\4_VA/BII.S_A%+:UCMH;J+B&\GM8&: M:12.&P0!N'7=4\R2YGMR\WHM&O7=+IJ/E;?*MTU'U=[/TZOKHB[\&?% L[#] MH?XH3/F%]8NXX'8\-#8P%8\>W)KK/V89-.^%G[+'A;5/$>HP:7:O9MJEY>WL M@1 9Y&E!8GN0ZCU)Q7B][;7/@W_@G=IM@F1K'BXQ1C^]))>W6\_7,9K?_:*T M+6]6^*GP8^&.@'15L[&RDU&*T\1+(UA=S6Z!(TD2,AGVJK$+G^+GBKY7!NGU M]V'_ (#%N7Z/S$Y*:Y^GO2^3:4?U7EJ>[?#_ /:0^&_Q2UYM%\,^*(-0U7RS M*MK)!-;O(@ZM'YJ+O Z_+GCFE\??M'?#?X7ZXFC>)?%5KIVJ,H=K58I9WB4] M&D\M&\L'(Y?%&K6X72M'\.6#V]M&TB%79 MI)&9WXX"\ 'GUSQ'[,?BKPWX0_9QU_XJ^*KFV?4/$%[>W^KW4^UI)G$KI';# M/)X4!8_]OIS4MI)OLKO[[)?-:];;=1I-M+N[+[KO[OE^!T_[.%_;>//C)\9_ M'5G-X[> ;BA'!!+@\5]$UX#^PWH*Z3^SWI-_P#9H[23 M7+NZU9H8E"J@DE8( !T 14Q[5[]6DH\EH=DE\[:_C.VM8$,DLTK!410,DDGH *:3;LA-J*NPOKZWTNSGO+R> M.VM8$,DLTK!410,DDGH *\BM;6[_ &@=0BO[^*6S^&]M('M+&0%)-:=3Q+*. MH@!&50_>ZGC HM;6[_:!U"*_OXI;/X;VT@>TL9 4DUIU/$LHZB $95#][J>, M"O8HXUAC5$4(BC:JJ, = !7K:9>K+^+_P"D?_;?^D_XMO!2>;.[_@+_ ,J> M;_N=E]O_ _$1QK#&J(H1%&U548 Z "G445Y![X4444 %%%% !1110 4444 M %%%% !1110 4444 %<-XJ_Y*IX$_P"N6H_^BXZ[FN&\5?\ )5/ G_7+4?\ MT7'7#C?X2_Q0_P#2XGJ9=_&E_@J?^FY'QN(%D@9!T4H1M(X'&.U9L?P[\*Q^'XM!3PSHZ:'%()H],6PB%LD@;<'$6W: M&!YSC.>:Z&BCK<.EC-\0>&M(\6:&? M_ASP5#+#X>\/Z7H,4N/,CTRRCME?'3(11FMNB@#-TCPUI'A_3&TW2]*LM-TY MF=C:6=ND41+DESL4 98DD\ _#/@E9E\.^'=)T!9CF4:78Q6P?_>V*,_C6[10 5R2_"/P*NM'5U\%^ M'1JQ?S3?C2H//WYSN\S9NSGOFNMHHZW#I8S[CP_I5WK-IJ\^F6 ?# M'C=81XB\.:3KX@YB&J6,5SY>?[N]3C\*WJ* *=IHVGZ?I:Z;:V-M;:&4\./X>TI_#R !-):RB-HH#;@!%MV##<].O-; ME%'F!GZUX>TKQ)IKZ=J^F6>JZ?)C?:7L"31-CIE&!!_*J/A?P#X9\$K*OAWP MYI.@++_K!I=C%;!\=,[%&:WJ* \C!F\ ^&+GQ$OB";PYI,NO+@#5'L8C=# P M,2E=W'UK0T70]-\.:?'8:3I]KI=C&69+6RA6&)2S%F(50 "223ZDDU>HH\@" MBBB@ HHKB?%GBR]O-4/ACPP5DUMU#7-XPW1:=&?XW]7/\*=^IXZX5JT:,>:7 MR75OLCIP^'GB9\D/5M[)=WY?\,M0\6>++V\U0^&/#!636W4-MV'C_Q_ M/HMW;^'O#UNFJ>+K]2;>U8_N[:/H;B / $'@JTN)IKA]4UV_ M82ZCJLX_>7$GI_LH.BJ. */ '@"#P5:7$TUP^J:[?L)=1U6VK;]%_+_ ,'N_DO,HHHKI.X**** "BBB M@ HHHH **** "BBB@ HHHH *SM4\.Z5K=U87.HZ99W]QI\OGV&?%E[:WFM^'-)UF[M?^/>XU"QBGDAYS\C.I*\^ ME;U% %#3=!TS1KB]GT_3K2QGOI/.NI+:!8VN) N^0@#!/#5 MKXDE\10^'M*A\02@K)JT=E$MTX(P090NX\<=:W:* ,_1?#VE>&[>6WTG3+/2 MX)IGN)(K*!(5>5SEW(4 %B>I/)K"7X1^!5UHZNO@OPZ-6+^:;\:5!Y^_.=WF M;-V<]\UUM%'F!GR>'M*EUR+6GTRS?6(H3;1Z@T"&X2(G)C$F-P4GG;G&:(_# M^E1ZY+K2:99IK$L MI-06!!!/#6J>(+;7KS MP]I5WKEM@0:G/91/QJMJ/PQ\':QKBZU?^$]#O=84AAJ%QIL,E MP".A$A7=Q]:Z:BC;8 K \4?#_P +^./)_P"$C\-Z1K_D_P"J_M2QBN?+S_=W MJZ=>7FEV M5U=Z:S/97$UNCR6K$;28F(RA(X.W'%6KZQMM4LYK2\MXKNUF4I+!.@='4]0R MG@CV-3T4>0;;'/\ ACX>^%O!+3-X=\-:/H+3?ZUM+L(K8O\ [VQ1G\:T(O#^ ME0ZY/K,>F6<>L3PK;RZ@L""XDB4Y5&DQN*@\@$XK0HH S](\/:5X?%V-+TRS MTT7<[75Q]C@2+SIF^](^T#3BL*?X1^!;K66U>;P7X>FU9G\QK^32H& MG+9SN,A3=GWS76T4>8&5XB\*Z)XPT\6&O:/I^MV(8.+;4;5+B/<.AVN",^]- MT[P?H.CWEO=V&B:=975O;?8X9[>TCC>*#=N\I6 R$W<[1QGG%:]% !1110 4 M454U;5K/0=-N=0U"YCL[*V0R2SRG"HH[FDW978FU%78:MJUGH.FW.H:A_&?4[;7==MI+/P=;.)=+T688:]8?=N;A?[O=4/U/ MN:3I-[\9]3MM=UVVDL_!ULXETO19AAKUA]VYN%_N]U0_4^_J]>'=*U#5K'5;K3+.YU M.P#BTO9K='FMPXPXC]:-%% &#JG@'PQKFM6^LZCXIWJ@.?QK;C\/Z5#KDVLQZ99QZQ/"MO+J"P M(+B2)3E4:3&XJ#R 3BM"B@#/L_#^E:?JU]JEKIEG;:G?A!=WL,")-<;!A/,< M#+[1P,DX'2J4'@3PU:^))?$4/A[2H?$$H*R:M'91+=.",$&4+N/''6MVB@#F M;?X8^#K77SKL'A/0X=;+;SJ4>FPK8%W9]\UTU%%'2P=;G,^(_ACX. M\8WR7NO^$]#UR\C 5+C4M-AN)% Z ,ZD@5?O?!^@ZEHL.D7>B:==:3"R-%83 M6D;P1E#E"L9&T%3R,#BM>BC8#/UCP]I7B!;1=4TRSU(6DZW5N+R!)?)F7.V1 M-P.UQDX8H- AN$B)R8Q)C<%)YVYQFM"B@"A MK6@Z9XDTV73]7TZTU6PE_P!9:WL"S1/]58$'\JJ^&?!OA_P7:/:^'M"TW0K9 MSN:'3+2.W1CZE4 !-;-% &=8^'-)TN\U&[LM+L[2ZU%Q)>SP6Z(]TP& TK 9 M<@<9;/%+HOA_2_#>E1:9I&FV>EZ;%N\NSLH$AA3<26PB@ 9))/'4FM"B@#D] M-^$G@;1=6&JZ?X,\/6.J!MXO;;2H(Y@WKO5 V??-:?B7P7X?\9P0P^(-"TW7 M88'\R*/4K..X6-O[RAP<'W%;-%'D'F9FG^&-'TF^DO;'2;&RO)(4MGN+>V2. M1HDSLC+ 9*KDX7H,\5IT44 %%%% !7-_$+XA:'\+_"MYXA\0W@L]/MAC@;I) M7/W8XUZL['@*/Y9-'Q"^(6A_"_PK>>(?$-X+/3[88X&Z25S]V.->K.QX"C^6 M37F'P]^'NN?$[Q59_$GXDV9LY;8^9X;\)2'='I"'I/..C73#!Y^YT'/W>NE2 M37M:ND5][?9?J^GW)\M6JT_9T]9/[DN[_1=?O:/A[\/=<^)WBJS^)/Q)LS9R MVQ\SPWX2D.Z/2$/2><=&NF&#S]SH.?N^YT5Q'Q&^(W_"(_9-)TFT_MGQ;J>5 MT_2T.,^LLI_@B7J6/7&!W(?[S&5%""]%T2_1+=M^K,Y2I8&DZE1^KZM_JWLD MO1!\1OB-_P (C]DTG2;3^V?%NIY73]+0XSZRRG^")>I8]<8' M&U#5'&,^D40_@B7H%'7&3V [:M:U:%*#H8=W3^*7\WE_A71==WT2YH ML5BE9KX8_P OF^\WU>R6BZN11117G'L!1110 4444 %%%% !1110 4444 %% M%% '.^//AYX<^)WA]]$\4Z1;ZUI;.)/L]P#\KC(#*0058 GD$'DURW@']FWX M:_#'6!JWASPK;6FJ*NU+VXFENIHP1@A'F=RG''RXXKTNBA>Z[H'JK,X+XD_ MKP+\7KJPNO%OA^'5KJP#+;S^=+#(BGJNZ-U)4_W3D=>*O>#/A)X0^'>HWM]X M;T*VT>XO+>&UF^RE@ABB!$:A,[5QN8G:!DG)R>:Z^BA::('KN>-WW['WP?U) M8!<>"K9S"SMO6ZN%>3>YD;S6$@,HW,3ARP'0<<5R7[2&GZCXD\*VWP6\$^#- M6@M]2-I#+JMO8>3I%A9+*&D'G<+N 3&P#/S>O%?2-%*VRZ7O;O8=W=RZ]SE/ M&'PM\*_$#PE%X:\1Z+;ZOHT001V\P(\LH,*R,I#*0.,J0<$UD?#O]G_P#\*- M2EU'POH"Z??R1&!KF6[GN9/+)!*AI78@$@=,=*]"HJKN[EU9-E91Z(\K\9?L MN_"[X@>)I_$&N^$H+O5[@ 3W$=S/ )\ >8L;JK]!]X'I73>*/A+X0\9>!X_ M!VKZ#:W7AF)(TBT]=T21"/A-A0AD('0J0:ZZBILKOSAV^C6\[^9,8BSR3-V+R.2[G_>)ZUUE%5=Z^9-EIY!5/6-'L?$.E7>F:G:0W M^GW<;0SVUP@>.1",%6!ZBKE%2TFK,J]M4>2^%?V4?A5X)URTU?1_"<=M?6DH MGMVDO;F:.%P^:Z&BJN]!=SGM"\ :!X;\2>(-?TZP%OJ^O/%)J5UYLCF,* */ _@'0?AOHK:3X Y_!8T>WMO"\ULUH^FV>ZWC\IOO*#&5(SSD@Y.3S7344K+E MY>@[N_-U.2UCX4^%=>T;PYI-]I*SZ;X>N+>ZTRW\Z15@D@7;$WRL-^T=FR#W M!J+XE?![P=\7K&UM?%VA0:Q':N9+=V=XI86.,[)(V5US@9P><#TKLJ*;][?U M^?<2]W;T^1Q?PY^#?@[X2QWB>%-%73#>;?M$C3RSR2[<[07E9FP-QXSWKFH? MV4OA-;ZU?ZK'X*LEO;TR&5O-EV*T@(=HX]^V)B"?F0*1V(KUFBAZN[!:;&;X M;\.Z=X1\/Z=HFD6JV6EZ? EM;6ZLS".-1A5RQ)/ ZDDFM*BBFVV[L222L@HH MJ"^OK?2[.>\O)X[:U@0R2S2L%1% R22>@ H2;=D#:BKL+Z^M]+LY[R\GCMK6 M!#)+-*P5$4#)))Z "O(K6UN_V@=0BO[^*6S^&]M('M+&0%)-:=3Q+*.H@!&5 M0_>ZGC HM;6[_:!U"*_OXI;/X;VT@>TL9 4DUIU/$LHZB $95#][J>,"O8HX MUAC5$4(BC:JJ, = !7K:9>K+^+_ .D?_;?^D_XMO!2>;.[_ ("_\J>;_N=E M]O\ P_$1QK#&J(H1%&U548 Z "G445Y![X4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !7&^-O#.N:IK^@:OH4^GQ7.F+&J>TA:]FM=59II_@SAO+^)?_ #W\*?\ M?FY_^+H\OXE_\]_"G_?FY_\ BZ[FBN?ZHO\ GY+[SK^OO_GU#_P%'#>7\2_^ M>_A3_OS<_P#Q='E_$O\ Y[^%/^_-S_\ %UW-%'U1?\_)?>'U]_\ /J'_ ("C MAO+^)?\ SW\*?]^;G_XNCR_B7_SW\*?]^;G_ .+KN:*/JB_Y^2^\/K[_ .?4 M/_ 4<-Y?Q+_Y[^%/^_-S_P#%T>7\2_\ GOX4_P"_-S_\77' MU]_\^H?^ HX;R_B7_P ]_"G_ 'YN?_BZ/+^)?_/?PI_WYN?_ (NNYHH^J+_G MY+[P^OO_ )]0_P# 4<-Y?Q+_ .>_A3_OS<__ !='E_$O_GOX4_[\W/\ \77< MT4?5%_S\E]X?7W_SZA_X"CAO+^)?_/?PI_WYN?\ XNCR_B7_ ,]_"G_?FY_^ M+KN:*/JB_P"?DOO#Z^_^?4/_ %'#>7\2_\ GOX4_P"_-S_\71Y?Q+_Y[^%/ M^_-S_P#%UW-%'U1?\_)?>'U]_P#/J'_@*.&\OXE_\]_"G_?FY_\ BZ/+^)?_ M #W\*?\ ?FY_^+KN:*/JB_Y^2^\/K[_Y]0_\!1PWE_$O_GOX4_[\W/\ \71Y M?Q+_ .>_A3_OS<__ !==S11]47_/R7WA]??_ #ZA_P" HX;R_B7_ ,]_"G_? MFY_^+H\OXE_\]_"G_?FY_P#BZ[FBCZHO^?DOO#Z^_P#GU#_P%'#>7\2_^>_A M3_OS<_\ Q='E_$O_ )[^%/\ OS<__%UW-%'U1?\ /R7WA]??_/J'_@*.&\OX ME_\ /?PI_P!^;G_XNCR_B7_SW\*?]^;G_P"+KN:*/JB_Y^2^\/K[_P"?4/\ MP%'#>7\2_P#GOX4_[\W/_P 71Y?Q+_Y[^%/^_-S_ /%UW-%'U1?\_)?>'U]_ M\^H?^ HX;R_B7_SW\*?]^;G_ .+H\OXE_P#/?PI_WYN?_BZ[FBCZHO\ GY+[ MP^OO_GU#_P !1PWE_$O_ )[^%/\ OS<__%T>7\2_^>_A3_OS<_\ Q==S11]4 M7_/R7WA]??\ SZA_X"CAO+^)?_/?PI_WYN?_ (NCR_B7_P ]_"G_ 'YN?_BZ M[FBCZHO^?DOO#Z^_^?4/_ 4<%<6GQ+NH7A^W^&;3S!M\^"WN#)'G^)0S8)'; M/%=%X3\)V7@_2Q9V8:1W8RW%U,=TMQ(?O2.W&IMH]TNC&U74V0B!KPMY2L?XFVC) ZX'7ID=:\B M\&_#WXF^#?MUQ#>^$K[5-0E\Z\U*]BNI+B=NP+!E 51P% [5[916E2C&I) M2;=T>)6PL*TXU)-IK:S/./+^+G_/SX*_\![S_P"+H\OXN?\ /SX*_P# >\_^ M+KT>BI]C_>?WB^JK^>7WGG'E_%S_ )^?!7_@/>?_ !='E_%S_GY\%?\ @/>? M_%UZ/11['^\_O#ZJOYY?>><>7\7/^?GP5_X#WG_Q='E_%S_GY\%?^ ]Y_P#% MUZ/11['^\_O#ZJOYY?>><>7\7/\ GY\%?^ ]Y_\ %T>7\7/^?GP5_P" ]Y_\ M77H]%'L?[S^\/JJ_GE]YYQY?Q<_Y^?!7_@/>?_%T>7\7/^?GP5_X#WG_ ,77 MH]%'L?[S^\/JJ_GE]YYQY?Q<_P"?GP5_X#WG_P 71Y?Q<_Y^?!7_ (#WG_Q= M>CT4>Q_O/[P^JK^>7WGG'E_%S_GY\%?^ ]Y_\71Y?Q<_Y^?!7_@/>?\ Q=>C MT4>Q_O/[P^JK^>7WGG'E_%S_ )^?!7_@/>?_ !='E_%S_GY\%?\ @/>?_%UZ M/11['^\_O#ZJOYY?>><>7\7/^?GP5_X#WG_Q='E_%S_GY\%?^ ]Y_P#%UZ/1 M1['^\_O#ZJOYY?>><>7\7/\ GY\%?^ ]Y_\ %T>7\7/^?GP5_P" ]Y_\77H] M%'L?[S^\/JJ_GE]YYQY?Q<_Y^?!7_@/>?_%T>7\7/^?GP5_X#WG_ ,77H]%' ML?[S^\/JJ_GE]YYQY?Q<_P"?GP5_X#WG_P 71Y?Q<_Y^?!7_ (#WG_Q=>CT4 M>Q_O/[P^JK^>7WGG'E_%S_GY\%?^ ]Y_\71Y?Q<_Y^?!7_@/>?\ Q=>CT4>Q M_O/[P^JK^>7WGG'E_%S_ )^?!7_@/>?_ !='E_%S_GY\%?\ @/>?_%UZ/11[ M'^\_O#ZJOYY?>><>7\7/^?GP5_X#WG_Q='E_%S_GY\%?^ ]Y_P#%UZ/11['^ M\_O#ZJOYY?>><>7\7/\ GY\%?^ ]Y_\ %T>7\7/^?GP5_P" ]Y_\77H]%'L? M[S^\/JJ_GE]YYQY?Q<_Y^?!7_@/>?_%T>7\7/^?GP5_X#WG_ ,77H]%'L?[S M^\/JJ_GE]YYQY?Q<_P"?GP5_X#WG_P 71Y?Q<_Y^?!7_ (#WG_Q=>CT4>Q_O M/[P^JK^>7WGG'E_%S_GY\%?^ ]Y_\71Y?Q<_Y^?!7_@/>?\ Q=>CT4>Q_O/[ MP^JK^>7WGG'E_%S_ )^?!7_@/>?_ !='E_%S_GY\%?\ @/>?_%UZ/11['^\_ MO#ZJOYY?>><>7\7/^?GP5_X#WG_Q='E_%S_GY\%?^ ]Y_P#%UZ/11['^\_O# MZJOYY?>><>7\7/\ GY\%?^ ]Y_\ %U#'\/?$GC+6+2X\?7VEW>EV#"6WTC2( MI4MYIL\23^826V]EZ>OOZ;11["+^)M^K%]3A+XY-KLWI\Q*Y'XK6/C/5/!5] M9> [W3=,\0W \N*_U3>8[=2#EU55;+^F1@$Y.<8/7T5V0ER24K7L=6VHRW5[.QR\T\GFY=V/4].P MKK?(_:+_ .?[X7_^ >H__':]KHKLEC)5).4HQ;?DH__ !VO:Z*CZR_Y(_<7]67\\OO/ M%/(_:+_Y_OA?_P" >H__ !VCR/VB_P#G^^%__@'J/_QVO:Z*/K+_ )(_<'U9 M?SR^\\4\C]HO_G^^%_\ X!ZC_P#':/(_:+_Y_OA?_P" >H__ !VO:Z*/K+_D MC]P?5E_/+[SQ3R/VB_\ G^^%_P#X!ZC_ /':/(_:+_Y_OA?_ . >H_\ QVO: MZ*/K+_DC]P?5E_/+[SQ3R/VB_P#G^^%__@'J/_QVCR/VB_\ G^^%_P#X!ZC_ M /':]KHH^LO^2/W!]67\\OO/%/(_:+_Y_OA?_P" >H__ !VCR/VB_P#G^^%_ M_@'J/_QVO:Z*/K+_ )(_<'U9?SR^\\4\C]HO_G^^%_\ X!ZC_P#':/(_:+_Y M_OA?_P" >H__ !VO:Z*/K+_DC]P?5E_/+[SQ3R/VB_\ G^^%_P#X!ZC_ /': M/(_:+_Y_OA?_ . >H_\ QVO:Z*/K+_DC]P?5E_/+[SQ3R/VB_P#G^^%__@'J M/_QVCR/VB_\ G^^%_P#X!ZC_ /':]KHH^LO^2/W!]67\\OO/%/(_:+_Y_OA? M_P" >H__ !VCR/VB_P#G^^%__@'J/_QVO:Z*/K+_ )(_<'U9?SR^\\4\C]HO M_G^^%_\ X!ZC_P#':/(_:+_Y_OA?_P" >H__ !VO:Z*/K+_DC]P?5E_/+[SQ M3R/VB_\ G^^%_P#X!ZC_ /':/(_:+_Y_OA?_ . >H_\ QVO:Z*/K+_DC]P?5 ME_/+[SQ3R/VB_P#G^^%__@'J/_QVCR/VB_\ G^^%_P#X!ZC_ /':]KHH^LO^ M2/W!]67\\OO/%/(_:+_Y_OA?_P" >H__ !VCR/VB_P#G^^%__@'J/_QVO:Z* M/K+_ )(_<'U9?SR^\\4\C]HO_G^^%_\ X!ZC_P#':/(_:+_Y_OA?_P" >H__ M !VO:Z*/K+_DC]P?5E_/+[SQ3R/VB_\ G^^%_P#X!ZC_ /':/(_:+_Y_OA?_ M . >H_\ QVO:Z*/K+_DC]P?5E_/+[SQ3R/VB_P#G^^%__@'J/_QVCR/VB_\ MG^^%_P#X!ZC_ /':]KHH^LO^2/W!]67\\OO/%/(_:+_Y_OA?_P" >H__ !VC MR/VB_P#G^^%__@'J/_QVO:Z*/K+_ )(_<'U9?SR^\\4\C]HO_G^^%_\ X!ZC M_P#':/(_:+_Y_OA?_P" >H__ !VO:Z*/K+_DC]P?5E_/+[SQ3R/VB_\ G^^% M_P#X!ZC_ /':/(_:+_Y_OA?_ . >H_\ QVO:Z*/K+_DC]P?5E_/+[SQ3R/VB M_P#G^^%__@'J/_QVCR/VB_\ G^^%_P#X!ZC_ /':]KHH^LO^2/W!]67\\OO/ M&/"?P;\2>(O'%MXQ^*NJ:5KNIZ7QHFD:-#+'IM@V/FN-DI+/.>@9B=H'';;[ M/116-2K*JTY=/N1K3I1I)J/7[V5=4-Z--N?[-6W:_P!A\@73,(M_8MM!./I^ ME>)>$?AM\5?"FJ:IJ_\ :'@[4];U-]USJ-_#=O-M'W8E*LH6->R@#WZ"O=Z* MZ,/C)X>$H12:EO=7^7H<6*R^GC*D*DY23AM9VU?7UMI?M?NSS'ROC+_S]>!? M_ :]_P#CE'E?&7_GZ\"_^ U[_P#'*].HJ_KC_P"?!?_ :]_\ CE'E?&7_ )^O O\ X#7O_P 5\9?\ GZ\"_P#@->__ !RO3J*/ MKC_Y]Q_\!#^S5_S^G_X$SS'ROC+_ ,_7@7_P&O?_ (Y1Y7QE_P"?KP+_ . U M[_\ '*].HH^N/_GW'_P$/[-7_/Z?_@3/,?*^,O\ S]>!?_ :]_\ CE'E?&7_ M )^O O\ X#7O_P 5\9?\ GZ\"_P#@->__ !RO3J*/KC_Y]Q_\!#^S5_S^G_X$SS'ROC+_ M ,_7@7_P&O?_ (Y1Y7QE_P"?KP+_ . U[_\ '*].HH^N/_GW'_P$/[-7_/Z? M_@3/,?*^,O\ S]>!?_ :]_\ CE'E?&7_ )^O O\ X#7O_P 5\9?\ GZ\"_P#@->__ !RO M3J*/KC_Y]Q_\!#^S5_S^G_X$SS'ROC+_ ,_7@7_P&O?_ (Y1Y7QE_P"?KP+_ M . U[_\ '*].HH^N/_GW'_P$/[-7_/Z?_@3/,?*^,O\ S]>!?_ :]_\ CE'E M?&7_ )^O O\ X#7O_P 5\9?\ GZ\"_P#@->__ !RO3J*/KC_Y]Q_\!#^S5_S^G_X$SS'R MOC+_ ,_7@7_P&O?_ (Y1Y7QE_P"?KP+_ . U[_\ '*].HH^N/_GW'_P$/[-7 M_/Z?_@3/,?*^,O\ S]>!?_ :]_\ CE'E?&7_ )^O O\ X#7O_P 5\9?\ GZ\"_P#@->__ M !RO3J*/KC_Y]Q_\!#^S5_S^G_X$SS'ROC+_ ,_7@7_P&O?_ (Y1Y7QE_P"? MKP+_ . U[_\ '*].HH^N/_GW'_P$/[-7_/Z?_@3/,?*^,O\ S]>!?_ :]_\ MCE'E?&7_ )^O O\ X#7O_P 5\9?\ GZ\"_P#@->__ !RO3J*/KC_Y]Q_\!#^S5_S^G_X$ MSS'ROC+_ ,_7@7_P&O?_ (Y1Y7QE_P"?KP+_ . U[_\ '*].HH^N/_GW'_P$ M/[-7_/Z?_@3/,?*^,O\ S]>!?_ :]_\ CE'E?&7_ )^O O\ X#7O_P 5\9?\ GZ\"_P#@ M->__ !RO3J*/KC_Y]Q_\!#^S5_S^G_X$SS'ROC+_ ,_7@7_P&O?_ (Y5:;X< M^+_'U]:0_$#4M'E\/6K^<=)T**:-+V0$%1.9&)*+C.T<$XSTKU>BFL=4CK", M8ONDKKT[>I+RNE/W:LYRCV)]3_UMGX1 MTLV\3=0L@C6(C_OJ:7\JTY7SQIO=J[_\!O\ G9&;DN6PSLN'(4QB(.206+!<$G!&FI]845\W?LW? MM5:E\4K/QOI_C/08?#GB7P@K2:A%;,WDE5WA^&)*E3&01N(.00:\7T7]N[XO M^+OASK'B30/ASI5Y;Z+))+J6KR"1+*"#C8BH9@TD@!RVUNA'R#K2;2^Z_E9] M1I-_?;YGWS7/^//'V@?#'PQ=^(O$^I1Z5H]KM$MS(C/@LP50%0%F))' !-?& M>L?MY?$_4OAK#XW\,_#.SA\-V(BAU;5]4D9H&N&8*5@42(Q7<0-WSXSR!CGO M/VC/VC9+7X _#W68/"6AZY?>-9;4KH?B*U-Y:J&CWGY,KN('=.UW1;H7NE:A"MQ;7 1D\R-AD':P!' MT(!K5KY3^.'[4^N?!'XL>$?A[X8\)66O+<:6KR:78PNDWG-O2&&#:VV- 4!. M5;"]*D^ O[4GCWQ;\;];^''Q'\)Z;X;U&SL6OA]@D+& (P61O,=6!20'J?LD?'SQ!^T1X:\2>(=6TJQTK3K?4S9 MZ=%:!]_EA Q\UF8AF&]1E0HZ\4H^\KKM?Y=/O*E[KL^]OG_P#WFN;\3?$OPA MX+N$M_$/BK1-"G<96+4]1AMV8>H#L":\_P#VM/C'<_ _X)ZOKVG%5UF=DL-/ M9@"$FDS\^#UVJ';'JHKQ7X#?L,>$/%WP_L?%?Q.CO_%'BKQ#"NH3R3W\T?D" M0;E&48%GVD$EB>>,<ZKK>O>)M1^U:G>:M>&=UMVG4+&BX"I&H67 X '/%5&TY4N7: M=OZ_!B?NJIS;PO\ U^1^B22+(BNC!T89#*<@CUIU8'BCQYX7\ PVS>(_$6D> M'8K@E8#JE]%:B3:!D+O89QD=/45\Z?ME?M)KX9^$&FQ_#S7;34M3\47;:=:Z MGI%TDXC10/-,ZQXHGM_-O-6^W2Q^3,RY;RU5@I"GNX;.,GKBN. M_P""=]K=>,/A/\3?!U]J%V_AW[2;.UFA?:\2S12+*8B00IP$;I@%LXYJ[?'' M=Q5_+>Q*=^671NWGM?\ 0^NE^+G@9M8321XT\/'56?RUL1JL'GEO[H3?NS[8 MKK*_,7]KSX"_#?P+KG@[P%\,-*NKGX@7MQ_I,,=Y+<.8V&$$@9BJ,3\WRA<* M"3P17Z0>"M)O-!\&Z%IFH7)O+^SL8+>XN"23+(D:JS9/7)!-$;2@Y>=O7T] ME>,U'NK^GKZDOB3Q9HG@W3?[0\0:QI^AV&\1_:M2NDMXMQZ+O<@9.#QFL;0? MB]X$\57R66B^-?#NL7K\+;V&JP3R-]%1R37RW_P42GE\7:M\*?AU;,3-KFK^ M;(B]0,I"A_\ (K_E7/?MA?L@?#7X6_!F]\7^$+&X\.:QI<]N4*7TTRS[Y50@ MB5V(8;MP*D?=K-2M'VDMKV_+]6:WJUO]W4R4O< M4WVOZ(^RZ*_-7Q]XL^,_CK]M /I/A'2K[Q9X0CE_L_1VN%^SBTRQ2:5OM"@N M5G0G#KSM&T8(KW?XB?M7_$)?'MI\-_AOX,T_Q5X[L[*.;7'E=OL=M,44R1I^ M\3"J6 W-)C) Y-9Q?-",NKZ>7?\ S[;%R7+-QZ+KY]OQT[[GUG17RW^SI^TY MX^^+WQEUOP;XC\*Z9X;BT'3V;4HXB\DZW@D5,*^\J$.2=N"?E^\:^G-0O8M- ML;F[G;9!;QM+(Q[*H))_(4Y6C%3>UK_+^D*/O2<5NM/F/?#&GZC;OY_LIANCN+659( MW'JK*2#^%?D_\+/$'P-UZU^(?B?XO?:M2\2:EJ$MSIFG6GVM)0&W.S!X\199 MG _>-QLZ<\^F? OXB>+?V7/V1=:\9?8HR^M:["FA6&KJYB*%/WDNU65L,$;& M",[ >G51^%N>C2CZ7;2MZZCDO?M'NU\E=W]-#]'J*^3-+_:Z\'/ 36,;:(JR8OM2NG8!$P9#L5E#OR@PHSEN_%ZG^VS\8O!-QX>USQA\, M])TOP?KDZ):0)<$:@Z-R" 92V=O/S1*#QTS5J+;^O7T\S M[GHKY4^-?[5WC?2?C1+\,/A?X4TO7?$-K DUQ)K5TL22%D5]D2F6(,0K*?O$ MG)PO&:T?%O[6FN_#7X/^&M2\5>"Y(/B7KUQ+96?A6!F&^1)"GF'(+!#\A &X MMO4 X.1"=X\RZ[>?33N4U:7*_P#AM+Z_(^FJ*^/? /[67Q4L?C7X;\"?$WP) MI.CGQ"<6HTJ?=/ #G:\BB:48R.0=A R>V*HG]L[XE^*?B5X\\'^ O -CXJN= M(O7@L)E+Q1Q0Q,ZR27#M(%8LRC: 4[\D\4/9/U_"U_NN+OY6_';\C[0HKY0^ M%O[5GCKXJ?LY>,_%^F>&-+;QGX?G,(M3(8[*50$=Y#OD!&U"Y*[^=HP><5X[ M^PSXH^(OAN/Q#XSOM'TU?AIJ=S=:EKWB2[D!N$>&)V*Q)YP;&]N\;=3S56]Z M2>EE>_Y?A^.@?9375VMZ;GZ(T5\0P_MK?%WQ%I>J>//#OPLL[GX6Z=(_FW=U M<%+IHT/S.&\P X[[8V .1GC-9WQ8_:.^)_BW]C.W\7MH>C6UOXBFNK#4KBV+ MQBUM&;R8S&KS;FD=MPR-P &=HZU$FXQ_X;_L:M9Z M!I-YJ>HW"6EA9PO<7%Q(<+'&H+,Q]@ 36%\./B?X9^+GAS^WO"6IC5])\Y[? M[0(9(OWBXW+MD56XR.W>OC/X4^//B1\"_P!D36[OQ9X.T&+PO::; = CO,3M MJ;7%O#] MM]EM(S+@[A&NX@$NHVCEF)Y&"1I)UEYW=]/N6W3J9Q?,D]MWY65M?Q_ M0^L:*^.O#/[6WQ7\(_%CPKX2^+O@#3?#]KXFF6"QGTV0[T+L$5C^^E5L,R@K M\I&[/L;WQ&_; \:Z)^T+KWPU\&^#+7Q=/:VL:6D,>])3=,B.SRR;]BQ(K'/R MCD#YA4]K:WO^&Y7>_2WX['UO17S#^S=^U5XC^(MQ\1=-\?\ AZST35?!J--= M?V7N*!4,@DC(+OEU,9Y#8/\ /B?A_P#M??&;XK:K%K7A7X::3J'@7^T4LY_* MN_-OX%9PNYPLNY< [L^3MQGG'-.*YI**ZI/RL]%^(F^5-OH[?-:_D?:E%%%( M84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 5Q_QA\)WOCSX5^+?#NFS+!?ZIIEQ:02.<*' M=" ">P).#]:["BHG%3BXOJ5&3C)270_/SX*_%#XX? #X>K\.X/@7JVKWUI-- M]FU01S?9PSN6RY2-DD )/(D7C'UKU'X"?"WQ!^S]\,?B;\2_'DD?_"::U;W& MJW<*,K?9PBR2!"1QN9V)(!('RCM7UE7$_&CX=3?%KX8Z_P"$(=6.AMJT(@-\ M+?S_ "UWJS#9N7.0"OWAUIU7*4)-:R:M?^OQ"FHJ44_A3O8_/W]G'X@?%KX; M_!W4=/\ !_PHU#Q!)XMGFN;/Q1;AY$C8_N2754(^5D8C>R#)SR#7HGB?]D/Q MAX9_8K;PQIUL=2\87&K1ZYJ=A;.&9_E*>2ASARB[#@=2&QGC/V/\)OA[;_"G MX;^'_"5MM=;6E51;DH];*_E%W7Y$4W M)6+[[0?#.K_":Z\#>'-*T[R+O5-2$L9E:.,)&(8W M1-N2 .]"LOA%J7C.?6K\SVVM6J2O!D%@CL\:,& M4[MVTLA&3D^GZ'T4I-RES]TT_.[O\OD$4HQY.B::\K*Q\/\ A;X'^._AA^SC M\7?$VL:==:K\2O'$3"33-,B-Q-$LKE2-L>&/#FI:G?RRV46H1: M?9O+Y.V,O(TFP':/-8$D\<&M#XS?"G7?$7Q]^ OA>QT'49_!_A6WBGN=2CM' M-G&8ROR/)C:&Q;H,$Y^<>M?8E%:>-]:T#4+'1-+L19:5>WMH\<,S;8X]T+L,,,"4Y7/WO>L+X2_" M_P 6^+OC-^T+XKU+1M1T.XU6UN-'T2XU*VDMQ,K[D5XRP&5"Q1?,./FK[.JA MKVFRZQH>H6$%[-IL]U;R01WMO_K8&92!(G^TI.1[BL'&T%'>T7'[]WZFW->3 M>UY)^EMEZ'YJ>&O%7QC^"'[-_B_P0OPWNO#EK"\\NH>*M1#1*L7S'W?4J?7@U]-Z-H]GX?TBRTO3 MH%M;"RA2WMX$^['&BA54?0 5T*6DF]W9?)?TON,7'6*6RN_F_P"F>%_MN_!C M7?C9\&?[-\-QKO$6_:C^/.@?"\Z% M#\$M7T[5M+T[R9/$$]M<>0B1QX,HB,07< ,_ZPC/8CBON^DZ\&L.5VE%/27Y MVL;#_ (4>$?A_K6M:KX^DM%*+,5W;3LSM7EF/R M@9)ROS/-/B%\"?!/QYL=#N_'OAD MWUU9P%HKVG@/P,WPCT$>7X0O)KE M=&CE:61Q*Z2&13(Q:0AXQE\--;E+:TM=+?A8^ /C-^UA\; MM:^%.LVG_"G]7\#P_9O)U+7KJ&X*QQMA&,0>) F7+7DT%MN MV-*P ) ).T84#:, 8X%%M)+O;\'MZ!LXOM?\5OZGPG^R_K7BOX9^+K6>]_9^ M\9:MXLUN[2'4?&.N27 :)9' =QOM,1H 2QR^3CEL8Q^BE%%:.5TE;8A1LV^Y M\(?M-77CC2_VP?#OC#3?AEXC\;:+X8LHEMX]/LI_(FE*R-D3)%( 5:1>QY3' M%+XN\/?&W]M75M)T?Q#X0F^%_P /+2X6YNDOF;[1*PXZ.%9VP2%&Q5!.23Q7 MW=16<$HI1>J3;^;=RY-R;DM&TE\DK'PQ\)K_[,GB [X[2SLO-#"02;&1_W:I\N MY3E0/:L+PW9_&/X$?M!_%*;0?A?>>+KGQ5>.]AK,F]+.%6E=T=I0NTC#C1 Z@E&:3@@8^7VKW#]HZXU>#X%^-ET'3[S5=7GTV6U MMK6P@::9VE'EY5%!)P&)X':O1Z*51>TAR;*UOPL.#Y)\^[O<^;/V2/V<_#OA M?X)^%IO%'@;2O^$M=9+JXFU72HC>Q,TC%%9G3>I5=O!Z5A?ML^!_$/Q1\5_" M7PGI6@ZCJ&A2:O\ :=4N[6T>2WMHPT: R.!M3Y&E/)%?6%%:RES5%/HFG;TV M,XQY8./5IJ_J?+/[?GPF\3_$KX8^'U\*Z3)K8T?41<-QTKSC]FOP2M]\4-$DM/V9AX!TZU+2WNM>(KB[NI(BJ$H;=;D+MHVOC.&[,% MCXPT^66*$P+)^[\P[#$_R8^9I.,Y&.E:_P"TQ\!O'XD^$FLZKX7O/BK9Z'HL M6GZUIUE/,99IE)+Y:+][AMP'F*#RG/7G]!**F,>6*2Z._P [-;?/7S*D^:3; MZJWXI[_+0^.OV7/#LVBZAXC\06GP 3X:V5CI_VDE]VWYBA[G+; M[+;^_<_-'4M0^.NK?LNP?#73/A-J^AZ3ID2V]_>&UF:[U!3-N"10; P!)R[# M<,*>0#@^I?M+_!OQA!^QW\.?"'AK0;W5Y],>TDU2PL86DGR(7+'RU!8_O7.< M D<5]N44Y/F4K[MI_-!'W&K;)-?>?#G[1!^(?QH_9T\!:';_ UUCP]=ZAK, M<4^E0PRW+6=K"A2-YR(U\L$L&^8# 6K?[2GPY\$/!UUXXT7P M[ID6GC2[%6>2-H_,4#:BLP!60$,%(!7GMG[8HH;?-S1T?-S?.UO\_FQ)+EY' MJK(;?XI?&?XB>)O#NIZ3=:G?O'I\>H67^"/PL\8>)OVE M= \9^'?A7JGP8T"S8OK$-U<2B&Y'.Y(XY(XSA^%V*I4=>,5^AE%.-HS4ET22 M^2M\UY=Q2]Z,HOJVW\W?^F%%%%(84444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445Y MMK&FWOB?XH7VF?V_JVE6=OID,ZQZ;<",%VD<$G*GL!7-7K.BHVC=MV_K[CMP MN'6(_5+IZGI-%<-_P *OE_Z'3Q5_P"!Z?\ QNC_ (5?+_T.GBK_ M ,#T_P#C=9>VK_\ /K\4;_5\+_S_ /\ R61W-%<-_P *OE_Z'3Q5_P"!Z?\ MQNC_ (5?+_T.GBK_ ,#T_P#C='MJ_P#SZ_%!]7PO_/\ _P#)9'*O\ P/3_ .-T>VK_ //K\4'U?"_\_P#_ M ,ED=S17#?\ "KY?^AT\5?\ @>G_ ,;H_P"%7R_]#IXJ_P# ]/\ XW1[:O\ M\^OQ0?5\+_S_ /\ R61W-%<-_P *OE_Z'3Q5_P"!Z?\ QNC_ (5?+_T.GBK_ M ,#T_P#C='MJ_P#SZ_%!]7PO_/\ _P#)9'*O\ P/3_ .-T>VK_ //K\4'U?"_\_P#_ ,ED=S17#?\ "KY? M^AT\5?\ @>G_ ,;H_P"%7R_]#IXJ_P# ]/\ XW1[:O\ \^OQ0?5\+_S_ /\ MR61W-%<-_P *OE_Z'3Q5_P"!Z?\ QNC_ (5?+_T.GBK_ ,#T_P#C='MJ_P#S MZ_%!]7PO_/\ _P#)9'*O\ MP/3_ .-T>VK_ //K\4'U?"_\_P#_ ,ED=S17#?\ "KY?^AT\5?\ @>G_ ,;H M_P"%7R_]#IXJ_P# ]/\ XW1[:O\ \^OQ0?5\+_S_ /\ R61W-%<-_P *OE_Z M'3Q5_P"!Z?\ QNC_ (5?+_T.GBK_ ,#T_P#C='MJ_P#SZ_%!]7PO_/\ _P#) M9'*O\ P/3_ .-T>VK_ //K M\4'U?"_\_P#_ ,ED=S17#?\ "KY?^AT\5?\ @>G_ ,;H_P"%7R_]#IXJ_P# M]/\ XW1[:O\ \^OQ0?5\+_S_ /\ R61W-%<-_P *OE_Z'3Q5_P"!Z?\ QNC_ M (5?+_T.GBK_ ,#T_P#C='MJ_P#SZ_%!]7PO_/\ _P#)9'*O\ P/3_ .-T>VK_ //K\4'U?"_\_P#_ ,ED M=S17#?\ "KY?^AT\5?\ @>G_ ,;H_P"%7R_]#IXJ_P# ]/\ XW1[:O\ \^OQ M0?5\+_S_ /\ R61W-%<-_P *OE_Z'3Q5_P"!Z?\ QNC_ (5?+_T.GBK_ ,#T M_P#C='MJ_P#SZ_%!]7PO_/\ _P#)9'S:EX?NY-MGK5R09('/_ "RN" !@]GZ=C[)XJ5-IUH]TT MO7MZC6"A536'JJ _^AOT;_P-3_&NNN+>&]MI8)XDGMYD*21R*&5U(P00>"".U>+S M>';/X'ZH\LVF0:C\/KR7+.]NLLNC2,>I)!+0$GZJ3^>E:I4IM.-N7KY?\#\C MYG%5:U%J4;FW=?\ "YO ?_0WZ-_X&I_C1_PN;P'_ -#?HW_@ M:G^-;=OX>T&Z@CG@TS3IH9%#I)';QLK*1D$$#D$5)_PBVB_] BP_\!D_PJOW M_=?<_P#,NV*_FC]S_P S _X7-X#_ .AOT;_P-3_&C_A _P#H;]&_\#4_QH_X7-X#_P"AOT;_ ,#4 M_P :W_\ A%M%_P"@18?^ R?X4?\ "+:+_P! BP_\!D_PHM7[K[G_ )A;%_S1 M^Y_YF!_PN;P'_P!#?HW_ (&I_C1_PN;P'_T-^C?^!J?XUO\ _"+:+_T"+#_P M&3_"C_A%M%_Z!%A_X#)_A1:OW7W/_,+8O^:/W/\ S,#_ (7-X#_Z&_1O_ U/ M\:/^%S> _P#H;]&_\#4_QK?_ .$6T7_H$6'_ (#)_A1_PBVB_P#0(L/_ &3 M_"BU?NON?^86Q?\ -'[G_F8'_"YO ?\ T-^C?^!J?XT?\+F\!_\ 0WZ-_P"! MJ?XUO_\ "+:+_P! BP_\!D_PH_X1;1?^@18?^ R?X46K]U]S_P PMB_YH_<_ M\S _X7-X#_Z&_1O_ -3_&C_ (7-X#_Z&_1O_ U/\:W_ /A%M%_Z!%A_X#)_ MA1_PBVB_] BP_P# 9/\ "BU?NON?^86Q?\T?N?\ F8'_ N;P'_T-^C?^!J? MXT?\+F\!_P#0WZ-_X&I_C6__ ,(MHO\ T"+#_P !D_PH_P"$6T7_ *!%A_X# M)_A1:OW7W/\ S"V+_FC]S_S,#_A _P#H;]&_\#4_ MQH_X7-X#_P"AOT;_ ,#4_P :W_\ A%M%_P"@18?^ R?X4?\ "+:+_P! BP_\ M!D_PHM7[K[G_ )A;%_S1^Y_YF!_PN;P'_P!#?HW_ (&I_C1_PN;P'_T-^C?^ M!J?XUO\ _"+:+_T"+#_P&3_"C_A%M%_Z!%A_X#)_A1:OW7W/_,+8O^:/W/\ MS,#_ (7-X#_Z&_1O_ U/\:/^%S> _P#H;]&_\#4_QK?_ .$6T7_H$6'_ (#) M_A1_PBVB_P#0(L/_ &3_"BU?NON?^86Q?\ -'[G_F8'_"YO ?\ T-^C?^!J M?XT?\+F\!_\ 0WZ-_P"!J?XUO_\ "+:+_P! BP_\!D_PH_X1;1?^@18?^ R? MX46K]U]S_P PMB_YH_<_\S _X7-X#_Z&_1O_ -3_&C_ (7-X#_Z&_1O_ U/ M\:W_ /A%M%_Z!%A_X#)_A1_PBVB_] BP_P# 9/\ "BU?NON?^86Q?\T?N?\ MF8'_ N;P'_T-^C?^!J?XT?\+F\!_P#0WZ-_X&I_C6__ ,(MHO\ T"+#_P ! MD_PH_P"$6T7_ *!%A_X#)_A1:OW7W/\ S"V+_FC]S_S,#_A _P#H;]&_\#4_QH_X7-X#_P"AOT;_ ,#4_P :W_\ A%M%_P"@18?^ M R?X4?\ "+:+_P! BP_\!D_PHM7[K[G_ )A;%_S1^Y_YF!_PN;P'_P!#?HW_ M (&I_C6QX=\;>'_%S3+HNLV.JM" 95M)UD* ]"0#QT-3_P#"+:+_ - BP_\ M 9/\*Y7QI\,4OGMM9\+FWT'Q3IX)M;F*,+%.IY,$ZK]Z-OS4\CW3=>.NC]/^ M')E+%07,[22Z*Z?RN]SOJXSQ9\9O G@/5!IOB/Q=H^AZ@8Q*+;4+Q(7*'.& M8C(.#S[&IOA_\0(?&=O-L -&>&'N 1W865&K).HWROJO MZ^_J:2JRJ4?:8>S?G^7D_7KN,_X::^$O_11_#/\ X,XO_BJ/^&FOA+_T4?PS M_P"#.+_XJN:^$'B+0_$VH7O@[QCX0T70?B+I"!KRP6RC\F]ASA;NU8K\\3>G M5#\K>_JG_" ^&/\ H7-)_P# &+_XFNVI##TIK'FC*/W/_,Y M#_AIKX2_]%'\,_\ @SB_^*H_X::^$O\ T4?PS_X,XO\ XJNO_P"$!\,?]"YI M/_@#%_\ $T?\(#X8_P"ATOO7^1K;$]X_<_\ ,Y#_ (:: M^$O_ $4?PS_X,XO_ (JC_AIKX2_]%'\,_P#@SB_^*KK_ /A ?#'_ $+FD_\ M@#%_\31_P@/AC_H7-)_\ 8O_ (FB^%[2^]?Y!;$]X_<_\SD/^&FOA+_T4?PS M_P"#.+_XJC_AIKX2_P#11_#/_@SB_P#BJZ__ (0'PQ_T+FD_^ ,7_P 31_P@ M/AC_ *%S2?\ P!B_^)HOA>TOO7^06Q/>/W/_ #.0_P"&FOA+_P!%'\,_^#.+ M_P"*H_X::^$O_11_#/\ X,XO_BJZ_P#X0'PQ_P!"YI/_ ( Q?_$T?\(#X8_Z M%S2?_ &+_P")HOA>TOO7^06Q/>/W/_,Y#_AIKX2_]%'\,_\ @SB_^*H_X::^ M$O\ T4?PS_X,XO\ XJNO_P"$!\,?]"YI/_@#%_\ $T?\(#X8_P"ATOO7^06Q/>/W/_ #.0_P"& MFOA+_P!%'\,_^#.+_P"*H_X::^$O_11_#/\ X,XO_BJZ_P#X0'PQ_P!"YI/_ M ( Q?_$T?\(#X8_Z%S2?_ &+_P")HOA>TOO7^06Q/>/W/_,Y#_AIKX2_]%'\ M,_\ @SB_^*H_X::^$O\ T4?PS_X,XO\ XJNO_P"$!\,?]"YI/_@#%_\ $T?\ M(#X8_P"ATOO7^0 M6Q/>/W/_ #.0_P"&FOA+_P!%'\,_^#.+_P"*H_X::^$O_11_#/\ X,XO_BJZ M_P#X0'PQ_P!"YI/_ ( Q?_$T?\(#X8_Z%S2?_ &+_P")HOA>TOO7^06Q/>/W M/_,Y#_AIKX2_]%'\,_\ @SB_^*H_X::^$O\ T4?PS_X,XO\ XJNO_P"$!\,? M]"YI/_@#%_\ $T?\(#X8_P"ATOO7^06Q/>/W/_ #.0_P"&FOA+_P!%'\,_^#.+_P"*K;\)?&7P M)X]U1M-\.>+]%UO4%C,IM;&]CEDV @%MH.<#(_.M3_A ?#'_ $+FD_\ @#%_ M\37'_$KX!Z!XXTF!M*BA\)^)M.D^U:3KVE6Z13V#9($UW6['2&G!:(7DZQ[P.N,]<9 M'YUPWPA^+U[X@U2[\$^-K2+0_B+I48>XM8R?L^HP9PMY:L?O1MW'5#D&NQ^( M/P^TCXE>'9=(U>$LF?,@N(^);:4?=DC;LP_7D'@U,:4*590Q-U'NNW==R:U6 MK4P\IX.SGT4KVOV?5&;_ ,+Q^'W_ $.>B?\ @='_ (T?\+Q^'W_0YZ)_X'1_ MXURW@6^MM*UQ?!7C72-,3Q"JEK#4ULXT@U>%?XTXPLH'WX_Q'%>E_P#"):'_ M - 73_\ P%C_ ,*[:]+"4)9A<1C\5#GA.":T:<973Z MIKFW_/=733.=_P"%X_#[_H<]$_\ Z/_ !H_X7C\/O\ H<]$_P# Z/\ QKHO M^$2T/_H"Z?\ ^ L?^%'_ B6A_\ 0%T__P !8_\ "N?FP7\LOO7_ ,B=?+F7 M\\/_ &7_P D<[_PO'X??]#GHG_@='_C1_PO'X??]#GHG_@='_C71?\ "):' M_P! 73__ %C_P */^$2T/\ Z NG_P#@+'_A1S8+^67WK_Y$.7,OYX?^ R_^ M2.=_X7C\/O\ H<]$_P# Z/\ QH_X7C\/O^AST3_P.C_QKHO^$2T/_H"Z?_X" MQ_X4?\(EH?\ T!=/_P# 6/\ PHYL%_++[U_\B'+F7\\/_ 9?_)'._P#"\?A] M_P!#GHG_ ('1_P"-'_"\?A]_T.>B?^!T?^-=%_PB6A_] 73_ /P%C_PH_P"$ M2T/_ * NG_\ @+'_ (4'_@,O_DCG?\ A>/P^_Z'/1/_ M .C_P :/^%X_#[_ *'/1/\ P.C_ ,:Z+_A$M#_Z NG_ /@+'_A1_P (EH?_ M $!=/_\ 6/_ HYL%_++[U_\B'+F7\\/_ 9?_)'._\ "\?A]_T.>B?^!T?^ M-'_"\?A]_P!#GHG_ ('1_P"-=%_PB6A_] 73_P#P%C_PH_X1+0_^@+I__@+' M_A1S8+^67WK_ .1#ES+^>'_@,O\ Y(YW_A>/P^_Z'/1/_ Z/_&C_ (7C\/O^ MAST3_P #H_\ &NB_X1+0_P#H"Z?_ . L?^%'_"):'_T!=/\ _ 6/_"CFP7\L MOO7_ ,B'+F7\\/\ P&7_ ,D<[_PO'X??]#GHG_@='_C1_P +Q^'W_0YZ)_X' M1_XUT7_"):'_ - 73_\ P%C_ ,*/^$2T/_H"Z?\ ^ L?^%'-@OY9?>O_ )$. M7,OYX?\ @,O_ )(YW_A>/P^_Z'/1/_ Z/_&C_A>/P^_Z'/1/_ Z/_&NB_P"$ M2T/_ * NG_\ @+'_ (4?\(EH?_0%T_\ \!8_\*.;!?RR^]?_ "(B?^!T?^-'_"\?A]_T.>B?^!T?^-=%_P (EH?_ $!= M/_\ 6/_ H_X1+0_P#H"Z?_ . L?^%'-@OY9?>O_D0Y/P^_P"AST3_ ,#H_P#&C_A>/P^_Z'/1/_ Z/_&NB_X1+0_^@+I__@+'_A1_ MPB6A_P#0%T__ ,!8_P#"CFP7\LOO7_R( MB?\ @='_ (T?\+Q^'W_0YZ)_X'1_XUT7_"):'_T!=/\ _ 6/_"C_ (1+0_\ MH"Z?_P" L?\ A1S8+^67WK_Y$.7,OYX?^ R_^2.=_P"%X_#[_H<]$_\ Z/_ M !H_X7C\/O\ H<]$_P# Z/\ QKHO^$2T/_H"Z?\ ^ L?^%'_ B6A_\ 0%T_ M_P !8_\ "CFP7\LOO7_R(B?\ @='_ (UT7_"):'_T!=/_ / 6/_"C_A$M#_Z NG_^ L?^%'-@ MOY9?>O\ Y$.7,OYX?^ R_P#DCG?^%X_#[_H<]$_\#H_\:/\ A>/P^_Z'/1/_ M .C_P :Z+_A$M#_ .@+I_\ X"Q_X4?\(EH?_0%T_P#\!8_\*.;!?RR^]?\ MR(B?^!T?^-'_ O'X??]#GHG_@='_C71 M?\(EH?\ T!=/_P# 6/\ PH_X1+0_^@+I_P#X"Q_X4'_@,O_DCG?^%X_#[_ M *'/1/\ P.C_ ,:/^%X_#[_H<]$_\#H_\:Z+_A$M#_Z NG_^ L?^%'_"):'_ M - 73_\ P%C_ ,*.;!?RR^]?_(ARYE_/#_P&7_R1SO\ PO'X??\ 0YZ)_P"! MT?\ C1_PO'X??]#GHG_@='_C71?\(EH?_0%T_P#\!8_\*/\ A$M#_P"@+I__ M ("Q_P"%'-@OY9?>O_D0Y/P^_P"AST3_ ,#H_P#&NB_X1+0_^@+I_P#X"Q_X4?\ "):'_P! 73__ %C M_P *.;!?RR^]?_(ARYE_/#_P&7_R1:TC6+'7].@O]-O(+^QF&Z*XMY Z.,XX M(X/(/Y5TDO/"ER_FZSX>MQS ?XKJV7L0/O(."!Q[> MGZ#KVG^)]'M-5TJ[CO=/ND$D,\1RK#^A[$'D$$&L\1AU"*JTG>#Z]4^S\_SW M1KA<7*I)T*ZY:L=UT:_FCW7XIZ/SOT445Q'I!1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %<-I__)9M8_[ UM_Z-DKN:X;3_P#DLVL?]@:V_P#1 MLE<.*^*E_B_1GJ8+X*_^#_VZ)W-%%%=QY84444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M5M2TVUUBPGLKV!+FTG0I)%(,JP-6:*32DK/8J,G%J479H\XTW4KKX5W\&D:O M.]UX7G<1Z?JDIRUJQZ03'^[_ '7_ /MZ'/!%=V\D,T:30R*4>.10RLI&""# MU!%1:EIMKK%A/97L"7-I.A22*095@:X'3=2NOA9?P:1J\[W7A>=Q'I^J2G+6 MC'I!,?[O]U_P/MYJ;P;Y9:TWL_Y?)^79]-GH>Q*,XBNH(YX)%FAD4.DD;!E M92,@@CJ"*)X(KNWDAFC2:&12CQR*&5E(P00>H(KR?_2?@-??\M;SX=7,GN\F MBNQ_,P$G_@.?SW_W?_!^7_ _+TV^3UP3_P"G?_I/_P!K_P"D^FWKE%1V]Q%= M01SP2+-#(H=)(V#*RD9!!'4$5)78>D%%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110!Q'Q ^'\VO7%MKV@W*Z5XMT]2+6\(^2=.I@G ^]&WYJ> M1[V?A_\ $"'QG;W-M+=/4BUO"/DG3J8)P/O1M^:GD>_-*$H2]I3^:[_ /!_,X*E.5*3 MK45>^Z[^:\_SV?1JI\7_ (06GQ0T^RN;:]DT'Q9I#FXT7Q!:@>=938Z'^_&W M1XSPP]\&LSX0?%^[\3:A>^#O&-E'H/Q%TA UY8*3Y-[#G"W=JQ^_$WIU0_*W MOU'P_P#B!%XSM[FVN;9M*\0Z>PBU'2IC\\#_ -X?WD;JK#@BLKXO_""T^*&G MV5S;7LF@^+-(&'O@UZ="O3K4U3J/W>C_E_P"! MW73=:[KX_P#:,/K?==_\I+_@/R]"HKRKX0?%^[\3:A>^#O&-E'H/Q%TA UY8 M*3Y-[#G"W=JQ^_$WIU0_*WOZK652G*E+ED=E.I&K'FB%%%%9&@4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% 'G_Q>^$-E\5-+M)([N70_%&E M2&YT;Q!: ?:+&?'4?WHVZ/&>&'O@C(^$/Q>O?$&J7?@GQM:1:'\1=*C#W%K& M3]GU&#.%O+5C]Z-NXZH<@UZO7G_Q>^$-E\5-+M)([N70_$^E2&YT;Q!: ?:+ M"?'4?WHVZ/&>&'O@CLIU(RC[&MMT?;_@=U\UY\E2G*,O:TM^J[_\'L_D_+>\ M=>!=,^(.AMINI*Z%6$UM=P-LGM9E^[+&W56!_P #Q7+>!?'6IZ5KB^"O&K(G MB%5+6&IJNR#5X5_C3LLH'WX_Q'%4_A#\7KW7]4N_!/C:TBT/XBZ5&'N+6,G[ M/J,&<+>6I/WHV[CJAR#7:^.O NF?$'0VTW4E="K":VNX&V3VLR_=EC;JK _X M'BNB,O9?[-B?AW36MK]5W3ZKKZV9P5:3J/ZY@]*BT:>BDE]F79KH]T^Z;3Z* MBO-/ OCK4]*UQ?!7C5D3Q"JEK#4U79!J\*_QIV64#[\?XCBO2ZXZ]"5"7++U M3Z-=U_7D]3OPN*ABH<\-&M&GNGU37?\ /=733"BBBNO45U8?$.@WI>+W71K_ #[/H<.*PL<5%-/EG'6,ENG^ MJ?5;-%#0=>T_Q/H]IJNE7<=[I]T@DAGB.58?T/8@\@@@U?KR'7M!U#X-:Q=^ M)_#%I)>^%KIS-K7A^W&6A/\ %=6R]B.K(."!^7IV@Z]I_BC1[35=*NX[W3[I M!)#/$Z,L+BI5).A77+5CNNC7\T> MZ?WIZ/ST****XCTPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *X;3_\ MDLVL?]@:V_\ 1LE=S7#:?_R6;6/^P-;?^C9*X<5\5+_%^C/4P7P5_P#!_P"W M1.YHHHKN/+"BBB@ HHHH *XCXQ?&#P]\#O!-QXG\2RS+91NL,<-L@>:>5L[4 M0$@9P">2 #S7;UYC^T1\"=-_:%^'M1/FM[NY<>6_O%']G[]IKPE^T9I^HS>'DO+*]T]E%U8:@BK*BMG:X* MLP93@C.<@CD#C/KE>!?LK_LFV'[--KK$W]M/K^LZIL2:Z^S^1''&A)5%3TMM1O"[#;+(I'I@#(Y QNY]S^%/[.?@[X+:Y?ZEX/74=/M[VW$#Z; M)J$D]H,,&#JLA9@W&,[NA/%:OQ&^&O@/XX:?=>'O$UC8:Z]BPWQK*!\\2>!K[1WU.&VU*422Z1MW$+N_ MA7Y.@P"'4XSR53]WW-G[VO?=Z_+3MHM@J:^]NM-.VRT^>O?7J:QXZL]8GMX=!N-2FMA86R$!/)B1UR =P)Y VC(R M)=1\*ZD;6'6$^9KZ"WDCD9B?XB%#'=U(QG)Y.-/C#K6M>*O$FN0+?"V-\\-M8QR#-$DALK/59C-)I]TO148 M]LE!QC(?D$KD_0'[/OC33?'WP9\(:MIEQ'/$VFP0RK&P)BF2-5DC8=B&!&*\ M/^/%]!\1OVO/@UX3TB1;N\\-SS:SJAA.X6L?R,JN1]TGRQP?[Z^HKKDE#$QI MQTC>UO*S_):W.6+U[^?_#Z6/K*OG7Q-^Q1X7^(&H:QJOC7Q)XB\1ZO M>SRRV]R]\T,>GH6)CC@B&5 08'.0<9P,XKZ*KYU^/7Q:UCQ9KTOP?^&#"Z\8 MW\>W5M64_N-#M6X=W8=)"#@*.1D=R*YI*[M%7D]OZZ>O1'1';5V77^NOIU.- M_9 ^*VM:/^S[\0K_ %[49O$%CX,O+R*QOKARSSPPQ;PFXY)&>G)P& Z 56^" MO[-.B?M!_#6T^(7Q/NM4U_Q7XB\R\AN%U":%=-C+L(U@1&"@ '!!'.,5ZIK MWP3T[X;_ +*/BCP)X;B>41Z%>+YA'[RZG:)BSMC^)F[=A@=JF_8TUZUU[]F? MP-+;2J_V6R-I, ?N21NRL#Z'@'Z$5J[2E-MW:45?[[ORNTC/6,8V5DW)V^ZR M^2;.%_9?UCQ5XL\!?$WX9:EXGO(]>\*ZC/HUIXB8>;F M!GBN,_:"_9)\*_"SX1:WX[T;Q%XCM_&NBQ+=IK]UJKO/<2;U!#],%B>-N#G' M7OV7['=U%JOCCX\^+XI%&B:CXE*6]V2!&ZP^:6<'IC$BG-4?$UW=_ML>,X_# MVCF6V^#6@W@?5=77*_VWK?C_=K-\U3EL[2<8MOMHKO\?F]#3W8 M.5_A4I:=]7I_6RU/4/#-CXA^.7[-/AA;WQ%?^&-9UK3+2:]U330$N2IVM)L/ M&PR*#\PZ;NAZ5\X?M0?L_P"A?LQ^"],^(GP]UK6M&\56FI00-+-J#S&_WYR' M!ZGYN,=VK27O5KT]-;OR M5_UV2ZOYFCW,UYI-E<7,?DW$L"221_W6*@D?@:N M4442=VVD**:23=PHHHJ2@HHHH **** "BBB@ JMJ6FVNL6$]E>P)2&:-)H9%*/'(H964C!!!Z@BHM2TVUUBQGLKV!+FTG4I) M%(,JP/:N!TW4KKX67\&D:O.]UX7G<1Z?JDIRUHQZ03'^[_=?\#[>:F\&^66M M-[/^7R?EV?39Z'L2C',HN45^^ZK^?S7][NNNZUNC*_TGX#7W_+6\^'5S)[O) MHKL?S,!)_P" Y_/UBWN(KJ".>"19H9%#I)&P964C(((Z@BB>"*[MY(9HTFAD M4H\XY=C]4**JZ7'--*T3PSHMEK:V]F-4U MYKF.1VMK5IEB3:4=0K$D\L&'S+Q7TOHVK6NO:18ZG92B>SO($N(9%Z,CJ&4_ MD17Q-\(_%GPZ^*]S\:/%/C;QEX=TB;QE-+HUC:ZIJMO!/!I\:;8W".X(R=K= M.L>:]1_8)^(/_"4_!E_#ES>0WNI>$KR32GE@E$B20@DPNK D%2N5!'!"55-- MPM+>RE\GT^5X_>PJ:3NMKN/W=?FU+\#=_:P^/^M? _P[H<7A33+76_%>LW3Q MVMC=QO(GDQH7F?:C*QP-HZ]_:N^^"/Q,A^,'PK\.^+85CB?4;8-<0QD[8IU) M65!GG =6QGMBOG>W^)'@[Q9^V;XCUGQ1XIT/1]'\#Z=_8VFQ:MJ$-N)KJ7/V MAT$C#=M&]"1_LU-^Q7XLTCPW\1/B;\+M)UBQUC1;._;6=#N;"Z2XA:VEQO17 M0D'9F,$ ]2U*C[T==Y+F7HG:WS7O!5]UZ?9LG\];_)^Z=5\0OC-\5+K]HFY^ M&7P\M/!Z_9M&35GN?$R7?S98*P#0M_M+@;?7FH-0_:*^(OP7US2X?C+X3T># MPWJ,ZVJ>*/"L\LEK;2MT$LSN/V8?'?VT*42UC>,MVE$R;,>^['YUGS>SI1J/7>_RDU^2T-%'VE5T]MOQB MG^;/;8Y%FC61&#HP#*RG((/0BO(?BIXY^*MOXLC\/?#CP18:@JVJW-QX@\07 M#16*,S,!$JH0SM\N3@\9&1SFNC^ 4UUEC=MH5D9"_4GR4Y/O77:[ MKNG^&=&O=6U6[BL--LXFFN+F=MJ1HHR236U:*IS:;T39C2DYQ3MJTCPCX'?M M%>*?$GQ2UKX8_$CPW9^'_&6GVWVV*;2Y&>UNH?EY4,6(X8$?,<\@X(Q4GB[X MZ>./%/Q4UCP!\)="T74+W08T;6-;\1S2K96TCC*PA8OG9L=QW!&.,US'[-^C MW_Q@^-WBSXZWMI+I^A7EO_9'AR"==LDULI4-.1V!V<>[-Z+?\PQD<$GOT((K+\2_$ MC]H+6-1UB?P7\.="L-$L+B6&#_A)KIQ=ZBL;%=\<:.@0-CY=YP00NZ@WGWK_N-.T].9;VY M8?)&BCD\]3V&:SE+]W&?77YM2:7STV[LT4??<%Y?DF_S^XP?V(AL\3 M>(KV36-0A_YX/(!MC/N ,GT+$=JM?M4?%Y/A]X"ET#2HVU/QMXH1],T;2K<; MI9'D&PRD=E0-G)XS@>N*K*RRVDC;C#*C%73=@9&1P<#((X'2N]KS/]F_X3O\%/@WX> M\*3RK-?6\;37DB'*F>1B[@>H!.T'N%KTRM:G*IM1V,J=W%.04445F:!1110 M4444 %%%% !1110!Q'Q ^'\VO7%MKV@W*Z5XMT]2+6\(^29.I@F ^]&WYJ>1 M[VOA_P#$"+QG;W-MG5#\K M>_4?#_X@1>,[>YMKFV;2O$.GL(M1TJ8_/ _]X'^)&ZJPX(K*^+_P@M/BAI]E M^#7IT*].M35.H_=Z/\ E_X' M==-UKO/Q_P"T8?6^Z[_Y-?\ ?EZ%17E7P@^+]WXFU"]\'>,;*/0?B+I"!KR MP4GR;V'.%N[5C]^)O3JA^5O?U6LJE.5*7+([*=2-6/-$****R- HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** //_ (O?"&R^*FEVDD=W+H?B M?2I#(+0#[ M183XZC^]&W1XSPP]\$=E.I&4?8UMNC[?\#NOFO/DJ4Y1E[6EOU7?_@]G\GY; MWCKP+IGQ!T-M-U)70JPFMKN!MD]K,OW98VZJP/\ @>*Y;P+XZU/2M<7P5XU9 M$\0JI:PU-5V0:O"O\:=EE ^_'^(XJG\(?B]>Z_JEWX)\;6D6A_$72HP]Q:QD M_9]1@S@7EJ3]Z-NXZH<@UVOCKP+IGQ!T-M-U)70JPFMKN!MD]K,OW98VZJP/ M^!XKHC+V7^S8GX=TUK:_5=T^JZ^MF<%6DZC^N8/2HM&GHI)?9EV:Z/=/NFT^ MBHKS3P+XZU/2M<7P5XU9$\0JI:PU-5V0:O"O\:=EE ^_'^(XKTNN.O0E0ERR M]4^C7=?UY/4[\+BH8J'/#1K1I[I]4UW_ #W5TTPHHHKG.L**** "BBB@#R7] MH#]I?PG^SGI>GW'B%+R]O-09EM;#3T5I7"XW.=S*%49')/?@'FN@^#7QD\._ M'3P3#XF\-23&S:1H)8+I DT$JX)1P"1G!!X)!!'->?\ [5'[*.G_ +2UCH[G M69- UC2C(L%UY'GQO&^"R.FY>Z@@@\<\'-=3^SK\!M-_9W^'J^&K"^EU2:6X M:[N[Z5!'YTK!5R$!.U0JJ ,GIUHI[2Y]^G]>GX^03WCR?/\ K^M#U&BBB@ K MXLU7X0^$OC7^W1X_TGQII1UK3[/0+2X@A-U-!Y;XA&08G4]&;C..:^TZ^*M2 M^#OA#XT?MT_$'2_&6D?VQ86N@VES#%]IF@VR;85W9B=2>&/!..:F*O5CI_-_ MZ2RF[4Y?+_TI'T7\+?V<_AY\%=2O=0\%^'O['O+R$03R?;;B?>@.X#$LC !?!W[3WBOQW-\6KV\UCQU9ZQ/;PZ#<:E-;"PMD(">3$CKD [@3R M!M&1DY/UA\+_ (+>"?@?INH6W@[2!HEG>.)[E6NYI@S*,!LRNV,#TQ7$_%;] MF/X=?'R.+Q- XTW7I$$MIXI\/W 21B!\CEE.V4# Y/.!@,*;=II&W.3R?I#X&[X6M]9SQ!=\6_ M!VY*XY'*GT-5\7/)ZOW;?X6KW_KL+X>6.WQ7]4]OS?\ PQ=^$O[/*_!;Q1<3 M>'O%FM3>$KBV:,^&M4F-S%!-N4K+"YY0 !@5P.?%OBK M0$\+_;UC\3:L]X1*TL8W 8"C R 0N>3S7-:;\$O!?QK_ &SOC%9^,]%_MFWL M;:QEMT^U3P;&:&,$YB=2>!WS2C[U2#W]V?X.WZ: _=A-;:Q_&S_74^EOA7^S M[X ^"=QJ$_@O0?[&EU!42Y;[9<3^8$)*C][(V,;CTQUH_:*D:+X"_$)T8HPT M*\PRG!'[EJT?A=\'?"'P7T>ZTKP;I']CV%U/]IEA^TS3[I-H7=F5V(X4< XX MK,_:-_Y('\0_^P#>?^B6K+$O]U+7H_R-U=7^SYXN\3_#WXU>)?@IXL MUNX\2P6=FNJ:!K%\VZYDM20#%(W\1&[J?[C=L >@_LE?\FU_#W_L%1_S->4> M ]2@^*G[>/B3Q'HDBWFA^%M 729KZ$[HI+AF^X&'!QF0?]LS794TQ,H+;WM/ M1.S^^R^=CDIZX=3>_NZ^K7Z7_,]&\7?M7Z#X9\3:KH=CX0\;^++K2I3#>S>' M=#:YA@< $@N64<9[<5TW@GX]^%_B+\-=3\:^'OMNHV.FI,;JP6 +>1R1)O:( MQL0-^,8&<'(YKS*U^.GQ2^+GB_Q5IOPJ\/>%[?1O#E^^F3ZMXLN9\7$Z<,$C M@^90/?.1CIT&'^PW_:<=: MYHWE!VWY;I_-=.VMSHE:,EVYK/[GU[Z?F?0GPK^)NC?&#P)IGBW03,-,OU8I M'=*JRQE6*LKA20""#T)KD-%_:>\$ZMX)\6^+Y);S3O#?AN_DTZXU"\A4)?A\9#"]J3JOA=.[+>8C54]=C/&>/[K M5[1X?_99L=6_9-TGX8ZA2VT5Y/>PJ&>*^+B8L02-P#G;C(R!U'6FWS1 MB>.O#]]XL\(ZIH^FZU<>';V\A,,>J M6B[IK?)&63D?-C(!SQG/:O"?"_Q:^)'PG^)7A+X>_%"WTG7K3Q"7MM)\4:,6 MC>22-0<7$)Z,?'3XP>++;]G7X<1:;=-I7C/QX^G:>;+=."C>(+M#@*@Z^2O M(S[GN1MN_MRJGA^/X0>(W01:7H?BVU>X91A8H^""?0 1FE'6*C/:4HZ=E=)^ MG-V[>HWI)N&\8RU\[77K:WWNW0Q/C)^R3X=^$_PIU7QKX%O]:TGQYX>M_P"T M3KAU*:26],>&D$JLQ4[E#'"@#/7(R*]0_P"$9E_:I^#O@+4[WQ)JGA[3+ZUC MO=5L]%E\EKYFC ,32=50/N.,'/M@&MW]J/Q%9:!^SKX]O;F>-89M(FMXF+## MO*OEH!ZY+BN<^%/BS2?@#^R9X.U3QA=?V;;V6D0N\;#]Z\D@+K$B]6<[L ?G M@ FE=IXEXV^&-G^RK^T)\)3\-]2U*TM/% M.HFQU/1)[MYXIHM\:LY#')XD)YS@J",\1ZS;^&K2% MEET#3;@V\5W*6R))74Y8 I&3CC/K@%OW:<54W3;[VOLO7RZ-Z;"7O3;AM9+UMN_^#U2OLSYK\$> M$3^SG^VAH'@/P7JFH2^$/$&DRWE[HUU<-,EJRK*0PST^:)<$\X8C)%?:M>!_ MLZ_!W7=/U[6OBC\0MDGQ!\2*%^RIS'I5IP4MD]\!=W^Z!UR3[Y5.ZC&,MUO] M[=ODM"='*4H[.WY;_,****DH**** "O(M>T'4/@WK%WXG\,6DE[X6NG,VM>' M[<9:$_Q75LO8CJR#@@?EZ[175A\0Z#>EXO==&O\ /L^APXK"QQ44T^6<=8R6 MZ?ZI]5LT9^@Z]I_BC1[35=*NX[W3[I!)#/$1:]H.H?!O M6+OQ/X8M)+WPM=.9M:\/VXRT)_BNK9>Q'5D'! _+TW0=>T_Q1H]IJNE7<=[I M]T@DAGB.58?T(Z$'D$$&KQ&'4$JM)W@]GU3[/S_/=&6%Q4JDG0KKEJQW71K^ M:/=/[T]'YZ%%%%<1Z84444 %%%% !1110 4444 %%%% !1110 5PVG_\EFUC M_L#6W_HV2NYKAM/_ .2S:Q_V!K;_ -&R5PXKXJ7^+]&>I@O@K_X/_;HG,_%#]E'P=\4/%C>*9+W7O#/B22-8 MIM4\.ZB;6:9% "ALJR\ 9 !X'I6I\(_V;_!?P;DU&ZTBWN]1UC4E\N]UC6+ M@W-W.G]UG( /< #.!G.!7J5%"]U60W[VK/F^\_8-\ -<72Z9K?B_P /:3=. M6FT32M9,=D^>H*,C-@^FZO:_ ?PX\.?#/PE;^&O#FEPZ?HT(8"W&7WEOO,Y; M)9CW)S72T4=.7H)ZNY\[:M^PSX!FUF\U#0-6\5>!Q>/OGM/#.K?9H')Z_(R- M@>P( [ 5Z'\'_P!G_P &? ^VNQX:T^07UZ<9K MT:BA>ZK('[VK"OF9/V"_"EIK&K:GIWCWX@Z-<:I:?"'X%VGP?DU1[?Q;XL\3B_6-63Q-J8NUBV[N8P$7 M:3NYZYP*XC4_V)_!,^IZG/H^O>+O"6G:I(TM[HOA_6#;6%P6^]NBVG@^@( Z M# KZ"HIO5W8EIL>?7'P+\*_\*?N_AKIMO/H7AJYM6M&&FR;9E5CEFWL&RS'J M6!SDYKR72OV#/#FA6$5CIOQ*^)>GV4((CMK77HXHTR)/%&H:2MP+AM2N;]);^0B0N%:1HRI4$XQM MZ >F:XNU_88T2QMHK:V^*/Q0M[>%0D<,7B%%1% P% $& .PKZ5HHZM]PZ)= MC*\*^'T\*>&],T:.]O=22QMTMUO-1F\VXF"C&Z1\#RO8$N;6="DD4@RK ]JLT4F ME)6>Q49.+4HNS1YQINI77PLOX-(U>=[KPO.XCT_5)3EK1CT@F/\ =_NO^!]O M0YX(KNWDAFC2:&12CQR*&5E(P00>H(J'4]/M-6T^XL[Z&.XLYD*2QRC*LOO7 M!?"74;N2XU?3;6:35/"MC)Y6G:I,?G;'WHE/_+1$.0']L<]O-@WA:D:&\9;= MU;I_A[/IL^A[%2*Q]&>)M:<;[R: M*['\S 2?^ Y_/UBWN(KJ".>"19H9%#I)&P964C(((Z@BJ7B#4M-TG0[V[UB6 M&'2XXF-PUQ@Q[,8((/7/3'?.*\\^!&FZG:V.K7,<4VG>#KJ?S=#TN]RUQ!$> M2V?X48\JAR0#U[G>/[FHJ<=4_P /^!_7I\E#_9JRH0UB^G\O_P!KV[/1:;>J M4445V'IA1110 4444 %%%% !1110 4444 %>;?M%Z?XLUKX,^)M*\$6']H^( MM2M_L4,?GQP[$D(61]TC*!A"W?.<5Z314RBIKE>Q49.+4ET/'?AW^RW\.?"O M@30=(U/P+X9U;4K.RBBNKZ\TBWFEGF"C>[.R$G+9ZGI7!:;\'/%7P8_:"\5> M(/AYX5M9/!>O: V;"RFM[2&WU&)#Y*+$67 9EZ@8'FL21BOI^BKDW*3ELW?; MS5O^"O-(B*48J.ZT_!I_H?.7[.O[*^A>'?AG;-\1_!V@ZYXUU"YGO]3GU2QM M[V5))')""0A@0!C[IQDMZU5\=?L^W?@OX[_#?QU\+?"FFV-E;22:?X@L=+2W ML8S:R<><4R@<@,QXRQVIQQ7TO13O[RDM+?=VMZ6T"WNN+UO_ ,/?UOJ?*GQ( M\(_%;PC^U1>?$;P5X"A\9Z;V35[>S"MO#,?WCALC8.V.>M0^)OAC\9 MOVG+K3M)^(VGZ5\// %OB[O;\JGUO M10_>DI/H[_U^?J$?=3BO0\+^&?C[XQW?B/2=(U_X+V7A+PP!Y4E];>(+6<6D M:H=@6&,Y(R%7 '&?:N3O?AS\3/@;\9?%WBWX=>&[+QSX:\7.MU?:)+J4=A/; M70SEUDD^4J2S'N?FQ@8!/U!15=5+KK\[D]''II^!\_?!_P"%'C+5OB_JOQ:^ M)-M9:5KDUB-+TK0;&<7"Z?;YRQ>4<,Y.?N\?,WJ /'YO"_QZF^.6H>/?$'PC M@\:2V;Q%9P6NFPACAXXRY)D(P=S8.>V<8^X:*6SBUI:]OG^N^OFQ[ MIIZWW^7Z;?<>5?#7QO\ %/Q%8:^_B[X;6_A&ZM;"\EPWR-Y9^0 MA>3_ 'O:OFSX<^'OV@?"/CS6?'7B'X-0^,?&>H$I'J5WXELHDL;?M#;QAV"+ MUYSDCZG/W111M+F7:W]>H?9Y7WO_ %_7Z'#?"7Q-XW\4:'=7'CKP;%X*U*.X M*0V<6I17HEBV@[]T? Y)&#SQ7+=/4BUO"/DF3J8)@/O1M^:GD>]GX?\ Q B\ M9V]S;7-LVE>(=/81:CI4Q^>!^S _Q(W56'!%==7CGQ+QX@^(VBV?@_Y/&^GL MKW>IQ_ZBSLR_'5_NZ[^GG_3[KS,1_LLO;4^KLX_ MS>G][\UOW70_%_X06GQ0T^RN;:]DT'Q9I#FXT7Q!:@>=938Z'^_&W1XSPP]\ M&LSX0?%^[\3:A>^#O&-E'H/Q%TA UY8*3Y-[#G"W=JQ^_$WIU0_*WOZH,X&> M37SI^U1)9>)-5\,^&O"T$US\85F6\T.[L)!')I,08"6YN9,$+;E1[N'_VA+#SVZ/^7_[7OVW7GIB/W'[^&_5?S?\ ![?<_+Z,HJII$=[#I-E' MJ4\-UJ*PHMS/;QF..24*-[*I)*J3D@$G [FK=>>SN"BBBD,**** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@#S_ .+WPALOBII=I)'=RZ'XGTJ0 MW.C>(+0#[183XZC^]&W1XSPP]\$9'PA^+U[K^J7?@GQM:1:'\1=*C#W%K&3] MGU&#.!>6I/WHV[CJAR#7J]?.W[5DVG^(;KPYX9\.V\UY\7C.+OP]/ITHBFTI M00)+J>3!V6^,JRL")/N@9Y'HX?\ ?VP\]NC_ )?_ +7O]_KP8C]Q^_AOU7\W M_![?=Z>S^.O NF?$'0VTW4E="K":VNX&V3VLR_=EC;JK _X'BN6\"^.M3TK7 M%\%>-61/$*J6L-35=D&KPK_&G990/OQ_B.*[W0X=0M]%L(M6N(;O5$@1;JXM MHC'')*%&]E0DE5)R0,G%>=_M 76B3^%X-'N[2;4_$5]+_P 22SL7V78NEY66 M-_\ EF$ZLYX SG.<5IA'[9_5)J\7M;[+[KR[IV5NS5SAS"/U9/,*3Y9Q6J>T METB[7U_E:NTW;5-I^I45A^";76['PGI=OXDNX;_7(X%6[N+=-J._L/7&,GC) M!.!G W*\V<>23BG>W5;,]FG-U(1FTU=7L]UY/S"BBBH- HHHH **** "BBB@ M KQ'QY^RAHGC?XCZAXWM_&7C3PGKE_;QVUP_AG54LU>- ?W1;'RKD;L9'2 MO;J*5M4QWTL>9?#'X&I\-=1OKJ3QYXW\8)=V_P!G:T\5:Q]N@C&02R+L7#<8 MSZ$UYY>?L&^ &N+I=,UOQ?X>TFZY)KR+Q/\ L1_#W6O$ M5UK>C77B#P-J%T2UPWA74?LB2DG).PJRK]% 'M7T#10_>?,]P7NKE6QY-\(? MV8_!7P8UJ[US2!J6I>(;N$P3ZOK%ZUQK3[ M+KN><_" MOX,_\*MO+^X_X3KQIXO^UQJGE>*M7^VI#M).Z,;%VDYY/? KK?&7A6S\<>$] M8\/:BTJ6.J6DMG.T#!9 CJ5)4D$ X/&0:V:*)>\N66P1]UW6Y\RV7[ _A&ST MZ+3&\=_$*YT>-?+&ER:X@MMG]W8L(P/88KW#X;_"_P ,?"3PW'H7A328=)TY M&WLL>6>5SP7=V)9VX')/8#I7544[O7S%9'A?B3]C_P (:YXNU;7]/UWQ7X4E MUB3S=3LO#NKM:6U\Y^\9$"DG.3G! Y/K77?![X"^%O@9_;L?A5+N"UU>XCN) M+:XF$B0E$V 1G:&QW.XL23UKT:BE'W59>@W[SNSX]^.'@;1_C+^VO\/M$AL_ M-F\.Z?\ VGKEQU0PK)O@A8>I?'X2^U?2?Q0^&&D_%KPR-%U>>_M(HYTNH;K3 M+IK>X@E7.UT<=",GJ".:Z^BDE:"AV;?S;O\ Y?=<;;,+7Q5>:WXF\::_9HT=E>^*M4-ZUHK#!\H;5 X)'(/6NZ^*/PYT[X MM> ]6\):M7*]A1]U\RW/ MF;3?V$/#^CV,-E8?$WXFV-G"NV*WMM?CCCC7T51 !]*]:C^"?A^Z^$X^'NN MRZAXLT0Q-%)/KER9[N7+EPS2@*=RD_*0!C KOZ*'[R:>S!:--=#Y]T?]B7P3 M97FF_P!JZ[XN\5:3ILBRV6@Z]K!N-/@9?N[8@J\#T)(['(KJOCM^S?X<_:"@ MT*+7=4UK2AHTKS6QT6YCA.Y@HRV^-^1M&",$9->L44/6U_7Y@M'='SG;_L4Z M7;7$4H^*OQ2)=4\0>)M&U32[;[ M-:R:'?1P;!N9MX+1,0_S'D$< 5[511O;R#OYG@GA7]D/3?"?B73-9C^)?Q(U M&2QN$N%M-0UY9+>8J<[)$$0W*>A&1D5[W113N[6%;6X4444AA1110 4444 % M>1:]H.H?!O6+OQ/X8M)+WPO=.9M:\/VXRT)_BNK9>Q'5D'! _+UVF331VT,D MTTBQ11J7>1R JJ!DDD] !75AZ\J,FK7B]&N__![/H<.+PL<3%._+*.L9+=/_ M "[K9HI:#KVG^*-'M-5TJ[CO=/ND$D,\1RK#^A'0@\@@@UH5XI\'X)M1^('B M'7/"B-I_PXNQA8)E.R]O0Q#W%LO'EQ] 3T8C@?W?:ZO&4(X>JX1?GYJ_1^:Z M_P!(SR_%2QF'56:L]5=;.WVH_P!U[K]5JRBBBN(](**** "BBB@ HHHH *** M* "BBB@ KAM/_P"2S:Q_V!K;_P!&R5W-<-I__)9M8_[ UM_Z-DKAQ7Q4O\7Z M,]3!?!7_ ,'_ +=$[FBBBNX\L**** "BBB@ HHKP7]M+XO\ B7X+?!>76_"J M*FIW%[%9?;6B$@M$<,3)M(()RH4;@1EJB4E!7?\ 5RHQ,+C^UUTL0RP:H8$C;YRP,3; %/W<@XSUSGBOL"MI1<;7ZF M<9*5_(****@HKZA?P:787-[=2K#:VT332R,:3\(U\+Z.V?$'C. M]AT"RC4_-B5L2GZ;,J?]\5YM#X1L_P!E?]J+X??V/P[DT]GHO6U_\EZL*GNQNM]WZ7M_F_D?8]>0^ /VI/!7Q M(^+&O?#W2&OAK6C^;OFGB1;>X,3A)!$PZC@$BM[X]_$B/X2_"'Q1XH+ M*L]G:,+4'^*X?Y(A_P!]LOX9KX]UGX87'[-/@'X(_%-8G75M+O0?$TF/GDBO M26??ZE Q3ZL*(:S][X=%\Y;?=U]4.2M#W?BU?RCJ_OZ'W#\0/&^G_#?P5K/B MC54GDT[2K9KF=+5 TK*O902 3]2/K7B=K^V]H$NDP:O61D2>8LK KCG(SQ77?M67$=W^S+X^GA=9(9-'=T=3D,IP01^%;'[.'/ M[/\ \.P>1_8%E_Z)6DKWGY6_'F_R$VK1MUO^'+_F=%\/OB-X<^*?AJ#7_"VJ MPZOI$-%1;7P_K&CQ:V;&(8CAN,Q@E5Z#)DDZ>H'85]6 M7EG;ZE9SVEW!'=6LZ-%+!,@=)$(P593P00<$&F_>@I1ZK[G=I_B@6DG&73\K M)_DSYQO/V^_AQ9R1W#:7XL;P_)+Y2^(AHS#3R6\::$OA'_ M (2DZK;#P[]D^W?VD7_<^1MW;\^F*\F_;&\4:+X,_9U\2:?=PPO)JMM_9.F: M>B#,L[_*@1!_<^]QTV_2O$?CMX=U?X9?L)^!?!FH.\%[>7=A87Z[N4#N\S1D M_P"R0J_\!I?$FH[WBE_V]W]-'\Q[-.6UFWZ+_/7[CU?_ (;H\"QQQ:A-H'C* MW\+2RB)/%4VANNF-DX#"3=NQG_9S[5ZMX]^,GA'X;^!X?%NM:LB:'<>6+6>V M4S&Z:1=T:Q!02Q8#([8YZ4>/?!NF7GP=U[PS]EB32_[%FLT@"C8B+"0N!VQ@ M8^E>6_L021>+/V8? \FJ6\-]+ILDZ6SW$8D,31S2*C(2/E(4[01SC(JM) _$WC+3_#-]IWB/PEJ.HL$L6\1Z M;]EBNF)PH1@[=3P"P SQ7?\ Q<^.'A;X*Z?8W'B*XN6N=0D:*QT^PMVGN;MQ M@E8T'IDS6D$M[:JZP7#Q*9(@V-X5B,J#@9QUP*7Q04EW:^2M^MU M\A_#.S[)_??_ (#^9X[\,/VN?!/Q/\9?\(DEKK?ACQ(REX=-\1V/V66< $G9 MAF&< G!() .!Q7ME?(WQ:BA^*O[;7PUTC0$6:Y\&1/J.N7T(X@0D,D+L.^0. M/^FOUKZYIQM*G&?>_P"#M?YBE>,W'T_%;!1112&%%%% !1110 4444 %%%% M!2,P4$DX Y)-#,%!). .237F]Y>7/Q:O9=.TZ62V\'P.8[W4(R5;4&!YAB/_ M #S[,XZ]!7-6K*DDDKR>R[_Y)=6=N&PSQ##X',=[J$9*MJ# \PQ'_GGV9QUZ"NUN[O2O!?A]YYW@TO2+"'EONQ MQ(.@ _IU)HN[O2O!?A]YYW@TO2+"'EONQQ(.@ _IU)KSS1M&OOC%JEMXA\0V MTEGX3MG$NDZ'.,-%(_"D^I:1IEV;*^U07823>K;9#'%L(8*0>K#=CM2NG) M0ZL=GRN71'V114%C>0ZE96]W;MYD%Q&LL;8ZJP!!_(U/5--.S)335T%%%%(9 MC:]XS\/^%;BQ@UK7=-T>>_D\JTCO[R.!KA\@;8PY&\\C@9ZBMFO@K]HCP;J' M[3OQ/^)MQI23B74=PFE ]3M1T^H6OJ[X _$Z+XJ?!?PUXK> M13-<60%YC^&>/Y)?_'E)^A%*+3IN;TZ_)WL_G:_S02]V:BO3YJUU^/X,[+Q% MXJT3PC9"\UW6+#1;0G;]HU&Z2"//IN<@4>'?%FA^,+,WF@ZSI^MV@.TW&G72 M7$8/IN0D5\A?L^_#O3/VL_$OBGXL?$2W.OV U*73M T:Z=C:VMO'@YV X8G< M!SQD,2"2,?0'A']FWP-\/?B GBWPIITGAN\:V>UN++3Y2EGCM^C_KJ=I8^/\ PQJ7B.X\/V?B/2;K7K;/ MGZ7!?1/=18Z[H@VY<9[BMZOS-UJQO/!_Q>^)WQ\\%^.HS>)'_RTL9S( MDR_^@C_@1K]!_%GQ(TCPK\,]0\;RSK+H]MIQU%)%/$J%-R!?=LJ![D5',O8J MJ^RO\TI?D_O3*Y7[7V:[NWR;7]>J+T?CSPU-XG?PW'XBTF3Q$B[FTA;Z(W:J M!N),.[>!CGITJQXB\5:)X0L?MNO:Q8:)9YV_:-1NDMX\^FYR!FO@CX"^$=0T M?]IOX3>)M=W'Q'XRT[5?$%\6SE?.28Q+[ 1[3CMN-=M\:+SPQH_[9UG<_&.T M2Y\#3Z*L.@2:E$9=.BN,KYAD4@KG._)8$#C=[^35[K\+"T]YK M5*UO-.VOXW]#Z\\->-?#WC2"2;P_KVF:[#'@/)IMY'<*N>F2C'%;$DBQ1L[L M$11EF8X 'J:X7X;_ R^'OA6YNO$7@;1M)T]=7A19+K1<"WGC4DJ55#Y?4GE M1S6G\2OASI7Q6\(W7AK7'NAI5T\;7$=G.86E5'#^66'.UL8(&"03R.M$KK;< M4==]A^C_ !0\&^(M6;2M*\6Z'J>J+G-E9ZE#+,,=?D5BWZ5T@KX?_;:^!_@#X4_#'0=;\%Z%;^&?%UOJ]M!IDVEEDFF8Y)!Y MRY&T'<>00.>>>Z_:MO=2\7:G\'?A;=W,MK;^+M05M<^SN4:6&%4:2+([$LQ^ MJBA>\DH[\RC]]G?Y)Z@_==Y;65<=\L[_281!*0)51@[+R_#9RV3D=>3GUS4?A1X2_ M:(T7P+XJ\7Z?)JR1::EY!IDDS"T+SQQN7>,8W,.@R<8)R#0O>3Y>CL_FKI_F M@V:OU7Y=/Q1Z#X9\<>'/&T,LWAWQ!I>O11'$DFF7L=RJ'T)1CBIO$7BO1/"- MD+S7=8T_1;0G:+C4;I+>//IN<@5\?:MX T/X5_MV?#S3_AU9KHHU#39I=;TZ MQ)$ AVR89DSA<[0<=,JIQD\_1?C/]G7P+\1O'">*?%6DGQ#>Q6BV<%K?R%[2 M!0S,66+IN8MR3GH,8H^*,9KK?\&U_7_ #X9.+Z6?WG;^'O%&C>+M/%]H6KV. MM6).T7.GW*3QY]-R$C-:E?&?P5\*Z?\ #S]NKQKX<\#1M9>$UT1)]2T^%RUO M!<'RRH ).""QP.VY@..*^S*>CC&:Z_YM?H+52<7T_P D_P!0HHHI#"BBB@ H MHHH **** "BBO//&_C?4;W63X/\ !Y27Q%(@:[OG&Z'2H3_RT?UD(^ZG?J>. MN=2HJ:NS&M6C1CS2^2ZM]D'C?QOJ-[K)\'^#RDOB*1 UW?.-T.E0G_EH_K(1 M]U._4\=>B\$>"-.\!Z,+&Q#RRR.9KJ\G.Z:ZF/WI)&[L3^72CP1X(T[P'HPL M;$/++(YFNKR<[IKJ8_>DD;NQ/Y=*XOXO_%^[\,ZA9>#O!UE'KWQ%U="UG8,3 MY-E#G#7=TP^Y$OIU<_*OL\/AYUIW?Q?@E_6[.1+V?^T8CXNB[>2[M]7U] ^+ M_P 7[OPSJ%EX.\'64>O?$75T+6=@Q/DV4.<-=W3#[D2^G5S\J^VG\(/A!:?" M_3[VYN;V37O%FKN+C6O$%T!YU[-CH/[D:]$C'"CWR:/A!\(+3X7Z?>W-S>R: M]XLU=Q<:UX@N@/.O9L=!_^37H5=]2I&$?8T=NK[_P# [+YORUIT MY2E[6KOT7;_@]W\EYE%%%<9V!1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%>6_&#XP7'A&\L?"7A*QC\0?$36$)L-,+'RK6/.&N[IA]R% M/S8C:O6/A+PE8Q^(/B)K"$V&F%CY5K' MG#7=TP^Y"GYL1M7N1>^#_P '[?X96=]?7U])X@\8ZPXGUKQ!,=8<3ZUX@N5'FWI_NHO5G/ %=J3F_JV&UON^_^45_P M7Y<$YQHQ>*Q3LELNW^(-08PZ9I%N?WMS)ZG M^ZB]6<\ 52^'7PZN-#O+GQ)XDN4U;QEJ"@7-TH_=6L?46\ /W8U_-CR:/AU\ M.KC0[RY\2>)+E-6\9:@H%S=*/W5K'U%O #]V-?S8\FN]HJU84(.A0=[_ !2[ M^2_N_GN^B6-"A4Q518K%*UOAC_+YOO-_=%:+JV4445YI[(4444 %%%% !17R M'^W_ /M">-_@O8>%K#P?/_9/]JF9[C51 DC#R]F(EW@J"=Q).,\#&.:[[]BC MXP^)OC5\&AK/BM5DU*UOI+(7RQ",7:*J$2;0 N?M7Z)X(^(^H>"(/!OC3Q9KEA;QW-PGAG2DO%CC< @G] MZ& ^9W5\N^ ?^4@'Q+_[%JT_]MZ2O*I&/K^";&](2EVM^+2_4[[X M>_M6>"?'WBI/"\L>L>$O$\@S%H_BBP:RN)?9II]O:Z/ DT[RLK%0%9U!^Z>^^TZ_C^66%C,B,%;J 0V<>JJ>U%=(F@_X2KP=X]\ M"64KB,:AXD\/O;VX)Z9968_I7J'COXLZ)X$^&-YX\<7&MZ!;6Z76_1PDSRQ, MR@.F752/F!SNZ UTNN:'8>)M'O-*U2TBOM.O(FAGMYE#)(C#!!%?*'['NB_\ M)-\(_BQ\+K^9KK2-*UF_T6U>0[MD$BLN!]&W-]6J)-\LU%:I77GJE;\45%+F MBY;-V?XO]&?5/A7Q+9>,O#.E:]IKL^GZE:QW<#. &V.H89&>#@\UPWPC_:'\ M*?&GQ!XKT?P]]L6Z\.7/V:Y-W&B)-\SJ)(BKMN3*'D@'IQS7B?[.7Q6F\&?L M=^*&U)]FK^ O[0TR5&/(DCRT*_FZJ/\ =K@?V<_",W[/OQD^$\MP6C@^(?A> M1+TR$\WVXW S[[6C7\36]HRK.,?A>WS3E'\(V^9E[T:5Y?$GK_VZTI?G?Y'U M[XZ^,FB?#_QIX.\+7UO?7>K>*;E[>RCLHT=8]@4M)*6=2J#<.0">#Q7<2RI# M&\DC!(T!9F8X ZDU\T:3%_PLK]NC5[\_O=.\ :%'9QGJJWESEB?KL9Q_P ! MKZ8DC66-D=0Z,,,K#((]#62NZ:EU=W\KV7Y7^9H]*CCT5OOM=_G;Y'SCK'[> MWPYTR2:>VTSQ3K&APR^5+X@T_2"VGHV:]R\-^.M!\7>$+7Q M3I6IP76@7%N;E+[=M01@'<6SC;C!R#@C!STKC/CYXF\-_"OX#^)IK^WM+728 M]-EL;;3TC5(Y'="D<*(!CDD< < $]J^9M2T+7?@[_P $UKJROA+9ZI?Q*TD+ M9#0Q7-TIV$=B8VY';<14N5H3MNK6]7T_4I1O*"[W^Y=?T/8;O]N7P+"MQ?6N M@>,=4\,V\IBE\46.B,^F(0<$F4L#@'_9KU;6?C%X/T'X;CQ[=ZW"/"C0)<)J M$89Q(KD!0J@;BQ) VXSG@TSX>^#],T_X.:!X;2UB.E_V+#:O!M&UU:$!\CON MR2?7)KQ#]@6UAUC]G^ZT?4X(=1M-'\17=M;QW48D5=C1RH0&!Y#N6!['FMI1 MY9SI7UCU[ZV?Z-&49NZ7]GM)R2 "K[R<'(^8J ,\D5Z[\3?BIX;^$/A9_$'B>_-EI_F+#'Y<;2R M32MG;&BJ"68X/Y$G KY^_;_N(/%GA#PK\-]-@74/%_B+5X6L;51EX8TW!YC_ M '5YQGTW>AKZ9M?#MI_9>DVM[;PW\FG"-H9;B,.4E1-HD7(^5L$\CGDU"]Z# M:TL[>JTO]VQ3]V:3UNK^G;[SQ;PC^VMX#\3>,M/\,WVG>(_"6HZBP2Q;Q'IO MV6*Z8G"A&#MU/ + #/%>_5\C?MJ1P_$SQ]\*_AKHJ+=>*9-775)I(QE[&T48 M=V/\(/+>_E_2OKBFK2AS>;7W6_6Z^0G>,[>2?WW_ . _F+1112&%%%% !111 M0 4444 %%%% !1110 444R::.VADFFD6**-2[R.0%50,DDGH * V"::.VADF MFD6**-2[R.0%50,DDGH *\=DDNOVA-0:*)IK+X:6LN))5RDFNR*?NKW%N".3 MU8C\B22Z_:$U!HHFFLOAI:RXDE7*2:[(I^ZO<6X(Y/5B/R]@M;6&QM8K>VB2 M"WA01QQ1J%5% P .@ [5Z^F7K_I[_Z1_P#;?^D_XMO US9_]0__ *<_^T_] M+_P_$6MK#8VL5O;1)!;PH(XXHU"JB@8 '0 =JEHHKR=]6>\DDK(****0PHH MHH **** "BBB@ HHHH **** "N&T_P#Y+-K'_8&MO_1LE=S7#:?_ ,EFUC_L M#6W_ *-DKAQ7Q4O\7Z,]3!?!7_P?^W1.YHHHKN/+"BBB@ HHHH *IZOH]AX@ MTVXT[5+*WU'3[A=DUK=Q++%(OHRL""/K5RBEOHPV,;PKX,T#P+IG]G>'=%L- M"L-QMFBBJW ****0'Q_\1/"Y2_G*L DA5MIVXYQG]V?6J/[1O[(MUI?PKU3Q'IGQ&^(/B?6O M#H&JV5IXBUH7L"M$0SLJ>6"'";B"#VK[.HJ;-048NS6M_.][_P!=BKIS5K6_KN?$?Q4\:#]K3_ (4CX"L;FXM+3Q% /$.NRV9"R6\<2LA"D@@'S%F MR",A#BN_\)?!^JZ:_Q7^)NKF:W;R;+6/$(N+224#,8DC,7S*'"G''3 M@BOIVBJFE)22TNV_OV^Y67RN3%N+BWK9)?=_FSXN\-^/+OQ[_P $]_%MI?K) M_;?A[3;C1+V-P=X:#:%S_P!LRF?<&K?P>_;@^&7A'X/^$- \_5]6\0:=I-M: M2:9INF2R2-,D:J54D!3R.N:^QJ* M]>./%MIX#\'ZUXCOTEDLM*M)+R9(%W.RHI8A1ZG%;E%*7PJ,-+*R_KKW''XN M:6MWK_7IH?G9\/\ ]I_X<>.OB4?B5\6M?E74K"1D\.^&+>QGGM=*CS_K68)M MDF. =W;@]E">Z_'R:R_:R_9BOM5^'$DVL36-\E[91FW>*2:6!OG15< D[6;' MJ<"OIZBA_"HK2VWK>]_,:;4N9ZWW]-K>1\D^(OVUO#WBSX6WFA:#INM7GQ-U M&P:P7PRFF3^=!=.FQBS%=NU22>N<#H.UC5O&4W[#?[(_ABSN+%=0\2E?LL<7 M6!+R;?,YD8=43+#C[VT 8SD?5U%$O>4K:.5K^BOHNV[_ *0H^[RIZJ-[?/J_ MN_,^$/@'^TA\$_ADFH^(_$?C*\\1?$77B)=7UJ32K@XZ$00_)\L2X P,9P. M /6?VN/VIO^%/\ @O0(O#["/5_%49:RU6YA8P6,&$W3LF"S,!(N$P>Y(.,' MZ6HHG[R2V7Z=OZ_X(1]UWW_S[_U_P#XQ_9[_ &B?@'\*=*AT33/$^H:OXCUF MZ5]2UF[TRX\_4+IVQN9BG"[F.!GC)ZDDG[.HHJI2YB4K!1114E!1110 4444 M %%%% !2,P522< 7ES\6KZ73M.EDMO!\#F.]U",E6U! M@>88C_SS[,XZ]!7-6K*DDDKR>R[_ .275G;AL,\0W*3Y81W?;_-OHNOI=HO+ MRY^+5[+IVG2R6W@^!S'>ZA&2K:@P/,,1_P">?9G'7H*[6[N]*\%^'WGG>#2] M(L(>=X-+TBPAR6/RQQ(.@ _IU)KSS1]'OOC M%JEMX@\0VTEGX3MG$NDZ'.,-3W??^NBZ!1116IT!1110 4444 %%% M% !1110 5\Y>.?V#?AGX_P#B9-XSU :I#/=3_:;S3;:X5;6YDSDLP*%AN/W@ MK#/M7T;11M)2ZH?1QZ,9##';PQQ1(L<4:A411@* , "GT44"VT05RWQ2\=6W MPS^'7B+Q3=E?*TNRDN K'&]P/D3ZLQ5?QKJ:YSQ_\/= ^*/AFX\/>)[ ZGH] MPZ/+:^?)"'*,&7+1LK8! .,XXJ)IRBTG8N#2DG+8^2_V;?!/[0GAKX:QZGX? MC^')M_%$S:[/)XB-^;Z1YP#F3R@$'RXP!V/K6G^QVNL_#7Q]\1_@SXL%C;W^ M[^V[./3& >1AOK7U]9VD-A:PVUO&L-O"BQQQH,!5 P M/8 5S=Y\+O#%_P#$.Q\=3:6#XJL;5K*#4%GD4B%MV4*!@C#YF^\I(SQ6LN5R M:M[K37RZ?R"(7<+XPT9; 8\;L#JK@COCZ7C^+'A&X\:6OA*WU^RO/$5S%).MA:R"5 MU1!EF?;D)[;B,]LUF?$SX _#[XPR12^+_"]GJ]S$NQ+HEX9PO]WS8V5\>V<< MU+\-?@7X"^#ZS?\ "(>&+/1I9EVR7";I9W7KM,LA9R,]LXH4G)+GW2MZV5EZ M>>XVK-N/5W]+N[_X!X'\ ?"=EXZ\:?M/>'=13?8ZIKC6DHQT5UF&1[C.1[BO M&_"?B77/B9H/@[]FC45G74=(\036VO38(!TNT;S$&?0\J/\ KFGK7WKX4^&_ MASP/K'B'5-$TT6-_K]U]LU*832/]HFY^;#,0O4\* .>E5]*^$OA+1/B#JOCB MQT6&W\5:I"MO=ZBKN6D0;>-I;:OW%R0 3@9S4P]V4;[)13]8I6^5[_)CEJI6 MW;DUZ2O?\+?-'B/Q @CM?VZ/@_#"BQQ1^']01$48"J(I@ /;%>L^(?$GPS^) M%YK7@;7KW0]7N[%U2]T;4BF^-B@96"O@GA@0Z=">H-;VI?#CP[JWCK2/&5WI MHE\2:3!);65]YT@,4<@(==@;8I:C@ M*UXCR6\S@# #/$RLV!P,DU.O*HO7>_SDW^I5U=M:;?@DOT/GW]GC3].^'?[7 M7BOP5\.=6DU+X>-I/VV\LTN3<6UA=[E 5'R>><=2<$@YV\?5WCSQYHGPT\)Z MAXC\17R:?I-BF^65N23T"J/XF)P !U)JI\//A7X2^$^DOIOA+0;30[21@T@M MU)>4CH7=B6$O"]Q.FZ)21>$?BU\"_']TX70--U>6TO+S.8X M5F";7)],!SG_ &:ZO_A@KX$_]"-_Y5[_ /\ C]>KO\+_ K-X!@\$SZ);77A M:&V2TCTVZ!F01H %&7)8D8&&)SD9SFGI'EZOXF>WL=+M+>0/)=,TR,2@'4;0>1QD@= MQ6WX[^+MA^S/\(O".C3P'6/%KZ?;:7I6B0-^\N[A(DCR?[J XRWO@&LW5E$88)/MEQ 40G)&(I%!Y]M6.L_$WQ,0U]-%.C):1\;;6'G[JX4''7: . ";W[0G M[0+_ [FL?!_A."+6?B1K@V:?8LP$=HAR/M,Y/"HN"0#UP>P)J+1?V(_@KX= MUBQU73_!?D7]C.ES;R_VI>OLD1@RMM:8@X('!!%;?Q&_96^%WQ:\32>(/%?A M<:IJ\D20M<_;[J'*J,*-LZUJWFJTEW.<[%RV![D]Z]AKQSP/\ ML@_"3X<>*+'Q'X=\)?V?K-BS-;W/]HWH[U['52:9*30444 M5)04444 %%%% !117GGC?QOJ-]K)\'^#RDOB*1 UW?,-T.E0G_EH_K(1]U._ M4\=621S-=7DYW374Q^])(W=B?RZ5Q?Q?^+]WX9U"R\'>#K*/7OB+JZ%K. MP8GR;*'.&N[IA]R)?3JY^5?9X?#U*T[OXOP2_K=G)%>S_P!HQ'Q=%V\EW;ZO MKZ!\7_B_=^&=0LO!W@ZRCU[XBZNA:SL&)\FRASAKNZ8?W-S>R:]XLU=Q<:UX@N@/.O9L=!_^31\(/A!:?"_3[VYN M;V37O%FKN+C6O$%T!YU[-CH/[D:]$C'"CWR:]"KOJ5(PC[&CMU??_@=E\WY; M4Z$;RQ\)>$K&/Q!\1-80FPTPL? M*M8\X:[NF'W(4_-B-J]R+WP?^#]O\,K.^OKZ^D\0>,=8<3ZUX@N5'FW(/&.L.)]9\07*CS;N3'"J/X(DZ)&. !6 MI\1?B+;^!;.VAAMGU;Q!J#&'3-(MS^]N9/4_W47JSG@"NS6;^K8;6^[[_P"4 M5_P7Y<$YQHQ>*Q3LELNW^(-08PZ9I%N?WMS M)ZG^ZB]6<\ 52^'7PZN-#O+GQ)XDN4U;QEJ"@7-TH_=6L?46\ /W8U_-CR:/ MAU\.KC0[RY\2>)+E-6\9:@H%S=*/W5K'U%O #]V-?S8\FN]IU:L*$'0H.]_B MEW\E_=_/=]$L:%"IBJBQ6*5K?#'^7S?>;^Z*T75LHHHKS3V0HHHH **** "B MBB@#'\5>#=!\<:6=-\1:-8:Y8;@_V;4+9)XPPZ, P.#[U;T?1=/\.Z9;Z=I5 MC;:;I]NNR&UM(EBBC7T55 'TJ[10 4444 %?$NO?&;PM\#?VY/'NK^,+R;3 M["]T&TMX)([:28N^V$XP@)QA6Y]J^VJ*2NIJ:Z7_ !5AZ.+B^MOP:?Z'Q?\ M%CXG:A^V98V7P[^&NAZLOAB\NXI=;\4ZA:-;VL4",&V1[OO,2 <<$[0 ,$D; M?[>,=EX-^%OPU(5HM*T?Q-8;BJEO+ABC<=O9:^M:*?PI?,.M?MZ>#M8TZ:T^'>E:[XY\3S*4L[&RTR54\P_=,C, 0H/)P#^'6NQ_9) M^#NJ_"'X93)XC96\4ZY?2ZOJ@5@PCEDQB/(X) SCC).,CFO;:*:M&[6[T^6 M_P#7H)W=ET6I^=OQUT+5/#_[0'BSX6:?;RC2?BCJ>E:@'0?*BB4FX/XLK$^P MKWW]M[09='^%_ASQII$'^F^!M9M-2B6,-.,5NFG? MTM9?)*Q3M*;D]FK6]=W\SYV_8IT^XU3P+XC^(%_"T-_XVURYU7$@^9;<.4B7 MZ##$>QKW[5M2AT72[S4+C=]GM(7GDV+N;:JEC@=S@5;HIRU5HZ622^2LA1T= MY:W=W\W<_.?3?VI/AY\8OBDOB_XJZS-8>']#G)\.^$([*:>,,/\ EZN652KO MZ+R!]!\WT=\0O$'A_P#;(_9O\;6/P_O)-2D $4/G6[P$W,1298QO ^]@#/3Y MJ^BJ*F45*G[/^K]_7^ME8I2<:GM/ZMV]/ZZGR1X1_;8\.Z#\*[#0M2TW6T^) MUA8+8'PO_9O^1,4HJ,?LK_ "LK M^A\ _ G]I/X1^&]:OOB#\0/%]QKGQ+UA<3SKI=P8--A[6UN-G X+#K^9/T- M\??VI--^%OP/T_QWHENVKMKPCCT?S8V2/=)&7624$!@H4$[>I.!QG(]XHI3] MZ/*M/\NW_!^>X1]V7,]?\_ZZ?(^$/@'^TA\$_ADFH^(_$?C*\\1?$77B)=7U MJ32K@XZ$00_)\L2X P,9P. /N;3=0@U?3;6^M7,EM=1+/$Q4J2C $'!Y'! M'6K-%4VFK6].R1*33O<****DH**** "BBB@ HHHH **** "BBF331VT,DTTB MQ11J7>1R JJ!DDD] !0&P331VT,DTTBQ11J7>1R JJ!DDD] !7CLDEU^T)J# M11--9?#2UEQ)*N4DUV13]U>XMP1R>K$?D2277[0FH-%$TUE\-+67$DJY2379 M%/W5[BW!')ZL1^7L%K:PV-K%;VT206\*"..*-0JHH& !T ':O7TR]?]/?\ MTC_[;_TG_%MX&N;/_J'_ /3G_P!I_P"E_P"'XBUM8;&UBM[:)(+>%!''%&H5 M44# Z #M4M%%>3OJSWDDE9!1112&%%%% !1110 4444 %%%% !1110 444 M4 %<-I__ "6;6/\ L#6W_HV2NYKR_4?%NC^$_C%J4FKW\5@DVCVZQM-D!B)9 M,C/XUYV,G&G[*4W9"O^ACLO\ MOL_X4?\ "XO!7_0QV7_?9_PK7Z[A?^?L?O1A_9N-_P"?$_\ P%_Y'945QO\ MPN+P5_T,=E_WV?\ "C_A<7@K_H8[+_OL_P"%'UW"_P#/V/WH/[-QO_/B?_@+ M_P CLJ*XW_A<7@K_ *&.R_[[/^%'_"XO!7_0QV7_ 'V?\*/KN%_Y^Q^]!_9N M-_Y\3_\ 7_D=E17&_\ "XO!7_0QV7_?9_PH_P"%Q>"O^ACLO^^S_A1]=PO_ M #]C]Z#^S<;_ ,^)_P#@+_R.RHKC?^%Q>"O^ACLO^^S_ (4?\+B\%?\ 0QV7 M_?9_PH^NX7_G['[T']FXW_GQ/_P%_P"1V5%<;_PN+P5_T,=E_P!]G_"C_A<7 M@K_H8[+_ +[/^%'UW"_\_8_>@_LW&_\ /B?_ ("_\CLJ*XW_ (7%X*_Z&.R_ M[[/^%'_"XO!7_0QV7_?9_P */KN%_P"?L?O0?V;C?^?$_P#P%_Y'945QO_"X MO!7_ $,=E_WV?\*/^%Q>"O\ H8[+_OL_X4?7<+_S]C]Z#^S<;_SXG_X"_P#( M[*BN-_X7%X*_Z&.R_P"^S_A1_P +B\%?]#'9?]]G_"CZ[A?^?L?O0?V;C?\ MGQ/_ ,!?^1V5%<;_ ,+B\%?]#'9?]]G_ H_X7%X*_Z&.R_[[/\ A1]=PO\ MS]C]Z#^S<;_SXG_X"_\ ([*BN-_X7%X*_P"ACLO^^S_A1_PN+P5_T,=E_P!] MG_"CZ[A?^?L?O0?V;C?^?$__ %_Y'945QO_ N+P5_T,=E_WV?\*/\ A<7@ MK_H8[+_OL_X4?7<+_P _8_>@_LW&_P#/B?\ X"_\CLJ*XW_A<7@K_H8[+_OL M_P"%'_"XO!7_ $,=E_WV?\*/KN%_Y^Q^]!_9N-_Y\3_\!?\ D=E17&_\+B\% M?]#'9?\ ?9_PH_X7%X*_Z&.R_P"^S_A1]=PO_/V/WH/[-QO_ #XG_P" O_([ M*BN-_P"%Q>"O^ACLO^^S_A1_PN+P5_T,=E_WV?\ "CZ[A?\ G['[T']FXW_G MQ/\ \!?^1V5%<;_PN+P5_P!#'9?]]G_"C_A<7@K_ *&.R_[[/^%'UW"_\_8_ M>@_LW&_\^)_^ O\ R.RHKC?^%Q>"O^ACLO\ OL_X4?\ "XO!7_0QV7_?9_PH M^NX7_G['[T']FXW_ )\3_P# 7_D=E2,P522< QTR62V\&Q-MO-03*/J##K#$>HC[,W?H.]1+&T=J,E.3V2:_I+ MNS6GEN(OS8B+IP6\I)K[K[M]%U]+L=>7ES\6KZ73M.EDMO!\#F.]U",E6U!@ M>88C_P \^S..O05VMW=Z5X+\/O/.\&EZ180Y+'Y8XD'0 ?TZDT7EYI/@KP[) M<3O#I>D:?#DG&U(D4= !^0 Y)]Z\%M/BIX1^*'B!=6\4Z_9Z=X;T^8G3= G? MYIY%.!<7(''^ZG0=3[XW6&=ZDDZDN^B_X$5^/J>1F>:TX(;:2S\)VSB72=#G&&N6'W;FX7]50_4^_J]<#_ ,+Z M^'O_ $-FG?\ ?9_PH_X7U\/O^ALT[_OL_P"%=%.I1IKXTV]W='F4:V%HIMU8 MN3W=UK_71=#OJ*X'_A?7P^_Z&S3O^^S_ (4?\+Z^'W_0V:=_WV?\*V^L4?YU M]Z.CZYAO^?L?O1WU%<#_ ,+Z^'W_ $-FG?\ ?9_PH_X7U\/O^ALT[_OL_P"% M'UBC_.OO0?7,-_S]C]Z.^HK@?^%]?#[_ *&S3O\ OL_X4?\ "^OA]_T-FG?] M]G_"CZQ1_G7WH/KF&_Y^Q^]'?45P/_"^OA]_T-FG?]]G_"C_ (7U\/O^ALT[ M_OL_X4?6*/\ .OO0?7,-_P _8_>COJ*X'_A?7P^_Z&S3O^^S_A1_POKX??\ M0V:=_P!]G_"CZQ1_G7WH/KF&_P"?L?O1WU%<#_POKX??]#9IW_?9_P */^%] M?#[_ *&S3O\ OL_X4?6*/\Z^]!]COJ*X M'_A?7P^_Z&S3O^^S_A1_POKX??\ 0V:=_P!]G_"CZQ1_G7WH/KF&_P"?L?O1 MWU%<#_POKX??]#9IW_?9_P */^%]?#[_ *&S3O\ OL_X4?6*/\Z^]!]COJ*X'_A?7P^_Z&S3O^^S_A63K'Q8_P"$VF3P M_P##J[AU+5+A!S+Q%)+22;[+B\$>"-. M\!Z,+&Q#RR2.9KJ\G.Z:ZF/WI)&[L3^72CP1X(T[P'HPL;$/+)(YFNKR<[IK MJ8_>DD;NQ/Y=*\M_:4_:S0G'VFY8#K*/7OB+JZ%K.P8GR;*'.&N[IA]R)?3JY^5?;3^$'P@M/A?I][B1CA1[Y->1?"#XL?!+X7Z?>W-S\3]*U[Q9J[BXU MKQ!=2'SKV;'0NT5Y%_PUQ\'/\ MHH6B_P#?T_X4?\-NT5Y M%_PUQ\'/^BA:+_W]/^%'_#7'P<_Z*%HO_?T_X4?5,3_S[E]S#ZUA_P#GXOO1 MZ[17D7_#7'P<_P"BA:+_ -_3_A1_PUQ\'/\ HH6B_P#?T_X4?5,3_P ^Y?